PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	WANG, J; KLEIN, JR				WANG, J; KLEIN, JR			THYMUS-NEUROENDOCRINE INTERACTIONS IN EXTRATHYMIC T-CELL DEVELOPMENT	SCIENCE			English	Article							INTESTINAL INTRAEPITHELIAL LYMPHOCYTES; BONE-MARROW ORIGIN; GROWTH-HORMONE; RADIATION CHIMERAS; NEGATIVE SELECTION; EPITHELIAL-CELLS; ATHYMIC MICE; ALPHA-BETA; RECEPTOR; MOUSE	Studies of the development of murine intestinal intraepithelial lymphocytes (IELs) have yielded markedly different results depending on the experimental system used. In athymic radiation chimeras, IELs consist of all subsets found in euthymic mice; adult mice that were athymic at birth have only IELs that are positive for T cell receptor gamma delta and CD8 alpha alpha. These differences are resolved by the finding that administration of the neuropeptide thyrotropin-releasing hormone to adult mice thymectomized as neonates leads to the development of all IEL T cells. Thus, a neuroendocrine signal initiated by the thymus during fetal or neonatal life appears to be required for subsequent extrathymic maturation of gut alpha beta T cells.	UNIV TULSA, DEPT BIOL SCI, TULSA, OK 74104 USA; UNIV TULSA, CTR STUDIES MOLEC BIOL & BIOTECHNOL, TULSA, OK 74104 USA	University of Tulsa; University of Tulsa					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035566, R23DK035566] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK035566, DK35566] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALK SP, 1991, SCIENCE, V253, P1411, DOI 10.1126/science.1716785; BANDEIRA A, 1991, P NATL ACAD SCI USA, V88, P43, DOI 10.1073/pnas.88.1.43; BEN E, 1991, LIFE SCI, V48, P2141, DOI 10.1016/0024-3205(91)90147-4; CONSTANT P, 1994, SCIENCE, V264, P267, DOI 10.1126/science.8146660; DARDENNE M, 1992, ANN NY ACAD SCI, V650, P85; FARBIS N, 1992, INT J IMMUNOPATH PH, V5, P93; GOFF BL, 1987, CLIN EXP IMMUNOL, V68, P580; GOFF BL, 1990, CLIN EXP IMMUNOL, V48, P2141; GUYGRAND D, 1991, IMMUNOL RES, V10, P296, DOI 10.1007/BF02919710; GUYGRAND D, 1993, CURR OPIN IMMUNOL, V5, P247, DOI 10.1016/0952-7915(93)90012-H; GUYGRAND D, 1991, J EXP MED, V173, P471, DOI 10.1084/jem.173.2.471; HENDERSON RS, 1981, THYMUS, V3, P359; HOLUB M, 1989, IMMUNOLOGY NUDE MICE, P141; KAISERLIAN D, 1989, EUR J IMMUNOL, V19, P1513, DOI 10.1002/eji.1830190827; KAISERLIAN D, 1993, EUR J IMMUNOL, V23, P2717, DOI 10.1002/eji.1830231053; KENAI H, 1993, EUR J IMMUNOL, V23, P1818, DOI 10.1002/eji.1830230813; KIYONO H, 1994, MUCOSAL IMMUNOLOGY I, P1; KLEIN JR, 1987, J IMMUNOL, V138, P58; KLEIN JR, 1986, J EXP MED, V164, P309, DOI 10.1084/jem.164.1.309; KLEIN JR, 1992, IMMUNOL TODAY, V13, P148, DOI 10.1016/0167-5699(92)90114-M; LEFRANCOIS L, 1991, IMMUNOL TODAY, V12, P436, DOI 10.1016/0167-5699(91)90015-L; LEFRANCOIS L, 1991, J IMMUNOL, V147, P1746; LIN T, 1993, EUR J IMMUNOL, V23, P1968, DOI 10.1002/eji.1830230836; LONDON SD, 1987, J EXP MED, V165, P830, DOI 10.1084/jem.165.3.830; MALOY KJ, 1991, IMMUNOLOGY, V72, P555; MAYRHOFER G, 1983, INT ARCH ALLER A IMM, V71, P317, DOI 10.1159/000233414; MAYRHOFER G, 1980, BLOOD, V55, P532; MISHELL BS, 1980, SELECTED METHODS CEL, P326; MOSLEY RL, 1992, J IMMUNOL METHODS, V156, P19; MOSLEY RL, 1994, DEV COMP IMMUNOL, V18, P155, DOI 10.1016/0145-305X(94)90243-7; MOSLEY RL, 1990, J IMMUNOL, V145, P1369; MOSLEY RL, 1992, TRANSPLANTATION, V53, P868, DOI 10.1097/00007890-199204000-00030; MURPHY WJ, 1993, J EXP MED, V178, P231, DOI 10.1084/jem.178.1.231; MURPHY WJ, 1992, J IMMUNOL, V149, P3851; PIERPAOL.W, 1972, EXPERIENTIA, V28, P1386; PIERPAOLI W, 1972, NATURE-NEW BIOL, V238, P282, DOI 10.1038/newbio238282a0; PIERPAOLI W, 1990, J NEUROIMMUNOL, V27, P99, DOI 10.1016/0165-5728(90)90059-V; PIERPAOLI W, 1975, CLIN EXP IMMUNOL, V20, P323; PIERPAOLI W, 1977, CELL IMMUNOL, V29, P16, DOI 10.1016/0008-8749(77)90271-4; POUSSIER P, 1992, J EXP MED, V176, P187, DOI 10.1084/jem.176.1.187; POUSSIER P, 1994, ANNU REV IMMUNOL, V12, P521, DOI 10.1146/annurev.immunol.12.1.521; POUSSIER P, 1993, J EXP MED, V178, P1947, DOI 10.1084/jem.178.6.1947; ROCHA B, 1992, IMMUNOL TODAY, V13, P449, DOI 10.1016/0167-5699(92)90074-H; ROCHA B, 1991, J EXP MED, V173, P483, DOI 10.1084/jem.173.2.483; SAKABE K, 1986, THYMUS, V8, P97; SCHILD H, 1994, CELL, V76, P29, DOI 10.1016/0092-8674(94)90170-8; STICKNEY D, 1993, MOL IMMUNOL, V30, P813, DOI 10.1016/0161-5890(93)90004-U; VIDAL K, 1993, J IMMUNOL, V151, P4642; VINEY JL, 1989, IMMUNOLOGY, V66, P583; WEIHE WH, 1984, EXP CELL BIOL, V52, P140; WHETSELL M, 1991, MOL CELL BIOL, V11, P5902, DOI 10.1128/MCB.11.12.5902	51	83	84	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 23	1994	265	5180					1860	1862		10.1126/science.8091211	http://dx.doi.org/10.1126/science.8091211			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH258	8091211				2022-12-28	WOS:A1994PH25800031
J	HURLEY, JC				HURLEY, JC			REAPPRAISAL OF THE ROLE OF ENDOTOXIN IN THE SEPSIS SYNDROME	LANCET			English	Article							RESPIRATORY-DISTRESS SYNDROME; ASSOCIATION; INFECTIONS; SEPTICEMIA; MORTALITY; PREDICTOR; FAILURE; DISEASE; DEATH; TRACT	There is strong evidence to implicate endotoxin released from gram negative bacteria in the pathogenesis of the sepsis syndrome and related conditions, but equally compelling data bring the role of endotoxin into doubt. Reappraisal of endotoxin and its release from gram negative bacteria suggests that it is not directly responsible for the complications of sepsis syndrome. Rather, release of endotoxin is a marker for the transition of gram negative organisms to cell-wall-deficient forms (L-forms) that may persist undetected despite antibiotic therapy directed against the parental form. This transition has two consequences in compromised patients: L-forms cause organ failure, and they serve as a sanctuary from which cell-wall-intact revertants may arise.			HURLEY, JC (corresponding author), CHILDRENS HOSP & MED CTR,DIV INFECT DIS,4800 SAND POINT WAY NE,POB C5371,SEATTLE,WA 98105, USA.			Hurley, James/0000-0002-5885-2084				ANDERSEN BM, 1984, SCAND J INFECT DIS, V16, P247, DOI 10.3109/00365548409070397; BELL RC, 1983, ANN INTERN MED, V99, P293, DOI 10.7326/0003-4819-99-3-293; BONE RC, 1989, CRIT CARE MED, V17, P389, DOI 10.1097/00003246-198905000-00002; BOUCEK MM, 1984, J PEDIATR-US, V105, P538, DOI 10.1016/S0022-3476(84)80416-3; BRANDTZAEG P, 1992, J CLIN INVEST, V89, P816, DOI 10.1172/JCI115660; BRANDTZAEG P, 1989, J INFECT DIS, V159, P195, DOI 10.1093/infdis/159.2.195; CASSELL GH, 1993, CLIN MICROBIOL REV, V6, P69, DOI 10.1128/CMR.6.1.69-87.1993; CASSELL GH, 1988, LANCET, V2, P240; DANNER RL, 1991, CHEST, V99, P169, DOI 10.1378/chest.99.1.169; FEIN AM, 1983, CHEST, V83, P40, DOI 10.1378/chest.83.1.40; FEINGOLD DS, 1969, NEW ENGL J MED, V281, P1159, DOI 10.1056/NEJM196911202812106; FOWLER AA, 1983, ANN INTERN MED, V98, P593, DOI 10.7326/0003-4819-98-5-593; GUTMAN LT, 1965, J CLIN INVEST, V44, P1945, DOI 10.1172/JCI105300; HURLEY JC, 1992, CLIN INFECT DIS, V15, P840, DOI 10.1093/clind/15.5.840; HURLEY JC, IN PRESS J INFECT DI; HURLEY JC, 1991, THESIS MELBOURNE U M; KAPLAN RL, 1979, ARCH INTERN MED, V139, P867, DOI 10.1001/archinte.139.8.867; KORVICK JA, 1992, ANTIMICROB AGENTS CH, V36, P620, DOI 10.1128/AAC.36.3.620; KREGER BE, 1980, AM J MED, V68, P344, DOI 10.1016/0002-9343(80)90102-3; Madoff S, 1986, BACTERIAL L FORMS; MARTIN MA, 1992, CLIN INFECT DIS, V14, P1213, DOI 10.1093/clinids/14.6.1213; MCKAY KA, 1966, NATURE, V212, P359, DOI 10.1038/212359a0; MIYATA T, 1989, LANCET, V2, P189; MONTGOMERY AB, 1985, AM REV RESPIR DIS, V132, P485; MOORE RD, 1987, J INFECT DIS, V155, P93, DOI 10.1093/infdis/155.1.93; NIEDERMAN MS, 1990, CLIN CHEST MED, V11, P633; OGNIBENE FP, 1986, NEW ENGL J MED, V315, P547, DOI 10.1056/NEJM198608283150904; PARSONS PE, 1992, AM REV RESPIR DIS, V146, P694, DOI 10.1164/ajrccm/146.3.694; PARSONS PE, 1989, AM REV RESPIR DIS, V140, P294, DOI 10.1164/ajrccm/140.2.294; PEPE PE, 1982, AM J SURG, V144, P124, DOI 10.1016/0002-9610(82)90612-2; SEIDENFELD JJ, 1986, AM REV RESPIR DIS, V134, P12; TANIMOTO H, 1991, ANTIBIOT CHEMOTHER, V44, P94; VANDENBROUCKEGRAULS CMJE, 1991, LANCET, V338, P859, DOI 10.1016/0140-6736(91)91510-2; VANDEVENTER SJH, 1988, LANCET, V1, P605; WORTEL CH, 1992, J INFECT DIS, V166, P1367, DOI 10.1093/infdis/166.6.1367; YAMAMOTO A, 1979, JPN J EXP MED, V49, P361; 1992, LANCET, V340, P1323; 1985, LANCET, V2, P594	38	37	38	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 1	1993	341	8853					1133	1135		10.1016/0140-6736(93)93139-R	http://dx.doi.org/10.1016/0140-6736(93)93139-R			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ687	8097815				2022-12-28	WOS:A1993KZ68700015
J	MCMANUS, IC; RICHARDS, P; WINDER, BC; SPROSTON, KA; VINCENT, CA				MCMANUS, IC; RICHARDS, P; WINDER, BC; SPROSTON, KA; VINCENT, CA			THE CHANGING CLINICAL-EXPERIENCE OF BRITISH MEDICAL-STUDENTS	LANCET			English	Article							DRESSERS	The UK National Health Service is undergoing fundamental reforms, which might have a detrimental effect on the training of doctors, not least with respect to the amount of clinical experience that medical students get. We compared the practical experience gained by two cohorts of students at medical schools throughout the UK, who had started their training in 1981 or 1986. The assessment was made by questionnaire at the end of their final clinical year. Experience of acute medical conditions, surgical operations, and practical procedures differed significantly between groups of medical schools, and showed a significant decline in the past five years. This decline in the clinical experience of medical students has coincided with the introduction of the health service reforms. We suspect that the university-based clinical education designed for a lifetime of change is in danger of being replaced by a dispersed clinical apprenticeship for current practice.			MCMANUS, IC (corresponding author), IMPERIAL COLL SCI TECHNOL & MED,ST MARYS HOSP,SCH MED,NORFOLK PL,LONDON W2 1PG,ENGLAND.		Vincent, Charles A/D-1134-2010	Vincent, Charles A/0000-0003-0270-0222; Winder, Belinda/0000-0002-9118-679X; McManus, Ian/0000-0003-3510-4814				CHANTLER C, 1992, BRIT MED J, V305, P71, DOI 10.1136/bmj.305.6845.71; DEAN M, 1992, LANCET, V339, P170, DOI 10.1016/0140-6736(92)90223-P; DEAN M, 1991, LANCET, V338, P874, DOI 10.1016/0140-6736(91)91515-V; JOLLY BC, 1989, MED EDUC, V23, P189, DOI 10.1111/j.1365-2923.1989.tb00885.x; LOCKWOOD DNJ, 1986, MED EDUC, V20, P216, DOI 10.1111/j.1365-2923.1986.tb01171.x; LOCKWOOD DNJ, 1986, J ROY SOC MED, V79, P38, DOI 10.1177/014107688607900112; MCMANUS IC, 1984, BRIT MED J, V289, P1201, DOI 10.1136/bmj.289.6453.1201; MCMANUS IC, 1989, BRIT MED J, V298, P723, DOI 10.1136/bmj.298.6675.723; RICHARDS P, 1992, BRIT MED J, V304, P625, DOI 10.1136/bmj.304.6827.625; SMITH J, 1992, BRIT MED J, V304, P1646, DOI 10.1136/bmj.304.6843.1646; WAKEFORD RE, 1983, ANN R COLL SURG ENG, V65, P274	11	46	46	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 10	1993	341	8850					941	944		10.1016/0140-6736(93)91225-B	http://dx.doi.org/10.1016/0140-6736(93)91225-B			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW981	8096278				2022-12-28	WOS:A1993KW98100017
J	DODWELL, DJ				DODWELL, DJ			CYTOTOXIC DRUGS - THE SEARCH FOR DOSE-RESPONSE	LANCET			English	Editorial Material							BONE-MARROW TRANSPLANTATION; BREAST-CANCER; CHEMOTHERAPY; INTENSITY; CARCINOMA; LYMPHOMA; HODGKINS; TUMORS				DODWELL, DJ (corresponding author), COOKRIDGE HOSP,LEEDS LS16 6QB,W YORKSHIRE,ENGLAND.							BASTHOLT L, 1992, P AM SOC CLIN ONCOL, V11, P51; BRONCHUD MH, 1989, BRIT J CANCER, V60, P121, DOI 10.1038/bjc.1989.234; BRUCE WR, 1966, JNCI-J NATL CANCER I, V37, P233; BUDMAN DR, 1992, P AM SOC CLIN ONCOL, V11, P29; CARMOPEREIRA J, 1987, BRIT J CANCER, V56, P471, DOI 10.1038/bjc.1987.226; COHEN MH, 1977, CANCER TREAT REP, V61, P349; Early Breast Cancer Trialists' Collaborative Group, 1992, LANCET, V339, P1; FIGUEREDO AT, 1985, J CLIN ONCOL, V3, P54, DOI 10.1200/JCO.1985.3.1.54; FISHER RI, 1992, P AM SOC CLIN ONCOL, V11, P1067; GIANNI AM, 1992, P AN M AM SOC CLIN, V11, P68; GIANNI AM, 1991, P AM SOC CLIN ONCOL, V10, P951; HARRIS AL, 1990, LANCET, V335, P186, DOI 10.1016/0140-6736(90)90277-C; HENDERSON IC, 1988, J CLIN ONCOL, V6, P1501, DOI 10.1200/JCO.1988.6.9.1501; HRYNIUK W, 1986, J CLIN ONCOL, V4, P1162, DOI 10.1200/JCO.1986.4.8.1162; HRYNIUK W, 1984, J CLIN ONCOL, V2, P1281, DOI 10.1200/JCO.1984.2.11.1281; HRYNIUK W, 1991, P AM SOC CLIN ONCOL, V10, P943; KAYE SB, 1992, LANCET, V340, P329, DOI 10.1016/0140-6736(92)91404-V; KESSINGER A, 1990, HEMATOL ONCOL CLIN N, V4, P577, DOI 10.1016/S0889-8588(18)30479-9; LEVIN L, 1987, J CLIN ONCOL, V5, P756, DOI 10.1200/JCO.1987.5.5.756; MCGUIRE WP, 1992, P AN M AM SOC CLIN, V11, P718; NICHOLS CR, 1991, J CLIN ONCOL, V9, P1163, DOI 10.1200/JCO.1991.9.7.1163; PETERS W, 1992, P AM SOC CLIN ONCOL, V11, P59; SAMSON MK, 1984, CANCER, V53, P1229; SLEASE RB, 1988, J CLIN ONCOL, V6, P1314, DOI 10.1200/JCO.1988.6.8.1314; VINCENT MD, 1988, CANCER CHEMOTH PHARM, V21, P255; WILLIAMS SF, 1990, SEMIN ONCOL, V17, P88; YI PI, 1990, SEMIN ONCOL, V17, P60; 1992, LANCET, V339, P71	28	7	7	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 6	1993	341	8845					614	616		10.1016/0140-6736(93)90366-O	http://dx.doi.org/10.1016/0140-6736(93)90366-O			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KQ234	8094841				2022-12-28	WOS:A1993KQ23400017
J	MACFARLANE, JT; COLVILLE, A; GUION, A; MACFARLANE, RM; ROSE, DH				MACFARLANE, JT; COLVILLE, A; GUION, A; MACFARLANE, RM; ROSE, DH			PROSPECTIVE-STUDY OF ETIOLOGY AND OUTCOME OF ADULT LOWER-RESPIRATORY-TRACT INFECTIONS IN THE COMMUNITY	LANCET			English	Article							ACUTE BRONCHITIS; PNEUMONIA; CHLAMYDIA; ETIOLOGY; STRAIN; TWAR	Community-acquired adult lower-respiratory-tract infections (LRTI) are generally thought to be caused by atypical and viral infections. We have studied 480 adults presenting to a single general practice with community-acquired LRTI between November, 1990, and December, 1991. The overall incidence was 44 cases per 1000 population per year, the incidence was 2-4 times higher in people aged 60 and over than in those aged less than 50.206 patients were studied in detail; among this group 91 (44%) had 113 pathogens identified. There were 92 bacteria (Streptococcus pneumoniae in 62 and Haemophilus influenzae in 16), 19 viruses (influenza virus in 12), and only 2 atypical pathogens (Mycoplasma pneumoniae and Coxiella burnetii). Pneumococcal infection was common in people who were 60 or older, those who had underlying chronic disease, or people with both features. There was moderate morbidity in terms of time in bed, time to return to normal activities, and days off work. 25% of patients returned for a second consultation with the general practitioner, in most because of unsatisfactory clinical progress. Community-acquired LRTI are very common,and the range of causative pathogens is similar to that for community-acquired pneumonia. Existing management strategies seem inadequate.	CITY HOSP,DEPT RADIOL,NOTTINGHAM NG5 1PB,ENGLAND; UNIV NOTTINGHAM HOSP,PUBL HLTH LAB SERV,NOTTINGHAM NG7 2UH,ENGLAND; STENHOUSE MED CTR,NOTTINGHAM,ENGLAND	University of Nottingham; University of Nottingham	MACFARLANE, JT (corresponding author), CITY HOSP,DEPT RESP MED,HUCKLAND RD,NOTTINGHAM NG5 1PB,ENGLAND.							BLACK DAK, 1975, BRIT J PREV SOC MED, V29, P222; BROOME CV, 1991, NEW ENGL J MED, V325, P1506, DOI 10.1056/NEJM199111213252109; DUNLAY J, 1984, J FAM PRACTICE, V18, P719; GRAYSTON JT, 1989, CHEST, V95, P664, DOI 10.1378/chest.95.3.664; HAGER H, 1987, REV INFECT DIS, V9, P1140; Howie J G, 1973, J R Coll Gen Pract, V23, P895; HOWIE JGR, 1978, BRIT MED J, V2, P1342, DOI 10.1136/bmj.2.6148.1342; MACFARLANE JT, 1982, LANCET, V2, P255; MARRIE TJ, 1987, ANN INTERN MED, V106, P507, DOI 10.7326/0003-4819-106-4-507; MURRAY HW, 1975, AM J MED, V58, P229, DOI 10.1016/0002-9343(75)90574-4; RODNICK JE, 1988, WESTERN J MED, V149, P347; SILLIS M, 1992, J INFECTION, V25, P77, DOI 10.1016/0163-4453(92)92130-B; SIMPSON REH, 1973, POSTGRAD MED J, V49, P763; VENKATESAN P, 1992, THORAX, V47, P329, DOI 10.1136/thx.47.5.329; VERHEIJ TJM, 1989, FAM PRACT, V6, P66, DOI 10.1093/fampra/6.1.66; Wallace R J Jr, 1988, Semin Respir Infect, V3, P49; WOODHEAD MA, 1987, LANCET, V1, P671; 1991, COMMUNICAB DIS REP, V1, P49; 1992, IMMUNISATION INFECTI; 1974, BMJ, V3, P1; 1987, Q J MED, V62, P195	21	292	306	1	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 27	1993	341	8844					511	514		10.1016/0140-6736(93)90275-L	http://dx.doi.org/10.1016/0140-6736(93)90275-L			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP083	8094769				2022-12-28	WOS:A1993KP08300002
J	DISANTO, JP; BONNEFOY, JY; GAUCHAT, JF; FISCHER, A; DESAINTBASILE, G				DISANTO, JP; BONNEFOY, JY; GAUCHAT, JF; FISCHER, A; DESAINTBASILE, G			CD40 LIGAND MUTATIONS IN X-LINKED IMMUNODEFICIENCY WITH HYPER-IGM	NATURE			English	Article							TUMOR NECROSIS FACTOR; HYPERIMMUNOGLOBULINEMIA-M; SWITCH; RECEPTOR; CLONING; CELLS	SIGNALLING for the B-cell immunoglobulin isotype switch requires T-cell-derived cytokines and T-B cell interaction, which operates primarily through the CD40 molecule on B cells with its ligand (CD40L) on activated T cells (reviewed in ref. 1). The CD40L is a type II membrane protein2-5 with homology to tumour necrosis factor-alpha and -beta6,7, and has important functions in B-cell activation and differentiation2,4,8. Human CD40L maps on Xq26.3-27.1 (ref. 3), the region where a primary immunodeficiency characterized by an immunoglobulin isotype switch defect (the hyper-IgM immunodeficiency syndrome, HIGM1) has been localized9,10. The hypothesis that HIGM1 involves an abnormality of the CD40L has been tested. We report here the lack of CD40L expression in four unrelated male children with the hyper-IgM syndrome. CD40L transcripts in these patients showed either deletions or point mutations clustered within a limited region of the CD40L. extracellular domain. These genetic alterations with abnormal CD40L expression provide a molecular basis for immunoglobulin isotype switch defects observed in this immunodeficiency.	GLAXO INST MOLEC BIOL,GENEVA 674,SWITZERLAND	GlaxoSmithKline	DISANTO, JP (corresponding author), HOP NECKER ENFANTS MALAD,INSERM,U132,149 RUE SEVRES,F-75743 PARIS 15,FRANCE.		Di Santo, James P/M-4298-2014; de Saint Basile, Genevieve/G-9731-2017	Di Santo, James P/0000-0002-7146-1862; de Saint Basile, Genevieve/0000-0002-1913-5269				ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; DEVRIES JE, 1991, CURR OPIN IMMUNOL, V3, P851, DOI 10.1016/S0952-7915(05)80003-2; DISANTO JP, 1993, EUR J IMMUNOL, V23, P320, DOI 10.1002/eji.1830230203; ECK MJ, 1989, J BIOL CHEM, V264, P17595; GAUCHAT JF, 1993, FEBS LETT, V315, P259, DOI 10.1016/0014-5793(93)81175-Y; GEHA RS, 1979, J CLIN INVEST, V64, P385, DOI 10.1172/JCI109473; GOUGEON ML, 1992, J CLIN IMMUNOL, V12, P92, DOI 10.1007/BF00918138; GRAF D, 1992, EUR J IMMUNOL, V22, P3191, DOI 10.1002/eji.1830221226; GRAY PW, 1984, NATURE, V312, P721, DOI 10.1038/312721a0; HENDRIKS RW, 1990, EUR J IMMUNOL, V20, P2603, DOI 10.1002/eji.1830201212; HOLLENBAUGH D, 1992, EMBO J, V11, P4313, DOI 10.1002/j.1460-2075.1992.tb05530.x; LANE P, 1992, EUR J IMMUNOL, V22, P2573, DOI 10.1002/eji.1830221016; MALLETT S, 1991, IMMUNOL TODAY, V12, P220, DOI 10.1016/0167-5699(91)90033-P; MAYER L, 1986, NEW ENGL J MED, V314, P409, DOI 10.1056/NEJM198602133140703; MENSINK EJBM, 1987, HUM GENET, V76, P96; NOELLE RJ, 1992, IMMUNOL TODAY, V13, P431, DOI 10.1016/0167-5699(92)90068-I; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P650; NOTARANGELO L D, 1992, Immunodeficiency Reviews, V3, P101; PADAYACHEE M, 1992, GENOMICS, V14, P551, DOI 10.1016/S0888-7543(05)80270-8; WANG AM, 1985, SCIENCE, V228, P149, DOI 10.1126/science.3856324; WINSHIP PR, 1989, NUCLEIC ACIDS RES, V17, P1266, DOI 10.1093/nar/17.3.1266	21	644	661	1	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 11	1993	361	6412					541	543		10.1038/361541a0	http://dx.doi.org/10.1038/361541a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL714	8094231				2022-12-28	WOS:A1993KL71400062
J	BARRES, BA; RAFF, MC				BARRES, BA; RAFF, MC			PROLIFERATION OF OLIGODENDROCYTE PRECURSOR CELLS DEPENDS ON ELECTRICAL-ACTIVITY IN AXONS	NATURE			English	Article							CENTRAL-NERVOUS-SYSTEM; GLIAL PROGENITOR-CELL; RAT OPTIC-NERVE; NEURONS; CHAIN; PDGF; LOCALIZATION; TETRODOTOXIN	OLIGODENDROCYTES myelinate axons in the vertebrate central nervous system. It would, therefore, make sense if axons played a part in controlling the number of oligodendrocytes that develop in a myelinated tract. Although oligodendrocytes themselves normally do not divide, the precursor cells that give rise to them do. Here we show that the proliferation of oligodendrocyte precursor cells in the developing rat optic nerve depends on electrical activity in neighbouring axons, and that this activity-dependence can be circumvented by experimentally increasing the concentration of platelet-derived growth factor, which is present in the optic nerve and stimulates these cells to proliferate in culture. These findings suggest that axonal electrical activity normally controls the production and/or release of the growth factors that are responsible for proliferation of oligodendrocyte precursor cells and thereby helps to control the number of oligodendrocytes that develop in the region.			BARRES, BA (corresponding author), UNIV LONDON UNIV COLL,DEPT BIOL,MRC,DEV NEUROBIOL PROGRAMME,MEDAWAR BLDG,LONDON WC1E 6BT,ENGLAND.		Messier, Claude/A-2322-2008	Messier, Claude/0000-0002-4791-1763				ANDERTON BH, 1980, J NEUROCYTOL, V9, P835, DOI 10.1007/BF01205022; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; BARRES BA, 1990, NEURON, V4, P507, DOI 10.1016/0896-6273(90)90109-S; CURRIE J, 1974, J COMP NEUROL, V156, P123, DOI 10.1002/cne.901560202; DELONG GR, 1962, J COMP NEUROL, V118, P205, DOI 10.1002/cne.901180207; EISENBARTH GS, 1979, P NATL ACAD SCI USA, V76, P4913, DOI 10.1073/pnas.76.10.4913; FRIEDMAN S, 1990, EUR J NEUROSCI, V2, P243, DOI 10.1111/j.1460-9568.1990.tb00416.x; GRATZNER HG, 1982, SCIENCE, V218, P474, DOI 10.1126/science.7123245; GYLLENSTEN L, 1963, J EMBRYOL EXP MORPH, V11, P255; MAGUAD JP, 1988, J IMMUNOL METHODS, V106, P95; ORKAND RK, 1966, J NEUROPHYSIOL, V29, P788, DOI 10.1152/jn.1966.29.4.788; PERRY VH, 1991, EUR J NEUROSCI, V3, P102, DOI 10.1111/j.1460-9568.1991.tb00815.x; PERRY VH, 1992, BIOESSAYS, V14, P401, DOI 10.1002/bies.950140610; PRINGLE N, 1989, EMBO J, V8, P1049, DOI 10.1002/j.1460-2075.1989.tb03472.x; RAFF MC, 1983, NATURE, V303, P390, DOI 10.1038/303390a0; RASMINSKY M, 1972, J PHYSIOL-LONDON, V227, P323, DOI 10.1113/jphysiol.1972.sp010035; RICCIO RV, 1985, NEUROSCIENCE, V16, P1027, DOI 10.1016/0306-4522(85)90113-7; RICHARDSON WD, 1988, CELL, V53, P309, DOI 10.1016/0092-8674(88)90392-3; SALZER JL, 1980, J CELL BIOL, V84, P767, DOI 10.1083/jcb.84.3.767; SASAHARA M, 1991, CELL, V64, P217, DOI 10.1016/0092-8674(91)90223-L; TAUBER H, 1980, NEUROSCI LETT, V16, P235, DOI 10.1016/0304-3940(80)90003-8; WEINREICH D, 1975, BRAIN RES, V84, P137, DOI 10.1016/0006-8993(75)90807-0; WHEELER DD, 1966, J CELL PHYSIOL, V67, P141, DOI 10.1002/jcp.1040670116; YEH HJ, 1991, CELL, V64, P209, DOI 10.1016/0092-8674(91)90222-K	24	477	494	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 21	1993	361	6409					258	260		10.1038/361258a0	http://dx.doi.org/10.1038/361258a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KH614	8093806				2022-12-28	WOS:A1993KH61400059
J	BONITA, R				BONITA, R			CARDIOVASCULAR-DISEASE - CARDIOVASCULAR-DISEASE IN OKINAWA	LANCET			English	Editorial Material							HEART-DISEASE; RISK-FACTORS; JAPAN; STROKE				BONITA, R (corresponding author), UNIV AUCKLAND,DEPT MED,AUCKLAND,NEW ZEALAND.							BLACKBURN H, 1989, CIRCULATION, V79, P718, DOI 10.1161/01.CIR.79.3.718; BONITA R, 1990, STROKE, V21, P989, DOI 10.1161/01.STR.21.7.989; KINJO K, 1991, HYPERTENS RES, V15, P111; MARMOT MG, 1989, BRIT MED J, V299, P1547, DOI 10.1136/bmj.299.6715.1547; SHI FL, 1989, STROKE, V20, P1581, DOI 10.1161/01.STR.20.11.1581; SHIMAMOTO T, 1989, CIRCULATION, V79, P503, DOI 10.1161/01.CIR.79.3.503; SUZUKI K, 1987, STROKE, V18, P402, DOI 10.1161/01.STR.18.2.402; TANAKA H, 1981, STROKE, V12, P460, DOI 10.1161/01.STR.12.4.460; UEDA K, 1981, STROKE, V12, P154, DOI 10.1161/01.STR.12.2.154; UESHIMA H, 1987, AM J EPIDEMIOL, V125, P62, DOI 10.1093/oxfordjournals.aje.a114512	10	5	5	2	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 8	1993	341	8854					1185	1185		10.1016/0140-6736(93)91007-9	http://dx.doi.org/10.1016/0140-6736(93)91007-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB017	8098080				2022-12-28	WOS:A1993LB01700009
J	NOSTEN, F; TERKUILE, FO; LUXEMBURGER, C; WOODROW, C; KYLE, DE; CHONGSUPHAJAISIDDHI, T; WHITE, NJ				NOSTEN, F; TERKUILE, FO; LUXEMBURGER, C; WOODROW, C; KYLE, DE; CHONGSUPHAJAISIDDHI, T; WHITE, NJ			CARDIAC EFFECTS OF ANTIMALARIAL TREATMENT WITH HALOFANTRINE	LANCET			English	Note								In a prospective electrocardiographic study of Karen patients with acute uncomplicated falciparum malaria, mefloquine (25 mg/kg) had no cardiac effects (n = 53), but halofantrine (72 mg/kg) induced consistent dose-related lengthening of the PR and QT intervals in all 61 patients treated. The likelihood of significant QTc prolongation (by more than 25% or a QTc of 0.55 s1/2 or more) was greater after halofantrine as retreatment following mefloquine failure than as primary treatment (7/10 vs 18/51; relative risk 2.0 [95% Cl 1.1-3.4], p = 0.04). More than 60% of the effect occurred with three doses of halofantrine (24 mg/kg). The arrhythmogenic potential of halofantrine should now be investigated.	MAHIDOL UNIV,FAC TROP MED,420-6 RAJKVITHI RD,BANGKOK 10400,THAILAND; SHOKLO MALARIA RES UNIT,MAE SOT,THAILAND; UNIV AMSTERDAM,ACAD MED CTR,INFECT DIS & TROP MED UNIT,1105 AZ AMSTERDAM,NETHERLANDS; US ARMED FORCES RES INST MED SCI,BANGKOK,THAILAND; JOHN RADCLIFFE HOSP,NUFFIELD DEPT MED,OXFORD OX3 9DU,ENGLAND	Mahidol University; Mahidol University; University of Amsterdam; Academic Medical Center Amsterdam; Walter Reed Army Institute of Research (WRAIR); Armed Forces Research Institute of Medical Science (AFRIMS); University of Oxford			Nosten, Francois/AAC-5509-2019; Kuile, Feiko ter/ABD-6681-2020; White, Nicholas J/I-4629-2012; White, Nick/AAC-6527-2019	Nosten, Francois/0000-0002-7951-0745; Kuile, Feiko ter/0000-0003-3663-5617; White, Nick/0000-0002-1897-1978; Kyle, Dennis/0000-0002-0238-965X; Woodrow, Charles/0000-0002-5134-7165	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		HASHIBA K, 1991, ANN NEW YORK ACAD S, V664, P1; KARBWANG J, 1990, CLIN PHARMACOKINET, V19, P264, DOI 10.2165/00003088-199019040-00002; KEERATITHAKUL D, 1991, THER DRUG MONIT, V13, P64, DOI 10.1097/00007691-199101000-00009; LAOTHAVORN P, 1992, Southeast Asian Journal of Tropical Medicine and Public Health, V23, P51; MILLER KD, 1989, NEW ENGL J MED, V321, P65, DOI 10.1056/NEJM198907133210201; MUNGER RG, 1991, LANCET, V338, P280, DOI 10.1016/0140-6736(91)90419-P; SHANKS GD, 1992, T ROY SOC TROP MED H, V86, P233, DOI 10.1016/0035-9203(92)90286-L; TERKUILE FO, 1993, LANCET, V341, P1044, DOI 10.1016/0140-6736(93)92409-M; 1990, T R SOC TROP MED S2, V84, P1	9	238	239	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 24	1993	341	8852					1054	1056		10.1016/0140-6736(93)92412-M	http://dx.doi.org/10.1016/0140-6736(93)92412-M			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ018	8096959				2022-12-28	WOS:A1993KZ01800005
J	SCOTT, P				SCOTT, P			IL-12 - INITIATION CYTOKINE FOR CELL-MEDIATED-IMMUNITY	SCIENCE			English	Editorial Material							INTERFERON-GAMMA; CUTANEOUS LEISHMANIASIS; MURINE LEISHMANIASIS; STIMULATORY FACTOR; SUBSETS; INTERLEUKIN-4; PURIFICATION				SCOTT, P (corresponding author), UNIV PENN,SCH VET MED,3800 SPRUCE ST,PHILADELPHIA,PA 19104, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030073] Funding Source: NIH RePORTER; NIAID NIH HHS [AI30073] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CHAN SH, 1991, J EXP MED, V173, P869, DOI 10.1084/jem.173.4.869; CHATELAIN R, 1992, J IMMUNOL, V148, P1182; CHEHIMI J, 1992, J EXP MED, V175, P789, DOI 10.1084/jem.175.3.789; CLERICI M, 1993, IMMUNOL TODAY, V14, P107, DOI 10.1016/0167-5699(93)90208-3; DANDREA A, 1992, J EXP MED, V176, P1387, DOI 10.1084/jem.176.5.1387; GAZZINELLI RT, 1993, J IMMUNOL, V150, pA86; HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59; HSIEH CS, 1992, P NATL ACAD SCI USA, V89, P6065, DOI 10.1073/pnas.89.13.6065; KOBAYASHI M, 1989, J EXP MED, V170, P827, DOI 10.1084/jem.170.3.827; LEGROS G, 1990, J EXP MED, V172, P921, DOI 10.1084/jem.172.3.921; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; SADICK MD, 1990, J EXP MED, V171, P115, DOI 10.1084/jem.171.1.115; SCOTT P, 1988, J EXP MED, V168, P1675, DOI 10.1084/jem.168.5.1675; SCOTT P, 1991, IMMUNOL TODAY, V12, P346, DOI 10.1016/0167-5699(91)90063-Y; SCOTT P, 1991, J IMMUNOL, V147, P3149; SCOTT P, 1993, J IMMUNOL, V150, pA86; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; STERN AS, 1990, P NATL ACAD SCI USA, V87, P6808, DOI 10.1073/pnas.87.17.6808; SWAIN SL, 1990, J IMMUNOL, V145, P3796; TRICHIERI G, IN PRESS PROG GROWTH; 1991, IMMUNOL REV, V123	22	548	573	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 23	1993	260	5107					496	497		10.1126/science.8097337	http://dx.doi.org/10.1126/science.8097337			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KY504	8097337				2022-12-28	WOS:A1993KY50400020
J	BURNS, A				BURNS, A			BRAIN IMAGING - COMPUTED-TOMOGRAPHY IN ALZHEIMERS-DISEASE	LANCET			English	Editorial Material							DEMENTIA				BURNS, A (corresponding author), UNIV MANCHESTER,SCH PSYCHIAT & BEHAV SCI,MANCHESTER M13 9PL,LANCS,ENGLAND.			Burns, Alistair/0000-0002-9837-0645				BURNS A, 1991, BRIT J PSYCHIAT, V159, P609, DOI 10.1192/bjp.159.5.609; BURNS A, 1991, BIOL PSYCHIAT, V29, P383, DOI 10.1016/0006-3223(91)90224-A; DECARLI C, 1990, NEUROLOGY, V40, P872, DOI 10.1212/WNL.40.6.872; DELEON MJ, 1993, LANCET, V341, P125, DOI 10.1016/0140-6736(93)92610-6; JACOBY RJ, 1980, BRIT J PSYCHIAT, V136, P256, DOI 10.1192/bjp.136.3.256; JOBST KA, 1992, LANCET, V340, P1179; LUXENBERG JS, 1987, NEUROLOGY, V37, P1135, DOI 10.1212/WNL.37.7.1135	7	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 6	1993	341	8845					601	602		10.1016/0140-6736(93)90360-S	http://dx.doi.org/10.1016/0140-6736(93)90360-S			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KQ234	8094836				2022-12-28	WOS:A1993KQ23400012
J	BYRN, C; OLSSON, I; FALKHEDEN, L; LINDH, M; HOSTEREY, U; FOGELBERG, M; LINDER, LE; BUNKETORP, O				BYRN, C; OLSSON, I; FALKHEDEN, L; LINDH, M; HOSTEREY, U; FOGELBERG, M; LINDER, LE; BUNKETORP, O			SUBCUTANEOUS STERILE WATER INJECTIONS FOR CHRONIC NECK AND SHOULDER PAIN FOLLOWING WHIPLASH INJURIES	LANCET			English	Article							LOW-BACK-PAIN; CONVERGENT NEURONS; MYOFASCIAL PAIN; STIMULATION; THERAPY; RELIEF; RAT	In many cases of whiplash injury symptoms persist and do not respond to treatment. There is uncontrolled evidence to suggest that intracutaneous injections of sterile water might help. Since that route may be unacceptable to patients the subcutaneous route is used in the randomised trial reported here. 40 patients with whiplash syndrome, mean age 46 years (24-73) were given subcutaneous injections of 0.3-0.5 ml sterile water or saline over tender and trigger points in the neck and shoulder. A maximum of three treatments were given during the first two months of the study and the patients were followed up for 8 months. The accidents had occurred 4-6 years previously. X-ray examinations revealed no traumatic spinal lesions. Neck mobility and pain levels were evaluated by a physiotherapist immediately before and after the first treatment and after 1, 3, and 8 months. After 3 months, the mean total mobility of the cervical spine had increased by 39-degrees in the sterile water group and 6-degrees in the saline group (p<0.05). Minimum and maximum levels of pain in the weeks just before treatment were evaluated by a visual analogue scale from 0 to 10. After 3 months the minimum pain level had fallen from 2.2 to 1.4 in the sterile water group but was not reduced in the saline group (p<0.02); the maximum had fallen from 8.1 to 3.8 in the sterile water group and from 8.3 to 7.5 in the saline group (p<0.001). After 3 months, 19 of 20 patients in the sterile water group assessed their condition as generally improved but only 6 in the saline group felt that they had got better. After 8 months there were still significant differences for minimum pain score and for mobility but not for maximum pain or for self-assessment of improvement.	LUNDBY HOSP, DEPT NEUROL, GOTHENBURG, SWEDEN; GOTHENBURG UNIV, E HOSP, DEPT ORTHOPAED, TRAFF INJURY REGISTER, S-41124 GOTHENBURG, SWEDEN; GOTHENBURG UNIV, SAHLGRENS HOSP, DEPT PSYCHIAT, S-41345 GOTHENBURG, SWEDEN; BACK HLTH, GOTHENBURG, SWEDEN	University of Gothenburg; Sahlgrenska University Hospital; University of Gothenburg	BYRN, C (corresponding author), GOTHENBURG UNIV, SAHLGRENS HOSP, DEPT ANAESTHESIA, S-41345 GOTHENBURG, SWEDEN.							BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BENGSTSSON J, 1981, UGESKRIFT LAEGER, V15, P3463; BONICA JJ, 1957, JAMA-J AM MED ASSOC, V164, P732, DOI 10.1001/jama.1957.02980070014003; BYRN C, 1991, ACTA ANAESTH SCAND, V35, P52, DOI 10.1111/j.1399-6576.1991.tb03240.x; Costa P.T., 1985, NEO PERSONALITY INVE; CROWE HE, 1928, M W ORTHOPEDIC ASS; FROST A, 1986, SCAND J RHEUMATOL, V15, P153, DOI 10.3109/03009748609102082; FROST FA, 1980, LANCET, V1, P499; Gammon GD, 1941, J CLIN INVEST, V20, P13, DOI 10.1172/JCI101190; GARVEY TA, 1989, SPINE, V14, P962, DOI 10.1097/00007632-198909000-00008; LEBARS D, 1979, PAIN, V6, P305, DOI 10.1016/0304-3959(79)90050-2; LEBARS D, 1979, PAIN, V6, P283, DOI 10.1016/0304-3959(79)90049-6; LYTZEN T, 1989, ACTA OBSTET GYN SCAN, V68, P341, DOI 10.3109/00016348909028669; MELZACK R, 1975, PAIN, V1, P357, DOI 10.1016/0304-3959(75)90073-1; ODENT M, 1975, NOUV PRESSE MED, V4, P188; OLSSON I, 1988, P VAGOCH TRAFIKDEKMI, P111; PARSONS CM, 1945, P SOC EXP BIOL MED, V60, P327; RAJ PP, 1986, PRACTICAL MANAGEMENT, P575; SJOBERG L, 1979, SCAND J PSYCHOL, V20, P1, DOI 10.1111/j.1467-9450.1979.tb00677.x; Spielberger C.D., 1972, ANXIETY CURRENT TREN; Travell JG, 1983, MYOFASCIAL PAIN DYSF; TROLLE GB, 1986, UGESKRIFT LAEGER, V20, P1200; WOOLF CJ, 1986, J NEUROSCI, V6, P1433	23	54	58	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 20	1993	341	8843					449	452		10.1016/0140-6736(93)90204-T	http://dx.doi.org/10.1016/0140-6736(93)90204-T			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN137	8094485				2022-12-28	WOS:A1993KN13700001
J	EVANS, I				EVANS, I			NEUROSCIENCE - NO COWORKER	LANCET			English	Editorial Material																		EWING JF, 1992, MOL CELL NEUROSCI, V3, P559, DOI 10.1016/1044-7431(92)90068-D; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352	2	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 13	1993	341	8842					414	414		10.1016/0140-6736(93)93001-H	http://dx.doi.org/10.1016/0140-6736(93)93001-H			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM416	8094181				2022-12-28	WOS:A1993KM41600016
J	SHAM, MH; VESQUE, C; NONCHEV, S; MARSHALL, H; FRAIN, M; DASGUPTA, R; WHITING, J; WILKINSON, D; CHARNAY, P; KRUMLAUF, R				SHAM, MH; VESQUE, C; NONCHEV, S; MARSHALL, H; FRAIN, M; DASGUPTA, R; WHITING, J; WILKINSON, D; CHARNAY, P; KRUMLAUF, R			THE ZINC FINGER GENE KROX20 REGULATES HOXB2 (HOX2.8) DURING HINDBRAIN SEGMENTATION	CELL			English	Article							HOMEOBOX-CONTAINING GENES; CRANIAL NEURAL CREST; DNA-BINDING DOMAINS; RETINOIC ACID; TRANSCRIPTIONAL ACTIVATOR; EXPRESSION PATTERN; VERTEBRATE HEAD; MOUSE HINDBRAIN; CULTURED-CELLS; NERVOUS-SYSTEM	The zinc finger gene Krox20 and many Hox homeobox genes are expressed in segment-restricted domains in the hindbrain. The restricted expression patterns appear before morphological segmentation, suggesting that these transcription factors may play an early role in the establishment and identity of rhombomeric segments. In this paper, we show that the HoxB2 (Hox2.8) gene is normally upregulated in rhombomeres (r) 3, 4, and 5, and we identify an enhancer region upstream of the gene that imposes r3/r5 expression in transgenic mice. This enhancer contains three Krox20-binding sites required in vitro for complex formation with Krox20 protein and in vivo for rhombomere-restricted expression. In transgenic mice, Krox20 expressed in ectopic domains can transactivate a reporter construct containing the HoxB2 r3/r5 enhancer. These data demonstrate that Krox20 is a part of the upstream transcriptional cascade that directly regulates HoxB2 expression during hindbrain segmentation.	ECOLE NORM SUPER,GENET MOLEC LAB,CNRS,URA 1302,F-75230 PARIS 05,FRANCE	Centre National de la Recherche Scientifique (CNRS)	SHAM, MH (corresponding author), NATL INST MED RES,MRC,EUKARYOT MOLEC GENET LAB,RIDGEWAY,MILL HILL,LONDON NW7 1AA,ENGLAND.		Vesque, Christine/L-9839-2017; Vesque, Christine/Q-8461-2019; Sham, Mai Har/AAX-3781-2020; Krumlauf, Robb/AAH-5012-2019	Sham, Mai Har/0000-0003-1179-7839; Krumlauf, Robb/0000-0001-9102-7927; Vesque, Christine/0000-0001-7983-4953; Charnay, Patrick/0000-0002-3847-6042	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AKAM M, 1987, DEVELOPMENT, V101, P1; AWGULEWITSCH A, 1992, NATURE, V358, P341, DOI 10.1038/358341a0; BALLING R, 1989, CELL, V58, P337, DOI 10.1016/0092-8674(89)90848-9; BONCINELLI E, 1991, TRENDS GENET, V7, P329, DOI 10.1016/0168-9525(91)90423-N; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHAVRIER P, 1990, EMBO J, V9, P1209, DOI 10.1002/j.1460-2075.1990.tb08228.x; CHISAKA O, 1992, NATURE, V355, P516, DOI 10.1038/355516a0; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; CONLON RA, 1992, DEVELOPMENT, V116, P357; CROSBY SD, 1991, MOL CELL BIOL, V11, P3835, DOI 10.1128/MCB.11.8.3835; FRASER S, 1990, NATURE, V344, P431, DOI 10.1038/344431a0; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; GALLIOT B, 1989, DEVELOPMENT, V107, P343; GILARDI P, 1991, BIOCHIMIE, V73, P85, DOI 10.1016/0300-9084(91)90079-G; GILARDIHEBENSTREIT P, 1992, ONCOGENE, V7, P2499; GREENBERG JM, 1990, NATURE, V344, P158, DOI 10.1038/344158a0; HOGAN B, 1986, MANIPULATING MOUSE E; HUNT P, 1991, CELL, V66, P1075, DOI 10.1016/0092-8674(91)90029-X; HUNT P, 1992, ANNU REV CELL BIOL, V8, P227, DOI 10.1146/annurev.cb.08.110192.001303; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; HUNT P, 1991, DEVELOPMENT, V112, P43; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KESSEL M, 1990, CELL, V61, P301, DOI 10.1016/0092-8674(90)90810-2; KRAUSS S, 1991, DEVELOPMENT, V113, P1193; KRAUSS S, 1991, NATURE, V353, P267, DOI 10.1038/353267a0; KRUMLAUF R, 1992, BIOESSAYS, V14, P245, DOI 10.1002/bies.950140408; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Le Douarin N., 1999, DEV CELL BIOL SERIES, V2nd, DOI [10.1017/CBO9780511897948, DOI 10.1017/CBO9780511897948, 10.1017/cbo9780511897948]; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LEMAIRE P, 1990, THESIS U PARIS 6 PAR; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; LUMSDEN A, 1990, TRENDS NEUROSCI, V13, P329, DOI 10.1016/0166-2236(90)90144-Y; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; LUMSDEN A, 1991, DEVELOPMENT, V113, P1281; Lumsden A.G.S., 1990, Seminars in Developmental Biology, V1, P117; MADEN M, 1992, MECH DEVELOP, V37, P13, DOI 10.1016/0925-4773(92)90011-8; MADEN M, 1991, DEVELOPMENT, V111, P35; MALICKI J, 1992, NATURE, V358, P345, DOI 10.1038/358345a0; MCGINNIS N, 1990, CELL, V63, P969, DOI 10.1016/0092-8674(90)90500-E; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MORRISSKAY G, 1987, TRENDS GENET, V3, P257, DOI 10.1016/0168-9525(87)90260-5; MORRISSKAY G, 1991, SEMINARS DEV BIOL, V2, P211; MURPHY P, 1989, NATURE, V341, P156, DOI 10.1038/341156a0; MURPHY P, 1991, DEVELOPMENT, V111, P61; NARDELLI J, 1992, NUCLEIC ACIDS RES, V20, P4137, DOI 10.1093/nar/20.16.4137; NARDELLI J, 1991, NATURE, V349, P175, DOI 10.1038/349175a0; NIETO MA, 1992, DEVELOPMENT, V116, P1137; NODEN DM, 1983, DEV BIOL, V96, P144, DOI 10.1016/0012-1606(83)90318-4; NODEN DM, 1988, DEVELOPMENT, V103, P121; PATWARDHAN S, 1991, ONCOGENE, V6, P917; REGULSKI M, 1987, EMBO J, V6, P767, DOI 10.1002/j.1460-2075.1987.tb04819.x; REGULSKI M, 1991, GENE DEV, V5, P278, DOI 10.1101/gad.5.2.278; RUBERTE E, 1991, DEVELOPMENT, V111, P45; SCOTT MP, 1992, CELL, V71, P551, DOI 10.1016/0092-8674(92)90588-4; SECHRIST J, 1992, IN PRESS DEVELOPMENT, V116; SERBEDZIJA GN, 1992, DEVELOPMENT, V116, P297; SHAM MH, 1992, EMBO J, V11, P1825, DOI 10.1002/j.1460-2075.1992.tb05234.x; SMITH SM, 1991, DEVELOPMENT, V111, P245; SUNDIN OH, 1990, GENE DEV, V4, P1267, DOI 10.1101/gad.4.8.1267; VESQUE C, 1992, NUCLEIC ACIDS RES, V20, P2485, DOI 10.1093/nar/20.10.2485; WHITING J, 1991, GENE DEV, V5, P2048, DOI 10.1101/gad.5.11.2048; Wilkinson D. G., 1990, POSTIMPLANTATION MAM, P155; WILKINSON DG, 1990, TRENDS NEUROSCI, V13, P335, DOI 10.1016/0166-2236(90)90145-Z; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x; WILKINSON DG, 1989, NATURE, V337, P461, DOI 10.1038/337461a0; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; WILKINSON DG, 1990, SEMINARS DEV BIOL, V1, P127	69	289	289	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 29	1993	72	2					183	196		10.1016/0092-8674(93)90659-E	http://dx.doi.org/10.1016/0092-8674(93)90659-E			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KK038	8093858				2022-12-28	WOS:A1993KK03800004
J	AREND, WP				AREND, WP			INTERLEUKINS AND ARTHRITIS - IL-1 ANTAGONISM IN INFLAMMATORY ARTHRITIS	LANCET			English	Editorial Material											AREND, WP (corresponding author), UNIV COLORADO,HLTH SCI CTR,DIV RHEUMATOL,DENVER,CO 80262, USA.							AREND WP, 1991, J CLIN INVEST, V88, P1445, DOI 10.1172/JCI115453; DINARELLO CA, 1991, BLOOD, V77, P1627; FIRESTEIN GS, 1992, J IMMUNOL, V149, P1054; MALYAK M, IN PRESS ARTHRITIS R	4	20	21	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 16	1993	341	8838					155	156		10.1016/0140-6736(93)90014-8	http://dx.doi.org/10.1016/0140-6736(93)90014-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG627	8093754				2022-12-28	WOS:A1993KG62700014
J	GREENWOOD, D				GREENWOOD, D			HONEY FOR SUPERFICIAL WOUNDS AND ULCERS	LANCET			English	Editorial Material											GREENWOOD, D (corresponding author), UNIV NOTTINGHAM HOSP,DEPT MICROBIOL,NOTTINGHAM NG7 2UH,ENGLAND.							ALLEN KL, 1991, J PHARM PHARMACOL, V43, P817, DOI 10.1111/j.2042-7158.1991.tb03186.x; CHIRIFE J, 1982, LANCET, V1, P560; Milne A. A., 1926, WINNIE THE POOH; WILLIX DJ, 1992, J APPL BACTERIOL, V73, P388, DOI 10.1111/j.1365-2672.1992.tb04993.x; ZUMLA A, 1989, J ROY SOC MED, V82, P374	5	25	29	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 9	1993	341	8837					90	91		10.1016/0140-6736(93)92564-A	http://dx.doi.org/10.1016/0140-6736(93)92564-A			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF870	8093411				2022-12-28	WOS:A1993KF87000011
J	COYTE, PC; WRIGHT, JG; HAWKER, GA; BOMBARDIER, C; DITTUS, RS; PAUL, JE; FREUND, DA; HO, E				COYTE, PC; WRIGHT, JG; HAWKER, GA; BOMBARDIER, C; DITTUS, RS; PAUL, JE; FREUND, DA; HO, E			WAITING-TIMES FOR KNEE-REPLACEMENT SURGERY IN THE UNITED-STATES AND ONTARIO	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CANADIAN HEALTH-CARE; SYSTEM; LISTS	Background. Canada, which has universal single-payer health insurance, is often criticized for waiting times for surgery that are longer than those in the United States. We compared waiting times for orthopedic consultations and knee-replacement surgery and patients' acceptance of them in the United States and in the province of Ontario, Canada. Methods. A stratified random sample of 1486 Medicare recipients (629 from the U.S. national sample, 428 from Indiana, and 429 from western Pennsylvania) and 516 people from Ontario who had been hospitalized for knee replacement between 1985 and 1989 were surveyed by mail in 1992. Patients were asked how long they had waited to see an orthopedic surgeon and to have surgery, the acceptability of these waiting times, and their overall satisfaction with surgery. Results. About 80 percent of the questionnaires were returned, but ndt all the respondents answered all the questions. The rate of response to specific questions was about 60 to 65 percent in both countries. The median waiting time for an initial orthopedic consultation was two weeks in the United States and four weeks in Ontario. The median waiting time for knee replacement after the operation had been planned was three weeks in the United States and eight weeks in Canada, In the United States, 95 percent of patients in the national sample considered their waiting time for surgery acceptable, as compared with 85.1 percent in Ontario, Overall satisfaction with surgery (''very or somewhat satisfied'') was 85.3 percent for all U.S. respondents and 83.5 percent for Canadian respondents. Conclusions. Waiting times for initial orthopedic consultation and for knee-replacement surgery were longer in Ontario than in the United States, but overall satisfaction with surgery was similar.	UNIV TORONTO,INST POLICY ANAL,TORONTO,ON,CANADA; SUNNYBROOK HLTH SCI CTR,INST CLIN EVALUAT SCI,TORONTO,ON,CANADA; HEARING HLTH CARE RES UNIT,TORONTO,ON,CANADA; HOSP SICK CHILDREN,DEPT SURG,DIV ORTHOPAED & CLIN EPIDEMIOL,TORONTO M5G 1X8,ON,CANADA; WOMENS COLL HOSP,DEPT MED,DIV RHEUMATOL,TORONTO,ON,CANADA; WELLESLEY COLL HOSP,DEPT MED,DIV RHEUMATOL,TORONTO M4Y 1J3,ON,CANADA; REGENSTRIEF INST HLTH CARE,DEPT MED,DIV GEN INTERNAL MED,INDIANAPOLIS,IN; RICHARD L ROUDEBUSH VET AFFAIRS MED CTR,INDIANAPOLIS,IN 46202; INDIANA UNIV,BOWEN RES CTR,INDIANAPOLIS,IN; RES TRIANGLE INST,RES TRIANGLE PK,NC 27709	University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Womens College Hospital; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; Indiana University System; Indiana University-Purdue University Indianapolis; Regenstrief Institute Inc; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center; Indiana University System; Indiana University-Purdue University Indianapolis; Research Triangle Institute	COYTE, PC (corresponding author), UNIV TORONTO,FAC MED,DEPT HLTH ADM,2ND FL,MCMURRICH BLDG,12 QUEENS PK CRES W,TORONTO M5S 1A8,ON,CANADA.				PHS HHS [6432] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BLOOM BS, 1987, MED CARE, V25, P131, DOI 10.1097/00005650-198702000-00006; Cox DR., 1989, ANAL BINARY DATA; DRAPER NR, 1981, APPLIED REGRESSION A; EVANS RG, 1989, NEW ENGL J MED, V320, P571, DOI 10.1056/NEJM198903023200906; GLOBERMAN S, 1991, J POLICY ANAL MANAG, V10, P247, DOI 10.2307/3325174; GLOBERMAN S, 1990, FRASER FORUM CRITICA, P5; GOLDACRE MJ, 1987, BRIT MED J, V295, P1105, DOI 10.1136/bmj.295.6606.1105; HARRIS WH, 1990, NEW ENGL J MED, V323, P801, DOI 10.1056/NEJM199009203231206; HAWKER GA, 1993, THESIS U TORONTO TOR; IGLEHART JK, 1989, NEW ENGL J MED, V321, P1767, DOI 10.1056/NEJM198912213212527; JESSEN RJ, 1978, STATISTICAL SURVEY T; KATZ SJ, 1991, JAMA-J AM MED ASSOC, V266, P1108, DOI 10.1001/jama.266.8.1108; Korcok M, 1978, Can Med Assoc J, V119, P1453; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; LINTON AL, 1990, NEW ENGL J MED, V322, P197, DOI 10.1056/NEJM199001183220311; McClave JT, 1985, STATISTICS-ABINGDON, V3rd; MORRIS AL, 1990, MED CARE, V28, P784, DOI 10.1097/00005650-199009000-00008; NAYLOR CD, 1992, CHEST, V101, P715, DOI 10.1378/chest.101.3.715; NAYLOR CD, 1991, HEALTH AFFAIR, V10, P110, DOI 10.1377/hlthaff.10.3.110; SCHWARTZ WB, 1984, NEW ENGL J MED, V310, P52, DOI 10.1056/NEJM198401053100120; SHAMESS B, 1992, CAN MED ASSOC J, V146, P2046; SHORT PF, 1988, UNINSURED AM 1987 PR; VAYDA E, 1989, Journal of Public Health Policy, V10, P359, DOI 10.2307/3342797; Walker M A, 1989, Health Manage Q, V11, P11; YOUNG WW, 1984, HLTH CARE FINANC R S, V5, P23; 1990, HOSPITAL STATISTICS; 1989, AM HOSPITAL ASS GUID	27	78	79	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 20	1994	331	16					1068	1071		10.1056/NEJM199410203311607	http://dx.doi.org/10.1056/NEJM199410203311607			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL560	8090168				2022-12-28	WOS:A1994PL56000007
J	FISCHL, MA; OLSON, RM; FOLLANSBEE, SE; LALEZARI, JP; HENRY, DH; FRAME, PT; REMICK, SC; SALGO, MP; LIN, AH; NAUSSKAROL, C; LIEBERMAN, J; SOO, WJ				FISCHL, MA; OLSON, RM; FOLLANSBEE, SE; LALEZARI, JP; HENRY, DH; FRAME, PT; REMICK, SC; SALGO, MP; LIN, AH; NAUSSKAROL, C; LIEBERMAN, J; SOO, WJ			ZALCITABINE COMPARED WITH ZIDOVUDINE IN PATIENTS WITH ADVANCED HIV-1 INFECTION WHO RECEIVED PREVIOUS ZIDOVUDINE THERAPY	ANNALS OF INTERNAL MEDICINE			English	Article						ZIDOVUDINE; ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS-RELATED COMPLEX; DIDEOXYCYTIDINE; HIV-1	HUMAN-IMMUNODEFICIENCY-VIRUS; AIDS-RELATED COMPLEX; PLACEBO-CONTROLLED TRIAL; PHASE-I TRIAL; DOUBLE-BLIND; 2',3'-DIDEOXYINOSINE DDI; AZIDOTHYMIDINE AZT; ACYCLOVIR; SUSCEPTIBILITIES; EFFICACY	Objective: To evaluate the safety and efficacy of zalcitabine (also known as dideoxycytidine [ddC]) in patients with advanced human immunodeficiency virus (HIV) infection. Design: Open-label, randomized study. Setting: AIDS Clinical Trials Units, university-affiliated medical centers, and private practice groups. Patients: Patients with the acquired immunodeficiency syndrome (AIDS) or advanced AIDS-related complex who had tolerated zidovudine for 48 weeks or more. Intervention: Fifty-nine patients received zidovudine (500 to 1200 mg/d) and 52 patients received zalcitabine (2.25 mg/d). Measurements: The primary end points were survival and time to an AIDS-defining event or death. Results: Because significantly more patients withdrew from zidovudine therapy, the median duration of treatment was greater in the zalcitabine group than in the zidovudine group (279.0 days compared with 174.5 days; P = 0.001). The estimated 12-month, event-free probabilities were 53% for the zalcitabine group and 57% for the zidovudine group (relative risk, 1.02; 95% CI, 0.5 to 2.2). The estimated 12-month survival rates were 81% for the zalcitabine group and 75% for the zidovudine group (relative risk, 1.39; CI, 0.5 to 3.8). The rate of decline in CD4 lymphocyte counts was significantly slower in the zalcitabine group than in the zidovudine group (-0.08 cells/day compared with -0.17 cells/day). Patients in the zalcitabine group had gained an average of 0.5 kg at week 20 and 0.4 kg at week 24, whereas patients in the zidovudine group had lost an average of 1.8 kg at week 20 and 2.4 kg at week 24 (P = 0.04 and P = 0.05, respectively). Moderate to severe peripheral neuropathy and ulcerative stomatitis occurred in 10 and 9 patients, respectively, in the zalcitabine group. Conclusions: The sample size for this study was smaller than planned, and no differences in survival and clinical end points were found. Slower rates of decline in CD4 lymphocyte counts and weight, however, were noted for the zalcitabine group.	OAKLAWN PHYSICIANS GRP, DALLAS, TX 75219 USA; DAVIES MED CTR, SAN FRANCISCO, CA USA; UNIV CALIF SAN FRANCISCO, MT ZION HOSP & MED CTR, SAN FRANCISCO, CA 94143 USA; GRAD HOSP PHILADELPHIA, PHILADELPHIA, PA 19146 USA; UNIV CINCINNATI, MED CTR, CINCINNATI, OH 45267 USA	California Pacific Medical Center; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Medical Center at Mount Zion; University of Pennsylvania; Pennsylvania Medicine; University System of Ohio; University of Cincinnati	FISCHL, MA (corresponding author), UNIV MIAMI, SCH MED, DEPT MED, R-60A, POB 016960, MIAMI, FL 33101 USA.		Henry, David/AAU-4650-2020	Henry, David/0000-0001-7169-7704				COOLEY TP, 1990, NEW ENGL J MED, V322, P1340, DOI 10.1056/NEJM199005103221902; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; CRUMPACKER CS, 1982, NEW ENGL J MED, V306, P343, DOI 10.1056/NEJM198202113060606; ERLICH KS, 1989, NEW ENGL J MED, V320, P293, DOI 10.1056/NEJM198902023200506; FISCHL MA, 1989, JAMA-J AM MED ASSOC, V262, P2405; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FISCHL MA, 1990, NEW ENGL J MED, V323, P1009, DOI 10.1056/NEJM199010113231501; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; KIEBURTZ KD, 1992, J ACQ IMMUN DEF SYND, V5, P60; LAMBERT JS, 1990, NEW ENGL J MED, V322, P1333, DOI 10.1056/NEJM199005103221901; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1990, ANTIMICROB AGENTS CH, V34, P436, DOI 10.1128/AAC.34.3.436; MERIGAN TC, 1989, ANN INTERN MED, V110, P189, DOI 10.7326/0003-4819-110-3-189; MITSUYA H, 1986, P NATL ACAD SCI USA, V83, P1911, DOI 10.1073/pnas.83.6.1911; NORRIS SA, 1988, J INFECT DIS, V157, P209, DOI 10.1093/infdis/157.1.209; RICHMAN DD, 1990, J ACQ IMMUN DEF SYND, V3, P743; RICHMAN DD, 1987, NEW ENGL J MED, V317, P192, DOI 10.1056/NEJM198707233170402; SCHNITTMAN SM, 1990, ANN INTERN MED, V113, P438, DOI 10.7326/0003-4819-113-6-438; VENET A, 1991, AIDS, V5, P283, DOI 10.1097/00002030-199103000-00006; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; YARCHOAN R, 1988, LANCET, V1, P76	22	85	94	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1993	118	10					762	769		10.7326/0003-4819-118-10-199305150-00002	http://dx.doi.org/10.7326/0003-4819-118-10-199305150-00002			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB649	8097082				2022-12-28	WOS:A1993LB64900002
J	SCARDI, S; HUMAR, F; PANDULLO, C; POLETTI, A				SCARDI, S; HUMAR, F; PANDULLO, C; POLETTI, A			ORAL CLONIDINE FOR HEART-RATE CONTROL IN CHRONIC ATRIAL-FIBRILLATION	LANCET			English	Letter											SCARDI, S (corresponding author), OSPED MAGGIORE TRIESTE,CTR CARDIOVASC,I-34133 TRIESTE,ITALY.							RODEN DM, 1988, CLIN PHARMACOL THER, V43, P648, DOI 10.1038/clpt.1988.90; ROTH A, 1992, ANN INTERN MED, V116, P388, DOI 10.7326/0003-4819-116-5-388; SCARDI S, 1991, Giornale Italiano di Cardiologia, V21, P503; ZAROWITZ BJ, 1992, AM HEART J, V123, P1094; 1982, LANCET, V1, P891	5	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 8	1993	341	8854					1211	1212		10.1016/0140-6736(93)91038-N	http://dx.doi.org/10.1016/0140-6736(93)91038-N			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB017	8098093				2022-12-28	WOS:A1993LB01700028
J	JHA, PKS; BERAL, V; PETO, J; HACK, S; HERMON, C; DEACON, J; MANT, D; CHILVERS, C; VESSEY, MP; PIKE, MC; MULLER, M; GISSMANN, L				JHA, PKS; BERAL, V; PETO, J; HACK, S; HERMON, C; DEACON, J; MANT, D; CHILVERS, C; VESSEY, MP; PIKE, MC; MULLER, M; GISSMANN, L			ANTIBODIES TO HUMAN PAPILLOMAVIRUS AND TO OTHER GENITAL INFECTIOUS AGENTS AND INVASIVE CERVICAL-CANCER RISK	LANCET			English	Article								Human papillomaviruses (HPVs) play an important part in the development of cervical cancer, but the role of other infectious agents, such as herpes simplex virus (HSV), is not clear. We assayed serum samples collected from 219 women with cervical cancer and from 387 controls for antibody to infectious agents. HPV 16-E7 and/or HPV 18-E7 antibodies were significantly related to cervical cancer risk (RR 1.9, 95% CI 1.2-3.2). Antibodies to HSV types 1 and 2, Chlamydia trachomatis, and to multiple infectious agents were associate with cervical cancer when seroprevalence rates in all cases and controls were compared, but when HPV-seropositive cases and controls were compared these associations were weaker and non-significant. This finding suggests that past infections with sexually transmitted infections other than HPV may be surrogate markers of exposure to HPV, and of no separate aetiological significance.	IMPERIAL CANC RES FUND,CANC EPIDEMIOL UNIT,OXFORD,ENGLAND; GERMAN CANC RES CTR,W-6900 HEIDELBERG 1,GERMANY; INST CANC RES,EPIDEMIOL SECT,SUTTON SM2 5PX,SURREY,ENGLAND; UNIV NOTTINGHAM,DEPT EPIDEMIOL,NOTTINGHAM NG7 2RD,ENGLAND; UNIV OXFORD,DEPT PUBL HLTH & PRIMARY CARE,OXFORD,ENGLAND	University of Oxford; Helmholtz Association; German Cancer Research Center (DKFZ); University of London; Institute of Cancer Research - UK; University of Nottingham; University of Oxford			Gissmann, Lutz/H-4688-2011; Mant, David CA/C-7763-2009					BLEUL C, 1991, J CLIN MICROBIOL, V29, P1579, DOI 10.1128/JCM.29.8.1579-1588.1991; Breslow N. E., 1980, IARC SCI PUBLICATION, V32; HILDESHEIM A, 1991, INT J CANCER, V49, P335, DOI 10.1002/ijc.2910490304; KOUTSKY L, 1991, JNCI-J NATL CANCER I, V83, P978, DOI 10.1093/jnci/83.14.978; LEY C, 1991, JNCI-J NATL CANCER I, V83, P997, DOI 10.1093/jnci/83.14.997; LORINCZ AT, 1992, OBSTET GYNECOL, V79, P328, DOI 10.1097/00006250-199203000-00002; MANDELSON MT, 1992, CANCER EPIDEM BIOMAR, V1, P281; MANN VM, 1990, CANCER RES, V50, P7815; MULLER M, 1992, VIROLOGY, V187, P508; SCHIFFMAN MH, 1992, JNCI-J NATL CANCER I, V84, P394, DOI 10.1093/jnci/84.6.394; SCHMAUZ R, 1989, INT J CANCER, V43, P805, DOI 10.1002/ijc.2910430511; SCHMIDT NJ, 1989, DIAGNOSTIC PROCEDURE, P265; SVENNERHOLM B, 1984, J CLIN MICROBIOL, V19, P235, DOI 10.1128/JCM.19.2.235-239.1984; TREHARNE JD, 1977, J CLIN PATHOL, V30, P510, DOI 10.1136/jcp.30.6.510	14	56	58	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 1	1993	341	8853					1116	1118		10.1016/0140-6736(93)93128-N	http://dx.doi.org/10.1016/0140-6736(93)93128-N			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ687	8097804				2022-12-28	WOS:A1993KZ68700004
J	CRAWFORD, ME; SORENSEN, MB; DAHL, JB				CRAWFORD, ME; SORENSEN, MB; DAHL, JB			INTENSIVE-CARE - INTERNATIONAL STANDARDS FOR INTENSIVE-CARE UNIT SAFETY	LANCET			English	Editorial Material									UNIV COPENHAGEN, MICU, DK-1168 COPENHAGEN, DENMARK	University of Copenhagen	CRAWFORD, ME (corresponding author), HVIDOVRE UNIV HOSP, DEPT ANAESTHESIOL, DK-2650 HVIDOVRE, DENMARK.							LASSEN HCA, 1953, LANCET, V264, P37; SAARELA E, 1991, INTENS CARE MED, V17, P264, DOI 10.1007/BF01713935; 1993, CRIT CARE MED, V21, P453; 1989, TXB CRITICAL CARE; 1993, EUR J ANAESTHESIO S7, V10, P12; 1993, INTENS CARE MED, V19, P178	6	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 24	1993	341	8852					1061	1061		10.1016/0140-6736(93)92417-R	http://dx.doi.org/10.1016/0140-6736(93)92417-R			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ018	8096964				2022-12-28	WOS:A1993KZ01800010
J	CHAN, SH; COSGROVE, D; WALTZINGER, C; BENOIST, C; MATHIS, D				CHAN, SH; COSGROVE, D; WALTZINGER, C; BENOIST, C; MATHIS, D			ANOTHER VIEW OF THE SELECTIVE MODEL OF THYMOCYTE SELECTION	CELL			English	Article							T-CELL RECEPTOR; TRANSGENIC MICE; ANTIGEN RECEPTOR; POSITIVE SELECTION; LYMPHOCYTES-T; NEGATIVE SELECTION; MHC MOLECULES; CD8 LINEAGE; THYMUS; EXPRESSION	Thymocyte commitment to the CD4 helper versus CD8 cytotoxic lineage has not been satisfactorily established. Two models have been elaborated: one based on instruction, the other on selection. Most previous results support the instructive model, but our comparison of thymocyte differentiation in MHC class II-, class I- and double-deficient mice provides data challenging it. There exists a significant population of CD4 single positive cells in class II-deficient animals that is intermediate in maturity between CD4+CD8+ and end-stage CD4+CD8- thymocytes and is selected on class I molecules; an equivalent CD8+CD4- population occurs in class I-deficient animals. We propose a selective model entailing two TCR-MHC molecule engagements: the first provokes random down-modulation of either CD4 or CD8 and a degree of differentiation; the second, requiring participation of the appropriate coreceptor, permits end-stage differentiation.			CHAN, SH (corresponding author), FAC MED STRASBOURG, INST CHIM BIOL,CNRS,GENET MOLEC EUCARYOTES LAB, INSERM, U184, F-67085 STRASBOURG, FRANCE.							BENDELAC A, 1992, J EXP MED, V175, P731, DOI 10.1084/jem.175.3.731; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; BOGUE M, 1992, P NATL ACAD SCI USA, V89, P11011, DOI 10.1073/pnas.89.22.11011; BORGULYA P, 1992, CELL, V69, P529, DOI 10.1016/0092-8674(92)90453-J; BORGULYA P, 1991, EMBO J, V10, P913, DOI 10.1002/j.1460-2075.1991.tb08024.x; BOYD RL, 1991, IMMUNOL TODAY, V12, P71, DOI 10.1016/0167-5699(91)90161-L; CANDEIAS S, 1991, P NATL ACAD SCI USA, V88, P6167, DOI 10.1073/pnas.88.14.6167; CHANG JF, 1991, J IMMUNOL, V147, P860; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; CROMPTON T, 1992, INT IMMUNOL, V4, P153, DOI 10.1093/intimm/4.2.153; EGERTON M, 1990, P NATL ACAD SCI USA, V87, P2579, DOI 10.1073/pnas.87.7.2579; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; GUIDOS CJ, 1990, J EXP MED, V172, P835, DOI 10.1084/jem.172.3.835; GUIDOS CJ, 1989, P NATL ACAD SCI USA, V86, P7542, DOI 10.1073/pnas.86.19.7542; HASKINS K, 1984, J EXP MED, V160, P452, DOI 10.1084/jem.160.2.452; HAUGHN L, 1992, NATURE, V358, P328, DOI 10.1038/358328a0; HAYAKAWA K, 1988, J EXP MED, V168, P1825, DOI 10.1084/jem.168.5.1825; HAYAKAWA K, 1991, IMMUNOL REV, V123, P145, DOI 10.1111/j.1600-065X.1991.tb00609.x; HUESMANN M, 1991, CELL, V66, P533, DOI 10.1016/0092-8674(81)90016-7; JANEWAY CA, 1988, NATURE, V335, P208, DOI 10.1038/335208a0; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; KISIELOW P, 1988, NATURE, V335, P730, DOI 10.1038/335730a0; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; KUBO RT, 1989, J IMMUNOL, V142, P2736; KYEWSKI B, 1992, IMMUNOL TODAY, V13, P288, DOI 10.1016/0167-5699(92)90038-9; MACPHAIL S, 1987, J IMMUNOL, V139, P4007; MCKISIC MD, 1991, J IMMUNOL, V147, P2868; NIKOLICZUGIC J, 1990, INT IMMUNOL, V2, P135, DOI 10.1093/intimm/2.2.135; NIKOLICZUGIC J, 1991, IMMUNOL TODAY, V12, P65, DOI 10.1016/0167-5699(91)90160-U; OHASHI PS, 1990, NATURE, V346, P861, DOI 10.1038/346861a0; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; RAMSDELL F, 1991, J IMMUNOL, V147, P1779; ROBEY EA, 1991, CELL, V64, P99, DOI 10.1016/0092-8674(91)90212-H; SCOTT B, 1989, NATURE, V338, P591, DOI 10.1038/338591a0; SEONG RH, 1992, NATURE, V356, P718, DOI 10.1038/356718a0; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; SHORES EW, 1991, EUR J IMMUNOL, V21, P1657, DOI 10.1002/eji.1830210711; SHORTMAN K, 1991, J EXP MED, V173, P323, DOI 10.1084/jem.173.2.323; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; SURH CD, 1992, J EXP MED, V176, P611, DOI 10.1084/jem.176.2.611; SWAT W, 1992, EUR J IMMUNOL, V22, P2367, DOI 10.1002/eji.1830220928; SWAT W, 1993, IN PRESS EUR J IMMUN; TEH HS, 1991, NATURE, V349, P241, DOI 10.1038/349241a0; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; TURKA LA, 1991, SCIENCE, V253, P778, DOI 10.1126/science.1831564; VANOERS NSC, 1992, EUR J IMMUNOL, V22, P735, DOI 10.1002/eji.1830220317; VERNACHIO J, 1989, J IMMUNOL, V142, P48; VONBOEHMER H, 1986, IMMUNOL TODAY, V7, P333; WILSON A, 1988, CELL IMMUNOL, V117, P312, DOI 10.1016/0008-8749(88)90121-9; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	52	283	286	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 23	1993	73	2					225	236		10.1016/0092-8674(93)90225-F	http://dx.doi.org/10.1016/0092-8674(93)90225-F			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KY505	8097430				2022-12-28	WOS:A1993KY50500006
J	MILLER, E; GOLDACRE, M; PUGH, S; COLVILLE, A; FARRINGTON, P; FLOWER, A; NASH, J; MACFARLANE, L; TETTMAR, R				MILLER, E; GOLDACRE, M; PUGH, S; COLVILLE, A; FARRINGTON, P; FLOWER, A; NASH, J; MACFARLANE, L; TETTMAR, R			RISK OF ASEPTIC-MENINGITIS AFTER MEASLES, MUMPS, AND RUBELLA VACCINE IN UK CHILDREN	LANCET			English	Article							SURVEILLANCE	Cases of aseptic meningitis associated with measles/mumps/rubella vaccine were sought in thirteen UK health districts following a reported cluster in Nottingham which suggested a risk of 1 in 4000 doses, substantially higher than previous estimates based on cases reported by paediatricians (4 per million). Cases were ascertained by obtaining vaccination records of children with aseptic meningitis diagnosed from cerebrospinal fluid samples submitted to Public Health Laboratories or discharged from hospital with a diagnosis of viral meningitis. Both methods identified vaccination 15-35 days before onset as a significant risk factor and therefore indicative of a causal association. With both, half the aseptic meningitis cases identified in children aged 12-24 months were vaccine-associated with onset 15-35 days after vaccine. The study confirmed that the true risk was substantially higher than suggested by case reports from paediatricians, probably about 1 in 11 000 doses. However, the possibility that the aseptic meningitis induced by vaccination was largely asymptomatic and a chance laboratory finding in children investigated for other clinical conditions, particularly febrile convulsions, could not be excluded. Comparison of national reports of virus-positive mumps meningitis cases before and after the introduction of this vaccine indicated that the risk from wild mumps was about 4-fold higher than from vaccine. Altogether, 28 vaccine-associated cases were identified, all in recipients of vaccines containing the Urabe mumps strain. The absence of cases in recipients of vaccine containing the Jeryl Lynn strain, despite its 14% market share, suggested a higher risk from Urabe vaccine. A prospective adverse event surveillance system using the study methods is currently being established to assess the risk, if any, from the Jeryl Lynn strain which is now the only mumps vaccine used in the UK.	PUBL HLTH LAB,LEICESTER,ENGLAND; PUBL HLTH LAB,NOTTINGHAM,ENGLAND; PUBL HLTH LAB,ASHFORD,ENGLAND; PUBL HLTH LAB,KENT,ENGLAND; UNIV OXFORD,DEPT PUBL HLTH MED,HLTH CARE EPIDEMIOL UNIT,OXFORD OX3 7LE,ENGLAND; PUBL HLTH LAB,PRESTON,ENGLAND; PUBL HLTH LAB,CHELMSFORD,ENGLAND	University of Oxford	MILLER, E (corresponding author), PUBL HLTH LAB SERV,DIV IMMUNISAT,61 COLINDALE AVE,LONDON NW9 5EQ,ENGLAND.			Farrington, Conor Patrick/0000-0002-7148-2612				AHRONHEIM GA, 1991, PEDIATR RES, V29, pA166; [Anonymous], 1989, LANCET, V2, P1015; BEGG NT, 1989, PUBLIC HEALTH, V103, P81, DOI 10.1016/S0033-3506(89)80021-6; BOTTIGER M, 1987, BRIT MED J, V295, P1264, DOI 10.1136/bmj.295.6608.1264; COLVILLE A, 1992, LANCET, V340, P786, DOI 10.1016/0140-6736(92)92322-7; FORSEY T, 1990, J GEN VIROL, V71, P987, DOI 10.1099/0022-1317-71-4-987; FUJINAGA T, 1991, PEDIATR INFECT DIS J, V10, P204, DOI 10.1097/00006454-199103000-00007; HOCKIN JC, 1988, CANADIAN DISEASES WE, V14, P210; MAGUIRE HC, 1991, CDR, pR60; MILLER C, 1989, PRACTITIONER, V233, P69; MORGANCAPNER P, 1988, BRIT MED J, V297, P770, DOI 10.1136/bmj.297.6651.770; NOKES DJ, 1991, LANCET, V338, P1309, DOI 10.1016/0140-6736(91)92601-W; Ocklitz H W, 1976, Kinderarztl Prax, V44, P145; PRENTICE RL, 1984, BIOMETRICS, V40, P445, DOI 10.2307/2531397; SUGIURA A, 1991, PEDIATR INFECT DIS J, V10, P209, DOI 10.1097/00006454-199103000-00008; WEIRSBITZKY S, 1983, LANCET, V341, P379; 1989, MMWR, V38, P388; 1992, PLCMO9211 DEP HLTH	18	136	140	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 17	1993	341	8851					979	982		10.1016/0140-6736(93)91069-X	http://dx.doi.org/10.1016/0140-6736(93)91069-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY368	8096942				2022-12-28	WOS:A1993KY36800002
J	OTTERVANGER, JP; PAALMAN, HJA; BOXMA, GL; STRICKER, BHC				OTTERVANGER, JP; PAALMAN, HJA; BOXMA, GL; STRICKER, BHC			TRANSMURAL MYOCARDIAL-INFARCTION WITH SUMATRIPTAN	LANCET			English	Note								For sumatriptan, tightness in the chest caused by an unknown mechanism has been reported in 3-5% of users. We describe a 47-year-old woman with an acute myocardial infarction after administration of sumatriptan 6 mg subcutaneously for cluster headache. The patient had no history of underlying ischaemic heart disease or Prinzmetal's angina. She recovered without complications.	NETHERLANDS CTR MONITORING ADVERSE DRUG REACT,POB 5406,2280 HK RIJSWIJK,NETHERLANDS; HOSP ST ANTONIUSHOVE,LEIDSCHENDAM,NETHERLANDS; HOSP ST ANTONIUSHOVE,ZOETERMEER,NETHERLANDS									BROWN EG, 1991, EUR NEUROL, V31, P339, DOI 10.1159/000116762; CASTLE WM, 1992, BRIT MED J, V305, P117, DOI 10.1136/bmj.305.6845.117-c; CONNOR HE, 1989, EUR J PHARMACOL, V161, P91, DOI 10.1016/0014-2999(89)90184-2; CURTIN T, 1992, BRIT MED J, V305, P713, DOI 10.1136/bmj.305.6855.713-d; Goldfisher JD, 1960, NEW ENGL J MED, V262, P860; INMAN W, 1992, BRIT MED J, V305, P714, DOI 10.1136/bmj.305.6855.714; STRICKER BHC, 1992, BRIT MED J, V305, P118, DOI 10.1136/bmj.305.6845.118-a; WILLETT F, 1992, BRIT MED J, V304, P1415, DOI 10.1136/bmj.304.6839.1415; WOLLERSHEIM H, 1987, NETH J MED, V30, P75; 1991, NEW ENGL J MED, V325, P322	10	136	136	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 3	1993	341	8849					861	862		10.1016/0140-6736(93)93064-8	http://dx.doi.org/10.1016/0140-6736(93)93064-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KV811	8096565				2022-12-28	WOS:A1993KV81100007
J	DONNAN, GA				DONNAN, GA			ANGIOGRAPHY, AIR-EMBOLISM, AND ULTRASOUND	LANCET			English	Letter											DONNAN, GA (corresponding author), AUSTIN HOSP,DEPT NEUROL,HEIDELBERG,VIC 3084,AUSTRALIA.		DONNAN, GEOFFREY A/A-9947-2008	Donnan, Geoffrey/0000-0001-6324-3403; White, Nicholas/0000-0002-1897-1978				MARKUS HS, 1993, STROKE, V24, P1; PUGSLEY W, 1990, VASCULAR SURG, V24, P34, DOI 10.1177/153857449002400107; SIEBLER M, 1992, STROKE, V23, P1652, DOI 10.1161/01.STR.23.11.1652; SPENCER MP, 1972, AEROSPACE MED, V43, P762; SPENCER MP, 1990, STROKE, V21, P415, DOI 10.1161/01.STR.21.3.415; Spencer MP, 1992, TRANSCRANIAL DOPPLER, P215	6	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 27	1993	341	8848					796	796		10.1016/0140-6736(93)90569-3	http://dx.doi.org/10.1016/0140-6736(93)90569-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU900	8096007				2022-12-28	WOS:A1993KU90000012
J	HORAN, MA				HORAN, MA			IMMUNOSENESCENCE AND MUCOSAL IMMUNITY	LANCET			English	Editorial Material							AGED MICE; RESPONSIVENESS; CELLS				HORAN, MA (corresponding author), UNIV HOSP S MANCHESTER,MANCHESTER M20 8LR,LANCS,ENGLAND.							ARRANZ E, 1992, GUT, V33, P882, DOI 10.1136/gut.33.7.882; ASTLE CM, 1984, J IMMUNOL, V132, P673; AVERILL LE, 1985, J IMMUNOL, V134, P3859; ERNST DN, 1987, J IMMUNOL, V138, P26; LIGHTHART GJ, 1984, MECH AGEING DEV, V28, P47; RUSSO C, 1990, Aging Immunology and Infectious Disease, V2, P211; TAYLOR L D, 1990, Aging Immunology and Infectious Disease, V2, P205; WADE A W, 1988, Aging Immunology and Infectious Disease, V1, P65; WADE AW, 1984, ADV IMMUNOL, V36, P143, DOI 10.1016/S0065-2776(08)60901-3; ZHARHARY D, 1986, EUR J IMMUNOL, V16, P1175, DOI 10.1002/eji.1830160924; ZHARHARY D, 1983, J EXP MED, V157, P1300, DOI 10.1084/jem.157.4.1300	11	7	7	1	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 27	1993	341	8848					793	794		10.1016/0140-6736(93)90566-Y	http://dx.doi.org/10.1016/0140-6736(93)90566-Y			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU900	8096004				2022-12-28	WOS:A1993KU90000009
J	ASCHER, MS; SHEPPARD, HW; WINKELSTEIN, W; VITTINGHOFF, E				ASCHER, MS; SHEPPARD, HW; WINKELSTEIN, W; VITTINGHOFF, E			DOES DRUG-USE CAUSE AIDS	NATURE			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; KAPOSIS SARCOMA; EPIDEMIOLOGY; COHORT; MEN		UNIV CALIF BERKELEY,SCH PUBL HLTH,DEPT BIOMED & ENVIRONM HLTH SCI,BERKELEY,CA 94720	University of California System; University of California Berkeley	ASCHER, MS (corresponding author), CALIF DEPT HLTH SERV,VIRAL & RICKETTSIAL DIS LAB,BERKELEY,CA 94704, USA.							ASCHER MS, 1990, J ACQ IMMUN DEF SYND, V3, P177; DUESBERG PH, 1987, CANCER RES, V47, P1199; DUESBERG PH, 1991, P NATL ACAD SCI USA, V88, P1575, DOI 10.1073/pnas.88.4.1575; DUESBERG PH, 1992, PHARMACOL THERAPEUT, V55, P201, DOI 10.1016/0163-7258(92)90052-2; FRIDLAND G, 1989, EPIDEMIOLOGY AIDS, P153; HAVERKOS HW, 1988, HLTH HAZARDS NITRITE, P96; JAFFE HW, 1983, ANN INTERN MED, V99, P145, DOI 10.7326/0003-4819-99-2-145; KASLOW RA, 1989, JAMA-J AM MED ASSOC, V261, P3424, DOI 10.1001/jama.261.23.3424; LIFSON AR, 1990, AM J EPIDEMIOL, V131, P221, DOI 10.1093/oxfordjournals.aje.a115492; PINCHING AJ, 1990, NATURE, V347, P328; SHEPPARD HW, 1992, J ACQ IMMUN DEF SYND, V5, P143; WEISS RA, 1990, NATURE, V345, P659, DOI 10.1038/345659a0; WINKELSTEIN W, 1987, JAMA-J AM MED ASSOC, V257, P321, DOI 10.1001/jama.257.3.321; 1981, MORTAL WKLY RPT, V30, P250; 1987, MORTAL WKLY RPT, V36, pS3	15	34	34	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 11	1993	362	6416					103	104		10.1038/362103a0	http://dx.doi.org/10.1038/362103a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KR028	8095697				2022-12-28	WOS:A1993KR02800018
J	LOWRIE, EG				LOWRIE, EG			RENAL-FAILURE - RENAL REPLACEMENT THERAPY - PRACTICE, CASE-MIX, AND OUTCOME	LANCET			English	Editorial Material											LOWRIE, EG (corresponding author), NATL MED CARE INC,WALTHAM,MA, USA.							Deming W, 1982, OUT CRISIS; Garvin D.A., 1988, MANAGING QUALITY; KHAN, 1993, LANCET, V341, P415; LOWRIE EG, 1992, KIDNEY INT, V42, pS22	4	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 13	1993	341	8842					412	413		10.1016/0140-6736(93)92999-A	http://dx.doi.org/10.1016/0140-6736(93)92999-A			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM416	8094179				2022-12-28	WOS:A1993KM41600014
J	PENTLAND, B				PENTLAND, B			REHABILITATION - QUADRIPLEGIA AND CARDIORESPIRATORY FITNESS	LANCET			English	Editorial Material											PENTLAND, B (corresponding author), ASTLEY AINSLIE HOSP,REHABIL STUDIES UNIT,EDINBURGH,SCOTLAND.							DAVIS G, 1990, KEY ISSUES NEUROLOGI, P155; HOFFMAN MD, 1986, SPORTS MED, V3, P312, DOI 10.2165/00007256-198603050-00002; HOOKER SP, 1992, J REHABIL RES DEV, V29, P1, DOI 10.1682/JRRD.1992.07.0001; NASH MS, 1991, PARAPLEGIA, V29, P590, DOI 10.1038/sc.1991.87; WEBER RJ, 1992, DISEASES SPINAL CORD, P429	5	6	6	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 13	1993	341	8842					413	414		10.1016/0140-6736(93)93000-Q	http://dx.doi.org/10.1016/0140-6736(93)93000-Q			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM416	8094180				2022-12-28	WOS:A1993KM41600015
J	MYERS, RM				MYERS, RM			THE PULSES OF SUBTRACTION	SCIENCE			English	Editorial Material							COMPETITIVE DNA REASSOCIATION; PHYSICAL MAP; CELL-LINES; SEQUENCES; CLONING; CHROMOSOME; DELETION; GENOME; MUTATIONS; STRATEGY		UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	MYERS, RM (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143, USA.							BAUTZ EKF, 1966, SCIENCE, V151, P328, DOI 10.1126/science.151.3708.328; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; GALAU GA, 1977, ARCH BIOCHEM BIOPHYS, V179, P584, DOI 10.1016/0003-9861(77)90147-3; KINZLER KW, 1989, NUCLEIC ACIDS RES, V17, P3645, DOI 10.1093/nar/17.10.3645; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KOHNE DE, 1977, BIOCHEMISTRY-US, V16, P5329, DOI 10.1021/bi00643a026; KUNKEL LM, 1985, P NATL ACAD SCI USA, V82, P4778, DOI 10.1073/pnas.82.14.4778; LAMAR EE, 1984, CELL, V37, P171, DOI 10.1016/0092-8674(84)90312-X; LANDER ES, 1987, SCIENCE, V236, P1567, DOI 10.1126/science.2884728; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; LUDECKE HJ, 1989, NATURE, V338, P348, DOI 10.1038/338348a0; MOR O, 1991, NUCLEIC ACIDS RES, V19, P117, DOI 10.1093/nar/19.1.117; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; NISHI Y, 1992, MAMM GENOME, V2, P11; NUSSBAUM RL, 1987, P NATL ACAD SCI USA, V84, P6521, DOI 10.1073/pnas.84.18.6521; OLSON MV, 1986, P NATL ACAD SCI USA, V83, P7826, DOI 10.1073/pnas.83.20.7826; PATANJALI SR, 1991, P NATL ACAD SCI USA, V88, P1943, DOI 10.1073/pnas.88.5.1943; SHILOH Y, 1987, GENE, V51, P53, DOI 10.1016/0378-1119(87)90473-2; STRAUS D, 1990, P NATL ACAD SCI USA, V87, P1889, DOI 10.1073/pnas.87.5.1889; WALKER C, 1983, GENETICS, V103, P125	20	16	30	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 12	1993	259	5097					942	943		10.1126/science.8094900	http://dx.doi.org/10.1126/science.8094900			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL800	8094900				2022-12-28	WOS:A1993KL80000033
J	DELACHAPELLE, A; SISTONEN, P; LEHVASLAIHO, H; IKKALA, E; JUVONEN, E				DELACHAPELLE, A; SISTONEN, P; LEHVASLAIHO, H; IKKALA, E; JUVONEN, E			FAMILIAL ERYTHROCYTOSIS GENETICALLY LINKED TO ERYTHROPOIETIN RECEPTOR GENE	LANCET			English	Note								Familial erythrocytosis is heterogeneous with diverse causes. Using a highly informative, simple sequence repeat polymorphism in the 5' region of the erythropoietin receptor gene (EPOR), we did linkage analysis in a large family whose clinical and genealogical features were known. There were no recombinations between the disease phenotype and the polymorphism, the logarithm of odds score for linkage at zero recombination being 6.37. This highly significant linkage indicates that a mutation in EPOR is most probably responsible for the disease phenotype in this family.	UNIV HELSINKI,DEPT MED 2,SF-00290 HELSINKI 29,FINLAND; UNIV HELSINKI,DEPT MED 3,SF-00290 HELSINKI 29,FINLAND	University of Helsinki; University of Helsinki	DELACHAPELLE, A (corresponding author), UNIV HELSINKI,DEPT MED GENET,HAARTMANINKATU 3,SF-00290 HELSINKI 29,FINLAND.							ADAMSON JW, 1975, SEMIN HEMATOL, V12, P383; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; EMANUEL PD, 1992, BLOOD, V79, P3019; JUVONEN E, 1991, BLOOD, V78, P3066; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; PENNY LA, 1991, GENOMICS, V11, P974, DOI 10.1016/0888-7543(91)90022-7	6	69	69	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 9	1993	341	8837					82	84		10.1016/0140-6736(93)92558-B	http://dx.doi.org/10.1016/0140-6736(93)92558-B			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF870	8093406				2022-12-28	WOS:A1993KF87000005
J	DIAMOND, ME; HUANG, W; EBNER, FF				DIAMOND, ME; HUANG, W; EBNER, FF			LAMINAR COMPARISON OF SOMATOSENSORY CORTICAL PLASTICITY	SCIENCE			English	Article							RAT BARREL CORTEX; DISCRIMINATION TASK; FIELD CORTEX; NEURONS; INFORMATION; REPRESENTATION; CONNECTIONS; DEPENDENCE; RESPONSES	During tactile learning there is a transformation in the way the primary somatosensory cortex integrates, represents, and distributes information from the skin. To define this transformation, the site of earliest modification has been identified in rat somatosensory cortex after a change in sensory experience. Afferent activity was manipulated by clipping all except two whiskers on one side of the snout (''whisker pairing''), and the receptive fields of neurons at different cortical depths were mapped 24 hours later. Neurons in layer IV, the target of the primary thalamic pathway, were unaltered, whereas neurons located above and below layer IV showed significant changes. These changes were similar to those that occur in layer IV after longer periods of whisker pairing. The findings support the hypothesis that the layers of cortex contribute differently to plasticity. Neurons in the supragranular and infragranular layers respond rapidly to changes in sensory experience and may contribute to subsequent modification in layer IV.	VANDERBILT UNIV,PEABODY COLL,INST DEV NEUROSCI,NASHVILLE,TN 37203	Vanderbilt University; Vanderbilt University Peabody College	DIAMOND, ME (corresponding author), UNIV UDINE,DEPT SCI & BIOMED TECHNOL,PHYSIOL SECT,PIAZZALE KOLBE 3,I-33100 UDINE,ITALY.		Huang, Wei/F-4937-2014	Huang, Wei/0000-0003-2785-5618; DIAMOND, Mathew Ernest/0000-0003-2286-4566	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025907] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-25907] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHISSAR E, 1992, SCIENCE, V257, P1412, DOI 10.1126/science.1529342; AKHTAR ND, 1991, J COMP NEUROL, V307, P200, DOI 10.1002/cne.903070204; ARMSTRONGJAMES M, 1992, J NEUROPHYSIOL, V68, P1345, DOI 10.1152/jn.1992.68.4.1345; ARMSTRONGJAMES M, 1991, J COMP NEUROL, V303, P193, DOI 10.1002/cne.903030203; ARMSTRONGJAMES M, 1993, J NEUROSCI, V13, P2149; ARMSTRONGJAMES M, IN PRESS J NEUROSCI; BENUSKOVA L, 1994, P NATL ACAD SCI USA, V91, P4791, DOI 10.1073/pnas.91.11.4791; BERNARDO KL, 1990, J COMP NEUROL, V291, P231, DOI 10.1002/cne.902910207; CALFORD MB, 1991, P ROY SOC B-BIOL SCI, V243, P269, DOI 10.1098/rspb.1991.0041; CHAPIN JK, 1987, J COMP NEUROL, V263, P326, DOI 10.1002/cne.902630303; DELACOUR J, 1987, NEUROSCIENCE, V23, P63, DOI 10.1016/0306-4522(87)90271-5; DIAMOND ME, 1992, J COMP NEUROL, V319, P66, DOI 10.1002/cne.903190108; DIAMOND ME, 1993, P NATL ACAD SCI USA, V90, P2602; FREGNAC Y, 1994, J NEUROPHYSIOL, V71, P1403, DOI 10.1152/jn.1994.71.4.1403; FRIEDBERG MH, 1991, THESIS BROWN U; HEBB DO, 1949, ORG BEHAVIOR; HUTSON KA, 1986, J NEUROPHYSIOL, V56, P1196, DOI 10.1152/jn.1986.56.4.1196; Kim U., 1993, Society for Neuroscience Abstracts, V19, P107; LU SM, 1993, SOMATOSENS MOT RES, V10, P1, DOI 10.3109/08990229309028819; NICOLELIS MAL, 1993, NATURE, V361, P533, DOI 10.1038/361533a0; NICOLELIS MAL, 1991, SOMATOSENS MOT RES, V8, P193, DOI 10.3109/08990229109144743; PASCUALLEONE A, 1993, BRAIN, V116, P39, DOI 10.1093/brain/116.1.39; RECANZONE GH, 1992, J NEUROPHYSIOL, V67, P1071, DOI 10.1152/jn.1992.67.5.1071; RECANZONE GH, 1992, J NEUROPHYSIOL, V67, P1031, DOI 10.1152/jn.1992.67.5.1031; WELKER C, 1971, BRAIN RES, V26, P259, DOI 10.1016/S0006-8993(71)80004-5; WOOLSEY TA, 1970, BRAIN RES, V17, P205, DOI 10.1016/0006-8993(70)90079-X; ZARZECKI P, 1993, J NEUROPHYSIOL, V69, P1422, DOI 10.1152/jn.1993.69.5.1422	27	234	236	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 23	1994	265	5180					1885	1888		10.1126/science.8091215	http://dx.doi.org/10.1126/science.8091215			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH258	8091215				2022-12-28	WOS:A1994PH25800039
J	BARONI, MD; MONTI, P; ALBERGHINA, L				BARONI, MD; MONTI, P; ALBERGHINA, L			REPRESSION OF GROWTH-REGULATED G1 CYCLIN EXPRESSION BY CYCLIC-AMP IN BUDDING YEAST	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; POSITIVE FEEDBACK; SIGNALING PATHWAY; PROTEIN-SYNTHESIS; S-CEREVISIAE; SIZE; GENE; CLN1; DIVISION	YEAST cell becomes committed to the cell division cycle only if it grows to a critical size(1-4) and reaches a critical rate of protein synthesis(5,6). The coordination between growth and division takes place at a control step during the G1 phase of the cell cycle called Start(4). It relies on the G1-specific cyclins encoded by CLN1, 2 and 3, which trigger Start through the activation of the Cdc28 protein kinase. In fact, the Cln cyclins are rate-limiting for Start execution and depend on growth. Here we report that the cyclic AMP signal pathway(11) modulates the dependency of Cln cyclins on growth. In particular, more growth is required to trigger Start because CLN1 and CLN2 are repressed by the cAMP signal, thus explaining the previously observed cAMP-dependent increase of the critical size and critical rate of protein synthesis(12). Cln3 is not inhibited by the cAMP pathway and counteracts this mechanism by partially mediating the growth-dependent expression of other G1 cyclins.			BARONI, MD (corresponding author), UNIV MILAN,DIPARTIMENTO FISIOL & BIOCHIM GEN,BIOCHIM COMPARATA SEZ,VIA CELORIA 26,I-20133 MILAN,ITALY.		Baroni, Maurizio David/AAL-8064-2021	Baroni, Maurizio David/0000-0001-6355-9950; Alberghina, Lilia/0000-0003-1694-931X				BARONI MD, 1992, EXP CELL RES, V201, P299, DOI 10.1016/0014-4827(92)90277-F; BARONI MD, 1989, MOL CELL BIOL, V9, P2715, DOI 10.1128/MCB.9.6.2715; Broach J R, 1990, Adv Cancer Res, V54, P79, DOI 10.1016/S0065-230X(08)60809-X; CAMERON S, 1988, CELL, V53, P555, DOI 10.1016/0092-8674(88)90572-7; CANNON JF, 1987, MOL CELL BIOL, V7, P2653, DOI 10.1128/MCB.7.8.2653; CHEREST H, 1985, GENE, V34, P269; CROSS FR, 1991, CELL, V65, P875, DOI 10.1016/0092-8674(91)90394-E; CROSS FR, 1990, MOL CELL BIOL, V10, P6482, DOI 10.1128/MCB.10.12.6482; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; DIRICK L, 1991, NATURE, V351, P754, DOI 10.1038/351754a0; FERNANDEZSARABIA MJ, 1992, GENE DEV, V6, P2417, DOI 10.1101/gad.6.12a.2417; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HUBLER L, 1993, MOL CELL BIOL, V13, P6274, DOI 10.1128/MCB.13.10.6274; IIDA H, 1984, J CELL BIOL, V98, P1185, DOI 10.1083/jcb.98.4.1185; JOHNSTON GC, 1977, EXP CELL RES, V105, P79, DOI 10.1016/0014-4827(77)90154-9; JOHNSTON GC, 1979, J BACTERIOL, V137, P1; KLEIN C, 1994, MOL CELL BIOL, V14, P1920, DOI 10.1128/MCB.14.3.1920; KOCH C, 1994, CURR OPIN CELL BIOL, V6, P451, DOI 10.1016/0955-0674(94)90039-6; LORINCZ A, 1979, J GEN MICROBIOL, V113, P287, DOI 10.1099/00221287-113-2-287; MARTEGANI E, 1984, EUR J BIOCHEM, V144, P205, DOI 10.1111/j.1432-1033.1984.tb08450.x; MOORE SA, 1988, J BIOL CHEM, V263, P9674; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; OGAS J, 1991, CELL, V66, P1015, DOI 10.1016/0092-8674(91)90445-5; POPOLO L, 1982, EXP CELL RES, V142, P69, DOI 10.1016/0014-4827(82)90410-4; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; REED SI, 1980, GENETICS, V95, P561; SMITH ME, 1990, YEAST, V6, P53, DOI 10.1002/yea.320060106; SUDBERY PE, 1980, NATURE, V288, P401, DOI 10.1038/288401a0; THEVELEIN JM, 1991, MOL MICROBIOL, V5, P1301, DOI 10.1111/j.1365-2958.1991.tb00776.x; TYERS M, 1993, EMBO J, V12, P1955, DOI 10.1002/j.1460-2075.1993.tb05845.x; WILSON RB, 1993, FEBS LETT, V325, P191, DOI 10.1016/0014-5793(93)81071-7	31	135	136	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 22	1994	371	6495					339	342		10.1038/371339a0	http://dx.doi.org/10.1038/371339a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH254	8090203				2022-12-28	WOS:A1994PH25400054
J	ZAMBON, A; TORRES, A; BIJVOET, S; GAGNE, C; MOORJANI, S; LUPIEN, PJ; HAYDEN, MR; BRUNZELL, JD				ZAMBON, A; TORRES, A; BIJVOET, S; GAGNE, C; MOORJANI, S; LUPIEN, PJ; HAYDEN, MR; BRUNZELL, JD			PREVENTION OF RAISED LOW-DENSITY-LIPOPROTEIN CHOLESTEROL IN A PATIENT WITH FAMILIAL HYPERCHOLESTEROLEMIA AND LIPOPROTEIN-LIPASE DEFICIENCY	LANCET			English	Note								Raised low-density lipoprotein (LDL) cholesterol is believed to predispose to development of atherosclerosis and coronary heart disease. Increased plasma LDL concentrations and premature coronary heart disease are present in familial hypercholesterolemia (FH), and the enzyme lipoprotein lipase (LPL) seems to have a key role in production of LDL. We describe a unique French Canadian individual who is both heterozygous for FH and homozygous for LPL deficiency (FH/LPL). In this patient, LDL cholesterol was strikingly low compared with both his FH (0.65 vs 5.84 mmol/L) and normolipidaemic (2.77 mmol/L) age-matched relatives despite the defect of LDL-receptor-mediated removal. No LDL peak was present in the cholesterol profile of the FH/LPL-deficient subject, as determined by density-gradient ultracentrifugation. Our results suggest that most LDL particles, in vivo, originate from triglyceride-rich lipoproteins, that LPL plays a vital part in this process, and that absence of LPL activity protects FH subjects against the increase in LDL cholesterol.	UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195; LAVAL UNIV HOSP,LIPID RES CTR,QUEBEC CITY,PQ,CANADA; UNIV BRITISH COLUMBIA,DEPT MED GENET,VANCOUVER V6T 1W5,BC,CANADA	University of Washington; University of Washington Seattle; Laval University; University of British Columbia			Hayden, Michael R/D-8581-2011; Zambon, Alberto/J-2122-2012	Hayden, Michael R/0000-0001-5159-1419; 	NHLBI NIH HHS [HL30086] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030086] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; BRUNZELL JD, 1989, METABOLIC BASIS INHE, V1, P1165; GOLDBERG IJ, 1988, J CLIN INVEST, V81, P561, DOI 10.1172/JCI113354; GOLDSTEIN JL, 1989, METABOLIC BASIS INHE, V1, P1215; HAVEL RJ, 1989, METABOLIC BASIS INHE, V1, P1129; KANE JP, 1989, METABOLIC BASIS INHE, V1, P1139; LEITERSDORF E, 1990, J CLIN INVEST, V85, P1014, DOI 10.1172/JCI114531; MA YH, 1991, NEW ENGL J MED, V324, P1761, DOI 10.1056/NEJM199106203242502; MONSALVE MV, 1990, J CLIN INVEST, V86, P728, DOI 10.1172/JCI114769; VERNE N, 1986, METHOD ENZYMOL, V128, P155	10	28	31	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 1	1993	341	8853					1119	1121		10.1016/0140-6736(93)93129-O	http://dx.doi.org/10.1016/0140-6736(93)93129-O			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ687	8097805				2022-12-28	WOS:A1993KZ68700005
J	JADRESIC, D				JADRESIC, D			PSYCHIATRY - OBSESSIONALITY IN TOURETTE SYNDROME	LANCET			English	Editorial Material							OBSESSIVE-COMPULSIVE DISORDER				JADRESIC, D (corresponding author), UNIV MANCHESTER,MANCHESTER ROYAL INFIRM,DEPT PSYCHIAT,MANCHESTER M13 9WL,LANCS,ENGLAND.							BAXTER LR, 1990, J CLIN PSYCHIAT, V51, P61; PAULS DL, 1990, J AM ACAD CHILD PSY, V29, P195, DOI 10.1097/00004583-199003000-00007; PITMAN RK, 1987, AM J PSYCHIAT, V144, P1166; ROBERTSON MM, 1993, BRIT J PSYCHIAT, V162, P114, DOI 10.1192/bjp.162.1.114; ROBERTSON MM, 1988, BRIT J PSYCHIAT, V152, P383, DOI 10.1192/bjp.152.3.383	5	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 24	1993	341	8852					1063	1063		10.1016/0140-6736(93)92420-X	http://dx.doi.org/10.1016/0140-6736(93)92420-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KZ018	8096967				2022-12-28	WOS:A1993KZ01800013
J	STORR, A				STORR, A			BROADCASTING SCIENCE - THE WOLPERT CONVERSATIONS	LANCET			English	Editorial Material																			0	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 24	1993	341	8852					1062	1063		10.1016/0140-6736(93)92419-T	http://dx.doi.org/10.1016/0140-6736(93)92419-T			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ018	8096966				2022-12-28	WOS:A1993KZ01800012
J	GENSER, N; MAIR, J; MAIER, J; DIENSTL, F; PUSCHENDORF, B; LECHLEITNER, P				GENSER, N; MAIR, J; MAIER, J; DIENSTL, F; PUSCHENDORF, B; LECHLEITNER, P			THROMBIN GENERATION DURING INFUSION OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR	LANCET			English	Letter									UNIV INNSBRUCK, DEPT MED CHEM & BIOCHEM, A-6020 INNSBRUCK, AUSTRIA	University of Innsbruck	GENSER, N (corresponding author), UNIV INNSBRUCK, DEPT INTERNAL MED, A-6020 INNSBRUCK, AUSTRIA.		Mair, Johannes/J-5822-2019					BAGLIN, 1993, LANCET, V341, P504; GULBA DC, 1991, CIRCULATION, V83, P937, DOI 10.1161/01.CIR.83.3.937	2	9	9	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 17	1993	341	8851					1038	1038		10.1016/0140-6736(93)91141-8	http://dx.doi.org/10.1016/0140-6736(93)91141-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY368	8096940				2022-12-28	WOS:A1993KY36800074
J	BARKER, DJP; GLUCKMAN, PD; GODFREY, KM; HARDING, JE; OWENS, JA; ROBINSON, JS				BARKER, DJP; GLUCKMAN, PD; GODFREY, KM; HARDING, JE; OWENS, JA; ROBINSON, JS			FETAL NUTRITION AND CARDIOVASCULAR-DISEASE IN ADULT LIFE	LANCET			English	Review							GROWTH-RETARDED FETUSES; PLACENTAL SIZE; LATE PREGNANCY; UNDERNUTRITION; INSULIN; WEIGHT; RISK	Babies who are small at birth or during infancy have increased rates of cardiovascular disease and non-insulin-dependent diabetes as adults. Some of these babies have low birthweights, some are small in relation to the size of their placentas, some are thin at birth, and some are short at birth and fail to gain weight in infancy. This paper shows how fetal undernutrition at different stages of gestation can be linked to these patterns of early growth. The fetuses' adaptations to undernutrition are associated with changes in the concentrations of fetal and placental hormones. Persisting changes in the levels of hormone secretion, a nd i n the sensitivity of tissues to them, may link fetal undernutrition with abnormal structure, function, and disease in adult life.	UNIV AUCKLAND,DEPT PEDIAT,AUCKLAND,NEW ZEALAND; UNIV ADELAIDE,DEPT OBSTET & GYNAECOL,ADELAIDE,SA 5001,AUSTRALIA	University of Auckland; University of Adelaide	BARKER, DJP (corresponding author), SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND.		Harding, Jane E/J-5853-2015; Owens, Julie A/C-9744-2009	Harding, Jane E/0000-0003-2697-1422; Owens, Julie A/0000-0002-7498-1353; Godfrey, Keith/0000-0002-4643-0618				BAKER DJP, 1992, FETAL INFANT ORIGINS; BARKER DJP, 1993, DIABETOLOGIA, V36, P62, DOI 10.1007/BF00399095; BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1992, BMJ-BRIT MED J, V304, P148, DOI 10.1136/bmj.304.6820.148; BARKER DJP, 1993, BRIT MED J, V306, P422, DOI 10.1136/bmj.306.6875.422; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BENEDIKTSSON R, 1993, LANCET, V341, P339, DOI 10.1016/0140-6736(93)90138-7; CETIN I, 1990, AM J OBSTET GYNECOL, V162, P253, DOI 10.1016/0002-9378(90)90860-A; DIVON MY, 1986, AM J OBSTET GYNECOL, V155, P1197, DOI 10.1016/0002-9378(86)90144-4; FALL CHD, 1992, BRIT MED J, V304, P801, DOI 10.1136/bmj.304.6830.801; FANCOURT R, 1976, BMJ-BRIT MED J, V1, P1435, DOI 10.1136/bmj.1.6023.1435; GARCIAARAGON J, 1992, DEVELOPMENT, V114, P869; GLUCKMAN PD, 1983, ENDOCRINOLOGY, V112, P1607, DOI 10.1210/endo-112-5-1607; GOTT AL, 1990, HUM REPROD, V5, P104, DOI 10.1093/oxfordjournals.humrep.a137028; HAHN P, 1984, J NUTR, V114, P1231, DOI 10.1093/jn/114.7.1231; HALES CN, 1992, DIABETOLOGIA, V35, P595, DOI 10.1007/BF00400248; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; HARDING J, 1992, EARLY HUM DEV, V29, P193, DOI 10.1016/0378-3782(92)90149-B; JOB JC, 1990, HORM RES, V33, P161, DOI 10.1159/000181502; LASSARRE C, 1991, PEDIATR RES, V29, P219, DOI 10.1203/00006450-199103000-00001; LAW CM, 1993, BRIT MED J, V306, P24, DOI 10.1136/bmj.306.6869.24; LEESE HJ, 1990, EARLY EMBRYO DEV PAR, P67; MCCRABB GJ, 1991, BRIT J NUTR, V65, P157, DOI 10.1079/BJN19910077; MELLOR DJ, 1982, RES VET SCI, V32, P377, DOI 10.1016/S0034-5288(18)32399-3; OLIVER MH, IN PRESS PED RES; OWENS JA, 1987, J DEV PHYSIOL, V9, P225; OWENS JA, 1988, FETAL NEONATAL GROWT, P49; OWENS JA, 1990, REPROD FERT DEVELOP, V3, P501; PEDERSEN JF, 1981, BRIT MED J, V283, P269, DOI 10.1136/bmj.283.6286.269; PERSSON E, 1992, ACTA PHYSIOL SCAND, V145, P195, DOI 10.1111/j.1748-1716.1992.tb09356.x; PHIPPS K, 1993, DIABETOLOGIA, V36, P225, DOI 10.1007/BF00399954; ROSEN T, 1990, LANCET, V336, P2825; SEIDMAN DS, 1991, BMJ-BRIT MED J, V302, P1235, DOI 10.1136/bmj.302.6787.1235; SNOW MHL, 1989, FETAL GROWTH, P1; SOOTHILL PW, 1987, BRIT MED J, V294, P1051, DOI 10.1136/bmj.294.6579.1051; TANGALAKIS K, 1992, EXP PHYSIOL, V77, P709, DOI 10.1113/expphysiol.1992.sp003637; VANASSCHE FA, 1977, BRIT J OBSTET GYNAEC, V84, P751, DOI 10.1111/j.1471-0528.1977.tb12486.x; WILLIAMS S, 1992, J CLIN EPIDEMIOL, V45, P1257, DOI 10.1016/0895-4356(92)90167-L; WINICK M, 1966, J NUTR, V89, P300, DOI 10.1093/jn/89.3.300	39	1988	2059	1	125	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 10	1993	341	8850					938	941		10.1016/0140-6736(93)91224-A	http://dx.doi.org/10.1016/0140-6736(93)91224-A			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW981	8096277				2022-12-28	WOS:A1993KW98100016
J	MARCHAL, G; SERRATI, C; RIOUX, P; PETITTABOUE, MC; VIADER, F; DELASAYETTE, V; LEDOZE, F; LOCHON, P; DERLON, JM; ORGOGOZO, JM; BARON, JC				MARCHAL, G; SERRATI, C; RIOUX, P; PETITTABOUE, MC; VIADER, F; DELASAYETTE, V; LEDOZE, F; LOCHON, P; DERLON, JM; ORGOGOZO, JM; BARON, JC			PET IMAGING OF CEREBRAL PERFUSION AND OXYGEN-CONSUMPTION IN ACUTE ISCHEMIC STROKE - RELATION TO OUTCOME	LANCET			English	Note							INFARCTION	We used positron emission tomography (PET) to assess the relation between combined imaging of cerebral blood flow and oxygen consumption 5-18 h after first middle cerebral artery (MCA) stroke and neurological outcome at 2 months. All 18 patients could be classified into three visually defined PET patterns of perfusion and oxygen consumption changes. Pattern I (7 patients) suggested extensive irreversible damage and was consistently associated with poor outcome. Pattern II (5) suggested continuing ischaemia and was associated with variable outcome. Pattern III (6), with hyperperfusion and little or no metabolic alteration, was associated with excellent recovery, which suggests that early reperfusion is beneficial. This relation between PET and outcome was highly significant (p<0.0005). The results suggest that within 5-18 h of stroke onset, PET is a good predictor of outcome in patterns I and III, for which therapy seems limited. The absence of predictive value for pattern II suggests that it is due to a reversible ischaemic state that is possibly amenable to therapy. These findings may have important implications for acute MCA stroke management and for patients' selection for therapeutic trials.	CYCERON,INSERM,U320,BI BECQUEREL,BP 5027,F-14021 CAEN,FRANCE; UNIV GENOA,NEUROL CLIN,I-16126 GENOA,ITALY; CTR HOSP REG & UNIV COTE NACRE,CAEN,FRANCE; CEA,DSV DPTE,CAEN,FRANCE; CAC F BACLESSE,CAEN,FRANCE; CHU PELLEGRIN,BORDEAUX,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Caen Normandie; University of Genoa; CHU de Caen NORMANDIE; CEA; CHU Bordeaux			Derlon, Jean-Michel/L-1721-2015	baron, jean-claude/0000-0002-5264-2588				BOGOUSSLAVSKY J, 1991, CEREBROVASC DIS, V1, P1; GIUBILEI F, 1990, STROKE, V21, P895, DOI 10.1161/01.STR.21.6.895; LIMBURG M, 1991, J NUCL MED, V32, P382; MARCHAL G, 1992, ARCH NEUROL-CHICAGO, V49, P1013, DOI 10.1001/archneur.1992.00530340029014; MARCHAL G, 1992, CEREBROVASC DIS, V2, P235; MARTINEZVILA E, 1990, STROKE, V21, P1023, DOI 10.1161/01.STR.21.7.1023; RINGELSTEIN EB, 1992, NEUROLOGY, V42, P289, DOI 10.1212/WNL.42.2.289; WADE DT, 1989, HDB CLIN NEUROLOGY, V11, P233; WARDLAW JM, 1992, STROKE, V23, P1826, DOI 10.1161/01.STR.23.12.1826; WISE RJS, 1983, BRAIN, V106, P197, DOI 10.1093/brain/106.1.197	10	209	218	3	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 10	1993	341	8850					925	927		10.1016/0140-6736(93)91214-7	http://dx.doi.org/10.1016/0140-6736(93)91214-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW981	8096267				2022-12-28	WOS:A1993KW98100006
J	LOBEL, HO; MIANI, M; ENG, T; BERNARD, KW; HIGHTOWER, AW; CAMPBELL, CC				LOBEL, HO; MIANI, M; ENG, T; BERNARD, KW; HIGHTOWER, AW; CAMPBELL, CC			LONG-TERM MALARIA PROPHYLAXIS WITH WEEKLY MEFLOQUINE	LANCET			English	Article							RESISTANT MALARIA; PREVENTION; TRAVELERS; AFRICA; RISK	The spread of chloroquine-resistant Plasmodium falpicarum malaria has led to increased use of mefloquine prophylaxis by US Peace Corps volunteers in sub-Saharan Africa. We compared long-term mefloquine with other drug regimens for effectiveness and tolerance. The incidence of Plasmodium falciparum infections and of adverse reactions was compared in Peace Corps volunteers who took chloroquine weekly, mefloquine weekly, mefloquine every other week, or weekly chloroquine plus daily proguanil. Weekly mefloquine was 94% more effective than chloroquine (95% Cl 86% to 97%), 86% more effective than chloroquine plus proguanil (95% Cl 67% to 94%), and 82% more effective than prophylaxis with mefloquine when taken every other week (95% Cl 68% to 90%). No serious adverse reactions were observed. Mild adverse events were equally frequent in mefloquine users and chloroquine users, and the frequency of these events declined with increasing duration of prophylaxis. Mefloquine is an effective and well-tolerated drug for prophylaxis of malaria by short-term and long-term travellers.	CTR DIS CONTROL,STAT SERV,ATLANTA,GA 30333; CTR DIS CONTROL,NATL CTR INFECT DIS,DIV PARASIT DIS,ATLANTA,GA 30333; CTR DIS CONTROL,INT HLTH PROGRAM OFF,ATLANTA,GA 30333; PEACE CORPS,OFF MED SERV,WASHINGTON,DC	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	LOBEL, HO (corresponding author), CTR DIS CONTROL,MALARIA BRANCH,ATLANTA,GA 30333, USA.							BERGQVIST Y, 1988, J CHROMATOGR-BIOMED, V432, P253, DOI 10.1016/S0378-4347(00)80650-7; BJORKMAN A, 1989, LANCET, V2, P865; CARME B, 1991, PRESSE MED, V20, P1113; GUESS HA, 1987, AM J EPIDEMIOL, V125, P340, DOI 10.1093/oxfordjournals.aje.a114535; Lobel H. O., 1986, Clinics in Tropical Medicine and Communicable Diseases, V1, P225; LOBEL HO, 1990, B WORLD HEALTH ORGAN, V68, P209; LOBEL HO, 1991, JAMA-J AM MED ASSOC, V265, P361, DOI 10.1001/jama.265.3.361; LUXEMBURGER C, 1991, LANCET, V338, P1268, DOI 10.1016/0140-6736(91)92131-K; MORAN JS, 1989, JAMA-J AM MED ASSOC, V262, P245, DOI 10.1001/jama.262.2.245; PEPPIATT R, 1990, J TROP MED HYG, V93, P397; STEFFEN R, 1992, 13TH INT C TROP MED; VENNING GR, 1983, BRIT MED J, V286, P544, DOI 10.1136/bmj.286.6364.544; WEINKE T, 1991, AM J TROP MED HYG, V45, P86, DOI 10.4269/ajtmh.1991.45.86; 1990, MMWR, V39, P630; 1992, CDC928280 PUBL; WHOMAL891054 SER PUB; 1992, INT TRAVEL HLTH	17	181	182	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 3	1993	341	8849					848	851		10.1016/0140-6736(93)93058-9	http://dx.doi.org/10.1016/0140-6736(93)93058-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KV811	8096560				2022-12-28	WOS:A1993KV81100002
J	DOWNIE, AC; FROST, PG; FIELDEN, P; JOSHI, D; DANCY, CM				DOWNIE, AC; FROST, PG; FIELDEN, P; JOSHI, D; DANCY, CM			BEDSIDE MEASUREMENT OF CREATINE-KINASE TO GUIDE THROMBOLYSIS ON THE CORONARY-CARE UNIT	LANCET			English	Article								Thrombolysis is effective in treating patients with acute myocardial infarction when started within 12 h of onset, and thus is in widespread use. Early diagnosis is essential but some patients admitted to the coronary care unit with myocardial infarction do not meet the diagnostic criteria on arrival, and thus do not undergo thrombolysis. We studied 117 patients admitted consecutively to our coronary care unit with suspected but unproven myocardial infarction; normally none would have received thrombolytic agents. In each patient creatine kinase levels were measured on admission and after intervals by nurses using capillary blood samples and a dry chemistry system. Infarction was subsequently confirmed in 29 patients. Of these, 17 (59%) were correctly diagnosed and underwent thrombolysis within 12 h on the basis of a raised creatine kinase measured at the bedside. Our findings suggest that use of a bedside assay by nurses allows additional patients with myocardial infarction to receive the benefit of thrombolytic therapy within the first 12 h.	CENT MIDDLESEX HOSP, NHS TRUST, LONDON NW10, ENGLAND									[Anonymous], 1988, LANCET, V2, P349; COLLINSON PO, 1989, J CLIN PATHOL, V42, P1126, DOI 10.1136/jcp.42.11.1126; GIBB I, 1985, BRIT MED J, V290, P1381, DOI 10.1136/bmj.290.6479.1381; TIMMIS AD, 1990, BMJ-BRIT MED J, V301, P941, DOI 10.1136/bmj.301.6758.941	4	8	9	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 20	1993	341	8843					452	454		10.1016/0140-6736(93)90205-U	http://dx.doi.org/10.1016/0140-6736(93)90205-U			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN137	8094486				2022-12-28	WOS:A1993KN13700002
J	ODRISCOLL, BR; KALRA, S; WILSON, M; PICKERING, CAC; CARROLL, KB; WOODCOCK, AA				ODRISCOLL, BR; KALRA, S; WILSON, M; PICKERING, CAC; CARROLL, KB; WOODCOCK, AA			DOUBLE-BLIND TRIAL OF STEROID TAPERING IN ACUTE ASTHMA	LANCET			English	Article								It is customary to tail off the dose of oral steroids after treatment of an acute exacerbation of asthma; the main reason for this practice is to avoid rebound asthma. We have carried out a randomised double-blind study to find out whether a tapering course of oral prednisolone has any advantage over an abruptly terminated course of prednisolone for an episode of acute asthma requiring hospital admission. We studied 35 patients admitted to hospital with acute asthma; their mean peak expiratory flow rate (PEFR) on admission was 173 L/min and their mean age was 32 years (range 18-55); all were using inhaled steroids on discharge (mean dose 908 mug daily). Each patient received 40 mg enteric-coated prednisolone daily for 10 days followed by a tapering course of either prednisolone 5 mg tablets (active taper) or identical placebo tablets (placebo taper), reducing from 7 tablets on day 11 to no tablets by day 18. The primary outcome measure was the PEFR on waking. Both groups responded well to treatment by day 10 (mean morning PEFR: active taper group 396 L/min, placebo taper group 391 L/min). There was no further significant change in PEFR in either group during the 7 days of active or placebo tapering or during the following 10 days (repeated measures analysis of variance, active vs placebo, p = 0.82). The groups were also similar in terms of secondary outcome measure-symptom scores, PEFR after morning bronchodilator treatment, evening PEFR, and treatment failures. This study suggests that steroid tapering is unnecessary in acute asthma; a personal asthma management plan with a reserve course of prednisolone may be more appropriate.	HOPE HOSP,SALFORD M6 8HD,LANCS,ENGLAND		ODRISCOLL, BR (corresponding author), WYTHENSHAWE HOSP,CHEST CLIN,N W LUNG CTR,MANCHESTER M23 9LT,LANCS,ENGLAND.			Woodcock, Ashley/0000-0002-5428-8578				[Anonymous], 1990, BMJ, V301, P651; CHAPMAN KR, 1991, NEW ENGL J MED, V324, P788, DOI 10.1056/NEJM199103213241202; FANTA CH, 1983, AM J MED, V74, P845, DOI 10.1016/0002-9343(83)91076-8; LEDERLE FA, 1987, ARCH INTERN MED, V147, P2201, DOI 10.1001/archinte.147.12.2201; LITTENBERG B, 1986, NEW ENGL J MED, V314, P150, DOI 10.1056/NEJM198601163140304; REA HH, 1986, THORAX, V41, P833, DOI 10.1136/thx.41.11.833; SALMERON S, 1989, AM REV RESPIR DIS, V140, P167, DOI 10.1164/ajrccm/140.1.167; WEBB J, 1981, THORAX, V36, P22, DOI 10.1136/thx.36.1.22; WEBB JR, 1986, BMJ-BRIT MED J, V292, P1045, DOI 10.1136/bmj.292.6527.1045; 1990, BMJ, V301, P797	10	95	98	4	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 6	1993	341	8841					324	327		10.1016/0140-6736(93)90134-3	http://dx.doi.org/10.1016/0140-6736(93)90134-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK939	8094111				2022-12-28	WOS:A1993KK93900002
J	BATEMAN, DN				BATEMAN, DN			SUMATRIPTAN	LANCET			English	Article							ORAL SUMATRIPTAN; MIGRAINE; 5-HYDROXYTRYPTAMINE; PHARMACOKINETICS; RECEPTORS; 5-HT1B				BATEMAN, DN (corresponding author), REG DRUG & THERAPEUT CTR,WOLFSON UNIT,CLAREMONT PL,NEWCASTLE TYNE NE1 4LP,ENGLAND.			Bateman, David Nicholas/0000-0002-8971-862X				BLAU JN, 1992, LANCET, V339, P1202, DOI 10.1016/0140-6736(92)91140-4; BROWN EG, 1991, EUR NEUROL, V31, P399; BUZZI MG, 1991, CEPHALALGIA, V11, P165, DOI 10.1046/j.1468-2982.1991.1104165.x; CURTIN T, 1992, BRIT MED J, V305, P713, DOI 10.1136/bmj.305.6855.713-d; CUTLER NR, 1991, CEPHALALGIA, V11, P222, DOI 10.1177/0333102491011S11120; DECHANT KL, 1992, DRUGS, V43, P776, DOI 10.2165/00003495-199243050-00010; DENBOER MO, 1991, BRIT J PHARMACOL, V102, P323; EDVINSSON L, 1989, CEPHALALGIA S10, V9, P39; FOWLER PA, 1991, EUR NEUROL, V31, P291, DOI 10.1159/000116756; FRIBERG L, 1991, LANCET, V338, P13, DOI 10.1016/0140-6736(91)90005-A; GOADSBY PJ, 1991, LANCET, V338, P782, DOI 10.1016/0140-6736(91)90666-D; INMAN W, 1992, BRIT MED J, V305, P714, DOI 10.1136/bmj.305.6855.714; LANCE JW, 1991, EUR NEUROL, V31, P279, DOI 10.1159/000116754; LANCE JW, 1992, LANCET, V339, P1207, DOI 10.1016/0140-6736(92)91141-T; PEARCE JMS, 1991, BRIT MED J, V303, P1491, DOI 10.1136/bmj.303.6816.1491; PEROUTKA SJ, 1989, EUR J PHARMACOL, V163, P133, DOI 10.1016/0014-2999(89)90406-8; SAXENA PR, 1991, TRENDS PHARMACOL SCI, V12, P223, DOI 10.1016/0165-6147(91)90556-8; 1991, NEW ENGL J MED, V325, P322; 1991, EUR NEUROL, V31, P314; 1991, EUR NEUROL, V31, P306; 1991, NEW ENGL J MED, V325, P316; 1992, CURR PROBL       JUN; 1991, EUR NEUROL, V31, P177	23	49	51	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 23	1993	341	8839					221	224		10.1016/0140-6736(93)90079-V	http://dx.doi.org/10.1016/0140-6736(93)90079-V			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ219	8093509				2022-12-28	WOS:A1993KJ21900016
J	NORRIS, R				NORRIS, R			ACUTE CORONARY-CARE - WHO SHOULD GO TO THE CCU IN 1993	LANCET			English	Editorial Material											NORRIS, R (corresponding author), TRAFFORD CTR MED RES, BRIGHTON, E SUSSEX, ENGLAND.							[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, Lancet, V1, P397; BETT J H N, 1989, Australian and New Zealand Journal of Medicine, V19, P572; BIRKHEAD JS, 1992, BMJ-BRIT MED J, V305, P445, DOI 10.1136/bmj.305.6851.445; CERQUEIRA MD, 1992, CIRCULATION, V86, P643; ROLLAG A, 1992, J INTERN MED, V232, P299, DOI 10.1111/j.1365-2796.1992.tb00589.x; WEAVER WD, 1992, CIRCULATION, V86, P16	7	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 23	1993	341	8839					212	212		10.1016/0140-6736(93)90073-P	http://dx.doi.org/10.1016/0140-6736(93)90073-P			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ219	8093504				2022-12-28	WOS:A1993KJ21900011
J	CHAUHAN, A; JAMEEL, S; DILAWARI, JB; CHAWLA, YK; KAUR, U; GANGULY, NK				CHAUHAN, A; JAMEEL, S; DILAWARI, JB; CHAWLA, YK; KAUR, U; GANGULY, NK			HEPATITIS-E VIRUS TRANSMISSION TO A VOLUNTEER	LANCET			English	Note							NON-B HEPATITIS; NON-A	Hepatitis E virus (HEV) causes an enteric non-A, non-B hepatitis. The disease occurs in epidemic settings and sporadically, and viral transmission is thought to be faecal-oral. We present here a single volunteer study of HEV transmission followed by disease. Clinical and biochemical features of the infection correlated with HEV detection in the stools and sera by reverse transcription/polymerase chain amplification. IgG antibody has persisted for 2 years. The presence of HEV in serum before clinical signs appeared suggests that in endemic areas sporadic transmission of HEV may also occur parenterally.	POSTGRAD INST MED EDUC & RES,DEPT EXPTL MED,CHANDIGARH 160012,INDIA; POSTGRAD INST MED EDUC & RES,DEPT HEPATOL,CHANDIGARH 160012,INDIA; INT CTR GENET ENGN & BIOTECHNOL,VIROL GRP,NEW DELHI,INDIA	Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh; Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh; Department of Biotechnology (DBT) India; International Center for Genetic Engineering & Biotechnology (ICGEB); International Center for Genetic Engineering & Biotechnology (ICGEB), New Delhi			Bambery, Upjeet/G-7593-2011					BALAYAN MS, 1983, INTERVIROLOGY, V20, P23, DOI 10.1159/000149370; BRADLEY DW, 1987, P NATL ACAD SCI USA, V84, P6277, DOI 10.1073/pnas.84.17.6277; CHAUHAN A, 1992, LANCET, V339, P1509, DOI 10.1016/0140-6736(92)91267-C; DAWSON GJ, 1992, LANCET, V340, P426, DOI 10.1016/0140-6736(92)91507-5; GUTTERIDGE F, 1981, WHO CHRON, V35, P212; JAMEEL S, 1992, J MED VIROL, V37, P263, DOI 10.1002/jmv.1890370405; KHUROO MS, 1980, AM J MED, V68, P818, DOI 10.1016/0002-9343(80)90200-4; PANDA SK, 1989, HEPATOLOGY, P466; ROBSON SC, 1992, LANCET, V339, P1424, DOI 10.1016/0140-6736(92)91250-C; TSAREV SA, 1992, P NATL ACAD SCI USA, V89, P559, DOI 10.1073/pnas.89.2.559	10	171	176	1	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 16	1993	341	8838					149	150		10.1016/0140-6736(93)90008-5	http://dx.doi.org/10.1016/0140-6736(93)90008-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG627	8093748				2022-12-28	WOS:A1993KG62700008
J	SMITH, WCS; JESUDASAN, K				SMITH, WCS; JESUDASAN, K			ELIMINATION OF LEPROSY AND PROSPECTS FOR REHABILITATION	LANCET			English	Editorial Material											SMITH, WCS (corresponding author), LEPROSY MISSION,SINGAPORE,SINGAPORE.							NOORDEEN SK, 1991, B WORLD HEALTH ORGAN, V69, P263; NOORDEEN SK, 1992, B WORLD HEALTH ORGAN, V70, P7; PETTIT JHS, 1964, LANCET, V2, P673, DOI 10.1016/S0140-6736(64)92482-1; SMITH WCS, 1992, LEPR REV S, V62, P23; 1982, WHO TECH REP SER, V675; 1991, ELIMINATION LEPROSY; 1985, WHO TECH REP SER, V716	7	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 9	1993	341	8837					89	90		10.1016/0140-6736(93)92563-9	http://dx.doi.org/10.1016/0140-6736(93)92563-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF870	8093410				2022-12-28	WOS:A1993KF87000010
J	BURROW, GN; FISHER, DA; LARSEN, PR				BURROW, GN; FISHER, DA; LARSEN, PR			MECHANISMS OF DISEASE - MATERNAL AND FETAL THYROID-FUNCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CONGENITAL HYPOTHYROIDISM; 3,5,3'-TRIIODOTHYRONINE SULFATE; AMNIOTIC-FLUID; TRIIODOTHYRONINE SULFATE; THYROXINE TREATMENT; RING DEIODINATION; SCREENING-PROGRAM; NORMAL-PREGNANCY; HORMONE LEVELS; ADULT PROGENY		CORNING NICHOLS INST,SAN JUAN CAPISTRANO,CA 92690; YALE UNIV,SCH MED,DEPT MED,NEW HAVEN,CT 06510; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA	Corning Inc; Yale University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School					NIDDK NIH HHS [DK 44128, DK 36256] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044128, R01DK036256] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABUID J, 1974, J CLIN ENDOCR METAB, V39, P263, DOI 10.1210/jcem-39-2-263; ABUID J, 1973, J CLIN INVEST, V52, P1195, DOI 10.1172/JCI107286; AIN KB, 1987, J CLIN ENDOCR METAB, V65, P689, DOI 10.1210/jcem-65-4-689; BALLABIO M, 1989, CLIN ENDOCRINOL, V31, P565, DOI 10.1111/j.1365-2265.1989.tb01280.x; BALLABIO M, 1991, J CLIN ENDOCR METAB, V73, P824, DOI 10.1210/jcem-73-4-824; BERNAL J, 1984, ENDOCRINOLOGY, V114, P677, DOI 10.1210/endo-114-2-677; BOYAGES SC, 1988, J CLIN ENDOCR METAB, V67, P1262, DOI 10.1210/jcem-67-6-1262; BURROW GN, 1990, J CLIN ENDOCR METAB, V71, P274, DOI 10.1210/jcem-71-2-274; CALVO R, 1990, J CLIN INVEST, V86, P889, DOI 10.1172/JCI114790; CASTILLO AP, 1985, ENDOCRINOLOGY, V117, P2457; CHOPRA IJ, 1992, J CLIN ENDOCR METAB, V75, P189, DOI 10.1210/jc.75.1.189; CONTEMPRE B, 1993, J CLIN ENDOCR METAB, V77, P1719, DOI 10.1210/jc.77.6.1719; DEELVIRA MCR, 1989, J ENDOCRINOL, V121, P331, DOI 10.1677/joe.0.1210331; DELANGE FM, 1991, WERNER INGBARS THYRO, P942; ELZAHERI MM, 1981, J CLIN INVEST, V67, P1126, DOI 10.1172/JCI110126; FERREIRO B, 1988, J CLIN ENDOCR METAB, V67, P853, DOI 10.1210/jcem-67-4-853; FISHER DA, 1981, NEW ENGL J MED, V304, P702, DOI 10.1056/NEJM198103193041205; FISHER DA, 1991, TRENDS ENDOCRIN MET, V2, P129, DOI 10.1016/1043-2760(91)90002-5; FISHER DA, 1989, BAILLIERE CLIN ENDOC, V3, P627, DOI 10.1016/S0950-351X(89)80046-1; FISHER DA, 1964, J CLIN ENDOCR METAB, V24, P393, DOI 10.1210/jcem-24-5-393; FISHER DA, 1989, PEDIATRICS, V83, P785; GLINOER D, 1992, THYROID, V2, P65, DOI 10.1089/thy.1992.2.65; GLINOER D, 1990, J CLIN ENDOCR METAB, V71, P276, DOI 10.1210/jcem-71-2-276; GLORIEUX J, 1988, PEDIATR RES, V24, P6, DOI 10.1203/00006450-198807000-00003; GLORIEUX J, 1985, J PEDIATR-US, V107, P913, DOI 10.1016/S0022-3476(85)80187-6; GONZALES LW, 1981, J CLIN ENDOCR METAB, V53, P21, DOI 10.1210/jcem-53-1-21; GUILLAUME J, 1985, J CLIN ENDOCR METAB, V60, P678, DOI 10.1210/jcem-60-4-678; HADJZADEH M, 1990, J ENDOCRINOL, V124, P387, DOI 10.1677/joe.0.1240387; HARAKAWA S, 1989, ACTA ENDOCRINOL-COP, V121, P739, DOI 10.1530/acta.0.1210739; HEYERDAHL S, 1991, J PEDIATR-US, V118, P850, DOI 10.1016/S0022-3476(05)82194-8; HIDAL JT, 1985, J CLIN INVEST, V76, P947, DOI 10.1172/JCI112094; HOUSTEK J, 1993, J CLIN ENDOCR METAB, V77, P382, DOI 10.1210/jc.77.2.382; ILICKI A, 1990, HORM RES, V33, P260, DOI 10.1159/000181532; KAPLAN MM, 1992, THYROID, V2, P147, DOI 10.1089/thy.1992.2.147; KAPLAN MM, 1988, J CLIN ENDOCR METAB, V66, P815, DOI 10.1210/jcem-66-4-815; KAPLAN MM, 1981, J CLIN INVEST, V67, P1208, DOI 10.1172/JCI110136; KIMURA M, 1990, OBSTET GYNECOL, V75, P775; KLEIN AH, 1972, J PEDIATR-US, V81, P912, DOI 10.1016/S0022-3476(72)80542-0; KLEIN AH, 1980, AM J OBSTET GYNECOL, V136, P626, DOI 10.1016/0002-9378(80)91014-5; KLEIN AH, 1978, J CLIN ENDOCR METAB, V47, P1034, DOI 10.1210/jcem-47-5-1034; KUNG MP, 1988, ENDOCRINOLOGY, V122, P1195, DOI 10.1210/endo-122-4-1195; LAFRANCHI SH, 1985, PEDIATRICS, V76, P734; LANDAU H, 1980, J CLIN ENDOCR METAB, V50, P799, DOI 10.1210/jcem-50-4-799; LARSEN PR, 1981, ENDOCR REV, V2, P87, DOI 10.1210/edrv-2-1-87; LIU H, 1992, THYROID, V2, P524; MAN EB, 1991, ANN CLIN LAB SCI, V21, P227; MANDEL SJ, 1992, J CLIN ENDOCR METAB, V75, P1133, DOI 10.1210/jc.75.4.1133; MANDEL SJ, 1990, NEW ENGL J MED, V323, P91, DOI 10.1056/NEJM199007123230204; MEINHOLD H, 1979, CLIN ENDOCRINOL, V10, P355, DOI 10.1111/j.1365-2265.1979.tb02090.x; MOL JA, 1985, ENDOCRINOLOGY, V117, P8, DOI 10.1210/endo-117-1-8; Morreale de Escobar G, 1983, CONGENITAL HYPOTHYRO, P85; NELSON M, 1987, J REPROD MED, V32, P888; OBREGON MJ, 1984, ENDOCRINOLOGY, V114, P305, DOI 10.1210/endo-114-1-305; OTTEN MH, 1983, SCIENCE, V221, P81, DOI 10.1126/science.6857270; PHAROAH POD, 1984, CLIN ENDOCRINOL, V21, P265, DOI 10.1111/j.1365-2265.1984.tb03468.x; PICKARD MR, 1990, AMINO ACIDS CHEM BIO, P828; POLK DH, 1988, AM J PHYSIOL, V254, pE337, DOI 10.1152/ajpendo.1988.254.3.E337; RAITI S, 1971, ARCH DIS CHILD, V46, P692, DOI 10.1136/adc.46.249.692; ROSS MG, 1988, BIOL NEONATE, V53, P98; ROTI E, 1983, ENDOCR REV, V4, P131, DOI 10.1210/edrv-4-2-131; ROTI E, 1981, J CLIN ENDOCR METAB, V53, P498, DOI 10.1210/jcem-53-3-498; ROVET J, 1987, J PEDIATR-US, V110, P700, DOI 10.1016/S0022-3476(87)80005-7; ROVET JF, 1986, GENETIC DISEASE SCRE, P281; RUTGERS M, 1989, ENDOCRINOLOGY, V125, P2822, DOI 10.1210/endo-125-6-2822; SANTINI F, 1993, ENDOCRINOLOGY, V133, P105, DOI 10.1210/en.133.1.105; SANTINI F, 1992, ENDOCRINOLOGY, V131, P1689, DOI 10.1210/en.131.4.1689; SANTINI F, 1992, PEDIATR RES, V31, P541, DOI 10.1203/00006450-199206000-00001; SILVA JE, 1984, J CLIN INVEST, V74, P1035, DOI 10.1172/JCI111471; SPAULDING SW, 1992, J CLIN ENDOCR METAB, V74, P1062, DOI 10.1210/jc.74.5.1062; TIMIRAS PS, 1989, BIOL NEONATE, V55, P376; TOMODA S, 1985, AM J PHYSIOL, V249, pR133, DOI 10.1152/ajpregu.1985.249.1.R133; VULSMA T, 1989, NEW ENGL J MED, V321, P13, DOI 10.1056/NEJM198907063210103; WEEKE J, 1982, ACTA ENDOCRINOL-COP, V101, P531, DOI 10.1530/acta.0.1010531; WOODS RJ, 1984, CLIN SCI, V67, P359, DOI 10.1042/cs0670359; WU SY, 1993, J CLIN ENDOCR METAB, V76, P1625, DOI 10.1210/jc.76.6.1625; WU SY, 1992, THYROID, V2, P101, DOI 10.1089/thy.1992.2.101; 1985, J PEDIATR, V107, P915	77	445	474	2	24	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 20	1994	331	16					1072	1078						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL560	8090169				2022-12-28	WOS:A1994PL56000008
J	BOTHERAS, L				BOTHERAS, L			HEALTH-CARE REFORMS AND THE PHARMACEUTICAL-INDUSTRY	NATURE			English	Article								As governments look ever more critically at the costs of drugs, those working in the pharmaceutical industry must become aware of the effects on their own career prospects.			BOTHERAS, L (corresponding author), MACMILLAN DAVIES,PHARMACEUT & HEALTHCARE,SALISBURY HOUSE,HERTFORD,HERTS,ENGLAND.							BOTHERAS L, 1994, NATURE, V367, P764, DOI 10.1038/367764a0	1	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 29	1994	371	6496					460	460		10.1038/371460a0	http://dx.doi.org/10.1038/371460a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PJ285	8090227	Bronze			2022-12-28	WOS:A1994PJ28500050
J	CRISPINO, JD; BLENCOWE, BJ; SHARP, PA				CRISPINO, JD; BLENCOWE, BJ; SHARP, PA			COMPLEMENTATION BY SR PROTEINS OF PRE-MESSENGER-RNA SPLICING REACTIONS DEPLETED OF U1 SNRNP	SCIENCE			English	Article							NUCLEAR RIBONUCLEOPROTEIN-PARTICLES; MESSENGER-RNA; SITE SELECTION; U6 SNRNA; SPLICEOSOME; COMPLEXES; YEAST; REGULATORS; SEQUENCE; REVEALS	Individual small nuclear ribonucleoproteins (snRNPs) U1, U2, and U4/U6 were removed from nuclear extracts of HeLa cells by antisense affinity depletion. Addition of a highly purified preparation of SR proteins fully restored splicing activity in reactions depleted of U1 snRNP but did not reconstitute splicing in reactions depleted of the other snRNPs. Affinity selection experiments revealed that spliceosomes lacking U1 snRNA formed in the U1 snRNP-depleted reactions reconstituted with SR proteins. Thus, high concentrations of SR proteins facilitate the assembly of precursor messenger RNA (pre-mRNA) into a spliceosome in the absence of interactions with U1 snRNP.	MIT,CTR CANC RES,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)				Crispino, John/0000-0002-8182-8306	NATIONAL CANCER INSTITUTE [P30CA014051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032486] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034277] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA14051] Funding Source: Medline; NIAID NIH HHS [R01-AI32486] Funding Source: Medline; NIGMS NIH HHS [R01-GM34277] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARABINO SML, 1990, CELL, V63, P293, DOI 10.1016/0092-8674(90)90162-8; CRISPINO JD, UNPUB; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FU XD, 1992, P NATL ACAD SCI USA, V89, P11224, DOI 10.1073/pnas.89.23.11224; FU XD, 1993, NATURE, V365, P82, DOI 10.1038/365082a0; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GRABOWSKI PJ, 1984, CELL, V37, P415, DOI 10.1016/0092-8674(84)90372-6; GRABOWSKI PJ, 1986, SCIENCE, V233, P1294, DOI 10.1126/science.3638792; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; KANDELSLEWIS S, 1993, SCIENCE, V262, P2035, DOI 10.1126/science.8266100; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; KONARSKA MM, 1986, CELL, V46, P845, DOI 10.1016/0092-8674(86)90066-8; KONFORTI BB, 1993, CELL, V75, P863, DOI 10.1016/0092-8674(93)90531-T; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; LESSER CF, 1993, SCIENCE, V262, P1982, DOI 10.1126/science.8266093; MICHAUD S, 1991, GENE DEV, V5, P2534, DOI 10.1101/gad.5.12b.2534; Moore M., 1993, RNA WORLD, P303; NILSEN TW, 1993, ANNU REV MICROBIOL, V47, P413, DOI 10.1146/annurev.mi.47.100193.002213; RYDER U, 1990, NUCLEIC ACIDS RES, V18, P7373, DOI 10.1093/nar/18.24.7373; SERAPHIN B, 1989, CELL, V59, P349, DOI 10.1016/0092-8674(89)90296-1; SERAPHIN B, 1988, EMBO J, V7, P2533, DOI 10.1002/j.1460-2075.1988.tb03101.x; SILICIANO PG, 1988, GENE DEV, V2, P1258, DOI 10.1101/gad.2.10.1258; SONTHEIMER E, 1982, SCIENCE, V262, P1989; TARN WY, UNPUB; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAHLER KM, 1983, MOL CELL BIOL, V13, P4023; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4; ZUO P, 1994, P NATL ACAD SCI USA, V91, P3363, DOI 10.1073/pnas.91.8.3363	30	148	150	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 23	1994	265	5180					1866	1869		10.1126/science.8091213	http://dx.doi.org/10.1126/science.8091213			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH258	8091213				2022-12-28	WOS:A1994PH25800033
J	ZOLI, G; BALLINGER, A; HEALY, J; ODONNELL, LJD; CLARK, M; FARTHING, MJG				ZOLI, G; BALLINGER, A; HEALY, J; ODONNELL, LJD; CLARK, M; FARTHING, MJG			PROMOTION OF GALLBLADDER EMPTYING BY INTRAVENOUS AMINO-ACIDS	LANCET			English	Article							TOTAL PARENTERAL-NUTRITION; BILIARY SLUDGE; CHOLECYSTOKININ; CONTRACTION; HUMANS; PLASMA	Patients receiving total intravenous nutrition have inert gallbladders; gallbladder sludge and gallstones often develop, but are preventable if gallbladder emptying can be improved. We measured the effect of giving rapid intravenous infusions of aminoacid solutions in eight normal subjects. Four regimens were tested (250 mL over 30 min, 250 mL over 10 min, 125 mL over 5 min, and 50 mL over 5 min). Gallbladder emptying, as measured by ultrasound and cholecystokinin release, depended on both the amount and the rate of aminoacid infusion. Rapid infusion of 125 mL of an aminoacid mixture (Synthamin 14 without electrolytes) over 5 min (2.1 g per min) produced a 64% reduction in gallbladder volume within 30 min, whereas a 50 mL infusion over 5 min produced only a 22% reduction. Intermittent rapid infusion of small amounts of aminoacids may prevent gallstones in patients receiving intravenous nutrition.	ST BARTHOLOMEWS HOSP,DEPT GASTROENTEROL,LONDON EC1A 7BE,ENGLAND; ST BARTHOLOMEWS HOSP,DEPT RADIOL,LONDON EC1A 7BE,ENGLAND; UNIV BOLOGNA,DEPT MED PATHOL,I-40126 BOLOGNA,ITALY	University of London; Queen Mary University London; University of London; Queen Mary University London; University of Bologna				ZOLI, Giorgio/0000-0002-3244-0663				CANO N, 1986, GASTROENTEROLOGY, V91, P313, DOI 10.1016/0016-5085(86)90562-7; DODDS WJ, 1985, AM J ROENTGENOL, V145, P1009, DOI 10.2214/ajr.145.5.1009; FISHER RS, 1982, DIGEST DIS SCI, V27, P1019, DOI 10.1007/BF01391749; HOPMAN WPM, 1985, RADIOLOGY, V157, P37, DOI 10.1148/radiology.157.1.3898222; LEE SP, 1992, NEW ENGL J MED, V326, P589, DOI 10.1056/NEJM199202273260902; LEE SP, 1988, GASTROENTEROLOGY, V94, P170, DOI 10.1016/0016-5085(88)90626-9; LIDDLE RA, 1985, J CLIN INVEST, V75, P1144, DOI 10.1172/JCI111809; LILJA P, 1982, GASTROENTEROLOGY, V83, P256; MESSING B, 1983, GASTROENTEROLOGY, V84, P1012; MESSING B, 1984, GASTROENTEROLOGY, V86, P1183; MURRAY FE, 1992, GUT, V33, P1123, DOI 10.1136/gut.33.8.1123; NEALON WH, 1990, AM J PHYSIOL, V259, pG173, DOI 10.1152/ajpgi.1990.259.2.G173; POTSON GJ, 1990, GASTROENTEROLOGY, V98, P993; SITZMANN JV, 1990, SURG GYNECOL OBSTET, V170, P25	14	26	27	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 15	1993	341	8855					1240	1241						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LC497	8098392				2022-12-28	WOS:A1993LC49700004
J	HOZAK, P; HASSAN, AB; JACKSON, DA; COOK, PR				HOZAK, P; HASSAN, AB; JACKSON, DA; COOK, PR			VISUALIZATION OF REPLICATION FACTORIES ATTACHED TO A NUCLEOSKELETON	CELL			English	Article							DNA-POLYMERASE-ALPHA; CELL NUCLEAR ANTIGEN; HELA-CELLS; RIBONUCLEOPROTEIN-PARTICLES; INTRACELLULAR-LOCALIZATION; ELECTRON-MICROSCOPY; MONOCLONAL-ANTIBODY; EUKARYOTIC CELLS; XENOPUS EGGS; MATRIX	HeLa cells in early S phase were encapsulated in agarose microbeads, permeabilized, and incubated with biotin-11-dUTP in a ''physiological'' buffer. Sites of DNA synthesis were then immunolabeled. As others have found, approximately 150 focal sites of synthesis were visible in each nucleus by light microscopy; they also contained DNA polymerase alpha and proliferating cell nuclear antigen. Electron microscopy of thick resinless sections from which approximately 90% of the chromatin had been removed revealed a similar number of dense, morphologically discrete ovoid bodies strung along a nucleoskeleton. The ovoids remained morphologically and functionally intact despite the removal of most of the chromatin. After 2.5 min of incubation with biotin-11-dUTP, the incorporated analog was associated only with ovoids; after 5 min it began to spread into the adjacent chromatin, which became extensively labeled after 1 hr. This provides visual evidence for polymerization ''factories'' fixed to a skeleton, with replication occurring as the template moves through them.	ACAD SCI PRAGUE, INST EXPTL MED, CS-12000 PRAGUE 2, CZECHOSLOVAKIA	Czech Academy of Sciences; Institute of Experimental Medicine of the Czech Academy of Sciences	HOZAK, P (corresponding author), UNIV OXFORD, SIR WILLIAM DUNN SCH PATHOL, S PARKS RD, OXFORD OX1 3RE, ENGLAND.		Hozak, Pavel/J-4182-2014; Hozak, Pavel/AAB-5359-2021	Hozak, Pavel/0000-0003-1901-1394; Hozak, Pavel/0000-0003-1901-1394; Cook, Peter/0000-0002-6639-188X; Hassan, Andrew/0000-0002-2517-6681	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ASCOLI CA, 1991, J CELL BIOL, V112, P785, DOI 10.1083/jcb.112.5.785; BENSCH KG, 1982, J BIOL CHEM, V257, P8391; BEREZNEY R, 1975, SCIENCE, V189, P291, DOI 10.1126/science.1145202; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; CARTER KC, 1991, J CELL BIOL, V115, P1191, DOI 10.1083/jcb.115.5.1191; COOK PR, 1988, J CELL SCI, V90, P1; COOK PR, 1991, CELL, V66, P627, DOI 10.1016/0092-8674(91)90109-C; DREYFUSS G, 1986, ANNU REV CELL BIOL, V2, P459, DOI 10.1146/annurev.cellbio.2.1.459; FEY EG, 1986, J CELL BIOL, V102, P1654, DOI 10.1083/jcb.102.5.1654; FUSCONI M, 1991, CLIN EXP IMMUNOL, V83, P291; HE DC, 1990, J CELL BIOL, V110, P569, DOI 10.1083/jcb.110.3.569; HUANG S, 1991, Genes and Development, V5, P2288, DOI 10.1101/gad.5.12a.2288; HURT E, 1991, EMBO J, V10, P195; HUTCHISON CJ, 1987, EMBO J, V6, P2003, DOI 10.1002/j.1460-2075.1987.tb02464.x; JACKSON DA, 1985, EMBO J, V4, P919, DOI 10.1002/j.1460-2075.1985.tb03719.x; JACKSON DA, 1986, EMBO J, V5, P1403, DOI 10.1002/j.1460-2075.1986.tb04374.x; JACKSON DA, 1988, J CELL SCI, V90, P365; JACKSON DA, 1991, BIOESSAYS, V13, P1, DOI 10.1002/bies.950130102; JACKSON DA, 1986, J MOL BIOL, V192, P77, DOI 10.1016/0022-2836(86)90465-1; JACKSON DA, 1988, EMBO J, V7, P3667, DOI 10.1002/j.1460-2075.1988.tb03248.x; JACKSON DA, 1990, EMBO J, V9, P567, DOI 10.1002/j.1460-2075.1990.tb08144.x; JACKSON DA, 1986, J MOL BIOL, V192, P65, DOI 10.1016/0022-2836(86)90464-X; JACKSON DA, 1990, NUCLEIC ACIDS RES, V18, P4385, DOI 10.1093/nar/18.15.4385; KILL IR, 1991, J CELL SCI, V100, P869; LASKEY RA, 1989, SCIENCE, V246, P609, DOI 10.1126/science.2683076; LENO GH, 1992, CELL, V69, P151, DOI 10.1016/0092-8674(92)90126-W; MARTELLI AM, 1990, EXP CELL RES, V190, P227, DOI 10.1016/0014-4827(90)90190-L; MCCREADY SJ, 1980, J CELL SCI, V46, P365; MILLS AD, 1989, J CELL SCI, V94, P471; NAKAMURA H, 1986, EXP CELL RES, V165, P291, DOI 10.1016/0014-4827(86)90583-5; NAKAMURA H, 1984, EXP CELL RES, V151, P123, DOI 10.1016/0014-4827(84)90362-8; NAKAYASU H, 1989, J CELL BIOL, V108, P1, DOI 10.1083/jcb.108.1.1; NELSON WG, 1986, ANNU REV BIOPHYS BIO, V15, P457, DOI 10.1146/annurev.bb.15.060186.002325; PARDOLL DM, 1980, CELL, V19, P527, DOI 10.1016/0092-8674(80)90527-9; RAO PN, 1968, SCIENCE, V160, P774, DOI 10.1126/science.160.3829.774; RASKA I, 1991, EXP CELL RES, V195, P27, DOI 10.1016/0014-4827(91)90496-H; RIS H, 1985, J CELL BIOL, V100, P1474, DOI 10.1083/jcb.100.5.1474; SAUNDERS WS, 1991, J CELL BIOL, V115, P919, DOI 10.1083/jcb.115.4.919; SPECTOR DL, 1990, P NATL ACAD SCI USA, V87, P147, DOI 10.1073/pnas.87.1.147; TUBO RA, 1987, J BIOL CHEM, V262, P5857; VAGNERCAPODANO AM, 1982, J ULTRA MOL STRUCT R, V78, P13, DOI 10.1016/S0022-5320(82)80010-5; WANG X, 1991, J CELL SCI, V98, P107; WASEEM NH, 1990, J CELL SCI, V96, P121; XING YG, 1991, J CELL BIOL, V112, P1055, DOI 10.1083/jcb.112.6.1055	46	429	435	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 23	1993	73	2					361	373		10.1016/0092-8674(93)90235-I	http://dx.doi.org/10.1016/0092-8674(93)90235-I			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KY505	8097433				2022-12-28	WOS:A1993KY50500016
J	CASTLE, W; FULLER, R; HALL, J; PALMER, J				CASTLE, W; FULLER, R; HALL, J; PALMER, J			SEREVENT NATIONWIDE SURVEILLANCE STUDY - COMPARISON OF SALMETEROL WITH SALBUTAMOL IN ASTHMATIC-PATIENTS WHO REQUIRE REGULAR BRONCHODILATOR TREATMENT	BRITISH MEDICAL JOURNAL			English	Article								Objective-To compare safety of salmeterol and salbutamol in treating asthma. Design-Double blind, randomised clinical trial in parallel groups over 16 weeks. Setting-General practices throughout the United Kingdom. Subjects-25180 patients with asthma considered to require regular treatment with bronchodilators who were recruited by their general practitioner (n=3516). Interventions-Salmeterol (Serevent) (50 mug twice daily) or salbutamol (200 mug four times a day) randomised in the ratio of two patients taking salmeterol to one taking salbutamol. All other drugs including prophylaxis against asthma were continued throughout the study. Main outcome measures-All serious events and reasons for withdrawals (medical and non-medical) whether or not they were considered to be related to the drugs. Results-Fewer medical withdrawals due to asthma occurred in patients taking salmeterol than in those taking salbutamol (2.91% v 3.79%; chi2=13.6, p=0.0002). Mortality and admissions to hospital were as expected. There was a small but nonsignificant excess mortality in the group taking salmeterol and a significant excess of asthma events including deaths in patients with severe asthma on entry. Use of more than two canisters of bronchodilator a month was particularly associated with the occurrence of an adverse asthma event. Conclusions-Treatment over 16 weeks with either salmeterol or salbutamol was not associated with an incidence of deaths related to asthma in excess of that predicted. Overall control of asthma was better in patients allocated to salmeterol. Serious adverse events occurred in patients most at risk on entry and were probably due to the disease rather than treatment.	GLAXO GRP RES LTD,GREENFORD UB6 0HE,MIDDX,ENGLAND; ALLEN & HANBURYS,UXBRIDGE UB11 1BT,MIDDX,ENGLAND; GLAXO RES INST,RES TRIANGLE PK,NC	GlaxoSmithKline; GlaxoSmithKline								[Anonymous], 1990, BMJ, V301, P651; BARNES PJ, 1992, ADVERSE DRUG REACT, V154, P579; DAHL R, 1991, EUR RESPIR J, V4, P1178; HILTON CJ, 1992, BRIT MED J, V304, P121, DOI 10.1136/bmj.304.6819.121-a; PEARCE N, 1991, CLIN EXP ALLERGY, V21, P401, DOI 10.1111/j.1365-2222.1991.tb01679.x; PEEL ET, 1980, AM REV RESPIR DIS, V121, P973; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SPITZER WO, IN PRESS N ENGL J ME; VANSCHAYCK CP, 1991, BRIT MED J, V303, P1426, DOI 10.1136/bmj.303.6815.1426; VATHENEN AS, 1988, LANCET, V1, P554; WALLER PC, 1992, BRIT MED J, V304, P1470, DOI 10.1136/bmj.304.6840.1470; ZACH M S, 1989, Archives of Disease in Childhood, V64, P1446; 1989, LANCET, V2, P199; 1990, ASTHMA; 1990, BMJ, V301, P797; 1992, EUR RESPIR J, V5, P601	16	383	390	0	12	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 17	1993	306	6884					1034	1037		10.1136/bmj.306.6884.1034	http://dx.doi.org/10.1136/bmj.306.6884.1034			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY448	8098238	Green Published, Bronze			2022-12-28	WOS:A1993KY44800019
J	KOMURO, H; RAKIC, P				KOMURO, H; RAKIC, P			MODULATION OF NEURONAL MIGRATION BY NMDA RECEPTORS	SCIENCE			English	Article							CEREBELLAR GRANULE CELLS; AMINO-ACIDS; L-GLUTAMATE; BRAIN; ASPARTATE; CHANNELS; CULTURES; AFFINITY; BINDING; ETHANOL	The N-methyl-D-aspartate (NMDA) subtype of the glutamate receptor is essential for neuronal differentiation and establishment or elimination of synapses in a developing brain. The activity of the NMDA receptor has now been shown to also regulate the migration of granule cells in slice preparations of the developing mouse cerebellum. First, blockade of NMDA receptors by specific antagonists resulted in the curtailment of cell migration. Second, enhancement of NMDA receptor activity by the removal of magnesium or by the application of glycine increased the rate of cell movement. Third, increase of endogenous extracellular glutamate by inhibition of its uptake accelerated the rate of cell migration. These results suggest that NMDA receptors may play an early role in the regulation of calcium-dependent cell migration before neurons reach their targets and form synaptic contacts.			KOMURO, H (corresponding author), YALE UNIV,SCH MED,NEUROBIOL SECT,NEW HAVEN,CT 06510, USA.							BALCAR VJ, 1972, J NEUROCHEM, V19, P2657, DOI 10.1111/j.1471-4159.1972.tb01325.x; BLANTON MG, 1992, J NEUROPHYSIOL, V67, P1185, DOI 10.1152/jn.1992.67.5.1185; BURGOYNE RD, 1988, NEUROSCI LETT, V91, P47, DOI 10.1016/0304-3940(88)90247-9; BURNASHEV N, 1992, SCIENCE, V256, P1566, DOI 10.1126/science.1317970; CAMBRAYDEAKIN MA, 1992, DEV BRAIN RES, V66, P25, DOI 10.1016/0165-3806(92)90136-K; CAVINESS VS, 1978, ANNU REV NEUROSCI, V1, P297, DOI 10.1146/annurev.ne.01.030178.001501; CHIZHMAKOV IV, 1992, J PHYSIOL-LONDON, V448, P453, DOI 10.1113/jphysiol.1992.sp019051; CHOI DW, 1991, GLUTAMATE CELL DEATH, P125; CLARREN SK, 1978, J PEDIATR-US, V92, P64, DOI 10.1016/S0022-3476(78)80072-9; CONNOR JA, 1987, J NEUROSCI, V7, P1384; CURTIS DR, 1970, EXP BRAIN RES, V10, P447; HASUO H, 1988, NEUROSCI LETT, V86, P77, DOI 10.1016/0304-3940(88)90186-3; HATTEN ME, 1990, TRENDS NEUROSCI, V13, P179, DOI 10.1016/0166-2236(90)90044-B; HONORE T, 1988, SCIENCE, V241, P701, DOI 10.1126/science.2899909; HOWE JR, 1991, J PHYSIOL-LONDON, V432, P143, DOI 10.1113/jphysiol.1991.sp018381; HUETTNER JE, 1988, P NATL ACAD SCI USA, V85, P1307, DOI 10.1073/pnas.85.4.1307; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; KOMURO H, 1992, SCIENCE, V257, P806, DOI 10.1126/science.1323145; LAURIE DJ, 1992, J NEUROSCI, V12, P4151; LEVI G, 1991, J NEUROCHEM, V56, P199, DOI 10.1111/j.1471-4159.1991.tb02581.x; LOVINGER DM, 1989, SCIENCE, V243, P1721, DOI 10.1126/science.2467382; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; OLVERMAN HJ, 1984, NATURE, V307, P460, DOI 10.1038/307460a0; PEARCE IA, 1987, FEBS LETT, V223, P143, DOI 10.1016/0014-5793(87)80525-2; RAKIC P, 1973, J COMP NEUROL, V152, P103, DOI 10.1002/cne.901520202; RAKIC P, 1981, TRENDS NEUROSCI, V4, P184, DOI 10.1016/0166-2236(81)90060-6; RAKIC P, 1971, J COMP NEUROL, V141, P283, DOI 10.1002/cne.901410303; RAKIC P, 1990, EXPERIENTIA, V46, P882, DOI 10.1007/BF01939380; Rakic P, 1985, CELL CONTACT ADHESIO, P67; RASHID NA, 1992, DEV BRAIN RES, V67, P301, DOI 10.1016/0165-3806(92)90231-K; SCHOUSBOE A, 1992, PROG BRAIN RES, V94, P199; ZU XZ, 1987, EUR J PHARMACOL, V141, P401	32	875	889	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 2	1993	260	5104					95	97		10.1126/science.8096653	http://dx.doi.org/10.1126/science.8096653			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KV423	8096653				2022-12-28	WOS:A1993KV42300036
J	LEVESQUE, H; VASSE, D; LEGALLICIER, B; CAILLEUX, N; MOORE, N; BORG, JY; COURTOIS, H				LEVESQUE, H; VASSE, D; LEGALLICIER, B; CAILLEUX, N; MOORE, N; BORG, JY; COURTOIS, H			PREVENTION OF VENOUS THROMBOEMBOLISM AFTER MAJOR ABDOMINAL-SURGERY - REPLY	LANCET			English	Letter							HEPARIN; THROMBOSIS		ROUEN UNIV HOSP,DEPT PHARMACOL,F-76233 BOIS GUILLAUME,FRANCE; ROUEN UNIV HOSP,DEPT HAEMATOL,VACOMED RES GRP,F-76233 BOIS GUILLAUME,FRANCE	CHU de Rouen; CHU de Rouen	LEVESQUE, H (corresponding author), ROUEN UNIV HOSP,DEPT INTERNAL MED,BP 100,F-76233 BOIS GUILLAUME,FRANCE.		Moore, Nicholas/B-2368-2013	Moore, Nicholas/0000-0003-1212-2817				ALBADA J, 1989, CIRCULATION, V80, P935, DOI 10.1161/01.CIR.80.4.935; CRUICKSHANK MK, 1991, ARCH INTERN MED, V151, P333, DOI 10.1001/archinte.151.2.333; DUROUX P, 1991, THROMB HAEMOSTASIS, V65, P1058; HULL RD, 1990, NEW ENGL J MED, V322, P1260, DOI 10.1056/NEJM199005033221802; HULL RD, 1992, NEW ENGL J MED, V326, P975, DOI 10.1056/NEJM199204093261502; LEIZOROVICZ A, 1992, BMJ-BRIT MED J, V305, P913, DOI 10.1136/bmj.305.6859.913; PRANDONI P, 1992, LANCET, V339, P441, DOI 10.1016/0140-6736(92)91054-C; SIMONNEAU G, 1991, THROMB HAEMOSTASIS, V65, P754	8	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 27	1993	341	8848					824	825						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU900	8096019				2022-12-28	WOS:A1993KU90000032
J	EASTWOOD, R				EASTWOOD, R			COMMUNITY PSYCHIATRY - HES MENTAL YOU KNOW	LANCET			English	Editorial Material											EASTWOOD, R (corresponding author), CLARKE INST PSYCHIAT, TORONTO M5T 1R8, ONTARIO, CANADA.							BROCKINGTON IF, 1993, BRIT J PSYCHIAT, V162, P93, DOI 10.1192/bjp.162.1.93; HALL P, 1993, BRIT J PSYCHIAT, V162, P99, DOI 10.1192/bjp.162.1.99	2	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 13	1993	341	8846					668	668		10.1016/0140-6736(93)90430-O	http://dx.doi.org/10.1016/0140-6736(93)90430-O			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR613	8095579				2022-12-28	WOS:A1993KR61300014
J	HOLMHANSEN, C; CONSTANTINE, NT				HOLMHANSEN, C; CONSTANTINE, NT			SALIVA AND HIV TESTING	LANCET			English	Letter									UNIV MARYLAND,SCH MED,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore	HOLMHANSEN, C (corresponding author), UNIV BERGEN,CTR INT HLTH,N-5021 BERGEN,NORWAY.							BARR CE, 1992, J AM DENT ASSOC, V123, P36; HOLMSTROM P, 1992, AIDS, V6, P738, DOI 10.1097/00002030-199207000-00020; SOTORAMIREZ LE, 1992, J CLIN MICROBIOL, V30, P2780	3	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 6	1993	341	8841					382	383						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK939	8094159				2022-12-28	WOS:A1993KK93900056
J	PRINS, JM; BULLER, HR; KUIJPER, EJ; TANGE, RA; SPEELMAN, P				PRINS, JM; BULLER, HR; KUIJPER, EJ; TANGE, RA; SPEELMAN, P			ONCE VERSUS THRICE DAILY GENTAMICIN IN PATIENTS WITH SERIOUS INFECTIONS	LANCET			English	Article							URINARY-TRACT INFECTION; BACTERIAL-INFECTIONS; AUDITORY TOXICITY; NETILMICIN; TOBRAMYCIN; AMIKACIN; SERUM; NEPHROTOXICITY; EFFICACY; SINGLE	Aminoglycosides are usually given in two or three divided doses. A once-daily regimen might be more effective and less toxic. We have conducted a randomised trial in consecutive patients with serious infections for whom an aminoglycoside seemed warranted. Exclusion criteria were neutropenia or severely impaired renal function. 123 patients were enrolled. For efficacy analysis only those patients were considered in whom treatment with the aminoglycoside was not stopped within 72 h (n=67); toxicity was analysed on patients receiving aminoglycosides for more than 48 h and not using other nephrotoxic medication (n=85). Gentamicin 4 mg/kg every day (OD) or gentamicin 1.33 mg/kg three times daily (MD) (with dose- reduction in case of renal dysfunction) were given intravenously. In almost all patients intravenous amoxycillin 1 g every 6 h was also started. Baseline characteristics were comparable in both arms. A good clinical response was observed in 32/35 (91%) of the OD and in 25/32 (78%) in the MD group (difference 13%, 95% confidence interval -6.4% to + 26.9%). 2 patients in each group died with uncontrolled infection. An insufficient bacteriological response (persistent positive cultures, resistance, or superinfection) was observed in 2 patients with OD and 3 patients with MD. In patients treated for more than 48 h duration of therapy and mean doses were 7.0 days (1590 mg) and 7.4 days (1672 mg) in OD and MD respectively. Mean first serum trough/peak levels were 0.6/10.2 mg/L and 1.4/5.2 mg/L. Nephrotoxicity (a rise in serum creatinine of 45 mumol/ L or more) developed in 2/40 (5%) in OD and 11/45 (24%) in MD (p=0.016). Risk factors for nephrotoxicity were duration of therapy and baseline creatinine clearance rate. High-tone audiometry was performed when possible; no significant differences were found in hearing loss (3/12 and 3/11) or prodromal signs of ototoxicity (5/12 and 4/11). A once-daily dosing regimen of gentamicin is at least as effective as and is less nephrotoxic than more frequent dosing.	UNIV AMSTERDAM, ACAD MED CTR, DEPT MED MICROBIOL, 1105 AZ AMSTERDAM, NETHERLANDS; UNIV AMSTERDAM, ACAD MED CTR, DEPT OTORHINOLARYNGOL, 1105 AZ AMSTERDAM, NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	PRINS, JM (corresponding author), UNIV AMSTERDAM, ACAD MED CTR, DEPT INTERNAL MED, INFECT DIS & TROP MED UNIT, MEIBERGDREEF 9, 1105 AZ AMSTERDAM, NETHERLANDS.		Prins, Jan M./AAF-4945-2020; Kuijper, ed/AAB-7853-2022	Kuijper, ed/0000-0001-5726-2405				Balows A, 1991, MANUAL CLIN MICROBIO; BENNETT WM, 1979, J INFECT DIS, V140, P576, DOI 10.1093/infdis/140.4.576; BRUMMETT RE, 1989, ANTIMICROB AGENTS CH, V33, P797, DOI 10.1128/AAC.33.6.797; CHEUNG R, 1990, BRIT J CLIN PHARMACO, V30, P1; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; DEBROE ME, 1991, J ANTIMICROB CHEMOTH, V27, P41, DOI 10.1093/jac/27.suppl_C.41; DEVRIES PJ, 1990, EUR J CLIN MICROBIOL, V9, P161; EISENBERG JM, 1987, ANN INTERN MED, V107, P900, DOI 10.7326/0003-4819-107-6-900; GILBERT DN, 1991, ANTIMICROB AGENTS CH, V35, P399, DOI 10.1128/AAC.35.3.399; HOLLENDER LF, 1989, J ANTIMICROB CHEMOTH, V23, P773, DOI 10.1093/jac/23.5.773; HULL JH, 1976, ANN INTERN MED, V85, P183, DOI 10.7326/0003-4819-85-2-183; HUY PTB, 1986, J CLIN INVEST, V77, P1492, DOI 10.1172/JCI112463; KAHLMETER G, 1984, J ANTIMICROB CHEMOTH, V13, P9, DOI 10.1093/jac/13.suppl_A.9; KAPUSNIK JE, 1988, J INFECT DIS, V158, P7, DOI 10.1093/infdis/158.1.7; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; MALLER R, 1991, J ANTIMICROB CHEMOTH, V27, P121, DOI 10.1093/jac/27.suppl_C.121; MALLER R, 1988, J ANTIMICROB CHEMOTH, V22, P75, DOI 10.1093/jac/22.1.75; MATTIE H, 1989, J ANTIMICROB CHEMOTH, V24, P281, DOI 10.1093/jac/24.3.281; POWELL SH, 1983, J INFECT DIS, V147, P918, DOI 10.1093/infdis/147.5.918; PROCTOR L, 1987, LARYNGOSCOPE, V97, P1443; SMITH CR, 1980, NEW ENGL J MED, V302, P1106, DOI 10.1056/NEJM198005153022002; SMITH CR, 1984, ANN INTERN MED, V101, P469, DOI 10.7326/0003-4819-101-4-469; STURM AW, 1989, J INFECT DIS, V159, P931, DOI 10.1093/infdis/159.5.931; TERBRAAK EW, 1990, AM J MED, V89, P58, DOI 10.1016/0002-9343(90)90099-Y; THOMAS DG, 1977, J AM STAT ASSOC, V72, P73, DOI 10.2307/2286908; TULKENS PM, 1991, J ANTIMICROB CHEMOTH, V27, P49, DOI 10.1093/jac/27.suppl_C.49; VANDERAUWERA P, 1987, ANTIMICROB AGENTS CH, V31, P1061, DOI 10.1128/AAC.31.7.1061; VANDERAUWERA P, 1991, ANTIMICROB AGENTS CH, V35, P640, DOI 10.1128/AAC.35.4.640; VERPOOTEN GA, 1989, CLIN PHARMACOL THER, V45, P22, DOI 10.1038/clpt.1989.4; VOGELMAN B, 1988, J INFECT DIS, V157, P287, DOI 10.1093/infdis/157.2.287; VOGELMAN BS, 1985, J ANTIMICROB CHEMOTH, V15, P37, DOI 10.1093/jac/15.suppl_A.37	31	307	308	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 6	1993	341	8841					335	339		10.1016/0140-6736(93)90137-6	http://dx.doi.org/10.1016/0140-6736(93)90137-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK939	8094114				2022-12-28	WOS:A1993KK93900005
J	SEMBA, RD; MUHILAL; WARD, BJ; GRIFFIN, DE; SCOTT, AL; NATADISASTRA, G; WEST, KP; SOMMER, A				SEMBA, RD; MUHILAL; WARD, BJ; GRIFFIN, DE; SCOTT, AL; NATADISASTRA, G; WEST, KP; SOMMER, A			ABNORMAL T-CELL SUBSET PROPORTIONS IN VITAMIN-A-DEFICIENT CHILDREN	LANCET			English	Article							COMMUNITY TRIAL; SOUTHERN INDIA; MORTALITY; DIARRHEA; SUPPLEMENTATION; PRESCHOOL; DISEASE; MEASLES; GROWTH; DEFECT	Although vitamin A deficiency in children seems to increase susceptibility to infection and community trials have shown that vitamin A supplementation can reduce childhood mortality from infectious diseases, the underlying biological mechanisms are largely unknown. We conducted a randomised, double-masked, placebo-controlled clinical trial among children in West Java, Indonesia, to determine whether vitamin A deficiency is associated with abnormalities in T-cell subsets and whether vitamin A supplementation affects T-cell subsets. We studied 55 children aged 3-6 years-30 with xerophthalmia and 25 without. Acutely malnourished children (< 80% of reference weight-for-height) were excluded. CD4/CD8 ratios and the proportions of circulating CD4 naive, CD4 memory, CD8, CD45RA, and CD8, CD45RO T-cell subsets were measured. Children with xerophthalmia had lower CD4/CD8 ratios (p < 0.08), lower proportions of CD4 naive T cells (p < 0.03), and higher proportions of CD8, CD45RO T cells (p < 0.04) than those without xerophthalmia. 26 children were given vitamin A supplementation (60 mg retinol equivalent) and 29 received placebo. 5 weeks later the vitamin A group had higher CD4/CD8 ratios (p < 0.001), higher proportions of CD4 naive T cells (p < 0.01), and lower proportions of CD8, CD45RO T cells (p < 0.05) than the placebo group. Vitamin-A-deficient children have underlying immune abnormalities in T-cell subsets and these abnormalities are reversible with vitamin A supplementation.	JOHNS HOPKINS UNIV,DANA CTR PREVENT OPHTHALMOL,SCH MED,WILMER INST,BALTIMORE,MD 21218; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT IMMUNOL & INFECT DIS,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,BALTIMORE,MD 21218; MINIST HLTH,CTR NUTR RES & DEV,BOGOR,INDONESIA; CICENDO EYE HOSP,BANDUNG,INDONESIA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Ministry of Health - Indonesia					NCRR NIH HHS [RR-04060] Funding Source: Medline; NEI NIH HHS [K11 EY00286] Funding Source: Medline; NIAID NIH HHS [R01 AI23047] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR004060] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [K11EY000286] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023047] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKBAR AN, 1991, IMMUNOL TODAY, V12, P184, DOI 10.1016/0167-5699(91)90050-4; AMATRUDA TT, 1986, RETINOIDS CELL DIFFE, P79; ARROYAVE G, 1982, BIOCH METHODOLOGY AS; BLOEM MW, 1990, AM J EPIDEMIOL, V131, P332, DOI 10.1093/oxfordjournals.aje.a115502; CARMAN JA, 1989, J IMMUNOL, V142, P388; COHEN BE, 1979, SURG GYNECOL OBSTET, V149, P658; COUTSOUDIS A, 1992, PEDIATR INFECT DIS J, V11, P203, DOI 10.1097/00006454-199203000-00006; DAULAIRE NMP, 1992, BMJ-BRIT MED J, V304, P207, DOI 10.1136/bmj.304.6821.207; DEANS JP, 1991, J IMMUNOL, V147, P4060; HAMILL PV, 1977, DHEW781650 NAT CTR H; HANNET I, 1992, IMMUNOL TODAY, V13, P215, DOI 10.1016/0167-5699(92)90157-3; HERRERA MG, 1992, LANCET, V340, P267, DOI 10.1016/0140-6736(92)92357-L; HUSSEY GD, 1990, NEW ENGL J MED, V323, P160, DOI 10.1056/NEJM199007193230304; Jelliffe DB, 1989, COMMUNITY NUTRITIONA, P633; KIEPIELA P, 1987, SCAND J INFECT DIS, V19, P185, DOI 10.3109/00365548709032397; KRISHNAN S, 1974, IMMUNOLOGY, V27, P383; MUHILAL PD, 1988, AM J CLIN NUTR, V48, P1271; RAHMATHULLAH L, 1990, NEW ENGL J MED, V323, P929, DOI 10.1056/NEJM199010043231401; RAHMATHULLAH L, 1991, AM J CLIN NUTR, V54, P568, DOI 10.1093/ajcn/54.3.568; SCHLOSSMAN SF, 1984, SPRINGER SEMIN IMMUN, V7, P9, DOI 10.1007/BF01891775; SEMBA RD, 1992, J NUTR, V122, P101, DOI 10.1093/jn/122.1.101; SOMMER A, 1986, LANCET, V1, P1169; SOMMER A, 1984, AM J CLIN NUTR, V40, P1090, DOI 10.1093/ajcn/40.5.1090; SOMMER A, 1983, LANCET, V2, P585; STEIN DS, 1992, J INFECT DIS, V165, P352, DOI 10.1093/infdis/165.2.352; UNDERWOOD BA, 1990, J NUTR, V120, P1459, DOI 10.1093/jn/120.suppl_11.1459; VIJAYARAGHAVAN K, 1990, LANCET, V336, P1342, DOI 10.1016/0140-6736(90)92895-O; WEST KP, 1988, AM J CLIN NUTR, V48, P1257, DOI 10.1093/ajcn/48.5.1257; WEST KP, 1991, LANCET, V338, P67, DOI 10.1016/0140-6736(91)90070-6	30	143	145	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 2	1993	341	8836					5	8		10.1016/0140-6736(93)92478-C	http://dx.doi.org/10.1016/0140-6736(93)92478-C			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF027	8093291				2022-12-28	WOS:A1993KF02700002
J	BROWN, RH				BROWN, RH			CLINICAL IMPLICATIONS OF BASIC RESEARCH - A TRANSGENIC-MOUSE MODEL OF AMYOTROPHIC-LATERAL-SCLEROSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SUPEROXIDE-DISMUTASE				BROWN, RH (corresponding author), MASSACHUSETTS GEN HOSP E,BOSTON,MA 02129, USA.							BECKMAN JS, 1993, NATURE, V364, P584, DOI 10.1038/364584a0; BOWLING AC, 1993, J NEUROCHEM, V61, P2322, DOI 10.1111/j.1471-4159.1993.tb07478.x; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; ROSEN DR, 1994, HUM MOL GENET, V3, P981, DOI 10.1093/hmg/3.6.981; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0	6	13	14	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 20	1994	331	16					1091	1092		10.1056/NEJM199410203311613	http://dx.doi.org/10.1056/NEJM199410203311613			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL560	8090173				2022-12-28	WOS:A1994PL56000013
J	LEW, J; HUANG, QQ; QI, Z; WINKFEIN, RJ; AEBERSOLD, R; HUNT, T; WANG, JH				LEW, J; HUANG, QQ; QI, Z; WINKFEIN, RJ; AEBERSOLD, R; HUNT, T; WANG, JH			A BRAIN-SPECIFIC ACTIVATOR OF CYCLIN-DEPENDENT KINASE-5	NATURE			English	Article							DIRECTED PROTEIN-KINASE; TAU-PROTEIN; PHOSPHORYLATION; SEQUENCE; IDENTIFICATION; NEUROFILAMENTS; CDC2; P34(CDC2); SUBUNIT; SITES	PHOSPHORYLATION of the neurofilament proteins of high and medium relative molecular mass, as well as of the Alzheimer's tau protein, is thought to be catalysed by a protein kinase with Cdc2-like substrate specificity(1-7). We have purified a novel Cdc2-like kinase from bovine brain(8) capable of phosphorylating both the neurofilament proteins(9) and tau(10). The purified enzyme is a heterodimer of cyclin-dependent kinase 5 (Cdk5)(9) and a novel regulatory subunit, p25 (ref. 8). When overexpressed and purified from Escherichia coli, p25 can activate Cdk5 in vitro. Unlike Cdk5, which is ubiquitously expressed in human tissue, the p25 transcript is expressed only in brain. A full-length complementary DNA clone showed that p25 is a truncated form of a larger protein precursor, p35, which seems to be the predominant form of the protein in crude brain extract. Cdk5/p35 is the first example of a Cdc2-like kinase with neuronal function.	UNIV CALGARY,MRC,SIGNAL TRANSDUCT GRP,CALGARY T2N 4N1,AB,CANADA; UNIV BRITISH COLUMBIA,BIOMED RES CTR,VANCOUVER,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT BIOCHEM & MOLEC BIOL,VANCOUVER,BC,CANADA; IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND	University of Calgary; University of British Columbia; University of British Columbia								ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GUAN RJ, 1992, J NEUROCHEM, V58, P1365, DOI 10.1111/j.1471-4159.1992.tb11351.x; HASEGAWA M, 1992, J BIOL CHEM, V267, P17047; HAYES TE, 1991, NEW BIOL, V3, P259; HELLMICH MR, 1992, P NATL ACAD SCI USA, V89, P10867, DOI 10.1073/pnas.89.22.10867; HISANAGA S, 1991, J BIOL CHEM, V266, P21798; ISHIGURO K, 1994, FEBS LETT, V342, P203, DOI 10.1016/0014-5793(94)80501-6; LEE VMY, 1988, P NATL ACAD SCI USA, V85, P1998, DOI 10.1073/pnas.85.6.1998; LEW J, 1992, J BIOL CHEM, V267, P25922; LEW J, 1992, J BIOL CHEM, V267, P13383; MAWALDEWAN M, 1992, J BIOL CHEM, V267, P19705; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; PAUDEL HK, 1993, J BIOL CHEM, V268, P23512; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; TSAI LH, 1993, DEVELOPMENT, V119, P1029; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; VULLIET R, 1992, J BIOL CHEM, V267, P22570; XIONG Y, 1992, CELL, V71, P504; XU ZS, 1992, J BIOL CHEM, V267, P4467	25	540	561	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 29	1994	371	6496					423	426		10.1038/371423a0	http://dx.doi.org/10.1038/371423a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PJ285	8090222				2022-12-28	WOS:A1994PJ28500044
J	WHITE, TD; SUWA, G; ASFAW, B				WHITE, TD; SUWA, G; ASFAW, B			AUSTRALOPITHECUS RAMIDUS, A NEW SPECIES OF EARLY HOMINID FROM ARAMIS, ETHIOPIA	NATURE			English	Article							MIDDLE PLIOCENE; KENYA; EVOLUTION; TABARIN; BARINGO; CHIMP; DNA	Seventeen hominoid fossils recovered from Pliocene strata at Aramis, Middle Awash, Ethiopia make up a series comprising dental, cranial and postcranial specimens dated to around 4.4 million years ago. When compared with Australopithecus afarensis and with modern and fossil apes the Aramis fossil hominids are recognized as a new species of Australopithecus-A. ramidus sp. nov. The antiquity and primitive morphology of A. ramidus suggests that it represents a long-sought potential root species for the Hominidae.	UNIV TOKYO, DEPT ANTHROPOL, BUNKYO KU, TOKYO 113, JAPAN; ETHIOPIAN MINIST CULTURE & SPORTS AFFAIRS, PALEOANTHROPOL LAB, ADDIS ABABA, ETHIOPIA	University of Tokyo	WHITE, TD (corresponding author), UNIV CALIF BERKELEY, HUMAN EVOLUTIONARY STUDIES LAB, BERKELEY, CA 94720 USA.		Klein, Richard G/B-5910-2009					ANDREWS P, 1991, PHILOS T R SOC B, V334, P199, DOI 10.1098/rstb.1991.0109; ANDREWS P, 1992, NATURE, V360, P641, DOI 10.1038/360641a0; BEGUN DR, 1992, SCIENCE, V257, P1929, DOI 10.1126/science.1411507; CLARK WEQ, 1950, J BEOL SOC, V105, P225; COFFING K, 1994, AM J PHYS ANTHROPOL, V93, P55, DOI 10.1002/ajpa.1330930104; Dart R. A., 1934, Folia Anatomica Japonica, V12, P207; DEAN D, 1992, NATURE, V359, P676, DOI 10.1038/359676a0; FERGUSON W W, 1983, Primates, V24, P397, DOI 10.1007/BF02381984; FERGUSON W W, 1984, Primates, V25, P519, DOI 10.1007/BF02381673; FERGUSON WW, 1989, PRIMATES, V30, P383, DOI 10.1007/BF02381261; FERGUSON WW, 1987, PRIMATES, V28, P258; FLEAGLE JG, 1991, J HUM EVOL, V21, P145, DOI 10.1016/0047-2484(91)90005-G; HASEGAWA M, 1985, J MOL EVOL, V22, P160, DOI 10.1007/BF02101694; HEINRICH RE, 1993, AM J PHYS ANTHROPOL, V92, P139, DOI 10.1002/ajpa.1330920203; HILL A, 1988, YEARB PHYS ANTHROPOL, V31, P49; HILL A, 1992, J HUM EVOL, V22, P439, DOI 10.1016/0047-2484(92)90079-O; HILL A, 1985, NATURE, V315, P222, DOI 10.1038/315222a0; JOHANSON DC, 1979, SCIENCE, V203, P321, DOI 10.1126/science.104384; KRAMER A, 1986, AM J PHYS ANTHROPOL, V70, P457, DOI 10.1002/ajpa.1330700406; LOVEJOY CO, 1993, ORIGIN AND EVOLUTION OF HUMANS AND HUMANNESS, P1; LOVEJOY CO, 1981, SCIENCE, V211, P341, DOI 10.1126/science.211.4480.341; PATTERSON B, 1970, NATURE, V226, P918, DOI 10.1038/226918a0; PICKFORD M, 1983, AM J PHYS ANTHROPOL, V60, P337, DOI 10.1002/ajpa.1330600306; PILBEAM D, 1986, AM ANTHROPOL, V88, P295, DOI 10.1525/aa.1986.88.2.02a00010; ROBINSON J. T., 1956, TRANSVAAL MUS MEM, V9, P1; SARICH VM, 1989, CLADISTICS, V5, P3, DOI 10.1111/j.1096-0031.1989.tb00480.x; SARICH VM, 1967, SCIENCE, V158, P1200, DOI 10.1126/science.158.3805.1200; WALKER A, 1984, AM J PHYS ANTHROPOL, V65, P47, DOI 10.1002/ajpa.1330650108; WARD S, 1987, AM J PHYS ANTHROPOL, V72, P21, DOI 10.1002/ajpa.1330720104; WHITE TD, 1993, NATURE, V366, P261, DOI 10.1038/366261a0; WHITE TD, 1986, ANTHROPOS BRNO, V23, P79; WOLDEGABRIEL G, 1994, NATURE, V371, P330, DOI 10.1038/371330a0	32	402	418	0	63	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	SEP 22	1994	371	6495					306	312		10.1038/371306a0	http://dx.doi.org/10.1038/371306a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH254	8090200				2022-12-28	WOS:A1994PH25400044
J	GREENOUGH, A				GREENOUGH, A			NEONATOLOGY - WHERE SHOULD THE UMBILICAL CATHETER GO	LANCET			English	Editorial Material							COMPLICATIONS				GREENOUGH, A (corresponding author), UNIV LONDON KINGS COLL HOSP,DEPT CHILD HLTH,LONDON SE5 8RX,ENGLAND.							BUTT WW, 1985, PEDIATRICS, V76, P250; HARRIS MS, 1978, J PERINAT MED, V6, P15, DOI 10.1515/jpme.1978.6.1.15; HENRY M, 1991, PEDIATR RES, V29, pA257; KEMPLEY ST, 1992, ARCH DIS CHILD-FETAL, V67, P855, DOI 10.1136/adc.67.7_Spec_No.855; MOKROHISKY ST, 1978, NEW ENGL J MED, V299, P561, DOI 10.1056/NEJM197809142991101; Schick J B, 1989, J Perinatol, V9, P382; 1992, PEDIATRICS, V90, P881	7	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 8	1993	341	8854					1186	1187		10.1016/0140-6736(93)91009-B	http://dx.doi.org/10.1016/0140-6736(93)91009-B			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB017	8098082				2022-12-28	WOS:A1993LB01700011
J	TSUTSUI, H; ISHIHARA, K; COOPER, G				TSUTSUI, H; ISHIHARA, K; COOPER, G			CYTOSKELETAL ROLE IN THE CONTRACTILE DYSFUNCTION OF HYPERTROPHIED MYOCARDIUM	SCIENCE			English	Article							VOLUME-OVERLOAD HYPERTROPHY; ADULT FELINE CARDIOCYTES; LOAD REGULATION; MICROTUBULE; INVITRO; TUBULIN; CAT; ENERGETICS; COLCHICINE; PRESSURE	Cardiac hypertrophy in response to systolic pressure loading frequently results in contractile dysfunction of unknown cause. In the present study, pressure loading increased the microtubule component of the cardiac muscle cell cytoskeleton, which was responsible for the cellular contractile dysfunction observed. The linked microtubule and contractile abnormalities were persistent and thus may have significance for the deterioration of initially compensatory cardiac hypertrophy into congestive heart failure.	MED UNIV S CAROLINA, DEPT MED, DIV CARDIOL, GAZES CARDIAC RES INST, CHARLESTON, SC 29401 USA; VET ADM MED CTR, CHARLESTON, SC 29403 USA; MED UNIV S CAROLINA, DEPT PHYSIOL, CHARLESTON, SC 29401 USA	Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Medical University of South Carolina			Tsutsui, Hiroyuki/A-4070-2012		NHLBI NIH HHS [HL37196] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037196] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BASSETT AL, 1973, CIRC RES, V32, P15, DOI 10.1161/01.RES.32.1.15; CAVENEY S, 1969, J CELL SCI, V4, P541; COOPER G, 1973, CIRC RES, V32, P140, DOI 10.1161/01.RES.32.2.140; COOPER G, 1986, CIRC RES, V58, P692, DOI 10.1161/01.RES.58.5.692; COOPER G, 1987, ANNU REV PHYSIOL, V49, P501, DOI 10.1146/annurev.ph.49.030187.002441; COOPER G, 1973, CIRC RES, V33, P213, DOI 10.1161/01.RES.33.2.213; DENNERLL TJ, 1988, J CELL BIOL, V107, P665, DOI 10.1083/jcb.107.2.665; GOLDSTEIN MA, 1979, J CELL BIOL, V80, P183, DOI 10.1083/jcb.80.1.183; GUNDERSEN GG, 1989, J CELL BIOL, V109, P2275, DOI 10.1083/jcb.109.5.2275; HILL TL, 1982, INT REV CYTOL, V78, P1, DOI 10.1016/S0074-7696(08)60105-9; HOCKING RR, 1985, ANAL LINEAR MODELS, P69; ITOH TJ, 1984, BIOCHIM BIOPHYS ACTA, V800, P21, DOI 10.1016/0304-4165(84)90089-8; IVES CL, 1986, IN VITRO CELL DEV B, V22, P500; KENT RL, 1989, AM J PHYSIOL, V257, pH1717, DOI 10.1152/ajpheart.1989.257.5.H1717; KLEIN I, 1983, CARDIOVASC RES, V17, P459, DOI 10.1093/cvr/17.8.459; LAMPIDIS TJ, 1986, EXP CELL RES, V164, P463, DOI 10.1016/0014-4827(86)90044-3; MANN DL, 1989, CIRC RES, V64, P1079, DOI 10.1161/01.RES.64.6.1079; MANN DL, 1991, CIRC RES, V68, P402, DOI 10.1161/01.RES.68.2.402; MARINO TA, 1985, AM J PHYSIOL, V249, pH371, DOI 10.1152/ajpheart.1985.249.2.H371; MIRANDA AF, 1973, TISSUE CELL, V5, P1, DOI 10.1016/S0040-8166(73)80002-3; NICK P, 1991, PLANT CELL PHYSIOL, V32, P873; OLMSTED JB, 1986, ANNU REV CELL BIOL, V2, P421, DOI 10.1146/annurev.cb.02.110186.002225; OSTLUND RE, 1980, J CELL BIOL, V85, P386, DOI 10.1083/jcb.85.2.386; OSTLUND RE, 1979, ANAL BIOCHEM, V96, P155, DOI 10.1016/0003-2697(79)90568-2; RAPPAPORT L, 1988, INT REV CYTOL, V113, P101; SACK DW, 1977, BASIC RES CARDIOL, V72, P268, DOI 10.1007/BF01906372; SCHAPER J, 1991, CIRCULATION, V83, P504, DOI 10.1161/01.CIR.83.2.504; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; SCHLIWA M, 1981, P NATL ACAD SCI-BIOL, V78, P4329, DOI 10.1073/pnas.78.7.4329; TSUTSUI H, 1992, CIRCULATION, V86, P5; TSUTSUI H, UNPUB; VIRTANEN I, 1980, EUR J CELL BIOL, V23, P80; YEN TJ, 1988, NATURE, V334, P580, DOI 10.1038/334580a0	33	248	248	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 30	1993	260	5108					682	687		10.1126/science.8097594	http://dx.doi.org/10.1126/science.8097594			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KZ641	8097594				2022-12-28	WOS:A1993KZ64100035
J	LUDLAM, CA; STEEL, CM				LUDLAM, CA; STEEL, CM			HEMOSTASIS - VONWILLEBRANDS VARIANTS	LANCET			English	Editorial Material									WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of Edinburgh	LUDLAM, CA (corresponding author), ROYAL EDINBURGH & ASSOCIATED HOSP,DEPT HAEMATOL,EDINBURGH EH3 9HB,MIDLOTHIAN,SCOTLAND.							GINSBURG D, 1985, SCIENCE, V228, P1401, DOI 10.1126/science.3874428; MCKUSICK VA, 1990, MENDELIAN INHERITANC, P972; von Willerbrand EA, 1931, ACTA MED SCAND, V76, P521; ZIMMERMAN TS, 1987, HUM PATHOL, V18, P140, DOI 10.1016/S0046-8177(87)80332-5; ZIMMERMANN TS, 1983, CLIN HAEMATOL, V12, P179	5	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 17	1993	341	8851					997	997		10.1016/0140-6736(93)91080-6	http://dx.doi.org/10.1016/0140-6736(93)91080-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY368	8096952				2022-12-28	WOS:A1993KY36800012
J	HORTON, R				HORTON, R			IMMUNOLOGY - NATURAL AUTOIMMUNITY	LANCET			English	Editorial Material																		BURNET FM, 1959, CLONAL SELECTION THE; COHEN IR, 1992, IMMUNOL TODAY, V13, P490, DOI 10.1016/0167-5699(92)90024-2; COHEN IR, 1992, IMMUNOL TODAY, V13, P441, DOI 10.1016/0167-5699(92)90071-E; COHEN IR, 1991, IMMUNOL TODAY, V12, P105, DOI 10.1016/0167-5699(91)90093-9; VIRELLA G, 1993, INTRO MED IMMUNOLOGY	5	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 10	1993	341	8850					932	933		10.1016/0140-6736(93)91220-G	http://dx.doi.org/10.1016/0140-6736(93)91220-G			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW981	8096273				2022-12-28	WOS:A1993KW98100012
J	PELTOLA, H				PELTOLA, H			CHILDHOOD INFECTION - HAEMOPHILUS-INFLUENZAE IN THE POSTVACCINATION ERA	LANCET			English	Editorial Material							HEMOPHILUS-INFLUENZAE; CHILDREN; PNEUMONIA; ETIOLOGY				PELTOLA, H (corresponding author), UNIV HELSINKI,CHILDRENS HOSP,SF-00100 HELSINKI 10,FINLAND.							CLANCY R, 1985, LANCET, V2, P1395; KORPPI M, 1992, ACTA PAEDIATR, V81, P989, DOI 10.1111/j.1651-2227.1992.tb12160.x; PELTOLA H, 1992, LANCET, V340, P592, DOI 10.1016/0140-6736(92)92117-X; PELTOLA H, 1977, PEDIATRICS, V60, P73; SHANN F, 1984, LANCET, V2, P537; SHAPIRO ED, 1993, JAMA-J AM MED ASSOC, V269, P264, DOI 10.1001/jama.269.2.264; SHAPIRO ED, 1988, JAMA-J AM MED ASSOC, V260, P1419, DOI 10.1001/jama.260.10.1419; TAKALA AK, 1991, J INFECT DIS, V164, P982, DOI 10.1093/infdis/164.5.982; WALL RA, 1986, B WORLD HEALTH ORGAN, V64, P553; WEINBERG GA, 1989, J INFECT DIS, V160, P634, DOI 10.1093/infdis/160.4.634	10	8	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 3	1993	341	8849					864	865		10.1016/0140-6736(93)93066-A	http://dx.doi.org/10.1016/0140-6736(93)93066-A			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KV811	8096567				2022-12-28	WOS:A1993KV81100009
J	ROWLANDJONES, SL; NIXON, DF; ALDHOUS, MC; GOTCH, F; ARIYOSHI, K; HALLAM, N; KROLL, JS; FROEBEL, K; MCMICHAEL, A				ROWLANDJONES, SL; NIXON, DF; ALDHOUS, MC; GOTCH, F; ARIYOSHI, K; HALLAM, N; KROLL, JS; FROEBEL, K; MCMICHAEL, A			HIV-SPECIFIC CYTOTOXIC T-CELL ACTIVITY IN AN HIV-EXPOSED BUT UNINFECTED INFANT	LANCET			English	Note							VIRUS; INFECTION	The factors necessary for protective immunity against HIV-1 are unknown. Important information about these factors should come from study of people at high risk of HIV infection who have not apparently become infected. Among these are the estimated 60-85% of children who may be exposed in utero or perinatally to HIV-1 but do not become infected. We observed the transient appearance of HIV-specific cytotoxic T-lymphocyte (CTL) activity in a baby born to HIV-1-infected parents, in whom all standard markers of infection remained negative. These findings suggest that HIV-specific CTLs may be a marker for recently exposed, but uninfected, individuals.	UNIV OXFORD,JOHN RADCLIFFE HOSP,DEPT PAEDIAT,OXFORD OX3 9DU,ENGLAND; JOHN RADCLIFFE HOSP,PUBL HLTH LAB,DEPT VIROL,OXFORD OX3 9DU,ENGLAND; UNIV EDINBURGH,ROYAL EDINBURGH INFIRM,DEPT MED,HIV IMMUNOL UNIT,EDINBURGH EH10 5HF,MIDLOTHIAN,SCOTLAND; ST MARYS HOSP,SCH MED,DEPT GENITOURINARY MED,LONDON,ENGLAND	University of Oxford; University of Oxford; Royal Infirmary of Edinburgh; University of Edinburgh; Imperial College London	ROWLANDJONES, SL (corresponding author), JOHN RADCLIFFE HOSP,INST MOLEC MED,MOLEC IMMUNOL GRP,OXFORD OX3 9DU,ENGLAND.		Nixon, Douglas/AAU-5734-2020	Nixon, Douglas/0000-0002-2801-1786				BALTIMORE D, 1989, NEW ENGL J MED, V321, P1673, DOI 10.1056/NEJM198912143212409; CHEYNIER R, 1992, EUR J IMMUNOL, V22, P2211, DOI 10.1002/eji.1830220905; CLERICI M, 1992, J INFECT DIS, V165, P1012, DOI 10.1093/infdis/165.6.1012; FROEBEL KS, 1991, AIDS, V5, P97, DOI 10.1097/00002030-199101000-00015; HUTTO C, 1991, J PEDIATR-US, V118, P347, DOI 10.1016/S0022-3476(05)82145-6; NIXON DF, 1988, NATURE, V336, P484, DOI 10.1038/336484a0; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; TOVO PA, 1992, LANCET, V339, P1249, DOI 10.1016/0140-6736(92)91592-V; YAP KL, 1978, NATURE, V273, P238, DOI 10.1038/273238a0; 1991, LANCET, V337, P253	10	355	362	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 3	1993	341	8849					860	861		10.1016/0140-6736(93)93063-7	http://dx.doi.org/10.1016/0140-6736(93)93063-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KV811	8096564				2022-12-28	WOS:A1993KV81100006
J	GLASER, WA				GLASER, WA			THE COMPETITION VOGUE AND ITS OUTCOMES	LANCET			English	Article							UNIVERSAL HEALTH-INSURANCE; PROMOTE QUALITY; PLAN; ECONOMY; 1990S	Social security and comprehensive health care financing were developed to protect all citizens and to redistribute money to cover costs. Their inspiration was social solidarity rather than pecuniary self-interest. The United States differed from other countries by continuing a private market in health, with many self-centred and competing providers and insurers; and its prevailing school of health economics deplored the national heath insurance and national health services that were universal in other countries and recommended devices that would eliminate ''market failure'' in health. When health economics grew in Europe during the 1970s and 1980s, the reformers' first presumption was that the voluminous American market-oriented literature must offer answers; but much of it proved superfluous, since European health care systems still had much competition and consumer choice, and they worked better than the reality in the United States. The United States itself has paid a heavy price for turning over health financing policy to the devotees of microeconomics and free markets, and today its serious problems in health are unsolved.So powerful is the pro-competitive ideology that it has now been adopted by the Democratic Clinton Administration, contradicting the heritage of Roosevelt, Truman, and Johnson.			GLASER, WA (corresponding author), NEW SCH SOCIAL RES,GRAD SCH MANAGEMENT & URBAN POLICY,66 5TH AVE,NEW YORK,NY 10011, USA.							ABELSMITH B, 1988, MILBANK Q, V66, P694, DOI 10.2307/3349936; Armstrong B.N., 1932, INSURING ESSENTIALS; BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V267, P2509, DOI 10.1001/jama.267.18.2509; BROWN ER, 1993, CHANGING US HLTH CAR; BUSH G, 1992, PRESIDENTS COMPREHEN; BUTLER S, 1989, NATIONAL HLTH SYSTEM; CAPLOVITZ D, 1963, POOR PAY MORE; CHANDRA J, 1985, PRIVATISATION NATION; DANZIGER S, 1981, J ECON LIT, V19, P980; DEKKER W, 1987, BEREIDHEID TOT VERAN; Donahue J. D., 1989, PRIVATIZATION DECISI; ENTHOVEN A, 1989, NEW ENGL J MED, V320, P94, DOI 10.1056/NEJM198901123200205; ENTHOVEN A, 1989, NEW ENGL J MED, V320, P29, DOI 10.1056/NEJM198901053200106; ENTHOVEN AC, 1985, POLITIQUES MANAGEMEN, V4, P1; FELDSTEIN M, 1981, HOSPITAL COSTS HLTH; FELDSTEIN MS, 1963, OXFORD ECON PAP, V15, P20; FERRARA PJ, 1980, SOCIAL SECURITY INHE; FREY BS, 1984, AM ECON REV, V74, P986; FRIEDMAN M, 1980, FREE TO CHOOSE, pCH4; GIRAUD P, 1985, RESEAUX SOINS MED DE; GLASER W, 1991, HLTH INSURANCE PRACT; Harter L. G., 1962, COMMONS HIS ASSAULT; HAUSER H, 1987, HLTH MAINTENANCE ORG; KOHLER PA, 1982, EVOLUTION SOCIAL INS; LANGWELL K, 1992, EFFECTS MANAGED CARE; LANGWELL KM, 1982, RES COMPETITION FINA; Lees DS, 1961, HLTH CHOICE; LEGRAND J, 1991, ECON J, V101, P1254; LIGHT DW, 1992, JAMA-J AM MED ASSOC, V267, P2503, DOI 10.1001/jama.267.18.2503; LUFT HS, 1907, HLTH MAINTENANCE ORG; MEYER JA, 1983, MARKET REFORMS HLTH; MORRISSEY M, 1902, PRICE SENSITIVITY HL; Olson M., 1981, NEW APPROACH EC HLTH; PAULY MV, 1991, HEALTH AFFAIR, V10, P5, DOI 10.1377/hlthaff.10.1.5; POEN MM, 1979, TRUMAN VERSUS MED LO, pCH1; RADAR BG, 1966, ACADEMIC MIND REFORM; ROBINSON JC, 1987, JAMA-J AM MED ASSOC, V257, P3241, DOI 10.1001/jama.257.23.3241; ROBINSON R, 1990, COMPETITION HLTH CAR; RODWIN VG, 1985, POLITIQUES MANAGEMEN, V4, P149; RODWIN VG, 1985, POLITIQUES MANAGEMEN, V4, P39; Roll E., 1973, HIST EC THOUGHT; Savas E. S, 1987, PRIVATISATION KEY GO; SCHUT FT, 1986, HLTH MAINTENANCE ORG; SELDON A, 1981, WHITHER WELFARE STAT; SHIELL A, 1991, HEALTH POLICY, V19, P141, DOI 10.1016/0168-8510(91)90003-G; Socolar D, 1992, J Am Health Policy, V2, P45; Thurow L, 1983, DANGEROUS CURRENTS S; VANDEVEN WPM, 1983, EC STAT BERICHTEN, V68, P110; VANDEVEN WPM, 1983, EC STATISTISCHE BERI, V68, P72; Vandongen R, 1983, J Hypertens, V1, P177, DOI 10.1097/00004872-198308000-00011; Wallack S S, 1991, Health Care Financ Rev Annu Suppl, P27; WEBBER D, 1991, COMP HLTH POLICY NEW, P49; WEINER JP, 1990, BUDGET HOLDING LESSO; 1990, WERKEN AAN ZORGVERNI; 1988, DERDE DEKKER BREIF N; 1980, PUBLIC INTREST; 1987, RAPPORT COMITE SAGES, P94	57	34	35	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 27	1993	341	8848					805	812		10.1016/0140-6736(93)90572-X	http://dx.doi.org/10.1016/0140-6736(93)90572-X			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KU900	8096010				2022-12-28	WOS:A1993KU90000015
J	THORNTON, H				THORNTON, H			A LADYPLAN FOR TRIAL RECRUITMENT - EVERYONES BUSINESS	LANCET			English	Letter																		FALLOWFIELD LJ, 1992, COMMUNICAITONS SKILL; HORTON R, 1993, LANCET, V341, P233, DOI 10.1016/0140-6736(93)90087-W; MUNZAROVA M, 1992, WORLD PROLIFE C INT; VONDONGEN JA, 1992, EUR J CANCER, V28, P626; 1992, BMJ, V305, P699; 1993, LANCET, V341, P429	6	8	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 27	1993	341	8848					795	796		10.1016/0140-6736(93)90568-2	http://dx.doi.org/10.1016/0140-6736(93)90568-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU900	8096006				2022-12-28	WOS:A1993KU90000011
J	KUZNIECKY, R; ANDERMANN, F; GUERRINI, R				KUZNIECKY, R; ANDERMANN, F; GUERRINI, R			CONGENITAL BILATERAL PERISYLVIAN SYNDROME - STUDY OF 31 PATIENTS	LANCET			English	Article							CHAVANY-MARIE SYNDROME; NEURONAL MIGRATION; CORTICAL DYSPLASIA; CENTRAL MACROGYRIA; DISORDERS; MICROGYRIA; EPILEPSY	Advances in neuroimaging techniques have enabled the recognition of developmental malformations of the brain during life. Careful correlation of clinical and imaging features has identified several new syndromes. We have studied 31 patients with a congenital neurological syndrome characterised by pseudobulbar palsy, cognitive deficits, and bilateral perisylvian abnormalities on imaging studies. All patients had diplegia of the facial pharyngeal, and masticatory muscles, of variable severity. Some patients had slight dysarthria, whereas others were unable to speak. 85% of patients had mental retardation, ranging from mild to severe. Epilepsy was present in 27 (87%) and commonly consisted of atypical absence, atonic/tonic, tonic-clonic seizures, and, less frequently, partial attacks. Seizures were poorly controlled in 55%. Magnetic resonance imaging showed bilateral perisylvian cortical malformations consistent with polymicrogyria, confirmed at necropsy. Division of the corpus callosum in several patients resulted in seizure improvement. This congenital bilateral perisylvian syndrome can be clinically diagnosed and confirmed by imaging studies. Further studies are necessary to elucidate its cause.	MCGILL UNIV,MONTREAL NEUROL INST,MONTREAL H3A 2T5,QUEBEC,CANADA; UNIV PISA,SCI INST STELLA MARIS,I-56100 PISA,ITALY	McGill University; IRCCS Fondazione Stella Maris; University of Pisa	KUZNIECKY, R (corresponding author), UNIV ALABAMA,DEPT NEUROL,UAB STN,BIRMINGHAM,AL 35294, USA.							AMBROSETTO G, 1990, ANN NEUROL, V28, P840, DOI 10.1002/ana.410280622; BARKOVICH AJ, 1987, AM J NEURORADIOL, V8, P1009; BARTH PG, 1987, CAN J NEUROL SCI, V14, P1; BARTH PG, 1985, ACTA NEUROPATHOL, V67, P345, DOI 10.1007/BF00687825; BECKER PS, 1989, ANN NEUROL, V25, P90, DOI 10.1002/ana.410250115; Benton AL, 1968, CORTEX, V93, P38, DOI DOI 10.1016/S0010-9452(68)80018-8; BORDARIER C, 1991, BRAIN DEV-JPN, V13, P126, DOI 10.1016/S0387-7604(12)80120-3; BOULLOCHE J, 1990, ARCH FR PEDIATR, V47, P115; DVORAK K, 1978, ACTA NEUROPATHOL, V44, P121; Foix C., 1926, REV NEUROL PARIS, V33, P214; GRAFFRADFORD NR, 1986, ANN NEUROL, V20, P632, DOI 10.1002/ana.410200513; KUZNIECKY R, 1988, ANN NEUROL, V23, P317, DOI 10.1002/ana.410230402; KUZNIECKY R, 1989, ANN NEUROL, V25, P547, DOI 10.1002/ana.410250604; LEITER G, 1980, LEITER INT PERFORMAN; LEVINE D, 1974, ACTA NEUROPATHOL BER, V229, P99; MARIANI C, 1980, J NEUROL, V223, P269, DOI 10.1007/BF00313341; NORMAN RM, 1958, J MENT SCI, V104, P758, DOI 10.1192/bjp.104.436.758; PALMINI A, 1991, NEUROLOGY, V41, P1656, DOI 10.1212/WNL.41.10.1656; PALMINI A, 1991, ANN NEUROL, V30, P741, DOI 10.1002/ana.410300602; Wechsler D., 2008, WECHSLER ADULT INTEL, P257; Wechsler DW., 1999, INTELLIGENCE SCALE C; WILLIAMS RS, 1976, ACTA NEUROPATHOL, V36, P269, DOI 10.1007/BF00685371; WORSTERDROUGHT C, 1953, MED PRESS, V230, P419; 1985, EPILEPSIA, V26, P268	24	251	255	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 6	1993	341	8845					608	612		10.1016/0140-6736(93)90363-L	http://dx.doi.org/10.1016/0140-6736(93)90363-L			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KQ234	8094839				2022-12-28	WOS:A1993KQ23400015
J	STEWART, LA; PARMAR, MKB				STEWART, LA; PARMAR, MKB			METAANALYSIS OF THE LITERATURE OR OF INDIVIDUAL PATIENT DATA - IS THERE A DIFFERENCE	LANCET			English	Article							RANDOMIZED CLINICAL-TRIALS; ADVANCED OVARIAN-CARCINOMA; COMBINATION CHEMOTHERAPY; CIS-PLATINUM; CYCLOPHOSPHAMIDE; CANCER; CHLORAMBUCIL; QUALITY; BIAS	The use of meta-analyses or overviews to combine formally the results of related randomised clinical trials is becoming increasingly common. However the distinction between analyses based on information extracted from the published literature and those based on collecting and reanalysing updated individual patient data is not clear. We have investigated the difference between meta-analysis of the literature (MAL) and meta-analysis of individual patient data (MAP) by comparing the two approaches using randomised trials of cisplatin-based therapy in ovarian cancer. The MAL was based on 788 patients and the MAP on 1329 and estimated median follow-ups were 3.5 and 6.5 years, respectively. The MAL gave a result of greater statistical significance (p=0.027 vs p=0.30) and an estimate of absolute treatment effect three times as large as the MAP (7.5% vs 2.5%). Publication bias, patient exclusion, length of follow-up, and method of analysis all contributed to this observed difference. The results of a meta-analysis of the literature alone may be misleading. Whenever possible, a meta-analysis of updated individual patient data should be done because this provides the least biased and most reliable means of addressing questions that have not been satisfactorily resolved by individual clinical trials.			STEWART, LA (corresponding author), MRC, CANC TRIALS OFF, 1 BROOKLANDS AVE, CAMBRIDGE CB2 2BB, ENGLAND.			Stewart, Lesley/0000-0003-0287-4724				ABE O, 1992, LANCET, V339, P71; ALTMAN DG, 1990, LANCET, V335, P149, DOI 10.1016/0140-6736(90)90014-V; [Anonymous], 1992, Lancet, V339, P1; BELL DR, 1982, AUST NZ J MED, V12, P245, DOI 10.1111/j.1445-5994.1982.tb02469.x; BUYSE M, 1988, JAMA-J AM MED ASSOC, V259, P3571; CARMOPEREIRA J, 1983, CANCER CHEMOTH PHARM, V10, P100, DOI 10.1007/BF00446218; CHALMERS TC, 1987, STAT MED, V6, P315, DOI 10.1002/sim.4780060320; CROWTHER D, 1986, UNPUB RANDOMISED TRI; DECKER DG, 1982, OBSTET GYNECOL, V60, P481; DICKERSIN K, 1992, JAMA-J AM MED ASSOC, V267, P374, DOI 10.1001/jama.267.3.374; Early Breast Cancer Trialists' Collaborative Group, 1990, TREATMENT EARLY BREA, V1; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; Freedman L S, 1982, Stat Med, V1, P121, DOI 10.1002/sim.4780010204; GRAY R, 1991, BRIT J CANCER, V63, P841, DOI 10.1038/bjc.1991.187; GREGORY WM, 1992, J CLIN ONCOL, V10, P334, DOI 10.1200/JCO.1992.10.2.334; HIMEL HN, 1986, JAMA-J AM MED ASSOC, V256, P1148, DOI 10.1001/jama.256.9.1148; KING JF, 1988, BRIT J OBSTET GYNAEC, V95, P211, DOI 10.1111/j.1471-0528.1988.tb06860.x; LEONARD RCF, 1989, CANCER CHEMOTH PHARM, V23, P105; MARSONI S, 1990, ANN ONCOL, V1, P343, DOI 10.1093/oxfordjournals.annonc.a057772; MASDING J, 1990, BRIT J OBSTET GYNAEC, V97, P342, DOI 10.1111/j.1471-0528.1990.tb01813.x; NICOLUCCI A, 1989, JAMA-J AM MED ASSOC, V262, P2101, DOI 10.1001/jama.262.15.2101; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; SIMES RJ, 1986, J CLIN ONCOL, V4, P1529, DOI 10.1200/JCO.1986.4.10.1529; STENNING SP, 1987, BRIT J CANCER, V56, P89, DOI 10.1038/bjc.1987.161; STEWART LA, 1991, BRIT MED J, V303, P884; STURGEON JFG, 1982, P AN M AM SOC CLIN, V1, P108; VANDENBROUCKEGRAULS CMJE, 1991, LANCET, V338, P859, DOI 10.1016/0140-6736(91)91510-2; VOGL SE, 1982, P AN M AM SOC CLIN, V1, P119; WHITEHEAD A, 1991, STAT MED, V10, P1665, DOI 10.1002/sim.4780101105; WILBUR DW, 1987, J SURG ONCOL, V34, P165, DOI 10.1002/jso.2930340306; WILLIAMS CJ, 1985, J CLIN ONCOL, V3, P1455, DOI 10.1200/JCO.1985.3.11.1455; WILLIAMS CJ, IN PRESS BR J CANCER; YUSUF S, 1987, STAT MED, V6, P281, DOI 10.1002/sim.4780060314; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; UNPUB COLLABORATIO 1; 1986, GYNAECOL ONCOL, V23, P1	36	605	608	0	16	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 13	1993	341	8842					418	422		10.1016/0140-6736(93)93004-K	http://dx.doi.org/10.1016/0140-6736(93)93004-K			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM416	8094183				2022-12-28	WOS:A1993KM41600018
J	QIN, SX; COBBOLD, SP; POPE, H; ELLIOTT, J; KIOUSSIS, D; DAVIES, J; WALDMANN, H				QIN, SX; COBBOLD, SP; POPE, H; ELLIOTT, J; KIOUSSIS, D; DAVIES, J; WALDMANN, H			INFECTIOUS TRANSPLANTATION TOLERANCE	SCIENCE			English	Article							T-CELLS; INDUCTION; ANTIBODIES; ABOLITION; COMPLEX	The maintenance of transplantation tolerance induced in adult mice after short-term treatment with nonlytic monoclonal antibodies to CD4 and CD8 was investigated. CD4+ T cells from tolerant mice disabled naive lymphocytes so that they too could not reject the graft. The naive lymphocytes that had been so disabled also became tolerant and, in turn, developed the capacity to specifically disable other naive lymphocytes. This process of ''infectious'' tolerance explains why no further immunosuppression was needed to maintain long-term transplantation tolerance.	UNIV CAMBRIDGE,DEPT PATHOL,CAMBRIDGE CB2 1QP,ENGLAND; NATL INST MED RES,MOLEC IMMUNOL LAB,LONDON NW7 1AA,ENGLAND	University of Cambridge; MRC National Institute for Medical Research			waldmann, herman/W-8051-2019	Waldmann, Herman/0000-0001-7519-6720; Cobbold, Stephen/0000-0003-1206-4880				BILLINGHAM RE, 1953, NATURE, V172, P603, DOI 10.1038/172603a0; BILLINGHAM RE, 1956, PHILOS T R SOC B, V239, P357, DOI 10.1098/rstb.1956.0006; COBBOLD SP, 1992, IMMUNOL REV, V129, P165, DOI 10.1111/j.1600-065X.1992.tb01423.x; COBBOLD SP, 1990, EUR J IMMUNOL, V20, P2747, DOI 10.1002/eji.1830201232; GRUCHALLA RS, 1983, TRANSPLANTATION, V36, P318, DOI 10.1097/00007890-198309000-00017; ISOBE M, 1992, SCIENCE, V255, P1125, DOI 10.1126/science.1347662; LANG G, 1988, EMBO J, V7, P1675, DOI 10.1002/j.1460-2075.1988.tb02995.x; MILLER JFA, 1990, COLD SPRING HARB SYM, V170, P87; QIN S, 1989, THESIS CAMBRIDGE U; QIN SX, 1990, EUR J IMMUNOL, V20, P2737, DOI 10.1002/eji.1830201231; QIN SX, 1989, J EXP MED, V169, P779, DOI 10.1084/jem.169.3.779; RAMSEIER H, 1973, EUR J IMMUNOL, V3, P156, DOI 10.1002/eji.1830030310; Rieber E. P., 1989, LEUKOCYTE TYPING, VIV, P229; TIGHE HP, 1987, THESIS CAMBRIDGE U; TOMONARI K, 1988, IMMUNOGENETICS, V28, P455, DOI 10.1007/BF00355379	15	745	773	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 12	1993	259	5097					974	977		10.1126/science.8094901	http://dx.doi.org/10.1126/science.8094901			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL800	8094901				2022-12-28	WOS:A1993KL80000044
J	INGLIS, TJJ; LACEY, RW; KAY, E; HAWKEY, PM; BODENHAM, A; CALVERT, RT				INGLIS, TJJ; LACEY, RW; KAY, E; HAWKEY, PM; BODENHAM, A; CALVERT, RT			MONOCLONAL ANTIENDOTOXIN AGENT HA-1A (CENTOXIN)	LANCET			English	Letter											INGLIS, TJJ (corresponding author), UNIV LEEDS,DEPT MICROBIOL,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND.							WENZEL RP, 1988, INT J EPIDEMIOL, V17, P225, DOI 10.1093/ije/17.1.225; ZEIGLER EJ, 1991, NEW ENGL J MED, V324, P429; 1993, MDR13193 MED CONTR A	3	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 30	1993	341	8840					303	303		10.1016/0140-6736(93)92651-9	http://dx.doi.org/10.1016/0140-6736(93)92651-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK245	8093933				2022-12-28	WOS:A1993KK24500030
J	JOYCE, CRB				JOYCE, CRB			PSYCHIATRY - INSIGHT	LANCET			English	Editorial Material											JOYCE, CRB (corresponding author), UNIV BERN,PSYCHIAT POLICLIN,CH-3000 BERN,SWITZERLAND.							[Anonymous], 1990, LANCET, V336, P408; Balint M., 1961, PSYCHOTHERAPEUTIC TE; Balint M., 1957, DOCTOR; CLAXTON G, 1992, I I              APR, P17; DAVID A, 1992, BRIT J PSYCHIAT, V161, P599, DOI 10.1192/bjp.161.5.599; DAVID AS, 1990, BRIT J PSYCHIAT, V156, P798, DOI 10.1192/bjp.156.6.798; ELJUNAID AQ, CITED INDIRECTLY; Malan D. H., 1963, STUDY BRIEF PSYCHOTH, DOI [10.1007/978-1-4613-4395-0, DOI 10.1007/978-1-4613-4395-0]; MARKOVA IS, 1992, BRIT J PSYCHIAT, V160, P850, DOI 10.1192/bjp.160.6.850; RAVEN P, 1992, BRIT J PSYCHIAT, V161, P717, DOI 10.1192/bjp.161.5.717a; Shah I., 1974, WAY SUFI; 1950, RUMI POET MYSTIC SEL	12	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 23	1993	341	8839					213	214		10.1016/0140-6736(93)90075-R	http://dx.doi.org/10.1016/0140-6736(93)90075-R			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ219	8093506				2022-12-28	WOS:A1993KJ21900013
J	BREWIN, TB				BREWIN, TB			HOW MUCH ETHICS IS NEEDED TO MAKE A GOOD DOCTOR	LANCET			English	Editorial Material																		Kennedy I., 1981, UNMASKING MED	1	12	12	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 16	1993	341	8838					161	163		10.1016/0140-6736(93)90019-D	http://dx.doi.org/10.1016/0140-6736(93)90019-D			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG627	8093758				2022-12-28	WOS:A1993KG62700018
J	BRADLEY, D; CARPENTER, R; SOMMER, H; HARTLEY, N; COEN, E				BRADLEY, D; CARPENTER, R; SOMMER, H; HARTLEY, N; COEN, E			COMPLEMENTARY FLORAL HOMEOTIC PHENOTYPES RESULT FROM OPPOSITE ORIENTATIONS OF A TRANSPOSON AT THE PLENA-LOCUS OF ANTIRRHINUM	CELL			English	Article							FLOWER DEVELOPMENT; TRANSCRIPTION FACTORS; MAJUS; EXPRESSION; ELEMENT; MORPHOGENESIS; MAIZE; GENES; TAM3	Recessive mutations at the plena (ple) locus result in a homeotic conversion of sex organs to sterile perianth organs in flowers of Antirrhinum majus. A complementary phenotype, in which sex organs replace sterile organs, is conferred by semidominant ovulata mutations. The ple locus was identified and isolated using a homologous gene, agamous from Arabidopsis, as a probe. The expression of ple is normally restricted to the inner two whorls of the flower, where sex organs develop. However, in ovulata mutants, ple is expressed ectopically in the outer two whorls of the flower and in vegetative organs. These mutants correspond to gain-of-function alleles of ple, suggesting that ple is sufficient for promoting sex organ development within the context of the flower. The plena and ovulata phenotypes result from opposite orientations of the transposon Tam3 inserted in the large intron of ple.	MAX PLANCK INST ZUCHTUNGSFORSCH,W-5000 COLOGNE 30,GERMANY	Max Planck Society	BRADLEY, D (corresponding author), AFRC,JOHN INNES RES CTR,INST PLANT SCI RES,COLNEY LANE,NORWICH NR4 7UH,ENGLAND.							BERGFELD R, 1956, Z INDUKT ABSTAMM VER, V87, P784, DOI 10.1007/BF00308511; BOWMAN JL, 1991, PLANT CELL, V3, P749, DOI 10.1105/tpc.3.8.749; CARPENTER R, 1990, GENE DEV, V4, P1483, DOI 10.1101/gad.4.9.1483; CARPENTER R, 1987, MOL GEN GENET, V207, P82, DOI 10.1007/BF00331494; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; COEN ES, 1991, NATURE, V353, P31, DOI 10.1038/353031a0; COEN ES, 1988, EMBO J, V7, P877, DOI 10.1002/j.1460-2075.1988.tb02891.x; COEN ES, 1986, CELL, V47, P285, DOI 10.1016/0092-8674(86)90451-4; COEN ES, 1990, CELL, V63, P1311, DOI 10.1016/0092-8674(90)90426-F; DREWS GN, 1991, CELL, V65, P991, DOI 10.1016/0092-8674(91)90551-9; GIERL A, 1989, ANNU REV GENET, V23, P71, DOI 10.1146/annurev.ge.23.120189.000443; GOODRICH J, 1992, CELL, V68, P955, DOI 10.1016/0092-8674(92)90038-E; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HAKE S, 1992, TRENDS GENET, V8, P109, DOI 10.1016/0168-9525(92)90065-C; HEHL R, 1991, PLANT MOL BIOL, V16, P369, DOI 10.1007/BF00020572; Hohn B, 1979, Methods Enzymol, V68, P299; HUIJSER P, 1992, EMBO J, V11, P1239, DOI 10.1002/j.1460-2075.1992.tb05168.x; JACK T, 1992, CELL, V68, P683, DOI 10.1016/0092-8674(92)90144-2; LUO D, 1991, PLANT J, V1, P59, DOI 10.1111/j.1365-313X.1991.00059.x; MA H, 1991, GENE DEV, V5, P484, DOI 10.1101/gad.5.3.484; MANDEL MA, 1992, CELL, V71, P133, DOI 10.1016/0092-8674(92)90272-E; MIZUKAMI Y, 1992, CELL, V71, P119, DOI 10.1016/0092-8674(92)90271-D; MURRAY NE, 1983, LAMBDA, V2, P395; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PASSMORE S, 1988, J MOL BIOL, V204, P593, DOI 10.1016/0022-2836(88)90358-0; SCHNEUWLY S, 1987, EMBO J, V6, P201, DOI 10.1002/j.1460-2075.1987.tb04739.x; SCHWARZSOMMER Z, 1992, EMBO J, V11, P251, DOI 10.1002/j.1460-2075.1992.tb05048.x; SCHWARZSOMMER Z, 1990, SCIENCE, V250, P931, DOI 10.1126/science.250.4983.931; SOMMER H, 1990, EMBO J, V9, P605, DOI 10.1002/j.1460-2075.1990.tb08152.x; STUBBE H, 1966, GENETIK ZYTOLOGIE AN; TANDA S, 1991, EMBO J, V10, P407, DOI 10.1002/j.1460-2075.1991.tb07962.x; TILNEYBASSET RAE, 1986, PLANT CHIMERAS; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0	34	436	449	0	38	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 15	1993	72	1					85	95		10.1016/0092-8674(93)90052-R	http://dx.doi.org/10.1016/0092-8674(93)90052-R			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KG955	8093684				2022-12-28	WOS:A1993KG95500012
J	LAURITZEN, JB; PETERSEN, MM; LUND, B				LAURITZEN, JB; PETERSEN, MM; LUND, B			EFFECT OF EXTERNAL HIP PROTECTORS ON HIP-FRACTURES	LANCET			English	Article							RISK	Most hip fractures seem to be related to trauma near the hip, so a controlled trial was conducted to investigate the effect of external hip protectors on the prevention of such fractures in residents of a nursing home. 10 of the 28 wards in the nursing home were randomised to receive external hip protectors; thus 167 women and 80 men were given protectors and 277 and 141 men no protectors. A fall register was set up for 2 treatment wards (45 residents) and 2 control wards (76 residents). There were 8 hip and 15 non-hip fractures in the hip-protector group and 31 hip and 27 non-hip fractures in the control group. The relative risk of hip fractures among women and men in the intervention group was 0.44 (95% CI 0.21-0.94). None of the 8 residents in the intervention group who had a hip fracture was wearing the device at the time of the fracture. 154 falls were registered and 20% of these falls produced a direct impact to the hip. In 25 falls direct impact to the hip was sustained at a time when hip protectors were not being worn, and 6 fractures were produced. The study indicates that external hip protectors can prevent hip fractures in nursing-home residents.			LAURITZEN, JB (corresponding author), UNIV COPENHAGEN,RIGSHOSP,DEPT ORTHOPAED SURG U2161,BLEGDAMSVEIJ 9,DK-2100 COPENHAGEN,DENMARK.			Petersen, Michael Mork/0000-0002-2324-6420; Lauritzen, Jes Bruun/0000-0003-4329-2130				BRESLOW NE, 1988, STAT ANAL CANC RES, V2, P69; CUMMINGS SR, 1989, J GERONTOL, V44, pM107; CUMMINGS SR, 1985, AM J MED, V78, P487, DOI 10.1016/0002-9343(85)90343-2; DIAS JJ, 1987, AGE AGEING, V16, P373, DOI 10.1093/ageing/16.6.373; EGSMOSE C, 1987, AGE AGEING, V16, P35, DOI 10.1093/ageing/16.1.35; FREEMAN MAR, 1974, J BONE JOINT SURG BR, VB 56, P698, DOI 10.1302/0301-620X.56B4.698; HAYES WC, 1991, T ORTHOPAED RES SOC, V16, P139; HIPP JA, 1991, T ORTHOPAED RES SOC, V16, P135; KATZ D, 1978, BIOMETRICS, V34, P469, DOI 10.2307/2530610; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; LAURITZEN JB, 1992, DAN MED BULL, V39, P91; LAURITZEN JB, 1990, ACTA ORTHOP SCAND, V61, P239; LOTZ JC, 1990, J BONE JOINT SURG AM, V72A, P689, DOI 10.2106/00004623-199072050-00008; MELTON LJ, 1988, J CLIN EPIDEMIOL, V41, P985; ROBINOVTICH SN, 1991, T ORTHO RES SOC, V16, P434; SLOAN J, 1981, INJURY, V12, P210; SMITH LD, 1953, J BONE JOINT SURG AM, V35-A, P367, DOI 10.2106/00004623-195335020-00009; WILLIAMS AR, 1982, OBSTET GYNECOL, V60, P696	18	432	440	0	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 2	1993	341	8836					11	13		10.1016/0140-6736(93)92480-H	http://dx.doi.org/10.1016/0140-6736(93)92480-H			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF027	8093267				2022-12-28	WOS:A1993KF02700004
J	LIPSKY, JJ				LIPSKY, JJ			ZALCITABINE AND DIDANOSINE	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; AIDS-RELATED COMPLEX; 2',3'-DIDEOXYINOSINE DDI; PHASE-I; INFECTION; 2',3'-DIDEOXYCYTIDINE; PHARMACOKINETICS; DIDEOXYINOSINE; BIOAVAILABILITY; DIDEOXYCYTIDINE		MAYO CLIN & MAYO FDN,DEPT PHARMACOL,CLIN PHARMACOL UNIT,ROCHESTER,MN 55905	Mayo Clinic	LIPSKY, JJ (corresponding author), MAYO CLIN & MAYO FDN,DEPT MED,ROCHESTER,MN 55905, USA.							BALIS FM, 1992, J INFECT DIS, V165, P99, DOI 10.1093/infdis/165.1.99; BRODER S, 1990, AM J MED, V88, pS2, DOI 10.1016/0002-9343(90)90413-8; BUTLER KM, 1991, NEW ENGL J MED, V324, P137, DOI 10.1056/NEJM199101173240301; CHEN CH, 1991, MOL PHARMACOL, V39, P625; DARBYSHIRE JH, 1992, LANCET, V340, P1346, DOI 10.1016/0140-6736(92)92524-J; GALINSKY RE, 1991, J PHARMACOL EXP THER, V257, P972; GROOPMAN JE, 1992, NEW ENGL J MED, V327, P639, DOI 10.1056/NEJM199208273270912; GUSTAVSON LE, 1990, J ACQ IMMUN DEF SYND, V3, P28; HARTMAN NR, 1990, CLIN PHARMACOL THER, V47, P647, DOI 10.1038/clpt.1990.86; INDORF AS, 1992, ANN INTERN MED, V117, P133, DOI 10.7326/0003-4819-117-2-133; KAHN JO, 1992, NEW ENGL J MED, V327, P581, DOI 10.1056/NEJM199208273270901; KATLAMA C, 1991, LANCET, V337, P183, DOI 10.1016/0140-6736(91)90854-I; KIERBURTZ KD, 1992, J ACQ IMMUN DEF SYND, V5, P60; KNUPP CA, 1991, CLIN PHARMACOL THER, V49, P523, DOI 10.1038/clpt.1991.63; LAI KK, 1991, ANN INTERN MED, V115, P283, DOI 10.7326/0003-4819-115-4-283; LAMBERT JS, 1990, NEW ENGL J MED, V322, P1333, DOI 10.1056/NEJM199005103221901; LELACHEUR SF, 1991, J ACQ IMMUN DEF SYND, V4, P538; LEVY JA, 1989, JAMA-J AM MED ASSOC, V261, P2997, DOI 10.1001/jama.261.20.2997; MCGOWAN JJ, 1990, REV INFECT DIS, V12, pS513; MCNEELY MC, 1989, J AM ACAD DERMATOL, V21, P1213, DOI 10.1016/S0190-9622(89)70332-7; MENG TC, 1992, ANN INTERN MED, V116, P13, DOI 10.7326/0003-4819-116-1-13; MITSUYA H, 1987, P NATL ACAD SCI USA, V84, P2033, DOI 10.1073/pnas.84.7.2033; PAI SM, 1992, J CLIN PHARMACOL, V32, P242, DOI 10.1002/j.1552-4604.1992.tb03832.x; PIZZO PA, 1990, J PEDIATR-US, V117, P799, DOI 10.1016/S0022-3476(05)83348-7; ROZENCWEIG M, 1990, REV INFECT DIS, V12, pS570; SHYU WC, 1991, CLIN PHARMACOL THER, V50, P503, DOI 10.1038/clpt.1991.175; SZEBENI J, 1989, P NATL ACAD SCI USA, V86, P3842, DOI 10.1073/pnas.86.10.3842; WHITCUP SM, 1992, AM J OPHTHALMOL, V113, P1; WHITCUP SM, 1992, NEW ENGL J MED, V326, P1226; YARCHOAN R, 1990, LANCET, V336, P526, DOI 10.1016/0140-6736(90)92085-V; YARCHOAN R, 1988, LANCET, V1, P76; YARCHOAN R, 1990, REV INFECT DIS, V12, pS522	32	19	20	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 2	1993	341	8836					30	32		10.1016/0140-6736(93)92496-G	http://dx.doi.org/10.1016/0140-6736(93)92496-G			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF027	8093278				2022-12-28	WOS:A1993KF02700017
J	LAZEBNIK, YA; KAUFMANN, SH; DESNOYERS, S; POIRIER, GG; EARNSHAW, WC				LAZEBNIK, YA; KAUFMANN, SH; DESNOYERS, S; POIRIER, GG; EARNSHAW, WC			CLEAVAGE OF POLY(ADP-RIBOSE) POLYMERASE BY A PROTEINASE WITH PROPERTIES LIKE ICE	NATURE			English	Article							DEATH GENE CED-3; ENZYME; APOPTOSIS; SYNTHETASE; INDUCTION; CDNA	RECENT studies suggest that proteases of the interleukin 1-beta-converting enzyme (ICE)/ced-3 family are involved in initiating the active phase of apoptosis(1-3). Here we identify a novel protease resembling ICE (prICE) that is active in a cell-free system that reproduces the morphological and biochemical events of apoptosis(4). prICE cleaves the nuclear enzyme poly(ADP-ribose) polymerase (PARP) at a tetrapeptide sequence identical to one of two ICE sites in pro-interleukin-1-beta. However, prICE does not cleave purified pro-interleukin-1-beta, and purified ICE does not cleave PARP, indicating that the two activities are distinct. Inhibition of prICE abolishes all manifestations of apoptosis in the extracts including morphological changes, cleavage of PARP and production of an oligonucleosomal ladder. These studies suggest that prICE might be pivotal in initiating the active phase of apoptosis in vitro and in intact cells.	JOHNS HOPKINS UNIV,SCH MED,DEPT ONCOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL,BALTIMORE,MD 21205; CHU LAVAL,RES CTR,DEPT MOLEC ENDOCRINOL,POLY ADP RIBOSE METAB GRP,ST FOY G1V 4G2,PQ,CANADA; UNIV LAVAL,ST FOY G1V 4G2,PQ,CANADA	Johns Hopkins University; Johns Hopkins University; Laval University; Laval University	LAZEBNIK, YA (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT CELL BIOL & ANAT,725 N WOLFE ST,BALTIMORE,MD 21205, USA.		Earnshaw, William/AAY-7438-2020	Poirier, Guy/0000-0002-4869-1424; Kaufmann, Scott/0000-0002-4900-7145; Earnshaw, William/0000-0002-7191-0621				BLACK RA, 1989, FEBS LETT, V247, P386, DOI 10.1016/0014-5793(89)81376-6; CHEMEY BW, 1987, P NATL ACAD SCI USA, V84, P8370; DELATOUR EB, 1988, CELL, V55, P937, DOI 10.1016/0092-8674(88)90239-5; ELLIS RE, 1991, REV CELL BIOL, V7, P663; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; HOWARD AD, 1991, J IMMUNOL, V147, P2964; HULETSKY A, 1989, J BIOL CHEM, V265, P8878; ITTEL ME, 1991, GENE, V102, P157, DOI 10.1016/0378-1119(91)90073-K; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KAUFMANN SH, 1993, CANCER RES, V53, P3976; LAMARRE D, 1988, BIOCHIM BIOPHYS ACTA, V950, P147, DOI 10.1016/0167-4781(88)90007-3; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; ODAKE S, 1991, BIOCHEMISTRY-US, V30, P2217, DOI 10.1021/bi00222a027; OHTSUBO M, 1987, GENE DEV, V1, P585, DOI 10.1101/gad.1.6.585; SAITO I, 1990, GENE, V90, P249, DOI 10.1016/0378-1119(90)90187-V; SAITOH H, 1992, CELL, V70, P115, DOI 10.1016/0092-8674(92)90538-N; SHI LF, 1992, J EXP MED, V175, P553, DOI 10.1084/jem.175.2.553; THOMBERRY NA, 1992, NATURE, V356, P768; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	22	2350	2426	2	47	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 22	1994	371	6495					346	347		10.1038/371346a0	http://dx.doi.org/10.1038/371346a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH254	8090205				2022-12-28	WOS:A1994PH25400056
J	TOKIWA, G; TYERS, M; VOLPE, T; FUTCHER, B				TOKIWA, G; TYERS, M; VOLPE, T; FUTCHER, B			INHIBITION OF G1 CYCLIN ACTIVITY BY THE RAS/CAMP PATHWAY IN YEAST	NATURE			English	Article							DEPENDENT PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; CELL-SIZE; POSITIVE FEEDBACK; GENE-EXPRESSION; BUDDING YEAST; S-CEREVISIAE; CAMP; TRANSCRIPTION; DIVISION	IN the yeast Saccharomyces cerevisiae, commitment to cell division (Start) requires growth to a critical cell size(1-3). The G1 cyclins Cln1, Cln2 and Cln3 activate the Cdc28 protein kinase and are rate-limiting activators of Start(4-6). When glucose is added to cells growing in a poor carbon source, the critical cell size required for Start is reset from a small to a large size(2,3,7). In yeast, glucose acts through Ras proteins to stimulate adenylyl cyclase, activating the three cyclic AMP-dependent protein kinases Tpk1, Tpk2 and Tpk3 (refs 8, 9). We find that stimulation of the Ras/cAMP pathway represses expression of CLN1, CLN2 and co-regulated genes, inhibiting Start. This helps explain the increase in critical size when cells are shifted from poor to rich medium. This connection between the molecules controlling growth (Ras/cAMP) and those controlling division (cyclins) helps explain how division is co-ordinated with growth.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724; SUNY STONY BROOK,GRAD PROGRAM GENET,STONY BROOK,NY 11792; UNIV TORONTO,BANTING & BEST DEPT MED RES,TORONTO M5G 1L6,ON,CANADA	Cold Spring Harbor Laboratory; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Toronto			Tyers, Michael/ABE-3194-2021					BARONI MD, 1992, EXP CELL RES, V201, P299, DOI 10.1016/0014-4827(92)90277-F; BARONI MD, 1989, MOL CELL BIOL, V9, P2715, DOI 10.1128/MCB.9.6.2715; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; CAMERON S, 1988, CELL, V53, P555, DOI 10.1016/0092-8674(88)90572-7; CANNON JF, 1987, MOL CELL BIOL, V7, P2653, DOI 10.1128/MCB.7.8.2653; CROSS FR, 1991, CELL, V65, P875, DOI 10.1016/0092-8674(91)90394-E; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; DIRICK L, 1992, NATURE, V357, P508, DOI 10.1038/357508a0; DIRICK L, 1991, NATURE, V351, P754, DOI 10.1038/351754a0; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; JAGADISH MN, 1977, NATURE, V269, P145, DOI 10.1038/269145a0; JOHNSTON GC, 1977, EXP CELL RES, V105, P79, DOI 10.1016/0014-4827(77)90154-9; JOHNSTON GC, 1979, J BACTERIOL, V137, P1; KOCH C, 1993, SCIENCE, V261, P1551, DOI 10.1126/science.8372350; LORINCZ A, 1979, J GEN MICROBIOL, V113, P287, DOI 10.1099/00221287-113-2-287; LOWNDES NF, 1992, NATURE, V357, P505, DOI 10.1038/357505a0; MITSUZAWA H, 1994, MOL GEN GENET, V243, P158, DOI 10.1007/BF00280312; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NASMYTH K, 1991, CELL, V66, P995, DOI 10.1016/0092-8674(91)90444-4; OGAS J, 1991, CELL, V66, P1015, DOI 10.1016/0092-8674(91)90445-5; RUSSELL M, 1993, MOL BIOL CELL, V4, P757, DOI 10.1091/mbc.4.7.757; THEVELEIN JM, 1987, J GEN MICROBIOL, V133, P2191; THEVELEIN JM, 1985, J GEN MICROBIOL, V131, P3199; TODA T, 1987, CELL, V50, P277, DOI 10.1016/0092-8674(87)90223-6; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; TYERS M, 1993, EMBO J, V12, P1955, DOI 10.1002/j.1460-2075.1993.tb05845.x; WILSON RB, 1988, MOL CELL BIOL, V8, P505, DOI 10.1128/MCB.8.1.505; WILSON RB, 1993, FEBS LETT, V325, P191, DOI 10.1016/0014-5793(93)81071-7; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H	30	170	171	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 22	1994	371	6495					342	345		10.1038/371342a0	http://dx.doi.org/10.1038/371342a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH254	8090204				2022-12-28	WOS:A1994PH25400055
J	THADANI, U; MARANDA, CR; AMSTERDAM, E; SPACCAVENTO, L; FRIEDMAN, RG; CHERNOFF, R; ZELLNER, S; GORWIT, J; HINDERAKER, PH				THADANI, U; MARANDA, CR; AMSTERDAM, E; SPACCAVENTO, L; FRIEDMAN, RG; CHERNOFF, R; ZELLNER, S; GORWIT, J; HINDERAKER, PH			LACK OF PHARMACOLOGICAL TOLERANCE AND REBOUND ANGINA-PECTORIS DURING TWICE-DAILY THERAPY WITH ISOSORBIDE-5-MONONITRATE	ANNALS OF INTERNAL MEDICINE			English	Article						ANGINA PECTORIS; ISOSORBIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXERCISE TOLERANCE	TRANSDERMAL NITROGLYCERIN PATCHES; ORAL ISOSORBIDE DINITRATE; CHRONIC STABLE ANGINA; GLYCERYL TRINITRATE; NITRATE TOLERANCE; DURATION; 5-MONONITRATE; INTERVALS; EFFICACY	Objective: To determine whether isosorbide-5-mononitrate (IS-5-MN), an active metabolite of isosorbide dinitrate, when given twice daily (in the morning and 7 hours later), prevents development of tolerance and reduction in exercise performance or is associated with a rebound increase in anginal attacks in patients with stable angina pectoris. Design: Multicenter, placebo-controlled, parallel-group, double-blind, randomized study. Setting: Four university teaching hospitals and five private cardiology outpatient clinics. Patients: 116 patients with stable exertional angina who stopped treadmill exercise because of angina pectoris. Intervention: After stopping all antianginal drugs with the exception of beta-blockers, patients received single-blind placebo for 1 week followed by either 20 mg of IS-5-MN (n = 60 patients) or placebo (n = 62 patients) twice daily at 0800 hours and 1500 hours for 2 weeks. Measurements: Serial symptom-limited exercise tests and patients' diaries recording activity and date, time, and severity of anginal attacks. Results: Compared with placebo recipients, patients receiving IS-5-MN walked significantly longer at 2, 5, and 7 hours after the 0800-hour dose (P < 0.01) and at 2 and 5 hours after the 1500-hour dose (P < 0.01). Before the morning (0800-hour) dose, exercise duration increased by 0.53 minutes in placebo recipients and by 0.85 minutes in those receiving IS-5-MN therapy (P = 0.10). Neither nocturnal nor early-morning anginal attacks; increased during IS-5-MN therapy compared with placebo. Headaches occurred in 19 (32%) patients in the IS-5-MN group and in 9 (15%)- patients in the placebo group but necessitated discontinuation of treatment in only 2 (3%) patients in the IS-5-MN group. Conclusion: Isosorbide-5-mononitrate, 20 mg twice daily given 7 hours apart, was well tolerated and improved exercise performance for 7 hours after the morning dose and for 5 hours after the afternoon dose without evidence of development of pharmacologic tolerance. No rebound increase in anginal attacks was found.	MCGILL UNIV, QUEEN ELIZABETH HOSP, MONTREAL, PQ, CANADA; UNIV CALIF DAVIS, SACRAMENTO, CA 95817 USA; WILFORD HALL USAF MED CTR, LACKLAND AFB, TX USA; CTR STRESS STUDIES SAN DIEGO, SAN DIEGO, CA 92103 USA; TAYLOR HOSP, RIDLEY PK, PA 19078 USA; CLIN PHYSIOL ASSOCIATES, FT MYERS, FL 33916 USA; ESCONDIDO CARDIOL, ESCONDIDO, CA 92025 USA; JACKSON CLIN, MADISON, WI 53701 USA	McGill University; University of California System; University of California Davis; United States Department of Defense; United States Air Force	THADANI, U (corresponding author), UNIV OKLAHOMA, HLTH SCI CTR, CARDIOL SECT, 920 STANTON YOUNG BLVD, 5SP-300, OKLAHOMA CITY, OK 73104 USA.							ABRAMS J, 1986, CIRCULATION, V74, P1181, DOI 10.1161/01.CIR.74.6.1181; ABRAMS J, 1988, JAMA-J AM MED ASSOC, V259, P396, DOI 10.1001/jama.259.3.396; ABRAMS J, 1989, AM J CARDIOL, V64, P931, DOI 10.1016/0002-9149(89)90844-8; ABSHAGEN U, 1987, MONONITRATE, V2, P28; BASSAN MM, 1990, J AM COLL CARDIOL, V16, P936, DOI 10.1016/S0735-1097(10)80344-4; BRUCE R A, 1969, Progress in Cardiovascular Diseases, V11, P371, DOI 10.1016/0033-0620(69)90027-9; COWAN C, 1987, BRIT MED J, V294, P544, DOI 10.1136/bmj.294.6571.544-a; CREAN PA, 1984, AM HEART J, V108, P1494, DOI 10.1016/0002-8703(84)90697-5; DEMOTS H, 1989, J AM COLL CARDIOL, V13, P786, DOI 10.1016/0735-1097(89)90216-7; FLAHERTY JT, 1989, DRUGS, V37, P523, DOI 10.2165/00003495-198937040-00006; FOX KM, 1991, BRIT HEART J, V66, P151; JAMES MA, 1985, BRIT HEART J, V53, P631; JONES JP, 1986, 2ND INT S MON BERL; KOHLI RS, 1986, AM J CARDIOL, V58, P727, DOI 10.1016/0002-9149(86)90345-0; PARKER JO, 1987, NEW ENGL J MED, V316, P1635; PARKER JO, 1984, AM J CARDIOL, V54, P471, DOI 10.1016/0002-9149(84)90233-9; PARKER JO, 1987, NEW ENGL J MED, V316, P1440, DOI 10.1056/NEJM198706043162303; POORVIN D, 1991, AM J CARDIOL, V68, P1263; REICHEK N, 1984, AM J CARDIOL, V54, P1, DOI 10.1016/0002-9149(84)90295-9; Rudolph W, 1983, Z Kardiol, V72 Suppl 3, P195; SCHAER DH, 1988, AM J CARDIOL, V61, P46, DOI 10.1016/0002-9149(88)91302-1; SILBER S, 1987, AM J MED, V83, P860, DOI 10.1016/0002-9343(87)90643-7; Tauchert M, 1983, Z Kardiol, V72 Suppl 3, P218; TAYLOR T, 1981, BIOPHARM DRUG DISPOS, V2, P255, DOI 10.1002/bdd.2510020306; THADANI U, 1987, CLIN PHARMACOL THER, V42, P58, DOI 10.1038/clpt.1987.108; THADANI U, 1987, MOD CONC CARDIOV DIS, V56, P49; THADANI U, 1992, AM J CARDIOL, V70, pB43, DOI 10.1016/0002-9149(92)90593-N; THADANI U, 1987, AM J CARDIOL, V60, P477, DOI 10.1016/0002-9149(87)90289-X; THADANI U, 1982, AM J CARDIOL, V49, P411, DOI 10.1016/0002-9149(82)90518-5; THADANI U, 1980, CIRCULATION, V61, P526, DOI 10.1161/01.CIR.61.3.526; THADANI U, 1987, Rational Drug Therapy, V21, P1; THADANI U, 1992, POSTGRAD MED, V91, P307; THADANI U, 1986, ANN INTERN MED, V105, P485, DOI 10.7326/0003-4819-105-4-485; THADANI U, 1988, CURR PROB CARDIOLOGY, V13, P731; THADANI U, 1990, J MYOCARD ISCHEMIA, V2, P13; THADANI U, 1989, CIRCULATION, V80, P216; WATERS DD, 1989, J AM COLL CARDIOL, V13, P421, DOI 10.1016/0735-1097(89)90521-4; ZIMRIN D, 1988, CIRCULATION, V77, P1376, DOI 10.1161/01.CIR.77.6.1376	38	58	56	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1994	120	5					353	359		10.7326/0003-4819-120-5-199403010-00001	http://dx.doi.org/10.7326/0003-4819-120-5-199403010-00001			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY497	8093132				2022-12-28	WOS:A1994MY49700001
J	SAURELCUBIZOLLES, MJ; JOBSPIRA, N; ESTRYNBEHAR, M				SAURELCUBIZOLLES, MJ; JOBSPIRA, N; ESTRYNBEHAR, M			ECTOPIC PREGNANCY AND OCCUPATIONAL EXPOSURE TO ANTINEOPLASTIC DRUGS	LANCET			English	Article							RISK-FACTORS; FETAL LOSS; NURSES	The incidence of ectopic pregnancy has risen substantially during the past two decades, but the aetiology of a third of cases remains unknown. We have used data from a survey of nurses in Paris, France, to examine the relation between ectopic pregnancy and various occupational exposures. We studied two groups of women-operating-theatre staff and nurses from other departments. The women were asked about outcomes of all pregnancies and occupational exposure to anaesthetic gases, formol, ionising radiation, and antineoplastic drugs during the first trimester of pregnancy. Of 734 pregnancies reported, 15 (2%) had been ectopic. In chi-square analysis, there were significant associations (p < 0.02) between ectopic pregnancy and exposure to antineoplastic drugs, the woman's age, and the number of previous pregnancies. Other occupational exposures and working in an operating theatre did not show significant associations. In logistic regression analysis with adjustment for gravidity, the odds ratio (by the exact method) for ectopic pregnancy associated with occupational exposure to antineoplastic drugs was 10.0 (95% Cl 2.1-56.2). Because we had only small numbers of ectopic pregnancies, the odds ratios we estimated have wide confidence intervals. Our findings should be confirmed by a larger study specifically designed to investigate the relation between antineoplastic exposure and ectopic pregnancy.	INSERM, U292, LE KREMLIN BICETRE, FRANCE; ASSISTANCE PUBL HOP PARIS, PARIS, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	SAURELCUBIZOLLES, MJ (corresponding author), INSERM, U149, 16 AVE PAUL VAILLANT COUTURIER, F-94807 VILLEJUIF, FRANCE.		Saurel-Cubizolles, Marie-Josephe/D-1571-2014	Saurel-Cubizolles, Marie-Josephe/0000-0002-2210-974X				CHOW WH, 1987, EPIDEMIOL REV, V9, P70, DOI 10.1093/oxfordjournals.epirev.a036309; COSTE J, 1991, AM J PUBLIC HEALTH, V81, P199, DOI 10.2105/AJPH.81.2.199; COSTE J, 1991, AM J EPIDEMIOL, V133, P839, DOI 10.1093/oxfordjournals.aje.a115964; ELIAS S, 1981, AM J OBSTET GYNECOL, V141, P698, DOI 10.1016/S0002-9378(15)33314-7; FALCK K, 1979, LANCET, V1, P1250; HIJRI KF, 1987, J AM STAT ASSOC, V82, P1110; JOBSPIRA N, IN PRESS CONTRACEPTI; MARCHBANKS PA, 1988, JAMA-J AM MED ASSOC, V259, P1823, DOI 10.1001/jama.259.12.1823; POLAND BJ, 1976, TERATOLOGY, V14, P315, DOI 10.1002/tera.1420140306; ROMAN E, 1984, J EPIDEMIOL COMMUN H, V38, P29, DOI 10.1136/jech.38.1.29; SAURELCUBIZOLLES MJ, 1992, BRIT J IND MED, V49, P276; SELEVAN SG, 1985, NEW ENGL J MED, V313, P1173, DOI 10.1056/NEJM198511073131901; SKOV T, 1992, BRIT J IND MED, V49, P855; STUCKER I, 1990, SCAND J WORK ENV HEA, V16, P102, DOI 10.5271/sjweh.1811; THORBURN J, 1986, EUR J OBSTET GYN R B, V23, P333, DOI 10.1016/0028-2243(86)90168-1	15	33	36	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 8	1993	341	8854					1169	1171		10.1016/0140-6736(93)91000-C	http://dx.doi.org/10.1016/0140-6736(93)91000-C			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB017	8098075				2022-12-28	WOS:A1993LB01700002
J	TYRER, P				TYRER, P			WHO IS FAILING THE MENTALLY-ILL	LANCET			English	Editorial Material							PSYCHIATRIC-SERVICES; ILLNESS; MODEL				TYRER, P (corresponding author), ST CHARLES HOSP,ST MARYS HOSP,SCH MED,ACAD UNIT PSYCHIAT,LONDON W10 6D2,ENGLAND.							BENNETT D, 1989, NETWORK CARING COMMU; DEAN C, 1990, BRIT MED J, V301, P1021, DOI 10.1136/bmj.301.6759.1021; DONOVAN CM, 1982, AM J PSYCHIAT, V139, P456; FERGUSON B, 1992, BRIT J PSYCHIAT, V160, P493, DOI 10.1192/bjp.160.4.493; GOLDBERG D, 1992, COMMON MENTAL DISORD, P162; GOURNAY K, 1992, EVALUATION EFFECTIVE; HOLLAND W, 1990, PUBLIC HEALTH IMPACT OF MENTAL DISORDER, P14; HOULT J, 1984, ACTA PSYCHIAT SCAND, V69, P359, DOI 10.1111/j.1600-0447.1984.tb02506.x; MERSON S, 1992, LANCET, V339, P1311, DOI 10.1016/0140-6736(92)91959-C; MUIJEN M, 1992, BRIT MED J, V304, P749, DOI 10.1136/bmj.304.6829.749; STEIN LI, 1980, ARCH GEN PSYCHIAT, V37, P392; TITMUSS R, 1963, TRENDS MENTAL HLTH S, P221; TYRER P, 1985, BRIT J PSYCHIAT, V146, P571, DOI 10.1192/bjp.146.6.571; TYRER P, 1984, BRIT J PSYCHIAT, V145, P15, DOI 10.1192/bjp.145.1.15; TYRER P, 1989, BRIT MED J, V299, P298, DOI 10.1136/bmj.299.6694.298; WELLER MPI, 1989, NATURE, V339, P249, DOI 10.1038/339249a0; WHITE E, 1990, 3RD QUINQ NAT COMM P; 1992, HLTH NATION STRATEGY; 1975, CMND6233; 1925, LANCET, V7, P124	20	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 8	1993	341	8854					1199	1201		10.1016/0140-6736(93)91015-E	http://dx.doi.org/10.1016/0140-6736(93)91015-E			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LB017	8098088				2022-12-28	WOS:A1993LB01700017
J	STARKEY, IR				STARKEY, IR			THE RITA TRIAL	LANCET			English	Letter											STARKEY, IR (corresponding author), WESTERN GEN HOSP,DEPT CARDIAC,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.							AKL ES, 1992, BRIT HEART J, V68, P176	1	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 17	1993	341	8851					1020	1020						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY368	8096894				2022-12-28	WOS:A1993KY36800027
J	APPLETON, RE; MONTIELVIESCA, F				APPLETON, RE; MONTIELVIESCA, F			VIGABATRIN IN INFANTILE SPASMS - WHY ADD ON	LANCET			English	Letter							ACTH				APPLETON, RE (corresponding author), ROYAL LIVERPOOL CHILDRENS NHS TRUST,DEPT NEUROL,ALDER HEY,LIVERPOOL L12 2AP,ENGLAND.							ARTEAGA R, 1992, EPILEPSIA, V33, P923, DOI 10.1111/j.1528-1157.1992.tb02202.x; CHIRON C, 1991, J CHILD NEUROL, V6, pS52; CHIRON C, 1990, LANCET, V335, P363, DOI 10.1016/0140-6736(90)90660-W; GIBBS JM, 1992, PEDIATR NEUROL, V8, P338, DOI 10.1016/0887-8994(92)90086-E; GLAZE DG, 1988, J PEDIATR-US, V112, P389, DOI 10.1016/S0022-3476(88)80318-4; Jeavons Peter M., 1992, P53; RIIKONEN R, 1980, ARCH DIS CHILD, V55, P664, DOI 10.1136/adc.55.9.664	7	35	36	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 10	1993	341	8850					962	962		10.1016/0140-6736(93)91255-K	http://dx.doi.org/10.1016/0140-6736(93)91255-K			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW981	8096297				2022-12-28	WOS:A1993KW98100042
J	BERITIC, T				BERITIC, T			OCCUPATIONAL-HEALTH - WORKERS AT HIGH-RISK - THE RIGHT TO KNOW	LANCET			English	Editorial Material											BERITIC, T (corresponding author), CROATIAN ACAD SCI & ARTS, ZAGREB, CROATIA.							BAKER EL, 1989, ANN NY ACAD SCI, V572, P144, DOI 10.1111/j.1749-6632.1989.tb13590.x; BERITIC T, 1988, BRIT J IND MED, V45, P433; LEGGE T, 1934, INDD MALADIES, P2; NEEDLEMAN C, 1993, AM J IND MED, V23, P11, DOI 10.1002/ajim.4700230104; RUDOLPH L, 1993, AM J IND MED, V23, P53, DOI 10.1002/ajim.4700230109; SCHULTE PA, 1993, AM J IND MED, V23, P3, DOI 10.1002/ajim.4700230103	6	1	1	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 10	1993	341	8850					933	934		10.1016/0140-6736(93)91221-7	http://dx.doi.org/10.1016/0140-6736(93)91221-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW981	8096274				2022-12-28	WOS:A1993KW98100013
J	CAPLAN, MS				CAPLAN, MS			RESPIRATORY-DISTRESS - PAF AND SURFACTANT PREPARATIONS	LANCET			English	Editorial Material							PLATELET-ACTIVATING-FACTOR; THERAPY				CAPLAN, MS (corresponding author), EVANSTON HOSP CORP,DEPT PEDIAT,EVANSTON,IL 60201, USA.							CHUNG KF, 1989, THORAX, V44, P108, DOI 10.1136/thx.44.2.108; FUJIWARA T, 1980, LANCET, V1, P55; SNYDER F, 1990, AM J PHYSIOL, V259, pC697, DOI 10.1152/ajpcell.1990.259.5.C697; YEE WFH, 1991, PEDIATR PULM, V11, P65, DOI 10.1002/ppul.1950110111; 1992, LANCET, V340, P1363	5	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 3	1993	341	8849					865	866		10.1016/0140-6736(93)93067-B	http://dx.doi.org/10.1016/0140-6736(93)93067-B			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KV811	8096568				2022-12-28	WOS:A1993KV81100010
J	MADL, C; GRIMM, G; KRAMER, L; YEGANEHFAR, W; STERZ, F; SCHNEIDER, B; KRANZ, A; SCHNEEWEISS, B; LENZ, K				MADL, C; GRIMM, G; KRAMER, L; YEGANEHFAR, W; STERZ, F; SCHNEIDER, B; KRANZ, A; SCHNEEWEISS, B; LENZ, K			EARLY PREDICTION OF INDIVIDUAL OUTCOME AFTER CARDIOPULMONARY-RESUSCITATION	LANCET			English	Article							MULTIMODALITY EVOKED-POTENTIALS; HOSPITAL CARDIAC-ARREST; BRAIN-FUNCTION; COMA; IMPROVEMENT	Prediction of individual outcome after cardiopulmonary resuscitation is of major medical, ethical, and socioeconomic interest but uncertain. We studied the early predictive potency of evoked potential recording after cardiac arrest in 66 resuscitated patients who returned to spontaneous circulation but were unconscious and mechanically ventilated. Detailed long-latency and short-latency sensory evoked potentials were recorded and neurological evaluations were done 4-48 h after admission to intensive care. In all 17 patients with favourable outcome (cerebral performance categories 1 and 2) the cortical evoked potential N70 peak, a reliable measure of cortical function, was detected between 74 and 116 ms. In 49 patients with bad outcome (categories 4 and 5) the N70 peak was absent in 35 or found with a delay between 121 and 171 ms in 14 (p < 0.05 vs favourable outcome). Thus the predictive ability was 100% with cutoff of 118 ms. To confirm reproducibility and validity, repeated tracings, and linked-earlobe referenced techniques were done and gave similar results. Early recording of long-latency evoked potentials after cardiopulmonary resuscitation is highly predictive of outcome.	UNIV VIENNA, DEPT MED 4, INTENS CARE UNIT, A-1010 VIENNA, AUSTRIA; UNIV VIENNA, DEPT EMERGENCY MED, A-1010 VIENNA, AUSTRIA; UNIV VIENNA, INST MED STAT, A-1010 VIENNA, AUSTRIA	University of Vienna; University of Vienna; University of Vienna								[Anonymous], 1986, Am J Emerg Med, V4, P72; BEDELL SE, 1983, NEW ENGL J MED, V309, P569, DOI 10.1056/NEJM198309083091001; BRUNKO E, 1987, ELECTROEN CLIN NEURO, V66, P15, DOI 10.1016/0013-4694(87)90133-7; CANT BR, 1986, EVOKED POTENTIAL, P58; CARONNA J J, 1978, Stroke, V9, P517; CUMMINS RO, 1991, ANN EMERG MED, V20, P861; DEBEYL DZ, 1989, BRAIN FAILURE UPDATE, P206; GRAY WA, 1991, NEW ENGL J MED, V325, P1393, DOI 10.1056/NEJM199111143252001; GREENBERG RP, 1977, J NEUROSURG, V47, P150, DOI 10.3171/jns.1977.47.2.0150; GRIMM G, 1992, ELECTROEN CLIN NEURO, V82, P119, DOI 10.1016/0013-4694(92)90154-A; GRIMM G, 1988, LANCET, V2, P1392; GRIMM G, 1991, INTENS CARE MED, V17, P94, DOI 10.1007/BF01691430; GRIMM G, 1990, KIDNEY INT, V38, P480, DOI 10.1038/ki.1990.229; GRIMM G, 1990, LANCET, V336, P963, DOI 10.1016/0140-6736(90)92419-I; Grundy B.L., 1988, EVOKED POTENTIALS IN; JACOBS P, 1990, CRIT CARE MED, V18, P1282, DOI 10.1097/00003246-199011000-00020; JENNETT B, 1975, LANCET, V1, P480; LUND I, 1976, LANCET, V2, P702; Maiese K, 1988, J INTENSIVE CARE MED, V3, P153; MULLIE A, 1988, LANCET, V1, P137; NAU HE, 1987, INTENS CARE MED, V13, P249, DOI 10.1007/BF00265113; PFURTSCHELLER G, 1985, ELECTROEN CLIN NEURO, V62, P88, DOI 10.1016/0168-5597(85)90020-6; PRIOR PF, 1985, BRIT J ANAESTH, V57, P63, DOI 10.1093/bja/57.1.63; TEASDALE G, 1974, LANCET, V2, P81; VAAGENES P, 1988, J CEREBR BLOOD F MET, V8, P262, DOI 10.1038/jcbfm.1988.57; 1988, CRIT CARE MED, V8, P807	26	135	137	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 3	1993	341	8849					855	858		10.1016/0140-6736(93)93061-5	http://dx.doi.org/10.1016/0140-6736(93)93061-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KV811	8096562				2022-12-28	WOS:A1993KV81100004
J	SUTHERLAND, LR; MAY, GR; SHAFFER, EA				SUTHERLAND, LR; MAY, GR; SHAFFER, EA			SULFASALAZINE REVISITED - A METAANALYSIS OF 5-AMINOSALICYLIC ACID IN THE TREATMENT OF ULCERATIVE-COLITIS	ANNALS OF INTERNAL MEDICINE			English	Article						COLITIS, ULCERATIVE; AMINOSALICYLIC ACIDS; SALICYLAZOSULFAPYRIDINE; METAANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG	INFLAMMATORY BOWEL-DISEASE; MAINTENANCE TREATMENT; DOUBLE-BLIND; PATIENTS INTOLERANT; AZODISAL SODIUM; TERM TREATMENT; SULPHASALAZINE; OLSALAZINE; MESALAZINE; TRIAL	Purpose: To assess the effectiveness of the newer 5-aminosalicylic acid (5-ASA) delivery systems compared with placebo or sulfasalazine for the treatment of active ulcerative colitis and for the maintenance of remission. Data Sources: Pertinent studies were selected using the MEDLINE and BIOS (1981 to 1992) data bases, reference lists from published articles, reviews, symposia proceedings, and abstracts from major gastrointestinal meetings. Study Selection: Randomized controlled trials of 5-ASA compared with placebo or sulfasalazine of a minimum of 4 weeks duration for active disease and a minimum of 6 months for maintenance of disease remission. Sixteen trials of 5-ASA for active disease, published either in abstract or full manuscript, were available. Eleven trials of 5-ASA for maintenance of remission were also reviewed. Data Extraction: Crude rates for either induction of remission (active disease studies) or maintenance of remission (relapse-prevention trials) based on the intention-to-treat principle were extracted from the studies by two independent observers. Each study was given a quality score, based on predetermined criteria. Results: Studies were placed in three groups: 5-ASA compared with placebo, 5-ASA compared with sulfasalazine for active disease, and 5-ASA compared with sulfasalazine for maintenance of remission. 5-Aminosalicylic acid was superior to placebo in the treatment of active ulcerative colitis (pooled odds ratio, 2.02; 95% Cl, 1.50 to 2.72). A dose-response effect for 5-ASA existed (P < 0.001). For active disease, the pooled odds ratio for 5-ASA compared with sulfasalazine was 1.1 5 (Cl, 0.83 to 1.61). When 5-ASA was compared with sulfasalazine for maintenance of disease remission, the pooled odds ratio was 0.85 (Cl, 0.64 to 1.15). Withdrawal rates and reported side effects were similar for 5-ASA compared with placebo- or sulfasalazine-treated patients. Conclusions: Although the newer 5-ASA preparations in a dose of at least 2 g/d are more effective than placebo in the treatment of ulcerative colitis, insufficient evidence exists to suggest that they are superior to sulfasalazine. Although they offer a benefit to the sulfasalazine-sensitive patient, use of 5-ASA preparations instead of sulfasalazine in the treatment of ulcerative colitis cannot yet be substantiated.	UNIV CALGARY, CALGARY T2N 1N4, ALBERTA, CANADA	University of Calgary								AHLUWALIA N K, 1992, Gastroenterology, V102, pA588; AHNFELTRONNE I, 1990, GASTROENTEROLOGY, V98, P1162, DOI 10.1016/0016-5085(90)90329-Y; Andreoli A, 1987, CLIN CONTROVERSIES I, P170; AZADKHAN AK, 1977, LANCET, V2, P892; Barbara L, 1987, CLIN CONTROVERSIES I, V173; BARON JH, 1962, LANCET, V1, P1094; BRESCI G, 1990, INT J TISSUE REACT, V12, P243; CHALMERS TC, 1981, CONTROL CLIN TRIALS, V2, P31, DOI 10.1016/0197-2456(81)90056-8; CHALMERS TC, 1988, DATA ANAL CLIN MED; CHAN RP, 1983, DIGEST DIS SCI, V28, P609, DOI 10.1007/BF01299921; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DEW MJ, 1983, BRIT MED J, V287, P23, DOI 10.1136/bmj.287.6384.23; DEW MJ, 1983, LANCET, V2, P801; DEW MJ, 1982, BMJ-BRIT MED J, V285, P1012, DOI 10.1136/bmj.285.6347.1012; DEW MJ, 1980, GUT, V21, pA449; DISSANAYAKE AS, 1973, GUT, V14, P923, DOI 10.1136/gut.14.12.923; DONALD IP, 1985, POSTGRAD MED J, V61, P1047, DOI 10.1136/pgmj.61.722.1047; ELIAKIM R, 1990, ISRAEL J MED SCI, V26, P47; EWE K, 1988, SCAND J GASTROENTERO, V23, P70, DOI 10.3109/00365528809101553; FEURLE GE, 1989, GUT, V30, P1354, DOI 10.1136/gut.30.10.1354; FLEIG WE, 1988, DIGESTION, V40, P173, DOI 10.1159/000199652; GARRETTO M, 1983, GASTROENTEROLOGY, V84, P1162; GIONCHETTI P, 1990, GASTROENTEROLOGY, V98, P251, DOI 10.1016/0016-5085(90)91334-3; GOOD L, 1992, Gastroenterology, V102, pA630; HABAL FM, 1988, AM J GASTROENTEROL, V83, P15; HABAL FM, 1985, GASTROENTEROLOGY, V88, P1409; HANAUER S, 1989, Gastroenterology, V96, pA195; HETZEL DJ, 1986, J GASTROEN HEPATOL, V1, P257, DOI 10.1111/j.1440-1746.1986.tb00121.x; HETZEL DJ, 1985, GASTROENTEROLOGY, V88, P1418; IRELAND A, 1987, GASTROENTEROLOGY, V92, P1447; IRELAND A, 1987, SCAND J GASTROENTERO, V22, P1038, DOI 10.3109/00365528708991953; IRELAND A, 1988, GUT, V29, P835, DOI 10.1136/gut.29.6.835; JEWELL DP, 1988, SCAND J GASTROENTERO, V23, P45, DOI 10.3109/00365528809101547; KHAN AKA, 1980, GUT, V21, P232; KIILERICH S, 1992, GUT, V33, P252, DOI 10.1136/gut.33.2.252; KJAERGAARD N, 1989, SCAND J GASTROENTERO, V24, P891, DOI 10.3109/00365528909089231; KLOTZ U, 1987, DIGEST DIS SCI, V32, pS46, DOI 10.1007/BF01312463; KRUIS W, 1992, Gastroenterology, V102, pA649; LAURITSEN K, 1986, GASTROENTEROLOGY, V91, P837, DOI 10.1016/0016-5085(86)90684-0; LAURITSEN K, 1986, GASTROENTEROLOGY, V90, P1513; LAW R, 1992, GASTROENTEROLOGY, V102, pA666; MCINTYRE PB, 1988, ALIMENT PHARM THERAP, V2, P237; MEYERS S, 1987, GASTROENTEROLOGY, V93, P1255, DOI 10.1016/0016-5085(87)90253-8; MEYERS S, 1988, SCAND J GASTROENTERO, V23, P29, DOI 10.3109/00365528809101544; MIGLIOLI M, 1990, EUR J GASTROEN HEPAT, V2, P229; MISIEWICZ JJ, 1965, LANCET, V1, P185; MULDER CJJ, 1988, ANN INTERN MED, V108, P911, DOI 10.7326/0003-4819-108-6-911_2; MULDER CJJ, 1988, GASTROENTEROLOGY, V95, P1449, DOI 10.1016/S0016-5085(88)80061-1; PORRO GB, 1989, GUT, V30, pA1467; Pruitt R E, 1991, J Tenn Med Assoc, V84, P237; RACHMILEWITZ D, 1989, BMJ-BRIT MED J, V298, P82, DOI 10.1136/bmj.298.6666.82; RAIMUNDO AH, 1992, GASTROENTEROLOGY, V102, pA81; RAO SS, 1987, SCAND J GASTROENTERO, V22, P332, DOI 10.3109/00365528709078600; RAO SSC, 1989, GUT, V30, P675, DOI 10.1136/gut.30.5.675; RIJK M C M, 1991, Gastroenterology, V100, pA243; RIJK MCM, 1992, AM J GASTROENTEROL, V87, P438; RILEY SA, 1988, GUT, V29, P669, DOI 10.1136/gut.29.5.669; RILEY SA, 1988, GASTROENTEROLOGY, V94, P1383, DOI 10.1016/0016-5085(88)90677-4; RILEY SA, 1987, GUT, V28, pA1390; RILEY SA, 1987, GASTROENTEROLOGY, V92, P1596; ROBINSON M, 1988, GASTROENTEROLOGY, V84, pA381; RUTGEERTS P, 1989, ALIMENT PHARM THERAP, V3, P183; SANDBERGGERTZEN H, 1986, GASTROENTEROLOGY, V90, P1024, DOI 10.1016/0016-5085(86)90882-6; SANDBERGGERTZEN H, 1985, GASTROENTEROLOGY, V88, P1568; SCHROEDER KW, 1987, NEW ENGL J MED, V317, P1625, DOI 10.1056/NEJM198712243172603; SCHROEDER KW, 1986, GASTROENTEROLOGY, V90, P1620; SELBY WS, 1985, BMJ-BRIT MED J, V291, P1373, DOI 10.1136/bmj.291.6506.1373; SHANAHAN F, 1990, IMMUNOPHARMACOLOGY, V20, P217, DOI 10.1016/0162-3109(90)90037-F; SHANAHAN F, 1986, IMMUNOPHARMACOLOGY, V11, P111, DOI 10.1016/0162-3109(86)90031-7; SNINSKY CA, 1991, ANN INTERN MED, V115, P350, DOI 10.7326/0003-4819-115-5-350; Sutherland LR, 1990, CAN J GASTROENTEROL, V4, P463; Svartz N, 1942, ACTA MED SCAND, V110, P577; TRUELOVE SC, 1955, BRIT MED J, V2, P1041, DOI 10.1136/bmj.2.4947.1041; TURUNEN U, 1987, SCAND J GASTROENTERO, V22, P798, DOI 10.3109/00365528708991917; VANHEES PAM, 1980, GUT, V21, P632, DOI 10.1136/gut.21.7.632; WILLOUGHBY CP, 1988, SCAND J GASTROENTERO, V23, P40, DOI 10.3109/00365528809101546; WRIGHT J P, 1992, Gastroenterology, V102, pA714; ZINBERG J, 1990, AM J GASTROENTEROL, V85, P562; ZINBERG J, 1987, GASTROENTEROLOGY, V92, P1711	79	212	218	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1993	118	7					540	549		10.7326/0003-4819-118-7-199304010-00009	http://dx.doi.org/10.7326/0003-4819-118-7-199304010-00009			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU079	8095128				2022-12-28	WOS:A1993KU07900009
J	VERSLUYS, C				VERSLUYS, C			ETHICS OF NEONATAL CARE	LANCET			English	Letter											VERSLUYS, C (corresponding author), WILKELMINA KINDERZIEKENHUIS,UTRECHT,NETHERLANDS.								0	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 27	1993	341	8848					794	795		10.1016/0140-6736(93)90567-Z	http://dx.doi.org/10.1016/0140-6736(93)90567-Z			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU900	8096005				2022-12-28	WOS:A1993KU90000010
J	EMBRETSON, J; ZUPANCIC, M; RIBAS, JL; BURKE, A; RACZ, P; TENNERRACZ, K; HAASE, AT				EMBRETSON, J; ZUPANCIC, M; RIBAS, JL; BURKE, A; RACZ, P; TENNERRACZ, K; HAASE, AT			MASSIVE COVERT INFECTION OF HELPER T-LYMPHOCYTES AND MACROPHAGES BY HIV DURING THE INCUBATION PERIOD OF AIDS	NATURE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; LYMPH-NODES; INSITU HYBRIDIZATION; VISNA VIRUS; LYMPHADENOPATHY; AMPLIFICATION; CELLS; DNA; PATHOGENESIS; MECHANISMS	ANIMAL and human lentiviruses elude host defences by establishing covert infections and eventually cause disease through cumulative losses of cells that die with activation of viral gene expression1-5. We used polymerase chain reaction in situ double-label methods6,7 to determine how many CD4+ lymphocytes are latently infected by human immunodeficiency virus (HIV) in patient lymph nodes and whether the pool of infected cells is large enough to account for immune depletion through continual activation of viral gene expression and attrition of cells responding to antigens. We discovered an extraordinarily large number of latently infected CD4+ lymphocytes and macrophages throughout the lymphoid system from early to late stages of infection, and confirmed8-14 the extracellular association of HIV with follicular dendritic cells. Follicular dendritic cells may transmit infection to cells as they migrate through lymphoid follicles. Latently infected lymphocytes and macrophages constitute an intracellular reservoir large enough ultimately to contribute to much of the immune depletion in AIDS, and represent a difficult problem that must be resolved in developing effective treatments and protective vaccine.	UNIV MINNESOTA,DEPT MICROBIOL,420 DELAWARE ST SE,MINNEAPOLIS,MN 55455; HENRY M JACKSON FDN,ROCKVILLE,MD 20850; US DEPT DEF,ARMED FORCES INST PATHOL,DEPT CARDIOVASC PATHOL,WASHINGTON,DC 20306; BERNHARD NOCHT INST TROP MED,W-2000 HAMBURG 36,GERMANY	University of Minnesota System; University of Minnesota Twin Cities; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc; United States Department of Defense; Bernhard Nocht Institut fur Tropenmedizin								ARMSTRONG JA, 1984, LANCET, V2, P370; BARONI CD, 1986, HISTOPATHOLOGY, V10, P5, DOI 10.1111/j.1365-2559.1986.tb02456.x; BIBERFELD P, 1986, AM J PATHOL, V125, P436; BRAHIC M, 1981, NATURE, V292, P240, DOI 10.1038/292240a0; BRAHIC M, 1989, CURR TOP MICROBIOL, V143, P9; CHESEBRO B, 1992, J VIROL, V66, P6547, DOI 10.1128/JVI.66.11.6547-6554.1992; EMBRETSON J, 1993, P NATL ACAD SCI USA, V90, P357, DOI 10.1073/pnas.90.1.357; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; FOX CH, 1991, J INFECT DIS, V164, P1051, DOI 10.1093/infdis/164.6.1051; GREENE WC, 1991, NEW ENGL J MED, V324, P308, DOI 10.1056/NEJM199101313240506; HAASE AT, 1986, NATURE, V322, P130, DOI 10.1038/322130a0; HAASE AT, 1990, P NATL ACAD SCI USA, V87, P4971, DOI 10.1073/pnas.87.13.4971; Haase AT, 1987, IN SITU HYBRIDIZATIO, P197; HARPER ME, 1986, P NATL ACAD SCI USA, V83, P772, DOI 10.1073/pnas.83.3.772; NUOVO GJ, 1991, AM J PATHOL, V139, P847; PELUSO R, 1985, VIROLOGY, V147, P231, DOI 10.1016/0042-6822(85)90246-6; RACZ P, 1986, PROG ALLERGY, V37, P81; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; SPIEGEL H, 1992, AM J PATHOL, V140, P15; STASKUS KA, 1991, MICROB PATHOGENESIS, V11, P67, DOI 10.1016/0882-4010(91)90095-R; TENNERRACZ K, 1986, AM J PATHOL, V123, P9	21	1330	1357	0	37	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 25	1993	362	6418					359	362		10.1038/362359a0	http://dx.doi.org/10.1038/362359a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KU176	8096068				2022-12-28	WOS:A1993KU17600066
J	LANDESBERG, G; LURIA, MH; COTEV, S; EIDELMAN, LA; ANNER, H; MOSSERI, M; SCHECHTER, D; ASSAF, J; EREL, J; BERLATZKY, Y				LANDESBERG, G; LURIA, MH; COTEV, S; EIDELMAN, LA; ANNER, H; MOSSERI, M; SCHECHTER, D; ASSAF, J; EREL, J; BERLATZKY, Y			IMPORTANCE OF LONG-DURATION POSTOPERATIVE ST-SEGMENT DEPRESSION IN CARDIAC MORBIDITY AFTER VASCULAR-SURGERY	LANCET			English	Article							PERIOPERATIVE MYOCARDIAL-ISCHEMIA; NONCARDIAC SURGERY; SILENT ISCHEMIA; MORTALITY; RISK; ASSOCIATION; EVENTS; INDEX	Major vascular surgery is associated with a high incidence of cardiac ischaemic complications. By means of continuous perioperative electrocardiographic recording, we studied 151 consecutive patients undergoing major vascular surgery to find out the characteristics of any myocardial ischaemia and the relation to outcome. 13 (8.6%) patients had postoperative cardiac events (6 myocardial infarctions, 2 unstable angina, and 5 congestive heart failure). There were 342 perioperative ischaemic episodes shown by ST-segment depression; 164 (48%) occurred postoperatively. Postoperative ischaemic episodes were significantly longer than episodes before or during operations (3.2 vs 1.7 and 1.5 min per h monitored, respectively, p<0.001). Both Detsky's cardiac risk index and long-duration (>2 h) preoperative ischaemia were predictive of postoperative cardiac complications (odds ratios in univariate analysis 3.3, p = 0.03, and 7.2, p = 0.009, respectively). However, long-duration (>2 h) postoperative ischaemia was the only factor significantly associated with cardiac morbidity in multivariate logistic regression analysis (odds ratio 21.7, p = .001). Long-duration ST-segment depression preceded most (84.6%) postoperative cardiac events, including myocardial infarctions, and no cardiac event was preceded by ST-segment elevation. 5 of the 6 postoperative myocardial infarctions were non-Q-wave infarctions. We conclude that long-duration subendocardial ischaemia, rather than acute coronary artery occlusion, may bring about postoperative myocardial injury and complications.	HADASSAH MED CTR, JERUSALEM, ISRAEL; HEBREW UNIV JERUSALEM, SCH MED, DEPT VASC SURG, JERUSALEM, ISRAEL; HEBREW UNIV JERUSALEM, SCH MED, DEPT CARDIOL, JERUSALEM, ISRAEL; HEBREW UNIV JERUSALEM, SCH MED, DEPT NUCL MED, JERUSALEM, ISRAEL; HEBREW UNIV JERUSALEM, SCH MED, DEPT PREOPERAT EVALUAT CLIN, JERUSALEM, ISRAEL	Hebrew University of Jerusalem; Hadassah University Medical Center; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem	LANDESBERG, G (corresponding author), HEBREW UNIV JERUSALEM, HADASSAH MED CTR, SCH MED, DEPT ANESTHESIOL & CRIT CARE MED, IL-91120 JERUSALEM, ISRAEL.							BLACKBURN H, 1960, CIRCULATION, V21, P1160, DOI 10.1161/01.CIR.21.6.1160; DEEDWANIA PC, 1990, CIRCULATION, V81, P748, DOI 10.1161/01.CIR.81.3.748; DETSKY AS, 1986, ARCH INTERN MED, V146, P2131, DOI 10.1001/archinte.146.11.2131; DUMM MI, 1989, LIPMAN MASSIE CLIN E; EAGLE KA, 1989, ANN INTERN MED, V110, P859, DOI 10.7326/0003-4819-110-11-859; FLEISHER LA, 1991, AM HEART J, V122, P980, DOI 10.1016/0002-8703(91)90461-P; FOX KM, 1990, CIRCULATION, V82, P155; GEER JC, 1980, AM J PATHOL, V98, P663; GEFT IL, 1982, CIRCULATION, V66, P1150, DOI 10.1161/01.CIR.66.6.1150; GOLDMAN L, 1977, NEW ENGL J MED, V297, P845, DOI 10.1056/NEJM197710202971601; HESS OM, 1988, CIRCULATION, V77, P967, DOI 10.1161/01.CIR.77.5.967; LANDESBERG G, 1993, J CARDIOTHOR VASC AN, V7, P1; MANGANO DT, 1990, NEW ENGL J MED, V323, P1781, DOI 10.1056/NEJM199012273232601; MANGANO DT, 1990, ANESTHESIOLOGY, V72, P153, DOI 10.1097/00000542-199001000-00025; MANGANO DT, 1991, J AM COLL CARDIOL, V17, P843, DOI 10.1016/0735-1097(91)90863-5; MCCANN RL, 1989, J VASC SURG, V9, P583, DOI 10.1067/mva.1989.vs0090583; RABY KE, 1989, NEW ENGL J MED, V321, P1296, DOI 10.1056/NEJM198911093211904; ROCCO MB, 1988, CIRCULATION, V78, P877, DOI 10.1161/01.CIR.78.4.877; SCHANG SJ, 1977, AM J CARDIOL, V39, P396, DOI 10.1016/S0002-9149(77)80095-7; STERN S, 1988, AM J CARDIOL, V61, P1233; WONG T, 1992, ANN INTERN MED, V116, P743, DOI 10.7326/0003-4819-116-9-743	21	223	231	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 20	1993	341	8847					715	719		10.1016/0140-6736(93)90486-Z	http://dx.doi.org/10.1016/0140-6736(93)90486-Z			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KT362	8095624				2022-12-28	WOS:A1993KT36200003
J	LEES, B; MOLLESON, T; ARNETT, TR; STEVENSON, JC				LEES, B; MOLLESON, T; ARNETT, TR; STEVENSON, JC			DIFFERENCES IN PROXIMAL FEMUR BONE-DENSITY OVER 2 CENTURIES	LANCET			English	Article							OSTEOPOROSIS; FRACTURE; CALCIUM; SPINE; WOMEN	The incidence of osteoporotic hip fractures in northern Europe has been increasing over the past few decades faster than the rate adjusted for increased life expectancy, One important factor that determines osteoporotic fracture risk is bone density. The restoration of a London church, during which skeletal material dating from 1729 to 1852 was recovered, gave us the opportunity to compare the rate of bone loss in the femora of these samples with that of present-day women. The rate of bone loss, as judged by dual energy X-ray absorptiometry, was significantly greater in modern-day women than in the women from two centuries ago, both pre-menopausally (p<0.05) and post-menopausally (p<0.01). The difference in bone loss in the Ward's triangle region between the Spitalfields samples and present-day women remained even when the assumed age at menopause was increased to 48 years or decreased to 42 years. The results suggest that differences in rates of bone loss over two centuries may partly account for the increasing incidence of hip fracture in modern-day women. Reasons for these differences are unclear, but one factor may be a lower degree of physical activity in present-day women.	WYNN INST METAB RES,21 WELLINGTON RD,LONDON NW8 9SQ,ENGLAND; BRITISH MUSEUM NAT HIST,DEPT PALEONTOL,LONDON SW7 5BD,ENGLAND; UNIV LONDON UNIV COLL,DEPT ANAT & DEV BIOL,LONDON WC1E 6BT,ENGLAND	Imperial College London; British Museum of Natural History; University of London; University College London			Arnett, Tim/AAW-4445-2021					ARMITAGE P, 1988, STATISTICAL METHODS; COX M, 1989, P HUGUENOT SOC, V25, P1; GILSANZ V, 1988, CALCIFIED TISSUE INT, V43, P260, DOI 10.1007/BF02555144; HAYES WC, 1991, RADIOL CLIN N AM, V29, P1; LEES B, 1992, OSTEOPOROSIS INT, V2, P146, DOI 10.1007/BF01623822; LEWIS AF, 1981, BMJ-BRIT MED J, V283, P1217, DOI 10.1136/bmj.283.6301.1217; MAZESS R, 1989, CALCIFIED TISSUE INT, V44, P228, DOI 10.1007/BF02556569; MAZESS RB, 1988, J BONE MINER RES, V3, P13; MOLLESON TI, IN PRESS SPITALFIELD; RIGGS BL, 1987, J CLIN INVEST, V80, P979, DOI 10.1172/JCI113191; STEVENSON JC, 1989, BRIT MED J, V298, P924, DOI 10.1136/bmj.298.6678.924; STEVENSON JC, 1988, BRIT MED J, V297, P15, DOI 10.1136/bmj.297.6640.15; Trotter M, 1952, AM J PHYS ANTHROP-NE, V10, P463, DOI 10.1002/ajpa.1330100407; Vega E, 1991, Osteoporos Int, V1, P81, DOI 10.1007/BF01880448; WALLACE WA, 1983, LANCET, V1, P1413; ZETTERBERG C, 1980, ACTA ORTHOP SCAND, V54, P681	16	81	83	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 13	1993	341	8846					673	675		10.1016/0140-6736(93)90433-H	http://dx.doi.org/10.1016/0140-6736(93)90433-H			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR613	8095581				2022-12-28	WOS:A1993KR61300016
J	TELENTI, A; IMBODEN, P; MARCHESI, F; LOWRIE, D; COLE, S; COLSTON, MJ; MATTER, L; SCHOPFER, K; BODMER, T				TELENTI, A; IMBODEN, P; MARCHESI, F; LOWRIE, D; COLE, S; COLSTON, MJ; MATTER, L; SCHOPFER, K; BODMER, T			DETECTION OF RIFAMPICIN-RESISTANCE MUTATIONS IN MYCOBACTERIUM-TUBERCULOSIS	LANCET			English	Article							POLYMERASE CHAIN-REACTION; RNA-POLYMERASE; ESCHERICHIA-COLI; DNA; GENE	Control of tuberculosis is threatened by widespread emergence of drug resistance in Mycobacterium tuberculosis. Understanding the molecular basis of resistance might lead to development of novel rapid methods for diagnosing drug resistance. We set out to determine the molecular basis of resistance to rifampicin, a major component of multidrug regimens used for treating tuberculosis. Resistance to rifampicin involves alterations of RNA polymerase. The gene that encodes the RNA polymerase subunit beta (rpoB) was cloned. Sequence information from this gene was used to design primers for direct amplification and sequencing of a 411 bp rpoB fragment from 122 isolates of M tuberculosis. Mutations involving 8 conserved aminoacids were identified in 64 of 66 rifampicin-resistant isolates of diverse geographical origin, but in none of 56 sensitive isolates. All mutations were clustered within a region of 23 aminoacids. Thus, substitution of a limited number of highly conserved aminoacids encoded by the rpoB gene appears to be the molecular mechanism responsible for ''single step'' high-level resistance to rifampicin in M tuberculosis. This information was used to develop a strategy (polymerase chain reaction-single-strand conformation polymorphism) that allowed efficient detection of all known rifampicin-resistant mutants. These findings provide the basis for rapid detection of rifampicin resistance, a marker of multidrug-resistant tuberculosis.	NATL INST MED RES,LONDON NW7 1AA,ENGLAND; INST PASTEUR,BACTERIAL MOLEC GENET LAB,F-75724 PARIS 15,FRANCE	MRC National Institute for Medical Research; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	TELENTI, A (corresponding author), UNIV BERN,INST MED MICROBIOL,FRIEDBUEHLSTR 51,CH-3010 BERN,SWITZERLAND.		Trajman, Anete/C-7679-2016; Lowrie, Douglas/B-8151-2013	Trajman, Anete/0000-0002-4000-4984; Lowrie, Douglas/0000-0003-2689-9627				ALDRAINEV I, 1990, J CHEMOTHER, V2, P147; CAVE MD, 1991, MOL CELL PROBE, V5, P73, DOI 10.1016/0890-8508(91)90040-Q; CULLITON BJ, 1992, NATURE, V356, P473, DOI 10.1038/356473a0; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; FISCHL MA, 1992, ANN INTERN MED, V117, P184, DOI 10.7326/0003-4819-117-3-184; FISH M, 1992, ANN INTERN MED, V117, P177; HEIL A, 1970, FEBS LETT, V11, P165, DOI 10.1016/0014-5793(70)80519-1; HONORE N, IN PRESS ANTIMICROB; HONORE NS, IN PRESS MOL MICROBI; HUI J, 1977, ANTIMICROB AGENTS CH, V11, P773, DOI 10.1128/AAC.11.5.773; HULMAN T, 1989, NUCLEIC ACIDS RES, V17, P4937; ILAYASHI K, 1991, PCR METH APPL, V1, P34; INDERLIED C, 1991, ANTIBIOTICS LABORATO, P136; JIN DJ, 1988, J MOL BIOL, V202, P45, DOI 10.1016/0022-2836(88)90517-7; LAGUNA F, 1991, J INFECTION, V23, P139, DOI 10.1016/0163-4453(91)92016-X; LISITSYN NA, 1984, MOL GEN GENET, V196, P173, DOI 10.1007/BF00334112; MARTIN C, 1990, MOL BIOL MYCOBACTERI, P121; MITCHISON D, 1985, BR MED B, V40, P84; MITCHISON DA, 1986, AM REV RESPIR DIS, V133, P423; MONNO L, 1991, LANCET, V337, P852, DOI 10.1016/0140-6736(91)92559-K; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; OVCHINNIKOV YA, 1981, EUR J BIOCHEM, V116, P621, DOI 10.1111/j.1432-1033.1981.tb05381.x; PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191; SCHOWALTER DB, 1989, ANAL BIOCHEM, V177, P90, DOI 10.1016/0003-2697(89)90019-5; SIDDIQI SH, 1981, J CLIN MICROBIOL, V13, P908, DOI 10.1128/JCM.13.5.908-912.1981; TELENTI A, 1993, J CLIN MICROBIOL, V31, P175, DOI 10.1128/JCM.31.2.175-178.1993; TSUKAMURA M, 1972, Tubercle, V53, P111, DOI 10.1016/0041-3879(72)90027-X; YAMADA T, 1985, ANTIMICROB AGENTS CH, V27, P921, DOI 10.1128/AAC.27.6.921; ZNANG Y, 1992, NATURE, V358, P591; 1992, MMWR, V41, P1	30	1028	1108	1	112	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 13	1993	341	8846					647	650		10.1016/0140-6736(93)90417-F	http://dx.doi.org/10.1016/0140-6736(93)90417-F			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR613	8095569				2022-12-28	WOS:A1993KR61300002
J	FALLOWFIELD, L				FALLOWFIELD, L			GIVING SAD AND BAD-NEWS	LANCET			English	Article							BREAST-CANCER; DIAGNOSIS; CONSULTATION	When bad news is broken insensitively the impact can be distressing for both giver and recipient. For the recipient especially, the effect can be longlasting. Poor training in communication skills leaves most doctors unable to give bad news appropriately. Doctors must realise what impact the news can have on the patient; must overcome fear of being blamed for the message and of a sense of failure for not being able to improve the situation; and must learn how to cope with the recipient's reaction. Doctors should prepare adequately for the meeting, ensure that the patient has understood the message, and see to the patient's immediate needs after the interview. If diagnostic investigations or therapeutic options are being discussed at the same time, giving the patient an audiotape recording of the interview is helpful.			FALLOWFIELD, L (corresponding author), UNIV LONDON LONDON HOSP,COLL MED,CRC,COMMUN & COUNSELLING RES CTR,LONDON E1 2AD,ENGLAND.			Fallowfield, Lesley/0000-0003-0577-4518				BIRD J, IN PRESS MED ED; BREWIN TB, 1991, LANCET, V337, P1207, DOI 10.1016/0140-6736(91)92870-8; CUNNINGHAM CC, 1984, DEV MED CHILD NEUROL, V26, P33; FALLOWFIELD LJ, 1987, J ROY SOC MED, V80, P696, DOI 10.1177/014107688708001113; FALLOWFIELD LJ, 1986, BMJ-BRIT MED J, V293, P1331, DOI 10.1136/bmj.293.6558.1331; FEIGEL H, 1976, DEATH CURRENT PERSPE; FINLAY I, 1991, BRIT MED J, V302, P1524, DOI 10.1136/bmj.302.6791.1524; FIRTHCOZENS J, 1987, BRIT MED J, V295, P533, DOI 10.1136/bmj.295.6597.533; HOGBIN B, 1989, BRIT J HOSP MED, V41, P330; MAGUIRE P, 1986, BRIT MED J, V292, P1573, DOI 10.1136/bmj.292.6535.1573; MCLAUCHLAN CAJ, 1990, BRIT MED J, V301, P1145, DOI 10.1136/bmj.301.6761.1145; OLIN HS, 1982, J MED EDUC, V47, P564; WOOLLEY H, 1989, BRIT MED J, V298, P1623, DOI 10.1136/bmj.298.6688.1623	13	196	197	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 20	1993	341	8843					476	478		10.1016/0140-6736(93)90219-7	http://dx.doi.org/10.1016/0140-6736(93)90219-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN137	8094499				2022-12-28	WOS:A1993KN13700016
J	VAITKUS, PT; CAPELESS, MA				VAITKUS, PT; CAPELESS, MA			ELECTROPHYSIOLOGICALLY GUIDED ANTIARRHYTHMIC THERAPY VERSUS BETA-BLOCKER THERAPY IN PATIENTS WITH VENTRICULAR TACHYARRHYTHMIAS	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter							TACHYCARDIA; DISEASE				VAITKUS, PT (corresponding author), UNIV VERMONT,BURLINGTON,VT 05405, USA.							CASSIDY DM, 1986, CIRCULATION, V73, P645, DOI 10.1161/01.CIR.73.4.645; POLL DS, 1984, CIRCULATION, V70, P451, DOI 10.1161/01.CIR.70.3.451; STEINBECK G, 1992, NEW ENGL J MED, V327, P987, DOI 10.1056/NEJM199210013271404; VAITKUS PT, 1991, CIRCULATION, V84, P672, DOI 10.1161/01.CIR.84.2.672	4	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 4	1993	328	5					357	357						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK247	8093552				2022-12-28	WOS:A1993KK24700023
J	GARCIA, HH; GILMAN, R; MARTINEZ, M; TSANG, VCW; PILCHER, JB; HERRERA, G; DIAZ, F; ALVARADO, M; MIRANDA, E				GARCIA, HH; GILMAN, R; MARTINEZ, M; TSANG, VCW; PILCHER, JB; HERRERA, G; DIAZ, F; ALVARADO, M; MIRANDA, E			CYSTICERCOSIS AS A MAJOR CAUSE OF EPILEPSY IN PERU	LANCET			English	Article							CEREBRAL CYSTICERCOSIS; TAENIA-SOLIUM; DIAGNOSIS; ASSAY; NEUROCYSTICERCOSIS; ANTIGENS; ELISA	In countries where cysticercosis is endemic, the proportion of epilepsy due to cysticercosis is not well documented. To investigate the association between cysticercosis and epilepsy, we used the enzyme-linked immunoelectrotransfer blot (EITB) assay to detect serum antibodies to Taenia solium in 498 consecutive outpatients at a neurology clinic in Lima, Peru. Every patient was classified as epileptic (n = 189) or non-epileptic (n = 309) after neurological, and where possible electroencephalographic, examination. A substantially higher proportion of epileptic than non-epileptic patients was seropositive in the EITB (22 [12%] vs 8 [3%], p<0.001). 19% of epileptic patients born outside Lima, 20% of those with late-onset epilepsy, and 29% of patients with both these characteristics were seropositive. Thus, in Peru, cysticercosis is an important aetiological factor for epilepsy.	CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,PARASIT DIS BRANCH,BLDG 23,MAIL STOP F-13,ATLANTA,GA 30341; UNIV PERUANA CAYETANO HEREDIA,LIMA,PERU; INST NACL CIENCIAS NEUROL,LIMA,PERU; JOHNS HOPKINS UNIV,BALTIMORE,MD 21218	Centers for Disease Control & Prevention - USA; Universidad Peruana Cayetano Heredia; Johns Hopkins University				Evans, Carlton/0000-0002-6873-5447	Wellcome Trust [057434] Funding Source: Medline	Wellcome Trust(Wellcome Trust)		ACHA JP, 1964, AM J TROP MED HYG, V13, P48; BENDING JJ, 1983, LANCET, V1, P922; CHOPRA JS, 1981, T ROY SOC TROP MED H, V75, P4; DELBRUTTO OH, 1988, REV INFECT DIS, V10, P1075; DIAZ F, 1992, AM J EPIDEMIOL, V135, P875, DOI 10.1093/oxfordjournals.aje.a116383; DIAZ JF, 1992, AM J TROP MED HYG, V46, P610, DOI 10.4269/ajtmh.1992.46.610; DIWAN AR, 1982, AM J TROP MED HYG, V31, P364, DOI 10.4269/ajtmh.1982.31.364; Dixon HBF, 1944, Q J MED, V13, P107; GAJDUSEK DC, 1978, PAPUA NEW GUINEA MED, V21, P329; GARCIA HH, 1991, LANCET, V338, P549; GONZALEZ AE, 1990, AM J TROP MED HYG, V43, P194, DOI 10.4269/ajtmh.1990.43.194; Mahajan R.C., 1982, P39; MCCORMICK GF, 1982, ARCH NEUROL-CHICAGO, V39, P534, DOI 10.1001/archneur.1982.00510210004002; MEDINA MT, 1990, ARCH INTERN MED, V150, P325, DOI 10.1001/archinte.150.2.325; NASH TE, 1984, NEW ENGL J MED, V311, P1492, DOI 10.1056/NEJM198412063112307; PLASCENCIA M, IN PRESS NEUROEPIDEM; SARTI E, 1992, AM J TROP MED HYG, V46, P677, DOI 10.4269/ajtmh.1992.46.677; SHORVON SD, 1990, LANCET, V336, P93, DOI 10.1016/0140-6736(90)91603-8; SHORVON SD, 1991, MANAGEMENT EPILEPSY; TELLEZGIRON E, 1987, AM J TROP MED HYG, V37, P169, DOI 10.4269/ajtmh.1987.37.169; TSANG VCW, 1989, J INFECT DIS, V159, P50, DOI 10.1093/infdis/159.1.50	21	174	180	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 23	1993	341	8839					197	200		10.1016/0140-6736(93)90064-N	http://dx.doi.org/10.1016/0140-6736(93)90064-N			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ219	8093496	Green Accepted			2022-12-28	WOS:A1993KJ21900003
J	HALLIWELL, B				HALLIWELL, B			RENAISSANCE OF PEROXISOMES	LANCET			English	Editorial Material											HALLIWELL, B (corresponding author), UNIV CALIF DAVIS,DAVIS MED CTR,DAVIS,CA 95616, USA.		Halliwell, Barry/C-8318-2009					DEDUVE C, 1966, PHYSIOL REV, V46, P322; LAZAROW PB, 1976, P NATL ACAD SCI USA, V73, P2043, DOI 10.1073/pnas.73.6.2043; MANNAERTS GP, 1992, CELL BIOCHEM FUNCT, V10, P141, DOI 10.1002/cbf.290100303; PALOSAARI PM, 1992, ANN MED, V24, P163, DOI 10.3109/07853899209147814; ROSCHER AA, 1992, CELL BIOCHEM FUNCT, V10, P201, DOI 10.1002/cbf.290100310; SHIMOZAWA N, 1992, SCIENCE, V255, P1132, DOI 10.1126/science.1546315	6	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 9	1993	341	8837					92	92		10.1016/0140-6736(93)92566-C	http://dx.doi.org/10.1016/0140-6736(93)92566-C			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF870	8093412				2022-12-28	WOS:A1993KF87000013
J	SHARP, D				SHARP, D			WHEN WINE IS RED	LANCET			English	Editorial Material																		EDDY P, 1992, TELEGRAPH MAGAZ 1205, P18; KLATSKY AL, 1992, ANN INTERN MED, V117, P646, DOI 10.7326/0003-4819-117-8-646; RENAUD S, 1992, LANCET, V339, P1523, DOI 10.1016/0140-6736(92)91277-F; SEIGNEUR M, 1990, J APPL CARDIOL, V5, P215; SIEMANN EH, 1992, AM J ENOL VITICULT, V43, P49	5	13	13	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 2	1993	341	8836					27	28		10.1016/0140-6736(93)92493-D	http://dx.doi.org/10.1016/0140-6736(93)92493-D			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF027	8093276				2022-12-28	WOS:A1993KF02700015
J	ODONOVAN, A; DAVIES, AA; MOGGS, JG; WEST, SC; WOOD, RD				ODONOVAN, A; DAVIES, AA; MOGGS, JG; WEST, SC; WOOD, RD			XPG ENDONUCLEASE MAKES THE 3' INCISION IN HUMAN DNA NUCLEOTIDE EXCISION-REPAIR	NATURE			English	Article							COMPLEMENTATION GROUP-G; PIGMENTOSUM GROUP-F; XERODERMA-PIGMENTOSUM; SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; RAD2; PROTEINS; DEFECTS; ERCC1; GENE	HUMANS With a defect in the XPG protein suffer from xeroderma pigmentosum (XP) resulting from an inability to perform DNA nucleotide excision repair properly(1-4). Here we show that XPG makes a structure-specific endonucleolytic incision in a synthetic DNA substrate containing a duplex region and single-stranded arms. One strand of the duplex is cleaved at the border with single-stranded DNA. A cut with the same polarity is also made in a bubble structure, at the 3' side of the centrally unpaired region. Normal cell extracts introduce a nick 3' to a platinum-DNA lesion, but an XP-G cell extract is defective in making this incision. These data show that XPG has a direct role in making one of the incisions required to excise a damaged oligonucleotide, by cleaving 3' to DNA damage during nucleotide excision repair.			ODONOVAN, A (corresponding author), IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND.		Wood, Richard/M-6319-2018	Wood, Richard/0000-0002-9495-6892; West, Stephen/0000-0001-8848-9418				ABOUSSEKHRA A, 1994, CURR OPIN GENET DEV, V4, P212, DOI 10.1016/S0959-437X(05)80047-4; ARLETT CF, 1980, CARCINOGENESIS, V1, P745, DOI 10.1093/carcin/1.9.745; BARDWELL L, IN PRESS SCIENCE; BENNETT RJ, 1993, CELL, V74, P1021, DOI 10.1016/0092-8674(93)90724-5; BIGGERSTAFF M, 1993, EMBO J, V12, P3685, DOI 10.1002/j.1460-2075.1993.tb06043.x; BOOTSMA D, 1993, NATURE, V363, P114, DOI 10.1038/363114a0; CARR AM, 1993, NUCLEIC ACIDS RES, V21, P1345, DOI 10.1093/nar/21.6.1345; HABRAKEN Y, 1993, NATURE, V366, P365, DOI 10.1038/366365a0; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; ICHIHASHI M, 1985, J INVEST DERMATOL, V85, P284, DOI 10.1111/1523-1747.ep12276776; KEIJZER W, 1979, MUTAT RES, V62, P183, DOI 10.1016/0027-5107(79)90231-8; LIN JJ, 1992, J BIOL CHEM, V267, P17693; MACINNES MA, 1993, MOL CELL BIOL, V13, P6393, DOI 10.1128/MCB.13.10.6393; MURRAY JM, 1994, MOL CELL BIOL, V14, P4878, DOI 10.1128/MCB.14.7.4878; NORRIS PG, 1987, BRIT J DERMATOL, V116, P861, DOI 10.1111/j.1365-2133.1987.tb04906.x; ODONOVAN A, 1993, NATURE, V363, P185, DOI 10.1038/363185a0; ODONOVAN A, 1994, J BIOL CHEM, V269, P15965; REARDON JT, 1993, COLD SPRING HARB SYM, V58, P605, DOI 10.1101/SQB.1993.058.01.067; SCHERLY D, 1993, NATURE, V363, P182, DOI 10.1038/363182a0; SHIOMI T, 1994, MUTAT RES, V314, P167, DOI 10.1016/0921-8777(94)90080-9; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SUNG P, 1993, J BIOL CHEM, V268, P26391; SVOBODA DL, 1993, J BIOL CHEM, V268, P1931; SZYMKOWSKI DE, 1992, P NATL ACAD SCI USA, V89, P10772, DOI 10.1073/pnas.89.22.10772; TOMKINSON AE, 1993, NATURE, V362, P860, DOI 10.1038/362860a0; VANVUUREN AJ, 1993, EMBO J, V12, P3693, DOI 10.1002/j.1460-2075.1993.tb06044.x; VERMEULEN W, 1993, AM J HUM GENET, V53, P185	27	392	402	1	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 29	1994	371	6496					432	435		10.1038/371432a0	http://dx.doi.org/10.1038/371432a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PJ285	8090225				2022-12-28	WOS:A1994PJ28500047
J	GRAYBIEL, AM; AOSAKI, T; FLAHERTY, AW; KIMURA, M				GRAYBIEL, AM; AOSAKI, T; FLAHERTY, AW; KIMURA, M			THE BASAL GANGLIA AND ADAPTIVE MOTOR CONTROL	SCIENCE			English	Review							OBSESSIVE-COMPULSIVE DISORDER; TERM SYNAPTIC DEPRESSION; PRIMATE PUTAMEN NEURONS; MONKEY DOPAMINE NEURONS; CAUDATE-NUCLEUS; RAT NEOSTRIATUM; VOLUNTARY MOVEMENT; PROJECTION NEURONS; SQUIRREL-MONKEY; GLOBUS-PALLIDUS	The basal ganglia are neural structures within the motor and cognitive control circuits in the mammalian forebrain and are interconnected with the neocortex by multiple loops. Dysfunction in these parallel loops caused by damage to the striatum results in major defects in voluntary movement, exemplified in Parkinson's disease and Huntington's disease. These parallel loops have a distributed modular architecture resembling local expert architectures of computational learning models. During sensorimotor learning, such distributed networks may be coordinated by widely spaced striatal interneurons that acquire response properties on the basis of experienced reward.	INST PHYS & CHEM RES, BIOMIMET CONTROL RES CTR, NEURAL CIRCUITS LAB, NAGOYA, AICHI 456, JAPAN; OSAKA UNIV, FAC HLTH & SPORT SCI, MACHIKANEYAMA, OSAKA 560, JAPAN	RIKEN; Osaka University	GRAYBIEL, AM (corresponding author), MIT, DEPT BRAIN & COGNIT SCI, 45 CARLETON ST, E25-618, CAMBRIDGE, MA 02139 USA.		soler, martha maricel m gomez/L-6025-2014	soler, martha maricel m gomez/0000-0002-4412-8108; Graybiel, Ann/0000-0002-4326-7720	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025529] Funding Source: NIH RePORTER; NINDS NIH HHS [NS25529] Funding Source: Medline; PHS HHS [NEI 02866] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AKINS PT, 1990, NATURE, V344, P240, DOI 10.1038/344240a0; ALBIN RL, 1989, TRENDS NEUROSCI, V12, P366, DOI 10.1016/0166-2236(89)90074-X; ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041; ALEXANDER GE, 1990, J NEUROPHYSIOL, V64, P164, DOI 10.1152/jn.1990.64.1.164; AOSAKI T, 1994, J NEUROSCI, V14, P3969; AOSAKI T, 1994, SCIENCE, V265, P412, DOI 10.1126/science.8023166; Aosaki T., 1993, Society for Neuroscience Abstracts, V19, P1585; Aosaki T., 1992, Society for Neuroscience Abstracts, V18, P693; AOSAKI T, UNPUB; APICELLA P, 1991, EXP BRAIN RES, V84, P672; BAXTER LR, 1992, ARCH GEN PSYCHIAT, V49, P681; BENKELFAT C, 1990, ARCH GEN PSYCHIAT, V47, P840; Bernstein N, 1967, COORDINATION REGULAT; BRESSLER SL, 1993, NATURE, V366, P153, DOI 10.1038/366153a0; CALABRESI P, 1992, NEUROSCI LETT, V142, P95, DOI 10.1016/0304-3940(92)90628-K; CALABRESI P, 1992, J NEUROSCI, V12, P4224; CONNOLLY CI, IN PRESS MODELS INFO, P163; COOK D, 1988, BEHAV NEURAL BIOL, V49, P332, DOI 10.1016/S0163-1047(88)90338-X; COOLS AR, 1980, BEHAV BRAIN RES, V1, P361, DOI 10.1016/S0166-4328(80)80073-8; Crick F., 1990, Seminars in the Neurosciences, V2, P263; CROSSMAN AR, 1987, NEUROSCIENCE, V21, P1, DOI 10.1016/0306-4522(87)90322-8; CUENOD M, 1979, DEV CHEM SPECIFICITY, P239; Damasio AR, 1989, NEURAL COMPUT, V1, P123, DOI 10.1162/neco.1989.1.1.123; DAVIS M, 1992, ANNU REV NEUROSCI, V15, P353, DOI 10.1146/annurev.neuro.15.1.353; DELONG MR, 1990, TRENDS NEUROSCI, V13, P281, DOI 10.1016/0166-2236(90)90110-V; DELONG MR, 1981, HDB PHYSL NERVOU 2 1, V2, P1054; DESBAN M, 1989, NEUROSCIENCE, V29, P551, DOI 10.1016/0306-4522(89)90130-9; DIFIGLIA M, 1990, TRENDS NEUROSCI, V13, P286, DOI 10.1016/0166-2236(90)90111-M; DIPELLEGRINO G, 1991, BRAIN, V114, P951; Eblen F., 1993, Society for Neuroscience Abstracts, V19, P1435; Eblen Frank, 1992, Society for Neuroscience Abstracts, V18, P309; ECKHORN R, 1988, BIOL CYBERN, V60, P121, DOI 10.1007/BF00202899; FILION M, 1988, BRAIN RES, V444, P165, DOI 10.1016/0006-8993(88)90924-9; FLAHERTY AW, 1993, J NEUROSCI, V13, P3222; FLAHERTY AW, 1991, J NEUROPHYSIOL, V66, P1249; FLAHERTY AW, 1994, J NEUROSCI, V14, P599; FLAHERTY AW, 1993, J NEUROSCI, V13, P1120; GAFFAN EA, 1988, J NEUROSCI, V8, P3144; GERFEN CR, 1992, TRENDS NEUROSCI, V15, P133, DOI 10.1016/0166-2236(92)90355-C; GIMENEZAMAYA JM, 1991, J NEUROSCI, V11, P779; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; Graybiel A M, 1991, Curr Opin Neurobiol, V1, P644, DOI 10.1016/S0959-4388(05)80043-1; GRAYBIEL AM, 1978, P NATL ACAD SCI USA, V75, P5723, DOI 10.1073/pnas.75.11.5723; GRAYBIEL AM, 1990, TRENDS NEUROSCI, V13, P244, DOI 10.1016/0166-2236(90)90104-I; GRAYBIEL AM, 1984, CIBA F SYMP, V107, P114; GRAYBIEL AM, IN PRESS MODELS INFO, P103; Hertz JA, 2018, INTRO THEORY NEURAL; Hikosaka O, 1991, Curr Opin Neurobiol, V1, P638, DOI 10.1016/S0959-4388(05)80042-X; HIKOSAKA O, 1989, J NEUROPHYSIOL, V61, P814, DOI 10.1152/jn.1989.61.4.814; HOOVER JE, 1993, SCIENCE, V259, P819, DOI 10.1126/science.7679223; Hornykiewicz O., 1966, BIOCH PHARM BASAL GA, P171; HOUK JC, 1993, TRENDS NEUROSCI, V16, P27, DOI 10.1016/0166-2236(93)90049-R; Jacobs RA, 1991, NEURAL COMPUT, V3, P79, DOI 10.1162/neco.1991.3.1.79; JIMENEZCASTELLANOS J, 1989, NEUROSCIENCE, V32, P297, DOI 10.1016/0306-4522(89)90080-8; JORDAN MI, IN PRESS HDB BRAIN T; KALASKA JF, 1992, SCIENCE, V255, P1517, DOI 10.1126/science.1549781; KAWAGUCHI Y, 1992, J NEUROPHYSIOL, V67, P1669, DOI 10.1152/jn.1992.67.6.1669; KAWAGUCHI Y, 1993, J NEUROSCI, V13, P4908; KIMURA M, 1990, EXP BRAIN RES, V82, P672; KIMURA M, 1992, EXP BRAIN RES, V89, P473; KIMURA M, 1992, BRAIN RES, V578, P204, DOI 10.1016/0006-8993(92)90249-9; KIMURA M, 1990, J NEUROPHYSIOL, V63, P1277, DOI 10.1152/jn.1990.63.6.1277; KIMURA M, 1984, P NATL ACAD SCI-BIOL, V81, P4998, DOI 10.1073/pnas.81.15.4998; KLAWANS H, 1992, TXB CLIN NEUROPHARMA; KORNHUBE.HH, 1965, PFLUG ARCH GES PHYS, V284, P1, DOI 10.1007/BF00412364; LeDoux J E, 1992, Curr Opin Neurobiol, V2, P191, DOI 10.1016/0959-4388(92)90011-9; LINDVALL O, 1990, SCIENCE, V247, P574, DOI 10.1126/science.2105529; LJUNGBERG T, 1992, J NEUROPHYSIOL, V67, P145, DOI 10.1152/jn.1992.67.1.145; LLINAS RR, 1988, SCIENCE, V242, P1654, DOI 10.1126/science.3059497; LLINAS RR, 1991, P NATL ACAD SCI USA, V88, P897, DOI 10.1073/pnas.88.3.897; LYTTON WW, 1991, J NEUROPHYSIOL, V66, P1059, DOI 10.1152/jn.1991.66.3.1059; MALACH R, 1986, J NEUROSCI, V6, P3436; MARR D, 1970, PROC R SOC SER B-BIO, V176, P161, DOI 10.1098/rspb.1970.0040; MCDONALD RJ, 1993, BEHAV NEUROSCI, V107, P3, DOI 10.1037/0735-7044.107.1.3; Mink J W, 1993, Curr Opin Neurobiol, V3, P950, DOI 10.1016/0959-4388(93)90167-W; Mishkin M., 1984, NEUROBIOL LEARN MEM, P65, DOI DOI 10.1523/JNEUROSCI.0840-16.2016; MURTHY VN, 1992, P NATL ACAD SCI USA, V89, P5670, DOI 10.1073/pnas.89.12.5670; MURTHY VN, IN PRESS OSCILLATORY; PACKARD MG, 1991, BEHAV NEUROSCI, V105, P295, DOI 10.1037/0735-7044.105.2.295; PARENT A, 1990, TRENDS NEUROSCI, V13, P254, DOI 10.1016/0166-2236(90)90105-J; PARTHASARATHY HB, 1992, J NEUROSCI, V12, P4468; PEEKE HVS, 1971, SCIENCE, V173, P80, DOI 10.1126/science.173.3991.80; Percheron G., 1989, NEURAL MECHANISMS DI, P103; RAPOPORT JL, 1988, JAMA-J AM MED ASSOC, V260, P2888, DOI 10.1001/jama.260.19.2888; ROLAND PE, 1989, EUR J NEUROSCI, V1, P3, DOI 10.1111/j.1460-9568.1989.tb00769.x; ROTHBLAT DS, 1993, J NEUROSCI, V13, P4372; ROUTTENBERG A, 1973, SCIENCE, V181, P83, DOI 10.1126/science.181.4094.83; SADIKOT AF, 1990, BRAIN RES, V510, P161, DOI 10.1016/0006-8993(90)90746-X; SAINTCYR JA, 1988, BRAIN, V111, P941, DOI 10.1093/brain/111.4.941; SANES JN, 1993, P NATL ACAD SCI USA, V90, P4470, DOI 10.1073/pnas.90.10.4470; SCHULTZ W, 1992, EXP BRAIN RES, V91, P363; SCHULTZ W, 1993, J NEUROSCI, V13, P900; Seitz R J, 1990, Neuroreport, V1, P57, DOI 10.1097/00001756-199009000-00016; SELEMON LD, 1990, J COMP NEUROL, V297, P359, DOI 10.1002/cne.902970304; SILLITO AM, 1994, NATURE, V369, P479, DOI 10.1038/369479a0; SINGER W, 1993, ANNU REV PHYSIOL, V55, P349, DOI 10.1146/annurev.physiol.55.1.349; STERIADE M, 1993, SCIENCE, V262, P679, DOI 10.1126/science.8235588; TANJI J, 1985, J NEUROPHYSIOL, V53, P129, DOI 10.1152/jn.1985.53.1.129; VONDERMALSBURG C, 1986, BIOL CYBERN, V54, P29, DOI 10.1007/BF00337113; VONKROSIGK M, 1993, SCIENCE, V261, P361, DOI 10.1126/science.8392750; WEXTER NS, 1991, ANNU REV NEUROSCI, V14, P503; WILSON CJ, 1990, J NEUROSCI, V10, P508; WILSON CJ, 1993, CHEM SIGNALING BASAL, V99, P277	103	959	971	4	132	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 23	1994	265	5180					1826	1831		10.1126/science.8091209	http://dx.doi.org/10.1126/science.8091209			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH258	8091209				2022-12-28	WOS:A1994PH25800022
J	NEWMAN, WP; MIDDAUGH, JP; PROPST, MT; ROGERS, DR				NEWMAN, WP; MIDDAUGH, JP; PROPST, MT; ROGERS, DR			ATHEROSCLEROSIS IN ALASKA NATIVES AND NON-NATIVES	LANCET			English	Note								Low mortality from coronary heart disease (CHD) among Eskimos has been attributed to less atherosclerosis in the coronary arteries because of a high dietary intake of omega-3 fatty acids. Other investigators attribute this low mortality to the fact that Eskimos have a high mortality from other causes before middle age, when CHD is common. However, most studies have been epidemiological, either by death-certificate review or risk-factor evaluation. We evaluated the extent of atherosclerotic lesions in the coronary arteries and aortas from Alaska Natives. Standardised comparisons between samples from 103 Native and 101 non-native residents show that the extent of raised lesions increases with age in both groups, but the prevalence of raised lesions in native specimens was consistently lower than in those from non-natives. This difference was statistically significant. The data suggest that the differences in CHD mortality between Alaska Natives and non-natives are, at least in part, the result of less atherosclerosis in natives.	ALASKA DIV PUBL HLTH,ANCHORAGE,AK; ALASKA MED EXAMINERS,ANCHORAGE,AK		NEWMAN, WP (corresponding author), LOUISIANA STATE UNIV,MED CTR,SCH MED,DEPT PATHOL,1901 PERDIDO ST,NEW ORLEANS,LA 70112, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042082] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-42082] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANG HO, 1971, LANCET, V1, P1143, DOI 10.1016/S0140-6736(71)91658-8; Bang HO, 1980, ADV NUTR RES, P1, DOI [DOI 10.1007/978-1-4757-4448-4_1, 10.1007/978-1-4757-4448-4_1]; BJERREGAARD P, 1988, INT J EPIDEMIOL, V17, P514, DOI 10.1093/ije/17.3.514; GUZMAN MA, 1974, LAB INVEST, V31, P398; GUZMAN MA, 1968, LAB INVEST, V18, P479; MIDDAUGH JP, 1990, AM J PUBLIC HEALTH, V80, P282, DOI 10.2105/AJPH.80.3.282; STRONG JP, 1978, LAB INVEST, V39, P358; TEJADA C, 1968, LAB INVEST, V18, P509; 1990, JAMA-J AM MED ASSOC, V264, P3018	9	115	118	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 24	1993	341	8852					1056	1057		10.1016/0140-6736(93)92413-N	http://dx.doi.org/10.1016/0140-6736(93)92413-N			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ018	8096960				2022-12-28	WOS:A1993KZ01800006
J	HARDING, MJ; PAUL, J; GILLIS, CR; KAYE, SB				HARDING, MJ; PAUL, J; GILLIS, CR; KAYE, SB			MANAGEMENT OF MALIGNANT TERATOMA - DOES REFERRAL TO A SPECIALIST UNIT MATTER	LANCET			English	Article							GERM-CELL TUMORS; TESTICULAR TERATOMA; CANCER; CISPLATIN; SURVIVAL; BLEOMYCIN; ETOPOSIDE; SCOTLAND	The causes of geographical differences in cancer survival among regions of the UK are unclear. Population-based audit of management of patients with non-seminomatous germ-cell tumours (NSGCT) in the west of Scotland enabled us to assess the relative contributions to outcome of recognised prognostic factors, treatment centre, and protocol treatment. Data on treatment and outcome were analysed for 440 (97%) of 454 men with NSGCT diagnosed between 1975 and 1989. All but 11 patients were treated at tertiary referral centres; 235 were treated at a single unit (unit 1) and 194 at four other units (2-5). 99 men have died, 89 (20%) from NSGCT. Independent prognostic factors for NSGCT survival were extent of tumour at diagnosis (p < 0.001), 5-year period of diagnosis (from 1975-79 to 1985-89, p < 0.001), and treatment unit (unit 1 vs units 2-5, p < 0.001). Unit 1, which had the best survival rates, treated most patients overall (53%), including the majority (70%) in the worst prognostic category (poor-prognosis metastatic disease). The proportion of men receiving nationally agreed protocol treatment was higher at unit 1 than elsewhere (97 vs 61%, p < 0.0001). However, analysis restricted to men who received protocol treatment, Adjusted for other important prognostic variables, still showed a survival advantage for this unit (relative death rate units 2-5 vs unit 1, 2.82 [95% Cl 1.53-5.19], p < 0.001). These findings suggest that centralisation of treatment for NSGCT improves outcome; the benefit seems to be additional to any advantage resulting from protocol treatment.	WESTERN INFIRM & ASSOCIATED HOSP,BEATSON ONCOL CTR,DEPT MED ONCOL,CANC RES CAMPAIGN,GLASGOW G11 6NT,SCOTLAND; RUCHILL HOSP,W SCOTLAND GREATER GLASGOW HLTH BOARD,CANC SURVEILLANCE UNIT,GLASGOW G20 9NB,SCOTLAND	Beatson Oncology Centre				Paul, James/0000-0001-7367-5816				AASS N, 1991, J CLIN ONCOL, V9, P818, DOI 10.1200/JCO.1991.9.5.818; ARMITAGE P, 1987, STATISTICAL METHODS; BOYLE P, 1987, EUR J CANCER CLIN ON, V23, P827, DOI 10.1016/0277-5379(87)90286-0; CHARLTON JRH, 1983, LANCET, V1, P691; CHILVERS CED, 1989, BRIT J CANCER, V59, P126, DOI 10.1038/bjc.1989.25; COX DR, 1972, J R STAT SOC B, V34, P187; EINHORN LH, 1977, ANN INTERN MED, V87, P292; FREEDMAN LS, 1987, LANCET, V2, P294; GILLIS CR, 1991, LANCET, V337, P611, DOI 10.1016/0140-6736(91)91673-I; GRAHAM J, 1988, BRIT J CANCER, V57, P182, DOI 10.1038/bjc.1988.38; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KARJALAINEN S, 1989, BMJ-BRIT MED J, V299, P1069, DOI 10.1136/bmj.299.6707.1069; LOEHRER PJ, 1986, J CLIN ONCOL, V4, P528, DOI 10.1200/JCO.1986.4.4.528; MCARDLE CS, 1991, BRIT MED J, V302, P1501, DOI 10.1136/bmj.302.6791.1501; MEAD GM, 1992, J CLIN ONCOL, V10, P85, DOI 10.1200/JCO.1992.10.1.85; NEWLANDS ES, 1986, BRIT J UROL, V58, P307, DOI 10.1111/j.1464-410X.1986.tb09061.x; OLIVER RTD, 1986, BRIT MED J, V292, P641, DOI 10.1136/bmj.292.6521.641; PECKHAM MJ, 1983, BRIT J CANCER, V47, P613, DOI 10.1038/bjc.1983.99; Silman A J, 1981, Community Med, V3, P291, DOI 10.1007/BF02549184; STILLER CA, 1988, ARCH DIS CHILD, V63, P23, DOI 10.1136/adc.63.1.23; THORNHILL JA, 1988, BRIT J UROL, V61, P244, DOI 10.1111/j.1464-410X.1988.tb06388.x; WILLIAMS SD, 1987, NEW ENGL J MED, V316, P1435, DOI 10.1056/NEJM198706043162302; WILSON S, 1992, J PUBLIC HEALTH MED, V14, P151; 1985, LANCET, V1, P8	24	130	130	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 17	1993	341	8851					999	1002		10.1016/0140-6736(93)91082-W	http://dx.doi.org/10.1016/0140-6736(93)91082-W			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY368	8096954				2022-12-28	WOS:A1993KY36800014
J	FALLA, TJ; DOBSON, SRM; CROOK, DWM; KRAAK, WAG; NICHOLS, WW; ANDERSON, EC; JORDENS, JZ; SLACK, MPF; MAYONWHITE, D; MOXON, ER				FALLA, TJ; DOBSON, SRM; CROOK, DWM; KRAAK, WAG; NICHOLS, WW; ANDERSON, EC; JORDENS, JZ; SLACK, MPF; MAYONWHITE, D; MOXON, ER			POPULATION-BASED STUDY OF NONTYPABLE HAEMOPHILUS-INFLUENZAE INVASIVE DISEASE IN CHILDREN AND NEONATES	LANCET			English	Article							NONTYPABLE HEMOPHILUS-INFLUENZAE; DNA PROBE; MENINGITIS; INFECTIONS; PROFILES; REGION	The extent of non-capsulate, non-serotypable Haemophilus influenzae (NST) as a cause of serious invasive disease in children has not been fully defined. We describe the epidemiology of these childhood infections from cases identified during a continuing prospective survey of invasive H influenzae disease in the Oxford region, U K. 408 strains of H influenzae were isolated from cases of invasive disease. 383 (94%) were H influenzae type b (Hib), 24 (6%) were NST strains, and 1 was a type f strain. 3 of the NST strains were non-capsulate type b mutants (b), but the remaining 21 strains were from the phylogenetically distinct and heterogeneous population of non-capsulate H influenzae (NC). 10 of the NC strains were isolated from neonates with sepsis; crude mortality rate was 40%, with an incidence of 4.6 cases per 100 000 livebirths. 11 NC strains were isolated from children after the neonatal period and under 10 years of age, 4 (36%) of which had severe, unrelated, predisposing conditions. The incidence of NC invasive diseases in these children was 0.5 per 100 000 per year. The attributable mortality for these infections was 10%. Infections due to these H influenzae strains are, after the implementation of Hib vaccines, likely to persist and represent a substantial proportion of the serious infections caused by this species.	JOHN RADCLIFFE HOSP,DEPT PAEDIAT,OXFORD OX3 9DU,ENGLAND; DEPT PUBL HLTH,OXFORD,ENGLAND	University of Oxford	FALLA, TJ (corresponding author), JOHN RADCLIFFE HOSP,PUBL HLTH LAB,OXFORD OX3 9DU,ENGLAND.		Jordens, Janet Z/C-7890-2011					BARENKAMP SJ, 1981, J INFECT DIS, V143, P668, DOI 10.1093/infdis/143.5.668; BOOY R, 1992, ARCH DIS CHILD, V67, P475, DOI 10.1136/adc.67.4.475; BRUCE KD, 1991, J CLIN MICROBIOL, V29, P291, DOI 10.1128/JCM.29.2.291-296.1991; DOBSON SRM, 1992, INFECT IMMUN, V60, P618, DOI 10.1128/IAI.60.2.618-622.1992; ESKOLA J, 1992, J INFECT DIS S1, V165, P137; FADEN H, 1991, PEDIATR INFECT DIS J, V10, P254, DOI 10.1097/00006454-199103000-00020; FRIESEN CA, 1986, REV INFECT DIS, V8, P777; HOISETH SK, 1985, INFECT IMMUN, V49, P389, DOI 10.1128/IAI.49.2.389-395.1985; KILIAN M, 1976, J GEN MICROBIOL, V93, P9, DOI 10.1099/00221287-93-1-9; KROLL JS, 1991, MOL CELL PROBE, V5, P375, DOI 10.1016/S0890-8508(06)80009-5; KROLL JS, 1990, MOL MICROBIOL, V4, P1853, DOI 10.1111/j.1365-2958.1990.tb02034.x; MURPHY TF, 1987, REV INFECT DIS, V9, P1; MURPHY TF, 1983, J INFECT DIS, V147, P838, DOI 10.1093/infdis/147.5.838; MUSSER JM, 1990, REV INFECT DIS, V12, P75; PITCHER DG, 1987, FEMS MICROBIOL LETT, V48, P283, DOI 10.1016/0378-1097(87)90177-7; PITCHER DG, 1989, LETT APPL MICROBIOL, V8, P151, DOI 10.1111/j.1472-765X.1989.tb00262.x; QUENTIN R, 1990, J GEN MICROBIOL, V136, P1203, DOI 10.1099/00221287-136-7-1203; SANTOSHAM M, 1992, J INFECT DIS S1, V165, P144; SHANN F, 1984, LANCET, V2, P537; TAKALA AK, 1991, ARCH DIS CHILD-FETAL, V66, P437, DOI 10.1136/adc.66.4_Spec_No.437; TUDORWILLIAMS G, 1989, ARCH DIS CHILD, V64, P517, DOI 10.1136/adc.64.4.517; VANALPHEN L, 1983, J INFECT DIS, V148, P75, DOI 10.1093/infdis/148.1.75; VANKETEL RJ, 1990, J MED MICROBIOL, V33, P271, DOI 10.1099/00222615-33-4-271; WALLACE RJ, 1983, REV INFECT DIS, V5, P123; WEINBERG GA, 1989, J INFECT DIS, V160, P634, DOI 10.1093/infdis/160.4.634; WENGER JD, 1992, J INFECT DIS, V165, pS34, DOI 10.1093/infdis/165-Supplement_1-S34; 1988, KEY POPULATION VITAL	27	90	92	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 3	1993	341	8849					851	854		10.1016/0140-6736(93)93059-A	http://dx.doi.org/10.1016/0140-6736(93)93059-A			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KV811	8096561				2022-12-28	WOS:A1993KV81100003
J	HULL, MA; RAWLINGS, J; MURRAY, FE; FIELD, J; MCINTYRE, AS; MAHIDA, YR; HAWKEY, CJ; ALLISON, SP				HULL, MA; RAWLINGS, J; MURRAY, FE; FIELD, J; MCINTYRE, AS; MAHIDA, YR; HAWKEY, CJ; ALLISON, SP			AUDIT OF OUTCOME OF LONG-TERM ENTERAL NUTRITION BY PERCUTANEOUS ENDOSCOPIC GASTROSTOMY	LANCET			English	Article							SURGICAL GASTROSTOMY; COMPLICATIONS; JEJUNOSTOMY	Percutaneous endoscopic gastrostomy (PEG) is the preferred method for administration of long-term enteral tube feeding. However, most published studies describe only short-term follow-up in any detail. We report the long-term outcome and complication rate after PEG insertion in 49 patients (mean [SE] age 64 [2] years) whose mean length of PEG feeding was 175 days (range 30-560). Data were collected prospectively. PEG insertion was technically successful in all cases, with a procedure-related mortality of 2%. Early (< 30 days) mortality and morbidity were 8% and 22%, respectively. Of 45 patients surviving for more than 30 days, 76% were able to return home and 6 patients were eventually able to revert to oral feeding. There were 27 late complications: 2 site infections, 17 mechanical problems, and 8 episodes of gastrointestinal dysfunction. 51% of patients had no problems at all and 22% had 2 or more complications. 47% of complications required a hospital visit for resolution. Long-term enteral feeding by PEG was safe, effective, and had a low complication rate. Our patients were managed by a specialist nutrition team, a policy that may reduce the complication rate and hospital visits for patients being fed at home, and allow early discharge of dysphagic patients, thereby reducing costs.	UNIV NOTTINGHAM HOSP,QUEENS MED CTR,DEPT THERAPEUT,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham	HULL, MA (corresponding author), UNIV NOTTINGHAM HOSP,QUEENS MED CTR,DEPT MED,NOTTINGHAM NG7 2UH,ENGLAND.							APELGREN KN, 1989, AM SURGEON, V55, P596; COGAN R, 1989, AM J GASTROENTEROL, V84, P1509; GAUDERER MWL, 1980, J PEDIATR SURG, V15, P872, DOI 10.1016/S0022-3468(80)80296-X; GRANT JP, 1988, ANN SURG, V207, P598, DOI 10.1097/00000658-198805000-00014; Himal H S, 1987, Surg Endosc, V1, P33, DOI 10.1007/BF00703085; JONES M, 1990, JPEN-PARENTER ENTER, V14, P533, DOI 10.1177/0148607190014005533; Kocan M J, 1986, J Neurosci Nurs, V18, P333; LARSON DE, 1987, GASTROENTEROLOGY, V93, P48, DOI 10.1016/0016-5085(87)90312-X; MORAN BJ, 1990, BRIT J SURG, V77, P858, DOI 10.1002/bjs.1800770805; Nelson J Kay, 1986, NUTR CLIN PRACT, V1, P193, DOI [10.1177/088453368600100405, DOI 10.1177/088453368600100405]; PARK RHR, 1992, BRIT MED J, V304, P1406, DOI 10.1136/bmj.304.6839.1406; PONSKY JL, 1985, AM J SURG, V149, P102, DOI 10.1016/S0002-9610(85)80017-9; PONSKY JL, 1981, GASTROINTEST ENDOSC, V27, P9, DOI 10.1016/S0016-5107(81)73133-X; STEFFES C, 1989, AM SURGEON, V55, P273; STELLATO TA, 1988, AM SURGEON, V54, P419; STERN JS, 1986, AM J GASTROENTEROL, V81, P1171; STIEGMANN GV, 1990, GASTROINTEST ENDOSC, V36, P1, DOI 10.1016/S0016-5107(90)70911-X; WICKS C, 1992, GUT, V33, P613, DOI 10.1136/gut.33.5.613; WOLFSEN HC, 1990, GASTROINTEST ENDOSC, V36, P261, DOI 10.1016/S0016-5107(90)71019-X; WOLFSEN HC, 1990, AM J GASTROENTEROL, V85, P1120	20	197	201	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 3	1993	341	8849					869	872		10.1016/0140-6736(93)93072-9	http://dx.doi.org/10.1016/0140-6736(93)93072-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KV811	8096573				2022-12-28	WOS:A1993KV81100015
J	POULSEN, SS				POULSEN, SS			GASTROENTEROLOGY - EPIDERMAL GROWTH-FACTOR IN THE GUT LUMEN	LANCET			English	Editorial Material							RAT; UROGASTRONE				POULSEN, SS (corresponding author), UNIV COPENHAGEN,INST MED ANAT,DK-1168 COPENHAGEN,DENMARK.			Poulsen, Steen Seier/0000-0003-4419-4911				DEMBINSKI A, 1982, J PHYSIOL-LONDON, V325, P35, DOI 10.1113/jphysiol.1982.sp014133; GOODLAD RA, 1987, GUT, V28, pS137; JORGENSEN PE, 1988, REGUL PEPTIDES, V23, P161, DOI 10.1016/0167-0115(88)90024-9; OLSEN PS, 1986, GUT, V27, P1443, DOI 10.1136/gut.27.12.1443; POULSEN SS, 1986, HISTOCHEMISTRY, V85, P389, DOI 10.1007/BF00982668; SHEVING LA, 1989, J BIOL CHEM, V264, P1735; SULLIVAN PB, 1991, LANCET, V338, P53, DOI 10.1016/0140-6736(91)90042-N; THOMPSON JF, 1988, AM J PHYSIOL, V254, pG429, DOI 10.1152/ajpgi.1988.254.3.G429; WALKERSMITH JA, 1985, LANCET, V2, P1239	9	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 3	1993	341	8849					866	867						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KV811	8096570				2022-12-28	WOS:A1993KV81100012
J	LINDSAY, R				LINDSAY, R			PREVENTION AND TREATMENT OF OSTEOPOROSIS	LANCET			English	Article							HORMONE-REPLACEMENT THERAPY; POSTMENOPAUSAL BONE LOSS; FLUORIDE TREATMENT; SODIUM-FLUORIDE; BREAST-CANCER; HIP FRACTURE; WOMEN; RISK; ESTROGEN; DENSITY		COLUMBIA UNIV COLL PHYS & SURG, NEW YORK, NY 10032 USA	Columbia University	LINDSAY, R (corresponding author), HELEN HAYES HOSP, DEPT MED, ROUTE 9W, W HAVERSTRAW, NY 10993 USA.				NIAMS NIH HHS [AR39191] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P50AR039191] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARNETT TR, 1986, J BONE MINER RES, V1, pA99; Avioli Louis V., 1993, P137; BARRETTCONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1861, DOI 10.1001/jama.265.14.1861; Carter D. R., 1990, J BONE MINER RES  S1, V5, P177, DOI [DOI 10.1002/JBMR.5650051372, 10.1002/jbmr.5650051372]; CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305; CHESNUT CH, 1983, METABOLISM, V32, P571, DOI 10.1016/0026-0495(83)90027-6; DAWSONHUGHES B, 1990, NEW ENGL J MED, V323, P878, DOI 10.1056/NEJM199009273231305; DELMAS PD, 1990, J BONE MINER RES  S1, V5, P143; EASTELL R, 1992, CLIN SCI, V83, P375, DOI 10.1042/cs0830375; FOGELMAN I, 1988, NUCL MED COMMUN, V9, P541, DOI 10.1097/00006231-198808000-00001; GALLAGHER JC, 1982, P NATL ACAD SCI-BIOL, V79, P3325, DOI 10.1073/pnas.79.10.3325; HEANEY RP, 1993, ANNU REV NUTR, V13, P287, DOI 10.1146/annurev.nu.13.070193.001443; HEDLUND LR, 1989, J BONE MINER RES, V4, P223; HULKA BS, 1990, CA-CANCER J CLIN, V40, P289, DOI 10.3322/canjclin.40.5.289; JOHNSTON CC, 1992, NEW ENGL J MED, V327, P82, DOI 10.1056/NEJM199207093270204; JOHNSTON CC, 1989, J BONE MINER RES S2, V4, P1; Kleerekoper M, 1991, Osteoporos Int, V1, P155, DOI 10.1007/BF01625446; KOMAR L, IN PRESS J AM GERIAT; LINDSAY R, 1990, OBSTET GYNECOL, V76, P290; LINDSAY R, 1978, CLIN SCI MOL MED, V54, P193, DOI 10.1042/cs0540193; LINDSAY R, 1984, OBSTET GYNECOL, V63, P759; LINDSAY R, 1988, OSTEOPOROSIS ETIOLOG, P333; MAMELLE N, 1988, LANCET, V2, P361, DOI 10.1016/S0140-6736(88)92834-6; MELTON LJ, 1983, OSTEOPOROTIC SYNDROM, P45; Muff R, 1991, Osteoporos Int, V1, P72, DOI 10.1007/BF01880446; OTT SM, 1989, ANN INTERN MED, V110, P267, DOI 10.7326/0003-4819-110-4-267; PARISIEN M, 1990, J CLIN ENDOCR METAB, V70, P930, DOI 10.1210/jcem-70-4-930; RAY WA, 1989, LANCET, V1, P687; REEVE J, 1980, BMJ-BRIT MED J, V280, P1340, DOI 10.1136/bmj.280.6228.1340; REGINSTER JY, 1987, LANCET, V2, P1481; REID IR, 1993, NEW ENGL J MED, V328, P460, DOI 10.1056/NEJM199302183280702; RIGGS BL, 1990, NEW ENGL J MED, V322, P802, DOI 10.1056/NEJM199003223221203; SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539; STEVENSON JC, 1990, LANCET, V336, P265, DOI 10.1016/0140-6736(90)91801-G; TURKEN S, 1989, J NATL CANCER I, V81, P1086, DOI 10.1093/jnci/81.14.1086; VOIGT LF, 1991, LANCET, V338, P274, DOI 10.1016/0140-6736(91)90417-N; WASNICH RD, 1983, NEW ENGL J MED, V309, P344, DOI 10.1056/NEJM198308113090605; WATTS NB, 1990, NEW ENGL J MED, V323, P73, DOI 10.1056/NEJM199007123230201	38	88	89	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 27	1993	341	8848					801	805		10.1016/0140-6736(93)90571-W	http://dx.doi.org/10.1016/0140-6736(93)90571-W			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU900	8096009	hybrid			2022-12-28	WOS:A1993KU90000014
J	BLADEN, JS; ANDERSON, AP; BELL, GD; RAMEH, B; EVANS, B; HEATLEY, DJT				BLADEN, JS; ANDERSON, AP; BELL, GD; RAMEH, B; EVANS, B; HEATLEY, DJT			NON-RADIOLOGICAL TECHNIQUE FOR 3-DIMENSIONAL IMAGING OF ENDOSCOPES	LANCET			English	Article							COLONOSCOPY	A novel system is described which images in three dimensions, the total configuration of a colonoscope without the use of conventional radiological techniques. A low intensity magnetic field is used in conjunction with a miniature inductive sensor. The system intrinsically safe and it is potentially inexpensive and capable of being used in a normal hospital environment. Clinical trials are described in which the system is validated in terms of its suitability for the application. Magnetic and conventional X-ray images obtained ex vivo with the endoscope held in various configurations and comparisons in the patients confirm the practical applicability of the new system.	IPSWICH HOSP,DEPT MED,IPSWICH IP4 5PD,ENGLAND; UNIV SHEFFIELD,DEPT ELECT & ELECTR ENGN,SHEFFIELD S10 2TN,S YORKSHIRE,ENGLAND; BT LABS,DIV SYST RES,IPSWICH,ENGLAND	Ipswich Hospital NHS Trust; Ipswich Hospital; University of Sheffield								HALL C, 1991, BRIT J SURG, V78, P542, DOI 10.1002/bjs.1800780509; HERMAN FN, 1990, DIS COLON RECTUM, V33, P540; KUIPERS JB, 1980, IEEE T INSTRUM MEAS, V29, P462, DOI 10.1109/TIM.1980.4314980; LINSAY DC, 1988, BMJ, V296, P167; PARRY BR, 1991, AUST NZ J SURG, V61, P419, DOI 10.1111/j.1445-2197.1991.tb00254.x; RAWLINSON J, 1990, CLIN RADIOL, V41, P2532; WAYE JD, 1991, GASTROINTEST ENDOSC, V37, P147, DOI 10.1016/S0016-5107(91)70673-1; WILLIAMS CB, 1990, PRACTICAL GASTROINTE, pCH9; WILLIAMS CB, 1992, ANN GASTROINTESTINAL, P133	9	58	62	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 20	1993	341	8847					719	722		10.1016/0140-6736(93)90487-2	http://dx.doi.org/10.1016/0140-6736(93)90487-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KT362	8095625				2022-12-28	WOS:A1993KT36200004
J	JEFFCOATE, W				JEFFCOATE, W			ALCOHOL-INDUCED PSEUDO-CUSHINGS SYNDROME	LANCET			English	Editorial Material							PLASMA-CORTISOL; BLOOD-PRESSURE; ADRENOCORTICOTROPIN; HYPOGLYCEMIA; RESPONSES; DISEASE; ETHANOL				JEFFCOATE, W (corresponding author), CITY HOSP NOTTINGHAM,DEPT MED,HUCKNALL RD,NOTTINGHAM NG5 1PB,ENGLAND.							BANNAN LT, 1984, CLIN SCI, V66, P659, DOI 10.1042/cs0660659; BERMAN JD, 1990, J CLIN ENDOCR METAB, V71, P712, DOI 10.1210/jcem-71-3-712; BERTAGNA X, 1992, NEW ENGL J MED, V327, P1024, DOI 10.1056/NEJM199210013271410; CHALMERS RJ, 1978, BRIT MED J, V1, P745, DOI 10.1136/bmj.1.6115.745; CRAPO L, 1979, METABOLISM, V28, P955, DOI 10.1016/0026-0495(79)90097-0; CZAJA E, 1961, CAN J BIOCHEM PHYSIO, V39, P327; DAVE JR, 1986, ENDOCRINOLOGY, V118, P280, DOI 10.1210/endo-118-1-280; DAVIS JRE, 1983, CLIN ENDOCRINOL, V19, P461, DOI 10.1111/j.1365-2265.1983.tb00020.x; ELLIS FW, 1966, J PHARMACOL EXP THER, V153, P121; FINK RS, 1981, CLIN ENDOCRINOL, V15, P97, DOI 10.1111/j.1365-2265.1981.tb02755.x; GLASS AR, 1981, METABOLISM, V30, P89, DOI 10.1016/0026-0495(81)90224-9; HASSELBALCH H, 1982, CLIN ENDOCRINOL, V16, P73, DOI 10.1111/j.1365-2265.1982.tb03149.x; JEFFCOATE WJ, 1980, PHARMACOL BIOCHEM BE, V13, P145, DOI 10.1016/S0091-3057(80)80023-2; JENKINS JS, 1968, BRIT MED J, V2, P804, DOI 10.1136/bmj.2.5608.804; KIRKMAN S, 1988, METABOLISM, V37, P390, DOI 10.1016/0026-0495(88)90141-2; MARKS V, 1977, P ROY SOC MED, V70, P337, DOI 10.1177/003591577707000511; MENDELSON JH, 1966, PSYCHOSOM MED, V28, P616, DOI 10.1097/00006842-196607000-00037; MERRY J, 1972, LANCET, V2, P990; PAGE SR, 1990, CLIN ENDOCRINOL, V33, P761, DOI 10.1111/j.1365-2265.1990.tb03913.x; ROSMAN PM, 1982, J CLIN ENDOCR METAB, V55, P709, DOI 10.1210/jcem-55-4-709; SMALS AG, 1976, BRIT MED J, V2, P1298, DOI 10.1136/bmj.2.6047.1298; STOTT DJ, 1987, CLIN SCI, V73, P411, DOI 10.1042/cs0730411; STREETEN DH, 1969, J CLIN ENDOCR METAB, V29, P1191, DOI 10.1210/jcem-29-9-1191; UR E, 1991, BAILLIERE CLIN ENDOC, V5, P79	24	15	15	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 13	1993	341	8846					676	677		10.1016/0140-6736(93)90434-I	http://dx.doi.org/10.1016/0140-6736(93)90434-I			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR613	8095582				2022-12-28	WOS:A1993KR61300017
J	CAMPBELL, S				CAMPBELL, S			RANDOMIZED COMPARISON OF AMNIOCENTESIS AND TRANSABDOMINAL AND CERVICAL CHORIONIC VILLUS SAMPLING - DUPLICATE PUBLICATION	LANCET			English	Letter											CAMPBELL, S (corresponding author), UNIV LONDON KINGS COLL HOSP,SCH MED & DENT,DEPT OBSTET & GYNAECOL,LONDON SE5 8RX,ENGLAND.							SMIDTJENSEN, 1992, LANCET, V340, P1237; SMIDTJENSEN S, 1991, ULTRASOUND OBST GYN, V1, P86, DOI 10.1046/j.1469-0705.1991.01020086.x	2	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 6	1993	341	8845					635	635		10.1016/0140-6736(93)90399-2	http://dx.doi.org/10.1016/0140-6736(93)90399-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KQ234	8094864				2022-12-28	WOS:A1993KQ23400047
J	JOHNSTONE, EC				JOHNSTONE, EC			SCHIZOPHRENIA - PROBLEMS IN CLINICAL-PRACTICE	LANCET			English	Article							FLUPHENAZINE DECANOATE; MAINTENANCE THERAPY; EXPRESSED EMOTION; NORTHWICK PARK; 1ST EPISODES; TRIAL; RELAPSE; ECT				JOHNSTONE, EC (corresponding author), UNIV EDINBURGH, ROYAL EDINBURGH HOSP, DEPT PSYCHIAT, EDINBURGH EH10 5HP, SCOTLAND.							[Anonymous], 1964, ARCH GEN PSYCHIAT, V10, P246; [Anonymous], 1896, PSYCHIATRIE; BEBBINGTON PE, 1987, BRIT MED BULL, V43, P704, DOI 10.1093/oxfordjournals.bmb.a072210; Bleuler E, 1911, DEMENTIA PRAECOX; BRANDON S, 1985, BRIT J PSYCHIAT, V146, P177, DOI 10.1192/bjp.146.2.177; BROWN GW, 1968, J HEALTH SOC BEHAV, V9, P203; BRUGHA TS, 1989, BRIT J PSYCHIAT, V155, P777, DOI 10.1192/bjp.155.6.777; DAVIS JM, 1976, AM J PSYCHIAT, V133, P208; DAVIS JM, 1975, AM J PSYCHIAT, V132, P1237; HOGARTY GE, 1984, J CLIN PSYCHIAT, V45, P36; HOGARTY GE, 1979, ARCH GEN PSYCHIAT, V36, P1283; HOGARTY GE, 1988, TREATMENT RESISTANCE; HOGE SK, 1990, ARCH GEN PSYCHIAT, V47, P949; JOHNSTONE EC, 1987, BRIT MED BULL, V43, P689, DOI 10.1093/oxfordjournals.bmb.a072209; JOHNSTONE EC, 1990, BRIT J PSYCHIAT, V157, P182, DOI 10.1192/bjp.157.2.182; JOHNSTONE EC, 1984, BRIT J PSYCHIAT, V145, P586, DOI 10.1192/bjp.145.6.586; JOHNSTONE EC, 1991, BR J PSYCHIATRY S13, V159; JOHNSTONE EC, 1992, DILEMMAS DIFFICULTIE; JOLLEY AG, 1990, BRIT MED J, V301, P837, DOI 10.1136/bmj.301.6756.837; KANE J, 1988, ARCH GEN PSYCHIAT, V45, P789; KANE JM, 1983, ARCH GEN PSYCHIAT, V40, P893; KANE JM, 1992, NEW BIOL VISTAS SCHI; LEFF J, 1989, BRIT J PSYCHIAT, V154, P58, DOI 10.1192/bjp.154.1.58; LIDZ T, 1965, SCHIZOPHRENIA FAMILY; LIN T, 1962, WHO16 PUBL HLTH PAP; MACMILLAN JF, 1986, BRIT J PSYCHIAT, V148, P133, DOI 10.1192/bjp.148.2.133; MACMILLAN JF, 1986, BRIT J PSYCHIAT, V148, P128, DOI 10.1192/bjp.148.2.128; MARDER SR, 1987, ARCH GEN PSYCHIAT, V44, P518; MCCREADIE RG, 1987, BRIT J PSYCHIAT, V150, P640, DOI 10.1192/bjp.150.5.640; Nutt D, 1990, J Psychopharmacol, V4, P171, DOI 10.1177/026988119000400312; POGUEGEILE MF, 1988, INT J MENT HEALTH, V16, P3; TAYLOR P, 1980, LANCET, V1, P1380; YOUNG A, 1992, CURR OPIN PSYCHIATR, V5, P56	33	9	9	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 27	1993	341	8844					536	538		10.1016/0140-6736(93)90292-O	http://dx.doi.org/10.1016/0140-6736(93)90292-O			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP083	8094782				2022-12-28	WOS:A1993KP08300015
J	BRAHAMS, D				BRAHAMS, D			PERSISTENT VEGETATIVE STATE	LANCET			English	Editorial Material																			0	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	FEB 13	1993	341	8842					428	428						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM416	8094184				2022-12-28	WOS:A1993KM41600020
J	BENEDIKTSSON, R; LINDSAY, RS; NOBLE, J; SECKL, JR; EDWARDS, CRW				BENEDIKTSSON, R; LINDSAY, RS; NOBLE, J; SECKL, JR; EDWARDS, CRW			GLUCOCORTICOID EXPOSURE INUTERO - NEW MODEL FOR ADULT HYPERTENSION	LANCET			English	Note							PROTEIN-TURNOVER; GROWTH; RATS; WEIGHT; FETAL	Hypertension is strongly predicted by the combination of low birthweight and a large placenta. This association could be due to increased fetal exposure to maternal glucocorticoids. Fetal protection is normally effected by placental 11beta-hydroxysteroid dehydrogenase (11beta-OHSD), which converts physiological glucocorticoids to inactive products. We found that rat placental 11beta-OHSD activity correlated positively with term fetal weight and negatively with placental weight. Offspring of rats treated during pregnancy with dexamethasone (which is not metabolised by 11beta-OHSD) had lower birthweights and higher blood pressure when adult than did offspring of control rats. Increased fetal glucocorticoid exposure secondary to attenuated placental 11beta-OHSD activity may link low birthweight and high placental weight with hypertension.	UNIV EDINBURGH,WESTERN GEN HOSP,DEPT MED,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of Edinburgh			Seckl, Jonathan R/C-3555-2013; Benediktsson, Rafn/R-2457-2018	Benediktsson, Rafn/0000-0002-2954-9801; Lindsay, Robert/0000-0002-9868-5217	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALEXANDER G, 1978, ABNORMAL FETAL GROWT, P149; BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BEITINS IZ, 1973, PEDIATR RES, V7, P509, DOI 10.1203/00006450-197305000-00004; CANAVAN JP, 1988, DIABETES, V37, P1671, DOI 10.2337/diabetes.37.12.1671; EDWARDS CRW, 1993, LANCET, V341, P355, DOI 10.1016/0140-6736(93)90148-A; HELLER CL, 1988, J STEROID BIOCHEM, V31, P119, DOI 10.1016/0022-4731(88)90214-2; REINISCH JM, 1978, SCIENCE, V202, P436, DOI 10.1126/science.705336; ROBINSON J, 1988, DIABETES, V37, P1665, DOI 10.2337/diabetes.37.12.1665; TONOLO G, 1988, J HYPERTENS, V6, P25	10	724	734	0	25	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 6	1993	341	8841					339	341		10.1016/0140-6736(93)90138-7	http://dx.doi.org/10.1016/0140-6736(93)90138-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK939	8094115				2022-12-28	WOS:A1993KK93900006
J	KAKKAR, VV; COHEN, AT; EDMONSON, RA; PHILLIPS, MJ; COOPER, DJ; DAS, SK; MAHER, KT; SANDERSON, RM; WARD, VP; KAKKAR, S				KAKKAR, VV; COHEN, AT; EDMONSON, RA; PHILLIPS, MJ; COOPER, DJ; DAS, SK; MAHER, KT; SANDERSON, RM; WARD, VP; KAKKAR, S			LOW-MOLECULAR-WEIGHT VERSUS STANDARD HEPARIN FOR PREVENTION OF VENOUS THROMBOEMBOLISM AFTER MAJOR ABDOMINAL-SURGERY	LANCET			English	Article							DEEP-VEIN THROMBOSIS; UNFRACTIONATED HEPARIN; PLUS DIHYDROERGOTAMINE; PROPHYLAXIS; PHARMACOKINETICS; KINETICS; FRAGMIN; INVIVO	Low-molecular-weight heparin (LMWH) is effective in the prevention of postoperative venous thromboembolism but does it have the safety advantages over standard heparin (SH) that have been claimed? In a multicentre randomised trial in 3809 patients undergoing major abdominal surgery (1894 LMWH, 1915 SH) heparin was given preoperatively and continued for at least 5 postoperative days Patients were assessed in the postoperative period and were followed up for at least 4 weeks, the emphasis being on safety. Major bleeding events occurred in 69 (3.6%) patients in the LMWH group and 91 (4.8%) patients in the SH group (relative risk 0.77, 95% confidence interval 0.56-1.04, p = 0.10). 93 indices of major bleeding were observed in the 69 LMWH patients and 141 in the SH patients. (p = 0.058). Severe bleeding was less frequent in the LMWH group (1.0% vs 1.9%; p = 0.02), as was wound haematoma (1.4% vs 2.7%, p = 0.007). Bleeding episodes with LMWH were less likely to lead to further surgery to evacuate a haematoma or to control bleeding, and injection site bruising was also less common in the LMWH group. No significant differences were found in the efficacy of the two agents. Perioperative death rates were 3.3% in the LMWH group and 2.5% in the SH group; pulmonary emboli were detected in 0.7% and 0.7%, and deep-vein thrombosis was diagnosed in 0.6% of patients in each group. Follow-up was done on 91 % of 3699 evaluable patients. There were 19 further deaths (10 LMWH, 9 S H group) and 25 patients with thromboembolic complications (15 and 10). Of the 3 patients with fatal pulmonary emboli during follow-up 2 had received LMWH and 1 SH. The two drugs were of similar efficacy. The primary end point, the frequency of major bleeding, showed a 23% reduction in the LMWH group, but this difference was not significant. The secondary safety end points revealed that LMWH was significantly better than SH. Fatal pulmonary embolism occurs rarely (0.09%) following discharge from hospital so the cost benefit ratio would not justify prolonged prophylaxis in this setting.	KINGS COLL,SCH MED & DENT,LONDON SE5,ENGLAND		KAKKAR, VV (corresponding author), THROMBOSIS RES INST,EMMANUEL KAYE BLDG,MANRESA RD,LONDON SW3 6LR,ENGLAND.							[Anonymous], 1975, LANCET, V2, P45; Bara L, 1988, Acta Chir Scand Suppl, V543, P65; BARROWCLIFFE T, 1992, LOW MOL WEIGHT HEPAR; BARZU T, 1984, NOUV REV FR HEMATOL, V26, P243; BAZU T, 1985, BIOCHIM BIOPHYS ACTA, V845, P196; BERGQVIST D, 1988, WORLD J SURG, V12, P349, DOI 10.1007/BF01655669; BRADBROOK ID, 1987, BRIT J CLIN PHARMACO, V23, P667, DOI 10.1111/j.1365-2125.1987.tb03100.x; BRATT G, 1986, THROMB RES, V42, P613, DOI 10.1016/0049-3848(86)90340-3; BRIANT L, 1989, THROMB HAEMOSTASIS, V61, P348; CARTER CJ, 1982, BLOOD, V59, P1239; CLARKEPEARSON DL, 1984, AM J OBSTET GYNECOL, V148, P1051, DOI 10.1016/0002-9378(84)90632-X; DESWART CAM, 1982, BLOOD, V60, P1251; ESQUIVEL CO, 1982, THROMB RES, V28, P389, DOI 10.1016/0049-3848(82)90120-7; FRYDMAN A, 1988, J CLIN PHARMACOL, V28, P608; HUBER O, 1992, ARCH SURG-CHICAGO, V127, P310; JORDAN RE, 1980, J BIOL CHEM, V255, P81; KAKKAR VV, 1986, HAEMOSTASIS, V16, P19; KAKKAR VV, 1989, AM J SURG, V157, P413, DOI 10.1016/0002-9610(89)90589-8; KAKKAR VV, 1982, BRIT MED J, V284, P375, DOI 10.1136/bmj.284.6313.375; KAKKAR VV, UNPUB RESULTS INT RA; KAKKAR VV, 1986, BRIT J SURG, V71, P786; KOLLER M, 1986, THROMB HAEMOSTASIS, V56, P243; LANE DA, 1986, J BIOL CHEM, V261, P3980; Leizorovicz A, 1991, BRIT J SURG, V78, P412; NURMOHAMED MT, 1992, LANCET, V340, P152, DOI 10.1016/0140-6736(92)93223-A; SALCUNI PF, 1988, CURR THER RES CLIN E, V43, P824; SALZMAN EW, 1980, ANN SURG, V191, P207, DOI 10.1097/00000658-198002000-00013; SASAHARA AA, 1986, BRIT J SURG, V73, P697, DOI 10.1002/bjs.1800730906; SOBEL M, 1991, J CLIN INVEST, V87, P1787, DOI 10.1172/JCI115198; STEINER RA, 1989, ARCH GYNECOL OBSTET, V244, P141, DOI 10.1007/BF00931291; VERSTRAETE M, 1990, DRUGS, V40, P498, DOI 10.2165/00003495-199040040-00003; 1988, BRIT J SURG, V75, P1058; 1992, REPORT NATIONAL CONF	33	300	304	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 30	1993	341	8840					259	265		10.1016/0140-6736(93)92614-Y	http://dx.doi.org/10.1016/0140-6736(93)92614-Y			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK245	8093915				2022-12-28	WOS:A1993KK24500002
J	GORE, SM				GORE, SM			OSIRIS TRIAL	LANCET			English	Letter											GORE, SM (corresponding author), MRC,BIOSTAT UNIT,CAMBRIDGE CB2 2SR,ENGLAND.							1987, BMJ, V294, P991; 1992, LANCET, V340, P1363	2	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 16	1993	341	8838					172	172		10.1016/0140-6736(93)90035-F	http://dx.doi.org/10.1016/0140-6736(93)90035-F			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG627	8093762				2022-12-28	WOS:A1993KG62700024
J	ROBERTSON, B; SPEER, CP				ROBERTSON, B; SPEER, CP			OSIRIS TRIAL	LANCET			English	Letter									UNIV GOTTINGEN,CHILDRENS CLIN,W-3400 GOTTINGEN,GERMANY	University of Gottingen	ROBERTSON, B (corresponding author), ST GORANS CHILDRENS HOSP,EXPTL PERINATAL PATHOL RES UNIT,S-11281 STOCKHOLM,SWEDEN.								0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 16	1993	341	8838					172	172						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG627	8093763				2022-12-28	WOS:A1993KG62700025
J	OSHAUGHNESSY, D; GOLDMAN, JM; RODDIE, M; SCHOFIELD, JB; KENNARD, C; SCOTT, J; SCARAVILLI, F; WARD, K; BROOKES, D; LEWIS, P				OSHAUGHNESSY, D; GOLDMAN, JM; RODDIE, M; SCHOFIELD, JB; KENNARD, C; SCOTT, J; SCARAVILLI, F; WARD, K; BROOKES, D; LEWIS, P			GRAND ROUNDS - HAMMERSMITH-HOSPITAL - CLINICOPATHOLOGICAL CONFERENCE	BRITISH MEDICAL JOURNAL			English	Discussion							PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; MARROW; INFECTION		CHARING CROSS & WESTMINSTER MED SCH,LONDON W6 8RF,ENGLAND; INST NEUROL,LONDON,ENGLAND	Imperial College London; University of London; University College London	OSHAUGHNESSY, D (corresponding author), HAMMERSMITH HOSP,DEPT HAEMATOL,LONDON W12 0HS,ENGLAND.							APPERLEY JF, 1987, EUR J HAEMATOL, V39, P185; DEROUIN F, 1992, CLIN INFECT DIS, V15, P267, DOI 10.1093/clinids/15.2.267; GIBSON PE, 1993, J MED VIROL, V39, P278, DOI 10.1002/jmv.1890390404; HILT DC, 1983, ANN NEUROL, V14, P543, DOI 10.1002/ana.410140509; HOCHBERG FH, 1988, J NEUROSURG, V68, P835, DOI 10.3171/jns.1988.68.6.0835; KENNARD C, 1979, J NEUROL NEUROSUR PS, V42, P931, DOI 10.1136/jnnp.42.10.931; KRUPP LB, 1985, ANN NEUROL, V17, P344, DOI 10.1002/ana.410170407; REECE DE, 1991, BONE MARROW TRANSPL, V8, P393; THOMPSON CB, 1986, BLOOD, V67, P195	9	15	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 23	1994	309	6949					262	265		10.1136/bmj.309.6949.262	http://dx.doi.org/10.1136/bmj.309.6949.262			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NZ180	8093206	Green Published			2022-12-28	WOS:A1994NZ18000027
J	FORTUIN, M; CHOTARD, J; JACK, AD; MAINE, NP; MENDY, M; HALL, AJ; INSKIP, HM; GEORGE, MO; WHITTLE, HC				FORTUIN, M; CHOTARD, J; JACK, AD; MAINE, NP; MENDY, M; HALL, AJ; INSKIP, HM; GEORGE, MO; WHITTLE, HC			EFFICACY OF HEPATITIS-B VACCINE IN THE GAMBIAN EXPANDED PROGRAM ON IMMUNIZATION	LANCET			English	Article							ENDEMIC AREA SENEGAL; VIRUS; INFANTS	Because of the high prevalence of hepatitis B virus (HBV) infection in The Gambia, HBV vaccination has been incorporated into the national expanded programme on immunisation. We have assessed the efficacy of the vaccine against HBV infection and chronic carriage by examining 720 3-4-year-old children who had received the vaccine in infancy and 816 who had not received it. The vaccine was 84% (95% CI 78-89%) effective against infection and 94% (84-98%) effective against chronic carriage. Vaccinated infants of mothers positive for hepatitis B surface and e antigens were at greater risk of breakthrough infection and chronic carriage than infants of uninfected mothers. The high vaccine efficacy against the HBV carrier state, the main risk factor for the development of chronic liver disease and liver cancer, offers hope that the prevalence of these diseases may be reduced in the future.	UNIV LONDON LONDON SCH HYG & TROP MED, LONDON SCH HYG & TROP MED, LONDON WC1E 7HT, ENGLAND; GOVT GAMBIA, DEPT MED & HLTH, BANJUL, SENEGAMBIA; MAC LABS, BANJUL, SENEGAMBIA; SOUTHAMPTON GEN HOSP, MRC, ENVIRONM EPIDEMIOL UNIT, SOUTHAMPTON SO9 4XY, HANTS, ENGLAND	University of London; London School of Hygiene & Tropical Medicine; University of Southampton	FORTUIN, M (corresponding author), INT AGCY RES CANC, GAMBIA HEPATITIS INTERVENT STUDY, POB 273, BANJUL, SENEGAMBIA.		Mendy, Maimuna/ABD-5038-2021; Ibrahim, Essam Hassan/G-1960-2018; Inskip, Hazel/L-5467-2018	Ibrahim, Essam Hassan/0000-0003-0130-2257; Inskip, Hazel/0000-0001-8897-1749				BAH E, 1990, BRIT J CANCER, V62, P647, DOI 10.1038/bjc.1990.347; BEASLEY RP, 1981, LANCET, V2, P1129; CARMAN WF, 1990, LANCET, V336, P325, DOI 10.1016/0140-6736(90)91874-A; CHOTARD J, 1992, J INFECT DIS, V166, P764, DOI 10.1093/infdis/166.4.764; COURSAGET P, 1986, LANCET, V2, P1143; COURSAGET P, 1987, J MED VIROL, V22, P1, DOI 10.1002/jmv.1890220102; HALL A J, 1987, Cancer Research, V47, P5782; HALL AJ, 1989, LANCET, V1, P1057; HARRISON TJ, 1991, J HEPATOL, V13, pS105, DOI 10.1016/0168-8278(91)90037-C; WHITTLE H, 1990, J INFECT DIS, V161, P1112, DOI 10.1093/infdis/161.6.1112; WHITTLE HC, 1991, LANCET, V337, P747, DOI 10.1016/0140-6736(91)91367-4; 1991, GAMBIA HEPATITIS INT, V6, P55	12	69	70	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 1	1993	341	8853					1129	1131		10.1016/0140-6736(93)93137-P	http://dx.doi.org/10.1016/0140-6736(93)93137-P			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ687	8097813				2022-12-28	WOS:A1993KZ68700013
J	LERMAN, A; GIBBONS, RJ; RODEHEFFER, RJ; BAILEY, KR; MCKINLEY, LJ; HEUBLEIN, DM; BURNETT, JC				LERMAN, A; GIBBONS, RJ; RODEHEFFER, RJ; BAILEY, KR; MCKINLEY, LJ; HEUBLEIN, DM; BURNETT, JC			CIRCULATING N-TERMINAL ATRIAL-NATRIURETIC-PEPTIDE AS A MARKER FOR SYMPTOMLESS LEFT-VENTRICULAR DYSFUNCTION	LANCET			English	Article							CONGESTIVE-HEART-FAILURE; MYOCARDIAL-INFARCTION; FACTOR PROHORMONE	Early identification of patients with symptomless left-ventricular dysfunction and early pharmacologic intrervention may have an impact on the outlook of patients with heart failure. Atrial natriuretic peptide (ANP) is a cardiac hormone that is released as a C-terminal (C-ANP) and an N-terminal peptide (N-ANP).Since N-ANP has reduced clearance rates compared with C-ANP, N-ANP circulates at higher concentrations. Based on the known increased concentration of C-ANP in symptomatic congestive heart failure, our study was designed to evaluate prospectively N-ANP profile and left-ventricular function in subjects with symptomless and symptomatic heart failure, and the role of plasma N-ANP as a marker for early identification of patients with heart failure. 180 patients who were referred for rest and exercise radionuclide angiography for evaluation of left-ventricular function were studied. Blood was taken for measurement of C-ANP and N-ANP before angiography. Patients were grouped according to New York Heart Association (NYHA) heart failure classification and left-ventricular function. Mean (SD) plasma N-ANP concentration in patients with symptomless left-ventricular dysfunction (NYHA class I, n=70) was 243 (256) pmol/L (range 27-922 pmol/L), and was higher (p<0.001) than in 25 control subjects (28 [13] pmol/L). A plasma N-ANP concentration above 54 pmol/L (mean+/-1.96SD of the control group) had a sensitivity of 90% and a specificity of 92% for detection of patients-with symptomless left-ventricular dysfunction. We have shown that plasma N-ANP concentrations are significantly increased in patients with symptomless left-ventricular dysfunction and that this peptide can serve as a marker for diagnosis of such patients.			LERMAN, A (corresponding author), MAYO CLIN & MAYO FDN,DEPT INTERNAL MED,DIV CARDIOVASC DIS,CARDIORENAL RES LAB,ROCHESTER,MN 55905, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036634] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36634, HL0711] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAKER BJ, 1991, AM HEART J, V122, P1395, DOI 10.1016/0002-8703(91)90583-4; BURNETT JC, 1986, SCIENCE, V231, P1145, DOI 10.1126/science.2935937; CALIFF RM, 1982, CONGESTIVE HEART FAI, P31; CALLAHAN RJ, 1982, J NUCL MED, V23, P315; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; COHN JN, 1982, NEW ENGL J MED, V306, P1129, DOI 10.1056/NEJM198205133061902; CURRIE MG, 1983, SCIENCE, V221, P71, DOI 10.1126/science.6857267; DAVIS KM, 1992, JAMA-J AM MED ASSOC, V267, P2625, DOI 10.1001/jama.267.19.2625; DEBOLD AJ, 1981, LIFE SCI, V28, P89, DOI 10.1016/0024-3205(81)90370-2; DEHMER GJ, 1980, AM J CARDIOL, V45, P293, DOI 10.1016/0002-9149(80)90648-7; FEDERMAN J, 1978, MAYO CLIN P, V53, P623; FRANCIS GS, 1990, CIRCULATION, V82, P1724, DOI 10.1161/01.CIR.82.5.1724; GIBBONS RJ, 1987, J AM COLL CARDIOL, V10, P33, DOI 10.1016/S0735-1097(87)80156-0; GIBBONS RJ, 1991, CIRCULATION S1, V84, P93; GLEMBOTSKI CC, 1988, J BIOL CHEM, V263, P16073; HEUBLEIN D M, 1989, Journal of the American College of Cardiology, V13, p9A; MASSIE BM, 1987, CIRCULATION, V75, P11; PEVAHOUSE JB, 1989, CLIN RES, V37, P583; RAINE AEG, 1986, NEW ENGL J MED, V315, P53; SANZ G, 1982, NEW ENGL J MED, V306, P1065, DOI 10.1056/NEJM198205063061801; SCHULZE RA, 1977, AM J MED, V62, P192, DOI 10.1016/0002-9343(77)90314-X; SHARPE N, 1988, LANCET, V1, P255; SUNDSFJORD JA, 1988, J CLIN ENDOCR METAB, V66, P605, DOI 10.1210/jcem-66-3-605; SVANEGAARD J, 1992, BRIT HEART J, V68, P38; WINTERS CJ, 1989, CIRCULATION, V80, P438, DOI 10.1161/01.CIR.80.3.438; WINTERS CJ, 1988, BIOCHEM BIOPH RES CO, V150, P231, DOI 10.1016/0006-291X(88)90510-4; WINTERS CJ, 1988, CHRONOBIOL INT, V5, P301; YUSUF S, 1989, HYPERTENSION S5, V13, P174; 1991, NEW ENGL J MED, V325, P293; 1992, NEW ENGL J MED, V327, P685	30	288	300	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 1	1993	341	8853					1105	1109		10.1016/0140-6736(93)93125-K	http://dx.doi.org/10.1016/0140-6736(93)93125-K			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ687	8097801				2022-12-28	WOS:A1993KZ68700001
J	GRECH, ED; DODD, NJF; BELLAMY, CM; PERRY, RA; MORRISON, WL; RAMSDALE, DR				GRECH, ED; DODD, NJF; BELLAMY, CM; PERRY, RA; MORRISON, WL; RAMSDALE, DR			FREE-RADICAL GENERATION DURING ANGIOPLASTY REPERFUSION FOR ACUTE MYOCARDIAL-INFARCTION	LANCET			English	Note							SPIN RESONANCE SPECTROSCOPY; ISCHEMIA; INJURY	We describe direct and quantitative evidence of free-radical production in the early stage after recanalisation in a patient undergoing primary coronary angioplasty for acute myocardial infarction. After successful initial dilation, the procedure was complicated by re-occlusion of the artery at the same site, with subsequent fall in free-radical generation. After repeat angioplasty, recanalisation was again accompanied by increased free-radical production.	CHRISTIE HOSP & HOLT RADIUM INST,PATERSON INST CANC RES,CRC DEPT BIOPHYS,MANCHESTER M20 9BX,LANCS,ENGLAND	Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research	GRECH, ED (corresponding author), CARDIOTHORAC CTR,DEPT CARDIOL,THOMAS DR,LIVERPOOL L14 3PE,ENGLAND.							BAKER JE, 1988, P NATL ACAD SCI USA, V85, P2786, DOI 10.1073/pnas.85.8.2786; BOLLI R, 1988, J CLIN INVEST, V82, P476, DOI 10.1172/JCI113621; COGHLAN JG, 1991, FREE RADICAL RES COM, V14, P409, DOI 10.3109/10715769109093429; de Lorgeril M, 1990, Am J Cardiovasc Pathol, V3, P143; GARLICK PB, 1987, CIRC RES, V61, P757, DOI 10.1161/01.RES.61.5.757; HEARSE DJ, 1990, CARDIOVASC DRUG THER, V4, P767, DOI 10.1007/BF00051274; JOLLY SR, 1984, CIRC RES, V54, P277, DOI 10.1161/01.RES.54.3.277; 1983, NEW ENGL J MED, V309, P331	8	47	49	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 17	1993	341	8851					990	991		10.1016/0140-6736(93)91074-V	http://dx.doi.org/10.1016/0140-6736(93)91074-V			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY368	8096946				2022-12-28	WOS:A1993KY36800006
J	GINTY, DD; KORNHAUSER, JM; THOMPSON, MA; BADING, H; MAYO, KE; TAKAHASHI, JS; GREENBERG, ME				GINTY, DD; KORNHAUSER, JM; THOMPSON, MA; BADING, H; MAYO, KE; TAKAHASHI, JS; GREENBERG, ME			REGULATION OF CREB PHOSPHORYLATION IN THE SUPRACHIASMATIC NUCLEUS BY LIGHT AND A CIRCADIAN CLOCK	SCIENCE			English	Article							C-FOS TRANSCRIPTION; GENE-EXPRESSION; RHYTHMS; PROTEIN; SYSTEM	Mammalian circadian rhythms are regulated by a pacemaker within the suprachiasmatic nuclei (SCN) of the hypothalamus. The molecular mechanisms controlling the synchronization of the circadian pacemaker are unknown; however, immediate early gene (IEG) expression in the SCN is tightly correlated with entrainment of SCN-regulated rhythms. Antibodies were isolated that recognize the activated, phosphorylated form of the transcription factor cyclic adenosine monophosphate response element binding protein (CREB). Within minutes after exposure of hamsters to light, CREB in the SCN became phosphorylated on the transcriptional regulatory site, Ser133. CREB phosphorylation was dependent on circadian time: CREB became phosphorylated only at times during the circadian cycle when light induced IEG expression and caused phase shifts of circadian rhythms. These results implicate CREB in neuronal signaling in the hypothalamus and suggest that circadian clock gating of light-regulated molecular responses in the SCN occurs upstream of phosphorylation of CREB.	HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02115; NORTHWESTERN UNIV,NSF,CTR BIOL TIMING,EVANSTON,IL 60208; NORTHWESTERN UNIV,DEPT BIOCHEM MOLEC BIOL & CELL BIOL,EVANSTON,IL 60208; NORTHWESTERN UNIV,DEPT NEUROBIOL & PHYSIOL,EVANSTON,IL 60208	Harvard University; Harvard Medical School; National Science Foundation (NSF); NSF - Center for Biological Timing; Northwestern University; Northwestern University; Northwestern University			Takahashi, Joseph S/E-8482-2012; Takahashi, Joseph S./Y-2781-2019	Takahashi, Joseph S/0000-0003-0384-8878; Takahashi, Joseph S./0000-0003-0384-8878	NIMH NIH HHS [F31 MH10241] Funding Source: Medline; NINDS NIH HHS [F32 NS08764, NS 28829] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [F31MH010241] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS008764, R37NS028829, R01NS028829] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABE H, 1991, NEUROSCI LETT, V127, P9, DOI 10.1016/0304-3940(91)90881-S; ABE H, 1992, BRAIN RES BULL, V28, P831, DOI 10.1016/0361-9230(92)90269-4; BADING H, 1991, SCIENCE, V253, P912, DOI 10.1126/science.1715095; COLWELL CS, 1990, BRAIN RES, V523, P117, DOI 10.1016/0006-8993(90)91643-U; COLWELL CS, 1992, J BIOL RHYTHMS; COMB M, 1987, TRENDS NEUROSCI, V10, P473, DOI 10.1016/0166-2236(87)90103-2; EBLING FJP, 1991, J NEUROENDOCRINOL, V3, P641, DOI 10.1111/j.1365-2826.1991.tb00329.x; Ginty D D, 1992, Curr Opin Neurobiol, V2, P312, DOI 10.1016/0959-4388(92)90121-Z; GINTY DD, UNPUB; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; Klein D.C., 1991, SUPRACHIASMATIC NUCL; KORNHAUSER JM, 1992, SCIENCE, V255, P1581, DOI 10.1126/science.1549784; KORNHAUSER JM, 1990, NEURON, V5, P127, DOI 10.1016/0896-6273(90)90303-W; MEIJER JH, 1989, PHYSIOL REV, V69, P671, DOI 10.1152/physrev.1989.69.3.671; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MISRA RP, 1991, MOL CELL BIOL, V11, P4545, DOI 10.1128/MCB.11.9.4545; PITTENDRIGH CS, 1981, HDB BEHAVIORAL NEURO, V4, P95; RANSONE LJ, 1989, GENE DEV, V3, P770, DOI 10.1101/gad.3.6.770; ROSBASH M, 1989, NEURON, V3, P387, DOI 10.1016/0896-6273(89)90199-2; RUSAK B, 1990, SCIENCE, V248, P1237, DOI 10.1126/science.2112267; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SPINDLER KR, 1984, J VIROL, V49, P132, DOI 10.1128/JVI.49.1.132-141.1984; Takahashi J S, 1991, Curr Opin Neurobiol, V1, P556, DOI 10.1016/S0959-4388(05)80028-5; TAKAHASHI JS, 1984, NATURE, V308, P186, DOI 10.1038/308186a0; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2	30	762	776	1	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 9	1993	260	5105					238	241		10.1126/science.8097062	http://dx.doi.org/10.1126/science.8097062			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KW452	8097062				2022-12-28	WOS:A1993KW45200046
J	PLAYFORD, RJ; WOODMAN, AC; CLARK, P; WATANAPA, P; VESEY, D; DEPREZ, PH; WILLIAMSON, RCN; CALAM, J				PLAYFORD, RJ; WOODMAN, AC; CLARK, P; WATANAPA, P; VESEY, D; DEPREZ, PH; WILLIAMSON, RCN; CALAM, J			EFFECT OF LUMINAL GROWTH-FACTOR PRESERVATION ON INTESTINAL GROWTH	LANCET			English	Article							RAT; PROLIFERATION; MUCOSA; GUT	Intestinal atrophy contributes to the clinical difficulties of patients who cannot eat normally. Atrophy is prevented by luminal food proteins but not by the equivalent amino acids. This observation is not explained by current theories of intestinal physiology. Epidermal growth factor (EGF) and transforming growth factor alpha (TGFalpha) are secreted into the gut lumen. We speculated that these are digested by pancreatic enzymes in fasting juice, but preserved when food proteins block the active sites of these enzymes. Studies based on molecular size and bioactivity confirmed that fasting human jejunal juice destroys EGF and TGFalpha. EGF, but not TGFalpha, was preserved when the milk protein casein or an enzyme inhibitor were present; elemental diets were ineffective. Diversion of pancreatic juice to the mid point of the small intestine in rats significantly increased luminal EGF-like bioactivity and all variables of growth in the proximal enzyme-free segment. Our findings support a novel mechanism of control of intestinal growth, which has important clinical implications. The addition of enzyme-inhibiting proteins such as casein to elemental diets may preserve intestinal integrity and function.	ROYAL POSTGRAD MED SCH, DEPT SURG, LONDON W12 0NN, ENGLAND; ROYAL POSTGRAD MED SCH, DEPT PHYS, LONDON W12 0NN, ENGLAND	Imperial College London; Imperial College London	PLAYFORD, RJ (corresponding author), ROYAL POSTGRAD MED SCH, DEPT MED, GASTROENTEROL UNIT, DU CANE RD, LONDON W12 0NN, ENGLAND.		Deprez, Pierre/AAC-5546-2019; Vesey, David A/C-2253-2011	Deprez, Pierre/0000-0001-8926-8967; Vesey, David A/0000-0002-2856-6650; Playford, Raymond/0000-0003-1235-8504				ALVERDY JC, 1988, SURGERY, V104, P185; BRAGG LE, 1991, NUTRITION, V7, P237; CHALLACOMBE DN, 1991, GUT, V32, P991, DOI 10.1136/gut.32.9.991; GOODLAD RA, 1987, GUT, V28, P573, DOI 10.1136/gut.28.5.573; LIDDLE RA, 1986, AM J PHYSIOL, V251, pG243, DOI 10.1152/ajpgi.1986.251.2.G243; MIURA S, 1992, GUT, V33, P484, DOI 10.1136/gut.33.4.484; MORIN CL, 1980, DIGEST DIS SCI, V25, P123, DOI 10.1007/BF01308310; NEWMAN BM, 1988, DIGESTION, V41, P172, DOI 10.1159/000199770; OLSEN PS, 1986, GASTROENTEROLOGY, V90, P911, DOI 10.1016/0016-5085(86)90867-X; POULSEN SS, 1987, SCAND J GASTROENTERO, V22, P20, DOI 10.3109/00365528709090965; ROYSTON JP, 1983, J ROY STAT SOC D-STA, V32, P297, DOI 10.2307/2987935; Schweder T., 1981, Applied Statistics, V30, P16, DOI 10.2307/2346653; SELDEN C, 1989, J HEPATOL, V9, P167, DOI 10.1016/0168-8278(89)90047-0; TERPSTRA OT, 1981, GASTROENTEROLOGY, V81, P475; ULSHEN MH, 1986, GASTROENTEROLOGY, V91, P1134, DOI 10.1016/S0016-5085(86)80008-7; VESEY DA, 1992, GUT, V33, P831, DOI 10.1136/gut.33.6.831; Winer BJ, 1971, STATISTICAL PRINCIPL, P201	17	98	101	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 3	1993	341	8849					843	848		10.1016/0140-6736(93)93057-8	http://dx.doi.org/10.1016/0140-6736(93)93057-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KV811	8096559				2022-12-28	WOS:A1993KV81100001
J	VANTRAPPEN, G; GEBOES, K				VANTRAPPEN, G; GEBOES, K			INFLAMMATORY BOWEL-DISEASE - GLYCOSAMINOGLYCANS AND THE GUT	LANCET			English	Editorial Material											VANTRAPPEN, G (corresponding author), CATHOLIC UNIV LEUVEN,DEPT MED,B-3000 LOUVAIN,BELGIUM.							KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; POOLE AR, 1986, BIOCHEM J, V236, P1; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; RUTGEERTS P, 1991, LANCET, V338, P771, DOI 10.1016/0140-6736(91)90663-A	4	7	8	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 20	1993	341	8847					730	731		10.1016/0140-6736(93)90495-3	http://dx.doi.org/10.1016/0140-6736(93)90495-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KT362	8095632				2022-12-28	WOS:A1993KT36200012
J	KOHEN, D				KOHEN, D			ELTOPRAZINE FOR AGGRESSION IN MENTAL HANDICAP	LANCET			English	Letter											KOHEN, D (corresponding author), CHARING CROSS & WESTMINSTER MED SCH,DEPT PSYCHIAT,LONDON W6 8RP,ENGLAND.							TIIHONEN, 1992, LANCET, V341, P307; VERHOEVEN, 1992, LANCET, V340, P1037	2	12	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 6	1993	341	8845					628	629		10.1016/0140-6736(93)90385-T	http://dx.doi.org/10.1016/0140-6736(93)90385-T			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KQ234	8094849				2022-12-28	WOS:A1993KQ23400030
J	SKOWRON, G; BOZZETTE, SA; LIM, L; PETTINELLI, CB; SCHAUMBURG, HH; AREZZO, J; FISCHL, MA; POWDERLY, WG; GOCKE, DJ; RICHMAN, DD; POTTAGE, JC; ANTONISKIS, D; MCKINLEY, GF; HYSLOP, NE; RAY, G; SIMON, G; REED, N; LOFARO, ML; UTTAMCHANDANI, RB; GELB, LD; SPERBER, SJ; MURPHY, RL; LEEDOM, JM; GRIECO, MH; ZACHARY, J; HIRSCH, MS; SPECTOR, SA; BIGLEY, J; SOO, WJ; MERIGAN, TC				SKOWRON, G; BOZZETTE, SA; LIM, L; PETTINELLI, CB; SCHAUMBURG, HH; AREZZO, J; FISCHL, MA; POWDERLY, WG; GOCKE, DJ; RICHMAN, DD; POTTAGE, JC; ANTONISKIS, D; MCKINLEY, GF; HYSLOP, NE; RAY, G; SIMON, G; REED, N; LOFARO, ML; UTTAMCHANDANI, RB; GELB, LD; SPERBER, SJ; MURPHY, RL; LEEDOM, JM; GRIECO, MH; ZACHARY, J; HIRSCH, MS; SPECTOR, SA; BIGLEY, J; SOO, WJ; MERIGAN, TC			ALTERNATING AND INTERMITTENT REGIMENS OF ZIDOVUDINE AND DIDEOXYCYTIDINE IN PATIENTS WITH AIDS OR AIDS-RELATED COMPLEX	ANNALS OF INTERNAL MEDICINE			English	Article						ZIDOVUDINE; ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS-RELATED COMPLEX; DOSE-RESPONSE RELATIONSHIP, DRUG; DIDEOXYCYTIDINE	PLACEBO-CONTROLLED TRIAL; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; DOUBLE-BLIND; AZIDOTHYMIDINE AZT; VIRUS-INFECTION; ANTIGEN LEVELS; SINGLE AGENT; PHASE-I; 3'-AZIDO-3'-DEOXYTHYMIDINE; 2',3'-DIDEOXYCYTIDINE	Objective: To determine whether alternating regimens consisting of zidovudine and 2',3'-dideoxycytidine (ddC) reduce the toxicity and maintain or increase the antiretroviral effect associated with each drug alone. Design: An unblinded, randomized (phase II) clinical trial in which seven treatment regimens were compared. Setting: Outpatient clinics of 12 AIDS Clinical Trials Units. Patients: One hundred thirty-one patients with the acquired immunodeficiency syndrome (AIDS) or AIDS-related complex and serum p24 antigenemia (greater-than-or-equal-to 70 pg/mL). Intervention: Treatments included weekly or monthly alternating zidovudine (200 mg every 4 hours) and ddC (0.01 or 0.03 mg/kg body weight every 4 hours); weekly intermittent zidovudine, 200 mg every 4 hours, or ddC, 0.03 mg/kg every 4 hours; and continuous zidovudine. Measurements: Toxicity, CD4 cell counts, serum p24 antigen levels, and clinical end points. Data were analyzed for the first 48 weeks of therapy (median follow-up, 40 weeks). Results: Hematologic toxicity was significantly less frequent in patients who received zidovudine therapy every other week (11% to 15%) or every other month (11% to 14%) than in those who received continuous zidovudine therapy (33%) (P < 0.02). Weekly alternating therapy with zidovudine and ddC, 0.03 mg/kg, or intermittent therapy with ddC, 0.03 mg/kg, produced high rates of peripheral neuropathy (41% and 50%, respectively). Neuropathy occurred in 10% to 21% of patients in the other three alternating-therapy limbs and in 17% of patients receiving zidovudine alone (intermittently or continuously). Initial increases in CD4 cell counts were sustained in three alternating-therapy limbs, but counts returned to baseline by week 28 in the remaining limbs. The median weight gain at week 48 was significantly greater in patients treated with alternating regimens (0.9 to 3.8 kg) compared with those treated with continuous zidovudine therapy (-0.7 kg) (P = 0.008). Patients treated with alternating regimens and those treated with continuous zidovudine had similarly sustained decreases in p24 antigen levels. Conclusions: These findings suggest that alternating therapy with zidovudine and ddC reduces the toxicity associated with each drug alone while maintaining strong antiretroviral activity.					Merigan, Thomas/AGQ-7464-2022	Powderly, William/0000-0001-7808-3086; Murphy, Robert/0000-0003-3936-2052				BERGER AR, IN PRESS NEUROLOGY; Cox DR., 1970, ANAL BINARY DATA; DEWOLF F, 1988, LANCET, V1, P373; DOURNON E, 1988, LANCET, V2, P1297; DUBINSKY RM, 1988, LANCET, V1, P832; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FISCHL MA, 1990, NEW ENGL J MED, V323, P1009, DOI 10.1056/NEJM199010113231501; GOTTLIEB M, 1989, 5TH P INT C AIDS MON; JACKSON GG, 1988, ANN INTERN MED, V108, P175, DOI 10.7326/0003-4819-108-2-175; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KLECKER RW, 1987, CLIN PHARMACOL THER, V41, P407, DOI 10.1038/clpt.1987.49; LEHMANN EL, 1975, NONPARAMETRICS; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; MENG TC, 1992, ANN INTERN MED, V116, P13, DOI 10.7326/0003-4819-116-1-13; MERIGAN TC, 1989, ANN INTERN MED, V110, P189, DOI 10.7326/0003-4819-110-3-189; MERIGAN TC, 1990, AM J MED, V88, pS11, DOI 10.1016/0002-9343(90)90415-A; NORRBY SR, 1992, BRIT MED J, V304, P13; RICHMAN DD, 1987, NEW ENGL J MED, V317, P192, DOI 10.1056/NEJM198707233170402; SIDTIS JJ, IN PRESS ANN NEUROL; SPECTOR SA, 1989, ANTIMICROB AGENTS CH, V33, P920, DOI 10.1128/AAC.33.6.920; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; YARCHOAN R, 1986, LANCET, V1, P575; YARCHOAN R, 1988, LANCET, V1, P76; 1987, MMWR S1S, V36, pS1; 1992, APR ANT DRUG PROD AD	26	65	67	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1993	118	5					321	330		10.7326/0003-4819-118-5-199303010-00001	http://dx.doi.org/10.7326/0003-4819-118-5-199303010-00001			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN688	8094279				2022-12-28	WOS:A1993KN68800001
J	ZOLDAN, J; FRIEDBERG, G; GOLDBERGSTERN, H; MELAMED, E				ZOLDAN, J; FRIEDBERG, G; GOLDBERGSTERN, H; MELAMED, E			ONDANSETRON FOR HALLUCINOSIS IN ADVANCED PARKINSONS-DISEASE	LANCET			English	Letter									TEL AVIV UNIV,BEILINSON MED CTR,PARKINSON RES CTR,IL-49100 PETAH TIQWA,ISRAEL; TEL AVIV UNIV,BEILINSON MED CTR,FELSENSTEIN CTR,IL-49100 PETAH TIQWA,ISRAEL	Rabin Medical Center; Tel Aviv University; Rabin Medical Center; Tel Aviv University	ZOLDAN, J (corresponding author), TEL AVIV UNIV,BEILINSON MED CTR,DEPT NEUROL,IL-49100 PETAH TIQWA,ISRAEL.							HONIGFEL.G, 1966, PSYCHOL REP, V19, P180, DOI 10.2466/pr0.1966.19.1.180; Klawans H L, 1988, J Neural Transm Suppl, V27, P117; MARTY M, 1990, NEW ENGL J MED, V322, P816, DOI 10.1056/NEJM199003223221205; Nausieda P A, 1984, Adv Neurol, V40, P271; OVERALL JE, 1988, PSYCHOPHARMACOL BULL, V24, P97; WHITE A, 1991, LANCET, V337, P1173, DOI 10.1016/0140-6736(91)92851-R	6	89	90	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 27	1993	341	8844					562	563		10.1016/0140-6736(93)90327-D	http://dx.doi.org/10.1016/0140-6736(93)90327-D			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP083	8094803				2022-12-28	WOS:A1993KP08300039
J	CAMPBELL, IT; SWAN, G				CAMPBELL, IT; SWAN, G			RESUSCITATION - GUIDELINES AND TRAINING IN CARDIOPULMONARY-RESUSCITATION	LANCET			English	Editorial Material											CAMPBELL, IT (corresponding author), WITHINGTON HOSP,DEPT OBSTET & GYNAECOL,MANCHESTER M20 8LR,LANCS,ENGLAND.							HERSHEY CO, 1982, LANCET, V1, P31, DOI 10.1016/S0140-6736(82)92567-3; PEDOE HT, 1992, BRIT MED J, V304, P1347; POSWILLO D, 1990, GENERAL ANAESTHESIA; SACK JB, 1992, JAMA-J AM MED ASSOC, V267, P379; SKINNER DV, 1985, BRIT MED J, V290, P1549, DOI 10.1136/bmj.290.6481.1549; WOOG RH, 1987, ANAESTH INTENS CARE, V15, P193, DOI 10.1177/0310057X8701500213; 1992, RESUSCITATION, V24, P111; 1987, J R COLL PHYSICIANS, V21, P1; 1992, RESUSCITATION, V24, P155; 1992, JAMA-J AM MED ASSOC, V268, P2171	10	3	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 20	1993	341	8843					470	471		10.1016/0140-6736(93)90216-4	http://dx.doi.org/10.1016/0140-6736(93)90216-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN137	8094496				2022-12-28	WOS:A1993KN13700013
J	THOMSEN, OO; WULFF, HR; MARTIN, A; SINGER, PA				THOMSEN, OO; WULFF, HR; MARTIN, A; SINGER, PA			WHAT DO GASTROENTEROLOGISTS IN EUROPE TELL CANCER-PATIENTS	LANCET			English	Article								This survey concerns the variation in attitudes among European gastroenterologists to truth telling in cases of cancer. Gastroenterologists in all parts of Europe were asked to consider a case of colonic cancer and to state what they would tell the patient and the patient's spouse. 260 replied. Gastroenterologists in northern Europe would usually reveal the diagnosis to both the patient and the patient's spouse, but some would inform only the spouse with the patient's permission. They would sometimes embellish the truth if the cancer had metastasised. Gastroenterologists in southern and eastern Europe would usually conceal the diagnosis from the patient, in many cases even when the patient asked to be told the truth. Most, however, would tell the spouse the full truth about both diagnosis and prognosis. The variation probably reflects differences in both doctors' attitudes and patients' expectations.	MONOBLOCCO OSPED,CATTEDRA MALATTIE APPARATO DIGERENTE,PADUA,ITALY; UNIV TORONTO,CTR BIOETH,TORONTO M5S 1A1,ONTARIO,CANADA; UNIV TORONTO,DEPT MED,TORONTO M5S 1A1,ONTARIO,CANADA	University of Toronto; University of Toronto	THOMSEN, OO (corresponding author), UNIV COPENHAGEN,HERLEV HOSP,DEPT MED C,DK-2730 HERLEV,DENMARK.							DALLAVORGIA P, 1992, J MED ETHICS, V18, P67, DOI 10.1136/jme.18.2.67; GILLON R, 1986, PHILOS MED ETHICS, P100	2	148	149	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 20	1993	341	8843					473	476		10.1016/0140-6736(93)90218-6	http://dx.doi.org/10.1016/0140-6736(93)90218-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN137	8094498				2022-12-28	WOS:A1993KN13700015
J	HO, DD; CAO, YZ; ZHU, TF; FARTHING, C; WANG, N; GU, GL; SCHOOLEY, RT; DAAR, ES				HO, DD; CAO, YZ; ZHU, TF; FARTHING, C; WANG, N; GU, GL; SCHOOLEY, RT; DAAR, ES			IDIOPATHIC CD4+ T-LYMPHOCYTOPENIA - IMMUNODEFICIENCY WITHOUT EVIDENCE OF HIV-INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PNEUMOCYSTIS-CARINII PNEUMONIA; LYMPHOTROPIC RETROVIRUS; HOMOSEXUAL MEN; DEFICIENCY; RISK; AIDS	Background. The human immunodeficiency virus (HIV), the etiologic agent of the acquired immunodeficiency syndrome (AIDS), infects and depletes CD4+ T lymphocytes. Recently, patients have been described with profound CD4+ T-lymphocytopenia but without evident HIV infection, a condition now termed idiopathic CD4+ T-lymphocytopenia, and a national surveillance network has been set up to investigate such cases. Methods. We studied 12 patients with CD4+ T-lymphocytopenia who were referred to us from three U.S. cities. Blood samples were tested for HIV with specific antibody assays, viral cultures, and polymerase-chain-reaction (PCR) techniques. Results. The patients (10 men and 2 women) ranged in age from 30 to 69 years. Eight had risk factors for HIV infection. The clinical manifestations were heterogeneous: five patients had opportunistic infections, five had syndromes of unknown cause, and two had no symptoms. Two patients died from acute complications of their immunodeficiency. The patients' lowest CD4+ lymphocyte counts ranged from 3 to 308 per cubic millimeter (mean, 149). Three patients had complete or partial spontaneous reversal of the CD4+ T-lymphocytopenia. Concomitant CD8+ T-lymphocytopenia was noted in three patients, and abnormal immunoglobulin levels were found in five. Multiple virologic studies by serologic testing, culture, and PCR were completely negative for HIV in all patients. Conclusions. Our 12 patients with idiopathic CD4+ T-lymphocytopenia appear to be epidemiologically, clinically, and immunologically heterogeneous. It is unclear whether this syndrome is new, transmissible, or acquired. Many of the clinical and immunologic features are distinct from those found in AIDS, and our extensive virologic. studies found no evidence of HIV infection. The cause of this condition remains unknown.	UNIV COLORADO, HLTH SCI CTR, DIV INFECT DIS, DENVER, CO 80262 USA; UNIV CALIF LOS ANGELES, CEDARS SINAI MED CTR,SCH MED,DEPT MED, DIV INFECT DIS, LOS ANGELES, CA USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	HO, DD (corresponding author), NYU, SCH MED, AARON DIAMOND AIDS RES CTR, 455 1ST AVE, NEW YORK, NY 10016 USA.		Zhu, Tuofu/G-6158-2010		NIAID NIH HHS [AI28747, AI25541, AI27742] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027742, R01AI025541, R01AI028747] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 1992, MMWR MORB MORTAL WKL, V41, P541; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; CASTRO A, 1992, LANCET, V339, P868, DOI 10.1016/0140-6736(92)90308-P; CLAVEL F, 1986, SCIENCE, V233, P343, DOI 10.1126/science.2425430; COHEN J, 1992, SCIENCE, V257, P1032, DOI 10.1126/science.257.5073.1032; CORTES E, 1989, NEW ENGL J MED, V320, P953, DOI 10.1056/NEJM198904133201501; COWLEY G, 1992, NEWSWEEK        0727, P41; DAAR ES, 1990, CLIN RES, V38, pA114; FAUCI AS, 1991, ANN INTERN MED, V114, P678, DOI 10.7326/0003-4819-114-8-678; FRIEDMANKIEN AE, 1990, LANCET, V335, P168, DOI 10.1016/0140-6736(90)90041-3; GAUTIER V, 1991, CLIN EXP ALLERGY, V21, P63, DOI 10.1111/j.1365-2222.1991.tb00805.x; GUPTA S, 1992, P NATL ACAD SCI USA, V89, P7831, DOI 10.1073/pnas.89.16.7831; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; JACOBS JL, 1991, NEW ENGL J MED, V324, P246, DOI 10.1056/NEJM199101243240407; KANKI PJ, 1986, SCIENCE, V232, P238, DOI 10.1126/science.3006256; KESSLER H, 1992, Morbidity and Mortality Weekly Report, V41, P578; LAURENCE J, 1992, LANCET, V340, P273, DOI 10.1016/0140-6736(92)92359-N; LEE H, 1989, SCIENCE, V244, P471, DOI 10.1126/science.2655084; MEYER RD, 1990, J INFECT DIS, V162, P1370, DOI 10.1093/infdis/162.6.1370; MOORE JP, 1992, LANCET, V340, P475, DOI 10.1016/0140-6736(92)91784-6; SMITH DK, 1993, NEW ENGL J MED, V328, P373, DOI 10.1056/NEJM199302113280601; SPIRA TJ, 1992, J CELL BIOCH SE, V16, P56	22	133	136	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 11	1993	328	6					380	385		10.1056/NEJM199302113280602	http://dx.doi.org/10.1056/NEJM199302113280602			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KL584	8093634				2022-12-28	WOS:A1993KL58400002
J	LION, T; HENN, T; GAIGER, A; KALHS, P; GADNER, H				LION, T; HENN, T; GAIGER, A; KALHS, P; GADNER, H			EARLY DETECTION OF RELAPSE AFTER BONE-MARROW TRANSPLANTATION IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA	LANCET			English	Note							POLYMERASE CHAIN-REACTION; CHRONIC MYELOID-LEUKEMIA	In patients with chronic myelogenous leukaemia (CML) treated by allogeneic bone marrow transplantation (BMT), detection of residual leukaemic cells carrying the characteristic bcr/abl rearrangement by highly sensitive techniques, such as qualitative polymerase chain reaction (PCR), is of limited value in predicting disease progression. We have therefore adapted the PCR for quantitative assessment of bcr/abl rearranged cells and applied this technique to the monitoring of residual disease in 28 CML patients during up to 106 months of follow-up after BMT. In 5 patients, quantitative PCR revealed increasing amounts of the pathological bcr/abl message, indicating the presence of a proliferating neoplastic clone, and all 5 had a subsequent relapse of disease. By contrast the remaining 23 patients have been in maintenance-free complete remission for up to 106 months post-BMT. The monitoring by quantitative PCR of residual leukaemic cells during the post-transplant course of CM L patients may allow early detection of relapse and provide a rationale for the timely initiation of treatment.	UNIV VIENNA,DEPT MED 1,A-1010 VIENNA,AUSTRIA	University of Vienna	LION, T (corresponding author), ST ANNA CHILDRENS HOSP,CHILDRENS CANC RES INST,KINDERSPITALGASSE 6,A-1090 VIENNA,AUSTRIA.		Gaiger, Alexander/GVS-1038-2022; Lion, MD, PhD, Professor, Thomas/C-3241-2016	Gaiger, Alexander/0000-0001-6340-3446; Lion, MD, PhD, Professor, Thomas/0000-0001-9346-0994				ARTHUR CK, 1988, BLOOD, V71, P1179; DELAGE R, 1991, BLOOD, V78, P2759; GABERT J, 1989, LANCET, V2, P1125; HUGHES TP, 1991, BLOOD, V77, P874; HUGHES TP, 1990, BONE MARROW TRANSPL, V5, P3; LION T, 1992, LEUKEMIA, V6, P495; LION T, 1992, BLOOD, V79, P3325; LION T, 1991, LEUKEMIA, V5, P156; PIGNON JM, 1990, LEUKEMIA, V4, P83; THOMPSON JD, 1992, BLOOD, V79, P1629	10	121	121	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 30	1993	341	8840					275	276		10.1016/0140-6736(93)92619-5	http://dx.doi.org/10.1016/0140-6736(93)92619-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK245	8093920				2022-12-28	WOS:A1993KK24500007
J	SHELDON, TA; SMITH, GD				SHELDON, TA; SMITH, GD			CONSENSUS CONFERENCES AS DRUG PROMOTION	LANCET			English	Editorial Material									UNIV GLASGOW,DEPT PUBL HLTH,GLASGOW G12 8QQ,SCOTLAND	University of Glasgow	SHELDON, TA (corresponding author), UNIV YORK,CTR HLTH ECON,YORK YO1 5DD,N YORKSHIRE,ENGLAND.		Davey Smith, George/A-7407-2013; Sheldon, Trevor/AAK-7088-2021	Davey Smith, George/0000-0002-1407-8314; Sheldon, Trevor/0000-0002-7479-5913				BERO LA, 1992, NEW ENGL J MED, V327, P1135, DOI 10.1056/NEJM199210153271606; DURRINGTON P, 1992, P CONSENSUS M HELD R; HANCHER L, 1987, J CONSUM POLICY, V10, P383, DOI 10.1007/BF00411481; KESSLER DA, 1990, JAMA-J AM MED ASSOC, V264, P2409, DOI 10.1001/jama.264.18.2409; LOMAS J, 1991, ANNU REV PUBL HEALTH, V12, P41, DOI 10.1146/annurev.pu.12.050191.000353; LYNOE N, 1988, SCAND J SOC MED, V16, P193, DOI 10.1177/140349488801600401; PITT L, 1988, EUR J MARKETING, V22, P7, DOI 10.1108/EUM0000000005281; SKRABANEK P, 1990, LANCET, V335, P1446, DOI 10.1016/0140-6736(90)91460-R; WADE VA, 1989, LANCET, V2, P1261; WORTMAN PM, 1988, J HEALTH POLIT POLIC, V13, P469, DOI 10.1215/03616878-13-3-469; 1991, SCRIP, P9	11	16	17	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 9	1993	341	8837					100	102		10.1016/0140-6736(93)92569-F	http://dx.doi.org/10.1016/0140-6736(93)92569-F			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF870	8093371				2022-12-28	WOS:A1993KF87000016
J	KREISWIRTH, B; KORNBLUM, J; ARBEIT, RD; EISNER, W; MASLOW, JN; MCGEER, A; LOW, DE; NOVICK, RP				KREISWIRTH, B; KORNBLUM, J; ARBEIT, RD; EISNER, W; MASLOW, JN; MCGEER, A; LOW, DE; NOVICK, RP			EVIDENCE FOR A CLONAL ORIGIN OF METHICILLIN RESISTANCE IN STAPHYLOCOCCUS-AUREUS	SCIENCE			English	Article							EXPRESSION; TRANSPOSON; CLONING; STRAINS; TN554; DNA	Soon after methicillin was introduced into clinical practice in the early 1960s, resistant strains of Staphylococcus aureus (MRSA) appeared, bearing a newly acquired resistance gene, mecA, that encodes a penicillin binding protein, PBP2a. MRSA have spread throughout the world, and an investigation of the clonality of 472 isolates by DNA hybridization was performed. All 472 isolates could be divided into six temporally ordered mecA hybridization patterns, and three of these were subdivided by the chromomosomal transposon Tn554. Each Tn554 pattern occurred in association with one and only one mecA pattern, suggesting that mecA divergence preceded the acquisition of Tn554 in all cases and therefore that mecA may have been acquired just once by S. aureus.	PUBL HLTH RES INST CITY NEW YORK INC, 455 1ST AVE, NEW YORK, NY 10016 USA; NEW YORK CITY DEPT HLTH, BUR LABS, NEW YORK, NY 10016 USA; VET ADM MED CTR, MED SERV, BOSTON, MA 02130 USA; MT SINAI HOSP, DEPT MICROBIOL, TORONTO M5G 1X5, ONTARIO, CANADA; PRINCESS MARGARET HOSP, TORONTO M4X 1K9, ONTARIO, CANADA	New York City Department of Health & Mental Hygiene; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre			Low, Donald/B-1726-2012; McGeer, Allison/AAB-6885-2020; mcgeer, allison/H-7747-2014	McGeer, Allison/0000-0001-5647-6137; mcgeer, allison/0000-0001-5647-6137; Novick, richard/0000-0003-4418-7893	NIAID NIH HHS [AI22159] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI022159, R01AI022159] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], COMMUNICATION; BECK WD, 1986, J BACTERIOL, V165, P373, DOI 10.1128/jb.165.2.373-378.1986; BRUMFIT W, 1989, NEW ENGL J MED, V320, P1899; DUBIN DT, 1990, MOL BIOL STAPHYLOCOC, P85; INGLIS B, 1988, J GEN MICROBIOL, V134, P1465; JEVONS MP, 1961, BRIT MED J, V1, P124, DOI 10.1136/bmj.1.5219.124-a; KREISWIRTH BN, 1986, ANN INTERN MED, V105, P704, DOI 10.7326/0003-4819-105-5-704; KREISWIRTH BN, UNPUB; KREISWIRTH BN, 1982, ANN INTERN MED, V96, P978; KREISWIRTH BN, 1990, MOL BIOL STAPHYLOCOC, P521; KROLEWSKI JJ, 1981, J MOL BIOL, V152, P19, DOI 10.1016/0022-2836(81)90093-0; LACEY RW, 1973, J MED MICROBIOL, V6, P511, DOI 10.1099/00222615-6-4-511; MULLIGAN ME, 1991, INFECT CONT HOSP EP, V12, P20, DOI 10.2307/30147085; MUSSER JM, 1992, J CLIN MICROBIOL, V30, P2058, DOI 10.1128/JCM.30.8.2058-2063.1992; NOVICK RP, 1972, J MOL BIOL, V68, P285, DOI 10.1016/0022-2836(72)90214-8; PATTEE PA, 1990, MOL BIOL STAPHYLOCOC, P41; PHILLIPS S, 1979, NATURE, V278, P476, DOI 10.1038/278476a0; SAFIGUEIREDO AM, 1991, J INFECT DIS, V164, P883; SONG M D, 1988, P352; Soolingen DV, 1991, J CLIN MICROBIOL, V29, P2578; SPEAKER MG, 1991, OPHTHALMOLOGY, V98, P639; STEWART G T, 1963, Br Med J, V1, P308; STEWART GC, 1980, J BACTERIOL, V144, P1200, DOI 10.1128/JB.144.3.1200-1202.1980; TESCH W, 1988, ANTIMICROB AGENTS CH, V32, P1494, DOI 10.1128/AAC.32.10.1494; UBUKATA K, 1989, J BACTERIOL, V171, P2882, DOI 10.1128/jb.171.5.2882-2885.1989	25	319	335	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 8	1993	259	5092					227	230		10.1126/science.8093647	http://dx.doi.org/10.1126/science.8093647			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KF719	8093647				2022-12-28	WOS:A1993KF71900031
J	COX, DR; GREEN, ED; LANDER, ES; COHEN, D; MYERS, RM				COX, DR; GREEN, ED; LANDER, ES; COHEN, D; MYERS, RM			ASSESSING MAPPING PROGRESS IN THE HUMAN-GENOME-PROJECT	SCIENCE			English	Editorial Material							CHROMOSOMES; MODEL		NIH,NATL CTR HUMAN GENOME RES,BETHESDA,MD 20892; WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142; MIT,DEPT BIOL,CAMBRIDGE,MA 02139; CTR ETUD POLYMORPHISME HUMAIN,F-75010 PARIS,FRANCE	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	COX, DR (corresponding author), STANFORD UNIV,DEPT GENET,STANFORD,CA 94305, USA.							BRANSCOMB E, 1990, GENOMICS, V8, P315; COX DR, 1990, SCIENCE, V250, P245, DOI 10.1126/science.2218528; GREEN ED, 1990, SCIENCE, V250, P94, DOI 10.1126/science.2218515; GYAPAY G, 1994, NAT GENET, V7, P248; OLSON M, 1989, SCIENCE, V245, P1434, DOI 10.1126/science.2781285; OLSON MV, 1993, COLD SPRING HARB SYM, V58, P349, DOI 10.1101/SQB.1993.058.01.041; VANDENENGH G, 1992, SCIENCE, V257, P1410, DOI 10.1126/science.1388286	7	31	33	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 30	1994	265	5181					2031	2032		10.1126/science.8091223	http://dx.doi.org/10.1126/science.8091223			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PJ912	8091223				2022-12-28	WOS:A1994PJ91200018
J	BENT, AF; KUNKEL, BN; DAHLBECK, D; BROWN, KL; SCHMIDT, R; GIRAUDAT, J; LEUNG, J; STASKAWICZ, BJ				BENT, AF; KUNKEL, BN; DAHLBECK, D; BROWN, KL; SCHMIDT, R; GIRAUDAT, J; LEUNG, J; STASKAWICZ, BJ			RPS2 OF ARABIDOPSIS-THALIANA - A LEUCINE-RICH REPEAT CLASS OF PLANT-DISEASE RESISTANCE GENES	SCIENCE			English	Article							ARTIFICIAL CHROMOSOME LIBRARY; AGROBACTERIUM-TUMEFACIENS; TRANSMEMBRANE PROTEIN; AVIRULENCE; TRANSDUCTION; MUTATIONS; AVRRPT2; IDENTIFICATION; TRANSFORMATION; INVOLVEMENT	Plant disease resistance genes function in highly specific pathogen recognition pathways. RPS2 is a resistance gene of Arabidopsis thaliana that confers resistance against Pseudomonas syringae bacteria that express avirulence gene avrRpt2. RPS2 was isolated by the use of a positional cloning strategy. The derived amino acid sequence of RPS2 contains leucine-rich repeat, membrane-spanning, leucine zipper, and P loop domains. The function of the RPS2 gene product in defense signal transduction is postulated to involve nucleotide triphosphate binding and protein-protein interactions and may also involve the reception of an elicitor produced by the avirulent pathogen.	UNIV CALIF BERKELEY, DEPT PLANT BIOL, BERKELEY, CA 94720 USA; JOHN INNES CTR PLANT SCI RES, CAMBRIDGE LAB, NORWICH NR4 7UJ, ENGLAND; CNRS, INST SCI VEGETALES, F-91198 GIF SUR YVETTE, FRANCE	University of California System; University of California Berkeley; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay			Bent, Andrew/E-5391-2016	Bent, Andrew/0000-0001-6610-9525; Schmidt, Renate/0000-0002-8037-3581				Alber T, 1992, CURR OPIN GENET DEV, V2, P205, DOI 10.1016/S0959-437X(05)80275-8; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; APOSTOL I, 1989, PLANT PHYSIOL, V90, P109, DOI 10.1104/pp.90.1.109; ATKINSON MM, 1990, PLANT PHYSIOL, V92, P215, DOI 10.1104/pp.92.1.215; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BENNETZEN JL, 1992, GENETIC ENG PRINCIPL, V14, P99; BENT AF, UNPUB; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; CHANG C, 1988, P NATL ACAD SCI USA, V85, P6856, DOI 10.1073/pnas.85.18.6856; CHANG SS, 1994, PLANT J, V5, P551, DOI 10.1046/j.1365-313X.1994.5040551.x; CHERRY JM, 1992, PLANT MOL BIOL REP, V10, P308; DANIELS MJ, 1984, J GEN MICROBIOL, V130, P2447; DIXON RA, 1990, ANNU REV PLANT PHYS, V41, P339, DOI 10.1146/annurev.pp.41.060190.002011; DOKE N, 1983, PHYSIOL PLANT PATHOL, V23, P345, DOI 10.1016/0048-4059(83)90019-X; ECKER J R, 1990, Methods (Orlando), V1, P186, DOI 10.1016/S1046-2023(05)80134-3; FELIX G, 1991, P NATL ACAD SCI USA, V88, P8831, DOI 10.1073/pnas.88.19.8831; Gibson S. I., 1992, Methods in Arabidopsis research., P119; GRILL E, 1991, MOL GEN GENET, V226, P484, DOI 10.1007/BF00260662; INNES RW, 1993, J BACTERIOL, V175, P4859, DOI 10.1128/JB.175.15.4859-4869.1993; JOHAL GS, 1992, SCIENCE, V258, P985, DOI 10.1126/science.1359642; Jones Jonathan D. G., 1992, Transgenic Research, V1, P285, DOI 10.1007/BF02525170; KEEN NT, 1990, ANNU REV GENET, V24, P447, DOI 10.1146/annurev.ge.24.120190.002311; KEEN NT, 1992, GENES INVOLVED PLANT, V8, P76; KEEN NT, 1993, APPLICATION BIOTECHN, P65; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; KONIECZNY A, 1993, PLANT J, V4, P403, DOI 10.1046/j.1365-313X.1993.04020403.x; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUNKEL BN, 1993, PLANT CELL, V5, P865, DOI 10.1105/tpc.5.8.865; Lacy G. H., 1982, PHYTOPATHOGENIC PROK, V2, P149; LAMB CJ, 1989, CELL, V56, P215, DOI 10.1016/0092-8674(89)90894-5; LEUNG J, 1994, SCIENCE, V264, P1448, DOI 10.1126/science.7910981; LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5615, DOI 10.1073/pnas.84.16.5615; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MARTIN GB, 1993, SCIENCE, V262, P1432, DOI 10.1126/science.7902614; MINDRINOS M, IN PRESS CELL; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHNEIDER DS, 1991, GENE DEV, V5, P797, DOI 10.1101/gad.5.5.797; SUZUKI N, 1990, P NATL ACAD SCI USA, V87, P8711, DOI 10.1073/pnas.87.22.8711; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; VERAESTRELLA R, 1994, PLANT PHYSIOL, V104, P209, DOI 10.1104/pp.104.1.209; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; WARD ER, 1990, PLANT MOL BIOL, V14, P561, DOI 10.1007/BF00027501; WHALEN MC, 1991, PLANT CELL, V3, P49, DOI 10.1105/tpc.3.1.49; WHITHAM S, IN PRESS CELL; WINANS SC, 1988, J BACTERIOL, V170, P4047, DOI 10.1128/jb.170.9.4047-4054.1988; YU GL, 1993, MOL PLANT MICROBE IN, V6, P434, DOI 10.1094/MPMI-6-434	46	747	835	7	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 23	1994	265	5180					1856	1860		10.1126/science.8091210	http://dx.doi.org/10.1126/science.8091210			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH258	8091210				2022-12-28	WOS:A1994PH25800030
J	BRADLEY, JF; JOHNSON, RC; GOODMAN, JL				BRADLEY, JF; JOHNSON, RC; GOODMAN, JL			THE PERSISTENCE OF SPIROCHETAL NUCLEIC-ACIDS IN ACTIVE LYME ARTHRITIS	ANNALS OF INTERNAL MEDICINE			English	Note							BORRELIA-BURGDORFERI; JOINT FLUID; DISEASE; EVOLUTION		UNIV MINNESOTA, SCH MED, DEPT MED, INFECT DIS SECT, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, SCH MED, DEPT MICROBIOL, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029739] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040448] Funding Source: NIH RePORTER; NIAID NIH HHS [AI29739] Funding Source: Medline; NIAMS NIH HHS [AR40448] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BARBOUR AG, 1984, YALE J BIOL MED, V57, P521; BECK G, 1989, J RHEUMATOL, V16, P800; DATTWYLER RJ, 1987, ARTHRITIS RHEUM, V30, P448, DOI 10.1002/art.1780300414; GOODMAN JL, 1991, INFECT IMMUN, V59, P269, DOI 10.1128/IAI.59.1.269-278.1991; HARDIN JA, 1979, NEW ENGL J MED, V301, P1358, DOI 10.1056/NEJM197912203012502; JOHNSTON YE, 1985, AM J PATHOL, V118, P26; LIEBLING MR, 1993, ARTHRITIS RHEUM-US, V36, P665, DOI 10.1002/art.1780360514; Rys Paul N., 1993, P203; SCHMIDLI J, 1988, J INFECT DIS, V158, P905, DOI 10.1093/infdis/158.4.905; SNYDMAN DR, 1986, ANN INTERN MED, V104, P798, DOI 10.7326/0003-4819-104-6-798; STEERE AC, 1990, NEW ENGL J MED, V323, P219, DOI 10.1056/NEJM199007263230402; STEERE AC, 1980, ARTHRITIS RHEUM, V23, P591, DOI 10.1002/art.1780230511; STEERE AC, 1987, ANN INTERN MED, V107, P725, DOI 10.7326/0003-4819-107-5-725	13	77	77	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1994	120	6					487	489		10.7326/0003-4819-120-6-199403150-00007	http://dx.doi.org/10.7326/0003-4819-120-6-199403150-00007			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NB625	8093136				2022-12-28	WOS:A1994NB62500007
J	HOLMGREN, G; ERICZON, BG; GROTH, CG; STEEN, L; SUHR, O; ANDERSEN, O; WALLIN, BG; SEYMOUR, A; RICHARDSON, S; HAWKINS, PN; PEPYS, MB				HOLMGREN, G; ERICZON, BG; GROTH, CG; STEEN, L; SUHR, O; ANDERSEN, O; WALLIN, BG; SEYMOUR, A; RICHARDSON, S; HAWKINS, PN; PEPYS, MB			CLINICAL IMPROVEMENT AND AMYLOID REGRESSION AFTER LIVER-TRANSPLANTATION IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS	LANCET			English	Article							P COMPONENT; SYSTEMIC AMYLOIDOSIS; BETA-FIBRILLOSES; PRE-ALBUMIN; POLYNEUROPATHY; PREALBUMIN; DEPOSITS; PROTEIN; VARIANT	Familial amyloid polyneuropathy (FAP) is a fatal autosomal dominant disorder. Progressive peripheral and autonomic neuropathy are associated with neural and visceral deposition of amyloid, derived most commonly from the Met-30 variant of the plasma protein transthyretin. We have reported previously that orthotopic liver transplantation causes prompt replacement of variant transthyretin by the donor wild-type in the plasma. We now report clinical outcome 1-2 years after transplantation. Three of the first four patients have improved general wellbeing, walking ability, and bowel function, and one of them has regained normal bladder and bowel function. There has been little objective improvement in peripheral neuropathy. The fourth patient, who had the most severe neurological deficits and a complicated postoperative course, has not improved but there has been no further deterioration in contrast to the inexorable progression before transplantation. Quantitative scintigraphy with radiolabelled serum amyloid P component showed visceral amyloid deposits in all three patients studied; in two who were followed serially the deposits regressed after transplantation in association with the clinical improvement. Another FAP patient who was also monitored prospectively for 2 years but who did not undergo transplantation, showed, as expected, progression of neuropathy and increased visceral amyloid deposition. Liver transplantation does therefore have important benefits in FAP during the first 2 years after surgery. Neurological decline is halted and amyloid deposits can be mobilised. The best timing and long-term results of the procedure must now be established.	SAHLGRENS UNIV HOSP,DEPT NEUROPHYSIOL,GOTHENBURG,SWEDEN; SAHLGRENS UNIV HOSP,DEPT NEUROL,GOTHENBURG,SWEDEN; UMEA UNIV HOSP,DEPT INTERNAL MED,S-90185 UMEA,SWEDEN; HUDDINGE HOSP,CTR TRANSPLANTAT,S-14186 HUDDINGE,SWEDEN; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT MED,IMMUNOL MED UNIT,LONDON W12 0HS,ENGLAND	Sahlgrenska University Hospital; Sahlgrenska University Hospital; Umea University; Imperial College London	HOLMGREN, G (corresponding author), UMEA UNIV HOSP,DEPT CLIN GENET,S-90185 UMEA,SWEDEN.		Ericzon, Bo-Goran/AAH-5328-2020; Hawkins, Philip N/C-5573-2008	Suhr, Ole/0000-0002-1175-2369	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BILHEIMER DW, 1984, NEW ENGL J MED, V311, P1658, DOI 10.1056/NEJM198412273112603; COSTA PP, 1978, P NATL ACAD SCI USA, V75, P4499, DOI 10.1073/pnas.75.9.4499; COSTA PP, 1990, FAMILIAL AMYLOIDOTIC; DWULET FE, 1986, J CLIN INVEST, V78, P880, DOI 10.1172/JCI112675; GLENNER GG, 1980, NEW ENGL J MED, V302, P1283, DOI 10.1056/NEJM198006053022305; GLENNER GG, 1980, NEW ENGL J MED, V302, P1333, DOI 10.1056/NEJM198006123022403; HAWKINS PN, 1988, LANCET, V1, P1413; HAWKINS PN, 1990, J CLIN INVEST, V86, P1862, DOI 10.1172/JCI114917; HAWKINS PN, 1990, NEW ENGL J MED, V323, P508, DOI 10.1056/NEJM199008233230803; HAWKINS PN, IN PRESS ARTH RHEUM; HOLMGREN G, 1988, CLIN GENET, V34, P333; HOLMGREN G, 1991, CLIN GENET, V40, P242; MACSWEENEY JE, 1991, NUCL J MED COMMUN, V12, P310; MCDONALD JC, 1989, NEW ENGL J MED, V321, P1100, DOI 10.1056/NEJM198910193211607; NELSON SR, 1991, LANCET, V338, P335, DOI 10.1016/0140-6736(91)90478-8; Pepys M. B, 1988, IMMUNOLOGICAL DISEAS, V1, P631; SARAIVA MJM, 1984, J CLIN INVEST, V74, P104, DOI 10.1172/JCI111390; STARZL TE, 1989, NEW ENGL J MED, V321, P1014, DOI 10.1056/NEJM198910123211505; TAWARA S, 1983, BIOCHEM BIOPH RES CO, V116, P880, DOI 10.1016/S0006-291X(83)80224-1	19	448	462	0	16	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 1	1993	341	8853					1113	1116		10.1016/0140-6736(93)93127-M	http://dx.doi.org/10.1016/0140-6736(93)93127-M			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ687	8097803				2022-12-28	WOS:A1993KZ68700003
J	DELAROCHEFORDIERE, A; ASSELAIN, B; CAMPANA, F; SCHOLL, SM; FENTON, J; VILCOQ, JR; DURAND, JC; POUILLART, P; MAGDELENAT, H; FOURQUET, A				DELAROCHEFORDIERE, A; ASSELAIN, B; CAMPANA, F; SCHOLL, SM; FENTON, J; VILCOQ, JR; DURAND, JC; POUILLART, P; MAGDELENAT, H; FOURQUET, A			AGE AS PROGNOSTIC FACTOR IN PREMENOPAUSAL BREAST-CARCINOMA	LANCET			English	Article							CONSERVING THERAPY; TUMOR RECURRENCE; CANCER REGISTRY; SURVIVAL; WOMEN; RADIOTHERAPY; MANAGEMENT; DIAGNOSIS; YOUNGER	Whether or not young age at diagnosis is an adverse prognostic factor in breast cancer has long been controversial, in part because much previous work has not taken due account of menopausal status and confounding factors. We have analysed the influence of age on prognosis in a consecutive series of 1703 patients with stage I-III breast cancer. All were premenopausal and all were treated in one centre (Institut Curie, Paris) between 1981 and 1985. Mean age was 44 years (range 23-55) and median follow-up was 82 months. Younger patients had significantly lower survival rates and higher local and distant relapse rates than older patients. The hazard rate of relapse decreased over time in the youngest age group (less-than-or-equal-to 33) to reach that of older patients after 5 years. The relation between the hazard of recurrence and age was a continuous one, best fitted by a log-linear function and indicating a 4% decrease in recurrence for every year of age. Multivariate analysis of both survival and disease-free interval demonstrated that the worse prognosis of young age was independent of other factors such as clinical tumour size, clinical node status, histological grade, hormone receptor status, locoregional treatment procedure, and adjuvant systemic therapy. This difference in outlook has yet to be explained biologically but it does suggest the need for a closer look at the natural history of breast cancer in young women.	INST CURIE,DEPT BIOSTAT,F-75231 PARIS 05,FRANCE; INST CURIE,DEPT MED ONCOL,F-75231 PARIS 05,FRANCE; INST CURIE,DEPT SURG,F-75231 PARIS 05,FRANCE; INST CURIE,DEPT PATHOL,F-75231 PARIS 05,FRANCE	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	DELAROCHEFORDIERE, A (corresponding author), INST CURIE,DEPT RADIOTHERAPY,26 RUE ULM,F-75231 PARIS 005,FRANCE.							ADAMI HO, 1986, NEW ENGL J MED, V315, P559, DOI 10.1056/NEJM198608283150906; BARTELINK H, 1988, RADIOTHER ONCOL, V11, P297, DOI 10.1016/0167-8140(88)90200-9; BLOOM HJS, 1957, BRIT J CANCER, V11, P339; CABANES PA, 1992, LANCET, V339, P1245, DOI 10.1016/0140-6736(92)91591-U; CLAUS EB, 1991, AM J HUM GENET, V48, P232; COX DR, 1972, J R STAT SOC B, V34, P187; FISHER B, 1991, LANCET, V338, P327, DOI 10.1016/0140-6736(91)90475-5; FOURQUET A, 1989, INT J RADIAT ONCOL, V17, P719, DOI 10.1016/0360-3016(89)90057-6; HOST H, 1986, CANCER-AM CANCER SOC, V57, P2217, DOI 10.1002/1097-0142(19860601)57:11<2217::AID-CNCR2820571124>3.0.CO;2-T; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KURTZ JM, 1990, J CLIN ONCOL, V8, P591, DOI 10.1200/JCO.1990.8.4.591; LANGLANDS AO, 1979, CLIN ONCOL, V5, P123; LEE CG, 1992, INT J RADIAT ONCOL, V23, P969, DOI 10.1016/0360-3016(92)90901-S; LEES AW, 1989, BREAST CANCER RES TR, V13, P143, DOI 10.1007/BF01806526; MAGDELENAT H, 1987, EUR J CANCER CLIN ON, V23, P425, DOI 10.1016/0277-5379(87)90381-6; MUELLER CB, 1978, SURGERY, V83, P123; NEMOTO T, 1980, CANCER, V45, P2917, DOI 10.1002/1097-0142(19800615)45:12<2917::AID-CNCR2820451203>3.0.CO;2-M; NOYES RD, 1982, CANCER, V49, P1302, DOI 10.1002/1097-0142(19820315)49:6<1302::AID-CNCR2820490638>3.0.CO;2-0; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; PILLERS EMK, 1992, LANCET, V339, P1483, DOI 10.1016/0140-6736(92)92079-U; RECHT A, 1988, INT J RADIAT ONCOL, V14, P3, DOI 10.1016/0360-3016(88)90043-0; RIBEIRO GG, 1981, CLIN RADIOL, V32, P231, DOI 10.1016/S0009-9260(81)80168-7; RIES LG, 1983, JNCI-J NATL CANCER I, V70, P693; ROSEN PP, 1984, ANN SURG, V199, P133, DOI 10.1097/00000658-198402000-00001; RUTQVIST LE, 1984, CANCER, V53, P1793, DOI 10.1002/1097-0142(19840415)53:8<1793::AID-CNCR2820530832>3.0.CO;2-Y; SANT M, 1991, EUR J CANCER, V27, P981, DOI 10.1016/0277-5379(91)90263-D; SOLIN LJ, 1989, INT J RADIAT ONCOL, V16, P373, DOI 10.1016/0360-3016(89)90333-7; STABLEIN DM, 1981, CONTROL CLIN TRIALS, V2, P149, DOI 10.1016/0197-2456(81)90005-2; VILCOQ JR, 1981, INT J RADIAT ONCOL, V7, P1327, DOI 10.1016/0360-3016(81)90027-4; VILCOQ JR, 1983, CONSERVATIVE MANAGEM, P213	30	350	351	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 24	1993	341	8852					1039	1043		10.1016/0140-6736(93)92407-K	http://dx.doi.org/10.1016/0140-6736(93)92407-K			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ018	8096955				2022-12-28	WOS:A1993KZ01800001
J	RAMIREZSOLIS, R; ZHENG, H; WHITING, J; KRUMLAUF, R; BRADLEY, A				RAMIREZSOLIS, R; ZHENG, H; WHITING, J; KRUMLAUF, R; BRADLEY, A			HOXB-4 (HOX-2.6) MUTANT MICE SHOW HOMEOTIC TRANSFORMATION OF A CERVICAL VERTEBRA AND DEFECTS IN THE CLOSURE OF THE STERNAL RUDIMENTS	CELL			English	Article							DNA-BINDING SPECIFICITY; HOMEOBOX GENE; TRANSGENIC MICE; TARGETED DISRUPTION; XENOPUS EMBRYOS; RETINOIC ACID; MOUSE EMBRYOS; EXPRESSION; DROSOPHILA; HOMEODOMAIN	Two Hoxb-4 (Hox-2.6) mutations were introduced into the mouse germline. The overt phenotype caused by one of the mutations was assayed on two different genetic backgrounds, an inbred 129SvEv and a hybrid 129SvEv-C57BL/6J. The allele hoxb-4r is a disruption of the first exon and causes two obvious skeletal changes: a partial homeotic transformation of the second cervical vertebra from axis to atlas and a defective morphogenesis of the sternum. Both phenotypes have incomplete penetrance and variable expressivity when assayed in the hybrid genetic background, but the sternum defect is completely penetrant in the inbred background. The mutant allele hoxb-4s has a premature stop codon, introduced by the ''hit and run'' method in the second exon, that disrupts the third helix of the homeodomain. This allele also causes the partial homeotic transformation of axis to atlas, but it does not affect the sternum.	BAYLOR COLL MED, HOWARD HUGHES MED INST, HOUSTON, TX 77030 USA; NATL INST MED RES, EUKARYOT MOLEC GENET LAB, LONDON NW7 1AA, ENGLAND	Baylor College of Medicine; Howard Hughes Medical Institute; MRC National Institute for Medical Research	RAMIREZSOLIS, R (corresponding author), BAYLOR COLL MED, INST MOLEC GENET, HOUSTON, TX 77030 USA.		Krumlauf, Robb/AAH-5012-2019	Krumlauf, Robb/0000-0001-9102-7927; Bradley, Allan/0000-0002-2349-8839				AWGULEWITSCH A, 1992, NATURE, V358, P341, DOI 10.1038/358341a0; BALLING R, 1989, CELL, V58, P337, DOI 10.1016/0092-8674(89)90848-9; BENDER W, 1983, SCIENCE, V221, P23, DOI 10.1126/science.221.4605.23; BONCINELLI E, 1988, HUM REPROD, V3, P880, DOI 10.1093/oxfordjournals.humrep.a136802; BONCINELLI E, 1991, TRENDS GENET, V7, P329, DOI 10.1016/0168-9525(91)90423-N; BRADLEY A, 1992, NATURE, V360, P313; BRAUN RE, 1990, BIOL REPROD, V43, P684, DOI 10.1095/biolreprod43.4.684; BRYSON V, 1945, ANAT REC, V91, P119, DOI 10.1002/ar.1090910204; CHEN JM, 1953, J ANAT, V87, P130; CHEN JM, 1952, J ANAT, V86, P373; CHISAKA O, 1992, NATURE, V355, P516, DOI 10.1038/355516a0; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; CHO KWY, 1988, EMBO J, V7, P2139, DOI 10.1002/j.1460-2075.1988.tb03053.x; DAVIS AC, 1992, MOL CELL BIOL, V12, P2769, DOI 10.1128/MCB.12.6.2769; DESPLAN C, 1988, CELL, V54, P1081, DOI 10.1016/0092-8674(88)90123-7; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; FEATHERSTONE MS, 1988, P NATL ACAD SCI USA, V85, P4760, DOI 10.1073/pnas.85.13.4760; FITZPATRICK VD, 1992, NATURE, V356, P610, DOI 10.1038/356610a0; GALLIOT B, 1989, DEVELOPMENT, V107, P343; GAUNT SJ, 1991, BIOESSAYS, V13, P505, DOI 10.1002/bies.950131004; GAUNT SJ, 1988, DEVELOPMENT, V104, P169; GAUNT SJ, 1989, DEVELOPMENT, V107, P131; GEADA AMC, 1992, DEVELOPMENT, V116, P497; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GRAHAM A, 1988, GENE DEV, V2, P1424, DOI 10.1101/gad.2.11.1424; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; GRUNEBERG H, 1950, J GENET, V50, P112, DOI 10.1007/BF02986799; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; HARVEY RP, 1988, CELL, V53, P687, DOI 10.1016/0092-8674(88)90087-6; HARVEY RP, 1986, EMBO J, V5, P1237, DOI 10.1002/j.1460-2075.1986.tb04352.x; HASTY P, 1991, NATURE, V350, P243, DOI 10.1038/350243a0; HOGAN B, 1985, TRENDS GENET, V1, P67, DOI 10.1016/0168-9525(85)90029-0; HOLLAND PWH, 1986, NATURE, V321, P251, DOI 10.1038/321251a0; HUNT P, 1992, ANNU REV CELL BIOL, V8, P227, DOI 10.1146/annurev.cb.08.110192.001303; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; HUNT P, 1991, DEVELOPMENT, V112, P43; JACOBSON AG, 1988, DEVELOPMENT, V104, P209; JEGALIAN BG, 1992, CELL, V71, P901, DOI 10.1016/0092-8674(92)90387-R; KAUFMAN TC, 1990, ADV GENET, V27, P9; KESSEL M, 1990, CELL, V61, P301, DOI 10.1016/0092-8674(90)90810-2; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KEYNES RJ, 1988, DEVELOPMENT, V103, P413; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI DOI 10.1083/JCB.108.2.229; KRUMLAUF R, 1992, BIOESSAYS, V14, P245, DOI 10.1002/bies.950140408; KUZIORA MA, 1988, CELL, V55, P477, DOI 10.1016/0092-8674(88)90034-7; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LEVINE M, 1988, CELL, V55, P537, DOI 10.1016/0092-8674(88)90209-7; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; LUFKIN T, 1992, NATURE, V359, P835, DOI 10.1038/359835a0; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; MCGINNIS N, 1990, CELL, V63, P969, DOI 10.1016/0092-8674(90)90500-E; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; McLAREN A., 1956, Journal of Genetics, V54, P440, DOI 10.1007/BF02982959; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MULLIGAN RC, 1980, SCIENCE, V209, P1422, DOI 10.1126/science.6251549; OLIVER G, 1988, EMBO J, V7, P3199, DOI 10.1002/j.1460-2075.1988.tb03187.x; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; OUDEJANS CBM, 1990, DEVELOPMENT, V108, P471; POLLOCK RA, 1992, CELL, V71, P911, DOI 10.1016/0092-8674(92)90388-S; PUSCHEL AW, 1990, DEVELOPMENT, V108, P435; RAMIREZSOLIS R, 1992, ANAL BIOCHEM, V201, P331, DOI 10.1016/0003-2697(92)90347-A; RUSSELL LB, 1979, TERATOLOGY, V20, P115, DOI 10.1002/tera.1420200115; SCOTT MP, 1992, CELL, V71, P551, DOI 10.1016/0092-8674(92)90588-4; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SHAM MH, 1992, EMBO J, V11, P1825, DOI 10.1002/j.1460-2075.1992.tb05234.x; SIMEONE A, 1988, NUCLEIC ACIDS RES, V16, P5379, DOI 10.1093/nar/16.12.5379; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Stern C.D., 1990, Seminars in Developmental Biology, V1, P109; THEILER K, 1988, ADV ANAT EMBRYOL CEL, V112, P1; TREISMAN J, 1989, CELL, V59, P553; WHITING J, 1991, GENE DEV, V5, P2048, DOI 10.1101/gad.5.11.2048; Wilkinson D. G., 1990, POSTIMPLANTATION MAM, P155; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0; WOLGEMUTH DJ, 1989, NATURE, V337, P464, DOI 10.1038/337464a0; WRIGHT CVE, 1989, CELL, V59, P81, DOI 10.1016/0092-8674(89)90871-4; ZIMMER A, 1989, NATURE, V338, P150, DOI 10.1038/338150a0	79	286	290	1	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 23	1993	73	2					279	294						16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KY505	8097432				2022-12-28	WOS:A1993KY50500010
J	BAUM, M				BAUM, M			NEW APPROACH FOR RECRUITMENT INTO RANDOMIZED CONTROLLED TRIALS	LANCET			English	Editorial Material											BAUM, M (corresponding author), ROYAL MARSDEN HOSP,DEPT SURG,FULHAM RD,LONDON SW3 6JJ,ENGLAND.							JAMES W, 1990, PEDIATR PERINAT EPID, V4, P255; MALCOLMSMITH S, 1992, EUROPEAN        1027, P29; STILLER C, 1992, INTRO NEW TREATMENTS, P119; WACHTER RM, 1992, NEW ENGL J MED, V326, P128, DOI 10.1056/NEJM199201093260209; 1992, BMJ, V305, P699; 1992, ASSESSING EFFECTS HL	6	58	58	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 27	1993	341	8848					812	813		10.1016/0140-6736(93)90573-Y	http://dx.doi.org/10.1016/0140-6736(93)90573-Y			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU900	8096011				2022-12-28	WOS:A1993KU90000016
J	MARKUS, H; LOH, A; ISRAEL, D; BUCKENHAM, T; CLIFTON, A; BROWN, MM				MARKUS, H; LOH, A; ISRAEL, D; BUCKENHAM, T; CLIFTON, A; BROWN, MM			MICROSCOPIC AIR-EMBOLISM DURING CEREBRAL-ANGIOGRAPHY AND STRATEGIES FOR ITS AVOIDANCE	LANCET			English	Article							CARDIAC-SURGERY; MICROEMBOLI; ARTERY; BYPASS; BRAIN	Cerebral angiography is associated with a risk of neurological complications and air embolism may contribute towards this risk. To test this hypothesis, transcranial doppler ultrasonography was used to monitor the presence of air emboli in the middle cerebral arteries of 7 patients undergoing cerebral angiography. Doppler signals consistent with numerous air emboli were noted during each injection of radiographic contrast. This phenomenon was studied further in sheep. Radiographic contrast medium was injected into the carotid artery while a major carotid branch was insonated transorbitally. Embolic signals similar to those seen in patients were noted. Air was introduced at two points. First, at the time of drawing up the contrast into the syringe, especially with more viscous media. Standing the media before injection resulted in a highly significant reduction of air embolism, reducing the total mean duration of emboli from 1.32 (SD 0.60) s after immediate injection to 0.04 (0.05) s after ten minutes standing for iohexol 340 mg/mL (p < 0.001 ). Second, air was introduced at the time of injection, possibly by the formation of cavitation bubbles under pressure. This occurred most prominently with the less viscous contrast media and with saline, and was significantly reduced by slow injection (mean duration of emboli for saline 2.85 [2.43] s with fast injection compared with 0.32 [0.37] s with slow injection, p = 0.004). Air embolism may contribute towards neurological dysfunction after angiography. Measures should be taken to reduce this by allowing contrast media to stand prior to injection, and by flushing catheters with saline injected slowly.	ATKINSON MORLEYS HOSP,DEPT NEURORADIOL,LONDON SW20,ENGLAND; ST GEORGE HOSP,DEPT SURG,LONDON SW17 0RE,ENGLAND; ST GEORGE HOSP,DEPT RADIOL,LONDON SW17 0RE,ENGLAND	St Georges University London; St Georges University London	MARKUS, H (corresponding author), ST GEORGE HOSP,SCH MED,DIV CLIN NEUROSCI,LONDON SW17 0RE,ENGLAND.			Brown, Martin M/0000-0002-3273-1356				AUSTEN WG, 1965, J SURG RES, V5, P283; COFFEY CE, 1983, NEUROLOGY, V33, P1416, DOI 10.1212/WNL.33.11.1416; DION JE, 1987, STROKE, V18, P997, DOI 10.1161/01.STR.18.6.997; FIESCHI C, 1989, J NEUROL SCI, V91, P311, DOI 10.1016/0022-510X(89)90060-9; FRITZ H, 1979, STROKE, V10, P581, DOI 10.1161/01.STR.10.5.581; GABRIEL KR, 1964, BIOMETRICS, V20, P459, DOI 10.2307/2528488; HANKEY GJ, 1990, STROKE, V21, P209, DOI 10.1161/01.STR.21.2.209; MARKUS HS, 1993, STROKE, V24, P1; MELDRUM BS, 1971, BRAIN RES, V25, P301, DOI 10.1016/0006-8993(71)90440-9; MENKIN M, 1977, ARCH NEUROL-CHICAGO, V34, P168, DOI 10.1001/archneur.1977.00500150054010; MOODY DM, 1990, ANN NEUROL, V28, P477, DOI 10.1002/ana.410280403; NEWMAN S, 1992, 1ST INT CONS C EMB D; PADAYACHEE TS, 1987, ANN THORAC SURG, V44, P298, DOI 10.1016/S0003-4975(10)62077-2; PFEIFFER FE, 1984, ARCH NEUROL-CHICAGO, V41, P1175, DOI 10.1001/archneur.1984.04050220073017; PFEIFFER FE, 1987, MAYO CLIN PROC, V62, P351, DOI 10.1016/S0025-6196(12)65438-X; PUGSLEY W, 1990, VASCULAR SURG, V24, P34, DOI 10.1177/153857449002400107; SHAW PJ, 1986, Q J MED, V58, P59; Spencer M P, 1969, Ann Thorac Surg, V8, P489; SPENCER MP, 1969, JOM-J OCCUP MED, V11, P238; SPENCER MP, 1990, STROKE, V21, P415, DOI 10.1161/01.STR.21.3.415; STUMP D, 1992, 1ST INT CONS C EMB D	21	113	121	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 27	1993	341	8848					784	787		10.1016/0140-6736(93)90561-T	http://dx.doi.org/10.1016/0140-6736(93)90561-T			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU900	8096000				2022-12-28	WOS:A1993KU90000004
J	COLLINS, J				COLLINS, J			METABOLIC DISEASE - TIME FOR FRUCTOSE SOLUTIONS TO GO	LANCET			English	Editorial Material											COLLINS, J (corresponding author), GUYS HOSP,NEWCOMEN CTR,LONDON SE1 9RT,ENGLAND.							ALI M, 1993, Q J MED, V86, P25; KREBS HA, 1975, ESSAYS MEDICAL BIOCH, V1, P81; OBERHAENSLI RD, 1987, LANCET, V2, P931	3	6	6	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 6	1993	341	8845					600	600		10.1016/0140-6736(93)90358-N	http://dx.doi.org/10.1016/0140-6736(93)90358-N			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KQ234	8094835				2022-12-28	WOS:A1993KQ23400010
J	SHANN, F				SHANN, F			NUTRITION - NUTRITIONAL INDEXES - Z, CENTILE, OR PERCENT	LANCET			English	Editorial Material											SHANN, F (corresponding author), ROYAL CHILDRENS HOSP,PARKVILLE,VIC 3052,AUSTRALIA.		Shann, Frank/C-9510-2011					DIBLEY MJ, 1987, AM J CLIN NUTR, V46, P736, DOI 10.1093/ajcn/46.5.736; SACHDEV HPS, 1992, INT J EPIDEMIOL, V21, P916, DOI 10.1093/ije/21.5.916; SULLIVAN K M, 1990, Food and Nutrition Bulletin, V12, P116; 1986, B WORLD HEALTH ORGAN, V64, P929	4	20	20	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 27	1993	341	8844					526	527		10.1016/0140-6736(93)90283-M	http://dx.doi.org/10.1016/0140-6736(93)90283-M			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP083	8094776				2022-12-28	WOS:A1993KP08300009
J	SEWELL, KL; TRENTHAM, DE				SEWELL, KL; TRENTHAM, DE			PATHOGENESIS OF RHEUMATOID-ARTHRITIS	LANCET			English	Article							II COLLAGEN; LYMPHOCYTE-T; INTERLEUKIN-2; SYNOVITIS; ACTIVATION; ANTIGENS; THERAPY; CELLS; MICE		HARVARD UNIV,SCH MED,BOSTON,MA 02215	Harvard University; Harvard Medical School	SEWELL, KL (corresponding author), BETH ISRAEL HOSP,DIV RHEUMATOL,330 BROOKLINE AVE,BOSTON,MA 02215, USA.							BACHA P, 1992, EUR J IMMUNOL, V22, P1673, DOI 10.1002/eji.1830220702; BIRKENFELD P, 1990, CLIN IMMUNOL IMMUNOP, V54, P14, DOI 10.1016/0090-1229(90)90002-8; BRAHN E, 1989, CELL IMMUNOL, V118, P491, DOI 10.1016/0008-8749(89)90396-1; BREEDVELD FC, 1987, RHEUM DIS CLIN N AM, V13, P531; CUSH JJ, 1991, CLIN ORTHOP RELAT R, V265, P9; FIRESTEIN GS, 1988, J EXP MED, V168, P1573, DOI 10.1084/jem.168.5.1573; FIRESTEIN GS, 1990, ARTHRITIS RHEUM, V33, P768, DOI 10.1002/art.1780330602; HARRIS ED, 1990, NEW ENGL J MED, V322, P1277, DOI 10.1056/nejm199005033221805; HEMLER ME, 1986, J CLIN INVEST, V78, P696, DOI 10.1172/JCI112629; IWAKURA Y, 1991, SCIENCE, V253, P1026, DOI 10.1126/science.1887217; JASON HE, 1991, J CLIN INVEST, V87, P1531; KOCK AE, 1986, ARTHRITIS RHEUM, V29, P471; LONDEI M, 1989, P NATL ACAD SCI USA, V86, P636, DOI 10.1073/pnas.86.2.636; MARX J, 1991, SCIENCE, V252, P27, DOI 10.1126/science.2011753; MOSS PAH, 1992, ANNU REV IMMUNOL, V10, P71, DOI 10.1146/annurev.iy.10.040192.000443; PALIARD X, 1991, SCIENCE, V253, P325, DOI 10.1126/science.1857971; PANAYI GS, 1992, ARTHRITIS RHEUM-US, V35, P729, DOI 10.1002/art.1780350702; PITZALIS C, 1987, J RHEUMATOL, V14, P662; PITZALIS C, 1988, EUR J IMMUNOL, V18, P1397, DOI 10.1002/eji.1830180915; ROUDIER J, 1989, P NATL ACAD SCI USA, V86, P5104, DOI 10.1073/pnas.86.13.5104; SEWELL KL, 1991, CLIN RES, V39, pA314; SOLINGER AM, 1990, J RHEUMATOL, V17, P562; TARKOWSKI A, 1989, ARTHRITIS RHEUM, V32, P1087, DOI 10.1002/anr.1780320906; TRUJILLO PE, 1992, RHEUMATOL INT, V11, P225, DOI 10.1007/BF00301499; WATSON W, 1992, ARTHRITIS RHEUM, V35, pS59; WEYAND CM, 1992, ARTHRITIS RHEUM-US, V35, P990, DOI 10.1002/art.1780350903; WILLIAMS WV, 1992, J CLIN INVEST, V90, P326, DOI 10.1172/JCI115866; WOOLEY PH, 1984, MAYO CLIN PROC, V59, P737, DOI 10.1016/S0025-6196(12)65583-9; ZHANG ZYJ, 1990, J IMMUNOL, V145, P2489	29	121	130	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 30	1993	341	8840					283	286		10.1016/0140-6736(93)92627-6	http://dx.doi.org/10.1016/0140-6736(93)92627-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK245	8093927				2022-12-28	WOS:A1993KK24500015
J	STEEL, M				STEEL, M			GENETICS - POLYMORPHISMS, PROTEINS, AND PHENOTYPES	LANCET			English	Editorial Material											STEEL, M (corresponding author), MRC,HUMAN GENET UNIT,EDINBURGH,SCOTLAND.							GOLDFARB LG, 1992, SCIENCE, V258, P806, DOI 10.1126/science.1439789; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MCKUSICK VA, 1990, MENDELIAN INHERITANC, pR11; MONK M, 1990, TRENDS GENET, V6, P110, DOI 10.1016/0168-9525(90)90124-O; TSUI LC, 1992, TRENDS GENET, V8, P392, DOI 10.1016/0168-9525(92)90301-J	5	6	6	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 23	1993	341	8839					212	213		10.1016/0140-6736(93)90074-Q	http://dx.doi.org/10.1016/0140-6736(93)90074-Q			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ219	8093505				2022-12-28	WOS:A1993KJ21900012
J	TENWOLDE, S; BREEDVELD, FC; DEVRIES, RRP; DAMARO, J; RUBENSTEIN, P; SCHREUDER, GMT; CLAAS, FHJ; VANROOD, JJ				TENWOLDE, S; BREEDVELD, FC; DEVRIES, RRP; DAMARO, J; RUBENSTEIN, P; SCHREUDER, GMT; CLAAS, FHJ; VANROOD, JJ			INFLUENCE OF NONINHERITED MATERNAL HLA ANTIGENS ON OCCURRENCE OF RHEUMATOID-ARTHRITIS	LANCET			English	Article							T-CELL REPERTOIRE; SELF-ANTIGENS; TOLERANCE	Many HLA-associated diseases occur in patients not carrying the putative predisposing antigen. The suggestion that this might be due to disease heterogeneity is not sufficiently supported by available data. We hypothesise that HLA-DR4-associated genetic susceptibility to rheumatoid arthritis is due to an effect of DR4 on T-cell receptor repertoire expression and that the presence of antigen in the mother is capable of producing this effect in her children, even when DR4 is not inherited by them. To investigate this possibility we HLA typed 94 rheumatoid arthritis patients and their parents and 86 control families. An increased frequency, compared with controls, of non-inherited maternal HLA-DR4 was found predominantly in the mothers of DR4-negative patients. Unexpectedly, we also found an increased frequency of non-inherited maternal HLA-DR4 and a decreased frequency of non-inherited maternal HLA-DR3 in the mothers of DR4-positive patients. The results of our analyses are consistent with our hypothesis.	UNIV HOSP LEIDEN,DEPT IMMUNOHAEMATOL,POB 9600,2300 RC LEIDEN,NETHERLANDS; LEIDEN UNIV HOSP,BLOOD BANK,2333 AA LEIDEN,NETHERLANDS; LEIDEN UNIV HOSP,DEPT RHEUMATOL,2333 AA LEIDEN,NETHERLANDS; NEW YORK BLOOD CTR,NEW YORK,NY 10021	Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); New York Blood Center								BLACKMAN M, 1990, SCIENCE, V248, P1335, DOI 10.1126/science.1972592; CLAAS FHJ, 1988, SCIENCE, V241, P1815, DOI 10.1126/science.3051377; FISHER RA, 1958, STATISTICAL METHODS; MULLBACHER A, 1983, J EXP MED, V157, P1324, DOI 10.1084/jem.157.4.1324; PULLEN AM, 1988, NATURE, V335, P796, DOI 10.1038/335796a0; ROBES MW, 1958, B RHEUM DIS, V9, P175; RUBINSTEIN P, 1990, 3RD INT C JEW GEN DI; TIWARI JL, 1985, HLA DISEASE ASS; VANROOD JJ, 1976, NATURE, V262, P795, DOI 10.1038/262795a0; ZHANG L, 1991, RES IMMUNOL, V142, P441, DOI 10.1016/0923-2494(91)90044-J	10	48	49	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 23	1993	341	8839					200	202						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ219	8093497				2022-12-28	WOS:A1993KJ21900004
J	GORES, PF; NAJARIAN, JS; STEPHANIAN, E; LLOVERAS, JJ; KELLEY, SL; SUTHERLAND, DER				GORES, PF; NAJARIAN, JS; STEPHANIAN, E; LLOVERAS, JJ; KELLEY, SL; SUTHERLAND, DER			INSULIN INDEPENDENCE IN TYPE-I DIABETES AFTER TRANSPLANTATION OF UNPURIFIED ISLETS FROM SINGLE DONOR WITH 15-DEOXYSPERGUALIN	LANCET			English	Note							ALLOGRAFTS	Islet transplantation has been slow to develop as a therapy for type I diabetes mellitus. Conventional immunosuppression does not protect islet allografts from early failure and by current techniques the yield of purified islets from a single pancreas is inadequate or only marginally in excess of the number needed to sustain normoglycaemia. We transplanted unpurified islets from a single pancreas concomitantly with a kidney to two uraemic diabetic patients. The novel agent 15-deoxyspergualin, along with antilymphocyte globulin, was used for induction immunosuppression, and azathioprine, prednisone, and cyclosporin for maintenance. Islet function has been sustained in both, and the second patient is insulin-independent and euglycaemic more than 6 months after transplantation.	UNIV MINNESOTA, DEPT SURG, MINNEAPOLIS, MN 55455 USA; BRISTOL MYERS SQUIBB, PHARMACEUT RES INST, WALLINGFORD, CT USA	University of Minnesota System; University of Minnesota Twin Cities; Bristol-Myers Squibb								FARNEY AC, 1991, SURGERY, V110, P427; KAUFMAN DB, 1990, J EXP MED, V172, P291, DOI 10.1084/jem.172.1.291; NADLER SG, 1992, SCIENCE, V258, P484, DOI 10.1126/science.1411548; RICORDI C, 1992, TRANSPLANTATION, V53, P407, DOI 10.1097/00007890-199202010-00027; SCHARP DW, 1991, TRANSPLANTATION, V51, P76, DOI 10.1097/00007890-199101000-00012; SOCCI C, 1991, ACTA DIABETOL, V28, P151, DOI 10.1007/BF00579718; STEPHANIAN E, 1992, J SURG RES, V52, P621, DOI 10.1016/0022-4804(92)90139-Q; TZAKIS AG, 1990, LANCET, V336, P402, DOI 10.1016/0140-6736(90)91946-8; WALTER PK, 1987, DIABETOLOGIA, V30, P38, DOI 10.1007/BF01788905; WARNOCK GL, 1992, DIABETOLOGIA, V35, P89, DOI 10.1007/BF00400857	10	182	183	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 2	1993	341	8836					19	21		10.1016/0140-6736(93)92484-B	http://dx.doi.org/10.1016/0140-6736(93)92484-B			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF027	8093268				2022-12-28	WOS:A1993KF02700007
J	THEURKAUF, WE				THEURKAUF, WE			PREMATURE MICROTUBULE-DEPENDENT CYTOPLASMIC STREAMING IN CAPPUCCINO AND SPIRE MUTANT OOCYTES	SCIENCE			English	Article							DROSOPHILA OOGENESIS; BICOID RNA; LOCALIZATION; ANTEROPOSTERIOR; PROTEIN; EMBRYO; VASA; POLE	Embryonic axis specification in Drosophila melanogaster is achieved through the asymmetric subcellular localization of morphogenetic molecules within the oocyte. The cappuccino and spire loci are required for both posterior and dorsoventral patterning. Time-lapse confocal microscopic analyses of living egg chambers demonstrated that these mutations induce microtubule reorganization and the premature initiation of microtubule-dependent ooplasmic streaming. As a result, microtubule organization is altered and bulk ooplasm rapidly streams during the developmental stages in which morphogens are normally localized. These changes in oocyte cytoarchitecture and dynamics appear to disrupt axial patterning of the embryo.			THEURKAUF, WE (corresponding author), SUNY STONY BROOK, DEPT BIOCHEM & CELL BIOL, STONY BROOK, NY 11794 USA.			Theurkauf, William/0000-0001-7342-1912				BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; CLARK I, 1994, CURR BIOL, V4, P289, DOI 10.1016/S0960-9822(00)00068-3; Driever Wolfgang, 1993, P301; GUTZEIT HO, 1982, J EMBRYOL EXP MORPH, V67, P101; HAY B, 1990, DEVELOPMENT, V109, P425; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; KOCH EA, 1983, CELL TISSUE RES, V228, P21; LASKO PF, 1990, GENE DEV, V4, P905, DOI 10.1101/gad.4.6.905; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; NEUMANSILBERBERG FS, 1993, CELL, V75, P165, DOI 10.1016/S0092-8674(05)80093-5; NUSSLEINVOLHARD C, 1989, CIBA F SYMP, V144, P37; POKRYWKA NJ, 1991, DEVELOPMENT, V113, P55; SCHUPBACH T, 1991, GENETICS, V129, P1119; Spradling Allan C., 1993, P1; St Johnston Daniel, 1993, P325; STJOHNSTON D, 1992, CELL, V68, P201; THEURKAUF WE, 1992, DEVELOPMENT, V115, P923; THEURKAUF WE, UNPUB	18	130	129	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 30	1994	265	5181					2093	2096		10.1126/science.8091233	http://dx.doi.org/10.1126/science.8091233			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PJ912	8091233				2022-12-28	WOS:A1994PJ91200030
J	SPRECHER, DL; ABRAMS, J; ALLEN, JW; KEANE, WF; CHRYSANT, SG; GINSBERG, H; FISCHER, JJ; JOHNSON, BF; THEROUX, P; JOKUBAITIS, L				SPRECHER, DL; ABRAMS, J; ALLEN, JW; KEANE, WF; CHRYSANT, SG; GINSBERG, H; FISCHER, JJ; JOHNSON, BF; THEROUX, P; JOKUBAITIS, L			LOW-DOSE COMBINED THERAPY WITH FLUVASTATIN AND CHOLESTYRAMINE IN HYPERLIPIDEMIC PATIENTS	ANNALS OF INTERNAL MEDICINE			English	Article						HYPERLIPIDEMIA; LIPOPROTEINS, LDL CHOLESTEROL; FLUVASTATIN; DRUG THERAPY, COMBINATION; CHOLESTYRAMINE	MODERATE HYPERCHOLESTEROLEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; DRUG-THERAPY; CHOLESTEROL; PLASMA; HYPERLIPOPROTEINEMIA; COMBINATION; SIMVASTATIN; COLESTIPOL; LOVASTATIN	Objective: To compare the low-density lipoprotein (LDL) cholesterol-lowering efficacy of low-dose combinations of cholestyramine and fluvastatin. Design: Randomized, double-blind, parallel group, placebo-controlled trial with a 24-week double-blind treatment period divided into three phases. Setting: Office-based clinics. Patients: Hypercholesterolemic, with LDL cholesterol of 4.14 mmol/L or greater (greater than or equal to 160 mg/dL) and plasma triglycerides of 3.39 mmol/L or less (less than or equal to 300 mg/dL). Four hundred sixty patients were screened; 224 patients were randomized into a double-blind treatment period; 203 completed the study; 6 dropped out because of adverse events. Intervention: Patients were treated with 10 mg or 20 mg of fluvastatin alone, 8 g or 16 g of cholestyramine alone, or combinations of these fluvastatin and cholestyramine dosages (six treatment groups). Measurements: Changes in lipid variables, particularly LDL cholesterol. Results: The 10-mg and 20-mg fluvastatin monotherapy groups showed considerable reductions in LDL cholesterol initially (- 20.1% [SD, 8.8%] and - 20.2% [SD, 10.1%], respectively); these reductions were maintained. Reductions in LDL cholesterol that resulted from the addition of cholestyramine, 8 g/d, to 10 mg of fluvastatin and 20 mg of fluvastatin were greater than those observed with monotherapy (10-mg fluvastatin [10-mg fluvastatin plus cholestyramine], 9.1%; 95% Cl, 3.8% to 14.4%) and 20-mg fluvastatin - [20-mg fluvastatin plus cholestyramine], 11.6%; Cl, 6.5% to 16.8%). The increase in cholestyramine dose to 16 g/d in the three combination groups provided only a modest additional response. Conclusions: Low-density lipoprotein cholesterol reductions of about 25% to 30% can be achieved with low-dose combination therapy with fluvastatin and cholestyramine. The addition of low-dose resin appears to produce greater overall cholesterol reduction than does a simple doubling of the fluvastatin dosage. The low-dose combination treatment was highly successful in achieving the goals of the National Cholesterol Education Program guidelines.	UNIV NEW MEXICO HOSP, DIV CARDIOL, ALBUQUERQUE, NM 87131 USA; HOSP GOOD SAMARITAN, HEART INC, LOS ANGELES, CA 90017 USA; HENNEPIN CTY MED CTR, DRUG EVALUAT UNIT, MINNEAPOLIS, MN 55415 USA; OKLAHOMA CARDIOVASC & HYPERTENS CTR, OKLAHOMA CITY, OK 73132 USA; DIABET & GLANDULAR DIS RES CTR, SAN ANTONIO, TX 78229 USA; UNIV MASSACHUSETTS, SCH MED, DEPT MED, DIV CLIN PHARMACOL, WORCESTER, MA 01655 USA; INST CARDIOL MONTREAL, MONTREAL H1T 1C8, PQ, CANADA; SANDOZ INC, RES INST, E HANOVER, NJ 07936 USA; UNIV CINCINNATI, MED CTR, CTR CHOLESTEROL RES, CINCINNATI, OH 45267 USA; UNIV OKLAHOMA, OKLAHOMA CITY, OK 73104 USA; COLUMBIA UNIV COLL PHYS & SURG, NEW YORK, NY 10032 USA	University of New Mexico; Hennepin County Medical Center; University of Massachusetts System; University of Massachusetts Worcester; Universite de Montreal; Institut de Cardiologie de Montreal; Novartis; Sandoz; University System of Ohio; University of Cincinnati; University of Oklahoma System; University of Oklahoma Health Sciences Center; Columbia University								ANGELIN B, 1991, ANN MED, V23, P177, DOI 10.3109/07853899109148044; [Anonymous], 1988, CLIN CHEM, V34, P193; DACOL PG, 1990, CURR THER RES CLIN E, V48, P798; EMMERICH J, 1990, EUR HEART J, V11, P149, DOI 10.1093/oxfordjournals.eurheartj.a059671; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; ILLINGWORTH DR, 1987, DRUGS, V33, P259, DOI 10.2165/00003495-198733030-00003; ILLINGWORTH DR, 1990, CLIN INVEST MED, V13, P211; ILLINGWORTH DR, 1988, CLIN CHEM, V34, pB123; ILLINGWORTH DR, 1989, CARDIOLOGY, V76, P83; ILLINGWORTH DR, 1988, ATHEROSCLER REV, V18, P161; ILLINGWORTH DR, 1987, RECENT ADV CARDIOL, V10, P71; KATHAWALA FG, 1991, MED RES REV, V11, P121; LEREN TP, 1988, ATHEROSCLEROSIS, V73, P135, DOI 10.1016/0021-9150(88)90034-2; LEVY RI, 1993, CIRCULATION, V87, P45; MOL MJTM, 1986, LANCET, V2, P936; MOL MJTM, 1988, ATHEROSCLEROSIS, V69, P131, DOI 10.1016/0021-9150(88)90006-8; PAN HY, 1990, CLIN PHARMACOL THER, V48, P201, DOI 10.1038/clpt.1990.136; REMMELL PS, 1980, J AM DIET ASSOC, V76, P357; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; SIRTORI CR, 1989, CURR THER RES CLIN E, V46, P230; STEINER PM, 1981, J CLIN CHEM CLIN BIO, V19, P850; SUPERKO HR, 1992, AM J CARDIOL, V70, P135, DOI 10.1016/0002-9149(92)91264-5; VEGA GL, 1987, JAMA-J AM MED ASSOC, V257, P33, DOI 10.1001/jama.257.1.33; 1982, US DHEW75628 PUBL	24	56	63	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1994	120	7					537	543		10.7326/0003-4819-120-7-199404010-00002	http://dx.doi.org/10.7326/0003-4819-120-7-199404010-00002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC764	8093139				2022-12-28	WOS:A1994NC76400002
J	PARMET, JL; BERMAN, AT; HORROW, JC; HARDING, S; ROSENBERG, H				PARMET, JL; BERMAN, AT; HORROW, JC; HARDING, S; ROSENBERG, H			THROMBOEMBOLISM COINCIDENT WITH TOURNIQUET DEFLATION DURING TOTAL KNEE ARTHROPLASTY	LANCET			English	Note							EMBOLISM	Despite prophylactic therapy, pulmonary embolism remains the leading cause of perioperative mortality in patients undergoing total knee arthroplasty (TKA). We used transoesophageal echocardiography to monitor 29 consecutive patients during TKA. Showers of substantial amounts of echogenic material, lasting for 3-15 min, were visible in the right atrium and ventricle within 10-15 s of tourniquet deflation in all patients. A 3 x 6 mm fresh thrombus was aspirated from the central circulation of one patient. Another patient, who had had a Greenfield filter placed for previous thromboembolism, showed very little echogenic material after tourniquet deflation. The composition and importance of these echogenic emboli remain uncertain.	HAHNEMANN UNIV,DEPT ORTHOPED,PHILADELPHIA,PA 19102	Drexel University	PARMET, JL (corresponding author), HAHNEMANN UNIV,DEPT ANESTHESIOL,BROAD & VINC,PHILADELPHIA,PA 19102, USA.							ERETH MH, 1992, MAYO CLIN PROC, V67, P1066, DOI 10.1016/S0025-6196(12)61121-5; Heinrich H, 1988, Acta Orthop Belg, V54, P12; MCGRATH BG, 1992, ANESTHESIOLOGY S, V77, pA1080; MCGRATH BJ, 1991, ANESTHESIOLOGY, V74, P618, DOI 10.1097/00000542-199103000-00034; MESSAHEL F M, 1991, Middle East Journal of Anesthesiology, V11, P187; ORSINI EC, 1986, CAN J SURG, V29, P385; Schlag G, 1988, Acta Orthop Belg, V54, P6; WEDEL DJ, 1993, ORTHOPEDIC ANESTHESI, P355; 1990, NATIONAL CTR HLTH 13, V113	9	84	85	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 24	1993	341	8852					1057	1058		10.1016/0140-6736(93)92414-O	http://dx.doi.org/10.1016/0140-6736(93)92414-O			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ018	8096961				2022-12-28	WOS:A1993KZ01800007
J	ABOULKER, JP; SWART, AM				ABOULKER, JP; SWART, AM			PRELIMINARY-ANALYSIS OF THE CONCORDE TRIAL	LANCET			English	Letter							PLACEBO-CONTROLLED TRIAL; ZIDOVUDINE; INFECTION		ROYAL BROMPTON NATL HEART & LUNG HOSP,DEPT CLIN EPIDEMIOL,MRC,CTR HIV CLIN TRIALS,LONDON SW3 6NP,ENGLAND	Imperial College London; Medical Research Council Clinical Trials Unit	ABOULKER, JP (corresponding author), INSERM,SC10,16 AV PAUL VAILLANT COUTURIER,F-194807 VILLEJUIF,FRANCE.							FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; HAMILTON JD, 1992, NEW ENGL J MED, V326, P437, DOI 10.1056/NEJM199202133260703; MERIGAN TC, 1991, BLOOD, V78, P900; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401	4	228	229	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 3	1993	341	8849					889	890		10.1016/0140-6736(93)93096-J	http://dx.doi.org/10.1016/0140-6736(93)93096-J			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KV811	8096582				2022-12-28	WOS:A1993KV81100027
J	JIAO, SS; GUREVICH, V; WOLFF, JA				JIAO, SS; GUREVICH, V; WOLFF, JA			LONG-TERM CORRECTION OF RAT MODEL OF PARKINSONS-DISEASE BY GENE-THERAPY	NATURE			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; GENETICALLY ENGINEERED CELLS; PRODUCE L-DOPA; BRAIN; CATECHOLAMINES; GRAFTS; SKIN	THE implantation of cells genetically modified to express tyrosine hydroxylase has been proposed for the treatment of Parkinson's disease1. Tyrosine hydroxylase converts tyrosine to L-DOPA and endogenous decarboxylase activity then converts L-DOPA to the neurotransmitter dopamine, which alleviates the symptoms of Parkinson's disease. Immortalized cells have been successfully used as intracerebral vehicles for transgene expression of tyrosine hydroxylase, but the tumorigenic potential of these cells prevents their application in humans1-4. Intracerebral expression of this enzyme has also been achieved using primary cells like skin fibroblasts5-7, but the ameliorating effect on a rat model for Parkinson's disease lasted for only a few weeks. We have found that co-transplantation of cultured myoblasts and myotubes enabled reporter genes to be expressed intracerebrally at high and stable levels8-10. Here we show that the intracerebral transplantation of plasmid-transfected primary muscle cells can substantially reduce for the long-term the asymmetric rotational behaviour in the rat model.	UNIV WISCONSIN,WAISMAN CTR,DEPT PEDIAT,MADISON,WI 53705; UNIV WISCONSIN,WAISMAN CTR,DEPT MED GENET,MADISON,WI 53705	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison								BIRKMAYER GJD, 1989, ACTA NEUROL SCAND, V80, P183, DOI 10.1111/j.1600-0404.1989.tb01800.x; BROWN ER, 1987, BIOCHEMISTRY-US, V26, P5208, DOI 10.1021/bi00390a046; CHEN LS, 1991, J CELL BIOCHEM, V45, P252, DOI 10.1002/jcb.240450305; CROMBEEN JP, 1978, J CHROMATOGR, V167, P219, DOI 10.1016/S0021-9673(00)91160-9; DAN Y, 1992, NATURE, V359, P733, DOI 10.1038/359733a0; FISHER LJ, 1991, NEURON, V6, P371, DOI 10.1016/0896-6273(91)90246-V; GAGE FH, 1987, NEUROSCIENCE, V23, P795, DOI 10.1016/0306-4522(87)90159-X; GAGE FH, 1991, NEURON, V6, P1, DOI 10.1016/0896-6273(91)90116-H; HORELLOU P, 1990, NEURON, V5, P393, DOI 10.1016/0896-6273(90)90078-T; JIAO S, 1992, NEUROSCI LETT, V137, P207, DOI 10.1016/0304-3940(92)90405-V; JIAO S, 1992, BRAIN RES, V575, P143, DOI 10.1016/0006-8993(92)90434-B; JIAO SS, IN PRESS CELL TRANSP; KAMAHORI M, 1991, J CHROMATOGR-BIOMED, V567, P351, DOI 10.1016/0378-4347(91)80141-X; KAPATOS G, 1982, J NEUROCHEM, V39, P1152, DOI 10.1111/j.1471-4159.1982.tb11509.x; MELAMED E, 1987, HDB PARKINSONS DISEA, P355; NORTON PA, 1985, MOL CELL BIOL, V5, P281, DOI 10.1128/MCB.5.2.281; PALMER TD, 1991, P NATL ACAD SCI USA, V88, P1330, DOI 10.1073/pnas.88.4.1330; Paxinos G., 2004, J CHEM INF MODEL, V5th; PERLOW MJ, 1979, SCIENCE, V204, P643, DOI 10.1126/science.571147; STROMBERG I, 1990, J NEUROSCI RES, V25, P405, DOI 10.1002/jnr.490250318; SVENDSEN H, 1981, J CHROMATOGR, V213, P429, DOI 10.1016/S0021-9673(00)80494-X; WAKAI S, 1986, BRAIN RES, V386, P209, DOI 10.1016/0006-8993(86)90157-5; WOLFF, 1992, HUM MOL GENET, V1, P363; WOLFF JA, 1989, P NATL ACAD SCI USA, V86, P9011, DOI 10.1073/pnas.86.22.9011	24	149	181	1	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 1	1993	362	6419					450	453		10.1038/362450a0	http://dx.doi.org/10.1038/362450a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KV424	8096625				2022-12-28	WOS:A1993KV42400084
J	FENG, GS; HUI, CC; PAWSON, T				FENG, GS; HUI, CC; PAWSON, T			SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE AS A TARGET OF PROTEIN-TYROSINE KINASES	SCIENCE			English	Article							SIGNAL TRANSDUCTION; PP60C-SRC; PHOSPHORYLATION; DOMAINS; SH2; AMPLIFICATION; ACTIVATION; RECEPTORS; FAMILY; GAP	A mouse phosphotyrosine phosphatase containing two Src homology 2 (SH2) domains, Syp, was identified. Syp bound to autophosphorylated epidermal growth factor (EGF) and platelet-derived growth factor (PDGF) receptors through its SH2 domains and was rapidly phosphorylated on tyrosine in PDGF- and EGF-stimulated cells. Furthermore, Syp was constitutively phosphorylated on tyrosine in cells transformed by v-src. This mammalian phosphatase is most closely related, especially in its SH2 domains, to the corkscrew (csw) gene product of Drosophila, which is required for signal transduction downstream of the Torso receptor tyrosine kinase. The Syp gene is widely expressed throughout embryonic mouse development and in adult tissues. Thus, Syp may function in mammalian embryonic development and as a common target of both receptor and nonreceptor tyrosine kinases.	MT SINAI HOSP,SAMUEL LUNENFELD RES INST,DIV MOLEC & DEV BIOL,TORONTO M5G 1X5,ONTARIO,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A8,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto			Pawson, Tony J/E-4578-2013					ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BOOKER GW, 1992, NATURE, V358, P684, DOI 10.1038/358684a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FENG G, UNPUB; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GUAN K, 1991, J BIOL CHEM, V266, P12964; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; HELDIN CH, 1991, TRENDS BIOCHEM SCI, V16, P450, DOI 10.1016/0968-0004(91)90175-U; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; HUI CC, IN PRESS NAT GENET; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; MARENGERE LEM, 1992, J BIOL CHEM, V267, P22779; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MATTHEWS RJ, 1991, IMMUNOGENETICS, V33, P33; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; Pawson T, 1992, CURR OPIN GENET DEV, V2, P4, DOI 10.1016/S0959-437X(05)80314-4; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; RUSSELL RB, 1992, FEBS LETT, V304, P15, DOI 10.1016/0014-5793(92)80579-6; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; YI TL, 1991, BLOOD, V78, P2222	38	625	645	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 12	1993	259	5101					1607	1611		10.1126/science.8096088	http://dx.doi.org/10.1126/science.8096088			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KR543	8096088				2022-12-28	WOS:A1993KR54300038
J	SPITZER, ED; SPITZER, SG; FREUNDLICH, LF; CASADEVALL, A				SPITZER, ED; SPITZER, SG; FREUNDLICH, LF; CASADEVALL, A			PERSISTENCE OF INITIAL INFECTION IN RECURRENT CRYPTOCOCCUS-NEOFORMANS MENINGITIS	LANCET			English	Note							SEPARATION	Patients with cryptococcal meningitis tend to have recurrences of infection. Although the original strain of Cryptococcus neoformans is assumed to persist in recurrent infections, this assumption has not been tested. Southern blot hybridisation with two genomic DNA probes and pulsed-field electrophoresis of intact chromosomes were used to investigate the genetic relation between initial and relapse isolates of C neoformans from patients with recurrent cryptococcal meningitis. Eleven isolates were obtained from four patients (three with AIDS, one with leukaemia). Isolates from each patient could be distinguished from those of the other patients; however, each patient's initial and recurrence isolates were clonally related. Our results provide strong evidence that clinical recurrences of cryptococcal meningitis result from persistence of the original infecting strain.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MED,DIV INFECT DIS,1300 MORRIS BANK PK AVE,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT LAB MED,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MICROBIOL & IMMUNOL,BRONX,NY 10461; SUNY STONY BROOK,SCH MED,DEPT PATHOL,STONY BROOK,NY 11794	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook			Spitzer, Eric/T-7455-2019	Spitzer, Eric/0000-0002-8794-2441	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI032430] Funding Source: NIH RePORTER; NIAID NIH HHS [AI32430] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CASADEVALL A, 1992, J CLIN MICROBIOL, V30, P1080, DOI 10.1128/JCM.30.5.1080-1084.1992; EDMAN JC, 1990, MOL CELL BIOL, V10, P4538, DOI 10.1128/MCB.10.9.4538; KWONCHUNG KJ, 1982, J CLIN MICROBIOL, V15, P535, DOI 10.1128/JCM.15.3.535-537.1982; KWONCHUNG KJ, 1992, INFECT IMMUN, V60, P1869, DOI 10.1128/IAI.60.5.1869-1874.1992; MUKHERJEE J, 1992, INFECT IMMUN, V60, P4534, DOI 10.1128/IAI.60.11.4534-4541.1992; PERFECT JR, 1989, INFECT IMMUN, V57, P2624, DOI 10.1128/IAI.57.9.2624-2627.1989; POLACHECK I, 1989, J GEN MICROBIOL, V135, P65; POWDERLY WG, 1992, CLIN INFECT DIS, V14, pS54, DOI 10.1093/clinids/14.Supplement_1.S54; SPITZER ED, 1992, J CLIN MICROBIOL, V30, P1094, DOI 10.1128/JCM.30.5.1094-1097.1992; ZUGER A, 1986, ANN INTERN MED, V104, P234, DOI 10.7326/0003-4819-104-2-234	10	155	156	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 6	1993	341	8845					595	596		10.1016/0140-6736(93)90354-J	http://dx.doi.org/10.1016/0140-6736(93)90354-J			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KQ234	8094831				2022-12-28	WOS:A1993KQ23400006
J	THOMAS, DJ; PENNOCK, JM; HAJNAL, JV; YOUNG, IR; BYDDER, GM; STEINER, RE				THOMAS, DJ; PENNOCK, JM; HAJNAL, JV; YOUNG, IR; BYDDER, GM; STEINER, RE			MAGNETIC-RESONANCE-IMAGING OF SPINAL-CORD IN MULTIPLE-SCLEROSIS BY FLUID-ATTENUATED INVERSION RECOVERY	LANCET			English	Note								Magnetic resonance imaging examination of the upper spinal cord was done in sixteen adult patients with clinically definite multiple sclerosis (MS) by T2 weighted fluid attenuated inversion recovery (FLAIR) scanning in which the signal from cerebrospinal fluid was suppressed. These scans were compared with matched images obtained with conventional T1 and T2 weighted pulse sequences (including contrast enhancement). 6 lesions (five patients) were seen with the conventional scans and 37 lesions (fourteen patients) were seen with the FLAIR scans. The FLAIR sequence considerably improves the ability of MRI to demonstrate spinal involvement in MS.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,ROBERT STEINER MAGNET RESONANCE UNIT,LONDON W12 0HS,ENGLAND; ST MARYS HOSP,DEPT NEUROL,LONDON,ENGLAND; NATL HOSP,LONDON WC1N 3BG,ENGLAND; PICKER INTL,WEMBLEY,MIDDX,ENGLAND	Imperial College London; Imperial College London; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust			Hajnal, Joseph/P-6251-2018	Hajnal, Joseph/0000-0002-2690-5495				FOG T, 1950, ARCH NEURO PSYCHIATR, V63, P382, DOI 10.1001/archneurpsyc.1950.02310210028003; HAJNAL JV, 1992, 11TH ANN M SOC MAGN, P1528; HONIG LS, 1989, J NEUROL NEUROSUR PS, V52, P459, DOI 10.1136/jnnp.52.4.459; KURTZKE JF, 1970, HDB CLIN NEUROLOGY, V7, P206; MARAVILLA KR, 1985, AM J ROENTGENOL, V144, P381, DOI 10.2214/ajr.144.2.381; MCDONALD WI, 1989, BRIT MED J, V299, P635, DOI 10.1136/bmj.299.6700.635; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; THORPE JW, 1992, 11TH ANN M SOC MAGN, P419; WALLACE CJ, 1992, AM J ROENTGENOL, V158, P849, DOI 10.2214/ajr.158.4.1546605; WHITE SJ, 1992, MAGNET RESON MED, V28, P153, DOI 10.1002/mrm.1910280116	10	67	68	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 6	1993	341	8845					593	594		10.1016/0140-6736(93)90353-I	http://dx.doi.org/10.1016/0140-6736(93)90353-I			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KQ234	8094830				2022-12-28	WOS:A1993KQ23400005
J	MATSUMURA, K; NONAKA, I; CAMPBELL, KP				MATSUMURA, K; NONAKA, I; CAMPBELL, KP			ABNORMAL EXPRESSION OF DYSTROPHIN-ASSOCIATED PROTEINS IN FUKUYAMA-TYPE CONGENITAL MUSCULAR-DYSTROPHY	LANCET			English	Note								The absence of dystrophin causes Duchenne muscular dystrophy. Dystrophin is associated with a large complex of sarcolemmal glycoproteins which provides a linkage to the extracellular matrix component laminin, and when dystrophin is absent all the dystrophin-associated proteins are much reduced. We report here that dystrophin-associated proteins have abnormally low expression in Fukuyama-type congenital muscular dystrophy (FCMD), despite near-normal expression of dystrophin. An abnormality of dystrophin-associated proteins in the sarcolemma seems to be a common denominator in the pathological processes leading to muscle cell necrosis in three forms of severe muscular dystrophy (Duchenne, Japanese Fukuyama-type, and north African Duchenne-like autosomal recessive).	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; NATL CTR NEUROL & PSYCHIAT,NATL INST NEUROSCI,TOKYO,JAPAN	Howard Hughes Medical Institute; University of Iowa; University of Iowa; National Center for Neurology & Psychiatry - Japan				Campbell, Kevin/0000-0003-2066-5889				ARAHATA K, 1989, P NATL ACAD SCI USA, V86, P7154, DOI 10.1073/pnas.86.18.7154; ARIKAWA E, 1991, J NEUROL SCI, V105, P79, DOI 10.1016/0022-510X(91)90122-N; BEGGS AH, 1992, P NATL ACAD SCI USA, V89, P623, DOI 10.1073/pnas.89.2.623; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; MATSUMURA K, 1992, NATURE, V359, P320, DOI 10.1038/359320a0; NONAKA I, 1979, HDB CLIN NEUROLOGY, V41, P27; OHLENDIECK K, IN PRESS NEUROLOGY	8	77	81	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 27	1993	341	8844					521	522		10.1016/0140-6736(93)90279-P	http://dx.doi.org/10.1016/0140-6736(93)90279-P			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP083	8094772				2022-12-28	WOS:A1993KP08300005
J	WILCKEN, B; LEUNG, KC; HAMMOND, J; KAMATH, R; LEONARD, JV				WILCKEN, B; LEUNG, KC; HAMMOND, J; KAMATH, R; LEONARD, JV			PREGNANCY AND FETAL LONG-CHAIN 3-HYDROXYACYL COENZYME-A DEHYDROGENASE-DEFICIENCY	LANCET			English	Note							ACID OXIDATION DEFECT	We report on eleven pregnancies in 5 mothers. 6 of the babies had long-chain 3-hydroxyacyl coenzyme A dehydrogenase (LCHAD) deficiency, and each of the pregnancies was complicated by features such as fatty liver and HELLP (haemolysis, elevated liver enzymes, low platelets) syndrome. By contrast, 3 of the mothers also gave birth to unaffected babies, and these pregnancies were largely uncomplicated. We conclude that there may be adverse effects on maternal liver function from a fetus with LCHAD deficiency. Heterozygosity in the, mother cannot alone account for the adverse effects because of the segregation of these effects with fetal LCHAD status.	CHILDRENS HOSP,SYDNEY,AUSTRALIA; INST CHILD HLTH,LONDON WC1N 1EH,ENGLAND	University of Sydney; University of London; University College London	WILCKEN, B (corresponding author), NEW S WALES HLTH DEPT,OLIVER LATHAM LAB,POB 53,SYDNEY,NSW 2113,AUSTRALIA.							HAGENFELDT L, 1990, J PEDIATR-US, V116, P387, DOI 10.1016/S0022-3476(05)82826-4; HALE DE, 1990, FATTY ACID OXIDATION, P503; JACKSON S, 1991, PEDIATR RES, V29, P406, DOI 10.1203/00006450-199104000-00016; SCHOEMAN MN, 1991, GASTROENTEROLOGY, V100, P544, DOI 10.1016/0016-5085(91)90228-D; STANLEY CA, 1990, INBORN METABOLIC DIS, P395; WEINSTEIN L, 1982, AM J OBSTET GYNECOL, V142, P159, DOI 10.1016/S0002-9378(16)32330-4	6	164	168	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 13	1993	341	8842					407	408		10.1016/0140-6736(93)92993-4	http://dx.doi.org/10.1016/0140-6736(93)92993-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM416	8094173				2022-12-28	WOS:A1993KM41600008
J	SEWELL, H				SEWELL, H			HLA AND DISEASE - NONINHERITED MATERNAL HLA ANTIGENS	LANCET			English	Editorial Material											SEWELL, H (corresponding author), UNIV NOTTINGHAM HOSP,DEPT IMMUNOL,NOTTINGHAM NG7 2UH,ENGLAND.							BILLINGHAM RE, 1953, NATURE, V172, P603, DOI 10.1038/172603a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; GERMAIN RN, 1991, NATURE, V353, P605, DOI 10.1038/353605a0; HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0; SEWELL HF, 1992, IMMUNOLOGICAL BASIS, P1; TODD JA, 1987, NATURE, V329, P599, DOI 10.1038/329599a0; 1992, LANCET, V340, P1404	8	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 23	1993	341	8839					211	211		10.1016/0140-6736(93)90072-O	http://dx.doi.org/10.1016/0140-6736(93)90072-O			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ219	8093503				2022-12-28	WOS:A1993KJ21900010
J	MURPHY, GS; BASRI, H; PURNOMO; ANDERSEN, EM; BANGS, MJ; MOUNT, DL; GORDEN, J; LAL, AA; PURWOKUSUMO, AR; HARJOSUWARNO, S; SORENSEN, K; HOFFMAN, SL				MURPHY, GS; BASRI, H; PURNOMO; ANDERSEN, EM; BANGS, MJ; MOUNT, DL; GORDEN, J; LAL, AA; PURWOKUSUMO, AR; HARJOSUWARNO, S; SORENSEN, K; HOFFMAN, SL			VIVAX MALARIA RESISTANT TO TREATMENT AND PROPHYLAXIS WITH CHLOROQUINE	LANCET			English	Article							FINGER-STICK BLOOD; PLASMODIUM-VIVAX; WHOLE-BLOOD; DESETHYLCHLOROQUINE; PYRIMETHAMINE; FALCIPARUM; INDONESIA; SAMPLES; PLASMA; SERUM	Chloroquine has been the treatment of choice for vivax malaria for more than 40 years. Lately, several case-reports have suggested the emergence of resistance to chloroquine in Plasmodium vivax in Papua New Guinea and Indonesia. We undertook prospective treatment and prophylaxis trials of chloroquine in children and adults with vivax malaria living in Irian Jaya (Indonesian New Guinea). 46 villagers with P vivax parasitaemia were treated with chloroquine by mouth (25 mg base/kg body weight divided over 3 days) and followed up for 14 days. Parasitaemia cleared initially but recurred within 14 days in 10 (22%) subjects. All recurrences were in children younger than 11 years, 7 of whom were younger than 4 years; the failure rate among children under 4 was 70%. 7 of the patients with recurrences were given a second course of chloroquine. In all, the infections initially cleared but recurrent parasitaemia developed in 5 (71%) within 14 days. Whole-blood chloroquine concentrations were consistently above those previously shown to cure P vivax blood infections (90 mug/L whole blood). Subjects whose initial infections cleared and who had no parasitaemia on day 14 received weekly prophylaxis with chloroquine. Despite the presence of expected blood chloroquine concentrations, P vivax parasitaemia developed in 9 of 17 subjects receiving prophylaxis during 8 weeks of follow-up (median time to parasitaemia 5.3 weeks). Chloroquine can no longer be relied upon for effective treatment or chemoprophylaxis of P vivax blood infections acquired in this part of New Guinea.	USN, MED RES UNIT 2, JAKARTA, INDONESIA; MINIST HLTH REPUBL INDONESIA, JAKARTA, INDONESIA; CTR DIS CONTROL, MALARIA BRANCH, ATLANTA, GA 30333 USA; USN, MED RES INST, BETHESDA, MD 20814 USA	University of 19 November Kolaka; Ministry of Health - Indonesia; Centers for Disease Control & Prevention - USA; Naval Medical Research Center (NMRC); United States Department of Defense; United States Navy				Gorden, Jed/0000-0003-0683-9547				ARIAS AE, 1989, TROP MED PARASITOL, V40, P21; BAIRD JK, 1991, AM J TROP MED HYG, V44, P547, DOI 10.4269/ajtmh.1991.44.547; BERGQVIST Y, 1983, J CHROMATOGR, V272, P137, DOI 10.1016/S0378-4347(00)86110-1; BERLINER RW, 1948, J CLIN INVEST, V27, P98, DOI 10.1172/JCI101980; BROCKELMAN C R, 1989, Southeast Asian Journal of Tropical Medicine and Public Health, V20, P41; Bruce-Chwatt LJ, 1981, CHEMOTHERAPY MALARIA; COLLIGNON P, 1991, J INFECT DIS, V164, P222, DOI 10.1093/infdis/164.1.222; DEAN AG, 1990, EPI INFO VERSION 5; DOBERSTYN EB, 1979, T ROY SOC TROP MED H, V73, P15, DOI 10.1016/0035-9203(79)90121-4; GORDON HH, 1947, ARCH INTERN MED, V79, P365, DOI 10.1001/archinte.1947.00220100015001; GORNHAM PCC, 1988, MALARIA PRINCIPLES P, V1, P61; GUSTAFSSON LL, 1983, LANCET, V1, P126; GUSTAFSSON LL, 1983, BRIT J CLIN PHARMACO, V15, P471, DOI 10.1111/j.1365-2125.1983.tb01532.x; MILLER KD, 1986, AM J TROP MED HYG, V35, P451, DOI 10.4269/ajtmh.1986.35.451; MOST H, 1946, JAMA-J AM MED ASSOC, V131, P963, DOI 10.1001/jama.1946.02870290013005; MOUNT DL, 1988, J CHROMATOGR-BIOMED, V428, P196, DOI 10.1016/S0378-4347(00)83908-0; PATCHEN LC, 1983, J CHROMATOGR, V278, P81, DOI 10.1016/S0378-4347(00)84758-1; Peters W, 1970, CHEMOTHERAPY DRUG RE; QARI SH, 1991, J BIOL CHEM, V266, P16297; RIECKMANN KH, 1989, LANCET, V2, P1183, DOI 10.1016/S0140-6736(89)91792-3; ROMBO L, 1987, TROP MED PARASITOL, V38, P49; ROMBO L, 1985, THER DRUG MONIT, V7, P211, DOI 10.1097/00007691-198506000-00013; ROMBO L, 1986, T ROY SOC TROP MED H, V80, P763, DOI 10.1016/0035-9203(86)90380-9; ROMBO L, 1987, B WORLD HEALTH ORGAN, V65, P879; SCHMIDT LH, 1978, AM J TROP MED HYG, V27, P703, DOI 10.4269/ajtmh.1978.27.703; SCHUURKAMP GJ, 1992, T ROY SOC TROP MED H, V86, P121, DOI 10.1016/0035-9203(92)90531-G; SCHUURKAMP GJ, 1989, T ROY SOC TROP MED H, V83, P607, DOI 10.1016/0035-9203(89)90370-2; SCHWARTZ IK, 1991, NEW ENGL J MED, V324, P927; WHITBY M, 1989, LANCET, V2, P1395, DOI 10.1016/S0140-6736(89)92002-3	29	166	169	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 9	1993	341	8837					96	100		10.1016/0140-6736(93)92568-E	http://dx.doi.org/10.1016/0140-6736(93)92568-E			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF870	8093414				2022-12-28	WOS:A1993KF87000015
J	SKRABANEK, P				SKRABANEK, P			ASYMMETRICAL AUTOIMMUNITY	LANCET			English	Editorial Material							HANDEDNESS											CHENGAPPA KNR, 1991, LANCET, V338, P694, DOI 10.1016/0140-6736(91)91268-Y; CHENGAPPA KNR, 1992, LIFE SCI, V51, P1843, DOI 10.1016/0024-3205(92)90035-N; CHYATTE C, 1980, J IRISH MED ASSOC, V73, P247; Coren S., 1992, LEFT HANDER SYNDROME; GESCHWIND N, 1982, P NATL ACAD SCI-BIOL, V79, P5097, DOI 10.1073/pnas.79.16.5097; SKRABANEK P, 1992, PERSPECT BIOL MED, V35, P182	6	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 2	1993	341	8836					26	27		10.1016/0140-6736(93)92491-B	http://dx.doi.org/10.1016/0140-6736(93)92491-B			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF027	8093274				2022-12-28	WOS:A1993KF02700013
J	KNOPPERS, BM; CHADWICK, R				KNOPPERS, BM; CHADWICK, R			THE HUMAN-GENOME-PROJECT - UNDER AN INTERNATIONAL ETHICAL MICROSCOPE	SCIENCE			English	Editorial Material									UNIV MONTREAL,CTR PUBL LAW RES,MONTREAL,PQ,CANADA; UNIV CENT LANCASHIRE,PRESTON,LANCS,ENGLAND	Universite de Montreal; University of Central Lancashire	KNOPPERS, BM (corresponding author), UNIV MONTREAL,FAC LAW,MONTREAL,PQ,CANADA.							[Anonymous], 1992, HUGO POSITION STATEM; BANKOWSKI Z, 1991, 24TH P CIOMS ROUND T, P1; 1992, INT DIGEST HLTH LEGI, V43, P745; 1994, INT DIGEST HLTH LEG, V45, P234; 1991, GUIDELINES USE GENET; 1991, INT DIGEST HLTH LEGI, V42, P346; 1993, B MED ETHICS, P10; 1993, ETHICS MAPPING HUMAN; 1990, INT DIGEST HLTH LEGI, V41, P615; 1993, GENETIC SCREENING ET; IN PRESS WHO TECH RE; 1993, 25 MIN HLTH SOC AFF; 1993, PROCEED CARE FINAL R; 1990, GUIDELINES RES SOMAT; 1991, INT DIGEST HLTH LEGI, V42, P338; 1994, B MED ETHICS, P19; 1994, ASSESSING GENETIC RI; 1993, B MED SUISSES, V74, P1454; 1993, INT DIGEST HLTH LEGI, V44, P57; 1993, INT DIGEST HLTH LEGI, V44, P363; 1992, CYSTIC FIBROSIS DNA; 1994, PATENTING HUMAN GENE; 1993, INT DIGEST HLTH LEG, V44, P247; 1993, INT DIGEST HLTH LEGI, V44, P753; 1991, GENETICS CANADIAN HL; 1994, B MED ETHICS, P8; 1993, GENETIC INFORMATION; 1992, GENETIC MONITORING S; 1991, INT DIGEST HLTH LEG, V42, P60; 1993, 27C45 UN DOC; 1992, GENETIC WITNESS FORE; 1990, B MED ETHICS, P8; 1992, GENETIC TESTING PRIV; 1992, INT DIGEST HLTH LEGI, V43, P284; 1994, INT DIGEST HLTH LEGI, V45, P150; 1994, INT DIGEST HLTH LEGI, V45, P130	36	49	49	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 30	1994	265	5181					2035	2036		10.1126/science.8091225	http://dx.doi.org/10.1126/science.8091225			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PJ912	8091225				2022-12-28	WOS:A1994PJ91200020
J	LYNCH, A; MARLAR, R; MURPHY, J; DAVILA, G; SANTOS, M; RUTLEDGE, J; EMLEN, W				LYNCH, A; MARLAR, R; MURPHY, J; DAVILA, G; SANTOS, M; RUTLEDGE, J; EMLEN, W			ANTIPHOSPHOLIPID ANTIBODIES IN PREDICTING ADVERSE PREGNANCY OUTCOME - A PROSPECTIVE-STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						ANTIBODIES, ANTIPHOSPHOLIPID; PREGNANCY COMPLICATION; BIRTH WEIGHT; APGAR SCORE; FETAL DEATH	SYSTEMIC LUPUS-ERYTHEMATOSUS; ANTICARDIOLIPIN ANTIBODIES; FETAL LOSS; CLINICAL-SIGNIFICANCE; ANTI-CARDIOLIPIN; IMMUNOGLOBULIN-G; ANTICOAGULANT; PREVALENCE; ASSOCIATION; THROMBOSIS	Objective: To determine if the presence of antiphospholipid antibody (aPL) in healthy pregnant women is associated with adverse pregnancy outcome, including 1) intrauterine fetal loss, 2) maternal pregnancy complications, 3) low birth weight, and 4) low 5-minute Apgar scores. Design: Prospective cohort study in women with normal pregnancies. Setting: Obstetrics clinic at the University of Colorado Health Sciences Center. Patients: Eligible patients included 451 low-risk, nulliparous pregnant women who came to the obstetrics clinic before 25 weeks gestation; 408 were enrolled and 389 had blood drawn at the first prenatal visit and completed clinical follow-up. Measurements: Blood for six aPL measures was drawn at the first prenatal visit and for 239 patients at delivery. Results: Ninety-five patients (24.4%) had elevated aPL levels by one or more measures at the first prenatal visit: 15.8% of the aPL-positive and 6.5% of the aPL-negative patients experienced fetal loss (relative risk, 2.44; 95% CI, 1.29 to 4.62). However, an elevated IgG anticardiolipin antibody level at the first prenatal visit was the only aPL measurement that was significantly associated with fetal loss (relative risk, 3.5; CI, 1.56 to 8.07). Adjustment for confounding variables decreased the relative risk of aPL for fetal loss slightly, but the difference remained statistically significant. Neither a positive aPL result at the initial visit nor a positive result at delivery was associated with maternal complications of pregnancy, low birth weight, or low Apgar scores. Conclusions: Patients with elevated aPL levels at their initial prenatal visit had an increase in fetal loss but no increase in maternal pregnancy complications, low birth weight, or low Apgar scores. Immunoglobulin G anticardiolipin antibody was the only single test of aPL significantly associated with fetal loss.	REAADS MED PROD, WESTMINSTER, CO 80234 USA		LYNCH, A (corresponding author), UNIV COLORADO, HLTH SCI CTR, DIV RHEUMATOL, BOX B115, 4200 E 9TH AVE, DENVER, CO 80262 USA.							ALARCONSEGOVIA D, 1989, J RHEUMATOL, V16, P482; BONNAR J, 1977, RECENT ADV BLOOD COA, P363; BRANCH DW, 1989, OBSTET GYNECOL, V73, P541; BRANCH DW, 1990, AM J OBSTET GYNECOL, V163, P210, DOI 10.1016/S0002-9378(11)90700-5; BROWN HL, 1990, 10TH SOC PER OBST AN; FEINSTEIN DI, 1992, BLOOD, V80, P859; FORT JG, 1987, ARTHRITIS RHEUM, V30, P752, DOI 10.1002/art.1780300705; GABBE SG, 1986, OBSTETRICS NORMAL PR; GALLI M, 1990, LANCET, V335, P1544, DOI 10.1016/0140-6736(90)91374-J; HARRIS EN, 1991, AM J OBSTET GYNECOL, V165, P1272; HARRIS EN, 1983, LANCET, V2, P1211; HARRIS EN, 1986, ARCH INTERN MED, V146, P2153, DOI 10.1001/archinte.146.11.2153; HULL RG, 1984, ANN RHEUM DIS, V43, P746, DOI 10.1136/ard.43.5.746; INFANTERIVARD C, 1991, NEW ENGL J MED, V325, P1063, DOI 10.1056/NEJM199110103251503; KEANE A, 1987, BRIT J RHEUMATOL, V26, P346; LASKIN CA, 1988, J RHEUMATOL, V15, P7; LEVINE SR, 1987, ARCH NEUROL-CHICAGO, V44, P876, DOI 10.1001/archneur.1987.00520200078024; LOCKSHIN MD, 1985, NEW ENGL J MED, V313, P152, DOI 10.1056/NEJM198507183130304; LOCKSHIN MD, 1987, J RHEUMATOL, V14, P259; LOCKSHIN MD, 1992, ARTHRITIS RHEUM, V35, P1234, DOI 10.1002/art.1780351017; LOCKWOOD CJ, 1989, AM J OBSTET GYNECOL, V161, P369, DOI 10.1016/0002-9378(89)90522-X; LOPEZ LR, 1992, AM J CLIN PATHOL, V98, P449, DOI 10.1093/ajcp/98.4.449; LOVE PE, 1990, ANN INTERN MED, V112, P682, DOI 10.7326/0003-4819-112-9-682; MANOUSSAKIS MN, 1987, CLIN EXP IMMUNOL, V69, P557; MCNEIL HP, 1991, ADV IMMUNOL, V49, P193; MCNEIL HP, 1990, P NATL ACAD SCI USA, V87, P4120, DOI 10.1073/pnas.87.11.4120; MULHALL BP, 1989, J CLIN IMMUNOL, V9, P208, DOI 10.1007/BF00916816; ONT HJ, 1992, AM J OBSTET GYNECOL, V167, P26; PARKE AL, 1991, ARTHRITIS RHEUM, V34, P1231, DOI 10.1002/art.1780341005; PETRI M, 1987, ANN INTERN MED, V106, P524, DOI 10.7326/0003-4819-106-4-524; POLZIN WJ, 1991, OBSTET GYNECOL, V78, P1108; RAUCH J, 1989, THROMB HAEMOSTASIS, V62, P892; ROBINSON RD, 1992, 5TH INT S ANT ANT SA; ROTE NS, 1992, AM J REPROD IMMUNOL, V28, P31, DOI 10.1111/j.1600-0897.1992.tb00753.x; SHI W, 1990, AUST NZ J MED, V20, P231, DOI 10.1111/j.1445-5994.1990.tb01025.x; TATE G, 1984, LANCET, V2, P587; TRIPLETT DA, 1989, AM J REPROD IMMUNOL, V20, P52, DOI 10.1111/j.1600-0897.1989.tb00639.x; ZARRABI MH, 1979, ANN INTERN MED, V91, P194, DOI 10.7326/0003-4819-91-2-194	38	172	177	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1994	120	6					470	475		10.7326/0003-4819-120-6-199403150-00004	http://dx.doi.org/10.7326/0003-4819-120-6-199403150-00004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NB625	8093135				2022-12-28	WOS:A1994NB62500004
J	COLEMAN, R; TREMBATH, RC; HARPER, JI				COLEMAN, R; TREMBATH, RC; HARPER, JI			CHROMOSOME 11Q13 AND ATOPY UNDERLYING ATOPIC ECZEMA	LANCET			English	Note								Genetic linkage has been reported between atopic respiratory disease and chromosome site 11q13. We recruited 95 multiplex families through probands with active atopic eczema. Linkage analyses between atopy and markers on 11q13 excluded a major susceptibility locus for atopy in this region. Nor was there significant deviation from the expected proportions of alleles shared by affected sib-pairs. When we analysed families according to parental atopic phenotype, we observed a positive lod score (0.8) in 19 families with unaffected fathers, in contrast to markedly negative scores for other combinations of affected parental phenotype. The possibility of a maternal influence on the inheritance of atopy cannot, therefore, be excluded.	HOSP SICK CHILDREN, DEPT DERMATOL, GREAT ORMOND ST, LONDON WC1N 3JH, ENGLAND; INST CHILD HLTH, MOTHERCARE UNIT CLIN GENET & FETAL MED, LONDON WC1N 1EH, ENGLAND; UNIV LEICESTER, DEPT MED, LEICESTER LE1 7RH, ENGLAND; UNIV LEICESTER, DEPT GENET, LEICESTER LE1 7RH, ENGLAND	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; University of Leicester; University of Leicester				Trembath, Richard/0000-0003-0550-3400				BRAY GEORGE W., 1931, JOUR ALLERGY, V2, P205, DOI 10.1016/S0021-8707(31)90069-5; COOKSON WOCM, 1988, LANCET, V1, P86; COOKSON WOCM, 1992, LANCET, V340, P381, DOI 10.1016/0140-6736(92)91468-N; COOKSON WOCM, 1989, LANCET, V1, P1292; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; ITO K, 1992, JAP J ALLERGOL, V4, P444; IWASAKI H, 1992, GENOMICS, V13, P7, DOI 10.1016/0888-7543(92)90194-W; SANDFORD AJ, 1993, LANCET, V341, P332, DOI 10.1016/0140-6736(93)90136-5; UEHARA M, 1989, ACTA DERM-VENEREOL, P78; VICKERS CFH, 1980, ACTA DERM-VENEREOL, V92, P113	10	66	67	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 1	1993	341	8853					1121	1122		10.1016/0140-6736(93)93130-S	http://dx.doi.org/10.1016/0140-6736(93)93130-S			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ687	8097806				2022-12-28	WOS:A1993KZ68700006
J	PHILLIPS, DIW				PHILLIPS, DIW			TWIN STUDIES IN MEDICAL-RESEARCH - CAN THEY TELL US WHETHER DISEASES ARE GENETICALLY-DETERMINED	LANCET			English	Editorial Material							BIRTH-WEIGHT				PHILLIPS, DIW (corresponding author), SOUTHAMPTON GEN HOSP,METAB PROGRAMMING GRP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND.							Barker DJP, 1992, FETAL INFANT ORIGINS; BLEKER OP, 1979, BRIT J OBSTET GYNAEC, V86, P111, DOI 10.1111/j.1471-0528.1979.tb10577.x; Bulmer M. G., 1970, BIOL TWINNING MAN; COREY LA, 1979, ACTA GENET MED GEMEL, V28, P41, DOI 10.1017/S0001566000009326; GRUENWALD P, 1970, BIOL NEONATE, V15, P79; NAEYE RL, 1966, PEDIATRICS, V37, P409; PHILLIPS DIW, IN PRESS Q J MED; PRICE B, 1950, AM J HUM GENET, V2, P293; PROPPING P, 1976, ACTA GENET MED GEMEL, V25, P249, DOI 10.1017/S0001566000014215; RAMOSARROYO MA, 1988, ACTA GENET MED GEMEL, V37, P229, DOI 10.1017/S0001566000003834; SEIDMAN DS, 1991, ARCH DIS CHILD, V66, P584, DOI 10.1136/adc.66.5.584	11	181	181	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 17	1993	341	8851					1008	1009		10.1016/0140-6736(93)91086-2	http://dx.doi.org/10.1016/0140-6736(93)91086-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY368	8096890				2022-12-28	WOS:A1993KY36800017
J	CROUSE, JR				CROUSE, JR			ISCHEMIC-HEART-DISEASE - REDUCED HEIGHT FOR WEIGHT AND CARDIOVASCULAR-DISEASE	LANCET			English	Editorial Material							MORTALITY; OBESITY				CROUSE, JR (corresponding author), WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT MED,WINSTON SALEM,NC 27103, USA.							BARKER DJP, 1986, LANCET, V1, P1077; BENSHLOMO Y, 1991, LANCET, V337, P530, DOI 10.1016/0140-6736(91)91307-G; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; KAPLAN NM, 1989, ARCH INTERN MED, V149, P1514, DOI 10.1001/archinte.149.7.1514; RAVELLI GP, 1976, NEW ENGL J MED, V295, P349, DOI 10.1056/NEJM197608122950701; SMITH GD, 1990, J EPIDEMIOL COMMUN H, V44, P265, DOI 10.1136/jech.44.4.265	6	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 10	1993	341	8850					931	932		10.1016/0140-6736(93)91218-B	http://dx.doi.org/10.1016/0140-6736(93)91218-B			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW981	8096271				2022-12-28	WOS:A1993KW98100010
J	KELLER, RJ; EISENBARTH, GS; JACKSON, RA				KELLER, RJ; EISENBARTH, GS; JACKSON, RA			INSULIN PROPHYLAXIS IN INDIVIDUALS AT HIGH-RISK OF TYPE-I DIABETES	LANCET			English	Note							CELL ACTIVITY	Prevention of type I diabetes is now a practical goal thanks to the ability to define confidently a high-risk group and the success of preventive strategies in animal models. We describe here a pilot trial of low-dose insulin to prevent diabetes in relatives of patients with type I diabetes.	JOSLIN DIABET CTR,BOSTON,MA; BRIGHAM & WOMENS HOSP,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; BARBARA DAVIS CTR CHILDHOOD DIABET,DENVER,CO	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	KELLER, RJ (corresponding author), CHILDRENS HOSP MED CTR,DIV ENDOCRINOL,300 LONGWOOD AVE,BOSTON,MA 02115, USA.							APPEL MC, 1989, DIABETOLOGIA, V32, pA461; ATKINSON MA, 1990, DIABETES, V39, P933, DOI 10.2337/diabetes.39.8.933; GOTFREDSEN CF, 1985, DIABETOLOGIA, V28, P933, DOI 10.1007/BF00703140; JACKSON R, 1988, CLIN RES, V36, pA585; PALMER JP, 1989, DIABETES, V38, P1211, DOI 10.2337/diabetes.38.10.1211; SHAN SC, 1989, NEW ENGL J MED, V320, P550; VARDI P, 1987, DIABETES, V36, P1286, DOI 10.2337/diabetes.36.11.1286; ZIEGLER AG, 1990, DIABETES CARE, V13, P762, DOI 10.2337/diacare.13.7.762; 1992, LANCET, V339, P1512	9	298	310	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 10	1993	341	8850					927	928		10.1016/0140-6736(93)91215-8	http://dx.doi.org/10.1016/0140-6736(93)91215-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW981	8096268				2022-12-28	WOS:A1993KW98100007
J	GONZALEZ, P; AGUADO, JM; MARTIN, MA; FERNANDEZCHACON, T; ORTUNO, B				GONZALEZ, P; AGUADO, JM; MARTIN, MA; FERNANDEZCHACON, T; ORTUNO, B			ONCE-DAILY AMINOGLYCOSIDE DOSING	LANCET			English	Letter									HOSP 12 OCTUBRE,DEPT BIOCHEM & NUCL MED,INFECT DIS UNIT,E-28041 MADRID,SPAIN	Hospital Universitario 12 de Octubre	GONZALEZ, P (corresponding author), HOSP 12 OCTUBRE,DEPT MICROBIOL,INFECT DIS UNIT,E-28041 MADRID,SPAIN.		Martin, Miguel A/S-2758-2018	Martin, Miguel A/0000-0003-4741-772X				GIBEY R, 1981, CLIN CHIM ACTA, V116, P25, DOI 10.1016/0009-8981(81)90165-0	1	12	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 3	1993	341	8849					895	895						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KV811	8096594				2022-12-28	WOS:A1993KV81100040
J	SLACK, JMW; HOLLAND, PWH; GRAHAM, CF				SLACK, JMW; HOLLAND, PWH; GRAHAM, CF			THE ZOOTYPE AND THE PHYLOTYPIC STAGE	NATURE			English	Editorial Material							DROSOPHILA HOMEOTIC GENES; PATTERN-FORMATION; HOMEOBOX; ORGANIZATION; HOMEODOMAIN; VERTEBRATES; EXPRESSION; MURINE		UNIV OXFORD,DEPT ZOOL,OXFORD OX1 3PS,ENGLAND	University of Oxford				Holland, Peter/0000-0003-1533-9376				BALLARD WW, 1981, AM ZOOL, V21, P391; Brusca R.C., 1990, INVERTEBRATES; CARRASCO AE, 1984, CELL, V37, P409, DOI 10.1016/0092-8674(84)90371-4; COSTA M, 1988, CELL, V55, P747, DOI 10.1016/0092-8674(88)90131-6; COWING DW, 1992, DEVELOPMENT, V116, P481; DEROBERTIS EM, 1991, DEVELOPMENT, V112, P669; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; FRASCH M, 1987, EMBO J, V6, P749, DOI 10.1002/j.1460-2075.1987.tb04817.x; GANS C, 1983, SCIENCE, V220, P268, DOI 10.1126/science.220.4594.268; GEHRING WJ, 1990, TRENDS GENET, V6, P323, DOI 10.1016/0168-9525(90)90253-3; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; Hall B. K., 1999, EVOLUTIONARY DEV BIO; HAMILTON WJ, 1976, HUMAN EMBRYOLOGY; HOLLAND PWH, 1992, DEVELOPMENT, V116, P653; KESSEL M, 1992, DEVELOPMENT, V115, P487; KRUMLAUF R, 1992, BIOESSAYS, V14, P245, DOI 10.1002/bies.950140408; Lawrence P., 1992, MAKING FLY GENETICS; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; Margulis L., 1988, 5 KINGDOMS ILLUSTRAT; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; NARDELLHAEFLIGER D, 1992, DEVELOPMENT, V116, P697; PATEL NH, 1992, NATURE, V357, P339, DOI 10.1038/357339a0; RAFF RA, 1987, DEV BIOL, V119, P6, DOI 10.1016/0012-1606(87)90201-6; Sander K., 1976, Advances in insect physiology. Volume 12., P125, DOI 10.1016/S0065-2806(08)60255-6; Sander K., 1983, DEV EVOLUTION, P137; SCHUMMER M, 1992, EMBO J, V11, P1815, DOI 10.1002/j.1460-2075.1992.tb05233.x; SCOTT MP, 1992, CELL, V71, P551, DOI 10.1016/0092-8674(92)90588-4; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; Seidel F., 1960, ZOOL ANZ, V164, P245; SHASHIKANT C S, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P207; SIMEONE A, 1992, NATURE, V358, P687, DOI 10.1038/358687a0; SLACK J, 1984, NATURE, V310, P364, DOI 10.1038/310364a0; SLACK JMW, 1980, J THEOR BIOL, V82, P105, DOI 10.1016/0022-5193(80)90092-2; WEBSTER PJ, 1992, MECH DEVELOP, V38, P25, DOI 10.1016/0925-4773(92)90035-I; Willmer P., 1990, INVERTEBRATE RELATIO; WOLPERT L, 1969, J THEOR BIOL, V25, P1, DOI 10.1016/S0022-5193(69)80016-0; WYSOCKADILLER JW, 1989, NATURE, V341, P760, DOI 10.1038/341760a0	37	497	506	1	47	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 11	1993	361	6412					490	492		10.1038/361490a0	http://dx.doi.org/10.1038/361490a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL714	8094230				2022-12-28	WOS:A1993KL71400028
J	SANDFORD, AJ; SHIRAKAWA, T; MOFFATT, MF; DANIELS, SE; RA, C; FAUX, JA; YOUNG, RP; NAKAMURA, Y; LATHROP, GM; COOKSON, WOCM; HOPKIN, JM				SANDFORD, AJ; SHIRAKAWA, T; MOFFATT, MF; DANIELS, SE; RA, C; FAUX, JA; YOUNG, RP; NAKAMURA, Y; LATHROP, GM; COOKSON, WOCM; HOPKIN, JM			LOCALIZATION OF ATOPY AND BETA-SUBUNIT OF HIGH-AFFINITY IGE RECEPTOR (FC-EPSILON-RI) ON CHROMOSOME-11Q	LANCET			English	Article							IMMUNOGLOBULIN-E; SERUM IGE; LYMPHOKINES; LINKAGE; ASTHMA	Atopy, a common familial syndrome underlying allergic asthma and rhinitis, is characterised by sustained immunoglobulin E (IgE) responses to common allergens. We have previously shown genetic linkage of atopy to the chromosome 11q13 marker D11S97 (pms51) through maternally derived alleles, but no likely candidate genes were known to lie near this marker. We have analysed maternally derived alleles from 155 sibling-pairs affected by atopy to seek evidence of linkage between the gene predisposing to atopy and other markers on chromosome 11q13. We found that the beta subunit of the high-affinity receptor for IgE (FcepsilonRI-beta) also lies on chromosome 11q13, and that it is in close genetic linkage with the gene for atopy. The known roles of FcepsilonRI in antigen-induced mast-cell degranulation and in the release of cytokines that enhance IgE production make the gene for its beta subunit a candidate for the chromosome 11 atopy locus.	JOHN RADCLIFFE HOSP,NUFFIELD DEPT MED,OXFORD OX3 9DU,ENGLAND; JUNTENDO UNIV,SCH MED,DEPT IMMUNOL,TOKYO 113,JAPAN; JAPANESE FDN CANC RES,INST CANC,DIV BIOCHEM,TOKYO 170,JAPAN; CTR ETUD POLYMORPHISME HUMAINE,PARIS,FRANCE; CHURCHILL HOSP,OSLER CHEST UNIT,OXFORD OX3 7LJ,ENGLAND	University of Oxford; Juntendo University; Japanese Foundation for Cancer Research; University of Oxford			Cookson, William/HHC-1790-2022		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARSHAD SH, 1992, LANCET, V339, P1493, DOI 10.1016/0140-6736(92)91260-F; BENSASSON SZ, 1990, P NATL ACAD SCI USA, V87, P1421, DOI 10.1073/pnas.87.4.1421; BIEBER T, 1992, J EXP MED, V175, P1285, DOI 10.1084/jem.175.5.1285; BLACKWELDER W C, 1985, Genetic Epidemiology, V2, P85, DOI 10.1002/gepi.1370020109; CLINE MG, 1989, THORAX, V44, P425, DOI 10.1136/thx.44.5.425; COOKSON WOCM, 1992, LANCET, V340, P381, DOI 10.1016/0140-6736(92)91468-N; COOKSON WOCM, 1989, LANCET, V1, P1292; HOLFORDSTREVENS V, 1984, J ALLERGY CLIN IMMUN, V73, P516, DOI 10.1016/0091-6749(84)90363-4; HUPP K, 1989, J IMMUNOL, V143, P3787; JULIER C, 1990, GENOMICS, V7, P335, DOI 10.1016/0888-7543(90)90167-S; KINET JP, 1988, P NATL ACAD SCI USA, V85, P6483, DOI 10.1073/pnas.85.17.6483; KJELLMAN NIM, 1976, CLIN ALLERGY, V6, P51, DOI 10.1111/j.1365-2222.1976.tb01411.x; KUSTER H, 1992, J BIOL CHEM, V267, P12782; LEE DA, 1983, BRIT MED J, V286, P1256, DOI 10.1136/bmj.286.6373.1256; MAGNUSSON CGM, 1988, ALLERGY, V43, P241, DOI 10.1111/j.1398-9995.1988.tb00896.x; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RUIZ RGG, 1992, CLIN EXP ALLERGY, V22, P762, DOI 10.1111/j.1365-2222.1992.tb02816.x; SHIRAKAWA T, 1991, CYTOGENET CELL GENET, V58, P1970; TANIGAMI A, 1992, AM J HUM GENET, V50, P56; TOKINO T, 1991, AM J HUM GENET, V48, P258; WANG B, 1992, J EXP MED, V175, P1353, DOI 10.1084/jem.175.5.1353; WAYE JS, 1987, HUM GENET, V77, P151, DOI 10.1007/BF00272383; WILLIAMSON R, 1991, CYTOGENET CELL GENET, V58, P1190, DOI 10.1159/000133727; YOUNG RP, 1992, J MED GENET, V29, P236, DOI 10.1136/jmg.29.4.236	25	259	273	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 6	1993	341	8841					332	334		10.1016/0140-6736(93)90136-5	http://dx.doi.org/10.1016/0140-6736(93)90136-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK939	8094113				2022-12-28	WOS:A1993KK93900004
J	KLEUSS, C; SCHERUBL, H; HESCHELER, J; SCHULTZ, G; WITTIG, B				KLEUSS, C; SCHERUBL, H; HESCHELER, J; SCHULTZ, G; WITTIG, B			SELECTIVITY IN SIGNAL TRANSDUCTION DETERMINED BY GAMMA-SUBUNITS OF HETEROTRIMERIC G-PROTEINS	SCIENCE			English	Article							ROD OUTER SEGMENTS; K+-CHANNEL; BETA; DIVERSITY; PHOSPHOLIPASE-A2; INHIBITION; CURRENTS	Various heterotrimeric guanine nucleotide-binding proteins have been identified on the basis of the individual subtypes of their alpha subunits. The betagamma complexes, composed of beta and gamma subunits, remain tightly associated under physiological conditions and have been assumed to constitute a common pool shared among various guanosine triphosphate (GTP)-binding (G) protein heterotrimers. Particular alpha and beta subunit subtypes participate in the signal transduction processes between somatostatin or muscarinic receptors and the voltage-sensitive L-type calcium channel in rat pituitary GH3 cells. Among gamma subunits the gamma3 subtype was found to be required for coupling of the somatostatin receptor to voltage-sensitive calcium channels, whereas the gamma4 subtype was found to be required for coupling of the muscarinic receptor to those channels.	FREE UNIV BERLIN,INST MOLEK BIOL & BIOCHEM,ARNIMALLEE 22,W-1000 BERLIN 33,GERMANY; FREE UNIV BERLIN,INST PHARMAKOL,W-1000 BERLIN 33,GERMANY	Free University of Berlin; Free University of Berlin								[Anonymous], [No title captured]; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; CERIONE RA, 1987, BIOCHEMISTRY-US, V26, P1485, DOI 10.1021/bi00379a041; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; FISHER KJ, 1992, MOL CELL BIOL, V12, P1585, DOI 10.1128/MCB.12.4.1585; GAUTAM N, 1990, P NATL ACAD SCI USA, V87, P7973, DOI 10.1073/pnas.87.20.7973; GAUTAM N, 1989, SCIENCE, V244, P971, DOI 10.1126/science.2499046; HELENE C, 1990, BIOCHIM BIOPHYS ACTA, V1049, P99, DOI 10.1016/0167-4781(90)90031-V; HILDEBRANDT JD, 1985, J BIOL CHEM, V260, P4867; HURLEY JB, 1984, P NATL ACAD SCI-BIOL, V81, P6948, DOI 10.1073/pnas.81.22.6948; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623, DOI 10.1073/pnas.84.11.3623; KIM D, 1989, NATURE, V337, P557, DOI 10.1038/337557a0; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KURACHI Y, 1989, NATURE, V337, P555, DOI 10.1038/337555a0; PRONIN AN, 1992, P NATL ACAD SCI USA, V89, P6220, DOI 10.1073/pnas.89.13.6220; ROSENTHAL W, 1988, EMBO J, V7, P1627, DOI 10.1002/j.1460-2075.1988.tb02989.x; SCHMIDT CJ, 1992, J BIOL CHEM, V267, P13807; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; TAMIR H, 1991, BIOCHEMISTRY-US, V30, P3929, DOI 10.1021/bi00230a018	22	368	376	3	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 5	1993	259	5096					832	834		10.1126/science.8094261	http://dx.doi.org/10.1126/science.8094261			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL110	8094261				2022-12-28	WOS:A1993KL11000039
J	DIMOPOULOS, MA; KANTARJIAN, H; ESTEY, E; OBRIEN, S; DELASALLE, K; KEATING, MJ; FREIREICH, EJ; ALEXANIAN, R				DIMOPOULOS, MA; KANTARJIAN, H; ESTEY, E; OBRIEN, S; DELASALLE, K; KEATING, MJ; FREIREICH, EJ; ALEXANIAN, R			TREATMENT OF WALDENSTROM MACROGLOBULINEMIA WITH 2-CHLORODEOXYADENOSINE	ANNALS OF INTERNAL MEDICINE			English	Article						WALDENSTROM MACROGLOBULINEMIA; 2-CHLORODEOXYADENOSINE; ANEMIA; WEIGHT LOSS; FEVER	HAIRY-CELL LEUKEMIA; INTERFERON; THERAPY; MYELOMA	Objective: To evaluate the activity of 2-chlorodeoxyadenosine (2CdA) in the treatment of patients with Waldenstrom macroglobulinemia. Design: Uncontrolled phase II trial. Setting: Tertiary, referral cancer center. Patients: Twenty-nine consecutive, symptomatic patients with Waldenstrom macroglobulinemia, of whom 9 were previously untreated. Intervention: 2-Chlorodeoxyadenosine was administered as a continuous intravenous infusion at a dose of 0.1 mg/kg body weight per day for 7 days. Only two courses of 2CdA were given and responding patients were then followed without further treatment. Measurements and Main Results: A total of 17 (59%) patients responded, including all of those who were newly diagnosed and 40% of those who had failed previous therapies. Treatment was well tolerated except for one death in a patient who had presented with severe pancytopenia. With a median follow-up of 7 months, only one responding patient has relapsed. Conclusion: 2-Chlorodeoxyadenosine is a nucleoside analog that was effective in most patients with Waldenstrom macroglobulinemia and was associated with little toxicity.			DIMOPOULOS, MA (corresponding author), UNIV TEXAS, MD ANDERSON CANC CTR, BOX 1, 1515 HOLCOMBE BLVD, HOUSTON, TX 77030 USA.		Dimopoulos, Meletios Athanasios/AAD-4130-2019	Dimopoulos, Meletios/0000-0001-8990-3254				ANDERSON KC, 1985, BLOOD, V65, P620; BEUTLER E, 1991, LEUKEMIA LYMPHOMA, V5, P1, DOI 10.3109/10428199109068099; BRUERA E, 1986, CANCER TREAT REP, V70, P545; CASE DC, 1991, CANCER INVEST, V9, P1, DOI 10.3109/07357909109032794; CLAMON GH, 1980, AM J HEMATOL, V9, P221, DOI 10.1002/ajh.2830090210; ESTEY EH, 1992, BLOOD, V79, P882; HORSMAN DE, 1983, AM J HEMATOL, V15, P97, DOI 10.1002/ajh.2830150111; JANE SM, 1988, AUST NZ J MED, V18, P77, DOI 10.1111/j.1445-5994.1988.tb02249.x; KANTARJIAN HM, 1990, BLOOD, V75, P1928; MACKENZIE MR, 1972, BLOOD-J HEMATOL, V39, P874, DOI 10.1182/blood.V39.6.874.874; MCLAUGHLIN P, 1982, BLOOD, V60, P851; OHNO R, 1985, CANCER CHEMOTH PHARM, V14, P34, DOI 10.1007/BF00552722; PETRUCCI MT, 1989, J INTERN MED, V226, P443, DOI 10.1111/j.1365-2796.1989.tb01422.x; PIRO LD, 1990, NEW ENGL J MED, V322, P1117, DOI 10.1056/NEJM199004193221605; PIRO LD, 1988, BLOOD, V72, P1069; QUESADA JR, 1988, AM J HEMATOL, V29, P1, DOI 10.1002/ajh.2830290102; [No title captured]	17	111	111	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1993	118	3					195	198		10.7326/0003-4819-118-3-199302010-00007	http://dx.doi.org/10.7326/0003-4819-118-3-199302010-00007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ439	8093333				2022-12-28	WOS:A1993KJ43900007
J	PORRECO, RP; HICKOK, DE; WILLIAMS, MA; KRENNING, C				PORRECO, RP; HICKOK, DE; WILLIAMS, MA; KRENNING, C			LOW-DOSE ASPIRIN AND HYPERTENSION IN PREGNANCY	LANCET			English	Letter							PREVENTION; FETAL; RISK				PORRECO, RP (corresponding author), ROCKY MT PERINATAL ASSOCIATES,1601 E 19TH AVE,SUITE 6500,DENVER,CO 80218, USA.							BENIGNI A, 1989, NEW ENGL J MED, V321, P357, DOI 10.1056/NEJM198908103210604; COLLINS R, 1989, EFFECTIVE CARE PREGN, V1, P512; COLLINS R, 1991, OXFORD DATABASE PERI; IMPERIALE TF, 1991, JAMA-J AM MED ASSOC, V266, P261; SCHIFF E, 1989, NEW ENGL J MED, V321, P351, DOI 10.1056/NEJM198908103210603; SIBAI BM, 1989, OBSTET GYNECOL, V74, P551; UZAN S, 1991, LANCET, V337, P1427, DOI 10.1016/0140-6736(91)93124-R	7	11	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 30	1993	341	8840					312	312		10.1016/0140-6736(93)92672-G	http://dx.doi.org/10.1016/0140-6736(93)92672-G			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK245	8093955				2022-12-28	WOS:A1993KK24500054
J	APPEL, LJ; STASON, WB				APPEL, LJ; STASON, WB			AMBULATORY BLOOD-PRESSURE MONITORING AND BLOOD-PRESSURE SELF-MEASUREMENT IN THE DIAGNOSIS AND MANAGEMENT OF HYPERTENSION	ANNALS OF INTERNAL MEDICINE			English	Review						HYPERTENSION; BLOOD PRESSURE MONITORS; AMBULATORY CARE; CARDIOVASCULAR DISEASES; ANTIHYPERTENSIVE AGENTS	LEFT-VENTRICULAR MASS; CORONARY HEART-DISEASE; SOCIETY PROTOCOL; ANTIHYPERTENSIVE THERAPY; MODERATE HYPERTENSION; MEASURING DEVICES; CARDIAC-FUNCTION; HOME; MILD; ACCURACY	Objective: To review published evidence on the use of ambulatory and self-measurement devices in the diagnosis and management of hypertension. Data Sources: Computerized literature searches and manual review of bibliographies. Study Selection: Articles documenting original research pertaining to the diagnosis, treatment, or prognosis of hypertension using ambulatory or self-measurement devices. Results: Studies that have compared office, self-measured, and ambulatory blood pressures have documented substantial, but nonsystematic, differences. Such findings have raised concern over the appropriateness of diagnosing hypertension and initiating drug therapy in individuals with high office blood pressure but comparatively low self-measured or ambulatory blood pressure (''office'' or ''white coat'' hypertension). Evidence from a large number of cross-sectional studies and a single prospective study suggests that blood pressure- related end-organ damage is more closely associated with ambulatory than with office blood pressure. Less evidence supports self-measured blood pressure in this regard, and data are insufficient to compare ambulatory and self-measured blood pressure in terms of cardiovascular disease risk prediction. The estimated resource cost of an ambulatory blood pressure test is approximately $120, whereas charges range from $100 to $450. The annualized resource cost of blood pressure self-measurement is $50 or less. On a national level, the annual direct costs of ambulatory blood pressure monitoring could be as high as $6 billion, if this technique were used routinely to diagnose and monitor hypertensive patients. The extent to which direct costs would be offset by savings from less frequent or more efficient treatment for hypertension cannot be estimated reliably. Several practical and technical issues also detract from the potential usefulness of ambulatory and self-measurement devices. Finally, there is some evidence that office blood pressures measured by well-trained nonphysicians may serve as an alternative to ambulatory and self-measurement techniques in estimating usual blood pressure. Conclusion: Limited clinical applications of ambulatory blood pressure monitoring and blood pressure self-measurement in the diagnosis and management of hypertension appear to be warranted. Endorsement of these technologies for routine clinical use, however, will require more convincing evidence of their clinical effectiveness.	JOHNS HOPKINS UNIV, SCH MED, BALTIMORE, MD 21205 USA; HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA	Johns Hopkins University; Harvard University; Harvard T.H. Chan School of Public Health			Appel, Larry/GLT-2608-2022		NHLBI NIH HHS [K08HL02642] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002642] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALDERMAN MH, 1981, HYPERTENSION, V3, P192, DOI 10.1161/01.HYP.3.2.192; ALDERMAN MH, 1990, J CLIN EPIDEMIOL, V43, P195, DOI 10.1016/0895-4356(90)90185-R; ANDERSEN AR, 1981, ACTA MED SCAND, V670, P97; ANTIVALLE M, 1986, J HYPERTENS       S5, V4, pS322; APPEL LJ, 1991, JAMA-J AM MED ASSOC, V266, P2226; Ayman D, 1940, AM J MED SCI, V200, P462; BABA S, 1990, J HYPERTENS, V8, P647, DOI 10.1097/00004872-199007000-00008; BATTIG B, 1989, J HYPERTENS, V7, pS59; BAUWENS F, 1992, INT J CARDIOL, V34, P335, DOI 10.1016/0167-5273(92)90032-X; BECKMAN M, 1981, ACTA MED SCAND, V210, P97; BIALY GB, 1988, ANGIOLOGY, V39, P752, DOI 10.1177/000331978803900808; BOTTINI PB, 1992, ARCH INTERN MED, V152, P139, DOI 10.1001/archinte.152.1.139; BROADHURST P, 1990, J HYPERTENS, V8, P595, DOI 10.1097/00004872-199007000-00002; BRUCE NG, 1988, J HYPERTENS, V6, P375; BURKE MJ, 1982, BRIT MED J, V285, P469, DOI 10.1136/bmj.285.6340.469; BURRIS JF, 1988, JAMA-J AM MED ASSOC, V260, P2508, DOI 10.1001/jama.1988.03410170056027; CARNAHAN JE, 1975, AM J MED SCI, V269, P69, DOI 10.1097/00000441-197501000-00008; CASALE PN, 1986, ANN INTERN MED, V105, P173, DOI 10.7326/0003-4819-105-2-173; CERASOLA G, 1989, J HYPERTENS, V7, pS332, DOI 10.1097/00004872-198900076-00162; CHEUNG DG, 1989, ARCH INTERN MED, V149, P2021, DOI 10.1001/archinte.149.9.2021; CLARK LA, 1987, PSYCHOPHYSIOLOGY, V24, P119, DOI 10.1111/j.1469-8986.1987.tb01872.x; CLEMENT DL, 1991, J HYPERTENS, V9, pS51; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; CORCORAN AC, 1955, ANN INTERN MED, V43, P1161, DOI 10.7326/0003-4819-43-6-1161; COX J, 1991, J HYPERTENS, V9, pS3; CREEVY PC, 1985, JAMA-J AM MED ASSOC, V254, P2411, DOI 10.1001/jama.1985.03360170051020; DEBLOK K, 1991, J HYPERTENS, V9, pS106; DESCOMBES BJ, 1984, HYPERTENSION, V6, P110, DOI 10.1161/01.HYP.6.1.110; DEVEREUX RB, 1983, CIRCULATION, V68, P470, DOI 10.1161/01.CIR.68.3.470; DIMMITT SB, 1989, LANCET, V1, P1103; DRAYER JIM, 1985, ARCH INTERN MED, V145, P271, DOI 10.1001/archinte.145.2.271; DRAYER JIM, 1983, ARCH INTERN MED, V143, P90, DOI 10.1001/archinte.143.1.90; DRAYER JIM, 1987, HYPERTENSION, V9, P61; ENSTROM I, 1991, J HYPERTENS, V9, P561, DOI 10.1097/00004872-199106000-00012; EVANS CE, 1989, J HYPERTENS, V7, P133; FITZGERALD DJ, 1985, IRISH MED J, V78, P216; FLAPAN AD, 1987, J HYPERTENS       S5, V5, pS491; FORROW L, 1988, JAMA-J AM MED ASSOC, V259, P3161, DOI 10.1001/jama.259.21.3161; FROHLICH ED, 1988, CIRCULATION, V11, pA501; GIACONI S, 1989, AM J HYPERTENS, V2, P259, DOI 10.1093/ajh/2.4.259; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; GILL JS, 1985, LANCET, V1, P567; GLANZ K, 1981, MED CARE, V19, P141, DOI 10.1097/00005650-198102000-00002; GOSSE P, 1986, J HYPERTENS, V4, pS297; GOSSE P, 1989, AM J HYPERTENS, V2, P78, DOI 10.1093/ajh/2.2.78; GOULD BA, 1982, BRIT MED J, V285, P1691, DOI 10.1136/bmj.285.6356.1691; HARSHFIELD GA, 1991, HDB RES METHODS CARD, P1; HAYNES RB, 1978, NEW ENGL J MED, V299, P741, DOI 10.1056/NEJM197810052991403; HAYNES RB, 1976, LANCET, V1, P1265; HOEGHOLM A, 1992, AM J HYPERTENS, V5, P64, DOI 10.1093/ajh/5.2.64; HUNT JC, 1985, ARCH INTERN MED, V145, P2231, DOI 10.1001/archinte.145.12.2231; IBRAHIM MM, 1977, ARCH INTERN MED, V137, P1125, DOI 10.1001/archinte.137.9.1125; JAMES GD, 1988, HYPERTENSION, V11, P545, DOI 10.1161/01.HYP.11.6.545; JOHNSON AL, 1978, CAN MED ASSOC J, V119, P1034; JULIUS S, 1964, J CHRON DIS, V17, P391, DOI 10.1016/0021-9681(64)90099-2; JULIUS S, 1990, HYPERTENSION, V16, P617, DOI 10.1161/01.HYP.16.6.617; JULIUS S, 1974, JAMA-J AM MED ASSOC, V229, P663, DOI 10.1001/jama.229.6.663; KENNY RA, 1987, J HYPERTENS, V5, P769, DOI 10.1097/00004872-198712000-00040; KLEINERT HD, 1984, HYPERTENSION, V6, P574, DOI 10.1161/01.HYP.6.4.574; KUWAJIMA I, 1992, AM HEART J, V123, P1307, DOI 10.1016/0002-8703(92)91038-3; LAHER MS, 1981, IRISH MED J, V74, P113; LAUGHLIN KD, 1980, J CHRON DIS, V33, P197, DOI 10.1016/0021-9681(80)90064-8; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; LEVY D, 1989, ANN INTERN MED, V110, P101, DOI 10.7326/0003-4819-110-2-101; LILLIENFELD AM, 1977, F EPIDEMIOLOGY, P65; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MANCIA G, 1983, LANCET, V2, P695; MANCIA G, 1987, HYPERTENSION, V6, P375; MANN SJ, 1991, JAMA-J AM MED ASSOC, V265, P2226, DOI 10.1001/jama.265.17.2226; MARABOTTI C, 1991, INT J CARDIOL, V31, P89, DOI 10.1016/0167-5273(91)90272-Q; MAROLF AP, 1987, NEPHRON, V47, P142, DOI 10.1159/000184574; MEJIA A, 1989, J HYPERTENS, V7, pS53; MEJIA AD, 1990, ARCH INTERN MED, V150, P1209, DOI 10.1001/archinte.150.6.1209; MENGDEN T, 1992, AM J HYPERTENS, V5, P154, DOI 10.1093/ajh/5.3.154; MEYERSABELLEK W, 1989, J HYPERTENS, V7, pS21; MIDANIK LT, 1991, PUBLIC HEALTH REP, V106, P85; MOULOPOULOS SD, 1990, AM HEART J, V119, P1147, DOI 10.1016/S0002-8703(05)80246-7; NIELSEN PE, 1986, ACTA MED SCAND, P147; OBRIEN E, 1991, J HYPERTENS, V9, P571; OBRIEN E, 1991, J HYPERTENS, V9, P573, DOI 10.1097/00004872-199106000-00016; OBRIEN E, 1990, J HYPERTENS, V8, P621, DOI 10.1097/00004872-199007000-00005; OBRIEN E, 1990, J HYPERTENS, V8, P607, DOI 10.1097/00004872-199007000-00004; OBRIEN E, 1991, J HYPERTENS, V9, P569, DOI 10.1097/00004872-199106000-00014; OBRIEN E, 1991, J HYPERTENS, V9, P567, DOI 10.1097/00004872-199106000-00013; OBRIEN E, 1988, J AMBULATORY MONITOR, V1, P285; OPSAHL JA, 1988, AM J HYPERTENS, V1, pS117, DOI 10.1093/ajh/1.3.117S; PADFIELD PL, 1987, LANCET, V2, P322; PALATINI P, 1985, J HYPERTENS, V3, pS425; PARATI G, 1987, J HYPERTENS, V5, P93, DOI 10.1097/00004872-198702000-00013; PEARCE KA, 1992, ARCH INTERN MED, V152, P750, DOI 10.1001/archinte.152.4.750; PERLMAN LV, 1970, ARCH INTERN MED, V125, P1000, DOI 10.1001/archinte.125.6.1000; PERLOFF D, 1989, J HYPERTENS, V7, pS3; PERLOFF D, 1983, JAMA-J AM MED ASSOC, V249, P2792, DOI 10.1001/jama.249.20.2792; PHILLIPS RA, 1989, J AM COLL CARDIOL, V14, P979, DOI 10.1016/0735-1097(89)90476-2; PHILLIPS RA, 1989, AM J CARDIOL, V64, pF62, DOI 10.1016/0002-9149(89)90748-0; PICKERING TG, 1988, JAMA-J AM MED ASSOC, V259, P225, DOI 10.1001/jama.259.2.225; PICKERING TG, 1982, JAMA-J AM MED ASSOC, V247, P992, DOI 10.1001/jama.247.7.992; PICKERING TG, 1992, ARCH INTERN MED, V152, P691, DOI 10.1001/archinte.152.4.691; PICKERING TG, 1986, J HYPERTENS, V4, pS328; POLK BF, 1980, HYPERTENSION, V2, P221, DOI 10.1161/01.HYP.2.2.221; PORCHET M, 1986, J CARDIOVASC PHARM, V8, P332, DOI 10.1097/00005344-198603000-00016; PRISANT LM, 1990, AM J HYPERTENS, V3, P81, DOI 10.1093/ajh/3.2.81; PRISANT LM, 1992, J HUM HYPERTENS, V6, P35; RAFERTY EB, 1974, HYPERTENSION ITS NAT, P219; RAVOGLI A, 1990, HYPERTENSION, V16, P491, DOI 10.1161/01.HYP.16.5.491; RICHARDSON JF, 1977, J R COLL GEN PRACT, V21, P698; RIZZONI D, 1992, AM J HYPERTENS, V5, P180, DOI 10.1093/ajh/5.3.180; ROCCELLA E, 1990, ARCH INTERN MED, V150, P2270; ROSE G, 1981, BMJ-BRIT MED J, V282, P1847, DOI 10.1136/bmj.282.6279.1847; ROSEN H, 1978, J AM OSTEOPATH ASSOC, V77, P373; RUDDY MC, 1988, J HYPERTENS, V6, pS412, DOI 10.1097/00004872-198812040-00129; SALAITA K, 1990, AM J HYPERTENS, V3, P366, DOI 10.1093/ajh/3.5.366; SCHERWITZ LW, 1982, MED CARE, V20, P727, DOI 10.1097/00005650-198207000-00008; SETARO JF, 1992, NEW ENGL J MED, V327, P543; SHIMADA K, 1990, HYPERTENSION, V16, P692, DOI 10.1161/01.HYP.16.6.692; SOKOLOW M, 1966, CIRCULATION, V34, P279; STAESSEN J, 1990, J HYPERTENS, V8, pS57; STASON WB, 1989, HYPERTENSION S1, V13, P145; VANDEWEIJGERT EJHM, 1992, NETH J MED, V40, P175; VERDECCHIA P, 1990, CIRCULATION, V81, P528, DOI 10.1161/01.CIR.81.2.528; VERMEERSCH P, 1987, J HYPERTENS       S5, V5, pS495; WAEBER B, 1987, LANCET, V2, P732; WEBER MA, 1988, JAMA-J AM MED ASSOC, V259, P3281, DOI 10.1001/jama.259.22.3281; WELIN L, 1982, ACTA MED SCAND, V211, P275; WHELTON PK, 1983, AM J EPIDEMIOL, V117, P46, DOI 10.1093/oxfordjournals.aje.a113514; WHITE LJ, 1986, ANN INTERN MED, V104, P275; WHITE WB, 1990, J HYPERTENS, V8, P591, DOI 10.1097/00004872-199007000-00001; WHITE WB, 1989, AM HEART J, V118, P782, DOI 10.1016/0002-8703(89)90593-0; WHITE WB, 1989, J HYPERTENS, V7, P967, DOI 10.1097/00004872-198912000-00007; WHITE WB, 1985, JAMA-J AM MED ASSOC, V253, P1724, DOI 10.1001/jama.253.12.1724; WHITE WB, 1990, AM J CARDIOL, V65, P60, DOI 10.1016/0002-9149(90)90026-W; WHITE WB, 1989, JAMA-J AM MED ASSOC, V261, P873; WHITE WB, 1989, AM J CARDIOL, V63, P1343, DOI 10.1016/0002-9149(89)91046-1; ZACHARIAH PK, 1988, MAYO CLIN PROC, V63, P1085, DOI 10.1016/S0025-6196(12)65503-7; 1992, CONSUMER REPORTS MAY, P295; 1960, ARCH INTERN MED, V106, P133; 1980, STATEMENT BLOOD PRES; 1987, ANSIAAMI SP101987 AM; 1990, J HYPERTENS, V8, pS135; 1987, CONSUMER REPORTS MAY, P314	140	176	180	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1993	118	11					867	882		10.7326/0003-4819-118-11-199306010-00008	http://dx.doi.org/10.7326/0003-4819-118-11-199306010-00008			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LD252	8093115				2022-12-28	WOS:A1993LD25200008
J	PRESANT, CA; SCOLARO, M; KENNEDY, P; BLAYNEY, DW; FLANAGAN, B; LISAK, J; PRESANT, J				PRESANT, CA; SCOLARO, M; KENNEDY, P; BLAYNEY, DW; FLANAGAN, B; LISAK, J; PRESANT, J			LIPOSOMAL DAUNORUBICIN TREATMENT OF HIV-ASSOCIATED KAPOSIS-SARCOMA	LANCET			English	Note							CRITERIA; AIDS	Compared with conventional chemotherapy, use of liposomes loaded with therapeutic agents is less toxic and more effective in experimental tumours in vivo. We have assessed efficacy and toxicity of liposomal daunorubicin (40 mg/m2 every 2 weeks) in 25 patients with HIV-associated Kaposi's sarcoma of poor prognosis. In 24 evaluable patients, there were 2 complete remissions (8.3%) and 13 partial remissions (54.2%). 5 of 11 patients with doxorubicin-resistant Kaposi's sarcoma had partial remissions. Median duration of response was 12 weeks. Quality of life improved after treatment with a response rate of 71% for physical performance and 74% for emotion. Myelosuppression was the commonest adverse event. Vomiting, stomatitis, and alopecia were rare and mild. Liposomal daunorubicin is safe and effective in HIV-associated Kaposi's sarcoma and improves quality of life. The treatment is effective even in patients resistant to other chemotherapy.	ST VINCENTS MED CTR,LOS ANGELES,CA 90057		PRESANT, CA (corresponding author), LOS ANGELES ONCOL INST,2131 W 3RD ST,LOS ANGELES,CA 90057, USA.		Blayney, Douglas/AAK-2920-2020	Blayney, Douglas/0000-0002-7931-4533				FORSSEN EA, 1992, CANCER RES, V51, P3255; FORSSEN EA, 1988, LIPOSOMES DRUG CARRI, P335; FRIEDMANKIEN AE, 1982, ANN INTERN MED, V96, P693, DOI 10.7326/0003-4819-96-6-693; GILL P, 1991, P AM SOC HEMATOL, V78, pA358; GILL PS, 1991, AM J MED, V90, P427, DOI 10.1016/0002-9343(91)80081-V; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; PRESANT CA, 1990, J NATL CANCER I, V82, P322, DOI 10.1093/jnci/82.4.322; PRESANT CA, 1990, LANCET, V335, P1307, DOI 10.1016/0140-6736(90)91188-G	8	85	85	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 15	1993	341	8855					1242	1243		10.1016/0140-6736(93)91147-E	http://dx.doi.org/10.1016/0140-6736(93)91147-E			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LC497	8098393				2022-12-28	WOS:A1993LC49700005
J	JICK, SS; TERRIS, BZ; JICK, H				JICK, SS; TERRIS, BZ; JICK, H			1ST TRIMESTER TOPICAL TRETINOIN AND CONGENITAL DISORDERS	LANCET			English	Article							1ST-TRIMESTER DRUG-USE; PHOTODAMAGED SKIN	We used information from the Group Health Cooperative of Puget Sound, Washington, USA, to evaluate the risk of birth defects in mothers exposed to topical tretinoin-a retinoid preparation used to treat acne-in the first trimester of pregnancy. We identified 215 women who delivered live or stillborn infants at Group Health Cooperative hospitals and who were exposed to topical tretinoin early in pregnancy, and 430 age-matched nonexposed women who delivered live or stillborn infants at the same hospitals. The prevalence of major anomalies among babies born to the exposed women was 1.9% and among babies born to the nonexposed women was 2.6%. The relative risk estimate for having a baby with a major congenital anomaly for exposed versus nonexposed women was 0.7 (95% Cl 0.2-2.3). We conclude that topical tretinoin is not associated with an increased risk for major congenital disorders.			JICK, SS (corresponding author), BOSTON UNIV,MED CTR,BOSTON COLLABORAT DRUG SURVEILLANCE PROGRAM,11 MUZZEY ST,LEXINGTON,MA 02173, USA.			Jick, Hershel/0000-0003-4270-5992; Jick, Susan/0000-0002-2215-1067				ASELTON P, 1985, OBSTET GYNECOL, V65, P451; BHAWAN J, 1991, ARCH DERMATOL, V127, P666, DOI 10.1001/archderm.127.5.666; CAMERA G, 1992, LANCET, V339, P687, DOI 10.1016/0140-6736(92)90854-V; De Wals P, 1991, Paediatr Perinat Epidemiol, V5, P445; JICK H, 1979, NEW ENGL J MED, V300, P218, DOI 10.1056/NEJM197902013000502; JICK H, 1981, JAMA-J AM MED ASSOC, V246, P343, DOI 10.1001/jama.246.4.343; LAMMER EJ, 1985, NEW ENGL J MED, V313, P837, DOI 10.1056/NEJM198510033131401; RAFAL ES, 1992, NEW ENGL J MED, V326, P368, DOI 10.1056/NEJM199202063260603; STERN RS, 1989, NEW ENGL J MED, V320, P1007, DOI 10.1056/NEJM198904133201510; WEINSTEIN GD, 1991, ARCH DERMATOL, V127, P659, DOI 10.1001/archderm.127.5.659	10	107	108	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 8	1993	341	8854					1181	1182		10.1016/0140-6736(93)91004-6	http://dx.doi.org/10.1016/0140-6736(93)91004-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB017	8098078	hybrid			2022-12-28	WOS:A1993LB01700006
J	WALDO, AL; WIT, AL				WALDO, AL; WIT, AL			MECHANISMS OF CARDIAC-ARRHYTHMIAS	LANCET			English	Article									UNIV HOSP CLEVELAND,DEPT MED,DIV CARDIOL,2074 ABINGTON RD,CLEVELAND,OH 44106; COLUMBIA UNIV COLL PHYS & SURG,DEPT PHARMACOL,NEW YORK,NY 10032	University Hospitals of Cleveland; Columbia University					NHLBI NIH HHS [HL30557, R01 HL38408, R01 HL31393] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038408, R01HL031393, P01HL030557] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Cranefield PF, 1988, CARD ARRHYTHMIAS H S; Hoffman B. F., 1982, NORMAL ABNORMAL COND, P429; HOFFMAN BF, 1964, AM J MED, V37, P670, DOI 10.1016/0002-9343(64)90017-8; HOFFMAN BF, 1981, CIRC RES, V49, P1, DOI 10.1161/01.RES.49.1.1; JACKMAN WM, 1988, PROG CARDIOVASC DIS, V31, P115, DOI 10.1016/0033-0620(88)90014-X; SINGER DH, 1967, CIRC RES, V21, P537, DOI 10.1161/01.RES.21.4.537; VASSALLE M, 1977, CIRC RES, V41, P269, DOI 10.1161/01.RES.41.3.269; WALDO AL, IN PRESS HURSTS HEAR; WIT AL, 1978, AM J PHYSIOL, V235, pH1, DOI 10.1152/ajpheart.1978.235.1.H1; WIT AL, 1992, VENTRICULAR ARRHYTHM	10	51	54	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 8	1993	341	8854					1189	1193		10.1016/0140-6736(93)91012-B	http://dx.doi.org/10.1016/0140-6736(93)91012-B			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB017	8098085				2022-12-28	WOS:A1993LB01700014
J	GARATTINI, S				GARATTINI, S			PAIN RELIEF - NARCOTIC DRUG-USE FOR SEVERE PAIN	LANCET			English	Editorial Material											GARATTINI, S (corresponding author), MARIO NEGRI INST PHARMACOL RES,I-20157 MILAN,ITALY.		Garattini, Silvio/AAA-6390-2020	Garattini, Silvio/0000-0003-0647-9297				1990, GAZZETTA OFFICI 1030, P14	1	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 24	1993	341	8852					1061	1062		10.1016/0140-6736(93)92418-S	http://dx.doi.org/10.1016/0140-6736(93)92418-S			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ018	8096965				2022-12-28	WOS:A1993KZ01800011
J	DAVIS, CB; KILLEEN, N; CROOKS, MEC; RAULET, D; LITTMAN, DR				DAVIS, CB; KILLEEN, N; CROOKS, MEC; RAULET, D; LITTMAN, DR			EVIDENCE FOR A STOCHASTIC MECHANISM IN THE DIFFERENTIATION OF MATURE SUBSETS OF T-LYMPHOCYTES	CELL			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CELL RECEPTOR; POSITIVE SELECTION; TRANSGENIC MICE; ANTIGEN RECEPTOR; ALPHA-3 DOMAIN; THYMIC SELECTION; CYTOPLASMIC TAIL; CD8 LINEAGE; MHC	Thymocytes that coexpress the CD4 and CD8 glycoproteins differentiate into mature CD4+ helper or CD8+ cytotoxic cells depending on whether their antigen receptors are specific for MHC class II or class I molecules, respectively. The mechanism of this decision process was investigated in mice whose T cell development was biased toward the class II-specific lineage. We found that constitutive expression of CD4 allows a developmentally arrested population of thymocytes that have mismatched class II-specific TCRs and the CD8 coreceptor to be rescued and to acquire a cytotoxic phenotype. This result is consistent with a two-step process of thymocyte maturation, in which there is stochastic down-regulation of either CD4 or CD8 and subsequent selection based on the ability of the TCR and remaining coreceptor to engage the same MHC molecule.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143; UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California Berkeley	DAVIS, CB (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143, USA.			Raulet, David/0000-0002-1257-8649				ALDRICH CJ, 1991, NATURE, V352, P718, DOI 10.1038/352718a0; BENDELAC A, 1991, NATURE, V353, P68, DOI 10.1038/353068a0; BENOIST C, 1989, CELL, V58, P1027, DOI 10.1016/0092-8674(89)90501-1; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; BERG LJ, 1990, CELL, V60, P1043, DOI 10.1016/0092-8674(90)90352-F; BILL J, 1989, NATURE, V341, P649, DOI 10.1038/341649a0; BLACKMAN MA, 1989, SCIENCE, V244, P214, DOI 10.1126/science.2784868; BORGULYA P, 1992, CELL, V69, P529, DOI 10.1016/0092-8674(92)90453-J; BORGULYA P, 1991, EMBO J, V10, P913, DOI 10.1002/j.1460-2075.1991.tb08024.x; BOTTOMLY K, 1989, EUR J IMMUNOL, V19, P617, DOI 10.1002/eji.1830190407; CAMMAROTA G, 1992, NATURE, V356, P799, DOI 10.1038/356799a0; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHAN SH, 1993, CELL, V73, P225, DOI 10.1016/0092-8674(93)90225-F; COHEN JJ, 1984, J IMMUNOL, V132, P38; COLLINS TL, 1992, J IMMUNOL, V148, P2159; CONNOLLY JM, 1990, P NATL ACAD SCI USA, V87, P2137, DOI 10.1073/pnas.87.6.2137; CRISPE IN, 1987, J IMMUNOL, V138, P2012; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GUYGRAND D, 1991, J EXP MED, V173, P471, DOI 10.1084/jem.173.2.471; Hogan B, 1986, MANIPULATING MOUSE E, P89; HUESMANN M, 1991, CELL, V66, P533, DOI 10.1016/0092-8674(81)90016-7; INGOLD AL, 1991, NATURE, V352, P721, DOI 10.1038/352721a0; JAMESON SC, 1991, J IMMUNOL, V147, P3185; JAMESON SC, 1990, J IMMUNOL, V145, P1324; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; KILLEEN N, 1992, J EXP MED, V176, P89, DOI 10.1084/jem.176.1.89; KILLEEN N, 1993, IN PRESS EMBO J; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; KONIG R, 1992, NATURE, V356, P796, DOI 10.1038/356796a0; LEE NA, 1992, J EXP MED, V175, P1013, DOI 10.1084/jem.175.4.1013; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LIAO NS, 1989, J EXP MED, V170, P135, DOI 10.1084/jem.170.1.135; MARRACK P, 1988, IMMUNOL TODAY, V9, P308, DOI 10.1016/0167-5699(88)91324-2; MICELI MC, 1991, P NATL ACAD SCI USA, V88, P2623, DOI 10.1073/pnas.88.7.2623; MISHELL BB, 1980, SELECTED METHODS CEL, P3; NIKOLICZUGIC J, 1991, IMMUNOL TODAY, V12, P65, DOI 10.1016/0167-5699(91)90160-U; OHASHI PS, 1990, NATURE, V346, P861, DOI 10.1038/346861a0; PIRCHER H, 1989, EMBO J, V8, P719, DOI 10.1002/j.1460-2075.1989.tb03431.x; RAHEMTULLA A, 1991, NATURE, V353, P180, DOI 10.1038/353180a0; RAMSDELL F, 1991, J IMMUNOL, V147, P1779; RAULET DH, 1980, J IMMUNOL, V125, P1136; ROBEY E, 1991, P NATL ACAD SCI USA, V88, P608, DOI 10.1073/pnas.88.2.608; ROBEY EA, 1991, CELL, V64, P99, DOI 10.1016/0092-8674(91)90212-H; ROCHA B, 1991, J EXP MED, V173, P483, DOI 10.1084/jem.173.2.483; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SEONG RH, 1992, NATURE, V356, P718, DOI 10.1038/356718a0; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SHORTMAN K, 1991, J EXP MED, V173, P323, DOI 10.1084/jem.173.2.323; SWAT W, 1992, EUR J IMMUNOL, V22, P2367, DOI 10.1002/eji.1830220928; TEH HS, 1991, NATURE, V349, P241, DOI 10.1038/349241a0; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; TORRESNAGEL N, 1992, EUR J IMMUNOL, V22, P2841, DOI 10.1002/eji.1830221113; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VANOERS NSC, 1992, EUR J IMMUNOL, V22, P735, DOI 10.1002/eji.1830220317; VONBOEHMER H, 1992, IMMUNOL TODAY, V13, P454, DOI 10.1016/0167-5699(92)90075-I; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WILSON A, 1988, CELL IMMUNOL, V117, P312, DOI 10.1016/0008-8749(88)90121-9; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; ZAMOYSKA R, 1989, NATURE, V342, P278, DOI 10.1038/342278a0; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	62	217	218	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 23	1993	73	2					237	247		10.1016/0092-8674(93)90226-G	http://dx.doi.org/10.1016/0092-8674(93)90226-G			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KY505	8097431				2022-12-28	WOS:A1993KY50500007
J	PELTOLA, H				PELTOLA, H			INFECTIOUS-DISEASES - MUMPS VACCINATION AND MENINGITIS	LANCET			English	Editorial Material							MEASLES; RUBELLA; EPIDEMIOLOGY; IMPACT				PELTOLA, H (corresponding author), UNIV HELSINKI,CHILDRENS HOSP,SF-00100 HELSINKI 10,FINLAND.							AFZAL MA, 1992, LANCET, V340, P980, DOI 10.1016/0140-6736(92)92874-F; ANDERSON RM, 1987, EPIDEMIOL INFECT, V99, P65, DOI 10.1017/S0950268800066875; COLVILLE A, 1992, LANCET, V340, P786, DOI 10.1016/0140-6736(92)92322-7; EHRENGUT W, 1989, LANCET, V2, P751; GALBRAITH NS, 1984, LANCET, V1, P91; KOSKINIEMI M, 1989, LANCET, V1, P31; NALIN DR, 1989, LANCET, V2, P1396; PELTOLA H, 1986, LANCET, V1, P137; PELTOLA H, 1986, LANCET, V1, P939; SOSIN DM, 1989, PEDIATRICS, V84, P779; 1977, ENCEPHALITIS SURVEIL; 1989, MMWR, V38, P388; 1992, LANCET, V340, P722	13	15	16	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 17	1993	341	8851					994	995		10.1016/0140-6736(93)91077-Y	http://dx.doi.org/10.1016/0140-6736(93)91077-Y			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY368	8096949				2022-12-28	WOS:A1993KY36800009
J	CURRAN, ME; ATKINSON, DL; EWART, AK; MORRIS, CA; LEPPERT, MF; KEATING, MT				CURRAN, ME; ATKINSON, DL; EWART, AK; MORRIS, CA; LEPPERT, MF; KEATING, MT			THE ELASTIN GENE IS DISRUPTED BY A TRANSLOCATION ASSOCIATED WITH SUPRAVALVULAR AORTIC-STENOSIS	CELL			English	Article							GEL-ELECTROPHORESIS; MESSENGER-RNA; 3' REGION; DNA; SEQUENCES; CLONING; FIBRILLIN	To identify genes involved in vascular disease, we investigated patients with supravalvular aortic stenosis (SVAS), an inherited vascular disorder that causes hemodynamically significant narrowing of large elastic arteries. Pulsed-field gel and Southern analyses showed that a translocation near the elastin gene cosegregated with SVAS in one family. DNA sequence analyses demonstrated that the translocation disrupted the elastin gene and localized the breakpoint to exon 28. Taken together with our previous study linking SVAS to the elastin gene in two additional families and existing knowledge of vascular biology, these data suggest that mutations in the elastin gene can cause SVAS.	UNIV UTAH,DIV CARDIOL,SALT LAKE CITY,UT 84112; UNIV UTAH,HOWARD HUGHES MED INST,SALT LAKE CITY,UT 84112; UNIV UTAH,ECCLES PROGRAM HUMAN MOLEC BIOL & GENET,SALT LAKE CITY,UT 84112; UNIV NEVADA,SCH MED,DEPT PEDIAT,LAS VEGAS,NV 89102	Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Nevada System of Higher Education (NSHE); University of Nevada Las Vegas	CURRAN, ME (corresponding author), UNIV UTAH,DEPT HUMAN GENET,SALT LAKE CITY,UT 84112, USA.		Toland, Amanda Ewart/E-4202-2011		NCRR NIH HHS [MO1-RR00064] Funding Source: Medline; NHLBI NIH HHS [R01HL4807] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000064] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BASHIR MM, 1989, J BIOL CHEM, V264, P8887; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BEUREN A J, 1972, Birth Defects Original Article Series, V8, P45; BLACK JA, 1963, LANCET, V2, P745; BRESSAN GM, 1987, BIOCHEMISTRY-US, V26, P1497, DOI 10.1021/bi00380a001; BURRY AF, 1958, BRIT HEART J, V20, P143; CHEN SJ, 1989, ONCOGENE, V4, P195; CHEVERS N, 1842, GUYS HOSP REP, V7, P387; Davidson J, 1987, CONNECTIVE TISSUE DI, P29; DIETZ HC, 1991, NATURE, V352, P337, DOI 10.1038/352337a0; EISENBERG R, 1964, AM J DIS CHILD, V108, P341, DOI 10.1001/archpedi.1964.02090010343002; EWART AK, 1993, IN PRESS P NATL ACAD, V90; FAZIO MJ, 1988, J INVEST DERMATOL, V91, P458, DOI 10.1111/1523-1747.ep12476591; FAZIO MJ, 1991, AM J HUM GENET, V48, P696; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GIACALONE JP, 1992, AM J HUM GENET, V50, P725; GRIMM T, 1980, Z KARDIOL, V69, P168; INDIK Z, 1987, CONNECT TISSUE RES, V16, P197, DOI 10.3109/03008208709006976; INDIK Z, 1987, P NATL ACAD SCI USA, V84, P809; JONES KL, 1975, J PEDIATR-US, V86, P718, DOI 10.1016/S0022-3476(75)80356-8; KUNKEL LM, 1977, P NATL ACAD SCI USA, V74, P1245, DOI 10.1073/pnas.74.3.1245; Maniatis T., 1982, MOL CLONING; MILEWICZ DM, 1992, J CLIN INVEST, V89, P79, DOI 10.1172/JCI115589; MORRIS CA, 1988, J PEDIATR-US, V113, P318, DOI 10.1016/S0022-3476(88)80272-5; MORRIS CA, 1991, P GREENWOOD GENET CT, V10, P81; OCONNOR WN, 1985, ARCH PATHOL LAB MED, V109, P179; PEROU M, 1961, ARCH PATHOL, V71, P113; PIERCE RA, 1990, BIOCHEMISTRY-US, V29, P9677, DOI 10.1021/bi00493a024; ROSENBLOOM J, 1991, EUK GENE EXPR, V1, P145; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; SANDBERG LB, 1981, NEW ENGL J MED, V304, P566, DOI 10.1056/NEJM198103053041004; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARTZ DC, 1984, CELL, V37, P67, DOI 10.1016/0092-8674(84)90301-5; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TROMP G, 1991, NUCLEIC ACIDS RES, V19, P4314, DOI 10.1093/nar/19.15.4314-a; UITTO J, 1991, BIOCHEM SOC T, V19, P824, DOI 10.1042/bst0190824; YEH H, 1987, COLLAGEN REL RES, V7, P235; YOON K, 1985, ARCH BIOCHEM BIOPHYS, V241, P684, DOI 10.1016/0003-9861(85)90595-8	40	329	338	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 9	1993	73	1					159	168		10.1016/0092-8674(93)90168-P	http://dx.doi.org/10.1016/0092-8674(93)90168-P			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KW753	8096434				2022-12-28	WOS:A1993KW75300016
J	MARSH, K				MARSH, K			MALARIA - PATARROYOS VACCINE	LANCET			English	Editorial Material											MARSH, K (corresponding author), KEMRI UNIT,KILIFI,KENYA.							ALONSO PL, 1991, LANCET, V337, P1499, DOI 10.1016/0140-6736(91)93194-E; COX FEG, 1991, TRENDS BIOTECHNOL, V9, P389, DOI 10.1016/0167-7799(91)90131-Z; MORENO A, 1989, BLOOD, V74, P389; NEWBOLD CI, 1992, BMJ-BRIT MED J, V304, P451	4	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 20	1993	341	8847					729	730		10.1016/0140-6736(93)90494-2	http://dx.doi.org/10.1016/0140-6736(93)90494-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KT362	8095631				2022-12-28	WOS:A1993KT36200011
J	DELANNOY, A; HANIQUE, G; FERRANT, A				DELANNOY, A; HANIQUE, G; FERRANT, A			2-CHLORODEOXYADENOSINE FOR PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC-LEUKEMIA RESISTANT TO FLUDARABINE	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter											DELANNOY, A (corresponding author), CLIN UNIV ST LUC,B-1200 BRUSSELS,BELGIUM.							CHESON BD, 1988, AM J HEMATOL, V29, P152, DOI 10.1002/ajh.2830290307; JULIUSSON G, 1992, NEW ENGL J MED, V327, P1056, DOI 10.1056/NEJM199210083271504; SAVEN A, 1991, LEUKEMIA LYMPHOMA, V5, P133, DOI 10.3109/10428199109103394	3	39	39	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 18	1993	328	11					812	812						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR848	8094888				2022-12-28	WOS:A1993KR84800026
J	DONNELLY, SC; STRIETER, RM; KUNKEL, SL; WALZ, A; ROBERTSON, CR; CARTER, DC; GRANT, IS; POLLOK, AJ; HASLETT, C				DONNELLY, SC; STRIETER, RM; KUNKEL, SL; WALZ, A; ROBERTSON, CR; CARTER, DC; GRANT, IS; POLLOK, AJ; HASLETT, C			INTERLEUKIN-8 AND DEVELOPMENT OF ADULT RESPIRATORY-DISTRESS SYNDROME IN AT-RISK PATIENT GROUPS	LANCET			English	Article							NEUTROPHIL CHEMOTACTIC FACTOR; GENE-EXPRESSION; LUNG; IL-8; MEDIATORS; LPS	Neutrophils have been implicated in the pathogenesis of the adult respiratory distress syndrome (ARDS). We have measured concentrations of the neutrophil attractant interleukin-8 in blood and bronchoalveolar lavage fluid (BAL) from patients at risk of ARDS. We studied 29 patients from three groups at risk of developing ARDS: multiple trauma (n=16), perforated bowel (n=6), and pancreatitis (n=7). ARDS developed in 7 of these patients. Interleukin-8 in BAL and blood samples taken on initial hospital presentation was measured by a sandwich enzyme-linked immunosorbent assay. The mean BAL interleukin-8 concentration was significantly higher for the patients who subsequently progressed to ARDS than for the non-ARDS group (3.06 [SE 2.64] vs 0.053 [0.010] ng/mL, p=0.0006). There was no difference between the groups in plasma interleukin-8 (6.23 [2.60] vs 5.12 [2.22] ng/mL, p=0.31 ). Immunocytochemistry suggested that the alveolar macrophage is an important source of interleukin-8 at this early stage in ARDS development. This study provides evidence of a relation between the presence of interleukin-8 in early BAL samples and the development of ARDS. The early appearance of interleukin-8 in BAL of patients at risk of ARDS may be an important prognostic indicator for the development of the disorder and reinforces the likely importance of neutrophils and the effects of their accumulation and activation in the pathogenesis of many cases of ARDS.	UNIV EDINBURGH,CITY HOSP,RESP MED UNIT,EDINBURGH EH10 5SB,MIDLOTHIAN,SCOTLAND; UNIV MICHIGAN,DEPT PATHOL & MED,DIV PULM & CRIT CARE MED,ANN ARBOR,MI 48109; UNIV BERN,THEODOR KOCHER INST,CH-3001 BERN,SWITZERLAND; ROYAL EDINBURGH & ASSOCIATED HOSP,DEPT ACCID & EMERGENCY,EDINBURGH EH3 9HB,MIDLOTHIAN,SCOTLAND; ROYAL EDINBURGH & ASSOCIATED HOSP,DEPT SURG,EDINBURGH EH3 9HB,MIDLOTHIAN,SCOTLAND; ROYAL EDINBURGH & ASSOCIATED HOSP,DEPT ANAESTHET,EDINBURGH EH3 9HB,MIDLOTHIAN,SCOTLAND; WESTERN GEN HOSP,INTENS THERAPY UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of Edinburgh; University of Michigan System; University of Michigan; University of Bern; Royal Infirmary of Edinburgh; Royal Infirmary of Edinburgh; Royal Infirmary of Edinburgh; University of Edinburgh				Donnelly, Seamas/0000-0001-7145-1843				BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; CHRISTNER P, 1985, AM REV RESPIR DIS, V131, P690; GREGORY H, 1988, BIOCHEM BIOPH RES CO, V151, P883, DOI 10.1016/S0006-291X(88)80364-4; HUBER AR, 1991, SCIENCE, V254, P99, DOI 10.1126/science.1718038; KOCH AE, 1991, J IMMUNOL, V147, P2187; KUNKEL SL, 1991, EXP LUNG RES, V17, P17, DOI 10.3109/01902149109063278; LARSEN GL, 1983, ANNU REV IMMUNOL, V1, P335, DOI 10.1146/annurev.iy.01.040183.002003; LYNCH JP, 1992, AM REV RESPIR DIS, V145, P1433, DOI 10.1164/ajrccm/145.6.1433; MCNAUGHTON PD, 1992, LANCET, V339, P469; MILLER EJ, 1992, AM REV RESPIR DIS, V146, P427, DOI 10.1164/ajrccm/146.2.427; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; OSBORNE DH, 1981, BRIT J SURG, V68, P758, DOI 10.1002/bjs.1800681103; PARSONS PE, 1992, AM REV RESPIR DIS, V146, P694, DOI 10.1164/ajrccm/146.3.694; PARSONS PE, 1989, AM REV RESPIR DIS, V140, P294, DOI 10.1164/ajrccm/140.2.294; PETTY TL, 1983, RECENT ADV RESPIRATO, P103; PEVERI P, 1988, J EXP MED, V167, P1547, DOI 10.1084/jem.167.5.1547; REPINE JE, 1991, AM REV RESPIR DIS, V144, P251, DOI 10.1164/ajrccm/144.2.251; RINALDO JE, 1990, CLIN CHEST MED, V11, P621; RINALDO JE, 1982, NEW ENGL J MED, V306, P900, DOI 10.1056/NEJM198204153061504; ROCKER GM, 1989, LANCET, V1, P120; SCHRODER JM, 1989, J IMMUNOL, V142, P244; STANDIFORD TJ, 1990, J CLIN INVEST, V86, P1945, DOI 10.1172/JCI114928; STANDIFORD TJ, 1992, AM J RESPIR CELL MOL, V6, P675; STRIETER RM, 1990, BIOCHEM BIOPH RES CO, V173, P725, DOI 10.1016/S0006-291X(05)80095-6; STRIETER RM, 1989, SCIENCE, V243, P1467, DOI 10.1126/science.2648570; The BAL Cooperative Group Steering Committee, 1990, AM REV RESPIR DIS, V141, pS169; WARSHAWSKI FJ, 1986, AM REV RESPIR DIS, V133, P797; WEILAND JE, 1986, AM REV RESPIR DIS, V133, P218; WILLEMS J, 1989, IMMUNOLOGY, V67, P540	29	577	607	0	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 13	1993	341	8846					643	647		10.1016/0140-6736(93)90416-E	http://dx.doi.org/10.1016/0140-6736(93)90416-E			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR613	8095568	Green Submitted			2022-12-28	WOS:A1993KR61300001
J	WU, TC; TRUJILLO, JM; KASHIMA, HK; MOUNTS, P				WU, TC; TRUJILLO, JM; KASHIMA, HK; MOUNTS, P			ASSOCIATION OF HUMAN PAPILLOMAVIRUS WITH NASAL NEOPLASIA	LANCET			English	Note							CARCINOMA; CAVITIES; SINUSES; DNA	Since HPV-57b has been identified by two different techniques in benign, premalignant, and malignant lesions of the nasal cavity, but not in cases of chronic sinusitis, HPV-57 should be recognised as at least a co-factor in the aetiology of nasal neoplasia. Paraffin sections of 22 histologically confirmed nasal tumours were screened by in-situ hybridisation with riboprobes specific for HPV-57b. Virus was demonstrated in 6 of 7 fungiform papillomas, 6 of 8 inverted papillomas, 1 of 3 inverted papillomas with dysplasia, and 2 of 4 inverted papillomas with carcinoma. The presence of HPV-57b was confirmed with the polymerase chain reaction, which identified an additional 4 positive samples, bringing the total to 86% positive specimens. The results underscore the importance of HPVs in the aetiology of cancers at extragenital sites.	JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT IMMUNOL & INFECT DIS, 615 N WOLFE ST, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV HOSP, DEPT OTOLARYNGOL HEAD & NECK SURG, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine								DEVILLIERS EM, 1989, VIROLOGY, V171, P248, DOI 10.1016/0042-6822(89)90532-1; FURUTA Y, 1991, LARYNGOSCOPE, V101, P79; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; HYAMS VJ, 1971, ANN OTO RHINOL LARYN, V80, P192, DOI 10.1177/000348947108000205; Kashima HK, 1987, PAPILLOMAVIRUSES HUM, P138; MILLS SE, 1989, DIAGNOTIC SURGICAL P, P664; RESPLER DS, 1987, ANN OTO RHINOL LARYN, V96, P170, DOI 10.1177/000348948709600206; SYRJANEN S, 1987, ACTA OTO-LARYNGOL, V104, P334, DOI 10.3109/00016488709107337; WEBER RS, 1988, ARCH OTOLARYNGOL, V114, P23; WU TC, 1991, AM J PATHOL, V138, P1461	10	55	58	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 27	1993	341	8844					522	524		10.1016/0140-6736(93)90280-T	http://dx.doi.org/10.1016/0140-6736(93)90280-T			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP083	8094773	hybrid			2022-12-28	WOS:A1993KP08300006
J	FIELDING, LP				FIELDING, LP			COLORECTAL-CARCINOMA - MESORECTAL EXCISION FOR RECTAL-CANCER	LANCET			English	Editorial Material											FIELDING, LP (corresponding author), ST MARYS HOSP,DEPT SURG,WATERBURY,CT 06706, USA.							ANDERSEN B, 1990, METHODOLOGICAL ISSUE, P72; ASTLER VB, 1954, ANN SURG, V139, P846, DOI 10.1097/00000658-195406000-00015; Beahrs OH, 1992, MANUAL STAGING CANCE, p[1992, 75]; FEINSTEIN AR, 1985, NEW ENGL J MED, V312, P1604, DOI 10.1056/NEJM198506203122504; FIELDING LP, 1978, LANCET, V2, P778; FIELDING LP, 1986, LANCET, V2, P904; FIELDING LP, 1991, J GASTROEN HEPATOL, V6, P325, DOI 10.1111/j.1440-1746.1991.tb00867.x; HERMANEK P, 1989, BAILLIERE CLIN GASTR, V3, P511, DOI 10.1016/0950-3528(89)90015-8	8	18	18	1	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 20	1993	341	8843					471	472		10.1016/0140-6736(93)90217-5	http://dx.doi.org/10.1016/0140-6736(93)90217-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN137	8094497				2022-12-28	WOS:A1993KN13700014
J	FRANKEL, EN; KANNER, J; GERMAN, JB; PARKS, E; KINSELLA, JE				FRANKEL, EN; KANNER, J; GERMAN, JB; PARKS, E; KINSELLA, JE			INHIBITION OF OXIDATION OF HUMAN LOW-DENSITY-LIPOPROTEIN BY PHENOLIC SUBSTANCES IN RED WINE	LANCET			English	Article							ISCHEMIC-HEART-DISEASE; ALCOHOL-CONSUMPTION; LIPID-PEROXIDATION; FLAVONOIDS; CHOLESTEROL; MECHANISMS; QUERCETIN; RISK	The ''French paradox'' (apparent compatibility of a high fat diet with a low incidence of coronary atherosclerosis) has been attributed to the regular drinking of red wine. However, the alcohol content of wine may not be the sole explanation for this protection. Red wine also contains phenolic compounds, and the antioxidant properties of these may have an important role. In in-vitro studies with phenolic substances in red wine and normal human low-density lipoprotein (LDL) we found that red wine inhibits the copper-catalysed oxidation of LDL. Wine diluted 1000-fold containing 10 mumol/L total phenolics inhibited LDL oxidation significantly more than alpha-tocopherol. Our findings show that the non-alcoholic components of red wine have potent antioxidant properties toward oxidation of human LDL.	UNIV CALIF DAVIS,DEPT NUTR,DAVIS,CA 95616; VOLCANI CTR,BET DAGAN,ISRAEL	University of California System; University of California Davis; VOLCANI INSTITUTE OF AGRICULTURAL RESEARCH	FRANKEL, EN (corresponding author), UNIV CALIF DAVIS,LIPID RES GRP,MRAK HALL,DAVIS,CA 95616, USA.		Frankel, Edwin N/G-1200-2011					AFANASEV IB, 1989, BIOCHEM PHARMACOL, V38, P1763, DOI 10.1016/0006-2952(89)90410-3; CAREW TE, 1987, P NATL ACAD SCI USA, V84, P7725, DOI 10.1073/pnas.84.21.7725; DAS NP, 1971, BIOCHEM PHARMACOL, V20, P3435, DOI 10.1016/0006-2952(71)90449-7; DEWHALLEY CV, 1990, BIOCHEM PHARMACOL, V39, P1743, DOI 10.1016/0006-2952(90)90120-A; ESTERBAUER H, 1992, FREE RADICAL BIO MED, V13, P341, DOI 10.1016/0891-5849(92)90181-F; ESTERBAUER H, 1989, FREE RADICAL RES COM, V6, P67, DOI 10.3109/10715768909073429; FRANKEL EN, 1992, LIPIDS, V27, P1047, DOI 10.1007/BF02535586; FRIEDMAN LA, 1986, AM J EPIDEMIOL, V124, P481, DOI 10.1093/oxfordjournals.aje.a114418; GEY KF, 1987, AM J CLIN NUTR, V45, P1368, DOI 10.1093/ajcn/45.5.1368; GRUNDY SM, 1986, JAMA-J AM MED ASSOC, V256, P2849, DOI 10.1001/jama.256.20.2849; GUGLER R, 1975, EUR J CLIN PHARMACOL, V9, P229, DOI 10.1007/BF00614022; Health. & N.R.C.U.C.o.D.a., 1989, DIET HLTH IMPLICATIO; HUSAIN SR, 1987, PHYTOCHEMISTRY, V26, P2489, DOI 10.1016/s0031-9422(00)83860-1; JIALAL I, 1990, ATHEROSCLEROSIS, V82, P185, DOI 10.1016/0021-9150(90)90039-L; KANNER J, 1985, ARCH BIOCHEM BIOPHYS, V237, P314, DOI 10.1016/0003-9861(85)90282-6; KANNER J, 1977, J FOOD SCI, V42, P60, DOI 10.1111/j.1365-2621.1977.tb01218.x; KINSELLA JE, 1990, AM J CLIN NUTR, V52, P1; LAZARUS NB, 1991, BRIT MED J, V303, P553, DOI 10.1136/bmj.303.6802.553; MANGIAPANE H, 1992, BIOCHEM PHARMACOL, V43, P445, DOI 10.1016/0006-2952(92)90562-W; MORONEY MA, 1988, J PHARM PHARMACOL, V40, P787, DOI 10.1111/j.2042-7158.1988.tb05173.x; NEGRESALVAYRE A, 1992, FREE RADICAL BIO MED, V12, P101, DOI 10.1016/0891-5849(92)90002-X; ORR JR, 1991, ANAL FATS OILS LIPOP, P524; PARTHASARATHY S, 1986, J CLIN INVEST, V77, P641, DOI 10.1172/JCI112349; RENAUD S, 1992, LANCET, V339, P1523, DOI 10.1016/0140-6736(92)91277-F; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; SIGNLETON VL, 1982, P U CALIFORNIA DAVIS, P215; SINGLETON V. L., 1965, AMER J ENOL VITICULT, V16, P144; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; TOREL J, 1986, PHYTOCHEMISTRY, V25, P383, DOI 10.1016/S0031-9422(00)85485-0; 1988, CIRCULATION, V77, pA721	30	1449	1513	0	114	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 20	1993	341	8843					454	457		10.1016/0140-6736(93)90206-V	http://dx.doi.org/10.1016/0140-6736(93)90206-V			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN137	8094487				2022-12-28	WOS:A1993KN13700003
J	DONNELLY, R; HILLIS, WS				DONNELLY, R; HILLIS, WS			MYOCARDIAL INJURY - CARDIAC TROPONIN-T	LANCET			English	Editorial Material							INFARCTION; HEART		WESTERN INFIRM & ASSOCIATED HOSP,DEPT CARDIOL,GLASGOW G11 6NT,SCOTLAND		DONNELLY, R (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT MED,STANFORD,CA 94305, USA.							ANDERSON PAW, 1992, BASIC RES CARDIOL, V87, P117; ANDERSON PAW, 1991, CIRC RES, V69, P1226, DOI 10.1161/01.RES.69.5.1226; GERHARDT W, 1992, CLIN CHEM, V38, P1194; GERHARDT W, 1991, CLIN CHEM, V37, P1405; HAMM CW, 1992, NEW ENGL J MED, V327, P146, DOI 10.1056/NEJM199207163270302; KATUS HA, 1991, CIRCULATION, V83, P902, DOI 10.1161/01.CIR.83.3.902; KATUS HA, 1992, CLIN CHEM, V38, P386; KATUS HA, 1991, AM J CARDIOL, V67, P1360, DOI 10.1016/0002-9149(91)90466-X; KOBAYASHI S, 1992, LANCET, V340, P726, DOI 10.1016/0140-6736(92)92262-E; MAIR J, 1991, LANCET, V337, P434, DOI 10.1016/0140-6736(91)91218-J; MAIR J, 1992, LANCET, V340, P1048, DOI 10.1016/0140-6736(92)93072-U; MAIR P, 1991, LANCET, V338, P693, DOI 10.1016/0140-6736(91)91266-W; TALASZ H, 1992, LANCET, V339, P1380, DOI 10.1016/0140-6736(92)91198-H	13	32	32	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 13	1993	341	8842					410	411		10.1016/0140-6736(93)92996-7	http://dx.doi.org/10.1016/0140-6736(93)92996-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM416	8094176				2022-12-28	WOS:A1993KM41600011
J	MCCARTHY, M				MCCARTHY, M			AIDS IMPACT SEEN AS SMALL IN THE UNITED-STATES	LANCET			English	Editorial Material																		1983, SOCIAL IMPACT AIDS U	1	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 13	1993	341	8842					429	430		10.1016/0140-6736(93)93016-T	http://dx.doi.org/10.1016/0140-6736(93)93016-T			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM416	8094185				2022-12-28	WOS:A1993KM41600023
J	FOWLER, PBS				FOWLER, PBS			WHO CLOFIBRATE CHOLESTEROL TRIAL - CLARIFICATIONS	LANCET			English	Letter							CORONARY HEART-DISEASE; HYPOTHYROIDISM				FOWLER, PBS (corresponding author), CHARING CROSS HOSP, LONDON W6 8RF, ENGLAND.							BALL MJ, 1991, J ROY SOC MED, V84, P527, DOI 10.1177/014107689108400908; BASTENIE PA, 1977, LANCET, V2, P155; BASTENIE PA, 1971, LANCET, V1, P203; FOWLER PBS, 1980, 15TH P INT C THER BR, V1, P94; HEADY JA, 1992, LANCET, V340, P1405, DOI 10.1016/0140-6736(92)92588-7; HEINONEN OP, 1972, LANCET, V1, P785; MARIOTTI S, 1992, LANCET, V339, P1506, DOI 10.1016/0140-6736(92)91265-A; MATHEWS JD, 1973, LANCET, V2, P754; POWELL J, 1987, BRIT J SURG, V74, P1139, DOI 10.1002/bjs.1800741220; TAYLOR S, 1978, BRIT MED J, V2, P1754	10	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 30	1993	341	8840					314	315		10.1016/0140-6736(93)92676-K	http://dx.doi.org/10.1016/0140-6736(93)92676-K			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK245	8093961				2022-12-28	WOS:A1993KK24500060
J	TIIHONEN, J; HAKOLA, P; PAANILA, J; TURTIAINEN, M				TIIHONEN, J; HAKOLA, P; PAANILA, J; TURTIAINEN, M			ELTOPRAZINE FOR AGGRESSION IN SCHIZOPHRENIA AND MENTAL-RETARDATION	LANCET			English	Letter											TIIHONEN, J (corresponding author), UNIV KUOPIO,NIUVANNIEMI HOSP,DEPT FORENS PSYCHIAT,SF-70240 KUOPIO,FINLAND.		Tiihonen, Jari/G-3078-2012	Tiihonen, Jari/0000-0002-0400-6798				HAKOLA HPA, 1982, LANCET, V1, P1358; MARKOVITZ PJ, 1991, AM J PSYCHIAT, V148, P1064; OLIVIER B, 1992, PROG NEURO-PSYCHOPH, V16, P847, DOI 10.1016/0278-5846(92)90104-M; RASMUSSEN D L, 1990, Drug Metabolism and Drug Interactions, V8, P159; TARDIFF K, 1992, ARCH GEN PSYCHIAT, V49, P493; VERHOEVEN, 1992, LANCET, V340, P1037	6	24	24	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 30	1993	341	8840					307	307		10.1016/0140-6736(93)92660-L	http://dx.doi.org/10.1016/0140-6736(93)92660-L			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KK245	8093942				2022-12-28	WOS:A1993KK24500040
J	OLD, R				OLD, R			HETEROZYGOTE ADVANTAGE - WHY ARE SOME DELETERIOUS GENES SO COMMON	LANCET			English	Editorial Material											OLD, R (corresponding author), UNIV WARWICK,DEPT BIOL SCI,COVENTRY CV4 7AL,W MIDLANDS,ENGLAND.							PRITCHARD DJ, 1991, HUM GENET, V87, P671; VULLIAMY T, 1992, TRENDS GENET, V8, P138, DOI 10.1016/0168-9525(92)90372-B	2	1	1	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 23	1993	341	8839					214	214		10.1016/0140-6736(93)90076-S	http://dx.doi.org/10.1016/0140-6736(93)90076-S			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ219	8093507				2022-12-28	WOS:A1993KJ21900014
J	KHANNA, R; RICHMOND, S				KHANNA, R; RICHMOND, S			OSIRIS TRIAL	LANCET			English	Letter							RESPIRATORY-DISTRESS SYNDROME; PREVENTION				KHANNA, R (corresponding author), PRINCESS MARY MATERN HOSP, MATERN SURVEY OFF, NEWCASTLE UPON TYNE NE2 3BD, ENGLAND.							Crowley P., 1989, EFFECTIVE CARE PREGN, P746; LIGGINS GC, 1972, PEDIATRICS, V50, P515; MUGFORD M, 1991, ARCH DIS CHILD-FETAL, V66, P757, DOI 10.1136/adc.66.7_Spec_No.757	3	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 16	1993	341	8838					174	174						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG627	8093766				2022-12-28	WOS:A1993KG62700028
J	MCPARTLIN, J; HALLIGAN, A; SCOTT, JM; DARLING, M; WEIR, DG				MCPARTLIN, J; HALLIGAN, A; SCOTT, JM; DARLING, M; WEIR, DG			ACCELERATED FOLATE BREAKDOWN IN PREGNANCY	LANCET			English	Note								During pregnancy there is an increased requirement for folate. We studied pregnant women to determine whether the increased requirement might be due to enhanced catabolism of the vitamin. Six normal pregnant women provided 24 h urine samples during each trimester and postpartum while taking a defined diet. The urines were assayed for the folate breakdown products p-aminobenzoylglutamate (pABGlu) and its acetylated derivative p-acetamidobenzoylglutamate (apBGlu) by high-pressure liquid chromatography. Mean concentration of excreted apABGlu rose significantly in the second trimester but returned to baseline postpartum. This increased rate of folate catabolism produces an extra demand for dietary folate of about 200-300 mug per day in pregnant women, a considerably greater value than recent recommendations.	UNIV DUBLIN TRINITY COLL,DEPT BIOCHEM,DUBLIN 2,IRELAND; ST JAMES HOSP,TRINITY COLL,SCH MED,DEPT CLIN MED,DUBLIN 8,IRELAND; ROTUNDA MATERN HOSP,DUBLIN,IRELAND	Trinity College Dublin; Trinity College Dublin								BHANDARI SD, 1990, AM J CLIN NUTR, V51, P87, DOI 10.1093/ajcn/51.1.87; IYENGAR L, 1972, BRIT J NUTR, V27, P313, DOI 10.1079/BJN19720096; KRUMDIECK CL, 1978, AM J CLIN NUTR, V31, P88, DOI 10.1093/ajcn/31.1.88; MCPARTLIN J, 1992, ANAL BIOCHEM, V206, P256, DOI 10.1016/0003-2697(92)90363-C; SAUBERLICH HE, 1990, FOLIC ACID METABOLIS, P211; Scott J. M., 1984, FOLATES PTERINS, P307; [No title captured]; 1991, COMA41 REP; 1989, RECOMMENDED DIETARY; 1988, REQUIREMENTS VITAMIN	10	139	141	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 16	1993	341	8838					148	149		10.1016/0140-6736(93)90007-4	http://dx.doi.org/10.1016/0140-6736(93)90007-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG627	8093747				2022-12-28	WOS:A1993KG62700007
J	LINCH, DC; WINFIELD, D; GOLDSTONE, AH; MOIR, D; HANCOCK, B; MCMILLAN, A; CHOPRA, R; MILLIGAN, D; HUDSON, GV				LINCH, DC; WINFIELD, D; GOLDSTONE, AH; MOIR, D; HANCOCK, B; MCMILLAN, A; CHOPRA, R; MILLIGAN, D; HUDSON, GV			DOSE INTENSIFICATION WITH AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN RELAPSED AND RESISTANT HODGKINS-DISEASE - RESULTS OF A BNLI RANDOMIZED TRIAL	LANCET			English	Article							CHEMOTHERAPY; ETOPOSIDE; CYCLOPHOSPHAMIDE; CARMUSTINE; LYMPHOMA	High-dose chemotherapy and radiotherapy with autologous bone-marrow transplantation (ABMT) are increasingly used for the treatment of relapsed and resistant Hodgkin's disease, although there has been no randomised trial of this treatment. The British National Lymphoma Investigation therefore undertook a randomised comparison of high-dose chemotherapy (BEAM=carmustine, etoposide, cytarabine, and melphalan) plus ABMT with the same drugs at lower doses not requiring bone-marrow rescue (mini-BEAM) in patients with active Hodgkin's disease, for whom conventional therapy had failed. 20 patients were assigned treatment with BEAM plus ABMT and 20 mini-BEAM. All have been followed up for at least 12 months (median 34 months). 5 BEAM recipients have died (2 from causes related to ABMT and 3 from disease progression) compared with 9 mini-BEAM recipients (all disease progression). This difference was not significant (p = 0.318). However, both event-free survival and progression-free survival showed significant differences in favour of BEAM plus ABMT (p = 0.025 and p = 0.005, respectively). Recruitment to the trial became increasingly difficult because patients refused randomisation and requested ABMT. It was therefore closed early (40 patients rather than 66 intended). Nevertheless, we found a dose-response effect in these patients with relapsed and resistant Hodgkin's disease. High doses facilitated by ABMT can lead to better disease-free survival.	MILTON KEYNES DIST GEN HOSP, DEPT HAEMATOL, MILTON KEYNES, ENGLAND; UNIV LONDON UNIV COLL, SCH MED, DEPT ONCOL, LONDON WC1E 6BT, ENGLAND; ROYAL HALLAMSHIRE HOSP, DEPT HAEMATOL, SHEFFIELD S10 2JF, S YORKSHIRE, ENGLAND; ROYAL HALLAMSHIRE HOSP, DEPT ONCOL, SHEFFIELD S10 2JF, S YORKSHIRE, ENGLAND; E BIRMINGHAM DIST GEN HOSP, DEPT HAEMATOL, BIRMINGHAM B9 5ST, W MIDLANDS, ENGLAND	University of London; University College London; UCL Medical School; University of Sheffield; University of Sheffield	LINCH, DC (corresponding author), UCL, SCH MED, DEPT HAEMATOL, 98 CHENIES MEWS, LONDON WC1E 6HX, ENGLAND.							CANELLOS GP, 1991, ANN ONCOL, V2, P1; CARELLA AM, 1988, J CLIN ONCOL, V6, P1411, DOI 10.1200/JCO.1988.6.9.1411; CHOPRA R, 1992, BRIT J HAEMATOL, V81, P197, DOI 10.1111/j.1365-2141.1992.tb08207.x; CHOPRA R, 1993, BLOOD, V81, P1137; Freedman L S, 1982, Stat Med, V1, P121, DOI 10.1002/sim.4780010204; GRIBBEN JG, 1987, HEMATOL ONCOL, V5, P281; HELLMAN S, 1989, CANCER PRINCIPLES PR, P1726; JAGGANATH S, 1989, J CLIN ONCOL, V7, P175; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kaplan H.S., 1980, HODGKINS DISEASE; LINCH DC, 1988, RECENT ADV HAEMATOLO, V5, P211; MACLENNAN KA, 1989, CANCER-AM CANCER SOC, V64, P1686, DOI 10.1002/1097-0142(19891015)64:8<1686::AID-CNCR2820640822>3.0.CO;2-I; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; REECE DE, 1991, J CLIN ONCOL, V9, P1871, DOI 10.1200/JCO.1991.9.10.1871; STEWART AK, 1991, LEUKEMIA LYMPHOMA, V5, P111, DOI 10.3109/10428199109068113; WHEELER C, 1990, J CLIN ONCOL, V8, P648, DOI 10.1200/JCO.1990.8.4.648; ZULIAN GB, 1989, BRIT J CANCER, V59, P631, DOI 10.1038/bjc.1989.128	17	803	838	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 24	1993	341	8852					1051	1054		10.1016/0140-6736(93)92411-L	http://dx.doi.org/10.1016/0140-6736(93)92411-L			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ018	8096958				2022-12-28	WOS:A1993KZ01800004
J	RAUFMAN, JP; NOTARFRANCESCO, V; RAFFANIELLO, RD; STRAUS, EW				RAUFMAN, JP; NOTARFRANCESCO, V; RAFFANIELLO, RD; STRAUS, EW			HISTAMINE-2 RECEPTOR ANTAGONISTS DO NOT ALTER SERUM ETHANOL LEVELS IN FED, NONALCOHOLIC MEN	ANNALS OF INTERNAL MEDICINE			English	Article						HISTAMINE H2 RECEPTOR BLOCKADERS; ALCOHOL DRINKING; ALCOHOL DEHYDROGENASE; PEPTIC ULCER	GASTRIC ALCOHOL-DEHYDROGENASE; HISTAMINE2-RECEPTOR ANTAGONISTS; H-2-RECEPTOR ANTAGONISTS; STANDARD THERAPY; DRUG-THERAPY; METABOLISM; CIMETIDINE; RANITIDINE	Objective: To determine whether the four histamine-2 receptor antagonists currently available for the treatment of acid-peptic disorders in the United States alter serum ethanol levels after moderate alcohol consumption. Design: Prospective, randomized crossover design comparing the effects of histamine-2 receptor antagonists and no treatment on serum ethanol levels. Each participant served as his own control. Participants: Twenty-five healthy nonalcoholic men (21 to 35 years old); two participants were withdrawn before starting the study. Setting: University medical center. Intervention: Cimetidine (400 mg twice daily), famotidine (20 mg twice daily), nizatidine (150 mg twice daily), ranitidine (150 mg twice daily), and no treatment for 7 days. After the last dose of medication, participants ate a standard meal; 1 hour later they drank ethanol (0.3 g/kg body weight in 500 mL of orange juice) over 8 minutes. Measurements: Simultaneous measurements of breath and serum (headspace gas chromatography) ethanol were made before and 10, 20, 30, 45, 60, 90, 120, 150, and 180 minutes after ingestion of ethanol. Results: Peak ethanol levels did not differ (mmol/L-; mean +/- SE) after cimetidine (3.0 +/- 0.3), famotidine (2.9 +/- 0.3), nizatidine (2.9 +/- 0.3), ranitidine (3.1 +/- 0.4), and no treatment (2.9 +/-4). Similarly, there was no difference in the area under the curve (mmol/L . h; mean +/- SE) after cimetidine (4.3 +/- 0.5), famotidine (3.8 +/- 0.4), nizatidine (4.2 +/- 0.5), ranitidine (3.9 +/- 0.4), and no treatment (4.0 +/- 0.5). Conclusions: In healthy nonalcoholic men, the histamine-2 receptor antagonists currently available in the United States do not alter serum ethanol levels following moderate alcohol consumption after an evening meal.			RAUFMAN, JP (corresponding author), SUNY HLTH SCI CTR, DIV DIGEST DIS, 450 CLARKSON AVE, BOX 1196, BROOKLYN, NY 11203 USA.							BARAONA E, 1991, LIFE SCI, V49, P1929, DOI 10.1016/0024-3205(91)90295-M; BENNION LJ, 1976, NEW ENGL J MED, V294, P9, DOI 10.1056/NEJM197601012940103; BRUNING JL, 1987, COMPUTATIONAL HDB ST, P18; BUCHSBAUM DG, 1991, ANN INTERN MED, V115, P774, DOI 10.7326/0003-4819-115-10-774; CABALLERIA J, 1989, GASTROENTEROLOGY, V96, P388, DOI 10.1016/0016-5085(89)91562-X; CHRISTMORE DS, 1984, J FORENSIC SCI, V29, P1038; COHEN J, 1958, STATISTICAL POWER AN, P12; DIPADOVA C, 1992, JAMA-J AM MED ASSOC, V267, P83, DOI 10.1001/jama.267.1.83; DOBRILLA G, 1984, HEPATO-GASTROENTEROL, V31, P35; FELDMAN M, 1990, NEW ENGL J MED, V323, P1749; FELDMAN M, 1990, NEW ENGL J MED, V323, P1672; FELL MS, 1990, ALCOHOL HEALTH RES W, V14, P18; FRASER AG, 1991, ALIMENT PHARM THERAP, V5, P263; HERNANDEZMUNOZ R, 1990, ALCOHOL CLIN EXP RES, V14, P946, DOI 10.1111/j.1530-0277.1990.tb01843.x; HOLTMANN G, 1988, DIGEST DIS SCI, V33, P767, DOI 10.1007/BF01540445; RANDALL T, 1992, JAMA-J AM MED ASSOC, V268, P303, DOI 10.1001/jama.1992.03490030013005; REED TE, 1976, CAN MED ASSOC J, V115, P851; REED TE, 1978, ALCOHOL CLIN EXP RES, V2, P83, DOI 10.1111/j.1530-0277.1978.tb04699.x; ROINE R, 1990, JAMA-J AM MED ASSOC, V264, P2406, DOI 10.1001/jama.264.18.2406; ROINE R, 1992, DIGEST DIS SCI, V37, P891, DOI 10.1007/BF01300387; SEITZ HK, 1984, HEPATOLOGY, V4, P1231, DOI 10.1002/hep.1840040623; TANAKA E, 1988, BRIT J CLIN PHARMACO, V26, P96, DOI 10.1111/j.1365-2125.1988.tb03370.x; WEBSTER LK, 1985, AUST NZ J MED, V15, P359, DOI 10.1111/j.1445-5994.1985.tb04058.x; ZAR JH, 1984, BIOSTAT ANAL, P122	24	29	29	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1993	118	7					488	494		10.7326/0003-4819-118-7-199304010-00002	http://dx.doi.org/10.7326/0003-4819-118-7-199304010-00002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU079	8095127				2022-12-28	WOS:A1993KU07900002
J	ADAMI, HO; BERGSTROM, R; SPAREN, P; BARON, J				ADAMI, HO; BERGSTROM, R; SPAREN, P; BARON, J			INCREASING CANCER RISK IN YOUNGER BIRTH COHORTS IN SWEDEN	LANCET			English	Article							EPIDEMIOLOGIC ASSESSMENT; TEMPORAL VARIATION; MEMORIAL LECTURE; AGE PERIOD; TRENDS; RATES; MORTALITY; PROGRESS; MODELS; DEATH	There is controversy about cancer mortality trends; some analyses show increasing mortality, but others suggest that rates are falling in the youngest age groups. We have investigated trends in cancer incidence in the whole of Sweden for the period 1958 to 1987. 837 085 cancer cases were registered during the period studied. Incidence rate patterns were studied by age-period-cohort modelling. The risk of cancer was higher for people born during the 1950s than for those born in 1873-82; for women the risk was doubled and for men it was trebled. Although the rate of increase slowed, it showed no sign of levelling off in the youngest birth cohorts. The frequency of smoking-related cancers increased greatly in both sexes, but such tumours could explain only part of the rise in total cancer. These trends predict a continuing rise in the incidence rate of cancer, and suggest a worrying pattern of increasing population exposure to carcinogenic influences.	UNIV UPPSALA, DEPT STAT, S-75105 UPPSALA, SWEDEN	Uppsala University	ADAMI, HO (corresponding author), UNIV HOSP UPPSALA, CANC EPIDEMIOL UNIT, S-75185 UPPSALA, SWEDEN.			Sparen, Par/0000-0002-5184-8971				ADAMI HO, 1992, ACTA ONCOL, V31, P1; ADAMI HO, 1990, AM J EPIDEMIOL, V132, P446, DOI 10.1093/oxfordjournals.aje.a115679; ADAMI HO, 1989, JNCI-J NATL CANCER I, V81, P1640, DOI 10.1093/jnci/81.21.1640; BAILAR JC, 1986, NEW ENGL J MED, V315, P968; BAILAR JC, 1990, ANN NY ACAD SCI, V609, P49, DOI 10.1111/j.1749-6632.1990.tb32056.x; BAILAR JC, 1986, NEW ENGL J MED, V314, P1226, DOI 10.1056/NEJM198605083141905; BRESLOW NE, 1984, APPL STAT-J ROY ST C, V33, P38; CLAYTON D, 1987, STAT MED, V6, P449, DOI 10.1002/sim.4780060405; CLAYTON D, 1987, STAT MED, V6, P469, DOI 10.1002/sim.4780060406; DAVIS DL, 1990, LANCET, V336, P474, DOI 10.1016/0140-6736(90)92020-I; DAVIS DL, 1992, LANCET, V340, P666, DOI 10.1016/0140-6736(92)92196-M; Day NE, 1982, TRENDS CANCER INCIDE, P51; DEVITA VT, 1986, NEW ENGL J MED, V315, P964; DOLL R, 1991, AM J EPIDEMIOL, V134, P675, DOI 10.1093/oxfordjournals.aje.a116143; DOLL R, 1990, EUR J CANCER, V26, P500; DOLL R, 1989, ACTA ONCOL, V28, P611; ENSTROM JE, 1977, SCIENCE, V195, P847, DOI 10.1126/science.841309; GREENSPAN EM, 1986, NEW ENGL J MED, V315, P963; HANSSON LE, 1991, INT J CANCER, V47, P499, DOI 10.1002/ijc.2910470405; HOLFORD TR, 1991, ANNU REV PUBL HEALTH, V12, P425, DOI 10.1146/annurev.pu.12.050191.002233; MARSHALL E, 1990, SCIENCE, V250, P900, DOI 10.1126/science.2237436; MATTSSON B, 1984, ACTA RADIOL ONCOL, V23, P305, DOI 10.3109/02841868409136026; MYERS MH, 1982, TRENDS CANCER INCIDE, P79; RATKIN GA, 1986, NEW ENGL J MED, V315, P964; RUTQVIST LE, 1989, ACTA ONCOL, V28, P771, DOI 10.3109/02841868909092306; SONDIK EJ, 1990, J NATL CANCER I, V82, P825; THORN M, 1990, AM J EPIDEMIOL, V132, P1066; 1990, CANCER INCIDENCE SWE	28	33	33	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 27	1993	341	8848					773	777		10.1016/0140-6736(93)90557-W	http://dx.doi.org/10.1016/0140-6736(93)90557-W			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU900	8095997				2022-12-28	WOS:A1993KU90000001
J	SINGH, B; ALSHAHWAN, SA; HABBAB, MA; ALDEEB, SM; BIARY, N				SINGH, B; ALSHAHWAN, SA; HABBAB, MA; ALDEEB, SM; BIARY, N			IDIOPATHIC LONG QT SYNDROME - ASKING THE RIGHT QUESTION	LANCET			English	Article								Infants and young children cannot describe symptoms of cardiogenic syncope accurately. If the attention in such cases is focused on the seizure activity that may follow, the patient will be treated inappropriately with anticonvulsants. We report such a presentation in 4 infants and young children (ages 6 to 48 months) with idiopathic long QT syndrome. All patients presented with recurrent seizures. All patients had a corrected QT interval (QTc) greater-than-or-equal-to 0.44 s and none had deafness. The diagnosis was suspected by careful history-taking which revealed episodes of loss of consciousness before convulsions in all patients. All patients were treated successfully with propranolol and remained free of symptoms during the follow-up period of 1-2 years. Screening the other family members revealed a prolonged QTc in 9 out of 16, and a history of 3 sudden and unexplained deaths in two families.	RIYADH ARMED FORCES HOSP, DEPT CARDIOL, RIYADH 11159, SAUDI ARABIA; RIYADH ARMED FORCES HOSP, DEPT NEUROL, RIYADH 11159, SAUDI ARABIA	Prince Sultan Military Medical City; Prince Sultan Military Medical City	SINGH, B (corresponding author), RIYADH ARMED FORCES HOSP, DEPT PAEDIAT, POB 7897, RIYADH 11159, SAUDI ARABIA.							Bazett HC, 1920, HEART-J STUD CIRC, V7, P353; CHAUDRON JM, 1976, AM HEART J, V91, P783, DOI 10.1016/S0002-8703(76)80544-3; JERVELL A, 1957, AM HEART J, V54, P59, DOI 10.1016/0002-8703(57)90079-0; MOSS A J, 1986, Journal of the American Medical Association, V256, P2985, DOI 10.1001/jama.256.21.2985; MOSS AJ, 1991, CIRCULATION, V84, P1136, DOI 10.1161/01.CIR.84.3.1136; ROMANO C, 1963, Clin Pediatr (Bologna), V45, P656; SCHWARTZ PJ, 1975, AM HEART J, V89, P378, DOI 10.1016/0002-8703(75)90089-7; SHAW TRD, 1981, Q J MED, V200, P451; VINCENT GM, 1992, NEW ENGL J MED, V327, P846, DOI 10.1056/NEJM199209173271204; WARD O C, 1964, J Ir Med Assoc, V54, P103	10	21	21	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 20	1993	341	8847					741	742		10.1016/0140-6736(93)90501-7	http://dx.doi.org/10.1016/0140-6736(93)90501-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KT362	8095637				2022-12-28	WOS:A1993KT36200017
J	BROOME, IJ				BROOME, IJ			ANESTHESIA - HEARING-LOSS AND DURAL PUNCTURE	LANCET			English	Editorial Material							SPINAL-ANESTHESIA				BROOME, IJ (corresponding author), FALKIRK & DIST ROYAL INFIRM, DEPT ANAESTHESIA, FALKIRK, SCOTLAND.							FOG J, 1990, ANESTH ANALG, V70, P517; LEE CM, 1986, ANESTH ANALG, V65, P312, DOI 10.1213/00000539-198603000-00016; MICHEL O, 1992, ANN OTO RHINOL LARYN, V101, P390, DOI 10.1177/000348949210100503; SUNDBERG A, 1992, ANAESTHESIA, V47, P981, DOI 10.1111/j.1365-2044.1992.tb03205.x; VANDAM LD, 1956, JAMA-J AM MED ASSOC, V161, P586, DOI 10.1001/jama.1956.02970070018005	5	7	7	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 13	1993	341	8846					667	668		10.1016/0140-6736(93)90429-K	http://dx.doi.org/10.1016/0140-6736(93)90429-K			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR613	8095578				2022-12-28	WOS:A1993KR61300013
J	FORGACS, I				FORGACS, I			INFLAMMATORY BOWEL-DISEASE - AUTOIMMUNITY IN ULCERATIVE-COLITIS	LANCET			English	Editorial Material							MONOCLONAL-ANTIBODY; IMMUNOGLOBULIN-G; EPITHELIUM; ANTIGEN; SERUM; COLON				FORGACS, I (corresponding author), UNIV LONDON KINGS COLL HOSP,DEPT GASTROENTEROL,LONDON SE5 8RX,ENGLAND.			Burns, Alistair/0000-0002-9837-0645				DAS KM, 1987, J IMMUNOL, V139, P77; DAS KM, 1990, GASTROENTEROLOGY, V98, P464, DOI 10.1016/0016-5085(90)90839-S; DAS KM, 1992, J CLIN GASTROENTEROL, V15, P311, DOI 10.1097/00004836-199212000-00009; HIBI T, 1990, GUT, V31, P1371, DOI 10.1136/gut.31.12.1371; MACDERMOTT RP, 1989, GASTROENTEROLOGY, V96, P764; SNOOK JA, 1991, GUT, V32, P163, DOI 10.1136/gut.32.2.163; SNOOK JA, 1989, Q J MED, V72, P835; TAKAHASHI F, 1985, J CLIN INVEST, V76, P311, DOI 10.1172/JCI111963; TAKAHASI F, 1990, GUT, V31, P1016, DOI 10.1136/gut.31.9.1016	9	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 6	1993	341	8845					602	602		10.1016/0140-6736(93)90361-J	http://dx.doi.org/10.1016/0140-6736(93)90361-J			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KQ234	8094837				2022-12-28	WOS:A1993KQ23400013
J	EBIHARA, T; SEKIZAWA, K; NAKAZAWA, H; SASAKI, H				EBIHARA, T; SEKIZAWA, K; NAKAZAWA, H; SASAKI, H			CAPSAICIN AND SWALLOWING REFLEX	LANCET			English	Letter											EBIHARA, T (corresponding author), TOHOKU UNIV,SCH MED,DEPT GERIATR MED,SENDAI,MIYAGI 980,JAPAN.		EBIHARA, TAKAE/M-9420-2019	EBIHARA, TAKAE/0000-0003-2325-7637				HOLZER P, 1991, PHARMACOL REV, V43, P143; NISHINO T, 1987, ANESTHESIOLOGY, V67, P995, DOI 10.1097/00000542-198712000-00024	2	74	77	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 13	1993	341	8842					432	432		10.1016/0140-6736(93)93023-T	http://dx.doi.org/10.1016/0140-6736(93)93023-T			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM416	8094188				2022-12-28	WOS:A1993KM41600029
J	HEIN, HO; SORENSEN, H; SUADICANI, P; GYNTELBERG, F				HEIN, HO; SORENSEN, H; SUADICANI, P; GYNTELBERG, F			ALCOHOL-CONSUMPTION, LEWIS PHENOTYPES, AND RISK OF ISCHEMIC-HEART-DISEASE	LANCET			English	Article							U-SHAPED CURVE; INSULIN RESISTANCE; LIPOPROTEINS; MORTALITY; GENETICS	We have previously found an increased risk of ischaemic heart disease (IHD) in men with the Lewis phenotype Le(a-b-) and suggested that the Lewis blood group has a close genetic relation with insulin resistance. We have investigated whether any conventional risk factors explain the increased risk in Le(a-b-) men. 3383 men aged 53-75 years were examined in 1985-86, and morbidity and mortality during the next 4 years were recorded. At baseline, we excluded 343 men with a history of myocardial infarction, angina pectoris, intermittent claudication, or stroke. The potential risk factors examined were alcohol consumption, physical activity, tobacco smoking, serum cotinine, serum lipids, body-mass index, blood pressure, prevalence of hypertension and non-insulin-dependent diabetes mellitus, and social class. In 280 (9.6%) men with Le(a-b-), alcohol was the only risk factor significantly associated with risk of IHD. There was a significant inverse dose-effect relation between alcohol consumption and risk; trend tests, with adjustment for age, were significant for fatal IHD (p=0.02), all IHD (p=0.03), and all causes of death (p=0.02). In 2649 (90.4%) men with other phenotypes, there was a limited negative association with alcohol consumption. In Le(a-b-) men, a group genetically at high risk of IHD, alcohol consumption seems to be especially protective. We suggest that alcohol consumption may modify insulin resistance in Le(a-b-) men.	STATE UNIV HOSP COPENHAGEN,RIGSHOSP,DEPT CLIN IMMUNOL,COPENHAGEN,DENMARK; UNIV COPENHAGEN,GLUSTROP HOSP,DEPT INTERNAL MED C,GLOSTRUP POPULAT STUDIES,DK-1168 COPENHAGEN,DENMARK	Rigshospitalet; University of Copenhagen; University of Copenhagen	HEIN, HO (corresponding author), STATE UNIV HOSP COPENHAGEN,RIGSHOSP,EPIDEMIOL RES UNIT,COPENHAGEN MALE STUDY,7122,DK-2200 COPENHAGEN N,DENMARK.							BURSTEIN M, 1970, J LIPID RES, V11, P583; Dean A. G., 1990, EPI INFO VERSION 5 W; EIBERG H, 1983, CLIN GENET, V24, P159; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; GYNTELBERG F, 1974, ACTA MED SCAND, V195, P375; GYNTELBERG F, 1973, DAN MED BULL, V20, P1; HEIN HO, 1992, J INTERN MED, V231, P477, DOI 10.1111/j.1365-2796.1992.tb00963.x; HEIN HO, 1992, J INTERN MED, V232, P471, DOI 10.1111/j.1365-2796.1992.tb00619.x; HHEIN HO, 1992, J INTERN MED, V232, P481; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P407; LOPESVIRELLA MF, 1977, CLIN CHEM, V23, P882; MARMOT M, 1991, BMJ-BRIT MED J, V303, P565, DOI 10.1136/bmj.303.6802.565; MOLLER DE, 1991, NEW ENGL J MED, V325, P938; MOORE RD, 1986, MEDICINE, V65, P242, DOI 10.1097/00005792-198607000-00004; MOURANT AE, 1976, DAMANIEWSKASOBCZAK D; NORUSIS M, 1988, SPS PC PLUS BASE MAN; NORUSIS MJ, 1988, SPSS PC PLUS ADV STA; ORIOL R, 1986, VOX SANG, V51, P161, DOI 10.1111/j.1423-0410.1986.tb01946.x; RAZAY G, 1992, BRIT MED J, V304, P80, DOI 10.1136/bmj.304.6819.80; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; ROSE GA, 1964, LANCET, V1, P296; ROSE GA, 1968, WHO MONOGRAPH SERIES, V56; RUSSELL JC, 1989, ARTERIOSCLEROSIS, V9, P122, DOI 10.1161/01.ATV.9.1.122; Schlesselman JJ, 1982, CASE CONTROL STUDIES; SEIDEL J, 1981, J CLIN CHEM, V19, P838; SHAPER AG, 1990, BRIT J ADDICT, V85, P837; SHAPER AG, 1988, LANCET, V2, P1267; Stahler F, 1977, Med Lab (Stuttg), V30, P29; SUADICANI P, 1992, ATHEROSCLEROSIS, V96, P33, DOI 10.1016/0021-9150(92)90035-F; Svalastoga Kaare, 1959, PRESTIGE CLASS MOBIL	30	68	70	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 13	1993	341	8842					392	396		10.1016/0140-6736(93)92987-5	http://dx.doi.org/10.1016/0140-6736(93)92987-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM416	8094167				2022-12-28	WOS:A1993KM41600002
J	XU, QB; WILLEIT, J; MAROSI, M; KLEINDIENST, R; OBERHOLLENZER, F; KIECHL, S; STULNIG, T; LUEF, G; WICK, G				XU, QB; WILLEIT, J; MAROSI, M; KLEINDIENST, R; OBERHOLLENZER, F; KIECHL, S; STULNIG, T; LUEF, G; WICK, G			ASSOCIATION OF SERUM ANTIBODIES TO HEAT-SHOCK PROTEIN-65 WITH CAROTID ATHEROSCLEROSIS	LANCET			English	Article							B-MODE ULTRASOUND; CELLULAR COMPOSITION; ADJUVANT ARTHRITIS; SYSTEM; INFARCTION; SPECIMENS; INFECTION; CHLAMYDIA; ARTERIES; DISEASE	Arteriosclerotic lesions can be induced in normocholesterolaemic rabbits by immunisation with heat-shock protein (hsp) 65, a stress protein expressed in high concentrations in human atherosclerotic lesions. If an immune reaction to hsp65 also plays a part in human atherogenesis, it should be possible to detect anti-hsp65 antibodies in patients with atherosclerotic lesions. To study the possible relation between immune reaction to hsp65 and atherosclerosis, 867 normal inhabitants of South Tyrol, aged 40-79 years, were selected randomly for determination of serum antibodies against hsp65, simultaneous sonographic assessment of carotid atherosclerotic lesions, and evaluation of established risk factors-ie, blood cholesterol, hypertension, smoking, diabetes mellitus, and obesity. Autoantibodies to nuclear antigens, thyroid antigens, and rheumatoid factors were also measured. Serum anti-hsp65 antibodies were significantly (p<0.05) increased in subjects aged 60-79 years with carotid atherosclerosis compared with those without lesions, and increased antibody concentration was independent of age, sex, and other established risk factors. On the other hand, the incidence and titres of autoantibodies did not correlate with carotid atherosclerotic lesions. Our data provide the first evidence of a strong correlation between anti-hsp65 antibodies and carotid atherosclerosis, suggesting that hsp65 might be involved in the pathogenesis of atherosclerosis.	UNIV INNSBRUCK, SCH MED, NEUROL CLIN, A-6020 INNSBRUCK, AUSTRIA; UNIV INNSBRUCK, SCH MED, INST GEN & EXPTL PATHOL, A-6020 INNSBRUCK, AUSTRIA; HOSP BRUNECK, INTERNAL MED CLIN, BRUNICO, ITALY	University of Innsbruck; University of Innsbruck	XU, QB (corresponding author), AUSTRIAN ACAD SCI, INST BIOMED AGING RES, RENNWEG 10, A-6020 INNSBRUCK, AUSTRIA.			Stulnig, Thomas/0000-0003-3300-6161				ADAM E, 1987, LANCET, V2, P291; BERBERIAN PA, 1990, AM J PATHOL, V136, P71; CROUSE JR, 1986, STROKE, V17, P270, DOI 10.1161/01.STR.17.2.270; ELIAS D, 1990, P NATL ACAD SCI USA, V87, P1576, DOI 10.1073/pnas.87.4.1576; GOWN AM, 1986, AM J PATHOL, V125, P191; GRANDIA AA, 1991, IMMUNOBIOLOGY, V182, P127, DOI 10.1016/S0171-2985(11)80196-8; HAJJAR DP, 1986, AM J PATHOL, V122, P62; HEISS G, 1991, AM J EPIDEMIOL, V134, P250, DOI 10.1093/oxfordjournals.aje.a116078; IVANYI L, 1990, J INFECT DIS, V162, P519, DOI 10.1093/infdis/162.2.519; JOHNSON AD, 1990, ATHEROSCLEROSIS, V84, P111; JONASSON L, 1986, ARTERIOSCLEROSIS, V6, P131, DOI 10.1161/01.ATV.6.2.131; KAUFMANN SHE, 1990, IMMUNOL TODAY, V11, P129, DOI 10.1016/0167-5699(90)90050-J; KIESSLING R, 1991, IMMUNOL REV, V121, P91, DOI 10.1111/j.1600-065X.1991.tb00824.x; LIBBY P, 1991, LAB INVEST, V64, P5; RES PCM, 1988, LANCET, V2, P478, DOI 10.1016/S0140-6736(88)90123-7; SAIKKU P, 1988, LANCET, V2, P983, DOI 10.1016/S0140-6736(88)90741-6; SALONEN R, 1988, ARTERIOSCLEROSIS, V8, P788, DOI 10.1161/01.ATV.8.6.788; SEIFERT PS, 1988, ATHEROSCLEROSIS, V73, P91, DOI 10.1016/0021-9150(88)90030-5; TELL GS, 1988, STROKE, V19, P423, DOI 10.1161/01.STR.19.4.423; THOM DH, 1991, ARTERIOSCLER THROMB, V11, P547, DOI 10.1161/01.ATV.11.3.547; TRAILL KN, 1985, MECH AGEING DEV, V33, P39, DOI 10.1016/0047-6374(85)90108-3; VALTONEN VV, 1991, ANN MED, V23, P539, DOI 10.3109/07853899109150515; VANEDEN W, 1988, NATURE, V331, P171, DOI 10.1038/331171a0; WAKUI H, 1991, INT J BIOCHEM, V23, P975, DOI 10.1016/0020-711X(91)90132-7; WICK G, 1982, IMMUNOFLUORESCENCE T, P219; Wick G., 1992, TRENDS FOOD SCI TECH, V3, P114; XU QB, 1990, CLIN IMMUNOL IMMUNOP, V56, P344, DOI 10.1016/0090-1229(90)90155-J; XU QB, 1992, ARTERIOSCLER THROMB, V12, P789, DOI 10.1161/01.ATV.12.7.789; YAMASHIROYA HM, 1988, AM J PATHOL, V130, P71	29	406	427	1	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 30	1993	341	8840					255	259		10.1016/0140-6736(93)92613-X	http://dx.doi.org/10.1016/0140-6736(93)92613-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK245	8093914				2022-12-28	WOS:A1993KK24500001
J	YAU, SC; ROBERTS, RG; BOBROW, M; MATHEW, CG				YAU, SC; ROBERTS, RG; BOBROW, M; MATHEW, CG			DIRECT DIAGNOSIS OF CARRIERS OF POINT MUTATIONS IN DUCHENNE MUSCULAR-DYSTROPHY	LANCET			English	Note							GENE	In about one-third of patients with Duchenne/Becker muscular dystrophy, the causative mutation does not involve gross alterations in the structure of the dystrophin gene. Prenatal diagnosis and carrier detection for such families is therefore dependent on the indirect method of linkage analysis with polymorphic DNA markers, a method that is subject to error. The identification of point mutations in the dystrophin gene in six affected males enabled us to develop direct assays, based on the polymerase chain reaction, that are specific for each of the mutations. In all six cases, the assays allowed us to offer families accurate carrier testing and prenatal diagnosis.			YAU, SC (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,DIV MED & MOLEC GENET,PAEDIAT RES UNIT,LONDON SE1 9RT,ENGLAND.		Mathew, Christopher G/G-3434-2015; Roberts, Roland G/C-3596-2009	Mathew, Christopher G/0000-0003-4178-1838; Roberts, Roland/0000-0001-6636-1579				ABBS S, 1990, GENOMICS, V7, P602, DOI 10.1016/0888-7543(90)90205-9; ABBS S, 1992, J MED GENET, V29, P191, DOI 10.1136/jmg.29.3.191; CLEMENS PR, 1991, AM J HUM GENET, V49, P951; DENDUNNEN JT, 1989, AM J HUM GENET, V45, P835; HALIASSOS A, 1989, NUCLEIC ACIDS RES, V17, P3606, DOI 10.1093/nar/17.9.3606; ROBERTS RG, 1992, P NATL ACAD SCI USA, V89, P2331, DOI 10.1073/pnas.89.6.2331; ROBERTS RG, 1990, LANCET, V336, P1523, DOI 10.1016/0140-6736(90)93305-9; VANESSEN AJ, 1992, HUM GENET, V88, P249, DOI 10.1007/BF00197255	8	8	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 30	1993	341	8840					273	275		10.1016/0140-6736(93)92618-4	http://dx.doi.org/10.1016/0140-6736(93)92618-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK245	8093919				2022-12-28	WOS:A1993KK24500006
J	MABEY, D				MABEY, D			ONCHOCERCIASIS - IVERMECTIN AND ONCHOCERCAL OPTIC-NERVE LESIONS	LANCET			English	Editorial Material							OCULAR ONCHOCERCIASIS; COMMUNITY				MABEY, D (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT CLIN SCI,LONDON WC1E 7HT,ENGLAND.			Mabey, David/0000-0002-0031-8276				GREENE BM, 1992, J INFECT DIS, V166, P15, DOI 10.1093/infdis/166.1.15; NEWLAND HS, 1991, BRIT J OPHTHALMOL, V75, P163, DOI 10.1136/bjo.75.3.163; REMME J, 1989, TROP MED PARASITOL, V40, P340; TAYLOR HR, 1989, AM J TROP MED HYG, V40, P494, DOI 10.4269/ajtmh.1989.40.494; WHITWORTH JAG, 1991, LANCET, V338, P1100, DOI 10.1016/0140-6736(91)91963-U; ZIMMERMAN PA, 1992, J INFECT DIS, V165, P964, DOI 10.1093/infdis/165.5.964	6	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 16	1993	341	8838					153	154		10.1016/0140-6736(93)90011-5	http://dx.doi.org/10.1016/0140-6736(93)90011-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG627	8093751				2022-12-28	WOS:A1993KG62700011
J	STARZL, TE; FUNG, J; TZAKIS, A; TODO, S; DEMETRIS, AJ; MARINO, IR; DOYLE, H; ZEEVI, A; WARTY, V; MICHAELS, M; KUSNE, S; RUDERT, WA; TRUCCO, M				STARZL, TE; FUNG, J; TZAKIS, A; TODO, S; DEMETRIS, AJ; MARINO, IR; DOYLE, H; ZEEVI, A; WARTY, V; MICHAELS, M; KUSNE, S; RUDERT, WA; TRUCCO, M			BABOON-TO-HUMAN LIVER-TRANSPLANTATION	LANCET			English	Article							CYCLOSPORINE	Our ability to control both the cellular and humoral components of xenograft rejection in laboratory experiments, together with an organ shortage that has placed limits on clinical transplantation services, prompted us to undertake a liver transplantation from a baboon to a 35-year-old man with B virus-associated chronic active hepatitis and human immunodeficiency virus infection. Liver replacement was performed according to conventional surgical techniques. Immunosuppression was with the FK 506-prednisone-prostaglandin regimen used routinely for hepatic allotransplantation, to which a daily non-myelotoxic dose of cyclophosphamide was added. During 70 days of survival, there was little evidence of hepatic rejection by biochemical monitoring or histopathological examination. Products of hepatic synthesis, including clotting factors, became those of the baboon liver with no obvious adverse effects. Death followed a cerebral and subarachnoid haemorrhage that was caused by an angioinvasive aspergillus infection. However, the underlying cause of death was widespread biliary sludge that formed in the biliary tree despite a seemingly satisfactory choledochojejunostomy. During life and in necropsy samples, there was evidence of the chimerism that we believe is integral to the acceptance of both xenografts and allografts. Our experience has shown the feasibility of controlling the rejection of the baboon liver xenograft in a human recipient. The biliary stasis that was the beginning of lethal infectious complications may be correctable by modifications of surgical technique. In further trials, the error of over-immunosuppression should be avoidable.	UNIV PITTSBURGH,HLTH SCI CTR,PITTSBURGH TRANSPLANT INST,PITTSBURGH,PA 15213; UNIV PITTSBURGH,HLTH SCI CTR,DEPT PATHOL,PITTSBURGH,PA 15213; UNIV PITTSBURGH,HLTH SCI CTR,DEPT INFECT DIS,PITTSBURGH,PA 15213; UNIV PITTSBURGH,HLTH SCI CTR,DEPT PAEDIAT,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	STARZL, TE (corresponding author), UNIV PITTSBURGH,HLTH SCI CTR,DEPT SURG,3601 5TH AVE,5C FALK CLIN,PITTSBURGH,PA 15213, USA.		FUNG, John Julian/A-2679-2012; Marino, Ignazio R./ABB-3729-2020	FUNG, John Julian/0000-0002-3038-0441; Marino, Ignazio/0000-0002-1519-8385	NIDDK NIH HHS [R01 DK029961-19, DK 29961] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK029961, R01DK029961] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALPER CA, 1969, SCIENCE, V163, P286, DOI 10.1126/science.163.3864.286; ASONUMA K, 1991, TRANSPLANTATION, V51, P164, DOI 10.1097/00007890-199101000-00025; BAILEY LL, 1985, JAMA-J AM MED ASSOC, V254, P3321, DOI 10.1001/jama.254.23.3321; BARNARD CN, 1977, S AFR MED J, V52, P1035; CANO MJ, 1990, COMP BIOCHEM PHYS B, V96, P647, DOI 10.1016/0305-0491(90)90208-B; CRAWFORD RJ, 1986, GENE, V46, P161, DOI 10.1016/0378-1119(86)90400-2; ESSEX M, 1992, AIDS ETIOLOGY DIAGNO, P3; FRANCAVILLA A, 1990, HEPATOLOGY, V12, P1134, DOI 10.1002/hep.1840120510; HASAN RI, IN PRESS TRANSPLANT; HASAN RIR, 1992, TRANSPLANT P, V24, P517; HITCHCOCK CR, 1964, JAMA-J AM MED ASSOC, V189, P158; IWAKI Y, 1988, CLIN TRANSPLANT, V2, P81; JACOBSON SK, 1991, LANCET, V337, P794, DOI 10.1016/0140-6736(91)91414-P; KARPAS A, 1992, P NATL ACAD SCI USA, V89, P8351, DOI 10.1073/pnas.89.17.8351; KELLY RH, 1980, CLIN CHEM, V26, P396; MANEZ R, IN PRESS TRANSPLANT; MORAN M, 1990, NEW ENGL J MED, V322, P1183, DOI 10.1056/NEJM199004263221703; MURASE N, IN PRESS TRANSPLANTA; PORTER KA, 1964, EXPERIENCE RENAL TRA, P284; STARZL TE, 1977, SURGERY, V81, P212; STARZL TE, 1964, TRANSPLANTATION, V2, P752; STARZL TE, 1992, LANCET, V339, P1579, DOI 10.1016/0140-6736(92)91840-5; STARZL TE, 1990, LIVER TRANSPLANT, P18; TAKAYA S, 1992, TRANSPLANTATION, V54, P927; TAKAYA S, IN PRESS TRANSPLANT; TODO S, 1991, HEPATOLOGY, V13, P619, DOI 10.1002/hep.1840130402; TZAKIS AG, 1990, TRANSPLANTATION, V49, P354, DOI 10.1097/00007890-199002000-00025; VALDIVIA LA, IN PRESS TRANSPLANTA; WOLPL A, 1985, TRANSPLANTATION, V40, P154, DOI 10.1097/00007890-198508000-00009	29	347	367	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 9	1993	341	8837					65	71		10.1016/0140-6736(93)92553-6	http://dx.doi.org/10.1016/0140-6736(93)92553-6			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF870	8093402	Green Accepted			2022-12-28	WOS:A1993KF87000001
J	JOUNG, JK; KOEPP, DM; HOCHSCHILD, A				JOUNG, JK; KOEPP, DM; HOCHSCHILD, A			SYNERGISTIC ACTIVATION OF TRANSCRIPTION BY BACTERIOPHAGE-LAMBDA CI-PROTEIN AND ESCHERICHIA-COLI CAMP RECEPTOR PROTEIN	SCIENCE			English	Article							INTEGRATION HOST FACTOR; POLYMERASE-ALPHA SUBUNIT; ESCHERICHIA-COLI; RNA-POLYMERASE; POSITIVE CONTROL; CYCLIC-AMP; CRYSTAL-STRUCTURE; PHAGE REPRESSOR; GENE; DNA	Two heterologous prokaryotic activators, the bacteriophage lambda cI protein (lambda cI) and the Escherichia coli cyclic AMP receptor protein (CRP), were shown to activate transcription synergistically from an artificial promoter bearing binding sites for both proteins. The synergy depends on a functional activation (positive control) surface on each activator. These results imply that both proteins interact directly with RNA polymerase and thus suggest a precise mechanism for transcriptional synergy: the interaction of two activators with two distinct surfaces of RNA polymerase.	HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02115	Harvard University; Harvard Medical School					OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP1OD006862] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44025] Funding Source: Medline; NIH HHS [DP1 OD006862] Funding Source: Medline	OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		AIBA H, 1982, NUCLEIC ACIDS RES, V10, P1345, DOI 10.1093/nar/10.4.1345; BEAMER LJ, 1992, J MOL BIOL, V227, P177, DOI 10.1016/0022-2836(92)90690-L; BELL A, 1990, NUCLEIC ACIDS RES, V18, P7243, DOI 10.1093/nar/18.24.7243; BUSBY S, 1994, J MOL BIOL, V241, P341, DOI 10.1006/jmbi.1994.1511; BUSHMAN FD, 1989, CELL, V58, P1163, DOI 10.1016/0092-8674(89)90514-X; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CHEN Y, 1994, SCIENCE, V265, P90, DOI 10.1126/science.8016656; CLAVERIEMARTIN F, 1991, P NATL ACAD SCI USA, V88, P1631, DOI 10.1073/pnas.88.5.1631; COSSART P, 1982, NUCLEIC ACIDS RES, V10, P1363, DOI 10.1093/nar/10.4.1363; DONG XR, 1992, J BIOL CHEM, V267, P14122; EBRIGHT RH, 1993, MOL MICROBIOL, V8, P797, DOI 10.1111/j.1365-2958.1993.tb01626.x; ESCHENLAUER AC, 1991, J BACTERIOL, V173, P5024, DOI 10.1128/jb.173.16.5024-5029.1991; GASTON K, 1990, CELL, V62, P733, DOI 10.1016/0092-8674(90)90118-X; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P2236, DOI 10.1073/pnas.79.7.2236; HEYDUK T, 1993, NATURE, V364, P548, DOI 10.1038/364548a0; HOCHSCHILD A, 1988, NATURE, V336, P353, DOI 10.1038/336353a0; HOCHSCHILD A, 1983, CELL, V32, P319, DOI 10.1016/0092-8674(83)90451-8; HOOVER TR, 1990, CELL, V63, P11, DOI 10.1016/0092-8674(90)90284-L; HORI R, 1994, CURR OPIN GENET DEV, V4, P236, DOI 10.1016/S0959-437X(05)80050-4; IGARASHI K, 1991, CELL, V65, P1015, DOI 10.1016/0092-8674(91)90553-B; ISHIHAMA A, 1992, MOL MICROBIOL, V6, P3283, DOI 10.1111/j.1365-2958.1992.tb02196.x; JENNINGS MP, 1993, MOL MICROBIOL, V9, P155, DOI 10.1111/j.1365-2958.1993.tb01677.x; JOHNSON AD, 1979, P NATL ACAD SCI USA, V76, P5061, DOI 10.1073/pnas.76.10.5061; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; JOUNG JK, 1993, P NATL ACAD SCI USA, V90, P3083, DOI 10.1073/pnas.90.7.3083; JOUNG JK, UNPUB; KINGSTON RE, 1994, CURR BIOL, V4, P325, DOI 10.1016/S0960-9822(00)00071-3; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; KULDELL N, 1994, J BACTERIOL, V176, P2991, DOI 10.1128/JB.176.10.2991-2998.1994; LI M, 1994, SCIENCE, V263, P75, DOI 10.1126/science.8272867; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; LODGE J, 1992, FEMS MICROBIOL LETT, V95, P271; MCKAY DB, 1981, NATURE, V290, P744, DOI 10.1038/290744a0; MCKAY DB, 1982, J BIOL CHEM, V257, P9518; MEYER BJ, 1980, J MOL BIOL, V139, P195, DOI 10.1016/0022-2836(80)90304-6; Miller J.H., 1972, EXPT MOL GENETICS; PABO CO, 1982, NATURE, V298, P443, DOI 10.1038/298443a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PTASHNE M, 1992, GENETIC SWITCH GENE; RICHET E, 1991, CELL, V66, P1185, DOI 10.1016/0092-8674(91)90041-V; ROSS W, 1993, SCIENCE, V262, P1407, DOI 10.1126/science.8248780; SCHRODER I, 1993, J BIOL CHEM, V268, P771; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; STEWART V, 1993, MOL MICROBIOL, V9, P425, DOI 10.1111/j.1365-2958.1993.tb01704.x; USHIDA C, 1990, NUCLEIC ACIDS RES, V18, P6325, DOI 10.1093/nar/18.21.6325; WALKER MS, 1992, J BACTERIOL, V174, P1119, DOI 10.1128/jb.174.4.1119-1123.1992; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; WHIPPLE FW, 1994, GENE DEV, V8, P1212, DOI 10.1101/gad.8.10.1212; ZHOU YH, 1993, P NATL ACAD SCI USA, V90, P6081, DOI 10.1073/pnas.90.13.6081; ZOU C, 1992, MOL MICROBIOL, V6, P2599, DOI 10.1111/j.1365-2958.1992.tb01437.x	52	64	64	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 23	1994	265	5180					1863	1866		10.1126/science.8091212	http://dx.doi.org/10.1126/science.8091212			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH258	8091212				2022-12-28	WOS:A1994PH25800032
J	AVORN, J; MONANE, M; GURWITZ, JH; GLYNN, RJ; CHOODNOVSKIY, I; LIPSITZ, LA				AVORN, J; MONANE, M; GURWITZ, JH; GLYNN, RJ; CHOODNOVSKIY, I; LIPSITZ, LA			REDUCTION OF BACTERIURIA AND PYURIA AFTER INGESTION OF CRANBERRY JUICE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ASYMPTOMATIC BACTERIURIA; ESCHERICHIA-COLI; ELDERLY WOMEN; ADHERENCE; URINARY; EPIDEMIOLOGY; POPULATION	Objective.-To determine the effect of regular intake of cranberry juice beverage on bacteriuria and pyuria in elderly women. Design.-Randomized, double-blind, placebo-controlled trial. Subjects.-Volunteer sample of 153 elderly women (mean age, 78.5 years). Intervention.-Subjects were randomly assigned to consume 300 mt per day of a commercially available standard cranberry beverage or a specially prepared synthetic placebo drink that was indistinguishable in taste, appearance, and vitamin C content but lacked cranberry content. Outcome Measures.-A baseline urine sample and six clean-voided study urine samples were collected at approximately 1-month intervals and tested quantitatively for bacteriuria and the presence of white blood cells. Results.-Subjects randomized to the cranberry beverage had odds of bacteriuria (defined as organisms numbering greater than or equal to 10(5)/mL) with pyuria that were only 42% of the odds in the control group (P=.004). Their odds of remaining bacteriuric-pyuric, given that they were bacteriuric-pyuric in the previous month, were only 27% of the odds in the control group (P=.006). Conclusions.-These findings suggest that use of a cranberry beverage reduces the frequency of bacteriuria with pyuria in older women. Prevalent beliefs about the effects of cranberry juice on the urinary tract may have microbiologic justification.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV GERONTOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,CTR GERIAT RES & TRAINING,BOSTON,MA; BRIGHAM & WOMENS HOSP,DEPT MED,DIV PREVENTIVE MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,HEBREW REHABILITAT CTR AGE,BOSTON,MA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	AVORN, J (corresponding author), BRIGHAM & WOMENS HOSP,DEPT MED,PROGRAM ANAL CLIN STRATEGIES,221 LONGWOOD AVE,BOSTON,MA 02115, USA.							ABRUTYN E, 1991, J AM GERIATR SOC, V39, P388, DOI 10.1111/j.1532-5415.1991.tb02905.x; BERK SL, 1989, MED CLIN N AM, V67, P273; Blatherwick NR, 1914, ARCH INTERN MED, V14, P409; BODEL PT, 1959, J LAB CLIN MED, V54, P881; BOSCIA JA, 1986, AM J MED, V80, P208, DOI 10.1016/0002-9343(86)90011-2; Fellers CR, 1933, J NUTR, V6, P455, DOI 10.1093/jn/6.5.455; KAHN HD, 1967, J AM DIET ASSOC, V51, P251; KINNEY AB, 1979, NURS RES, V28, P287; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; MCLEOD DC, 1978, AM J HOSP PHARM, V35, P654; MOEN D. V., 1962, WISCONSIN MED JOUR, V61, P282; NICKEY KE, 1975, ARCH PHYS MED REHAB, V56, P556; NICOLLE LE, 1987, AM J MED, V83, P27, DOI 10.1016/0002-9343(87)90493-1; NICOLLE LE, 1988, J INFECT DIS, V157, P65, DOI 10.1093/infdis/157.1.65; NORDENSTAM G, 1989, AM J EPIDEMIOL, V130, P1176, DOI 10.1093/oxfordjournals.aje.a115446; OFEK I, 1991, NEW ENGL J MED, V324, P1599; Papas P N, 1966, Southwest Med, V47, P17; SCHMIDT DR, 1988, MICROBIOS, V55, P173; Schultz A, 1984, J Community Health Nurs, V1, P159, DOI 10.1207/s15327655jchn0103_5; Schultz BM., 1991, GERIATR NEPHROL UROL, V1, P29, DOI [10.1007/BF00451859, DOI 10.1007/BF00451859]; SOBOTA AE, 1984, J UROLOGY, V131, P1013, DOI 10.1016/S0022-5347(17)50751-X; SOURANDER LB, 1966, ANN MED INTERNAE S45, V55, P7; ZAFRIRI D, 1989, ANTIMICROB AGENTS CH, V33, P92, DOI 10.1128/AAC.33.1.92; ZINSSER HH, 1964, MED CLIN N AM, V48, P293, DOI 10.1016/S0025-7125(16)33463-0	24	361	380	2	43	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 9	1994	271	10					751	754		10.1001/jama.271.10.751	http://dx.doi.org/10.1001/jama.271.10.751			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY288	8093138				2022-12-28	WOS:A1994MY28800028
J	OU, CY; TAKEBE, Y; WENIGER, BG; LUO, CC; KALISH, ML; AUWANIT, W; YAMAZAKI, S; GAYLE, HD; YOUNG, NL; SCHOCHETMAN, G				OU, CY; TAKEBE, Y; WENIGER, BG; LUO, CC; KALISH, ML; AUWANIT, W; YAMAZAKI, S; GAYLE, HD; YOUNG, NL; SCHOCHETMAN, G			INDEPENDENT INTRODUCTION OF 2 MAJOR HIV-1 GENOTYPES INTO DISTINCT HIGH-RISK POPULATIONS IN THAILAND	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PRINCIPAL NEUTRALIZING DETERMINANT; SEQUENCE-ANALYSIS; TYPE-1; AIDS; SUBSTITUTIONS; EVOLUTION; REGIONS	To investigate the genetic heterogeneity and epidemiological distribution of human immunodeficiency virus type 1 (HIV-1) in Thailand, we determined proviral sequences for 63 HIV-1-infected patients in various risk groups from all over the country between April and July, 1991. Two distinct genotypes of HIV-1, A and B, were found to segregate by mode of transmission. Of 29 sexually infected patients, 25 (86%) had HIV-1 of genotype A and 4 (14%) had genotype B. Among 29 injecting drug users, probably parenterally infected, only 7 (24%) had genotype A and 22 (76%) had genotype B. This segregation is unlikely to have arisen by chance (p < 0.001). No patient was found to have dual infection. Nucleotide divergence averaged 3.4% among genotype-A-infected patients and 3.5% among genotype-B-infected patients, but 22.0% between the genotypes. 37 of 40 isolates (both genotypes) had the GPGQ tetrapeptide at the tip of the V3 loop, which is common in African HIV-1 strains but rare in North American and European strains, where the GPGR motif predominates. These findings suggest that the waves of HIV-1 infection in injecting drug users and in sexually infected patients in Thailand may not be epidemiologically linked. The nucleotide divergence data point to the separate introductions of the two genotypes into Thailand. Further studies in Thailand and neighbouring countries will be useful in the design and selection of candidate HIV vaccines.	NATL INST HLTH,TOKYO 141,JAPAN; NATL INST HLTH,BANGKOK,THAILAND; HIV AIDS COLLABORAT,BANGKOK,THAILAND	National Institute of Health Sciences - Japan; Ministry of Public Health - Thailand				Weniger, Bruce/0000-0002-5450-5464				ALIZON M, 1986, CELL, V46, P63, DOI 10.1016/0092-8674(86)90860-3; BALFE P, 1990, J VIROL, V64, P6221, DOI 10.1128/JVI.64.12.6221-6233.1990; DELASSUS S, 1991, J VIROL, V65, P225, DOI 10.1128/JVI.65.1.225-231.1991; GOLDSMITH MF, 1991, JAMA-J AM MED ASSOC, V266, P1048, DOI 10.1001/jama.266.8.1048; GOODENOW M, 1989, J ACQ IMMUN DEF SYND, V2, P344; HATTORI T, 1991, AIDS RES HUM RETROV, V7, P825, DOI 10.1089/aid.1991.7.825; KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581; LAROSA GJ, 1990, SCIENCE, V249, P932, DOI 10.1126/science.2392685; MELOEN RH, 1989, J GEN VIROL, V70, P1505, DOI 10.1099/0022-1317-70-6-1505; MYERHANS A, 1989, CELL, V58, P901; Myers G, 1992, COMPILATION ANAL NUC; ORAM JD, 1991, AIDS RES HUM RETROV, V7, P605, DOI 10.1089/aid.1991.7.605; OU CY, 1992, AIDS RES HUM RETROV, V8, P1471, DOI 10.1089/aid.1992.8.1471; OU CY, 1992, SCIENCE, V256, P1165, DOI 10.1126/science.256.5060.1165; OU CY, 1992, 8 INT C AIDS AMST; PAU CP, 1993, AIDS, V7, P337, DOI 10.1097/00002030-199303000-00005; Phongpaichit Pasuk, 1982, PEASANT GIRLS BANGKO, P71; ROGERS MF, 1989, NEW ENGL J MED, V320, P1649, DOI 10.1056/NEJM198906223202503; SIRIPRAPASRI T, 1991, AIDS, V5, P579; STARCICH BR, 1986, CELL, V45, P637, DOI 10.1016/0092-8674(86)90778-6; Traisupa A., 1990, Thai AIDS Journal, V2, P57; TRAISUPA A, 1987, GENITOURIN MED, V63, P106; Ungchusak K., 1989, Thai AIDS Journal, V1, P57; VANICHSENI S, 1990, THAI AIDS J, V1, P75; VARTANIAN JP, 1991, J VIROL, V65, P1779, DOI 10.1128/JVI.65.4.1779-1788.1991; WANGROONGSARB Y, 1985, Southeast Asian Journal of Tropical Medicine and Public Health, V16, P517; Weniger B G, 1991, AIDS, V5 Suppl 2, pS71, DOI 10.1097/00002030-199101001-00011; 1984, WKLY EPIDEMIOL SURVE, V15, P509; 1989, 1989 ANN STAT REP TO, P1	29	294	306	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 8	1993	341	8854					1171	1174		10.1016/0140-6736(93)91001-3	http://dx.doi.org/10.1016/0140-6736(93)91001-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB017	8098076				2022-12-28	WOS:A1993LB01700003
J	KNIPSCHILD, P				KNIPSCHILD, P			SEARCHING FOR ALTERNATIVES - LOSER PAYS	LANCET			English	Editorial Material											KNIPSCHILD, P (corresponding author), UNIV LIMBURG,DEPT EPIDEMIOL,POB 616,6200 MD MAASTRICHT,NETHERLANDS.							Hofstee W.K.B., 1980, EMPIRISCHE DISCUSSIE; KLEIJNEN J, 1991, BRIT MED J, V302, P316, DOI 10.1136/bmj.302.6772.316; KLEIJNEN J, 1992, PHARM WEEKBLAD, V14, P316, DOI 10.1007/BF01977620; KLEIJNEN J, 1992, BRIT J CLIN PHARMACO, V34, P352, DOI 10.1111/j.1365-2125.1992.tb05642.x; KNIPSCHILD P, 1989, BRIT MED J, V299, P491, DOI 10.1136/bmj.299.6697.491; KNIPSCHILD P, 1988, BRIT MED J, V297, P1578, DOI 10.1136/bmj.297.6663.1578; KNIPSCHILD P, 1988, PHARMACEUTISCH WEEKB, V123, P4; TERRIET G, 1990, J CLIN EPIDEMIOL, V43, P1191, DOI 10.1016/0895-4356(90)90020-P	8	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 1	1993	341	8853					1135	1136		10.1016/0140-6736(93)93140-V	http://dx.doi.org/10.1016/0140-6736(93)93140-V			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ687	8097816				2022-12-28	WOS:A1993KZ68700016
J	TEVELDE, ER				TEVELDE, ER			REPRODUCTIVE MEDICINE - DISAPPEARING OVARIAN FOLLICLES AND REPRODUCTIVE AGING	LANCET			English	Editorial Material							CHILDBEARING; FECUNDITY				TEVELDE, ER (corresponding author), UNIV UTRECHT HOSP,DEPT OBSTET & GYNAECOL,3511 GV UTRECHT,NETHERLANDS.							BONGAARTS J, 1982, 89 CTR POL STUD POP, P1; FADDY MJ, 1992, HUM REPROD, V7, P1342, DOI 10.1093/oxfordjournals.humrep.a137570; HENDERSON SA, 1968, NATURE, V218, P22, DOI 10.1038/218022a0; LERIDON H, 1977, P202; MOSHER WD, 1991, FERTIL STERIL, V56, P192; SAUER MV, 1993, LANCET, V341, P321, DOI 10.1016/0140-6736(93)90132-Z; SPEROFF L, 1989, CLIN GYNECOLOGIC END, P124; STEIN ZA, 1985, AM J EPIDEMIOL, V121, P327, DOI 10.1093/oxfordjournals.aje.a114004; Treloar AE, 1981, MATURITAS, V19, P49; VANNOORDZAADSTRA BM, 1991, BMJ-BRIT MED J, V302, P1361, DOI 10.1136/bmj.302.6789.1361	10	17	17	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 1	1993	341	8853					1125	1126		10.1016/0140-6736(93)93133-L	http://dx.doi.org/10.1016/0140-6736(93)93133-L			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ687	8097809				2022-12-28	WOS:A1993KZ68700009
J	HSIEH, CS; MACATONIA, SE; TRIPP, CS; WOLF, SF; OGARRA, A; MURPHY, KM				HSIEH, CS; MACATONIA, SE; TRIPP, CS; WOLF, SF; OGARRA, A; MURPHY, KM			DEVELOPMENT OF TH1 CD4+ T-CELLS THROUGH IL-12 PRODUCED BY LISTERIA-INDUCED MACROPHAGES	SCIENCE			English	Article							INHIBITS CYTOKINE PRODUCTION; TUMOR-NECROSIS-FACTOR; LYMPHOCYTES-T; IFN-GAMMA; CUTANEOUS LEISHMANIASIS; LYMPHOKINE PRODUCTION; STIMULATORY FACTOR; INTERFERON-GAMMA; HELPER CELL; SCID MICE	Development of the appropriate CD4+ T helper (T(H)) subset during an immune response is important for disease resolution. With the use of naive, ovalbumin-specific alphabeta T cell receptor transgenic T cells, it was found that heat-killed Listeria monocytogenes induced T(H)1 development in vitro through macrophage production of interleukin-12 (IL-12). Moreover, inhibition of macrophage production of IL-12 may explain the ability of IL-10 to suppress T(H)1 development. Murine immune responses to L. monocytogenes in vivo are of the appropriate T(H)1 phenotype. Therefore, this regulatory pathway may have evolved to enable innate immune cells, through interactions with microbial pathogens, to direct development of specific immunity toward the appropriate T(H) phenotype.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110; DNAX RES INST MOLEC & CELLULAR BIOL INC,PALO ALTO,CA 94304; GENET INST,CAMBRIDGE,MA 02140	Washington University (WUSTL); Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.			Yang, Chen/G-1379-2010	O'Garra, Anne/0000-0001-9845-6134	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007200] Funding Source: NIH RePORTER; NIGMS NIH HHS [5 T32 GM07200-17] Funding Source: Medline; PHS HHS [1 PO1 A131238-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BANCROFT GJ, 1989, J IMMUNOL, V143, P127; BOTTOMLY K, 1988, IMMUNOL TODAY, V9, P268, DOI 10.1016/0167-5699(88)91308-4; CHAN SH, 1991, J EXP MED, V173, P869, DOI 10.1084/jem.173.4.869; CROFT M, 1992, J EXP MED, V176, P1431, DOI 10.1084/jem.176.5.1431; DANDREA A, 1992, J EXP MED, V176, P1387, DOI 10.1084/jem.176.5.1387; DAYNES RA, 1990, J EXP MED, V171, P979, DOI 10.1084/jem.171.4.979; de Waal Malefyt R., 1991, J EXP MED, V174, P1209, DOI DOI 10.1084/JEM.174.5.1209; FINKELMAN FD, 1991, J EXP MED, V174, P1179, DOI 10.1084/jem.174.5.1179; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; FIORENTINO DF, 1991, J IMMUNOL, V146, P3444; GAJEWSKI TF, 1988, J IMMUNOL, V140, P4245; HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59; HSIEH CC, UNPUB; HSIEH CS, 1992, P NATL ACAD SCI USA, V89, P6065, DOI 10.1073/pnas.89.13.6065; HSIEH CS, IN PRESS INT IMMUNOL; KOBAYASHI M, 1989, J EXP MED, V170, P827, DOI 10.1084/jem.170.3.827; KULLBERG MC, 1992, J IMMUNOL, V148, P3264; LEGROS G, 1990, J EXP MED, V172, P921, DOI 10.1084/jem.172.3.921; LI TK, 1993, J IMMUNOL, V150, P1680; MACATONIA SE, UNPUB; MAGEE DM, 1988, J IMMUNOL, V141, P3203; MAGGI E, 1992, J IMMUNOL, V148, P2142; MIELKE MEA, 1988, INFECT IMMUN, V56, P1920, DOI 10.1128/IAI.56.8.1920-1925.1988; MOORE KE, IN PRESS; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; NAUME B, 1992, J IMMUNOL, V148, P2429; SCOTT P, 1988, J EXP MED, V168, P1675, DOI 10.1084/jem.168.5.1675; SCOTT P, 1991, IMMUNOL TODAY, V12, P346, DOI 10.1016/0167-5699(91)90063-Y; SCOTT P, 1991, J IMMUNOL, V147, P3149; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; SHER A, 1991, J IMMUNOL, V147, P2713; SHER A, 1992, IMMUNOL REV, V127, P183, DOI 10.1111/j.1600-065X.1992.tb01414.x; SHER A, 1992, ANNU REV IMMUNOL, V10, P385, DOI 10.1146/annurev.iy.10.040192.002125; SILVA JS, 1992, J EXP MED, V175, P169, DOI 10.1084/jem.175.1.169; Steinmann RM, 1999, ANNU REV IMMUNOL, V9, P271; SWAIN SL, 1991, J IMMUNOL, V147, P2991; SWAIN SL, 1990, J IMMUNOL, V145, P3796; TRIPP CS, IN PRESS P NATL ACAD; URBAN JF, 1992, IMMUNOL REV, V127, P205, DOI 10.1111/j.1600-065X.1992.tb01415.x; WHERRY JC, 1991, INFECT IMMUN, V59, P1709, DOI 10.1128/IAI.59.5.1709-1715.1991	43	2901	2980	3	119	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 23	1993	260	5107					547	549		10.1126/science.8097338	http://dx.doi.org/10.1126/science.8097338			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KY504	8097338				2022-12-28	WOS:A1993KY50400036
J	GREIG, S; AKAM, M				GREIG, S; AKAM, M			HOMEOTIC GENES AUTONOMOUSLY SPECIFY ONE ASPECT OF PATTERN IN THE DROSOPHILA MESODERM	NATURE			English	Article							EMBRYOS; EXPRESSION; TWIST; GRADIENT; PROTEIN	TRANSPLANTATION and ablation experiments have led to the generalization that in insects the mesoderm is naive, and that pattern is imposed upon it by the ectoderm1-6. This has been demonstrated directly by mosaic analysis for the case of one muscle in Drosophila. The unique character of this muscle depends on the activity of sex-determining and homeotic genes, not in the muscle itself, but in the nerve that innervates it7. Indirect evidence suggests, however, that homeotic genes specify some aspects of mesoderm patterning autonomously. Homeotic genes are expressed in the mesoderm, and are regulated in a segment-specific pattern analogous to, but different from, that seen in the ectoderm6,8. Moreover, the effects of homeotic mutations on the muscles do not always mirror transformations seen in the epidermis9,10. Here we examine this problem directly, by expressing homeotic genes ectopically in the mesoderm without altering their expression in the overlying ectoderm. We find that the pattern of adult muscle precursor cells characteristic of the thorax can be converted to that seen in the abdomen by expressing the homeotic gene abdominal-A specifically in the mesoderm.	DEPT GENET,CAMBRIDGE CB2 1QR,ENGLAND		GREIG, S (corresponding author), WELLCOME CRC INST,TENNIS COURT RD,CAMBRIDGE CB2 1QR,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AKAM ME, 1985, EMBO J, V4, P1689, DOI 10.1002/j.1460-2075.1985.tb03838.x; BATE MA, 1991, DEVELOPMENT, V113, P7; BEER J, 1987, ROUX ARCH DEV BIOL, V196, P222, DOI 10.1007/BF00376346; Bock E, 1942, ROUX ARCH, V141, P159; BRAND A, IN PRESS DEVELOPMENT; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; Cohen SM., 1993, DEV DROSOPHILA MELAN; FISCHER JA, 1988, NATURE, V332, P853, DOI 10.1038/332853a0; Haget A., 1953, Bulletin Biol Paris, V87, P123; HOOPER JE, 1986, EMBO J, V5, P2321, DOI 10.1002/j.1460-2075.1986.tb04500.x; JIANG J, 1991, GENE DEV, V5, P1881, DOI 10.1101/gad.5.10.1881; JIANG J, 1991, GENE DEV, V5, P265, DOI 10.1101/gad.5.2.265; KARCH F, 1990, GENE DEV, V4, P1573, DOI 10.1101/gad.4.9.1573; LAWRENCE PA, 1986, CELL, V45, P505, DOI 10.1016/0092-8674(86)90282-5; LAWRENCE PA, 1983, GENETICS NEW FRONTIE; LEPTIN M, 1991, GENE DEV, V5, P1568, DOI 10.1101/gad.5.9.1568; MACIAS A, 1990, DEVELOPMENT, V110, P1197; ORNITZ DM, 1991, P NATL ACAD SCI USA, V88, P698, DOI 10.1073/pnas.88.3.698; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; SAHOTA TS, 1967, CAN J ZOOLOG, V45, P421, DOI 10.1139/z67-053; THISSE C, 1991, CELL, V65, P1191, DOI 10.1016/0092-8674(91)90014-P; WILLIAMS GJA, 1980, J EMBRYOL EXP MORPH, V58, P13	23	143	147	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 15	1993	362	6421					630	632		10.1038/362630a0	http://dx.doi.org/10.1038/362630a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KX438	8096627				2022-12-28	WOS:A1993KX43800047
J	INGLIS, TJJ; SHERRATT, MJ; SPROAT, LJ; GIBSON, JS; HAWKEY, PM				INGLIS, TJJ; SHERRATT, MJ; SPROAT, LJ; GIBSON, JS; HAWKEY, PM			GASTRODUODENAL DYSFUNCTION AND BACTERIAL-COLONIZATION OF THE VENTILATED LUNG	LANCET			English	Article							MULTIPLE TRAUMA PATIENTS; RESPIRATORY-TRACT; NOSOCOMIAL PNEUMONIA; COLONIZATION; DECONTAMINATION; CIMETIDINE; INFECTIONS; FLORA	The source of ventilator-associated pneumonia (gastric or oropharyngeal flora) remains controversial. We investigated the source of bacterial colonisation of the ventilated lung in 100 consecutive intensive-care patients. Gram-negative bacilli were isolated from the lower respiratory tract in 19 patients. Bacteria isolated from the stomach contents either previously or at the same time were identical to lower respiratory isolates in 11 patients. No gram-negative oropharyngeal isolate was identical to a lower respiratory tract isolate. Gastric bacterial overgrowth with gram-negative bacilli was associated with the presence of bilirubin in the stomach contents. Detectable bilirubin was also associated with subsequent acquisition of gram-negative bacilli in the lower respiratory tract. Only 5 gastric aspirate specimens with pH <3.5 contained gram-negative bacilli. These results establish a relation between duodenal reflux and subsequent bacterial colonisation of the lower respiratory tract. Restoration of normal gastroduodenal motility might help prevent pneumonia in intensive-care patients.	UNIV LEEDS,DEPT MICROBIOL,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND; GEN INFIRM,INTENS CARE UNIT,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND	University of Leeds; Leeds General Infirmary			Sherratt, Michael J/A-1175-2015	Sherratt, Michael J/0000-0003-4759-6617				ATHERTON ST, 1978, LANCET, V2, P968; CRAIG CP, 1984, AM J INFECT CONTROL, V12, P233, DOI 10.1016/0196-6553(84)90114-7; CRAVEN DE, 1986, AM REV RESPIR DIS, V133, P792; DONOWITZ LG, 1986, INFECT CONT HOSP EP, V7, P23, DOI 10.1017/S0195941700063748; DRIKS MR, 1987, NEW ENGL J MED, V317, P1376, DOI 10.1056/NEJM198711263172204; DUMOULIN GC, 1982, LANCET, V1, P242; GRAY JDA, 1967, GUT, V8, P574, DOI 10.1136/gut.8.6.574; GRAYCEY M, 1983, HUMAN INTESTINAL MIC, P495; HAMMOND JMJ, 1992, LANCET, V340, P5, DOI 10.1016/0140-6736(92)92422-C; Hawkey PM, 1989, MED BACTERIOLOGY PRA; HAWKEY PM, 1989, MED BACTERIOLOGY PRA, P247; INGLIS T, 1991, BR J ANAESTHESIOL, V68, P499; JOHANSON WG, 1972, ANN INTERN MED, V77, P701, DOI 10.7326/0003-4819-77-5-701; Malloy HT, 1937, J BIOL CHEM, V119, P481; POWER I, 1989, ANAESTHESIA, V44, P563, DOI 10.1111/j.1365-2044.1989.tb11442.x; RUDDELL WSJ, 1980, LANCET, V1, P672; STOUTENBEEK CP, 1984, INTENS CARE MED, V10, P185, DOI 10.1007/BF00259435; STOUTENBEEK CP, 1987, J TRAUMA, V27, P357, DOI 10.1097/00005373-198704000-00003; WOODS CR, 1992, J CLIN MICROBIOL, V30, P2921, DOI 10.1128/JCM.30.11.2921-2929.1992	19	133	135	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 10	1993	341	8850					911	913		10.1016/0140-6736(93)91208-4	http://dx.doi.org/10.1016/0140-6736(93)91208-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW981	8096263				2022-12-28	WOS:A1993KW98100002
J	MOK, J				MOK, J			HIV-1 INFECTION - BREAST-MILK AND HIV-1 TRANSMISSION	LANCET			English	Editorial Material											MOK, J (corresponding author), CITY HOSP EDINBURGH,REG INFECT DIS UNIT,EDINBURGH EH10 5SB,MIDLOTHIAN,SCOTLAND.							BELEC L, 1990, PEDIATRICS, V85, P1022; CUTTING WAM, 1993, PEDIATR AIDS HIV INF, V4, P1; DUNN DT, 1992, LANCET, V340, P585, DOI 10.1016/0140-6736(92)92115-V; GOLDMAN AS, 1982, J PEDIATR-US, V100, P563, DOI 10.1016/S0022-3476(82)80753-1; NEWBURG DS, 1992, PEDIATR RES, V31, P22, DOI 10.1203/00006450-199201000-00004; PIZZO PA, 1991, NEW ENGL J MED, V325, P652, DOI 10.1056/NEJM199108293250909; RYDER RW, 1991, AIDS, V5, P709, DOI 10.1097/00002030-199106000-00010; TOZZI AE, 1990, AIDS, V4, P1293, DOI 10.1097/00002030-199012000-00021; 1992, CONSENSUS STATEMENT	9	8	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 10	1993	341	8850					930	931		10.1016/0140-6736(93)91217-A	http://dx.doi.org/10.1016/0140-6736(93)91217-A			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW981	8096270				2022-12-28	WOS:A1993KW98100009
J	ZAAIJER, HL; CUYPERS, HTM; REESINK, HW; WINKEL, IN; GERKEN, G; LELIE, PN				ZAAIJER, HL; CUYPERS, HTM; REESINK, HW; WINKEL, IN; GERKEN, G; LELIE, PN			RELIABILITY OF POLYMERASE CHAIN-REACTION FOR DETECTION OF HEPATITIS-C VIRUS	LANCET			English	Note								The polymerase chain reaction (PCR) is used to detect hepatitis C virus (HCV) RNA, and the results of this assay may have a bearing on management of patients. We tested 31 laboratories for performance of HCV PCR with a coded panel that comprised 4 HCV-positive plasma samples, 6 HCV-negative samples, and two dilution series of HCV-positive plasma. 15 (48%) laboratories had faultless results with both dilution series, and 16 (52%) laboratories reported erroneous results with one or both series. 10 (32%) laboratories had faultless results when testing undiluted plasma samples, 11 (35%) produced a false-negative result with a weak-positive sample, and 10 (32%) produced false negative and/or false positive results. Only 5 (16%) laboratories performed faultlessly with the entire panel of samples. Reports of presence of HCV should be interpreted with care until reliable HCV-RNA detection becomes widely available.	UNIV MAINZ,MED KLIN & POLIKLIN,W-6500 MAINZ,GERMANY	Johannes Gutenberg University of Mainz	LELIE, PN (corresponding author), NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,EUROHEP CONCERTED ACT VIRAL HEPATITIS,1066 CX AMSTERDAM,NETHERLANDS.							BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; GARSON JA, 1991, LANCET, V338, P1466, DOI 10.1016/0140-6736(91)92775-W; KIEVITS T, 1991, J VIROL METHODS, V35, P273, DOI 10.1016/0166-0934(91)90069-C; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; SUGITANI M, 1992, LANCET, V339, P1018, DOI 10.1016/0140-6736(92)90538-E; THALER MM, 1991, LANCET, V338, P17, DOI 10.1016/0140-6736(91)90006-B	7	394	401	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 20	1993	341	8847					722	724		10.1016/0140-6736(93)90488-3	http://dx.doi.org/10.1016/0140-6736(93)90488-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KT362	8095626				2022-12-28	WOS:A1993KT36200005
J	GOUREVITCH, MN; SELWYN, PA; DAVENNY, K; BUONO, D; SCHOENBAUM, EE; KLEIN, RS; FRIEDLAND, GH				GOUREVITCH, MN; SELWYN, PA; DAVENNY, K; BUONO, D; SCHOENBAUM, EE; KLEIN, RS; FRIEDLAND, GH			EFFECTS OF HIV-INFECTION ON THE SEROLOGIC MANIFESTATIONS AND RESPONSE TO TREATMENT OF SYPHILIS IN INTRAVENOUS-DRUG-USERS	ANNALS OF INTERNAL MEDICINE			English	Article						SYPHILIS; SUBSTANCE ABUSE, INTRAVENOUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS SEROPOSITIVITY; HUMAN IMMUNODEFICIENCY SEROPREVALENCE	IMMUNODEFICIENCY-VIRUS-INFECTION; SEXUALLY-TRANSMITTED DISEASE; SECONDARY SYPHILIS; TREPONEMA-PALLIDUM; PRIMARY CARE; RISK-FACTORS; COCAINE USE; PATIENT; CLINICS; TESTS	Objective: To describe the effects of human immunodeficiency virus (HIV) infection on the serologic manifestations and response to treatment of syphilis in intravenous drug users. Design: Cohort study of intravenous drug users. Setting: Medical clinic in a hospital-based methadone maintenance treatment program in New York City. Patients: Fifty patients with syphilis, of whom 31 were HIV seropositive and 19 HIV seronegative. Measurements: Serologic tests for syphilis and clinical manifestations. Results: Stage of syphilis at presentation was not associated with HIV serologic status. No unusual or fulminant manifestations of early syphilis or neurosyphilis were noted among HIV-seropositive cases. Maximum nontreponemal titers were higher among HIV-seropositive (median, 1:128) than among HIV-seronegative (median, 1:32) patients with syphilis (P = 0.05); this difference was present only among patients with first-episode syphilis. All 26 evaluable, HIV-seropositive patients treated for syphilis responded appropriately, including 13 patients given standard or less-than-standard doses of penicillin. Seven of 43 patients (16%) showed reversion to negative treponemal antibody assay results after treatment for syphilis; this finding was not associated with HIV infection, CD4 count, or stage of syphilis. Low nontreponemal titer was weakly associated with treponemal test reversion. Conclusions: Infection with HIV did not alter the stage at presentation, clinical course, serologic manifestations, or response to treatment of syphilis in this cohort of intravenous drug users.			GOUREVITCH, MN (corresponding author), MONTEFIORE MED CTR, ALBERT EINSTEIN COLL MED, DEPT EPIDEMIOL & SOCIAL MED, BRONX, NY 10467 USA.			Schoenbaum, Ellie/0000-0002-0878-284X; Gourevitch, Marc/0000-0001-6865-2126	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004347] Funding Source: NIH RePORTER; NIDA NIH HHS [R01 DA04347-05] Funding Source: Medline; PHS HHS [U64/CCU200714] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BERRY CD, 1987, NEW ENGL J MED, V316, P1587, DOI 10.1056/NEJM198706183162507; CHERUBIN CE, 1968, ANN INTERN MED, V69, P739, DOI 10.7326/0003-4819-69-4-739; CHIASSON MA, 1991, AIDS, V5, P1121, DOI 10.1097/00002030-199109000-00011; DRUSIN LM, 1974, AM J MED, V56, P429, DOI 10.1016/0002-9343(74)90626-3; DRUSIN LM, 1984, UROL CLIN N AM, V11, P121; FARLEY TA, 1990, SEX TRANSM DIS, V17, P163, DOI 10.1097/00007435-199010000-00003; FIUMARA N, 1989, J AM ACAD DERMATOL, V21, P141, DOI 10.1016/S0190-9622(89)80357-3; FULLILOVE RE, 1990, JAMA-J AM MED ASSOC, V263, P851, DOI 10.1001/jama.263.6.851; GILES AJH, 1979, BRIT J VENER DIS, V55, P62; GREGORY N, 1990, J AM ACAD DERMATOL, V22, P1061, DOI 10.1016/0190-9622(90)70153-9; HAAS JS, 1990, J INFECT DIS, V162, P862, DOI 10.1093/infdis/162.4.862; HARRIS WDM, 1967, NEW YORK STATE J MED, V67, P2967; HICKS CB, 1987, ANN INTERN MED, V107, P492, DOI 10.7326/0003-4819-107-4-492; HOOK EW, 1989, J INFECT DIS, V160, P530, DOI 10.1093/infdis/160.3.530; HUTCHINSON CM, 1991, ARCH INTERN MED, V151, P511, DOI 10.1001/archinte.151.3.511; HUTCHINSON CM, 1992, 8 INT C AIDS 3 STD W; JOHNS DR, 1987, NEW ENGL J MED, V316, P1569, DOI 10.1056/NEJM198706183162503; JOHNSON PDR, 1991, AIDS, V5, P419, DOI 10.1097/00002030-199104000-00010; KATZ DA, 1989, ARCH NEUROL-CHICAGO, V46, P895, DOI 10.1001/archneur.1989.00520440085024; LANSKA MJ, 1988, NEUROLOGY, V38, P1297, DOI 10.1212/WNL.38.8.1297; LARSEN SA, 1990, MANUAL TESTS SYPHILI, P19; LUKEHART SA, 1988, ANN INTERN MED, V109, P855, DOI 10.7326/0003-4819-109-11-855; MINKOFF HL, 1990, AM J OBSTET GYNECOL, V163, P521, DOI 10.1016/0002-9378(90)91188-I; MUSHER DM, 1990, ANN INTERN MED, V113, P872, DOI 10.7326/0003-4819-113-11-872; QUINN TC, 1990, ARCH INTERN MED, V150, P1297, DOI 10.1001/archinte.150.6.1297; RADOLF JD, 1988, J AM ACAD DERMATOL, V18, P423, DOI 10.1016/S0190-9622(88)70062-6; ROLFS RT, 1990, AM J PUBLIC HEALTH, V80, P853, DOI 10.2105/AJPH.80.7.853; ROLFS RT, 1990, JAMA-J AM MED ASSOC, V264, P1432, DOI 10.1001/jama.264.11.1432; ROMANOWSKI B, 1991, ANN INTERN MED, V114, P1005, DOI 10.7326/0003-4819-114-12-1005; Schlesselman JJ, 1982, CASE CONTROL STUDIES; SCHOENBAUM EE, 1989, NEW ENGL J MED, V321, P874, DOI 10.1056/NEJM198909283211306; SCHOENBAUM EE, 1990, SEX TRANSM DIS, V17, P190, DOI 10.1097/00007435-199010000-00008; SCHROETER AL, 1972, J AMER MED ASSOC, V221, P471, DOI 10.1001/jama.221.5.471; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SELWYN PA, 1989, ANN INTERN MED, V111, P761, DOI 10.7326/0003-4819-111-9-761; SHULKIN D, 1988, AM J MED, V85, P425, DOI 10.1016/0002-9343(88)90600-6; TELZAK EE, 1991, AIDS, V5, P591, DOI 10.1097/00002030-199105000-00020; WHARTON M, 1990, MMWR-MORBID MORTAL W, V39, P34; WUEPPER KD, 1966, J AMER MED ASSOC, V195, P868, DOI 10.1001/jama.1966.03100100120044; 1989, MMWR S8, V38, P5	40	69	71	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1993	118	5					350	355		10.7326/0003-4819-118-5-199303010-00005	http://dx.doi.org/10.7326/0003-4819-118-5-199303010-00005			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN688	8094280				2022-12-28	WOS:A1993KN68800005
J	GANDEVIA, SC				GANDEVIA, SC			MUSCLE FATIGUE - DOES THE DIAPHRAGM FATIGUE DURING PARTURITION	LANCET			English	Editorial Material											GANDEVIA, SC (corresponding author), PRINCE WALES MED RES INST, RANDWICK, AUSTRALIA.		Gandevia, Simon C/D-5009-2011	Gandevia, Simon C/0000-0002-1345-3821				BELLEMARE F, 1987, J APPL PHYSIOL, V62, P1307, DOI 10.1152/jappl.1987.62.3.1307; BELLEMARE F, 1982, J APPL PHYSIOL, V53, P1190, DOI 10.1152/jappl.1982.53.5.1190; GANDEVIA SC, 1990, J PHYSIOL-LONDON, V428, P387, DOI 10.1113/jphysiol.1990.sp018218; MCKENZIE DK, 1992, J PHYSIOL-LONDON, V454, P643, DOI 10.1113/jphysiol.1992.sp019284; NAVA S, 1992, AM REV RESPIR DIS, V146, P1226, DOI 10.1164/ajrccm/146.5_Pt_1.1226	5	1	1	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 6	1993	341	8841					347	348		10.1016/0140-6736(93)90144-6	http://dx.doi.org/10.1016/0140-6736(93)90144-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK939	8094121				2022-12-28	WOS:A1993KK93900012
J	GALE, RE; WHEADON, H; GOLDSTONE, AH; BURNETT, AK; LINCH, DC				GALE, RE; WHEADON, H; GOLDSTONE, AH; BURNETT, AK; LINCH, DC			FREQUENCY OF CLONAL REMISSION IN ACUTE MYELOID-LEUKEMIA	LANCET			English	Article							ACUTE NONLYMPHOCYTIC LEUKEMIA; X-CHROMOSOME INACTIVATION; DNA; DIFFERENTIATION; POLYMORPHISMS; DIAGNOSIS; DISORDERS; TUMORS; CELLS; GENE	Analysis of X-chromosome inactivation patterns in females has been used to assess clonality of various tumours and for prenatal diagnosis of X-linked disorders. Studies with these methods in acute myeloid leukaemia suggest that a significant proportion of cases have clonal remissions (ie, persistence of the malignant clone), which may represent return to a preleukaemic state. We therefore analysed X-chromosome inactivation patterns with differential methylation patterns of heterozygotes for three DNA probes, HPRT, PGK, and M27beta, in leukaemic patients and normal controls. As expected, blast cells from 67 of 68 analysable samples (99%) were monoclonal or had a skewed X-inactivation pattern. A skewed pattern in remission was also found in 26 of 77 patients (34%), proportion only slightly greater than control (16/75, 21%). In 7 of 10 patients with a skewed pattern in myeloid cells there was similar skewing in the T cells, which is compatible with the concept of a constitutively skewed X-chromosome inactivation pattern of haemopoietic cells in these patients. Our study illustrates the difficulty of interpreting clonality in individual tumour samples and emphasises the importance of comparisons with non-malignant tissue of the same cell type from that individual and from normal control populations.	UNIV HOSP WALES, DEPT HAEMATOL, CARDIFF, WALES	Cardiff University	GALE, RE (corresponding author), UCL, SCH MED, DEPT HAEMATOL, LONDON WC1E 6HX, ENGLAND.		SHAKOORI, ABDUL RAUF/Q-9373-2019	Wheadon, Helen/0000-0001-9902-3170				ABKOWITZ JL, 1988, BLOOD, V71, P1687; BARTRAM CR, 1989, LEUKEMIA, V3, P247; BURNETT AK, 1991, HEMATOL ONCOL, V1, P111; CHANARIN I, 1989, LABORATORY HAEMATOLO; CHESON BD, 1990, J CLIN ONCOL, V8, P813, DOI 10.1200/JCO.1990.8.5.813; FEARON ER, 1986, NEW ENGL J MED, V315, P15, DOI 10.1056/NEJM198607033150103; FEARON ER, 1987, SCIENCE, V238, P193, DOI 10.1126/science.2889267; FEY MF, 1987, BRIT J HAEMATOL, V67, P489, DOI 10.1111/j.1365-2141.1987.tb06174.x; FEY MF, 1992, J CLIN INVEST, V89, P1438, DOI 10.1172/JCI115733; Fialkow P J, 1972, Adv Cancer Res, V15, P191, DOI 10.1016/S0065-230X(08)60375-9; FIALKOW PJ, 1981, BLOOD, V57, P1068; FIALKOW PJ, 1991, BLOOD, V77, P1415; FIALKOW PJ, 1987, NEW ENGL J MED, V317, P468, DOI 10.1056/NEJM198708203170802; FRASER NJ, 1989, GENOMICS, V5, P144, DOI 10.1016/0888-7543(89)90099-2; GALE RE, 1992, LEUKEMIA, V6, P649; GALE RE, 1991, BRIT J HAEMATOL, V79, P193, DOI 10.1111/j.1365-2141.1991.tb04521.x; HODGES E, 1991, BRIT J HAEMATOL, V77, P315, DOI 10.1111/j.1365-2141.1991.tb08577.x; KELLER G, 1985, NATURE, V318, P149, DOI 10.1038/318149a0; KERE J, 1987, BLOOD, V70, P1349; KIBBELAAR RE, 1992, BLOOD, V79, P1823; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; Maniatis T., 1982, MOL CLONING; POWLES RL, 1979, LANCET, V2, P674; PUCK JM, 1990, NEW ENGL J MED, V322, P1063, DOI 10.1056/NEJM199004123221508; SINGER JW, 1991, SEMIN HEMATOL, V28, P1; TILLY H, 1986, NEW ENGL J MED, V314, P246; TURHAN AG, 1989, NEW ENGL J MED, V320, P1655, DOI 10.1056/NEJM198906223202504; VOGELSTEIN B, 1987, CANCER RES, V47, P4806; WAINSCOAT JS, 1990, CANCER RES, V50, P1355	29	62	62	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 16	1993	341	8838					138	142		10.1016/0140-6736(93)90004-Z	http://dx.doi.org/10.1016/0140-6736(93)90004-Z			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG627	8093744				2022-12-28	WOS:A1993KG62700004
J	VALORI, R				VALORI, R			LINES WRITTEN ON READING ANOTHER REVIEW ARTICLE ABOUT THE IRRITABLE-BOWEL-SYNDROME	LANCET			English	Editorial Material											VALORI, R (corresponding author), MIDDLESEX HOSP,LONDON W1N 8AA,ENGLAND.								0	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 2	1993	341	8836					36	37		10.1016/0140-6736(93)92498-I	http://dx.doi.org/10.1016/0140-6736(93)92498-I			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF027	8093280				2022-12-28	WOS:A1993KF02700019
J	ZURLO, JJ; ONEILL, D; POLIS, MA; MANISCHEWITZ, J; YARCHOAN, R; BASELER, M; LANE, HC; MASUR, H				ZURLO, JJ; ONEILL, D; POLIS, MA; MANISCHEWITZ, J; YARCHOAN, R; BASELER, M; LANE, HC; MASUR, H			LACK OF CLINICAL UTILITY OF CYTOMEGALOVIRUS BLOOD AND URINE CULTURES IN PATIENTS WITH HIV-INFECTION	ANNALS OF INTERNAL MEDICINE			English	Article						CYTOMEGALOVIRUSES; HUMAN IMMUNODEFICIENCY VIRUS; VIRUS CULTIVATION; VIREMIA; VIRURIA; ACQUIRED IMMUNODEFICIENCY SYNDROME	IMMUNE-DEFICIENCY SYNDROME; ACQUIRED IMMUNODEFICIENCY SYNDROME; HOMOSEXUAL MEN; VIRUS INFECTION; SYNDROME AIDS; RETINITIS; MANIFESTATION; DISEASE; GUANINE	Objective: To determine the clinical significance of cytomegalovirus (CMV) blood and urine cultures in patients with human immunodeficiency virus (HIV) infection. Design: Inception cohort of patients with HIV infection and CMV culture data. Setting: Government referral-based research hospital. Patients: A total of 322 HIV-infected patients who had a CMV blood culture and 293 HIV-infected patients who had a CMV urine culture within 7 days of a CD4 determination. Measurements: Cytomegalovirus blood and urine culture results; circulating CD4 lymphocyte counts; pathologic or retinopathic findings of CMV disease. Results: Nine of 26 patients (34.6%) with CMV viremia subsequently developed CMV end-organ disease compared with 11 of 74 (14.9%) patients without viremia, (difference, 19.7%; 95% CI, -0.3% to 39.7%). Fifteen of 47 patients (31.9%) with CMV viruria developed end-organ disease compared with 4 of 43 (9.3%) patients without viruria, (difference, 22.6%; CI, 6.7% to 38.5%). Cytomegalovirus culture positivity had poor predictive value for the subsequent development of end-organ disease (35% for viremia and 28% for viruria). Further, patients with proven end-organ disease were often not viremic (45%), but most were viruric (88%). Cytomegalovirus viremia did not correlate with the presence of either fever or weight loss in this patient group. Both blood culture positivity and urine culture positivity varied inversely with the CD4 count (P = 0.0001 for both associations). Conclusions: The likelihood that a blood or urine culture will be positive in a patient with HIV infection correlates better with immunologic status than with current or future clinical status. Although the absence of CMV viruria may suggest that CMV disease is not present, CMV blood and urine cultures have poor diagnostic and predictive value and therefore should be used primarily for research purposes or drug susceptibility testing and not for making clinical decisions.	NIH, WARREN GRANT MAGNUSON CLIN CTR, BETHESDA, MD 20892 USA; US FDA, CTR BIOL EVALUAT & RES, BETHESDA, MD 20892 USA; NCI, FREDERICK CANC RES & DEV CTR, PROGRAM RESOURCES INC DYNCORP, FREDERICK, MD 21702 USA; NIAID, BETHESDA, MD 20892 USA; NCI, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)				Polis, Michael/0000-0002-9151-2268	OFFICE OF THE DIRECTOR, NCI [N01CO074102] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74102] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALTHAZAR EJ, 1985, AM J ROENTGENOL, V144, P1201, DOI 10.2214/ajr.144.6.1201; DREW WL, 1981, J INFECT DIS, V143, P188, DOI 10.1093/infdis/143.2.188; DREW WL, 1985, ANN INTERN MED, V103, P61, DOI 10.7326/0003-4819-103-1-61; FRANK D, 1984, AM J GASTROENTEROL, V79, P201; FRIEDMAN AH, 1983, BRIT J OPHTHALMOL, V67, P372, DOI 10.1136/bjo.67.6.372; HENDERLY DE, 1987, AM J OPHTHALMOL, V103, P316; JACOBSON MA, 1988, ANN INTERN MED, V108, P585, DOI 10.7326/0003-4819-108-4-585; LANE HC, 1985, AM J MED, V78, P417, DOI 10.1016/0002-9343(85)90332-8; MASUR H, 1986, ANN INTERN MED, V104, P41, DOI 10.7326/0003-4819-104-1-41; MCKENZIE R, 1991, MEDICINE, V70, P326, DOI 10.1097/00005792-199109000-00004; MINTZ L, 1983, ANN INTERN MED, V99, P326, DOI 10.7326/0003-4819-99-3-326; MURRAY JF, 1984, NEW ENGL J MED, V310, P1682, DOI 10.1056/NEJM198406213102529; PALESTINE AG, 1991, ANN INTERN MED, V115, P665, DOI 10.7326/0003-4819-115-9-665; PALESTINE AG, 1984, OPHTHALMOLOGY, V91, P1092; PALESTINE AG, 1986, AM J OPHTHALMOL, V101, P95, DOI 10.1016/0002-9394(86)90470-8; QUINNAN GV, 1984, JAMA-J AM MED ASSOC, V252, P72, DOI 10.1001/jama.252.1.72	16	81	84	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1993	118	1					12	17		10.7326/0003-4819-118-1-199301010-00003	http://dx.doi.org/10.7326/0003-4819-118-1-199301010-00003			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KE605	8093214				2022-12-28	WOS:A1993KE60500003
J	ROBINSON, SR; HAMPSON, ECGM; MUNRO, MN; VANEY, DI				ROBINSON, SR; HAMPSON, ECGM; MUNRO, MN; VANEY, DI			UNIDIRECTIONAL COUPLING OF GAP-JUNCTIONS BETWEEN NEUROGLIA	SCIENCE			English	Article							RAT OPTIC-NERVE; ADULT-RABBIT; MEMBRANE CHANNELS; CELL JUNCTION; ASTROCYTES; OLIGODENDROCYTES; EXPRESSION; RETINA; IMMUNOHISTOCHEMISTRY; INJECTION	Gap junctions permit the passage of ions and small molecules between cells, thereby providing a basis for direct intercellular communication. In the rabbit retina, the low molecular weight dyes Lucifer yellow and biocytin passed readily from astrocytes into adjacent astrocytes, oligodendrocytes, and Muller cells. However, the dyes rarely passed from either oligodendrocytes or Muller cells into astrocytes. Unidirectional passage of dye suggests the presence of an asymmetric barrier to the movement of molecules through heterologous gap junctions and indicates the potential for a hierarchy of command between interconnected cells.			ROBINSON, SR (corresponding author), UNIV QUEENSLAND,DEPT PHYSIOL & PHARMACOL,VIS TOUCH & HEARING RES CTR,BRISBANE 4072,AUSTRALIA.		Robinson, Stephen R./AAU-3219-2021; Hampson, Edith/G-2692-2011; Robinson, Stephen R/B-7155-2013	Robinson, Stephen R./0000-0002-0987-0075; 				BENNETT MVL, 1991, NEURON, V6, P305, DOI 10.1016/0896-6273(91)90241-Q; BUTT AM, 1989, GLIA, V2, P470, DOI 10.1002/glia.440020609; DERMIETZEL R, 1990, ANAT EMBRYOL, V182, P517; DERMIETZEL R, 1989, P NATL ACAD SCI USA, V86, P10148, DOI 10.1073/pnas.86.24.10148; DERMIETZEL R, 1993, TRENDS NEUROSCI, V16, P186, DOI 10.1016/0166-2236(93)90151-B; FLAGGNEWTON J, 1979, SCIENCE, V205, P404, DOI 10.1126/science.377490; FLAGGNEWTON JL, 1980, SCIENCE, V207, P771, DOI 10.1126/science.7352287; GIAUME C, 1991, NEURON, V6, P133, DOI 10.1016/0896-6273(91)90128-M; HORIKAWA K, 1988, J NEUROSCI METH, V25, P1, DOI 10.1016/0165-0270(88)90114-8; KETTENMANN H, 1988, GLIA, V1, P64, DOI 10.1002/glia.440010108; KETTENMANN H, 1983, J NEUROSCI, V3, P506; LOEWENSTEIN WR, 1981, PHYSIOL REV, V61, P829, DOI 10.1152/physrev.1981.61.4.829; NAUS CCG, 1991, NEUROSCI LETT, V126, P33, DOI 10.1016/0304-3940(91)90364-Y; RANSOM BR, 1990, GLIA, V3, P258, DOI 10.1002/glia.440030405; RANSOM BR, 1991, GLIA, V4, P37, DOI 10.1002/glia.440040105; REICHENBACH A, 1988, J HIRNFORSCH, V29, P481; ROBAIN O, 1970, J NEUROL SCI, V11, P445, DOI 10.1016/0022-510X(70)90003-1; ROBINSON SR, 1990, J COMP NEUROL, V292, P178, DOI 10.1002/cne.902920203; ROBINSON SR, 1989, NEUROSCI LETT, V106, P261, DOI 10.1016/0304-3940(89)90174-2; SCHERER J, 1991, J COMP NEUROL, V312, P175, DOI 10.1002/cne.903120202; SCHNITZER J, 1986, CELL TISSUE RES, V246, P91; SHERIDAN JD, 1985, ANNU REV PHYSIOL, V47, P337; SONTHEIMER H, 1990, P NATL ACAD SCI USA, V87, P9833, DOI 10.1073/pnas.87.24.9833; SPIEGEL K, 1988, Society for Neuroscience Abstracts, V14, P578; STEWART WW, 1978, CELL, V14, P741, DOI 10.1016/0092-8674(78)90256-8; VANEY DI, 1992, J NEUROSCI METH, V44, P217, DOI 10.1016/0165-0270(92)90013-4; VANEY DI, 1991, NEUROSCI LETT, V125, P187, DOI 10.1016/0304-3940(91)90024-N; VONBLANKENFELD G, 1993, GLIA, V7, P322, DOI 10.1002/glia.440070407; YAMAMOTO T, 1990, J COMP NEUROL, V302, P853, DOI 10.1002/cne.903020414	29	172	176	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 12	1993	262	5136					1072	1074						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG187	8093125				2022-12-28	WOS:A1993MG18700041
J	BOMMERT, K; CHARLTON, MP; DEBELLO, WM; CHIN, GJ; BETZ, H; AUGUSTINE, GJ				BOMMERT, K; CHARLTON, MP; DEBELLO, WM; CHIN, GJ; BETZ, H; AUGUSTINE, GJ			INHIBITION OF NEUROTRANSMITTER RELEASE BY C2-DOMAIN PEPTIDES IMPLICATES SYNAPTOTAGMIN IN EXOCYTOSIS	NATURE			English	Article							SQUID GIANT SYNAPSE; PROTEIN KINASE-C; TRANSMITTER RELEASE; BINDING; FAMILY; P65; DNA	NEUROTRANSMITTER release is triggered by Ca2+ ions binding to an unknown Ca2+ receptor within presynaptic terminals1,2. Synaptotagmin, a Ca2+-binding protein of synaptic and other secretory vesicles3, has been proposed to mediate vesicle-plasma membrane interactions during neurotransmitter release4-9. Here we test this hypothesis using the giant synapse of the squid Loligo pealei, which because of its unusually large size and well established physiology is uniquely suited for dissecting presynaptic events10. We find that injection of peptides from the C2 domains of synaptotagmin into squid giant presynaptic terminals rapidly and reversibly inhibits neurotransmitter release. Our data are consistent with these peptides competitively blocking release after synaptic vesicle docking and indicate that Ca2+ probably initiates neurotransmitter release by regulating the interaction of synaptotagmin with an acceptor protein.	MAX PLANCK INST BRAIN RES,DEPT NEUROCHEM,W-6000 FRANKFURT 71,GERMANY; UNIV TORONTO,DEPT PHYSIOL,TORONTO M5S 1A8,ONTARIO,CANADA; DUKE UNIV,MED CTR,DEPT NEUROBIOL,DURHAM,NC 27710; NIH,DEV NEUROBIOL LAB,BETHESDA,MD 20892	Max Planck Society; University of Toronto; Duke University; National Institutes of Health (NIH) - USA	BOMMERT, K (corresponding author), MARINE BIOL LAB,WOODS HOLE,MA 02543, USA.		Bommert, Kurt/G-9247-2011; Augustine, George James/J-9228-2013					ADLER EM, 1991, J NEUROSCI, V11, P1496; AUGUSTINE GJ, 1987, ANNU REV NEUROSCI, V10, P633, DOI 10.1146/annurev.ne.10.030187.003221; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; ELFERINK LA, 1993, CELL, V72, P153, DOI 10.1016/0092-8674(93)90059-Y; GREENINGLOH G, 1987, NATURE, V328, P215; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HESS SD, 1993, SCIENCE, V259, P1169, DOI 10.1126/science.8438167; Katz B., 1969, RELEASE NEURAL TRANS; LEVEQUE C, 1992, P NATL ACAD SCI USA, V89, P3625, DOI 10.1073/pnas.89.8.3625; LLINAS R, 1991, J PHYSIOL-LONDON, V436, P257, DOI 10.1113/jphysiol.1991.sp018549; LLINAS RR, 1984, CURR TOP MEMBR TRANS, V22, P519; MATTHEW WD, 1981, J CELL BIOL, V91, P257, DOI 10.1083/jcb.91.1.257; MOCHLYROSEN D, 1992, BIOCHEMISTRY-US, V31, P8120, DOI 10.1021/bi00150a003; OSSES LR, 1989, BIOL BULL, V177, P146, DOI 10.2307/1541842; PERIN MS, 1991, J BIOL CHEM, V266, P615; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; PETRENKO AG, 1991, NATURE, V353, P65, DOI 10.1038/353065a0; PUMPLIN DW, 1978, NEUROSCIENCE, V3, P685, DOI 10.1016/0306-4522(78)90065-9; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAPIRA R, 1987, NATURE, V325, P58, DOI 10.1038/325058a0; SHOJIKASAI Y, 1992, SCIENCE, V256, P1820, DOI 10.1126/science.256.5065.1820; SMITH SJ, 1988, CALCIUM ION CHANNEL, P147; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; SUDHOF TC, 1989, SCIENCE, V245, P1474, DOI 10.1126/science.2506642; SWANDULLA D, 1991, NEURON, V7, P915, DOI 10.1016/0896-6273(91)90337-Y; TRIMBLE WS, 1991, REV NEUROSCI, V14, P93; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; WENDLAND B, 1991, NEURON, V6, P993, DOI 10.1016/0896-6273(91)90239-V	31	282	284	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 13	1993	363	6425					163	165		10.1038/363163a0	http://dx.doi.org/10.1038/363163a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LB801	8097867				2022-12-28	WOS:A1993LB80100048
J	PIJNENBORG, L; van der Maas, PJ; VANDELDEN, JJM; LOOMAN, CWN				PIJNENBORG, L; van der Maas, PJ; VANDELDEN, JJM; LOOMAN, CWN			LIFE-TERMINATING ACTS WITHOUT EXPLICIT REQUEST OF PATIENT	LANCET			English	Article								In the Dutch nationwide study on medical decisions concerning the end of life (MDEL) life-terminating acts without the explicit request of the patient (LAWER) were noted in 0.8% of all deaths. We present here quantitative information and a discussion of the main issues raised by LAWER. In 59% of LAWER the physician had some information about the patient's wish; in 41% discussion on the decision would no longer have been possible. In LAWER patients tend to be younger and more likely to be male and to have cancer than in non-acute deaths generally. The physician (specialist or general practitioner) knew the patient on average 2.4 years and 7.2 years, respectively. Life was shortened by between some hours and a week at most in 86%. ln 83% the decision has been discussed with relatives and in 70% with a colleague. In nearly all cases, according to the physician, the patient was suffering unbearably, there was no chance of improvement, and palliative possibilities were exhausted. MDEL probably will increase in number in future but interviews with Dutch physicians suggest a possible fall in LAWER, even though there will always be some situations in which a well-considered LAWER decision may have to be made.	UNIV UTRECHT, CTR BIOETH & HLTH LAW, UTRECHT, NETHERLANDS	Utrecht University	PIJNENBORG, L (corresponding author), ERASMUS UNIV, DEPT PUBL HLTH, POB 1738, 3000 DR ROTTERDAM, NETHERLANDS.		Lindtjorn, Bernt/K-9465-2018	Lindtjorn, Bernt/0000-0002-6267-6984				KUHSE H, 1992, BIOETHICS NEWS, V11, P1; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; van der Maas PJ, 1992, HEALTH POLICY, V22, P1; VANDELDEN JJM, IN PRESS BIOETHICS; VANDERWAL G, 1991, HUISARTS WET, V34, P523; 1992, LANCET, V340, P757; 1988, JAMA-J AM MED ASSOC, V259, P272; 1992, END LIFE MED PRACTIC	8	87	87	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 8	1993	341	8854					1196	1199		10.1016/0140-6736(93)91014-D	http://dx.doi.org/10.1016/0140-6736(93)91014-D			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB017	8098087				2022-12-28	WOS:A1993LB01700016
J	CHOI, SS; LAGAKOS, SW; SCHOOLEY, RT; VOLBERDING, PA				CHOI, SS; LAGAKOS, SW; SCHOOLEY, RT; VOLBERDING, PA			CD4+ LYMPHOCYTES ARE AN INCOMPLETE SURROGATE MARKER FOR CLINICAL PROGRESSION IN PERSONS WITH ASYMPTOMATIC HIV-INFECTION TAKING ZIDOVUDINE	ANNALS OF INTERNAL MEDICINE			English	Article						HUMAN IMMUNODEFICIENCY VIRUS; ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIGENS, CD4; BIOLOGICAL MARKERS; ZODOVUDINE	AIDS-RELATED COMPLEX; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; EFFICACY; AZT	Objective: To determine the extent to which lymphocytes, particularly those with the CD4 surface antigen, are a surrogate marker for the development of the acquired immunodeficiency syndrome (AIDS) in persons with asymptomatic human immunodeficiency virus (HIV) infection. Design: Analysis of data from the AIDS Clinical Trials Group Protocol 019, a placebo-controlled, double-blind, randomized trial. Setting: University-based referral centers. Patients: Asymptomatic HIV-infected patients with 500 or fewer CD4+ cells/mm3 at baseline who were given placebo (350 patients) or one of two daily doses of zidovudine (725 patients). Measurements: Baseline and interim measurements of CD4+ and other leukocytes were assessed. Patients were followed for progression to AIDS. Results: Patients' lymphocyte levels were correlated with progression to AIDS (P < 0.001; relative risk for each depletion of 50 CD4+ cells/mm3, 1.75; 95% Cl, 1.53 to 2.01); however, only a small portion (0% to 37%) of the effect of zidovudine on this progression was statistically explained by its effect on CD4+ lymphocyte levels. A substantial portion of zidovudine's effect on delaying progression to AIDS that was independent of the levels of these markers occurred within the first 16 weeks of therapy. In patients who had not progressed to AIDS by week 16, most of the subsequent zidovudine effect in reducing the risk for progression could be explained by its effect on net CD4+ percent (percentage of CD4+ lymphocytes among all leukocytes) for the first 16 weeks of therapy. Conclusion: Levels of CD4+ lymphocytes are an incomplete surrogate marker for progression to AIDS, and the association is especially weak during the first 16 weeks of zidovudine therapy.	HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA; UNIV COLORADO, HLTH SCI CTR, DIV INFECT DIS, DENVER, CO 80262 USA; UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94143 USA	Harvard University; Harvard T.H. Chan School of Public Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of California System; University of California San Francisco	CHOI, SS (corresponding author), MCGILL UNIV, DEPT EPIDEMIOL & BIOSTAT, PURVIS HALL, 1020 PINE AVE W, MONTREAL H3A 1A2, PQ, CANADA.				NIAID NIH HHS [N01-AI-95030] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI095030] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON TW, 1971, STATISTICAL ANAL TIM; [Anonymous], 1989, NEW ENGL J MED, V321, P406; BYAR DP, 1990, NEW ENGL J MED, V323, P1343, DOI 10.1056/NEJM199011083231912; Cox D. R., 1984, ANAL SURVIVAL DATA; DEGRUTTOLA V, 1993, IN PRESS J ACQUIR IM; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; GLASER JB, 1991, J INFECT DIS, V164, P761, DOI 10.1093/infdis/164.4.761; JACOBSON MA, 1991, BRIT MED J, V302, P73, DOI 10.1136/bmj.302.6768.73; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; MACHADO SG, 1990, J ACQ IMMUN DEF SYND, V3, P1065; PAXTON H, 1989, CLIN IMMUNOL IMMUNOP, V52, P68, DOI 10.1016/0090-1229(89)90194-3; PRENTICE RL, 1989, STAT MED, V8, P431, DOI 10.1002/sim.4780080407; RINALDO C, 1991, J INFECT DIS, V164, P638, DOI 10.1093/infdis/164.4.638; STEIN DS, 1992, J INFECT DIS, V165, P352, DOI 10.1093/infdis/165.2.352; TAYLOR JMG, 1989, J ACQ IMMUN DEF SYND, V2, P114; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; 1990, SURROGATE ENDPOINTS	18	192	194	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1993	118	9					674	680		10.7326/0003-4819-118-9-199305010-00003	http://dx.doi.org/10.7326/0003-4819-118-9-199305010-00003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY502	8096373				2022-12-28	WOS:A1993KY50200003
J	MOSIER, DE; GULIZIA, RJ; MACISAAC, PD; TORBETT, BE; LEVY, JA				MOSIER, DE; GULIZIA, RJ; MACISAAC, PD; TORBETT, BE; LEVY, JA			RAPID LOSS OF CD4+ T-CELLS IN HUMAN-PBL-SCID MICE BY NONCYTOPATHIC HIV ISOLATES	SCIENCE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; MONONUCLEAR PHAGOCYTES; PRODUCTIVELY INFECT; MACROPHAGE TROPISM; HOST RANGE; GP120; AIDS; IDENTIFICATION; PATHOGENESIS; RETROVIRUSES	Human immunodeficiency virus (HIV) isolates differ in cell tropism, replication, pathogenicity, and syncytial induction in vitro. CD4+ T cells were enumerated in severe combined immunodeficient mice transplanted with human peripheral blood leukocytes (hu-PBL-SCID mice) and infected with HIV isolates with different in vitro cytopathicity. Two noncytopathic, macrophage-tropic strains, HIV-1SF162 and HIV-2UC1, induced extensive CD4+ T cell depletion, whereas HIV-1SF33, which is highly cytopathic for T cells in vitro, caused little CD4+ T cell depletion at equivalent virus burden. In vitro cytopathicity assays therefore do not predict CD4 depletion in the hu-PBL-SCID model.	MED BIOL INST, LA JOLLA, CA 92037 USA; UNIV CALIF SAN FRANCISCO, SCH MED, CANC RES INST, DEPT MED, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	MOSIER, DE (corresponding author), SCRIPPS RES INST, DEPT IMMUNOL, LA JOLLA, CA 92037 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029182, U01AI030238, R01AI024499, R21AI029182] Funding Source: NIH RePORTER; NIAID NIH HHS [AI24499, AI30238, AI29182] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CASTRO BA, 1990, VIROLOGY, V178, P527, DOI 10.1016/0042-6822(90)90350-Z; CASTRO BA, 1988, AIDS, V2, P17; CHENGMAYER C, 1991, J VIROL, V65, P6931, DOI 10.1128/JVI.65.12.6931-6941.1991; CHENGMAYER C, 1990, J VIROL, V64, P4390, DOI 10.1128/JVI.64.9.4390-4398.1990; CHENGMAYER C, 1988, SCIENCE, V240, P80, DOI 10.1126/science.2832945; EVANS LA, 1987, J IMMUNOL, V138, P3415; EVANS LA, 1988, SCIENCE, V240, P1522, DOI 10.1126/science.2836951; EVANS LA, 1989, BIOCHIM BIOPHYS ACTA, V989, P237; FENYO EM, 1988, J VIROL, V62, P4414; FOLKS TM, 1986, J EXP MED, V164, P280, DOI 10.1084/jem.164.1.280; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; GENDELMAN HE, 1989, AIDS, V3, P475, DOI 10.1097/00002030-198908000-00001; HWANG SS, 1991, SCIENCE, V253, P71, DOI 10.1126/science.1905842; LEVY JA, 1988, NATURE, V333, P519, DOI 10.1038/333519a0; LEVY JA, 1985, VIROLOGY, V147, P441, DOI 10.1016/0042-6822(85)90146-1; LEVY JA, 1984, SCIENCE, V225, P840, DOI 10.1126/science.6206563; LIU ZQ, 1990, J VIROL, V64, P6148, DOI 10.1128/JVI.64.12.6148-6153.1990; MCCUNE JM, 1990, SCIENCE, V250, P1152, DOI 10.1126/science.2174574; MOSIER DE, 1988, NATURE, V335, P256, DOI 10.1038/335256a0; MOSIER DE, 1991, SCIENCE, V251, P791, DOI 10.1126/science.1990441; MOSIER DE, UNPUB; OBRIEN WA, 1990, NATURE, V348, P69, DOI 10.1038/348069a0; SAAG MS, 1988, NATURE, V334, P440, DOI 10.1038/334440a0; SHIODA T, 1991, NATURE, V349, P167, DOI 10.1038/349167a0; STUBLE H, UNPUB; TATENO M, 1988, VIROLOGY, V167, P299, DOI 10.1016/0042-6822(88)90084-0; TERSMETTE M, 1988, J VIROL, V62, P2026, DOI 10.1128/JVI.62.6.2026-2032.1988; TORBETT BE, 1991, IMMUNOL REV, V124, P139, DOI 10.1111/j.1600-065X.1991.tb00620.x; WAINHOBSON S, 1989, AIDS, V3, P13; WATKINS BA, 1990, SCIENCE, V249, P549, DOI 10.1126/science.2200125; WESTERVELT P, 1991, P NATL ACAD SCI USA, V88, P3097, DOI 10.1073/pnas.88.8.3097; YORKHIGGINS D, 1990, J VIROL, V64, P4016, DOI 10.1128/JVI.64.8.4016-4020.1990	32	170	177	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 30	1993	260	5108					689	692		10.1126/science.8097595	http://dx.doi.org/10.1126/science.8097595			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KZ641	8097595				2022-12-28	WOS:A1993KZ64100037
J	SANCHEZ, JL; DEFRAITES, RF; SHARP, TW; HANSON, RK				SANCHEZ, JL; DEFRAITES, RF; SHARP, TW; HANSON, RK			MEFLOQUINE OR DOXYCYCLINE PROPHYLAXIS IN UNITED-STATES TROOPS IN SOMALIA	LANCET			English	Letter							MALARIA		USN,MED RES INST,BETHESDA,MD 20814; USN,ENVIRONM & PREVENT MED UNIT 6,HONOLULU,HI	Naval Medical Research Center (NMRC); United States Department of Defense; United States Navy; United States Department of Defense; United States Navy	SANCHEZ, JL (corresponding author), WALTER REED ARMY INST RES,DIV PREVENT MED,WASHINGTON,DC 20307, USA.							ARTHUR JD, 1990, LANCET, V35, P972; BERN JL, 1992, J TROP MED HYG, V95, P167; LOBEL HO, 1991, JAMA-J AM MED ASSOC, V265, P361, DOI 10.1001/jama.265.3.361; PATCHEN LC, 1989, NEW ENGL J MED, V321, P1415; ROUVEIX B, 1989, ANN INTERN MED, V110, P577, DOI 10.7326/0003-4819-110-7-577; STEFFEN R, 1990, B WORLD HEALTH ORGAN, V68, P313; WEINKE T, 1991, AM J TROP MED HYG, V45, P86, DOI 10.4269/ajtmh.1991.45.86	7	37	37	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 17	1993	341	8851					1021	1022		10.1016/0140-6736(93)91107-W	http://dx.doi.org/10.1016/0140-6736(93)91107-W			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY368	8096898				2022-12-28	WOS:A1993KY36800030
J	TIRET, L; KEE, F; POIRIER, O; NICAUD, V; LECERF, L; EVANS, A; CAMBOU, JP; ARVEILER, D; LUC, G; AMOUYEL, P; CAMBIEN, F				TIRET, L; KEE, F; POIRIER, O; NICAUD, V; LECERF, L; EVANS, A; CAMBOU, JP; ARVEILER, D; LUC, G; AMOUYEL, P; CAMBIEN, F			DELETION POLYMORPHISM IN ANGIOTENSIN-CONVERTING ENZYME GENE ASSOCIATED WITH PARENTAL HISTORY OF MYOCARDIAL-INFARCTION	LANCET			English	Note								In a European study an insertion (I)/deletion (D) polymorphism in the angiotensin converting enzyme (ACE) gene has been shown to be associated with the risk of myocardial infarction (MI). In the same study, we investigated the association of the polymorphism with a parental history of fatal MI. There was an excess of both DD (odds ratio 2.6, p = 0.02) and ID (odds ratio = 1.9, p = 0.08) genotypes among those having a parental history of MI, confirming that genetic variation in the ACE locus could be involved in the risk of MI.	INSERM,SC7,17 RUE FER A MOULIN,F-75005 PARIS,FRANCE; INSERM,U258,F-75005 PARIS,FRANCE; MONICA PROJECT BELFAST,BELFAST,NORTH IRELAND	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)			Cambien, Francois/AAP-9751-2020	Amouyel, Philippe/0000-0001-9088-234X; LECERF, LAURE/0000-0001-8342-5298				CAMBIEN F, 1992, NATURE, V359, P641, DOI 10.1038/359641a0; CAMBIEN F, 1988, AM J HUM GENET, V43, P774; HUBERT C, 1991, J BIOL CHEM, V266, P15377; PARRA HJ, 1992, ARTERIOSCLER THROMB, V12, P701, DOI 10.1161/01.ATV.12.6.701; RIGAT B, 1990, J CLIN INVEST, V86, P1343, DOI 10.1172/JCI114844; TIRET L, 1992, AM J HUM GENET, V51, P197	6	253	257	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 17	1993	341	8851					991	992		10.1016/0140-6736(93)91075-W	http://dx.doi.org/10.1016/0140-6736(93)91075-W			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY368	8096947				2022-12-28	WOS:A1993KY36800007
J	VANDEPERRE, P; SIMONON, A; HITIMANA, DG; DABIS, F; MSELLATI, P; MUKAMABANO, B; BUTERA, JB; VANGOETHEM, C; KARITA, E; LEPAGE, P				VANDEPERRE, P; SIMONON, A; HITIMANA, DG; DABIS, F; MSELLATI, P; MUKAMABANO, B; BUTERA, JB; VANGOETHEM, C; KARITA, E; LEPAGE, P			INFECTIVE AND ANTIINFECTIVE PROPERTIES OF BREAST-MILK FROM HIV-1-INFECTED WOMEN	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; MILK; ANTIBODIES; IGG; TRANSMISSION; SUBCLASSES; KIGALI; RWANDA; SYSTEM; HIV-1	Human immunodeficiency virus type 1 (HIV-1) is transmitted mainly by cell-to-cell contact. We postulated that transmission of HIV-1 through breastmilk could be favoured by the presence of infected cells, by deficiency of anti-infective substances in breastmilk, or both factors. 215 HIV-1-infected women were enrolled at delivery in Kigali, Rwanda; milk samples were collected 15 days, 6 months, and 18 months post partum. HIV-1 IgG, secretory IgA, and IgM were assayed by western blot, for the latter two after removal of IgG with protein G. In the 15-day and 6-month samples, we sought viral genome in milk cells by a double polymerase chain reaction with three sets of primers (gag, pol, and env). HIV-1 infection in the offspring was defined according to serological and clinical criteria. At 15 days, 6 months, and 18 months postpartum, HIV-1 specific IgG was detected in 95%, 98%, and 97% of breastmilk samples, IgA in 23%, 28%, and 41%, and IgM in 66%, 78%, and 41%. In children who survived longer than 18 months, the probability of infection was associated with lack of persistence of IgM and IgA in their mothers' milk (adjusted chi2 for trend, p = 0.01 for IgM and p = 0.05 for IgA). The presence of HIV-1-infected cells in the milk 15 days post partum was strongly predictive of HIV-1 infection in the child, by both univariate (p < 0.05) and multivariate analysis (p = 0.01). The combination of HIV-1-infected cells in breastmilk and a defective IgM response was the strongest predictor of infection. HIV-1 infection in breastfed children born to infected mothers is associated with the presence of integrated viral DNA in the mothers' milk cells. IgM and IgA anti-HIV-1 in breastmilk may protect against postnatal transmission of the virus.	CTR HOSP KIGALI,DEPT PAEDIAT,KIGALI,RWANDA; UNIV BORDEAUX 2,INSERM,U330,F-33076 BORDEAUX,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux	VANDEPERRE, P (corresponding author), NATL AIDS CONTROL PROGRAMME,AIDS REFERENCE LAB,BP 780,KIGALI,RWANDA.		DABIS, FRANCOIS/S-9298-2019; Van de Perre, Philippe/B-9692-2008	DABIS, FRANCOIS/0000-0002-1614-8857; Van de Perre, Philippe/0000-0002-3912-0427				BELEC L, 1990, PEDIATRICS, V85, P1022; BRANDTZAEG P, 1975, IMMUNOLOGY, V29, P559; BRANDTZAEG P, 1979, IMMUNOLOGY BREAST MI, P91; BULTERYS M, 1992, 8TH INT C AIDS 3RD S, V1; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; DUNN DT, 1992, LANCET, V340, P585, DOI 10.1016/0140-6736(92)92115-V; FLEISS JL, 1973, STATISTICAL METHODS, P99; GOLDMAN AS, 1982, J PEDIATR-US, V100, P563, DOI 10.1016/S0022-3476(82)80753-1; HANSON LA, 1985, PEDIATRICS, V75, P172; LAMON EW, 1975, J IMMUNOL, V114, P1171; LEPAGE P, 1991, AIDS, V5, P295, DOI 10.1097/00002030-199103000-00008; MAASINDERWIESEN F, 1978, DEUT TIERARZTL WOCH, V85, P309; MULLER F, 1991, CLIN EXP IMMUNOL, V83, P203, DOI 10.1111/j.1365-2249.1991.tb05615.x; NARA PL, 1987, J VIROL, V61, P3173, DOI 10.1128/JVI.61.10.3173-3180.1987; RUFF A, 1992, 8TH INT C AIDDS 3RD, V1; SATO H, 1992, VIROLOGY, V186, P712, DOI 10.1016/0042-6822(92)90038-Q; SCHUPBACH J, 1989, AIDS, V3, P583, DOI 10.1097/00002030-198909000-00005; VANDEPERRE P, 1992, CLIN INFECT DIS, V15, P502, DOI 10.1093/clind/15.3.502; VANDEPERRE P, 1992, AIDS RES HUM RETROV, V8, P435, DOI 10.1089/aid.1992.8.435; VANDEPERRE P, 1988, J PEDIATR-US, V113, P1039, DOI 10.1016/S0022-3476(88)80578-X; VANDEPERRE P, 1991, NEW ENGL J MED, V325, P593, DOI 10.1056/NEJM199108293250901; WELSH JK, 1979, J PEDIATR-US, V94, P1, DOI 10.1016/S0022-3476(79)80340-6; WOLFF H, 1992, J ACQ IMMUN DEF SYND, V5, P65; ZOLLAPAZNER S, 1992, 7TH CENT GARD M MARN, P62; 1986, WKLY EPIDEMIOL REC, V61, P69; 1992, FEB M TECHN WORK GRO; 1992, GLOBAL PROGRAM AIDS; 1992, LANCET, V339, P1007	28	193	197	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 10	1993	341	8850					914	918		10.1016/0140-6736(93)91210-D	http://dx.doi.org/10.1016/0140-6736(93)91210-D			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW981	8096264				2022-12-28	WOS:A1993KW98100003
J	WEISSKOPF, MG; ZALUTSKY, RA; NICOLL, RA				WEISSKOPF, MG; ZALUTSKY, RA; NICOLL, RA			THE OPIOID PEPTIDE DYNORPHIN MEDIATES HETEROSYNAPTIC DEPRESSION OF HIPPOCAMPAL MOSSY FIBER SYNAPSES AND MODULATES LONG-TERM POTENTIATION	NATURE			English	Article							CA3 PYRAMIDAL CELLS; GUINEA-PIG; RAT HIPPOCAMPUS; N-TYPE; CALCIUM CHANNELS; DENTATE GYRUS; BINDING-SITES; PAIRED-PULSE; RECEPTOR; NEURONS	The mossy fibre pathway in the hippocampus uses glutamate as a neurotransmitter, but also contains the opioid peptide dynorphin. Synaptic release of dynorphin causes a presynaptic inhibition of neighbouring mossy fibres and inhibits the induction and expression of mossy fibre long-term potentiation. These findings demonstrate a physiological role for a neuropeptide in the central nervous system, provide a functional basis for the coexistence of a neuropeptide with classic neurotransmitters and demonstrate the very different roles played by these two classes of signalling molecules.	UNIV CALIF SAN FRANCISCO, GRAD PROGRAM NEUROSCI, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco								ADAMSON P, 1989, EUR J PHARMACOL, V174, P63, DOI 10.1016/0014-2999(89)90874-1; BEAN BP, 1989, NATURE, V340, P153, DOI 10.1038/340153a0; BRADLER JE, 1990, NEUROSCIENCE, V35, P265, DOI 10.1016/0306-4522(90)90080-N; CAUDLE RM, 1990, J PHARMACOL EXP THER, V252, P1361; CHAVKIN C, 1982, SCIENCE, V215, P413, DOI 10.1126/science.6120570; COLLIER TJ, 1984, BRAIN RES, V310, P384, DOI 10.1016/0006-8993(84)90166-5; CRAWFORD IL, 1973, NATURE, V244, P442, DOI 10.1038/244442a0; CREAGER R, 1980, J PHYSIOL-LONDON, V299, P409, DOI 10.1113/jphysiol.1980.sp013133; DECKER MW, 1991, SYNAPSE, V7, P151, DOI 10.1002/syn.890070209; GALL C, 1981, J COMP NEUROL, V198, P335, DOI 10.1002/cne.901980211; GALLAGHER M, 1988, OPIOIDS HIPPOCAMPUS, P118; GANNON RL, 1991, BRAIN RES, V548, P242, DOI 10.1016/0006-8993(91)91127-M; GAUCHY C, 1991, NEUROSCIENCE, V41, P449, DOI 10.1016/0306-4522(91)90340-T; GILLAN MGC, 1982, BRIT J PHARMACOL, V77, P461, DOI 10.1111/j.1476-5381.1982.tb09319.x; GOLDSTEIN A, 1987, TRENDS PHARMACOL SCI, V8, P456, DOI 10.1016/0165-6147(87)90038-1; GROSS RA, 1987, P NATL ACAD SCI USA, V84, P5469, DOI 10.1073/pnas.84.15.5469; HOKFELT T, 1991, NEURON, V7, P867, DOI 10.1016/0896-6273(91)90333-U; IWAMA T, 1986, NEUROSCI LETT, V63, P190, DOI 10.1016/0304-3940(86)90060-1; JAN LY, 1982, J PHYSIOL-LONDON, V327, P219, DOI 10.1113/jphysiol.1982.sp014228; JAN YN, 1983, TRENDS NEUROSCI, V6, P320, DOI 10.1016/0166-2236(83)90148-0; KAMIYA H, 1988, NEUROSCI LETT, V91, P84, DOI 10.1016/0304-3940(88)90253-4; KATO M, 1992, BRAIN RES, V574, P138, DOI 10.1016/0006-8993(92)90810-V; KATZ B, 1968, J PHYSIOL-LONDON, V195, P481, DOI 10.1113/jphysiol.1968.sp008469; LUNDBERG JM, 1983, TRENDS NEUROSCI, V6, P325, DOI 10.1016/0166-2236(83)90149-2; LUPICA CR, 1991, SYNAPSE, V8, P237, DOI 10.1002/syn.890080402; MALLART A, 1968, J PHYSIOL-LONDON, V196, P593, DOI 10.1113/jphysiol.1968.sp008525; MARTIN MR, 1983, NEUROPEPTIDES, V4, P45, DOI 10.1016/0143-4179(83)90007-0; MCFADZEAN I, 1987, NEUROSCIENCE, V20, P231, DOI 10.1016/0306-4522(87)90015-7; MCGINTY JF, 1983, P NATL ACAD SCI-BIOL, V80, P589, DOI 10.1073/pnas.80.2.589; MCLEAN S, 1987, J COMP NEUROL, V255, P497, DOI 10.1002/cne.902550403; MOSBERG HI, 1983, P NATL ACAD SCI-BIOL, V80, P5871, DOI 10.1073/pnas.80.19.5871; NEUMAIER JF, 1988, J PHARMACOL EXP THER, V244, P564; NICOLL RA, 1977, P NATL ACAD SCI USA, V74, P2584, DOI 10.1073/pnas.74.6.2584; NOCK B, 1990, J PHARMACOL EXP THER, V254, P412; PINNOCK RD, 1992, BRAIN RES, V583, P237, DOI 10.1016/S0006-8993(10)80029-0; ROLLS ET, 1990, COLD SPRING HARB SYM, V55, P995; STAUBLI U, 1990, SYNAPSE, V5, P333, DOI 10.1002/syn.890050410; STORMMATHISEN J, 1983, NATURE, V301, P517, DOI 10.1038/301517a0; TAKEMORI AE, 1988, J PHARMACOL EXP THER, V246, P255; TERRIAN DM, 1988, BRAIN RES BULL, V21, P343, DOI 10.1016/0361-9230(88)90146-3; WAGNER JJ, 1991, J NEUROCHEM, V57, P333, DOI 10.1111/j.1471-4159.1991.tb02132.x; WAGNER JJ, 1992, J NEUROSCI, V12, P132; XIANG JZ, 1990, NEUROPHARMACOLOGY, V29, P439, DOI 10.1016/0028-3908(90)90165-N; ZALUTSKY RA, 1990, SCIENCE, V248, P1619, DOI 10.1126/science.2114039; ZALUTSKY RA, 1992, NEUROSCI LETT, V138, P193, DOI 10.1016/0304-3940(92)90503-Y; ZALUTSKY RA, 1991, TRANSMITTER AMINO AC, V6, P415; ZIEGLGANSBERGER W, 1979, SCIENCE, V205, P415, DOI 10.1126/science.451610; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13; ZUKIN RS, 1988, P NATL ACAD SCI USA, V85, P4061, DOI 10.1073/pnas.85.11.4061	49	252	259	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 1	1993	362	6419					423	427		10.1038/362423a0	http://dx.doi.org/10.1038/362423a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KV424	8096624				2022-12-28	WOS:A1993KV42400074
J	SUN, SC; GANCHI, PA; BALLARD, DW; GREENE, WC				SUN, SC; GANCHI, PA; BALLARD, DW; GREENE, WC			NF-KAPPA-B CONTROLS EXPRESSION OF INHIBITOR I-KAPPA-B-ALPHA - EVIDENCE FOR AN INDUCIBLE AUTOREGULATORY PATHWAY	SCIENCE			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; TRANS-ACTIVATOR PROTEIN; NECROSIS FACTOR-ALPHA; DNA-BINDING SUBUNIT; TRANSCRIPTION FACTOR; 65-KD SUBUNIT; GENE-EXPRESSION; T-CELLS; ENHANCER; REL	The eukaryotic transcription factor nuclear factor-kappa B (NF-kappaB) participates in many parts of the genetic program mediating T lymphocyte activation and growth. Nuclear expression of NF-kappaB occurs after its induced dissociation from its cytoplasmic inhibitor IkappaBalpha. Phorbol ester and tumor necrosis factor-alpha induction of nuclear NF-kappaB is associated with both the degradation of preformed IkappaBalpha and the activation of IkappaBalpha gene expression. Transfection studies indicate that the IkappaBalpha gene is specifically induced by the 65-kilodalton transactivating subunit of NF-kappaB. Association of the newly synthesized IkappaBalpha with p65 restores intracellular inhibition of NF-kappaB DNA binding activity and prolongs the survival of this labile inhibitor. Together, these results show that NF-kappaB controls the expression of IkappaBalpha by means of an inducible autoregulatory pathway.	UNIV CALIF SAN FRANCISCO,GLADSTONE INST VIROL & IMMUNOL,POB 419100,SAN FRANCISCO,CA 94141; SAN FRANCISCO GEN HOSP,SAN FRANCISCO,CA 94141; VANDERBILT UNIV,HOWARD HUGHES MED INST,NASHVILLE,TN 37232	University of California System; University of California San Francisco; The J David Gladstone Institutes; San Francisco General Hospital Medical Center; Howard Hughes Medical Institute; Vanderbilt University					NATIONAL CANCER INSTITUTE [T32CA009111] Funding Source: NIH RePORTER; NCI NIH HHS [5T32CA09111] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARIMA N, 1992, J IMMUNOL, V149, P83; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BAEUERLE PA, 1988, COLD SPRING HARB SYM, V53, P789, DOI 10.1101/SQB.1988.053.01.089; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAEUERLE PA, 1990, MOL ASPECTS CELLULAR, P409; BALLARD D W, 1989, New Biologist, V1, P83; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BOHNLEIN E, 1988, CELL, V53, P827, DOI 10.1016/0092-8674(88)90099-2; CHMITZ ML, 1991, EMBO J, V10, P3805; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMAN M, 1987, CURRENT PROTOCOLS MO; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GOUGH NM, 1988, ANAL BIOCHEM, V173, P93, DOI 10.1016/0003-2697(88)90164-9; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; KAUFMAN JD, 1987, MOL CELL BIOL, V7, P3759, DOI 10.1128/MCB.7.10.3759; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LOWENTHAL JW, 1989, P NATL ACAD SCI USA, V86, P2331, DOI 10.1073/pnas.86.7.2331; MEYER M, 1992, EMBO J, V11, P2991, DOI 10.1002/j.1460-2075.1992.tb05369.x; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; MUESING MA, 1987, CELL, V48, P691, DOI 10.1016/0092-8674(87)90247-9; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; SUN SY, UNPUB; THORNELL A, 1988, MOL CELL BIOL, V8, P1625, DOI 10.1128/MCB.8.4.1625; TONGSTARKSEN SE, 1987, P NATL ACAD SCI USA, V84, P6845, DOI 10.1073/pnas.84.19.6845; URBAN MB, 1990, GENE DEV, V4, P1975, DOI 10.1101/gad.4.11.1975; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0	45	1028	1052	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 26	1993	259	5103					1912	1915		10.1126/science.8096091	http://dx.doi.org/10.1126/science.8096091			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KU172	8096091				2022-12-28	WOS:A1993KU17200036
J	FISCHER, AA				FISCHER, AA			PAIN RELIEF - STERILE WATER FOR WHIPLASH SYNDROME	LANCET			English	Editorial Material											FISCHER, AA (corresponding author), CUNY MT SINAI SCH MED,DEPT REHABIL MED,NEW YORK,NY 10029, USA.							Fischer AA, 1990, J MANUAL MED, V5, P145; Fischer AA, 1987, CLIN J PAIN, V2, P207; KRAUS H, 1991, MT SINAI J MED, V58, P235; TRAVELL JG, 1983, TRIGGER POINT MANUAL, V1; [No title captured]	5	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 20	1993	341	8843					470	470		10.1016/0140-6736(93)90215-3	http://dx.doi.org/10.1016/0140-6736(93)90215-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN137	8094495				2022-12-28	WOS:A1993KN13700012
J	VICTORA, CG; TOMASI, E; OLINTO, MTA; BARROS, FC				VICTORA, CG; TOMASI, E; OLINTO, MTA; BARROS, FC			USE OF PACIFIERS AND BREAST-FEEDING DURATION	LANCET			English	Note								Pacifiers are widely used in many developing countries. Although their use is not recommended for breastfeeding infants, there have been no published reports on the association between pacifier use and risk of early weaning. In a study of 354 infants in Brazil, mothers were asked about pacifier use at age 1 month, duration of breastfeeding, and introduction of other foods. Among 249 children still breastfed at 1 month, the risk that a child would be weaned at any age between 1 and 24 months was higher in pacifier users than in non-users (hazard ratio 3.0, 95% CI 2.0-4.6). The association remained even after adjustment for the child's age, sex, birthweight, socioeconomic status, and age at introduction of bottle-feeding.			VICTORA, CG (corresponding author), UNIV FED PELOTAS,CP 464,BR-96100 PELOTAS,RS,BRAZIL.		Victora, Cesar Gomes/Y-2455-2019; Barros, Fernando C/D-4857-2013; Tomasi, Elaine/AAH-2226-2021; Victora, Cesar G/D-4476-2013; Olinto, Maria Teresa Anselmo/AAH-5897-2021	Victora, Cesar Gomes/0000-0002-2465-2180; Victora, Cesar G/0000-0002-2465-2180; Olinto, Maria Teresa Anselmo/0000-0002-3950-4594				HELSING E, 1982, BREASTFEEDING PRACTI; KING FS, 1985, HELPING MOTHERS BREA; MATHUR G P, 1990, Indian Pediatrics, V27, P1187; MURAHOVSCHI J, 1982, CARTILHA AMAMENTACAO; RIORDAN J, 1991, PRACTICAL GUIDE BREA, P47; SEHGAL S K, 1990, Indian Pediatrics, V27, P263; VICTORA C, IN PRESS P C NURITIO; VICTORA CG, 1987, LANCET, V2, P319; 1989, PROTECTING PROMOTING	9	76	92	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 13	1993	341	8842					404	406		10.1016/0140-6736(93)92991-2	http://dx.doi.org/10.1016/0140-6736(93)92991-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM416	8094171				2022-12-28	WOS:A1993KM41600006
J	CHAN, P; PATEL, M; BETTERIDGE, L; MUNRO, E; SCHACHTER, M; WOLFE, J; SEVER, P				CHAN, P; PATEL, M; BETTERIDGE, L; MUNRO, E; SCHACHTER, M; WOLFE, J; SEVER, P			ABNORMAL GROWTH-REGULATION OF VASCULAR SMOOTH-MUSCLE CELLS BY HEPARIN IN PATIENTS WITH RESTENOSIS	LANCET			English	Note								Proliferation of vascular smooth muscle cells (VSMC) underlies myointimal hyperplasia, which can lead to restenosis after angioplasty and vascular surgery. We propose that some individuals have an intrinsic capacity for this exaggerated response to vascular injury, partly through decreased sensitivity to the physiological growth inhibitor heparin. We investigated the effect of heparin on VSMC from restenotic lesions and from apparently normal vessels of the same patients, and VSMC from control patients undergoing primary bypass procedures. Cells from patients with restenosis (both restenotic lesion and undiseased vein) showed much lower sensitivity to growth inhibition by heparin than the controls (median inhibition 8 [95% CI - 2 to 25] vs 22 [15-44]%, p<0.001); this finding suggests aberrant growth regulation in these cells.	ST MARYS HOSP,DEPT VASC SURG,LONDON,ENGLAND	Imperial College London	CHAN, P (corresponding author), IMPERIAL COLL SCI TECHNOL & MED,ST MARYS HOSP,SCH MED,DEPT CLIN PHARMACOL,LONDON W2 1NY,ENGLAND.							AU YPT, 1992, J BIOL CHEM, V267, P3438; CHAN P, IN PRESS EUR J VASC; CLOWES AW, 1977, NATURE, V265, P625, DOI 10.1038/265625a0; DARTSCH PC, 1990, ARTERIOSCLEROSIS, V10, P62, DOI 10.1161/01.ATV.10.1.62; LEHMANN K G, 1991, Journal of the American College of Cardiology, V17, p181A; PUKAC LA, 1992, J BIOL CHEM, V267, P3707; RESINK TJ, 1989, J CELL PHYSIOL, V138, P137, DOI 10.1002/jcp.1041380119; SCHWARTZ SM, 1986, CIRC RES, V58, P427, DOI 10.1161/01.RES.58.4.427; SNOW AD, 1990, AM J PATHOL, V137, P313; YLAHERTTUALA S, 1986, LAB INVEST, V54, P402	10	58	59	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 6	1993	341	8841					341	342		10.1016/0140-6736(93)90139-8	http://dx.doi.org/10.1016/0140-6736(93)90139-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK939	8094116				2022-12-28	WOS:A1993KK93900007
J	BLATT, SP; LUCEY, CR; BUTZIN, CA; HENDRIX, CW; LUCEY, DR				BLATT, SP; LUCEY, CR; BUTZIN, CA; HENDRIX, CW; LUCEY, DR			TOTAL LYMPHOCYTE COUNT AS A PREDICTOR OF ABSOLUTE CD4+ COUNT AND CD4+ PERCENTAGE IN HIV-INFECTED PERSONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HOMOSEXUAL MEN; RISK; COHORT; AIDS; PNEUMONIA; DECLINE; TYPE-1	Objective.-To determine whether the total lymphocyte count (TLC) accurately predicts a low absolute CD4+ T-cell count and CD4+ percentage in persons infected with human immunodeficiency virus (HIV). Design.-Retrospective analysis of data collected in the US Air Force HIV Natural History Study. Setting.-Military medical center that performs annual medical evaluation of all HIV-infected US Air Force personnel. Patients.-A total of 828 consecutive patients with no prior history of zidovudine use, evaluated from January 1985 through July 1991. For patients with multiple observations over time, a single data point within each 6-month interval was included in the analysis (N=2866). Measurements and Main Results.-The sensitivity, specificity, and likelihood ratio (LR) of the TLC, in the range of 1.00x10(9)/L to 2.00x10(9)/L, in predicting an absolute CD4+ T-cell count less than 0.20x10(9)/L or a CD4+ percentage less than 20% were calculated. In addition, the LR and pretest probability of significant immunosuppression were used to calculate posttest probabilities of a low CD4+ count for a given TLC value. The LR of the TLC in predicting an absolute CD4+ count <0.20x10(9)/L increased from 2.4 (95% confidence interval, 2.2 to 2.5) for all TLCs less than 2.00x10(9)/L, to 33.2 (95% confidence interval, 24.1 to 45.7) for all TLCs less than 1.00x10(9)/L. The specificity for this prediction increased from 57% to 97% over this range. The LR also increased from 1.4 (95% confidence interval, 1.3 to 1.6) for all TLCs less than 2.00x10(9)/L to 9.7 (95% confidence interval, 7.1 to 13.1) for all TLCs less than 1.00x10(9)/L in predicting a CD4+ percentage less than 20%. Conclusions.-The TLC, between 1.00x10(9)/L and 2.00x10(9)/L, appears to be a useful predictor of significant immunosuppression as measured by a CD4+ T-cell count less than 0.20x10(9)/L in HIV-infected persons. The LR fora given TLC value and the pretest probability of immunosuppression can be used to determine the posttest probability of significant immunosuppression in individual patients. For example, in a patient with a TLC less than 1.50x10(9)/L and a pretest probability of 16%, the posttest probability of a low CD4+ T-cell count increases to 53%. In contrast, a TLC greater than 2.00x10(9)/L in an individual with a pretest probability of 30% will decrease the posttest probability of a low CD4+ T-cell count to less than 4%. Physicians should find these data useful to help predict the risk for opportunistic infection among HIV-infected persons who present with syndromes that are potentially compatible with opportunistic infection but who have not had recent or prior CD4+ T-cell analysis.	WILFORD HALL USAF MED CTR,CLIN INVEST DIRECTORATE,LACKLAND AFB,TX 78236; SW FDN BIOMED RES,CTR AIDS RES,SAN ANTONIO,TX 78284; MIL MED CONSORTIUM APPL RETROVIRAL RES,SAN ANTONIO,TX; WALTER REED ARMY MED CTR,GEN MED SERV,WASHINGTON,DC 20307	United States Department of Defense; United States Air Force; Texas Biomedical Research Institute; United States Department of Defense; United States Army; Walter Reed National Military Medical Center	BLATT, SP (corresponding author), WILFORD HALL USAF MED CTR,DEPT MED,INFECT DIS SERV,HIV PROGRAM,SGHMMI HIV,2200 BERGQUIST DR,LACKLAND AFB,TX 78236, USA.		Hendrix, Craig W/G-4182-2014	Hendrix, Craig W/0000-0002-5696-8665				[Anonymous], 1990, Wkly Epidemiol Rec, V65, P221; BURCHAM J, 1991, AIDS, V5, P365, DOI 10.1097/00002030-199104000-00002; CROWE SM, 1991, J ACQ IMMUN DEF SYND, V4, P770; DETELS R, 1987, INT J EPIDEMIOL, V16, P271, DOI 10.1093/ije/16.2.271; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; GOEDERT JJ, 1986, SCIENCE, V231, P992, DOI 10.1126/science.3003917; HECKERLING PS, 1988, J GEN INTERN MED, V3, P604, DOI 10.1007/BF02596109; KATZ MH, 1991, ARCH INTERN MED, V151, P105, DOI 10.1001/archinte.151.1.105; Kleinbaum DG, 1982, EPIDEMIOLOGIC RES PR, P298; KOVACS JA, 1992, CLIN INFECT DIS, V14, P1005, DOI 10.1093/clinids/14.5.1005; LUCEY DR, 1991, J ACQ IMMUN DEF SYND, V4, P24; LUCEY DR, 1991, J INFECT DIS, V164, P631, DOI 10.1093/infdis/164.4.631; MALONE JL, 1990, J ACQ IMMUN DEF SYND, V3, P144; MASUR H, 1989, ANN INTERN MED, V111, P223, DOI 10.7326/0003-4819-111-3-223; MELBYE M, 1986, ANN INTERN MED, V104, P496, DOI 10.7326/0003-4819-104-4-496; MUNOZ A, 1988, J ACQ IMMUN DEF SYND, V1, P396; PHAIR J, 1990, NEW ENGL J MED, V322, P161, DOI 10.1056/NEJM199001183220304; POLK BF, 1987, NEW ENGL J MED, V316, P61, DOI 10.1056/NEJM198701083160201; SACKETT DL, 1985, CLIN EPIDEMIOLOGY BA, P108; SLOAN P, 1991, 7 INT C AIDS FLOR; TAYLOR JMG, 1989, J ACQ IMMUN DEF SYND, V2, P114; 1992, MMWR, V41, P608; 1992, MMWR, V41, P1; 1988, J ACQ IMMUN DEF SYND, V1, P390	24	63	67	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 3	1993	269	5					622	626		10.1001/jama.269.5.622	http://dx.doi.org/10.1001/jama.269.5.622			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ444	8093628				2022-12-28	WOS:A1993KJ44400030
J	HANSSON, GK				HANSSON, GK			ATHEROSCLEROSIS - IMMUNOLOGICAL MARKERS OF ATHEROSCLEROSIS	LANCET			English	Editorial Material											HANSSON, GK (corresponding author), SAHLGRENS UNIV HOSP,DEPT CLIN CHEM,S-41345 GOTHENBURG,SWEDEN.		Hansson, Goran K/B-7423-2012	Hansson, Goran/0000-0003-4148-5190				JONASSON L, 1986, ARTERIOSCLEROSIS, V6, P131, DOI 10.1161/01.ATV.6.2.131; KIESSLING R, 1991, IMMUNOL REV, V121, P91, DOI 10.1111/j.1600-065X.1991.tb00824.x; LIBBY P, 1991, LAB INVEST, V64, P5; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; SALONEN JT, 1992, LANCET, V339, P883, DOI 10.1016/0140-6736(92)90926-T	5	18	18	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 30	1993	341	8840					278	278		10.1016/0140-6736(93)92621-Y	http://dx.doi.org/10.1016/0140-6736(93)92621-Y			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK245	8093922				2022-12-28	WOS:A1993KK24500009
J	TARNOWMORDI, W				TARNOWMORDI, W			OSIRIS TRIAL	LANCET			English	Letter											TARNOWMORDI, W (corresponding author), UNIV DUNDEE,NINEWELLS HOSP & MED SCH,CTR RES HUMAN DEV,DUNDEE DD1 9SY,SCOTLAND.								0	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 16	1993	341	8838					174	174						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG627	8093765				2022-12-28	WOS:A1993KG62700029
J	BRENNER, MK; RILL, DR; MOEN, RC; KRANCE, RA; MIRRO, J; ANDERSON, WF; IHLE, JN				BRENNER, MK; RILL, DR; MOEN, RC; KRANCE, RA; MIRRO, J; ANDERSON, WF; IHLE, JN			GENE-MARKING TO TRACE ORIGIN OF RELAPSE AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION	LANCET			English	Note							LEUKEMIA	Bone marrow harvested for autologous bone-marrow transplantation may contain residual malignant cells even when it is judged to be in remission. Genetic marking and subsequent detection of these cells in recipients would give useful information about the origin of relapse after transplantation. We transferred the neomycin-resistance gene into bone-marrow cells harvested from children with acute myeloid leukaemia in remission. Two patients have relapsed since reinfusion of the marked cells. In both, the resurgent blast cells contained the neomycin-resistance gene marker; thus, remission marrow can contribute to disease recurrence. This method of tracking malignant cells should enable the development of better marrow purging strategies.	GENET THERAPY INC, CLIN LABS, GAITHERSBURG, MD USA; CHILDRENS HOSP PITTSBURGH, DIV HEMATOL ONCOL, PITTSBURGH, PA USA; ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, MEMPHIS, TN 38101 USA; UNIV TENNESSEE, CTR HLTH SCI, COLL MED, DEPT PEDIAT, MEMPHIS, TN 38163 USA; UNIV TENNESSEE, CTR HLTH SCI, COLL MED, DEPT MED, MEMPHIS, TN 38163 USA; NHLBI, BETHESDA, MD 20892 USA	Novartis; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			Brenner, Malcolm/Y-2509-2019		NATIONAL CANCER INSTITUTE [P30CA021765, P01CA020180] Funding Source: NIH RePORTER; NCI NIH HHS [5 P01 CA 20180, CA 21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENDER MA, 1987, J VIROL, V61, P1639, DOI 10.1128/JVI.61.5.1639-1646.1987; BRENNER M, 1991, HUM GENE THER, V2, P137; CORNETTA K, 1989, J VIROL METHODS, V23, P187, DOI 10.1016/0166-0934(89)90132-8; COUSTANSMITH E, IN PRESS LEUKEMIA; EMMINGER W, 1992, ANN HEMATOL, V64, P181, DOI 10.1007/BF01696220; ERICKSON P, 1992, BLOOD, V80, P1825; GORIN NC, 1990, BLOOD, V75, P1606; RILL DR, 1992, BLOOD, V79, P2694; YEAGER AM, 1986, NEW ENGL J MED, V315, P141, DOI 10.1056/NEJM198607173150301	9	891	904	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 9	1993	341	8837					85	86		10.1016/0140-6736(93)92560-G	http://dx.doi.org/10.1016/0140-6736(93)92560-G			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF870	8093407				2022-12-28	WOS:A1993KF87000007
J	JOHNELL, O; COOPER, C; MELTON, LJ				JOHNELL, O; COOPER, C; MELTON, LJ			HOW DO WE PREVENT HIP-FRACTURES	LANCET			English	Editorial Material									MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON,ENGLAND; MAYO CLIN & MAYO FDN,CLIN EPIDEMIOL SECT,ROCHESTER,MN 55905	University of Southampton; Mayo Clinic	JOHNELL, O (corresponding author), MALMO GEN HOSP,DEPT ORTHOPAED,S-21401 MALMO,SWEDEN.							[Anonymous], 1989, GUIDE CLIN PREVENTIV; CUMMINGS SR, 1990, JAMA-J AM MED ASSOC, V263, P665, DOI 10.1001/jama.263.5.665; LAW MR, 1991, BMJ-BRIT MED J, V303, P453, DOI 10.1136/bmj.303.6800.453; Melton LJ, 1991, J BONE MINER RES  S1, V6, pS136; RIGGS BL, 1992, NEW ENGL J MED, V327, P620; 1991, PRIORITIZATION HLTH	6	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 9	1993	341	8837					89	89		10.1016/0140-6736(93)92562-8	http://dx.doi.org/10.1016/0140-6736(93)92562-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF870	8093409				2022-12-28	WOS:A1993KF87000009
J	HOGE, CW; SHLIM, DR; RAJAH, R; TRIPLETT, J; SHEAR, M; RABOLD, JG; ECHEVERRIA, P				HOGE, CW; SHLIM, DR; RAJAH, R; TRIPLETT, J; SHEAR, M; RABOLD, JG; ECHEVERRIA, P			EPIDEMIOLOGY OF DIARRHEAL ILLNESS ASSOCIATED WITH COCCIDIAN-LIKE ORGANISM AMONG TRAVELERS AND FOREIGN RESIDENTS IN NEPAL	LANCET			English	Article							CAMPYLOBACTER-JEJUNI; TRAVELERS; CHILDREN	A newly described organism called CLB (coccidian-like or cyanobacterium-like body) has been identified in cases of prolonged diarrhoea. To confirm an association of CLB with disease and identify risk factors for transmission, we conducted a case-control study of travellers and foreign residents at two outpatient clinics in Kathmandu, Nepal. Patients without diarrhoea were matched to CLB cases by clinic and date of visit. For comparison, patients with other causes of diarrhoea were also studied. Stools were examined for enteric pathogens with standard microbiological and molecular genetic techniques. CLB was identified in 108 (11%) of 964 individuals with gastrointestinal symptoms compared with only 1 (1%) of 96 symptom-free controls (p=0.003). 7% of residents in the US Embassy community acquired the infection. The diarrhoeal illness associated with CLB lasted a median of 7 weeks (interquartile range 4-9) compared with 9 days (4-19) for individuals with other causes of diarrhoea (p<0.0001). The prevalence of other enteric pathogens was no higher among CLB cases than among symptom-free controls. Patients with CLB infection were more likely than controls to report consumption of untreated water (odds ratio 3.98; 95% Cl 1.29-13.14); organisms of the same appearance were identified in an epidemiologically implicated water sample. The significant association of CLB with prolonged diarrhoea, and the low rate of other enteropathogens in CLB cases, strongly supports the hypothesis that CLB is a new pathogen. Epidemiological and environmental data suggest that the organism is waterborne.	US EMBASSY, MED CLIN, Kathmandu, NEPAL; CANADIAN INT WATER & ENERGY CONSULTANTS CLIN, Kathmandu, NEPAL		HOGE, CW (corresponding author), USA, MED COMPONENT, ARMED FORCES RES INST MED SCI, DEPT BACTERIOL IMMUNOL & MOLEC GENET, BANGKOK 10400, THAILAND.							CONNOR BA, IN PRESS ANN INTERN; DEAN AG, 1972, J INFECT DIS, V125, P407, DOI 10.1093/infdis/125.4.407; ECHEVERRIA P, 1989, J INFECT DIS, V159, P543, DOI 10.1093/infdis/159.3.543; ECHEVERRIA P, 1990, P95; HART AS, 1990, LANCET, V335, P169, DOI 10.1016/0140-6736(90)90042-4; LONG EG, 1990, J CLIN MICROBIOL, V28, P1101, DOI 10.1128/JCM.28.6.1101-1104.1990; LONG EG, 1991, J INFECT DIS, V164, P199, DOI 10.1093/infdis/164.1.199; ORTEGA YR, 1993, IN PRESS N ENGL J ME; POLLOK RCG, 1992, LANCET, V340, P556, DOI 10.1016/0140-6736(92)91759-2; SACK DA, 1975, INFECT IMMUN, V11, P334, DOI 10.1128/IAI.11.2.334-336.1975; SHLIM DR, 1991, AM J TROP MED HYG, V45, P383, DOI 10.4269/ajtmh.1991.45.383; SOAVE R, 1986, CLIN RES, V34, pA533; STEELE TW, 1984, PATHOLOGY, V16, P263, DOI 10.3109/00313028409068535; TAYLOR DN, 1988, JAMA-J AM MED ASSOC, V260, P1245, DOI 10.1001/jama.260.9.1245; WANG WLL, 1983, J CLIN MICROBIOL, V18, P803, DOI 10.1128/JCM.18.4.803-807.1983; 1991, MMWR, V40, P325; 1991, 90762 CTR DIS CONTR	17	142	149	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 8	1993	341	8854					1175	1179		10.1016/0140-6736(93)91002-4	http://dx.doi.org/10.1016/0140-6736(93)91002-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB017	8098077				2022-12-28	WOS:A1993LB01700004
J	RIDKER, PM; VAUGHAN, DE; STAMPFER, MJ; MANSON, JE; HENNEKENS, CH				RIDKER, PM; VAUGHAN, DE; STAMPFER, MJ; MANSON, JE; HENNEKENS, CH			ENDOGENOUS TISSUE-TYPE PLASMINOGEN-ACTIVATOR AND RISK OF MYOCARDIAL-INFARCTION	LANCET			English	Article							CORONARY-ARTERY DISEASE; HEART-DISEASE; INHIBITOR; PLASMA; THROMBOEMBOLISM; AGE	Endogenous tissue-type plasminogen activator (tPA) has been hypothesised to be a marker of baseline fibrinolytic capacity. We therefore tested whether tPA antigen is associated with the occurrence of future myocardial infarction (MI) among apparently healthy individuals. tPA antigen concentrations were measured at baseline in plasma samples from 231 apparently healthy men from the Physicians' Health Study cohort who later developed MI, and in an equal number of controls matched for age and smoking habit who remained free of reported cardiovascular disease during a follow-up of 60.2 months. In crude matched-pair analyses, baseline concentrations of tPA antigen were higher in cases than controls (p=0.03) and strongly associated with risk of future MI. Specifically, the relative risks of developing a first MI from lowest (referent) to highest quintiles of tPA antigen were 1.00, 1.27, 1.75, 1.88, and 2.81 (p for trend 0.008, 95% Cl for the relative risk in the fifth as compared with first quintile 1.47 to 5.37, p=0.002). Analyses which adjusted for risk factors that affect progression of atherosclerosis, particularly HDL-cholesterol, abolished the statistical significance of this association, a finding which suggests that elevations of tPA antigen are a result rather than a cause of atherosclerotic coronary disease. These prospective data suggest that endogenous tPA concentrations increase as a consequence of important preclinical atherosclerosis and therefore may be a marker for risk of future MI.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV PREVENT MED,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,CHANNING LAB,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT PREVENT MED,BOSTON,MA 02115; W ROXBURY VET ADM HOSP,CTR RES THROMBOSIS,BOSTON,MA; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	RIDKER, PM (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV CARDIOL,900 COMMONWEALTH AVE E,BOSTON,MA 02115, USA.				NCI NIH HHS [CA-34944] Funding Source: Medline; NHLBI NIH HHS [HL-26490, HL-34595] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034595] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1989, NEW ENGL J MED, V321, P129; AZNAR J, 1988, BRIT HEART J, V59, P535; FUSTER V, 1992, NEW ENGL J MED, V326, P310; HAMSTEN A, 1987, LANCET, V2, P3; HAMSTEN A, 1985, NEW ENGL J MED, V313, P1557, DOI 10.1056/NEJM198512193132501; JANSSON JH, 1991, EUR HEART J, V12, P157, DOI 10.1093/oxfordjournals.eurheartj.a059862; LUSKUTOFF DJ, 1989, PROG HEMOST THROMB, V9, P887; MEHTA J, 1987, J AM COLL CARDIOL, V9, P263, DOI 10.1016/S0735-1097(87)80373-X; NILSSON TK, 1992, CIRCULATION, V86, P598; OLOFSSON BO, 1989, EUR HEART J, V10, P77; OSEROFF A, 1989, J LAB CLIN MED, V113, P88; PARAMO JA, 1985, BRIT MED J, V291, P573, DOI 10.1136/bmj.291.6495.573; Petrakis N L, 1985, Natl Cancer Inst Monogr, V67, P193; PRINS MH, 1991, ARCH INTERN MED, V151, P1721, DOI 10.1001/archinte.151.9.1721; RANBY M, 1986, CLIN CHEM, V32, P2160; Ridker Paul M., 1992, Circulation, V86, pI325; RIDKER PM, 1992, CIRCULATION, V85, P1822, DOI 10.1161/01.CIR.85.5.1822; RIDKER PM, 1991, CIRCULATION, V83, P1098, DOI 10.1161/01.CIR.83.3.1098; RIDKER PM, 1992, CURR OPIN LIPIDOL, V3, P285; SPRENGERS ED, 1987, BLOOD, V69, P381; VANDEKERCKHOVE Y, 1988, THROMB RES, V50, P449, DOI 10.1016/0049-3848(88)90274-5; WALKER ID, 1977, THROMB RES, V10, P509, DOI 10.1016/0049-3848(77)90160-8; WIMAN B, 1991, PROG CARDIOVASC DIS, V34, P179, DOI 10.1016/0033-0620(91)90012-B; WINN DM, 1990, EPIDEMIOL REV, V12, P56, DOI 10.1093/oxfordjournals.epirev.a036062; 1971, ISCHEMIC HEART DISEA	25	569	575	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 8	1993	341	8854					1165	1168		10.1016/0140-6736(93)90998-V	http://dx.doi.org/10.1016/0140-6736(93)90998-V			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB017	8098074				2022-12-28	WOS:A1993LB01700001
J	STIRLING, D; LUDLAM, CA				STIRLING, D; LUDLAM, CA			BLEEDING DISORDERS - HEMOPHILIA-B AND FACTOR-IX MUTATIONS	LANCET			English	Editorial Material							HEMOPHILIA-B; PROMOTER; LEYDEN				STIRLING, D (corresponding author), ROYAL EDINBURGH & ASSOCIATED HOSP,DEPT HAEMATOL,EDINBURGH EH3 9HB,MIDLOTHIAN,SCOTLAND.							ALBERTS B, 1989, MOL BIOL CELL, P551; BRIET E, 1985, ANN INTERN MED, V103, P225, DOI 10.7326/0003-4819-103-2-225; Brownlee G, 1988, REC ADV HAEMATOL, V5, P251; CROSSLEY M, 1990, NATURE, V345, P444, DOI 10.1038/345444a0; CROSSLEY M, 1992, SCIENCE, V257, P377, DOI 10.1126/science.1631558; GIANNELLI F, 1991, NUCLEIC ACIDS RES, V19, P2193, DOI 10.1093/nar/19.suppl.2193; RAMJI DP, 1991, NUCLEIC ACIDS RES, V19, P1139, DOI 10.1093/nar/19.5.1139; REIJNEN MJ, 1992, P NATL ACAD SCI USA, V89, P6300, DOI 10.1073/pnas.89.14.6300; VELTKAMP JJ, 1970, SCAND J HAEMATOL, V7, P82	9	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 1	1993	341	8853					1127	1128		10.1016/0140-6736(93)93136-O	http://dx.doi.org/10.1016/0140-6736(93)93136-O			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ687	8097812				2022-12-28	WOS:A1993KZ68700012
J	EIKENBOOM, JCJ; REITSMA, PH; PEERLINCK, KMJ; BRIET, E				EIKENBOOM, JCJ; REITSMA, PH; PEERLINCK, KMJ; BRIET, E			RECESSIVE INHERITANCE OF VONWILLEBRANDS DISEASE TYPE-I	LANCET			English	Article							POLYMERASE CHAIN-REACTION; VON-WILLEBRANDS DISEASE; FACTOR GENE; FACTOR-VIII; POLYMORPHISM; VARIANT; FAMILY; EXPRESSION; MULTIMERS; MUTATION	The inheritance of type I von Willebrand's disease is thought to be autosomally dominant. The laboratory profile may, however, vary between affected people, even within a single family. There is also a large variation in the severity of clinical symptoms. To see if there is an association between the von Willebrand factor genotype, the laboratory profile, and the severity of the clinical symptoms we did a genetic analysis of four families with type I von Willebrand's disease. The proband of each family proved to be a compound heterozygote for defects in the von Willebrand factor gene. Simple heterozygotes in these families were either symptomless or only mildly affected. One of the identified mutations, which was shared by the probands of three of the four families, may have a carrier prevalence of 1:50 in the general population. These results suggest that the inheritance of von Willebrand's disease is often recessive rather than dominant and so have important implications for diagnosis and genetic counselling.	CATHOLIC UNIV LEUVEN,CTR THROMBOSIS & VASC RES,B-3000 LOUVAIN,BELGIUM	KU Leuven	EIKENBOOM, JCJ (corresponding author), UNIV HOSP LEIDEN,AEMOSTASIS & THROMBOSIS RES CTR,DEPT HAEMATOL,BLDG 1C2-R,POB 9600,2300 RC LEIDEN,NETHERLANDS.		Eikenboom, Jeroen/F-9156-2018	Eikenboom, Jeroen/0000-0002-3268-5759				ABILDGAARD CF, 1980, BLOOD, V56, P712; BERNDT MC, 1991, THROMB HAEMOSTASIS, V65, P1180; BLOOM AL, 1979, THROMB RES, V15, P502; CACHERIS PM, 1991, J BIOL CHEM, V266, P13499; DONNER M, 1991, BRIT J HAEMATOL, V78, P403, DOI 10.1111/j.1365-2141.1991.tb04455.x; EIKENBOOM JCJ, 1992, THROMB HAEMOSTASIS, V68, P448; GAUCHER C, 1991, BRIT J HAEMATOL, V78, P506, DOI 10.1111/j.1365-2141.1991.tb04480.x; HOLMBERG L, 1992, CIRCULATION S1, V86, pS416; HOYER LW, 1980, BLOOD, V55, P1056; JORIEUX S, 1992, BLOOD, V79, P563; KRONER PA, 1991, J BIOL CHEM, V266, P19146; KUNKEL GR, 1990, NUCLEIC ACIDS RES, V18, P4961, DOI 10.1093/nar/18.16.4961-a; MANCUSO DJ, 1991, BIOCHEMISTRY-US, V30, P253, DOI 10.1021/bi00215a036; MANCUSO DJ, 1989, J BIOL CHEM, V264, P19514; MILLER CH, 1979, BLOOD, V54, P117; MOHRI H, 1988, J BIOL CHEM, V263, P17901; NICHOLS WC, 1991, P NATL ACAD SCI USA, V88, P3857, DOI 10.1073/pnas.88.9.3857; PEAKE IR, 1990, BLOOD, V76, P555; PEAKE IR, 1990, BLOOD, V75, P654; PEERLINCK K, 1992, BRIT J HAEMATOL, V80, P358, DOI 10.1111/j.1365-2141.1992.tb08145.x; RODEGHIERO F, 1987, BLOOD, V69, P454; RUGGERI ZM, 1987, BLOOD, V70, P895; STANDEN GR, 1990, BRIT J HAEMATOL, V76, P242, DOI 10.1111/j.1365-2141.1990.tb07879.x; TULEY EA, 1991, P NATL ACAD SCI USA, V88, P6377, DOI 10.1073/pnas.88.14.6377; VANAMSTEL HKP, 1990, NUCLEIC ACIDS RES, V18, P4957, DOI 10.1093/nar/18.16.4957-a; WEISS HJ, 1986, BLOOD, V68, P149	26	112	114	1	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 17	1993	341	8851					982	986		10.1016/0140-6736(93)91070-3	http://dx.doi.org/10.1016/0140-6736(93)91070-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY368	8096943				2022-12-28	WOS:A1993KY36800003
J	HATAKE, K; IZUMI, T; IMAGAWA, S; OHTA, M; MIURA, Y				HATAKE, K; IZUMI, T; IMAGAWA, S; OHTA, M; MIURA, Y			MACROPHAGE COLONY-STIMULATING FACTOR AND PLATELET RECOVERY AFTER CHEMOTHERAPY	LANCET			English	Letter											HATAKE, K (corresponding author), JICHI MED SCH,DEPT INTERNAL MED,DIV HAEMATOL,MINAMI KAWACHI,TOCHIGI 32904,JAPAN.							HATAKE K, 1986, INT J IMMUNOPHARMACO, V8, P573; KHWAJA A, 1992, BRIT J HAEMATOL, V81, P228; MOTOYOSHI K, 1986, EXP HEMATOL, V14, P1069	3	9	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 10	1993	341	8850					963	963		10.1016/0140-6736(93)91257-M	http://dx.doi.org/10.1016/0140-6736(93)91257-M			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW981	8096299				2022-12-28	WOS:A1993KW98100045
J	VANDENBROUCKEGRAULS, CMJE				VANDENBROUCKEGRAULS, CMJE			PNEUMONIA - TOWARDS BETTER PREVENTION OF PNEUMONIA IN THE INTENSIVE-CARE UNIT	LANCET			English	Editorial Material							RESPIRATORY-TRACT; DECONTAMINATION				VANDENBROUCKEGRAULS, CMJE (corresponding author), ACAD ZIEKENHUIS,DEPT CLIN MICROBIOL,UTRECHT,NETHERLANDS.		Vandenbroucke-Grauls, Christina/AAO-7953-2020	Vandenbroucke-Grauls, Christina/0000-0003-2074-1597				ATHERTON ST, 1978, LANCET, V2, P968; GODARD J, 1990, INTENS CARE MED, V16, P307, DOI 10.1007/BF01706355; HEYLAND D, 1992, CHEST, V101, P187, DOI 10.1378/chest.101.1.187; JOHANSON WG, 1972, ANN INTERN MED, V77, P70; PUGIN J, 1991, JAMA-J AM MED ASSOC, V265, P2704, DOI 10.1001/jama.265.20.2704; VANDENBROUCKEGRAULS CMJE, 1991, LANCET, V338, P859, DOI 10.1016/0140-6736(91)91510-2	6	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 10	1993	341	8850					932	932		10.1016/0140-6736(93)91219-C	http://dx.doi.org/10.1016/0140-6736(93)91219-C			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW981	8096272				2022-12-28	WOS:A1993KW98100011
J	BADING, H; GINTY, DD; GREENBERG, ME				BADING, H; GINTY, DD; GREENBERG, ME			REGULATION OF GENE-EXPRESSION IN HIPPOCAMPAL-NEURONS BY DISTINCT CALCIUM SIGNALING PATHWAYS	SCIENCE			English	Article							DEPENDENT PROTEIN-KINASE; IMMEDIATE EARLY GENES; NMDA RECEPTOR ACTIVATION; C-FOS; SYNAPTIC ACTIVATION; DENDRITIC SPINES; NERVOUS-SYSTEM; MESSENGER-RNA; CALMODULIN; CHANNELS	Calcium ions (Ca2+) act as an intracellular second messenger and can enter neurons through various ion channels. Influx of Ca2+ through distinct types of Ca2+ channels may differentially activate biochemical processes. N-Methyl-D-aspartate (NMDA) receptors and L-type Ca2+ channels, two major sites of Ca2+ entry into hippocampal neurons, were found to transmit signals to the nucleus and regulated gene transcription through two distinct Ca2+ signaling pathways. Activation of the multifunctional Ca2+-calmodulin-dependent protein kinase (CaM kinase) was evoked by stimulation of either NMDA receptors or L-type Ca2+ channels; however, activation of CaM kinase appeared to be critical only for propagating the L-type Ca2+ channel signal to the nucleus. Also, the NMDA receptor and L-type Ca2+ channel pathways activated transcription by means of different cis-acting regulatory elements in the c-fos promoter. These results indicate that Ca2+, depending on its mode of entry into neurons, can activate two distinct signaling pathways. Differential signal processing may provide a mechanism by which Ca2+ controls diverse cellular functions.	HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,200 LONGWOOD AVE,BOSTON,MA 02115	Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028829, F32NS008764, R37NS028829] Funding Source: NIH RePORTER; NINDS NIH HHS [NS28829, 2F32 NS 08764] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BADING H, 1991, SCIENCE, V253, P912, DOI 10.1126/science.1715095; BADING H, UNPUB; Bashir Z I, 1992, Curr Opin Neurobiol, V2, P328, DOI 10.1016/0959-4388(92)90124-4; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; BLAUSTEIN MP, 1988, TRENDS NEUROSCI, V11, P438, DOI 10.1016/0166-2236(88)90195-6; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; COLE AJ, 1989, NATURE, V340, P474, DOI 10.1038/340474a0; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DOROSHENKO PA, 1988, NEUROSCIENCE, V27, P1073, DOI 10.1016/0306-4522(88)90211-4; ELY CM, 1990, J CELL BIOL, V110, P731, DOI 10.1083/jcb.110.3.731; FRANDSEN A, 1991, J NEUROCHEM, V56, P1075, DOI 10.1111/j.1471-4159.1991.tb02031.x; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; Ginty D D, 1992, Curr Opin Neurobiol, V2, P312, DOI 10.1016/0959-4388(92)90121-Z; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GORELICK FS, 1988, J BIOL CHEM, V263, P17209; GREENBERG DA, 1987, BRAIN RES, V404, P401, DOI 10.1016/0006-8993(87)91403-X; GREENBERG ME, 1986, SCIENCE, V234, P80, DOI 10.1126/science.3749894; GUTHRIE PB, 1991, NATURE, V354, P76, DOI 10.1038/354076a0; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HANSON PI, 1989, NEURON, V3, P59, DOI 10.1016/0896-6273(89)90115-3; HERNANDEZCRUZ A, 1990, SCIENCE, V247, P858, DOI 10.1126/science.2154851; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LI GD, 1992, MOL PHARMACOL, V42, P489; LOEFFLER JP, 1990, J NEUROCHEM, V54, P1812, DOI 10.1111/j.1471-4159.1990.tb01240.x; MACNICOL M, 1990, J BIOL CHEM, V265, P18055; MILLER RJ, 1991, PROG NEUROBIOL, V37, P255, DOI 10.1016/0301-0082(91)90028-Y; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; Misra R, UNPUB; MOLLOY SS, 1991, P NATL ACAD SCI USA, V88, P4756, DOI 10.1073/pnas.88.11.4756; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; MULLER W, 1991, NATURE, V354, P73, DOI 10.1038/354073a0; MURPHY TH, 1991, NEURON, V7, P625, DOI 10.1016/0896-6273(91)90375-A; OCORR KA, 1991, NEURON, V6, P907, DOI 10.1016/0896-6273(91)90231-N; REGEHR WG, 1990, NATURE, V345, P807, DOI 10.1038/345807a0; REGEHR WG, 1989, NATURE, V341, P533, DOI 10.1038/341533a0; RIVERA V M, 1990, New Biologist, V2, P751; RIVERA VM, UNPUB; ROTHMAN SM, 1987, TRENDS NEUROSCI, V10, P299, DOI 10.1016/0166-2236(87)90177-9; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SMITH SJ, 1988, TRENDS NEUROSCI, V11, P458, DOI 10.1016/0166-2236(88)90199-3; Snutch T P, 1992, Curr Opin Neurobiol, V2, P247, DOI 10.1016/0959-4388(92)90111-W; SZEKELY AM, 1989, MOL PHARMACOL, V35, P401; Thomas P, 1992, Curr Opin Neurobiol, V2, P308, DOI 10.1016/0959-4388(92)90120-A; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; Treisman R, 1990, Semin Cancer Biol, V1, P47; TSIEN RW, 1988, TRENDS NEUROSCI, V11, P431, DOI 10.1016/0166-2236(88)90194-4; VANBELLE H, 1981, CELL CALCIUM, V2, P483, DOI 10.1016/0143-4160(81)90007-5; WESTENBROEK RE, 1990, NATURE, V347, P281, DOI 10.1038/347281a0; WISDEN W, 1990, NEURON, V4, P603, DOI 10.1016/0896-6273(90)90118-Y; YUSTE R, 1991, NEURON, V6, P333, DOI 10.1016/0896-6273(91)90243-S	55	994	1008	0	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 9	1993	260	5105					181	186		10.1126/science.8097060	http://dx.doi.org/10.1126/science.8097060			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KW452	8097060				2022-12-28	WOS:A1993KW45200028
J	GRAY, WA				GRAY, WA			OUTCOME PREDICTION - NEARLY SUCCESSFUL RESUSCITATION	LANCET			English	Editorial Material											GRAY, WA (corresponding author), PRESBYTERIAN HOSP,DIV CARDIOL,ALBUQUERQUE,NM 87102, USA.								0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 3	1993	341	8849					866	866		10.1016/0140-6736(93)93068-C	http://dx.doi.org/10.1016/0140-6736(93)93068-C			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KV811	8096569				2022-12-28	WOS:A1993KV81100011
J	QARI, SH; SHI, YP; GOLDMAN, IF; UDHAYAKUMAR, V; ALPERS, MP; COLLINS, WE; LAL, AA				QARI, SH; SHI, YP; GOLDMAN, IF; UDHAYAKUMAR, V; ALPERS, MP; COLLINS, WE; LAL, AA			IDENTIFICATION OF PLASMODIUM-VIVAX-LIKE HUMAN MALARIA PARASITE	LANCET			English	Article							CIRCUMSPOROZOITE PROTEIN GENE; IMMUNODOMINANT EPITOPE; FALCIPARUM; POLYMORPHISM; SEQUENCE; VACCINE; VARIANT	There are four species of human malarial parasite and several monkey ones, and in evolutionary terms the human and non-human primate plasmodia may be related. The tools of molecular biology have lately pointed to the existence of two types of Plasmodium vivax. Using specific oligonucleotides we have identified a human malaria parasite resembling P vivax under the microscope but with circumsporozoite (CS) protein differing from those of P vivax types 1 and 2. The CS protein of this ''P vivax-like'' malaria parasite is identical to that of P simiovale, a monkey parasite resembling P ovale, a human one, morphologically. Polyclonal serum raised against a partial repeat sequence of the P vivax-like malaria parasite specifically reacted with P simiovale sporozoites but not with those of P vivax types 1 and 2, P ovale, or P simium. Sera collected from people living in malaria endemic regions of Papua New Guinea and Brazil contained antibodies that specifically reacted with the synthetic peptides representing the repeat sequences of CS protein of this P vivax-like parasite. A comparison of the CS protein gene sequences of P simiovale and the P vivax-like malaria parasites with those of other primate parasites, data on serological cross-reactivity, and 18S ribosomal DNA analyses suggest that the new human malaria parasite described here is distinct from P falciparum, P malariae, P vivax, and P ovale, the four known species of human parasite.	CTR DIS CONTROL, NATL CTR INFECT DIS, MALARIA BRANCH, ATLANTA, GA 30333 USA; PAPUA NEW GUINEA INST MED RES, GOROKA, PAPUA N GUINEA	Centers for Disease Control & Prevention - USA; PNG Institute Of Medical Research				Qari, Shoukat/0000-0002-0016-4414	NIAID NIH HHS [1-Y02-AI-00006-01] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARNOT DE, 1985, SCIENCE, V230, P815, DOI 10.1126/science.2414847; ARNOT DE, 1990, MOL BIOCHEM PARASIT, V43, P147, DOI 10.1016/0166-6851(90)90140-H; ARNOT DE, 1988, P NATL ACAD SCI USA, V85, P8102, DOI 10.1073/pnas.85.21.8102; COATNEY GR, 1971, AM J TROP MED HYG, V20, P795, DOI 10.4269/ajtmh.1971.20.795; COATNEY GR, 1971, PRIMATE MALARIAS; DELACRUZ VF, 1987, J BIOL CHEM, V262, P11935; Dissanaike A. S., 1965, Ceylon Journal of Medical Science, V14, P27; GALINSKI MR, 1987, CELL, V48, P311, DOI 10.1016/0092-8674(87)90434-X; KAIN KC, 1991, J INFECT DIS, V164, P208, DOI 10.1093/infdis/164.1.208; LAL AA, 1988, J BIOL CHEM, V263, P5495; LAL AA, 1988, MOL BIOCHEM PARASIT, V30, P291, DOI 10.1016/0166-6851(88)90099-0; LAL AA, 1991, J BIOL CHEM, V266, P6686; LOCKYER MJ, 1991, MOL BIOCHEM PARASIT, V45, P179, DOI 10.1016/0166-6851(91)90041-4; LOCKYER MJ, 1987, MOL BIOCHEM PARASIT, V22, P101, DOI 10.1016/0166-6851(87)90073-9; MCCUTCHAN TF, 1992, MOL BIOCHEM PARASIT, V50, P37, DOI 10.1016/0166-6851(92)90242-C; MCCUTCHAN TF, 1985, SCIENCE, V230, P1381, DOI 10.1126/science.2416057; NUSSENZWEIG V, 1989, ADV IMMUNOL, V45, P283, DOI 10.1016/S0065-2776(08)60695-1; OZAKI LS, STRUCTURE PLASMODIUM; QARI SH, 1992, MOL BIOCHEM PARASIT, V55, P105, DOI 10.1016/0166-6851(92)90131-3; QARI SH, 1991, J BIOL CHEM, V266, P16297; ROSENBERG R, 1989, SCIENCE, V245, P973, DOI 10.1126/science.2672336; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHI YP, 1992, AM J TROP MED HYG, V47, P844, DOI 10.4269/ajtmh.1992.47.844; WATERS AP, 1989, LANCET, V1, P1343; YOSHIDA N, 1990, EXP PARASITOL, V71, P386, DOI 10.1016/0014-4894(90)90064-J	25	73	73	1	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 27	1993	341	8848					780	783		10.1016/0140-6736(93)90559-Y	http://dx.doi.org/10.1016/0140-6736(93)90559-Y			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU900	8095999				2022-12-28	WOS:A1993KU90000003
J	MURCH, SH; MACDONALD, TT; WALKERSMITH, JA; LEVIN, M; LIONETTI, P; KLEIN, NJ				MURCH, SH; MACDONALD, TT; WALKERSMITH, JA; LEVIN, M; LIONETTI, P; KLEIN, NJ			DISRUPTION OF SULFATED GLYCOSAMINOGLYCANS IN INTESTINAL INFLAMMATION	LANCET			English	Article							SUBENDOTHELIAL EXTRACELLULAR-MATRIX; CONNECTIVE-TISSUE POLYSACCHARIDES; HEPARAN-SULFATE; CROHNS-DISEASE; ULCERATIVE-COLITIS; LYMPHOCYTES-T; ENDOGLYCOSIDASE; MUCOSUBSTANCES; PATHOGENESIS; ALBUMIN	We have studied the distribution and nature of sulphated glycosaminoglycans (GAGs) within normal and inflamed intestine. There is increasing evidence that these negatively charged polysaccharides, which both regulate the ability of albumin to leave the vasculature and inhibit thrombosis, may be affected by inflammatory cells and their products. We obtained samples of freshly resected intestinal tissue from eight controls, eleven patients with Crohn's disease, and six with ulcerative colitis. Sulphated GAGs were detected by means of a gold-conjugated poly-L-lysine probe, and the tissue density of anionic sites was assessed semiquantitatively by means of a Lennox graticule. In normal intestine there was staining in the vascular endothelium and the subepithelial basal lamina and throughout the extracellular matrix of the lamina propria and submucosa. Tissue from the patients with inflammatory bowel disease showed inflammation macroscopically and on histology. There were profound abnormalities of extracellular matrix GAGs, limited to the mucosa in ulcerative colitis and greatest in the submucosa in Crohn's disease. There was also substantial loss of GAGs from the subepithelial basal lamina in both disorders and from the vascular endothelium in submucosa in Crohn's disease. The extent of local GAG disruption was associated with the distribution of macrophages immunoreactive for tumour necrosis factor alpha and the activation marker RM 3/1. We suggest that inflammatory disruption of vascular and connective tissue GAGs may be an important pathogenetic mechanism, contributing to the leakage of protein and fluid, thrombosis, and tissue remodelling seen in inflammatory bowel disease.	ST MARYS HOSP,DEPT CHILD HLTH,LONDON,ENGLAND	Imperial College London	MURCH, SH (corresponding author), ST BARTHOLOMEWS HOSP,DEPT PAEDIAT GASTROENTEROL,LONDON EC1A 7BE,ENGLAND.		Lionetti, Paolo/AAC-2626-2019	Lionetti, Paolo/0000-0001-8029-3904; Klein, Nigel/0000-0003-3925-9258	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BEEKEN WL, 1972, GASTROENTEROLOGY, V62, P207; BORN GVR, 1985, BRIT J EXP PATHOL, V66, P543; BRAEGGER CP, 1992, LANCET, V339, P89, DOI 10.1016/0140-6736(92)90999-J; CHOY MY, 1990, GUT, V31, P1365, DOI 10.1136/gut.31.12.1365; COMPER WD, 1978, PHYSIOL REV, V58, P255, DOI 10.1152/physrev.1978.58.1.255; COMPER WD, 1990, BIOCHEM J, V269, P561, DOI 10.1042/bj2690561; EXLEY AR, 1990, LANCET, V335, P1275, DOI 10.1016/0140-6736(90)91337-A; FILIPE MI, 1970, GUT, V11, P229, DOI 10.1136/gut.11.3.229; FRIDMAN R, 1987, J CELL PHYSIOL, V130, P85, DOI 10.1002/jcp.1041300113; GOTLOIB L, 1988, RESUSCITATION, V16, P179, DOI 10.1016/0300-9572(88)90045-7; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KLEIN NJ, 1992, J CELL SCI, V102, P821; KLEIN NJ, 1993, HISTOCHEM J, V25, P291, DOI 10.1007/BF00159120; LEE J C L, 1968, Gastroenterology, V54, P76; LENNOX B, 1975, J CLIN PATHOL, V28, P99, DOI 10.1136/jcp.28.2.99; LINDAHL U, 1978, ANNU REV BIOCHEM, V47, P385, DOI 10.1146/annurev.bi.47.070178.002125; MACDONALD TT, 1988, J EXP MED, V167, P1341, DOI 10.1084/jem.167.4.1341; MALIK AB, 1989, J INVEST DERMATOL, V93, pS62, DOI 10.1111/1523-1747.ep12581072; MAST BA, 1992, PLAST RECONSTR SURG, V89, P503, DOI 10.1097/00006534-199203000-00019; MATZNER Y, 1985, J CLIN INVEST, V76, P1306, DOI 10.1172/JCI112104; MURCH SH, 1992, LANCET, V339, P381, DOI 10.1016/0140-6736(92)90077-G; NAPARSTEK Y, 1984, NATURE, V310, P241, DOI 10.1038/310241a0; PAPPENHEIMER JR, 1951, AM J PHYSIOL, V167, P13, DOI 10.1152/ajplegacy.1951.167.1.13; POWERS MR, 1989, J CELL PHYSIOL, V141, P558, DOI 10.1002/jcp.1041410314; ROSENZWEIG LJ, 1982, LAB INVEST, V47, P177; SAWYER PN, 1972, B NEW YORK ACAD MED, V48, P235; SHEAHAN DG, 1976, AM J ANAT, V146, P103, DOI 10.1002/aja.1001460202; SMITH JAW, 1988, DISEASES SMALL INTES, P328; SUNERGREN KP, 1987, J APPL PHYSIOL, V63, P1987; WAKEFIELD AJ, 1989, LANCET, V2, P1057	30	141	143	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 20	1993	341	8847					711	714		10.1016/0140-6736(93)90485-Y	http://dx.doi.org/10.1016/0140-6736(93)90485-Y			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KT362	8095623				2022-12-28	WOS:A1993KT36200002
J	FILLER, AG; HOWE, FA; HAYES, CE; KLIOT, M; WINN, HR; BELL, BA; GRIFFITHS, JR; TSURUDA, JS				FILLER, AG; HOWE, FA; HAYES, CE; KLIOT, M; WINN, HR; BELL, BA; GRIFFITHS, JR; TSURUDA, JS			MAGNETIC-RESONANCE NEUROGRAPHY	LANCET			English	Note								Radiological methods exist for generating tissue-specific images of bone, vessels, lymphatics, abdominal viscera, and the central nervous system, but there has been no reliable means to generate a clinical image of a nerve. We present the first ''image neurogram'' and report a method for producing such images by use of commercial magnetic resonance imaging systems. The image depicts a human nerve in situ in relation with a nerve graft, wherein the nerve is rendered in isolation much like a vessel appears in isolation in a subtraction angiogram.	UNIV WASHINGTON,DEPT RADIOL,SEATTLE,WA 98195; ST GEORGE HOSP,SCH MED,CRC,BIOMED MAGNET RESONANCE RES GRP,LONDON,ENGLAND; ST GEORGE HOSP,SCH MED,DEPT NEUROSURG,LONDON,ENGLAND	University of Washington; University of Washington Seattle; St Georges University London; St Georges University London	FILLER, AG (corresponding author), UNIV WASHINGTON,DEPT NEUROL SURG,RI 20,SEATTLE,WA 98195, USA.		Griffiths, John R/F-2853-2010; Howe, Franklyn A/C-3307-2008	Howe, Franklyn/0000-0002-7135-3351	NINDS NIH HHS [5T32 NS-07144-09] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007144] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		FILLER AG, 1992, RADIOLOGY S, V185, P157; HAYES CE, 1991, MAGNET RESON MED, V18, P309, DOI 10.1002/mrm.1910180206; HOWE FA, 1992, MAGNET RESON MED, V28, P328, DOI 10.1002/mrm.1910280215; ROEMER PB, 1990, MAGNET RESON MED, V16, P192, DOI 10.1002/mrm.1910160203; TSURUDA J, 1992, AM J NEURORADIOL, V13, P1411	5	144	152	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 13	1993	341	8846					659	661		10.1016/0140-6736(93)90422-D	http://dx.doi.org/10.1016/0140-6736(93)90422-D			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR613	8095572				2022-12-28	WOS:A1993KR61300006
J	MARKHAM, AF				MARKHAM, AF			THE POLYMERASE CHAIN-REACTION - A TOOL FOR MOLECULAR MEDICINE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ENZYMATIC AMPLIFICATION; THERMUS-AQUATICUS; DNA AMPLIFICATION; PERIPHERAL-BLOOD; SEQUENCES; GENE; PRIMER				MARKHAM, AF (corresponding author), ST JAMES UNIV HOSP, DEPT MED, MOLEC MED UNIT, W RIDING MED RES TRUST, LEEDS LS9 7TF, W YORKSHIRE, ENGLAND.							CAMBIEN F, 1992, NATURE, V359, P641, DOI 10.1038/359641a0; CHELLY J, 1988, NATURE, V333, P858, DOI 10.1038/333858a0; CHIEN A, 1976, J BACTERIOL, V127, P1550, DOI 10.1128/JB.127.3.1550-1557.1976; Erlich H.A., 1989, PCR TECHNOLOGY; FERRIE RM, 1992, AM J HUM GENET, V51, P251; Fountain J. W., 1992, American Journal of Human Genetics, V51, pA51; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HANDYSIDE AH, 1989, LANCET, V1, P347; INNIS MA, 1990, PCR PROTOCOLS; JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H; KLEPPE K, 1971, J MOL BIOL, V56, P341, DOI 10.1016/0022-2836(71)90469-4; LO YMD, 1989, LANCET, V2, P1363; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; McPherson M. J., 1991, PCR PRACTICAL APPROA; NELSON DL, 1989, P NATL ACAD SCI USA, V86, P6686, DOI 10.1073/pnas.86.17.6686; NEWTON CR, 1989, NUCLEIC ACIDS RES, V17, P2503, DOI 10.1093/nar/17.7.2503; OCHMAN H, 1988, GENETICS, V120, P621; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; RICHARDS RI, 1992, CELL, V70, P709, DOI 10.1016/0092-8674(92)90302-S; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SARKAR G, 1990, NATURE, V343, P27, DOI 10.1038/343027a0; SIDRANSKY D, 1992, SCIENCE, V256, P102, DOI 10.1126/science.1566048; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; SMITH B, 1991, LANCET, V338, P1227, DOI 10.1016/0140-6736(91)92100-G; TINDALL KR, 1988, BIOCHEMISTRY-US, V27, P6008, DOI 10.1021/bi00416a027; TODD JA, 1987, NATURE, V329, P599, DOI 10.1038/329599a0; TRIGLIA T, 1988, NUCLEIC ACIDS RES, V16, P8186, DOI 10.1093/nar/16.16.8186; WEBER JL, 1989, AM J HUM GENET, V44, P388; WHITE TJ, 1989, TRENDS GENET, V5, P185, DOI 10.1016/0168-9525(89)90073-5	32	23	23	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 13	1993	306	6875					441	446		10.1136/bmj.306.6875.441	http://dx.doi.org/10.1136/bmj.306.6875.441			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM700	8096415	Green Published, Bronze			2022-12-28	WOS:A1993KM70000028
J	ESMONDE, TFG; WILL, RG; SLATTERY, JM; KNIGHT, R; HARRIESJONES, R; DESILVA, R; MATTHEWS, WB				ESMONDE, TFG; WILL, RG; SLATTERY, JM; KNIGHT, R; HARRIESJONES, R; DESILVA, R; MATTHEWS, WB			CREUTZFELDT-JAKOB DISEASE AND BLOOD-TRANSFUSION	LANCET			English	Note							TRANSMISSION; ENGLAND; WALES	Epidemiological surveillance of Creutzfeldt-Jakob disease (CJD) in the UK identified 21 patients who had received a blood transfusion and 29 who had donated blood, out of a total of 202 definite and probable cases. This frequency of blood transfusion or donation did not differ from that in age and sex matched controls, and the clinical features in patients with a history of blood transfusion were similar to those of classical CJD and clearly distinct from CJD in recipients of human growth hormone. This evidence does not suggest that blood transfusion is a major risk factor for CJD.	WESTERN GEN HOSP, DEPT CLIN NEUROSCI, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND; UNIV OXFORD, RADCLIFFE INFIRM, DEPT CLIN NEUROL, OXFORD OX2 6HE, ENGLAND; POOLE GEN HOSP, DEPT MED ELDERLY, POOLE, DORSET, ENGLAND	University of Edinburgh; Radcliffe Infirmary; University of Oxford; Poole Hospital								BROWN P, 1992, LANCET, V340, P24, DOI 10.1016/0140-6736(92)92431-E; COUSENS SN, 1990, J NEUROL NEUROSUR PS, V53, P459, DOI 10.1136/jnnp.53.6.459; DOI T, 1991, Nagasaki Igakkai Zasshi, V66, P104; GAJDUSEK D C, 1990, P2289; HARRIESJONES R, 1988, J NEUROL NEUROSUR PS, V51, P1113, DOI 10.1136/jnnp.51.9.1113; MANUELIDIS EE, 1985, LANCET, V2, P896; MASTERS CL, 1979, ANN NEUROL, V5, P177, DOI 10.1002/ana.410050212; TATEISHI J, 1985, LANCET, V2, P1074; WATKINS AM, 1991, BRIT MED J, V302, P1537, DOI 10.1136/bmj.302.6791.1537	9	140	142	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 23	1993	341	8839					205	207		10.1016/0140-6736(93)90068-R	http://dx.doi.org/10.1016/0140-6736(93)90068-R			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ219	8093499				2022-12-28	WOS:A1993KJ21900006
J	MILLER, LC; LYNCH, EA; ISA, S; LOGAN, JW; DINARELLO, CA; STEERE, AC				MILLER, LC; LYNCH, EA; ISA, S; LOGAN, JW; DINARELLO, CA; STEERE, AC			BALANCE OF SYNOVIAL-FLUID IL-1-BETA AND IL-1 RECEPTOR ANTAGONIST AND RECOVERY FROM LYME ARTHRITIS	LANCET			English	Note							MONONUCLEAR-CELLS; INTERLEUKIN-1	Borrelia burgdorferi, the causative agent of Lyme disease, is a potent inducer of interleukin-1beta (IL-1beta), a cytokine implicated in the pathogenesis of inflammatory arthritis. The balance between IL-1 and the IL-1 receptor antagonist (IL-1ra), a naturally occurring inhibitor of IL-1, might influence disease expression. To explore this possibility, we have done a retrospective study that compared the clinical course of Lyme arthritis in 83 patients with concentrations of IL-1beta and IL-1ra in the patients' synovial fluid. Patients with high concentrations of IL-1ra and low concentrations of IL-1beta had rapid resolution of attacks of arthritis, whereas patients with the reverse pattern of cytokine concentrations had long intervals to recovery. Thus, the balance between synovial fluid IL-1beta and IL-1ra concentrations relates to the time to recovery from an episode of Lyme arthritis.	TUFTS UNIV,NEW ENGLAND MED CTR,DEPT MED,BOSTON,MA 02111	Tufts Medical Center; Tufts University	MILLER, LC (corresponding author), TUFTS UNIV,NEW ENGLAND MED CTR,DEPT PEDIAT,BOSTON,MA 02111, USA.			Steere, Allen/0000-0002-5268-9853				AREND WP, 1991, J CLIN INVEST, V88, P1445, DOI 10.1172/JCI115453; AREND WP, 1990, ARTHRITIS RHEUM-US, V33, P305, DOI 10.1002/art.1780330302; COMINELLI F, 1990, J CLIN INVEST, V86, P972, DOI 10.1172/JCI114799; DINARELLO CA, 1991, BLOOD, V77, P1627; ENDRES S, 1988, CLIN IMMUNOL IMMUNOP, V49, P424, DOI 10.1016/0090-1229(88)90130-4; MILLER LC, 1992, J CLIN INVEST, V90, P906, DOI 10.1172/JCI115966; POUTSIAKA DD, 1991, BLOOD, V78, P1275; STEERE AC, 1990, NEW ENGL J MED, V323, P219, DOI 10.1056/NEJM199007263230402; STEERE AC, 1980, ARTHRITIS RHEUM, V23, P591, DOI 10.1002/art.1780230511; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906	10	166	175	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 16	1993	341	8838					146	148		10.1016/0140-6736(93)90006-3	http://dx.doi.org/10.1016/0140-6736(93)90006-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG627	8093746				2022-12-28	WOS:A1993KG62700006
J	MORLEY, C				MORLEY, C			OSIRIS TRIAL	LANCET			English	Letter							RESPIRATORY-DISTRESS SYNDROME; SYNTHETIC SURFACTANT; MORTALITY-RATE; INFANTS; BIRTH				MORLEY, C (corresponding author), UNIV CAMBRIDGE, ADDENBROOKES HOSP, SCH CLIN MED, DEPT PAEDIAT, CAMBRIDGE CB2 2QQ, ENGLAND.			Morley, Colin/0000-0001-5388-0214				BOSE C, 1990, J PEDIATR-US, V117, P947, DOI 10.1016/S0022-3476(05)80143-X; CORBET A, 1991, J PEDIATR-US, V118, P277, DOI 10.1016/S0022-3476(05)80502-5; LONG W, 1991, J PEDIATR-US, V118, P595, DOI 10.1016/S0022-3476(05)83388-8; LONG W, 1991, NEW ENGL J MED, V325, P1696, DOI 10.1056/NEJM199112123252404; MORLEY CJ, 1987, BRIT MED J, V294, P991; PHIBBS RH, 1991, PEDIATRICS, V88, P1; STEVENSON D, 1992, J PEDIATR-US, V120, pS3, DOI 10.1016/S0022-3476(05)81226-0; WILKINSON A, 1985, LANCET, V2, P287	8	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 16	1993	341	8838					172	173						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG627	8093764				2022-12-28	WOS:A1993KG62700026
J	HERMEKING, H; EICK, D				HERMEKING, H; EICK, D			MEDIATION OF C-MYC-INDUCED APOPTOSIS BY P53	SCIENCE			English	Article							TUMOR-SUPPRESSOR P53; CELL-CYCLE; PROTEIN; GROWTH; GENE; FIBROBLASTS; INDUCTION; BINDING; ANTIGEN; TARGET	The cellular proto-oncogene c-myc is involved in cell proliferation and transformation but is also implicated in the induction of programmed cell death (apoptosis). The same characteristics have been described for the tumor suppressor gene p53, the most commonly mutated gene in human cancer. In quiescent mouse fibroblasts expressing wildtype p53 protein, activation of c-Myc was found to induce apoptosis and cell cycle reentry, preceded by stabilization of p53. In contrast, in quiescent p53-null fibroblasts, activation of c-Myc induced cell cycle reentry but not apoptosis. These results suggest that p53 mediates apoptosis as a safeguard mechanism to prevent cell proliferation induced by oncogene activation.	GSF MUNICH,FORSCHUNGSZENTRUM UMWELT & GESUNDHEIT,INST KLIN MOLEK BIOL & TUMORGENET,D-81377 MUNICH,GERMANY	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health								ASKEW DS, 1991, ONCOGENE, V6, P1915; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HARVEY M, 1993, ONCOGENE, V8, P2457; HERMEKING H, IN PRESS P NATL ACAD; HERMEKING H, UNPUB; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; PERRY ME, 1993, CURR OPIN GENET DEV, V3, P50, DOI 10.1016/S0959-437X(05)80340-5; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; Sambrook J, 1989, MOL CLONING LABORATO; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649	26	718	731	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 30	1994	265	5181					2091	2093		10.1126/science.8091232	http://dx.doi.org/10.1126/science.8091232			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PJ912	8091232				2022-12-28	WOS:A1994PJ91200029
J	MURRAY, JC; BUETOW, KH; WEBER, JL; LUDWIGSEN, S; SCHERPBIERHEDDEMA, T; MANION, F; QUILLEN, J; SHEFFIELD, VC; SUNDEN, S; DUYK, GM; WEISSENBACH, J; GYAPAY, G; DIB, C; MORRISSETTE, J; LATHROP, GM; VIGNAL, A; WHITE, R; MATSUNAMI, N; GERKEN, S; MELIS, R; ALBERTSEN, H; PLAETKE, R; ODELBERG, S; WARD, D; DAUSSET, J; COHEN, D; CANN, H				MURRAY, JC; BUETOW, KH; WEBER, JL; LUDWIGSEN, S; SCHERPBIERHEDDEMA, T; MANION, F; QUILLEN, J; SHEFFIELD, VC; SUNDEN, S; DUYK, GM; WEISSENBACH, J; GYAPAY, G; DIB, C; MORRISSETTE, J; LATHROP, GM; VIGNAL, A; WHITE, R; MATSUNAMI, N; GERKEN, S; MELIS, R; ALBERTSEN, H; PLAETKE, R; ODELBERG, S; WARD, D; DAUSSET, J; COHEN, D; CANN, H			A COMPREHENSIVE HUMAN LINKAGE WITH CENTIMORGAN DENSITY	SCIENCE			English	Article							FRAGMENT LENGTH POLYMORPHISMS; POLYMERASE CHAIN-REACTION; HUMAN GENOME; HUMAN DNA; HUNTINGTONS-DISEASE; GEL-ELECTROPHORESIS; MYOTONIC-DYSTROPHY; GENETIC-ANALYSIS; MAP; CEPH	In the last few years there have been rapid advances in developing genetic maps for humans, greatly enhancing our ability to localize and identify genes for inherited disorders. Through the collaborative efforts of three large groups generating microsatellite markers and the efforts of the 110 CEPH collaborators, a comprehensive human linkage map is presented here. consists of 5840 loci, of which 970 are uniquely ordered, covering 4000 centimorgans on the sex-averaged map. Of these loci, 3617 are polymerase chain reaction-formatted short tandem repeat polymorphisms, and another 427 are genes. The map has markers at an average density of 0.7 centimorgan, providing a resource for ready transference to physical maps and achieving one of the first goals of the Human Genome Project-a comprehensive, high-density genetic map.	UNIV IOWA,DEPT PEDIAT,IOWA CITY,IA 52245; UNIV IOWA,DEPT BIOL,IOWA CITY,IA 52245; FOX CHASE CANC CTR,PHILADELPHIA,PA 19111; MARSHFIELD MED RES FDN,MARSHFIELD,WI 54449; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; GENETHON,F-91100 EVRY,FRANCE; CHU LAVAL,LAVAL G1K 7P4,PQ,CANADA; INSERM,F-75010 PARIS,FRANCE; UNIV UTAH,ECCLES INST HUMAN GENET,SALT LAKE CITY,UT; YALE UNIV,DEPT GENET,NEW HAVEN,CT 06510; CTR ETUD POLYMORPHISME HUMAIN,F-75010 PARIS,FRANCE	University of Iowa; University of Iowa; Fox Chase Cancer Center; Harvard University; Harvard Medical School; Laval University; Institut National de la Sante et de la Recherche Medicale (Inserm); Utah System of Higher Education; University of Utah; Yale University			Manion, Frank J./I-9373-2019; Vignal, Alain/I-6253-2017	Manion, Frank J./0000-0003-1030-6348; Vignal, Alain/0000-0002-6797-2125				ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; ARNHEIM N, 1985, P NATL ACAD SCI USA, V82, P6970, DOI 10.1073/pnas.82.20.6970; ATTWOOD J, 1994, GENOMICS, V19, P203, DOI 10.1006/geno.1994.1049; BANCHS I, 1994, HUM MUTAT, V3, P365, DOI 10.1002/humu.1380030407; Bell J, 1937, PROC R SOC SER B-BIO, V123, P119, DOI 10.1098/rspb.1937.0046; BOEHNKE M, 1994, AM J HUM GENET, V55, P379; BOTSTEIN D, 1980, AM J HUM GENET, V32, P314; BOWCOCK AM, 1993, GENOMICS, V16, P486, DOI 10.1006/geno.1993.1215; BOWCOCK AM, 1992, GENOMICS, V14, P833, DOI 10.1016/S0888-7543(05)80101-6; BROOK JD, 1993, NAT GENET, V3, P279; BUETOW KH, 1991, AM J HUM GENET, V49, P985; BUETOW KH, 1994, NAT GENET, V6, P391, DOI 10.1038/ng0494-391; CARDUCCI C, 1992, BIOTECHNIQUES, V13, P735; CHAKRAVARTI A, 1984, AM J HUM GENET, V36, P1239; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P3685, DOI 10.1073/pnas.91.9.3685; COHEN D, 1993, NATURE, V366, P698, DOI 10.1038/366698a0; COLLINS F, 1993, SCIENCE, V262, P43, DOI 10.1126/science.8211127; COLLINS FS, 1992, NAT GENET, V1, P3, DOI 10.1038/ng0492-3; COOPER DN, 1985, HUM GENET, V69, P201, DOI 10.1007/BF00293024; COTTON RGH, 1988, P NATL ACAD SCI USA, V85, P4397, DOI 10.1073/pnas.85.12.4397; DAUSSET J, 1990, GENOMICS, V6, P575, DOI 10.1016/0888-7543(90)90491-C; DAVIES JL, 1994, NATURE, V371, P130, DOI 10.1038/371130a0; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; DONISKELLER H, 1987, CELL, V51, P319, DOI 10.1016/0092-8674(87)90158-9; DRACOPOLI NC, 1991, GENOMICS, V9, P686, DOI 10.1016/0888-7543(91)90362-I; DUYK GM, 1990, P NATL ACAD SCI USA, V87, P8995, DOI 10.1073/pnas.87.22.8995; ELSTON RC, 1971, HUM HERED, V21, P523, DOI 10.1159/000152448; GUSELLA JF, 1983, NATURE, V306, P234, DOI 10.1038/306234a0; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; H/CEPH Collaborative Mapping Group, 1992, SCIENCE, V258, P67; HASEMAN JK, 1972, BEHAV GENET, V2, P3, DOI 10.1007/BF01066731; HASHIMOTO L, 1994, NATURE, V371, P160; HASTBACKA J, 1992, NAT GENET, V2, P204, DOI 10.1038/ng1192-204; IMBERT G, 1993, NAT GENET, V4, P72, DOI 10.1038/ng0593-72; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; JORDE LB, 1994, AM J HUM GENET, V54, P884; KAJIWARA K, 1994, SCIENCE, V264, P1604, DOI 10.1126/science.8202715; KEATS BJB, 1981, LINKAGE CHROMOSOME M; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KUNST CB, 1994, CELL, V77, P853, DOI 10.1016/0092-8674(94)90134-1; KWOK P, IN PRESS GENOMICS; LANDER ES, 1987, P NATL ACAD SCI USA, V84, P2363, DOI 10.1073/pnas.84.8.2363; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; LOVETT M, 1991, P NATL ACAD SCI USA, V88, P9628, DOI 10.1073/pnas.88.21.9628; MATERA AG, 1992, HUM MOL GENET, V1, P535, DOI 10.1093/hmg/1.7.535; MATISE TC, 1994, NAT GENET, V6, P384, DOI 10.1038/ng0494-384; MONACO AP, 1985, NATURE, V316, P842, DOI 10.1038/316842a0; MORTON NE, 1955, AM J HUM GENET, V7, P277; MURRAY JC, 1984, P NATL ACAD SCI-BIOL, V81, P3486, DOI 10.1073/pnas.81.11.3486; MYERS RM, 1985, NUCLEIC ACIDS RES, V13, P3131, DOI 10.1093/nar/13.9.3131; NAKAMURA Y, 1987, SCIENCE, V235, P1616, DOI 10.1126/science.3029872; OLSON M, 1989, SCIENCE, V245, P1434, DOI 10.1126/science.2781285; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; OTT J, 1974, AM J HUM GENET, V26, P588; RICHARDS B, 1993, HUM MOL GENET, V2, P159, DOI 10.1093/hmg/2.2.159; SHERRINGTON R, 1991, AM J HUM GENET, V49, P966; SMEETS HJM, 1989, HUM GENET, V83, P245, DOI 10.1007/BF00285165; SPURR NK, 1992, GENOMICS, V14, P1055, DOI 10.1016/S0888-7543(05)80129-6; THEILMANN J, 1989, J MED GENET, V26, P676, DOI 10.1136/jmg.26.11.676; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WHITE RL, 1990, GENOMICS, V6, P393, DOI 10.1016/0888-7543(90)90469-B; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231	66	509	532	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 30	1994	265	5181					2049	2054		10.1126/science.8091227	http://dx.doi.org/10.1126/science.8091227			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PJ912	8091227				2022-12-28	WOS:A1994PJ91200022
J	NYSTROM, L; RUTQVIST, LE; WALL, S; LINDGREN, A; LINDQVIST, M; RYDEN, S; ANDERSSON, I; BJURSTAM, N; FAGERBERG, G; FRISELL, J; TABAR, L; LARSSON, LG				NYSTROM, L; RUTQVIST, LE; WALL, S; LINDGREN, A; LINDQVIST, M; RYDEN, S; ANDERSSON, I; BJURSTAM, N; FAGERBERG, G; FRISELL, J; TABAR, L; LARSSON, LG			BREAST-CANCER SCREENING WITH MAMMOGRAPHY - OVERVIEW OF SWEDISH RANDOMIZED TRIALS	LANCET			English	Article							MORTALITY	Despite encouraging results from screening trials the efficacy of mammography in reducing mortality remains somewhat controversial. Five studies have been done in Sweden. This overview, based on 282 777 women followed for 5-13 years in randomised trials in Malmo, Kopparberg, Ostergotland, Stockholm, and Gothenburg, reveals a 24% (95% confidence interval 13-34%) significant reduction of breast cancer mortality among those invited to mammography screening compared with those not invited. To avoid the potential risk of differential misclassification causes of death were assessed by an independent end-point committee after a blinded review of all fatal breast cancer cases. The mortality reduction was similar, irrespective of the end-point used for evaluation (''breast cancer as underlying cause of death'' or ''breast cancer present at death''). There was a consistent risk reduction associated with screening in all studies, although the point estimate of the relative risk for all ages varied non-significantly between 0.68 and 0.84. The cumulative breast cancer mortality by time since randomisation was estimated at 1.3 per 1000 within 6 years in the invited group compared with 1.6 in the control group. The corresponding figures after 9 years are 2.6 and 3.3 and after 12 years 3.9 and 5.1. The largest reduction of breast cancer mortality (29%) was observed among women aged 50-69 at randomisation. Among women 40-49 there was a non-significant 13% reduction. In this younger age group cumulative breast cancer mortality was similar in the invited and control group during the first 8 years of follow-up. After 8 years there was a difference in favour of the invited women. There was no evidence of any detrimental effect of screening in terms of breast cancer mortality in any age group. Among women aged 70-74 years screening seems to have had only a marginal impact.	KAROLINSKA HOSP, CTR ONCOL, S-10401 STOCKHOLM 60, SWEDEN; ACAD HOSP UPPSALA, S-75014 UPPSALA, SWEDEN; ANGELHOLM HOSP, ANGELHOLM, SWEDEN; MALMO GEN HOSP, S-21401 MALMO, SWEDEN; SAHLGRENS UNIV HOSP, S-41345 GOTHENBURG, SWEDEN; LINKOPING UNIV HOSP, S-58185 LINKOPING, SWEDEN; SODER SJUKHUSET, STOCKHOLM, SWEDEN; FALUN CENT HOSP, FALUN, SWEDEN; UMEA UNIV HOSP, CTR ONCOL, S-90185 UMEA, SWEDEN	Karolinska Institutet; Karolinska University Hospital; Sahlgrenska University Hospital; Linkoping University; Sodersjukhuset Hospital; Falun Hospital; Umea University	NYSTROM, L (corresponding author), UMEA UNIV, DEPT EPIDEMIOL & PUBL HLTH, S-90185 UMEA, SWEDEN.		Tabar, Laszlo Kornel/AGT-3287-2022					ANDERSSON I, 1988, BRIT MED J, V297, P943, DOI 10.1136/bmj.297.6654.943; BAILAR JC, 1976, ANN INTERN MED, V84, P77, DOI 10.7326/0003-4819-84-1-77; DUFFY S, 1989, AUG NORD CANC UN S S; FRISELL J, 1991, BREAST CANCER RES TR, V18, P49, DOI 10.1007/BF01975443; GUSTAFSSON L, 1990, QUEST PROGRAM SYSTEM; LUNDGREN B, 1976, CANCER, V38, P1124, DOI 10.1002/1097-0142(197609)38:3<1124::AID-CNCR2820380312>3.0.CO;2-P; RUTQVIST LE, 1990, INT J CANCER, P76; SHAPIRO S, 1971, J AMER MED ASSOC, V215, P1777; TABAR L, 1985, LANCET, V1, P829, DOI 10.1016/S0140-6736(85)92204-4; 1990, MAMMOGRAPHIC SCREENI	10	755	768	1	32	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 17	1993	341	8851					973	978		10.1016/0140-6736(93)91067-V	http://dx.doi.org/10.1016/0140-6736(93)91067-V			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY368	8096941				2022-12-28	WOS:A1993KY36800001
J	STIERLE, A; STROBEL, G; STIERLE, D				STIERLE, A; STROBEL, G; STIERLE, D			TAXOL AND TAXANE PRODUCTION BY TAXOMYCES-ANDREANAE, AN ENDOPHYTIC FUNGUS OF PACIFIC YEW	SCIENCE			English	Article								Taxomyces andreanae, a fungal endophyte, was isolated from the phloem (inner bark) of the Pacific yew, Taxus brevifolia. The fungus is hyphomyceteous and, when grown in a semi-synthetic liquid medium, produced taxol and related compounds. Taxol was identified by mass spectrometry, chromatography, and reactivity with monoclonal antibodies specific for taxol. Both [1-C-14]acetic acid and L-[U-C-14]phenylalanine served as precursors of [C-14]taxol in fungal cultures. No taxol was detected in zero-time cultures or in the small agar plugs used to inoculate the culture flasks.	MONTANA COLL MINERAL SCI & TECHNOL,DEPT CHEM & GEOCHEM,BUTTE,MT 59701		STIERLE, A (corresponding author), MONTANA STATE UNIV,DEPT PLANT PATHOL,BOZEMAN,MT 59717, USA.							BUNKERS GJ, 1991, MYCOL RES, V95, P347, DOI 10.1016/S0953-7562(09)81246-X; CARDELLINA JH, 1991, J LIQ CHROMATOGR, V14, P659, DOI 10.1080/01483919108049278; CRAGG GM, 1991, CANCER CELL-MON REV, V3, P233; DEMAIN AL, 1981, SCIENCE, V214, P987, DOI 10.1126/science.6946560; FLEMING PE, 1993, J AM CHEM SOC, V115, P805, DOI 10.1021/ja00055a072; GROTHAUS PG, UNPUB 2ND NAT CANC I; KINGSTON DGI, 1991, PHARMACOL THERAPEUT, V52, P1, DOI 10.1016/0163-7258(91)90085-Z; LANG A, 1970, ANN REV PLANT PHYSIO, V21, P537, DOI 10.1146/annurev.pp.21.060170.002541; MCCLURE TD, 1992, J AM SOC MASS SPECTR, V3, P672, DOI 10.1016/1044-0305(92)85009-9; Mossmann T., 1983, J IMMUNOL METHODS, V65, P55; PINKERTON F, 1976, P NATL ACAD SCI USA, V73, P4007, DOI 10.1073/pnas.73.11.4007; ROWENSKY EK, 1990, J NATL CANCER I, V82, P1247; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; STOWE BB, 1957, ANNU REV PLANT PHYS, V8, P181, DOI 10.1146/annurev.pp.08.060157.001145; STROBEL G, 1993, MYCOTAXON, V47, P71; STROBEL GA, 1992, PLANT SCI, V84, P65, DOI 10.1016/0168-9452(92)90209-5; WANI MC, 1971, J AM CHEM SOC, V93, P2325, DOI 10.1021/ja00738a045	18	1118	1616	24	433	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 9	1993	260	5105					214	216		10.1126/science.8097061	http://dx.doi.org/10.1126/science.8097061			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KW452	8097061				2022-12-28	WOS:A1993KW45200038
J	GRAY, D; KEATING, NA; MURDOCK, J; SKENE, AM; HAMPTON, JR				GRAY, D; KEATING, NA; MURDOCK, J; SKENE, AM; HAMPTON, JR			IMPACT OF HOSPITAL THROMBOLYSIS POLICY ON OUT-OF-HOSPITAL RESPONSE TO SUSPECTED MYOCARDIAL-INFARCTION	LANCET			English	Article							TISSUE PLASMINOGEN-ACTIVATOR; TRIAL; EDUCATION; PATIENT; DELAY	The treatment of acute myocardial infarction changed when several trials reported that thrombolytic agents given within a few hours of infarction improved outcome. We present data from the Nottingham Heart Attack Register comparing 1982-84, when thrombolysis was not available, and 1989-90, when it was hospital policy to give thrombolysis to all patients who arrived within 6 hours of the onset of symptoms, in the absence of a specific contraindication. The number of patients referred with symptoms suggestive of acute myocardial infarction increased by 75% from 1982 to 1990; a diagnosis of ''possible infarction'' was made in about half of all patients in 1982-84 and 23% in 1989-90. Our current thrombolytic policy has had little impact on patient and general practitioner (GP) behaviour. The GP was contacted by most patients. The median time between the onset of a patient's symptoms and admission to hospital when the GP was involved was 229 min in 1 982-84 and 21 0 min in 1989-90; when he was not involved in arranging the admission median times to admission were 89 min and 75 min, respectively. By 6 hours from symptom onset, 60% of patients had been admitted; by 12 hours, about 70% were in hospital and by 24 hours, 80%. Of 7855 patients admitted with suspected acute myocardial infarction in 1989-90, 4465 were admitted within 6 hours of symptom onset. Of these, 736 (16%) patients received a thrombolytic drug, 389 (9%) patients had a specific, documented contraindication to thrombolysis. Although we estimate that the policy has saved about 8 lives per year, it is not surprising that there has been no improvement in overall case fatality after myocardial infarction.	UNIV NOTTINGHAM, DEPT MATH, BRITISH HEART FDN, CARDIOVASC STAT UNIT, NOTTINGHAM NG7 2RD, ENGLAND	University of Nottingham	GRAY, D (corresponding author), UNIV NOTTINGHAM HOSP, QUEENS MED CTR, DIV CARDIOVASC MED, NOTTINGHAM NG7 2UH, ENGLAND.							ALTHOUSE R, 1990, AM J CARDIOL, V66, P1298, DOI 10.1016/0002-9149(90)91157-2; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, Lancet, V1, P397; ARMSTRONG A, 1972, BRIT HEART J, V34, P67; BIRKHEAD JS, 1992, BMJ-BRIT MED J, V305, P445, DOI 10.1136/bmj.305.6851.445; BOSSAERT L, 1991, EUR HEART J, V12, P965; BOUTEN MJM, 1992, EUR HEART J, V13, P925, DOI 10.1093/oxfordjournals.eurheartj.a060294; BRUGEMANN J, 1992, EUR HEART J, V13, P787; CHAMBERLAIN DA, 1988, LANCET, V1, P545; HERLITZ J, 1989, AM J CARDIOL, V64, P90, DOI 10.1016/0002-9149(89)90659-0; HO MT, 1989, ANN EMERG MED, V18, P727, DOI 10.1016/S0196-0644(89)80004-6; JAGGER JD, 1987, LANCET, V1, P34; KENNEDY JW, 1988, CIRCULATION, V77, P345, DOI 10.1161/01.CIR.77.2.345; OROURKE MF, 1989, THROMBOLYSIS CARDIOV, P302; PELL ACH, 1992, BMJ-BRIT MED J, V304, P83, DOI 10.1136/bmj.304.6819.83; RAWLES JM, 1988, BRIT MED J, V296, P882, DOI 10.1136/bmj.296.6626.882; ROWLEY JM, 1992, BRIT HEART J, V67, P255; ROWLEY JM, 1982, BRIT MED J, V284, P1741, DOI 10.1136/bmj.284.6331.1741; SCHOFER J, 1990, AM J CARDIOL, V66, P1429, DOI 10.1016/0002-9149(90)90528-9; WILCOX RG, 1988, LANCET, V2, P525; WILCOX RG, 1992, 14TH C EUR SOC CARD, P2429; 1987, REV FED ARG CARDIOL, V16, P238	22	47	47	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 13	1993	341	8846					654	657		10.1016/0140-6736(93)90420-L	http://dx.doi.org/10.1016/0140-6736(93)90420-L			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR613	8095570				2022-12-28	WOS:A1993KR61300004
J	KING, M; ELLIOTT, C				KING, M; ELLIOTT, C			LEGITIMATE DOUBLE-THINK	LANCET			English	Article									TRINITY HALL CAMBRIDGE,CAMBRIDGE CB2 1TJ,ENGLAND	University of Cambridge	KING, M (corresponding author), UNIV LEEDS,SCH MED,INST EPIDEMIOL & HLTH SERV RES,DEPT CLIN MED,34 HYDE TERRACE,LEEDS LS2 9LN,W YORKSHIRE,ENGLAND.							KING M, 1990, LANCET, V336, P664, DOI 10.1016/0140-6736(90)92156-C; LITHELL UB, 1992, LANCET, V339, P377, DOI 10.1016/0140-6736(92)91704-C; SCHEPERHUGHES N, 1991, LANCET, V337, P1144, DOI 10.1016/0140-6736(91)92800-H; SCOONES I, IN PRESS ENV POPULAT; 1992, HUMAN DEV REPORT; 1988, ALMA ATA YEAR 2000 R	6	27	28	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 13	1993	341	8846					669	672		10.1016/0140-6736(93)90431-F	http://dx.doi.org/10.1016/0140-6736(93)90431-F			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR613	8095580				2022-12-28	WOS:A1993KR61300015
J	ALMOHANA, JMA; LOWE, GDO; MURRAY, GD; BURNS, HG				ALMOHANA, JMA; LOWE, GDO; MURRAY, GD; BURNS, HG			ASSOCIATION OF FIBRINOLYTIC TESTS WITH OUTCOME OF ACUTE UPPER-GASTROINTESTINAL-TRACT BLEEDING	LANCET			English	Article							HEMORRHAGE	Endogenous fibrinolysis may play a part in acute upper-gastrointestinal-tract bleeding by causing digestion of haemostatic plugs. We assessed the predictive value of fibrinolytic tests for hospital outcome in a prospective study of 122 patients with acute upper-gastrointestinal-tract bleeding who Underwent endoscopy. Serum fibrin degradation products (FDP) were above the normal range in 32% (95% CI 21-44%) of patients who survived and did not require transfusion or surgery, in 53% (37-69%) of patients who survived without surgery but required transfusion, and in 100% (82-100%) of patients who required surgery or died. Multivariate analysis showed that after adjustment for the effects of established risk factors (age, pulse rate, blood pressure, haemoglobin, site of bleeding, and stigmata of active bleeding at endoscopy), serum FDP was a powerful independent predictor of outcome (p=0.003). Doubling of serum FDP was associated with a 59% increase in the risk of a poor outcome (95% CI 14-120%). These findings are consistent with roles for endogenous fibrinolysis in gastrointestinal-tract bleeding, for fibrinolytic tests in prediction of adverse outcome, and for fibrinolytic inhibitors in treatment.	UNIV GLASGOW,ROYAL INFIRM,DEPT SURG,GLASGOW G31 2ER,SCOTLAND; UNIV GLASGOW,ROYAL INFIRM,DEPT MED,GLASGOW G31 2ER,SCOTLAND	Royal Infirmary of Edinburgh; University of Glasgow; Royal Infirmary of Edinburgh; University of Glasgow				Murray, Gordon/0000-0001-9866-4734				BERTAGLIA E, 1983, HAEMOSTASIS, V13, P328; BOOTH NA, 1991, BLOOD COAGULATION HA, P115; ELMS MJ, 1983, THROMB HAEMOSTASIS, V50, P591; HARRIS DCH, 1982, MED J AUSTRALIA, V2, P35, DOI 10.5694/j.1326-5377.1982.tb124207.x; HAVERKATE F, 1974, HAEMOSTASIS, V1, P55; HENRY DA, 1989, BMJ-BRIT MED J, V298, P1142, DOI 10.1136/bmj.298.6681.1142; LANGMAN MJS, 1985, GUT, V26, P217, DOI 10.1136/gut.26.3.217; LOWE GDO, 1980, BLOOD COAGULATION HA, P222; LOWE GDO, 1991, BLOOD COAGULATION HA, P177; MACLEOD IA, 1982, BRIT J SURG, V69, P256, DOI 10.1002/bjs.1800690509; NIEUWENHUIZEN W, 1991, BLOOD COAGULATION HA, P151; POLLER L, 1979, J CLIN PATHOL S, V14, P63; STOREY DW, 1981, NEW ENGL J MED, V305, P915, DOI 10.1056/NEJM198110153051603	13	12	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 27	1993	341	8844					518	521		10.1016/0140-6736(93)90278-O	http://dx.doi.org/10.1016/0140-6736(93)90278-O			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP083	8094771				2022-12-28	WOS:A1993KP08300004
J	KEIRSE, MJNC				KEIRSE, MJNC			OBSTETRICS - LOW-DOSE ASPIRIN IN PREGNANCY	LANCET			English	Editorial Material							REGULAR SALICYLATE INGESTION				KEIRSE, MJNC (corresponding author), LEIDEN UNIV HOSP,DEPT OBSTET & GYNAECOL,2333 AA LEIDEN,NETHERLANDS.							BEAUFILS M, 1985, LANCET, V1, P840, DOI 10.1016/S0140-6736(85)92207-X; COLLINS E, 1975, LANCET, V2, P335; COLLINS R, 1992, OXFORD DATABASE PERI; DEKKER GA, 1989, THESIS U ROTTERDAM; LEWIS RB, 1973, LANCET, V2, P1159; PARAZZINI F, 1993, LANCET, V341, P396; SCOTT JR, 1987, OBSTET GYNECOL, V70, P645; TURNER G, 1975, LANCET, V2, P338	8	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 13	1993	341	8842					412	412		10.1016/0140-6736(93)92998-9	http://dx.doi.org/10.1016/0140-6736(93)92998-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM416	8094178				2022-12-28	WOS:A1993KM41600013
J	KHAN, IH; CATTO, GRD; EDWARD, N; FLEMING, LW; HENDERSON, IS; MACLEOD, AM				KHAN, IH; CATTO, GRD; EDWARD, N; FLEMING, LW; HENDERSON, IS; MACLEOD, AM			INFLUENCE OF COEXISTING DISEASE ON SURVIVAL ON RENAL-REPLACEMENT THERAPY	LANCET			English	Article							FAILURE	Survival of patients on renal-replacement therapy (RRT) is no longer improving. Increasingly, such patients are older and have co-morbid conditions affecting organs other than the kidney. In a retrospective study, we calculated actuarial survival of 375 patients starting RRT during a 6 1/2 year period at renal units in Aberdeen and Dundee, UK, after stratification of patients into three risk groups (low, medium, and high) based predominantly on co-morbidity and to a lesser extent on age. 2-year survival differed significantly between low, medium, and high risk groups both before (86%, 60%, and 35%, respectively; p<0.002 for all comparisons) and after (90%, 70%, 46%; p<0.004 for all comparisons) excluding early deaths (within 90 days of starting RRT). Overall survival was 61% in Aberdeen and 68% in Dundee (p=0.04), but 73% and 74%, respectively, when deaths in the first 90 days were excluded (p=0.73). We conclude that RRT is a highly successful treatment (86% 2-year survival) for patients aged under 70 with no co-morbid conditions (low-risk group); that coexisting non-renal disease has an important influence on survival of patients on RRT; and that risk stratification and analysis of data including and excluding early deaths should allow more valid comparison of data from different centres.	ABERDEEN ROYAL INFIRM,RENAL UNIT,ABERDEEN AB9 2ZB,SCOTLAND; UNIV DUNDEE,NINEWELLS HOSP & MED SCH,RENAL UNIT,DUNDEE DD1 9SY,SCOTLAND	University of Aberdeen; University of Dundee	KHAN, IH (corresponding author), UNIV ABERDEEN,DEPT MED & THERAPEUT,ABERDEEN AB9 2ZD,SCOTLAND.							CROMBIE IK, 1986, HLTH B EDIN, V44, P153; FASSBINDER W, 1991, NEPHROL DIAL TRANSPL, V6, P5; FEEST TG, 1990, BRIT MED J, V301, P897, DOI 10.1136/bmj.301.6757.897; GEERLINGS W, 1991, NEPHROL DIAL TRANSPL, V6, P5; HELD PJ, 1987, JAMA-J AM MED ASSOC, V257, P645, DOI 10.1001/jama.257.5.645; HORINA JH, 1992, LANCET, V339, P183, DOI 10.1016/0140-6736(92)90251-W; HULL AR, 1990, AM J KIDNEY, V15, P422; KRAMER P, 1984, P EUR DIAL TRANSPLAN, V21, P2; LOWRIE EG, 1990, AM J KIDNEY DIS, V15, P458, DOI 10.1016/S0272-6386(12)70364-5; PASQUALI S, 1990, CLIN NEPHROL, V34, P247; SMITH T, 1991, BRIT MED J, V303, P1395, DOI 10.1136/bmj.303.6814.1395; WILLIAMS AJ, 1989, Q J MED, V72, P749; WINEARLS CG, 1992, LANCET, V339, P432, DOI 10.1016/0140-6736(92)90119-N; WRIGHT LF, 1991, AM J KIDNEY DIS, V17, P25, DOI 10.1016/S0272-6386(12)80245-9; 1989, USRDS1989 NIH NAT I	15	239	241	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 13	1993	341	8842					415	418		10.1016/0140-6736(93)93003-J	http://dx.doi.org/10.1016/0140-6736(93)93003-J			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM416	8094182				2022-12-28	WOS:A1993KM41600017
J	DEVOGELAER, JP; DEDEUXCHAISNES, CN; DONNEZ, J				DEVOGELAER, JP; DEDEUXCHAISNES, CN; DONNEZ, J			ENDOMETRIOSIS	LANCET			English	Letter									ST LUC UNIV HOSP,DEPT GYNAECOL,B-1200 BRUSSELS,BELGIUM	Universite Catholique Louvain; Cliniques Universitaires Saint-Luc	DEVOGELAER, JP (corresponding author), ST LUC UNIV HOSP,DEPT RHEUMATOL,B-1200 BRUSSELS,BELGIUM.							CANN CE, 1987, CALCIUM REGULATION B, V9, P123; DEVOGELAER JP, 1992, IN PRESS 3RD P WORLD; SHAW, 1992, LANCET, V340, P1267; STEVENSON JC, 1989, HORM RES, V32, P161, DOI 10.1159/000181335	4	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 30	1993	341	8840					312	313		10.1016/0140-6736(93)92673-H	http://dx.doi.org/10.1016/0140-6736(93)92673-H			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK245	8093956				2022-12-28	WOS:A1993KK24500055
J	KATSENI, VL; GILROY, CB; RYAIT, BK; ARIYOSHI, K; BIENIASZ, PD; WEBER, JN; TAYLORROBINSON, D				KATSENI, VL; GILROY, CB; RYAIT, BK; ARIYOSHI, K; BIENIASZ, PD; WEBER, JN; TAYLORROBINSON, D			MYCOPLASMA-FERMENTANS IN INDIVIDUALS SEROPOSITIVE AND SERONEGATIVE FOR HIV-1	LANCET			English	Article							INCOGNITUS; AIDS; IDENTIFICATION; INFECTION	Mycoplasmas have been suggested as a co-factor to explain various puzzling features of infection by human immunodeficiency virus 1 (HIV-1). We sought Mycoplasma fermentans by means of a semi-nested polymerase chain reaction (PCR) in samples of peripheral-blood mononuclear cells (PBMC), throat swabs, and urine samples from 117 HIV-seropositive patients (of whom 114 were homosexual men). M fermentans was detected in 12 (10%) PBMC samples, 15 (23%) of 65 throat samples, and 4 (8%) of 55 urine samples from the seropositive subjects. The organism was detected in similar proportions among 73 HIV-seronegative patients recruited from a sexually transmitted diseases clinic (9%, 20%, and 6%, respectively); again, most of the men (40 of 50) in this group were homosexual. We found no association between infection by the mycoplasma and stage of disease, CD4 count, or HIV-1 load. These findings do not, however, eliminate the possibility that the mycoplasmal infection could affect the speed of disease progression.	ST MARYS HOSP,SCH MED,DEPT GENITOURINARY MED & COMMUNICABLE DIS,JEFFERISS WING,PRAED ST,LONDON W2 1NY,ENGLAND; CLIN RES CTR,DIV SEXUALLY TRANSMITTED DIS,HARROW HA1 3UJ,MIDDX,ENGLAND	Imperial College London								BAUER FA, 1991, HUM PATHOL, V22, P63, DOI 10.1016/0046-8177(91)90063-U; CHOWDHURY MIH, 1990, BIOCHEM BIOPH RES CO, V170, P1365; DAWSON MS, 1991, PROGRAM ABSTRACTS GE, P134; HAWKINS RE, 1992, J INFECT DIS, V165, P581, DOI 10.1093/infdis/165.3.581; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HU WS, 1990, GENE, V93, P67, DOI 10.1016/0378-1119(90)90137-G; LEMAITRE M, 1990, RES VIROLOGY, V141, P5, DOI 10.1016/0923-2516(90)90052-K; LO SC, 1989, AM J TROP MED HYG, V41, P601, DOI 10.4269/ajtmh.1989.41.601; LO SC, 1991, SCIENCE, V251, P1074, DOI 10.1126/science.1705362; 1991, LANCET, V337, P20	10	80	83	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 30	1993	341	8840					271	273		10.1016/0140-6736(93)92617-3	http://dx.doi.org/10.1016/0140-6736(93)92617-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK245	8093918				2022-12-28	WOS:A1993KK24500005
J	ABIOSE, A; JONES, BR; COUSENS, SN; MURDOCH, I; CASSELSBROWN, A; BABALOLA, OE; ALEXANDER, NDE; NUHU, I; EVANS, J; IBRAHIM, UF; MAHMOOD, AO				ABIOSE, A; JONES, BR; COUSENS, SN; MURDOCH, I; CASSELSBROWN, A; BABALOLA, OE; ALEXANDER, NDE; NUHU, I; EVANS, J; IBRAHIM, UF; MAHMOOD, AO			REDUCTION IN INCIDENCE OF OPTIC-NERVE DISEASE WITH ANNUAL IVERMECTIN TO CONTROL ONCHOCERCIASIS	LANCET			English	Article							OCULAR ONCHOCERCIASIS; SIERRA-LEONE; COMMUNITY	The safety and efficacy of ivermectin in the prevention of blindness from onchocerciasis have been established in many studies that have addressed the drug's effects on the front of the eye. We undertook a study with sufficient statistical power to detect an effect on optic nerve disease (OND), probably the main cause of blindness in the disorder. The trial was based in 34 mesoendemic communities in Kaduna State, Nigeria. Villagers aged 5 years and older were randomly assigned annual dosing with ivermectin or placebo for 3 years. Participants underwent medical and ophthalmological examinations before the first, third, and fourth treatments. 3522 villagers aged 15 and older were re-examined at least once. Skin-snip samples were taken at baseline for calculation of microfilarial load. The outcome measure was development of disc pallor accompanied by objective evidence of deterioration in visual function; 116 subjects (45 ivermectin-treated, 71 placebo-treated) showed such changes during the trial. The incidence rate ratio (ivermectin vs placebo) was 0.90 (95% CI 0.54-1.51) for subjects with loads of 0-10 mf (microfilariae) per mg skin and 0.52 (0.29-0.93) for subjects with more than 10 mf/mg. The incidence rate ratio varied little when account was taken of age, sex, presence of pre-existing disc pallor in one eye, previous use of diethylcarbamazine citrate, or doses of ivermectin or placebo received. There was evidence that ivermectin reduced the incidence of OND in subjects with microfilarial loads above 10 mf/mg but had little effect in those with lower loads. Sustained annual delivery of ivermectin could prevent a substantial proportion of onchocercal blindness in mesoendemic communities.	INST OPHTHALMOL,INT CTR EYE HLTH,BATH ST,LONDON EC1V 9EL,ENGLAND; AHMADU BELLO UNIV,DEPT OPHTHALMOL,KADUNA,NIGERIA; NATL EYE CTR,KADUNA,NIGERIA; NIGERIAN INST TRYPANOSOMIASIS RES,KADUNA,NIGERIA; UNIV LONDON LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,LONDON WC1E 7HT,ENGLAND	University of London; London School of Hygiene & Tropical Medicine; University College London; Ahmadu Bello University; University of London; London School of Hygiene & Tropical Medicine			Murdoch, Ian/Z-2527-2019; Evans, Jennifer/F-4672-2012	Evans, Jennifer/0000-0002-6137-2030				ARMITAGE P, 1987, STATISTICAL METHODS; BIRD AC, 1980, BRIT J OPHTHALMOL, V64, P191, DOI 10.1136/bjo.64.3.191; DADZIE KY, 1989, TROP MED PARASITOL, V40, P335; Dawson CR, 1981, GUIDE TRACHOMA CONTR; LUTY AJF, 1990, TROP MED PARASITOL, V41, P371; REMME J, 1989, TROP MED PARASITOL, V40, P340; SEMBA RD, 1990, OPHTHALMOLOGY, V97, P1334; WHITWORTH JAG, 1991, LANCET, V338, P1100, DOI 10.1016/0140-6736(91)91963-U; 1987, TECH REP SER WHO, V752	9	59	59	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 16	1993	341	8838					130	134		10.1016/0140-6736(93)90002-X	http://dx.doi.org/10.1016/0140-6736(93)90002-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG627	8093742				2022-12-28	WOS:A1993KG62700002
J	WOODS, KL				WOODS, KL			CARDIAC-FUNCTION - HYPOMAGNESEMIA AND THE MYOCARDIUM	LANCET			English	Editorial Material							MAGNESIUM				WOODS, KL (corresponding author), UNIV LEICESTER,DEPT PHARMACOL & THERAPEUT,LEICESTER LE1 7RH,ENGLAND.							ALTURA BM, 1987, CAN J PHYSIOL PHARM, V65, P729, DOI 10.1139/y87-120; ENGLAND MR, 1992, JAMA-J AM MED ASSOC, V268, P2395, DOI 10.1001/jama.268.17.2395; HEARSE DJ, 1978, J THORAC CARDIOV SUR, V75, P877; WHITE RE, 1989, BIOCHEM PHARMACOL, V38, P859, DOI 10.1016/0006-2952(89)90272-4; WOODS KL, 1992, LANCET, V339, P1553, DOI 10.1016/0140-6736(92)91828-V	5	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 16	1993	341	8838					155	155		10.1016/0140-6736(93)90013-7	http://dx.doi.org/10.1016/0140-6736(93)90013-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG627	8093753				2022-12-28	WOS:A1993KG62700013
J	MILLER, WR				MILLER, WR			HORMONAL FACTORS AND RISK OF BREAST-CANCER	LANCET			English	Editorial Material													Miller, William/AAY-5398-2020					ANBAZHAGAN R, 1992, LANCET, V339, P1056; EKBOM A, 1992, LANCET, V340, P1015, DOI 10.1016/0140-6736(92)93019-J; KVALE G, 1987, AM J EPIDEMIOL, V126, P842, DOI 10.1093/oxfordjournals.aje.a114721; SANDSON TA, 1992, LANCET, V339, P523, DOI 10.1016/0140-6736(92)90341-Y; TRICHOPOULOS D, 1972, JNCI-J NATL CANCER I, V48, P605; TRICHOPOULOS D, 1990, LANCET, V335, P939, DOI 10.1016/0140-6736(90)91000-Z; VESSEY MP, 1989, P ROY SOC EDINB B, V95, P35, DOI 10.1017/S0269727000010538	7	21	21	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 2	1993	341	8836					25	26		10.1016/0140-6736(93)92489-G	http://dx.doi.org/10.1016/0140-6736(93)92489-G			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF027	8093272				2022-12-28	WOS:A1993KF02700011
J	SPIRO, HM				SPIRO, HM			SLUGGISH BOWELS AND GALLSTONES	LANCET			English	Editorial Material																		BURKITT DP, 1970, LANCET, V2, P1237; Cleave TL, 1962, PEPTIC ULCER; OSLER W, 1901, PRINCIPLES PRACTICE, P562	3	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 2	1993	341	8836					26	26		10.1016/0140-6736(93)92490-K	http://dx.doi.org/10.1016/0140-6736(93)92490-K			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF027	8093273	hybrid			2022-12-28	WOS:A1993KF02700012
J	GUILLEMOT, F; NAGY, A; AUERBACH, A; ROSSANT, J; JOYNER, AL				GUILLEMOT, F; NAGY, A; AUERBACH, A; ROSSANT, J; JOYNER, AL			ESSENTIAL ROLE OF MASH-2 IN EXTRAEMBRYONIC DEVELOPMENT	NATURE			English	Article							EMBRYONIC STEM-CELLS; SCUTE GENE-COMPLEX; NERVOUS-SYSTEM; MOUSE	THE outer layer of the blastocyst, or trophectoderm, is the first cell lineage to differentiate in the mouse embryo(1,2), but little is known about the genetic control of its development. Lineage-specific transcription factors may be important in lineage specification, and the product of the Mash-2 gene(3,4) fulfils the criteria for such a factor. Mash-2 is a mammalian member of the achaete-scute family(5-7) which encodes basic-helix-loop-helix transcription factors(8) and is strongly expressed in the extraembryonic trophoblast lineage. Mash-2 transcripts are found in the female germ line and in the embryo throughout preimplantation development, but are highly expressed later only in the ectoplacental cone, the chorion and their derivatives in the placenta. Mash-2 transcripts are not found in primary and secondary giant cells, yolk sac or allantois at any post-implantation stage, and are present only transiently and at low levels in the embryo during gastrulation. To analyse the role of Mash-2 in development, we have used gene targeting to generate mice having no Mash-2 function. We report here that Mash-2(-1-) embryos die from placental failure at 10 days postcoitum. In mutant placentas, spongiotrophoblast cells and their precursors are absent and chorionic ectoderm is reduced. We have rescued this placental mutant phenotype by constructing chimaeras with tetraploid wild-type embryos which contribute almost exclusively to extraembryonic tissues(9,10). Mash-2(-1-) embryos developed normally and adult Mash-2(-1-) mice were viable, demonstrating that Mash-2 has no major role in the embryo itself. Mash-2 is the first transcription factor shown to play a critical part in the development of the mammalian trophoblast lineage.	MT SINAI HOSP,SAMUEL LUNENFELD RES INST,TORONTO M5G 1X5,ON,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A8,ON,CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto			Nagy, Andras/G-6465-2013; Guillemot, Francois/AAV-1482-2021	Nagy, Andras/0000-0003-4311-0413; 				CAMPUZANO S, 1992, TRENDS GENET, V8, P202, DOI 10.1016/0168-9525(92)90234-U; COLOSI P, 1988, MOL ENDOCRINOL, V2, P579, DOI 10.1210/mend-2-6-579; FERRARA N, 1991, J CELL BIOCHEM, V47, P211, DOI 10.1002/jcb.240470305; FINNERTY H, 1993, ONCOGENE, V8, P2293; GHYSEN A, 1988, GENE DEV, V2, P495, DOI 10.1101/gad.2.5.495; GUILLEMOT F, 1993, MECH DEVELOP, V42, P171, DOI 10.1016/0925-4773(93)90006-J; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; KAUFMAN MH, 1983, BIOL TROPHOBLAST, P23; LESCISIN KR, 1989, GENE DEV, V2, P1639; LINZER DIH, 1985, P NATL ACAD SCI USA, V82, P4356, DOI 10.1073/pnas.82.13.4356; MANO H, 1990, ONCOGENE, V5, P1781; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MORRE C, 1989, CELL, V56, P777; NAGY A, 1990, DEVELOPMENT, V110, P815; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Nagy A., 1993, Gene targeting: a practical approach., P147; Rossant J., 1986, EXPT APPROACHES MAMM, P97; VILLARES R, 1987, CELL, V50, P415, DOI 10.1016/0092-8674(87)90495-8; WURST W, 1993, GENE TARGETING PRACT, P31	20	503	516	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 22	1994	371	6495					333	336		10.1038/371333a0	http://dx.doi.org/10.1038/371333a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH254	8090202				2022-12-28	WOS:A1994PH25400052
J	SERJEANT, GR; SERJEANT, BE; THOMAS, PW; ANDERSON, MJ; PATOU, G; PATTISON, JR				SERJEANT, GR; SERJEANT, BE; THOMAS, PW; ANDERSON, MJ; PATOU, G; PATTISON, JR			HUMAN PARVOVIRUS INFECTION IN HOMOZYGOUS SICKLE-CELL DISEASE	LANCET			English	Article							APLASTIC CRISIS; ANEMIA	We studied the epidemiology of human parvovirus B19 infection in 308 children with homozygous sickle cell (SS) disease and 239 controls with a normal haemoglobin (AA) genotype followed from birth in a cohort study. Annual serum samples identified the time and frequency of B19 infection, which did not differ between SS and AA children, about 40% of each group developing specific IgG by age 15. B19 infection followed an epidemic pattern similar to that observed for aplastic crises; accounted for all 91 aplastic crises that occurred; and was found in an additional 23 SS patients, of whom 10 showed mild haematological changes and 13 no changes. The magnitude or duration of IgG response did not differ between these groups. No patient had 2 attacks of aplasia and no patient nor control had 2 attacks of B19 infection. Following B19 infection, serial specific IgG concentrations remained high after 5 years in only 45% of SS patients, although the rarity of recurrent aplasia suggests lifelong immunity. B19 infection accounts for most if not all aplastic crises in SS disease, but at least 20% of infections do not result in aplasia. An effective vaccine against B19 might make an important contribution to the management of sickle cell disease.	UNIV COLL & MIDDLESEX SCH MED,DEPT MED MICROBIOL,LONDON,ENGLAND	University of London; University College London	SERJEANT, GR (corresponding author), UNIV W INDIES,MRC LABS,KINGSTON 7,JAMAICA.			Thomas, Peter/0000-0003-2478-4324				ANDERSON MJ, 1985, J INFECT DIS, V152, P257, DOI 10.1093/infdis/152.2.257; ANDERSON MJ, 1985, J MED VIROL, V15, P163, DOI 10.1002/jmv.1890150209; BALKARAN B, 1992, J PEDIATR-US, V120, P360, DOI 10.1016/S0022-3476(05)80897-2; CHARNEY E, 1964, AM J DIS CHILD, V107, P450, DOI 10.1001/archpedi.1964.02080060452004; CHERNOFF AI, 1951, AMA AM J DIS CHILD, V82, P310, DOI 10.1001/archpedi.1951.02040040324004; COHEN BJ, 1983, J HYG CAMB, V91, P1113; DUNCAN JR, 1983, LANCET, V2, P14; EDWARDS JMB, 1981, J INFECTION, V3, P316, DOI 10.1016/S0163-4453(81)91863-6; GOLDSTEIN AR, 1987, ARCH DIS CHILD, V62, P585, DOI 10.1136/adc.62.6.585; HILKOVITZ G, 1960, ARCH INTERN MED, V105, P76, DOI 10.1001/archinte.1960.00270130092011; KELLEHER JF, 1983, J PEDIATR-US, V102, P720, DOI 10.1016/S0022-3476(83)80243-1; KELLEHER JF, 1984, AM J DIS CHILD, V138, P402; LEIKIN SL, 1957, AMA J DIS CHILD, V93, P128, DOI 10.1001/archpedi.1957.02060040130005; MIESCH DC, 1957, ARCH INTERN MED, V99, P461, DOI 10.1001/archinte.1957.00260030143014; RAO KRP, 1983, ANN INTERN MED, V98, P930, DOI 10.7326/0003-4819-98-6-930; SERJEANT BE, 1974, CLIN CHEM, V20, P666; SERJEANT GR, 1981, BRIT J HAEMATOL, V48, P533, DOI 10.1111/j.1365-2141.1981.tb02750.x; SERJEANT GR, 1981, LANCET, V2, P595; SINGER K, 1950, J LAB CLIN MED, V35, P721	19	82	87	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 15	1993	341	8855					1237	1240		10.1016/0140-6736(93)91145-C	http://dx.doi.org/10.1016/0140-6736(93)91145-C			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LC497	8098391				2022-12-28	WOS:A1993LC49700003
J	STEEL, M				STEEL, M			CELL-DIFFERENTIATION - NEW LIGHT ON G-PROTEINS	LANCET			English	Editorial Material											STEEL, M (corresponding author), WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.							HELPER JR, 1992, TRENDS BIOCHEM SCI, V17, P383; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; WANG HY, 1992, NATURE, V358, P334, DOI 10.1038/358334a0; WATKINS DC, 1992, SCIENCE, V258, P1373, DOI 10.1126/science.1455234; WITTINGHOFER A, 1991, TRENDS BIOCHEM SCI, V16, P382, DOI 10.1016/0968-0004(91)90156-P; 1990, LANCET, V336, P1291	6	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 8	1993	341	8854					1187	1188		10.1016/0140-6736(93)91010-J	http://dx.doi.org/10.1016/0140-6736(93)91010-J			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB017	8098083				2022-12-28	WOS:A1993LB01700012
J	MOTWANI, JG; MCALPINE, H; KENNEDY, N; STRUTHERS, AD				MOTWANI, JG; MCALPINE, H; KENNEDY, N; STRUTHERS, AD			PLASMA BRAIN NATRIURETIC PEPTIDE AS AN INDICATOR FOR ANGIOTENSIN-CONVERTING-ENZYME INHIBITION AFTER MYOCARDIAL-INFARCTION	LANCET			English	Article							CONGESTIVE HEART-FAILURE; ACTIVATION	Brain natriuretic peptide (BNP) is a cardiac ventricular hormone that may be a sensitive and specific marker of changes in ventricular function. In a prospective, randomised open trial with 16 patients followed for 6 months after first Q wave anterior myocardial infarction we set out to determine: whether BNP concentrations are raised acutely, the effect on circulating BNP of angiotensin-converting enzyme (ACE) inhibition, how BNP and atrial natriuretic peptide (ANP) concentrations compared as correlates of left-ventricular ejection fraction, and whether plasma BNP concentrations could distinguish patients with low (<40%) and relatively preserved (>40%) ejection fractions. Plasma concentrations of BNP measured on days 2, 7, 8, 42, and 180 postinfarction were significantly raised in patients compared with normal controls and to a proportionately greater degree than ANP concentrations. Treatment with placebo (n=8) or oral captopril (n=8) from day 8 resulted in significantly lower BNP concentrations at days 42 (p=0.05) and 180 (p<0.05) in the captopril-treated group. Compared with ANP, BNP concentrations were much more strongly correlated with radionuclide-measured left-ventricular ejection fraction at days 2, 42, and 180. All 8 patients with baseline (day 2) ejection fractions of 40% or above had plasma BNP concentrations less than 10 pmol/L, whereas the 8 patients with ejection fractions less than 40% had BNP concentrations greater than 10 pmol/L. Our findings suggest that measurements of circulating BNP may identify those patients with significant left-ventricular dysfunction who have been highlighted by the Survival and Ventricular Enlargement study as likely to benefit from long-term ACE inhibition after myocardial infarction.	UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT CLIN PHARMACOL,DUNDEE DD1 9SY,SCOTLAND; UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT CARDIOL,DUNDEE DD1 9SY,SCOTLAND; UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT MED PHYS,DUNDEE DD1 9SY,SCOTLAND	University of Dundee; University of Dundee; University of Dundee				Struthers, Allan/0000-0002-2926-2528	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BROWN RA, 1989, J CLIN PATHOL, V42, P4, DOI 10.1136/jcp.42.1.4; FRANCIS GS, 1990, AM J CARDIOL, V66, pD33, DOI 10.1016/0002-9149(90)90474-F; HOSODA K, 1991, HYPERTENSION, V17, P1152, DOI 10.1161/01.HYP.17.6.1152; KUBO SH, 1990, CIRCULATION, V81, P107; LANG CC, 1992, CLIN SCI, V83, P143, DOI 10.1042/cs0830143; LANG CC, 1992, CLIN SCI, V83, P519, DOI 10.1042/cs0830519; MCALPINE HM, 1988, BRIT HEART J, V60, P117; MOTWANI JG, 1993, AM J CARDIOL, V71, P281, DOI 10.1016/0002-9149(93)90791-A; MUKOYAMA M, 1991, J CLIN INVEST, V87, P1402, DOI 10.1172/JCI115146; MUKOYAMA M, 1990, LANCET, V3350, P8015; NGO L, 1991, AM J MED SCI, V301, P157, DOI 10.1097/00000441-199103000-00002; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; SHARPE N, 1991, LANCET, V337, P872, DOI 10.1016/0140-6736(91)90202-Z; SUDOH T, 1988, NATURE, V332, P78, DOI 10.1038/332078a0; TOMODA H, 1988, AM J CARDIOL, V62, P1122, DOI 10.1016/0002-9149(88)90561-9; 1992, NEW ENGL J MED, V327, P685	16	198	218	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 1	1993	341	8853					1109	1113		10.1016/0140-6736(93)93126-L	http://dx.doi.org/10.1016/0140-6736(93)93126-L			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ687	8097802				2022-12-28	WOS:A1993KZ68700002
J	BENDALL, RP; LUCAS, S; MOODY, A; TOVEY, G; CHIODINI, PL				BENDALL, RP; LUCAS, S; MOODY, A; TOVEY, G; CHIODINI, PL			DIARRHEA ASSOCIATED WITH CYANOBACTERIUM-LIKE BODIES - A NEW COCCIDIAN ENTERITIS OF MAN	LANCET			English	Article								Faecal excretion of cysts known as cyanobacterium-like bodies (CLB) is associated with a diarrhoeal illness, which is often prolonged and severe. It is seen mainly in travellers and immunocompromised patients. Recently these cysts have been shown to be coccidian oocysts. We describe three patients who developed diarrhoea while travelling abroad. Stool samples from all three patients contained CLB. Jejunal aspirates from two patients also yielded CLB. Conventional histology of jejunal biopsy specimens confirmed that two patients had enteritis. Electromicroscopy of the same biopsy specimens revealed intraepithelial coccidia. These findings suggest that the small bowel is the site of infection of this new coccidian disease.	UNIV LONDON UNIV COLL, DEPT HISTOPATHOL, LONDON WC1E 6BT, ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED, DEPT ELECTRONMICROSCOPY, LONDON WC1E 7HT, ENGLAND	University of London; University College London; University of London; London School of Hygiene & Tropical Medicine	BENDALL, RP (corresponding author), HOSP TROP DIS, DEPT CLIN PARASITOL, 4 ST PANCRAS WAY, LONDON NW1 0PE, ENGLAND.							ENTZEROTH R, 1984, ZBL BAKT-INT J MED M, V256, P280, DOI 10.1016/S0174-3031(84)80002-5; HART AS, 1990, LANCET, V335, P169, DOI 10.1016/0140-6736(90)90042-4; LONG EG, 1990, J CLIN MICROBIOL, V28, P1101, DOI 10.1128/JCM.28.6.1101-1104.1990; LONG EG, 1991, J INFECT DIS, V164, P199, DOI 10.1093/infdis/164.1.199; POLLOK RCG, 1992, LANCET, V340, P556, DOI 10.1016/0140-6736(92)91759-2; SHLIM DR, 1991, AM J TROP MED HYG, V45, P383, DOI 10.4269/ajtmh.1991.45.383; SOAVE R, 1986, CLIN RES, V34, pA533	7	102	108	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 6	1993	341	8845					590	592		10.1016/0140-6736(93)90352-H	http://dx.doi.org/10.1016/0140-6736(93)90352-H			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KQ234	8094829				2022-12-28	WOS:A1993KQ23400004
J	VANDEKELFT, E; VANVYVE, M				VANDEKELFT, E; VANVYVE, M			SACRAL MENINGEAL CYSTS AND PERINEAL PAIN	LANCET			English	Letter											VANDEKELFT, E (corresponding author), ANTWERP UNIV HOSP,DEPT NEUROSURG,B-2560 EDEGEM,BELGIUM.							NABORS MW, 1988, J NEUROSURG, V68, P366, DOI 10.3171/jns.1988.68.3.0366; Tarlov IM, 1938, ARCH NEURO PSYCHIATR, V40, P1067, DOI 10.1001/archneurpsyc.1938.02270120017001; VANDEKELFT E, 1991, NEUROSURGERY, V29, P223, DOI 10.1227/00006123-199108000-00009	3	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 20	1993	341	8843					500	501		10.1016/0140-6736(93)90260-N	http://dx.doi.org/10.1016/0140-6736(93)90260-N			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN137	8094525				2022-12-28	WOS:A1993KN13700054
J	DUNCAN, RA; VONREYN, CF; ALLIEGRO, GM; TOOSSI, Z; SUGAR, AM; LEVITZ, SM				DUNCAN, RA; VONREYN, CF; ALLIEGRO, GM; TOOSSI, Z; SUGAR, AM; LEVITZ, SM			IDIOPATHIC CD4+ T-LYMPHOCYTOPENIA - 4 PATIENTS WITH OPPORTUNISTIC INFECTIONS AND NO EVIDENCE OF HIV-INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PNEUMOCYSTIS-CARINII PNEUMONIA; IMMUNODEFICIENCY VIRUS TYPE-1; DISSEMINATED HISTOPLASMOSIS; MICROBIAL SYNERGISM; ABSENCE; CANDIDIASIS; MARKERS; CELLS; MEN	Background and Methods. We describe four patients without major risk factors for human immunodeficiency virus (HIV) infection, each of whom presented with severe opportunistic infections and was found to have idiopathic CD4+ T-lymphocytopenia. We performed assays to detect the presence of retroviruses and undertook immunophenotyping of subgroups of peripheral-blood lymphocytes. Results. The opportunistic infections at presentation included Pneumocystis carinii pneumonia, cryptococcal meningitis (two patients, one with concurrent pulmonary tuberculosis), and histoplasma-induced brain abscess. During 10 to 68 months of observation, none of the four patients had evidence of infection with HIV type 1 or 2 or human T-cell lymphotropic virus type I or II on the basis of epidemiologic, serologic, or polymerase-chain-reaction studies or culture, nor was there any detectable reverse transcriptase activity. Although all the patients had severe, persistent CD4+ T-lymphocytopenia (range, 12 to 293 cells per cubic millimeter), the CD4+ cell count progressively declined in only one and was accompanied by multiple opportunistic infections. All four patients had significantly reduced numbers of circulating CD8+ T cells, natural killer cells, or B cells (or all three). Conclusions. These four patients had idiopathic CD4+ T-lymphocytopenia with opportunistic infections but no evidence of HIV infection. Instead of the progressive, selective depletion of CD4+ T cells characteristic of HIV infection, some patients with idiopathic immunodeficiency have stable CD4+ cell counts accompanied by reductions in the levels of several other lymphocyte sub-groups.	BOSTON CITY HOSP,THORNDIKE MEM LAB,DEPT MED,BOSTON,MA 02118; BOSTON UNIV HOSP,SCH MED,BOSTON,MA 02218; DARTMOUTH HITCHCOCK MED CTR,DEPT MED,INFECT DIS SECT,LEBANON,NH; CLEVELAND VET AFFAIRS MED CTR,CLEVELAND,OH; CASE WESTERN RESERVE UNIV,CLEVELAND,OH 44106; BOSTON CITY HOSP,MAXWELL FINLAND LAB INFECT DIS,BOSTON,MA 02118	Boston Medical Center; Boston University; Dartmouth College; Case Western Reserve University; Boston Medical Center	DUNCAN, RA (corresponding author), BOSTON CITY HOSP,EVANS MEM DEPT CLIN RES,THORNDIKE BLDG 311,818 HARRISON AVE,BOSTON,MA 02118, USA.				NIAID NIH HHS [AI-25780] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025780] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 1992, MMWR MORB MORTAL WKL, V41, P1; [Anonymous], 1992, MMWR MORB MORTAL WKL, V41, P541; BOFILL M, 1992, CLIN EXP IMMUNOL, V88, P243, DOI 10.1111/j.1365-2249.1992.tb03068.x; BRUNVAND MW, 1991, CANCER, V67, P2407, DOI 10.1002/1097-0142(19910501)67:9<2407::AID-CNCR2820670932>3.0.CO;2-X; CASTRO A, 1992, LANCET, V339, P868, DOI 10.1016/0140-6736(92)90308-P; COZON G, 1990, NEW ENGL J MED, V322, P132; DAAR ES, 1990, CLIN RES, V38, pA114; DAUS H, 1989, LANCET, V2, P559; DAVEY RT, 1992, MANUAL CLIN LABORATO, P364; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; FAUCI AS, 1991, ANN INTERN MED, V114, P678, DOI 10.7326/0003-4819-114-8-678; Fletcher MA, 1992, MANUAL CLIN LAB IMMU, V4th, P213; FRENTZ G, 1988, CANCER, V61, P294, DOI 10.1002/1097-0142(19880115)61:2<294::AID-CNCR2820610218>3.0.CO;2-8; GARTNER S, 1990, TECHNIQUES HIV RES, P53; GATENBY PA, 1989, LANCET, V1, P1027, DOI 10.1016/S0140-6736(89)92677-9; GAUTIER V, 1991, CLIN EXP ALLERGY, V21, P63, DOI 10.1111/j.1365-2222.1991.tb00805.x; GIORGI JV, 1992, MANUAL CLIN LABORATO, P174; GOTTLIEB MS, 1981, NEW ENGL J MED, V305, P1425, DOI 10.1056/NEJM198112103052401; GUPTA S, 1992, P NATL ACAD SCI USA, V89, P7831, DOI 10.1073/pnas.89.16.7831; HANSEN ER, 1990, ARCH DERMATOL, V126, P1604, DOI 10.1001/archderm.126.12.1604; HERRMANN K, 1988, ARCH DERMATOL RES, V280, P399, DOI 10.1007/BF00429977; HERSEY P, 1983, J IMMUNOL, V131, P171; JACKSON JB, 1990, NEW ENGL J MED, V322, P217, DOI 10.1056/NEJM199001253220402; JACOBS JL, 1991, NEW ENGL J MED, V324, P246, DOI 10.1056/NEJM199101243240407; JOHNSON VA, 1990, TECHNIQUES HIV RES, P98; JOWITT SN, 1991, LANCET, V337, P500, DOI 10.1016/0140-6736(91)93445-F; KESSLER H, 1992, Morbidity and Mortality Weekly Report, V41, P578; LAURENCE J, 1992, LANCET, V340, P273, DOI 10.1016/0140-6736(92)92359-N; LEHMANN PF, 1983, AM J MED, V75, P790, DOI 10.1016/0002-9343(83)90409-6; LEHMANN PF, 1989, INT ARCH ALLER A IMM, V90, P213, DOI 10.1159/000235027; LEHMANN PF, 1987, INT ARCH ALLER A IMM, V84, P311, DOI 10.1159/000234440; MACKOWIAK PA, 1978, NEW ENGL J MED, V298, P21, DOI 10.1056/NEJM197801052980105; MACKOWIAK PA, 1978, NEW ENGL J MED, V298, P83, DOI 10.1056/NEJM197801122980206; MASUR H, 1981, NEW ENGL J MED, V305, P1431, DOI 10.1056/NEJM198112103052402; MURPHY JW, 1988, REV INFECT DIS, V10, pS432; OU CY, 1990, AIDS RES HUM RETROV, V6, P1323, DOI 10.1089/aid.1990.6.1323; PANKHURST C, 1989, LANCET, V1, P672; PARKER JW, 1990, CLIN IMMUNOL IMMUNOP, V55, P187, DOI 10.1016/0090-1229(90)90097-A; PAYAN DG, 1984, J CLIN IMMUNOL, V4, P98, DOI 10.1007/BF00915042; PHAIR J, 1990, NEW ENGL J MED, V322, P161, DOI 10.1056/NEJM199001183220304; REICHERT T, 1991, CLIN IMMUNOL IMMUNOP, V60, P190, DOI 10.1016/0090-1229(91)90063-G; ROUSE BT, 1986, REV INFECT DIS, V8, P850; Scalzini A, 1990, Acta Neurol (Napoli), V12, P301; SELIGMANN M, 1991, LANCET, V337, P57, DOI 10.1016/0140-6736(91)93382-J; SIEGAL FP, 1981, NEW ENGL J MED, V305, P1439, DOI 10.1056/NEJM198112103052403; SMITH DK, 1993, NEW ENGL J MED, V328, P373, DOI 10.1056/NEJM199302113280601; STEIN DS, 1992, J INFECT DIS, V165, P352, DOI 10.1093/infdis/165.2.352; STOBO JD, 1976, J CLIN INVEST, V57, P319, DOI 10.1172/JCI108283; SUGAR AM, 1990, REV INFECT DIS, V12, pS338; WATSON SR, 1983, J IMMUNOL, V131, P984; WILLIAMS RC, 1983, AM J MED, V75, P807, DOI 10.1016/0002-9343(83)90412-6; WILSON CB, 1990, PRINCIPLES PRACTICE, P101	52	183	189	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 11	1993	328	6					393	398		10.1056/NEJM199302113280604	http://dx.doi.org/10.1056/NEJM199302113280604			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KL584	8093636				2022-12-28	WOS:A1993KL58400004
J	SMITH, DK; NEAL, JJ; HOLMBERG, SD				SMITH, DK; NEAL, JJ; HOLMBERG, SD			UNEXPLAINED OPPORTUNISTIC INFECTIONS AND CD4+ T-LYMPHOCYTOPENIA WITHOUT HIV-INFECTION - AN INVESTIGATION OF CASES IN THE UNITED-STATES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PATIENT; CELLS; IMMUNODEFICIENCY; ABSENCE; CANDIDIASIS; DEFICIENCY; COUNT; AIDS	Background. The clinical and public health importance of recent reports of patients with CD4+ T-lymphocytopenia without human immunodeficiency virus (HIV) infection is unclear. We conducted investigations to determine the demographic, clinical, and immunologic features of patients with idiopathic CD4+ T-lymphocytopenia; whether the syndrome is epidemic or transmissible; and the possible causes. Methods. We reviewed 230,179 cases in the Centers for Disease Control and Prevention (CDC) AIDS Reporting System and performed interviews, medical-record reviews, and laboratory analyses of blood specimens from adults and adolescents who met the CDC case definition of idiopathic CD4+ T-lymphocytopenia (<300 CD4+ cells per cubic millimeter or a CD4+ cell count <20 percent of total T cells on two occasions and no evidence of infection on HIV testing), their sexual contacts, household contacts, and persons who had donated blood to them. Results. We interviewed 31 of the 47 patients identified with idiopathic CD4+ T-lymphocytopenia and 23 of their contacts. There were 29 male and 18 female patients, with a mean age of 43 years (range, 17 to 78); 39 were white, 4 were Asian, 2 were Hispanic, and 2 were black. Eighteen patients (38 percent) had one or more risk factors for HIV infection: seven had hemophilia, six had engaged in homosexual sex, six had received blood transfusions, and two had had heterosexual sex partners who were at risk for HIV infection. The other 29 patients (62 percent) had no identified risk factors for HIV infection. Nineteen persons (40 percent) had AIDS-defining illnesses (18 had opportunistic infections), 25 (53 percent) had conditions that were not AIDS-defining, and 3 (6 percent) were asymptomatic. We tested blood from 28 patients: 8 (29 percent) were found to have CD4+ T-lymphocyte counts of less than 300 cells per cubic millimeter, and 6 had CD8+ T-lymphocytopenia (<250 cells per cubic millimeter). Ten sex partners, three household contacts, and four children of the patients, as well as six persons who had donated blood to the patients, were immunologically and clinically normal. Conclusions. This investigation of patients with idiopathic CD4+ T-lymphocytopenia and unexplained opportunistic infections indicates that the disorder is rare and represents various clinical and immunologic states. The investigation of contacts revealed no evidence of a new transmissible agent that causes lymphocytopenia.			SMITH, DK (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV HIV AIDS,MAILSTOP E-45,ATLANTA,GA 30333, USA.							ALEDORT LM, 1993, NEW ENGL J MED, V328, P441, DOI 10.1056/NEJM199302113280614; BACH MA, 1981, J IMMUNOL, V127, P980; CASTRO A, 1992, LANCET, V339, P868, DOI 10.1016/0140-6736(92)90308-P; CHESS Q, 1984, DIAGN CLIN IMMUNOL, V2, P148; COZON G, 1990, NEW ENGL J MED, V322, P132; CUNNINGHAMRUNDLES C, 1989, J CLIN IMMUNOL, V9, P22, DOI 10.1007/BF00917124; DAAR ES, 1990, CLIN RES, V38, pA114; DAUS H, 1989, LANCET, V2, P559; DENNY T, 1992, JAMA-J AM MED ASSOC, V267, P1484, DOI 10.1001/jama.267.11.1484; DUNCAN RA, 1993, NEW ENGL J MED, V328, P393, DOI 10.1056/NEJM199302113280604; FOLKS T, 1986, J IMMUNOL, V136, P4049; GAJDUSEK DC, 1976, NCI MONOGRAPH, V43; GATENBY PA, 1989, LANCET, V1, P1027, DOI 10.1016/S0140-6736(89)92677-9; GAUTIER V, 1991, CLIN EXP ALLERGY, V21, P63, DOI 10.1111/j.1365-2222.1991.tb00805.x; GUPTA S, 1992, P NATL ACAD SCI USA, V89, P7831, DOI 10.1073/pnas.89.16.7831; HANSEN ER, 1990, ARCH DERMATOL, V126, P1604, DOI 10.1001/archderm.126.12.1604; HO DD, 1993, NEW ENGL J MED, V328, P380, DOI 10.1056/NEJM199302113280602; HODGE TW, 1991, HUM IMMUNOL, V30, P99, DOI 10.1016/0198-8859(91)90077-M; JOWITT SN, 1991, LANCET, V337, P500, DOI 10.1016/0140-6736(91)93445-F; LAURENCE J, 1992, LANCET, V340, P273, DOI 10.1016/0140-6736(92)92359-N; LEHMANN PF, 1983, AM J MED, V75, P790, DOI 10.1016/0002-9343(83)90409-6; MALONE JL, 1992, J INFECT DIS, V165, P185, DOI 10.1093/infdis/165.1.185; MALONE JL, 1990, J ACQ IMMUN DEF SYND, V3, P144; OU CY, 1988, SCIENCE, V239, P295, DOI 10.1126/science.3336784; PANKHURST C, 1989, LANCET, V1, P672; REICHERT T, 1991, CLIN IMMUNOL IMMUNOP, V60, P190, DOI 10.1016/0090-1229(91)90063-G; Scalzini A, 1990, Acta Neurol (Napoli), V12, P301; SELIGMANN M, 1991, LANCET, V337, P57, DOI 10.1016/0140-6736(91)93382-J; SHAFER RW, 1991, AIDS, V5, P399, DOI 10.1097/00002030-199104000-00007; SORIANO V, 1992, LANCET, V340, P607, DOI 10.1016/0140-6736(92)92140-B; SPIRA TJ, 1993, NEW ENGL J MED, V328, P386, DOI 10.1056/NEJM199302113280603; VERMUND SH, 1993, NEW ENGL J MED, V328, P442, DOI 10.1056/NEJM199302113280615; WEISS SH, 1992, LANCET, V340, P608; WILLIAMS RC, 1983, AM J MED, V75, P807, DOI 10.1016/0002-9343(83)90412-6; 1992, MMWR MORB MORTAL WEE, V41, P578; 1992, MMWR MORB MORTAL WEE, V41, P541	36	335	343	0	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 11	1993	328	6					373	379		10.1056/NEJM199302113280601	http://dx.doi.org/10.1056/NEJM199302113280601			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KL584	8093633				2022-12-28	WOS:A1993KL58400001
J	SAUER, MV; PAULSON, RJ; LOBO, RA				SAUER, MV; PAULSON, RJ; LOBO, RA			PREGNANCY AFTER AGE 50 - APPLICATION OF OOCYTE DONATION TO WOMEN AFTER NATURAL MENOPAUSE	LANCET			English	Article							OVARIAN FAILURE; FERTILITY	The age at which the uterus no longer provides a receptive environment for embryo implantation and development remains unknown. We assessed whether menopausal women between the ages of 50 and 59 years could be prepared for pregnancy with oocyte donation. All potential recipients underwent extensive screening to ensure that they were in excellent physical, reproductive, and psychological health before enrolment. Of 18 patients initially screened (mean [SD] age 52.2 years [2.5]), 14 couples were entered into the study. Oocytes were donated by fertile women (28.1 [2.7] years) who provided gametes after pituitary downregulation with leuprolide acetate and routine ovarian hyperstimulation by human menopausal gonadotropin. 22 donor follicle aspirations resulted in 21 embryo transfers to 14 recipients. Pregnancies were established in 9 women. 1 pregnancy ended in a preclinical loss. The ratio of clinical pregnancies per transfer attempt was 38% (8/21), with an implantation rate per transferred embryo of 19%. Of the 8 clinical pregnancies, 1 spontaneous abortion occurred at 7 weeks' gestation. 3 women have delivered, 2 at 35 weeks' by emergency caesarean section for worsening preeclampsia and 1 at 37 weeks' after a normal vaginal birth. 4 pregnancies continue to progress normally beyond the second trimester. Women may become pregnant after the age of natural menopause by means of in-vitro fertilisation of donated oocytes. However, thorough medical screening before embryo transfer is essential to reduce to a minimum obstetric risks common in this older population.	UNIV SO CALIF, DEPT OBSTET & GYNECOL, DIV REPROD ENDOCRINOL, LOS ANGELES, CA 90089 USA	University of Southern California								BUEHLER JW, 1986, JAMA-J AM MED ASSOC, V255, P53, DOI 10.1001/jama.255.1.53; CNATTINGIUS S, 1992, JAMA-J AM MED ASSOC, V268, P886; HOLINKA CF, 1979, BIOL REPROD, V20, P1201, DOI 10.1095/biolreprod20.5.1201; MAROULIS GB, 1991, SEMIN REPROD ENDOCR, V9, P165, DOI 10.1055/s-2007-1019407; NAVOT D, 1991, LANCET, V337, P1375, DOI 10.1016/0140-6736(91)93060-M; PAULSON RJ, 1992, FERTIL STERIL, V58, P551; SAUER MV, 1992, JAMA-J AM MED ASSOC, V268, P1275, DOI 10.1001/jama.268.10.1275; SAUER MV, 1992, FERTIL STERIL, V58, P16; SAUER MV, 1991, INT J GYNECOL OBSTET, V35, P61, DOI 10.1016/0020-7292(91)90065-D; SAUER MV, 1989, FERTIL STERIL, V52, P433; SAUER MV, 1991, FERTIL STERIL, V55, P39; SAUER MV, 1992, HUM REPROD, V7, P726, DOI 10.1093/oxfordjournals.humrep.a137726; SAUER MV, 1990, NEW ENGL J MED, V323, P1157, DOI 10.1056/NEJM199010253231702; SAUER MV, 1991, GYNECOL OBSTET INVES, V32, P118, DOI 10.1159/000293009; SAUER MV, 1992, 39TH ANN M SOC GYN I; SERHAL PF, 1989, LANCET, V1, P1185; STENE J, 1977, ANN HUM GENET, V40, P299, DOI 10.1111/j.1469-1809.1977.tb00194.x	17	127	130	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 6	1993	341	8841					321	323		10.1016/0140-6736(93)90132-Z	http://dx.doi.org/10.1016/0140-6736(93)90132-Z			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK939	8094110				2022-12-28	WOS:A1993KK93900001
J	PANTALEO, G; GRAZIOSI, C; FAUCI, AS				PANTALEO, G; GRAZIOSI, C; FAUCI, AS			THE IMMUNOPATHOGENESIS OF HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							MAMMARY-TUMOR VIRUS; T-CELL RECEPTOR; TOXIC LYMPHOCYTES-T; PRIMARY MONONUCLEAR PHAGOCYTES; FOLLICULAR DENDRITIC CELLS; PRIMARY HIV-1 INFECTION; GROWTH-FACTOR-BETA; HTLV-III/LAV; PERIPHERAL-BLOOD; CLONAL DELETION		NIAID, IMMUNOREGULAT LAB, BLDG 10, RM 11B13, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			graziosi, cecilia/M-1882-2019; Pantaleo, Giuseppe/K-6163-2016; Ulatan, Jeffrey/AAM-5560-2020	Ulatan, Jeffrey/0000-0002-3756-0568				ABE R, 1989, J EXP MED, V170, P1059, DOI 10.1084/jem.170.4.1059; ABRAMS DI, 1984, ANN INTERN MED, V100, P801, DOI 10.7326/0003-4819-100-6-801; ACHAORBEA H, 1991, NATURE, V350, P207, DOI 10.1038/350207a0; AMADORI A, 1992, J IMMUNOL, V148, P2709; AMEISEN JC, 1991, IMMUNOL TODAY, V12, P102; ARMSTRONG JA, 1985, IMMUNOL TODAY, V6, P121, DOI 10.1016/0167-5699(85)90076-3; ARMSTRONG JA, 1991, ACCESSORY CELLS IN HIV AND OTHER RETROVIRAL INFECTIONS, P69; BAGASRA O, 1992, NEW ENGL J MED, V326, P1385, DOI 10.1056/NEJM199205213262103; BIBERFELD P, 1987, ACTA PATH MICRO IM A, V95, P47; BILL J, 1989, J EXP MED, V169, P1405, DOI 10.1084/jem.169.4.1405; BISWAS P, 1992, J EXP MED, V176, P739, DOI 10.1084/jem.176.3.739; BLATTNER W, 1988, SCIENCE, V241, P515, DOI 10.1126/science.3399881; CHOI YW, 1991, NATURE, V350, P203, DOI 10.1038/350203a0; CHOWDHURY MIH, 1990, BIOCHEM BIOPH RES CO, V170, P1365; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; COLE BC, 1991, IMMUNOL TODAY, V12, P271, DOI 10.1016/0167-5699(91)90125-D; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; DALGLEISH AG, 1992, LANCET, V339, P824, DOI 10.1016/0140-6736(92)90277-A; DUVALL E, 1986, IMMUNOL TODAY, V7, P115, DOI 10.1016/0167-5699(86)90152-0; DYSON PJ, 1991, NATURE, V349, P531, DOI 10.1038/349531a0; EMILIE D, 1990, J CLIN INVEST, V86, P148, DOI 10.1172/JCI114678; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; ENSOLI B, 1989, SCIENCE, V243, P223, DOI 10.1126/science.2643161; FAUCI AS, 1991, ANN INTERN MED, V114, P678, DOI 10.7326/0003-4819-114-8-678; FAUCI AS, 1985, ANN INTERN MED, V102, P800, DOI 10.7326/0003-4819-102-6-800; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; FAUCI AS, 1991, HARRISONS PRINCIPLES, V2, P1402; FOX CH, 1991, J INFECT DIS, V164, P1051, DOI 10.1093/infdis/164.6.1051; FRANKEL WN, 1991, NATURE, V349, P526, DOI 10.1038/349526a0; GAINES H, 1990, AIDS, V4, P995, DOI 10.1097/00002030-199010000-00008; GARRY RF, 1989, AIDS, V3, P683, DOI 10.1097/00002030-198911000-00001; GOLDING H, 1989, J CLIN INVEST, V83, P1430, DOI 10.1172/JCI114034; GOLDING H, 1988, J EXP MED, V167, P914, DOI 10.1084/jem.167.3.914; GOUGEON ML, 1991, CR ACAD SCI III-VIE, V312, P529; GRAHAM NMH, 1991, LANCET, V338, P265, DOI 10.1016/0140-6736(91)90414-K; GRAZIOSI C, 1992, CLIN RES, V40, pA333; GROUX H, 1992, J EXP MED, V175, P331, DOI 10.1084/jem.175.2.331; HABESHAW JA, 1990, IMMUNOL TODAY, V11, P418, DOI 10.1016/0167-5699(90)90162-3; HARPER ME, 1986, P NATL ACAD SCI USA, V83, P772, DOI 10.1073/pnas.83.3.772; HASELTINE WA, 1991, FASEB J, V5, P2349, DOI 10.1096/fasebj.5.10.1829694; HILDRETH JEK, 1989, AIDS S1, V3, pS111; HO DD, 1985, LANCET, V1, P602; IMBERTI L, 1991, SCIENCE, V254, P860, DOI 10.1126/science.1948066; JANEWAY C, 1991, NATURE, V349, P459, DOI 10.1038/349459a0; JENKINSON EJ, 1989, EUR J IMMUNOL, V19, P2175, DOI 10.1002/eji.1830191132; KAPPLER J, 1989, SCIENCE, V244, P811, DOI 10.1126/science.2524876; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KOYANAGI Y, 1988, SCIENCE, V241, P1673, DOI 10.1126/science.3047875; LAURENTCRAWFORD AG, 1991, VIROLOGY, V185, P829, DOI 10.1016/0042-6822(91)90554-O; LAZDINS JK, 1991, J IMMUNOL, V147, P1201; LEMP GF, 1990, JAMA-J AM MED ASSOC, V263, P402, DOI 10.1001/jama.263.3.402; LIFSON JD, 1986, SCIENCE, V232, P1123, DOI 10.1126/science.3010463; LINETTE GP, 1988, SCIENCE, V241, P573, DOI 10.1126/science.2899908; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MARRACK P, 1991, NATURE, V349, P524, DOI 10.1038/349524a0; MCCONKEY DJ, 1989, J IMMUNOL, V143, P1801; MCDOUGAL JS, 1985, J IMMUNOL, V135, P3151; MERRILL JE, 1991, FASEB J, V5, P2391, DOI 10.1096/fasebj.5.10.2065887; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; MICHAEL NL, 1992, J VIROL, V66, P310, DOI 10.1128/JVI.66.1.310-316.1992; MITTLER RS, 1989, SCIENCE, V245, P1380, DOI 10.1126/science.2571187; NAIR BC, 1992, SCIENCE, V255, P1430, DOI 10.1126/science.1542792; NEWELL MK, 1990, NATURE, V347, P286, DOI 10.1038/347286a0; NIXON DF, 1988, NATURE, V336, P484, DOI 10.1038/336484a0; NOVAK RM, 1990, AIDS RES HUM RETROV, V6, P973, DOI 10.1089/aid.1990.6.973; PALIARD X, 1991, SCIENCE, V253, P325, DOI 10.1126/science.1857971; PANTALEO G, 1991, J EXP MED, V173, P511, DOI 10.1084/jem.173.2.511; PANTALEO G, 1991, P NATL ACAD SCI USA, V88, P9838, DOI 10.1073/pnas.88.21.9838; PANTALEO G, 1992, CLIN RES, V40, pA253; Parrott D M, 1981, Prog Allergy, V28, P193; PLATA F, 1987, NATURE, V328, P348, DOI 10.1038/328348a0; POLI G, 1992, AIDS RES HUM RETROV, V8, P191, DOI 10.1089/aid.1992.8.191; POLI G, 1989, SCIENCE, V244, P575, DOI 10.1126/science.2470148; POLI G, 1991, J EXP MED, V173, P589, DOI 10.1084/jem.173.3.589; PRICE RW, 1988, SCIENCE, V239, P586, DOI 10.1126/science.3277272; RAGNI MV, 1992, J ACQ IMMUN DEF SYND, V5, P120; RAMMENSEE HG, 1989, NATURE, V339, P541, DOI 10.1038/339541a0; RIECKMANN P, 1991, J IMMUNOL, V147, P2922; RIECKMANN P, 1991, J EXP MED, V173, P1, DOI 10.1084/jem.173.1.1; ROSENBERG ZF, 1990, IMMUNOL TODAY, V11, P176, DOI 10.1016/0167-5699(90)90070-P; ROSENBERG ZF, 1991, FASEB J, V5, P2382, DOI 10.1096/fasebj.5.10.1676689; ROSENBERG ZF, 1989, AIDS RES HUM RETROV, V5, P1, DOI 10.1089/aid.1989.5.1; ROUSE RV, 1982, J IMMUNOL, V128, P2243; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; SHIBATA D, 1989, AM J PATHOL, V135, P697; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SODROSKI J, 1986, NATURE, V322, P470, DOI 10.1038/322470a0; SPIEGEL H, 1992, AM J PATHOL, V140, P15; STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415; TENNERRACZ K, 1986, AM J PATHOL, V123, P9; TENNERRACZ K, 1985, LANCET, V1, P105; TERAI C, 1991, J CLIN INVEST, V87, P1710, DOI 10.1172/JCI115188; TERSMETTE M, 1989, J VIROL, V63, P2118, DOI 10.1128/JVI.63.5.2118-2125.1989; TEW JG, 1990, IMMUNOL REV, V117, P185, DOI 10.1111/j.1600-065X.1990.tb00573.x; TINDALL B, 1991, AIDS, V5, P1, DOI 10.1097/00002030-199101000-00001; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; WALKER BD, 1987, NATURE, V328, P345, DOI 10.1038/328345a0; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; WESTERMANN J, 1990, IMMUNOL TODAY, V11, P406, DOI 10.1016/0167-5699(90)90160-B; WILLIAMS GJ, 1989, J INTERFERON RES, V9, P709, DOI 10.1089/jir.1989.9.709; Wood G S, 1990, Prog AIDS Pathol, V2, P25; WOODLAND D, 1990, SCIENCE, V247, P964, DOI 10.1126/science.1968289; WOODLAND DL, 1991, NATURE, V349, P529, DOI 10.1038/349529a0; YAMAMOTO JK, 1986, J INTERFERON RES, V6, P243; ZACK JA, 1992, J VIROL, V66, P1717, DOI 10.1128/JVI.66.3.1717-1725.1992; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	106	964	987	1	48	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 4	1993	328	5					327	335						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK247	8093551				2022-12-28	WOS:A1993KK24700008
J	SCHWARER, AP; JIANG, YZ; BROOKES, PA; BARRETT, AJ; BATCHELOR, JR; GOLDMAN, JM; LECHLER, RI				SCHWARER, AP; JIANG, YZ; BROOKES, PA; BARRETT, AJ; BATCHELOR, JR; GOLDMAN, JM; LECHLER, RI			FREQUENCY OF ANTI-RECIPIENT ALLOREACTIVE HELPER T-CELL PRECURSORS IN DONOR BLOOD AND GRAFT-VERSUS-HOST DISEASE AFTER HLA-IDENTICAL SIBLING BONE-MARROW TRANSPLANTATION	LANCET			English	Article							LEUKEMIA; ALLELES; INVIVO	A substantial proportion of patients undergoing allogeneic bone-marrow transplantation (BMT) develop moderate-to-severe acute graft-versus-host disease (GVHD). Anti-recipient helper (interleukin-2-producing) T-lymphocyte precursors (HTLp) have an important role in the control and amplification of the alloreactive immune response that initiates GVHD. We used a limiting dilution assay to measure the frequency of HTLp in the blood of marrow donors for 25 patients undergoing genotypically HLA-identical BMT for chronic myeloid leukaemia (n = 20), acute myeloid leukaemia (4), or thalassaemia (1). HTLp frequencies in donor blood ranged from 1 in 18 x 10(3) to less than 1 in 500 x 10(3); they were significantly higher (p = 0.02) in patients with grade II-IV acute GVHD than in those with grade 0-I GVHD. The HTLp assay seems sufficiently sensitive to detect clinically significant minor histocompatibility antigen differences between the donor and recipient. The assay should prove valuable in selecting the best donor/recipient combination and could indicate the need to intensify GVHD prophylaxis when the only available donor has a high HTLp frequency.	ROYAL POSTGRAD MED SCH,DEPT HAEMATOL,DU CANE RD,LONDON W12 0NN,ENGLAND; ROYAL POSTGRAD MED SCH,DEPT IMMUNOL,LONDON W12 0HS,ENGLAND	Imperial College London; Imperial College London								BATCHELOR JR, 1991, TRANSPLANT P, V23, P1711; BEATTY PG, 1985, NEW ENGL J MED, V313, P765, DOI 10.1056/NEJM198509263131301; BIDWELL JL, 1988, TRANSPLANTATION, V45, P640, DOI 10.1097/00007890-198803000-00027; BISHOP DK, 1989, TRANSPLANTATION, V47, P671, DOI 10.1097/00007890-198904000-00020; CIVIN CI, 1990, EXP HEMATOL, V18, P461; CLOUSE KA, 1984, J IMMUNOL, V132, P2961; COHEN J, 1988, BONE MARROW TRANSPL, V3, P193; DEGAST GC, 1992, BONE MARROW TRANSPL, V9, P87; DESTGROTH SF, 1982, J IMMUNOL METHODS, V49, pR11, DOI 10.1016/0022-1759(82)90269-1; GILLIS S, 1977, NATURE, V268, P154, DOI 10.1038/268154a0; GLUCKSBERG H, 1974, TRANSPLANTATION, V18, P295, DOI 10.1097/00007890-197410000-00001; GOLDMAN JM, 1988, ANN INTERN MED, V108, P806, DOI 10.7326/0003-4819-108-6-806; GOLDMAN JM, 1986, NEW ENGL J MED, V314, P202, DOI 10.1056/NEJM198601233140403; GOULMY E, 1991, BONE MARROW TRANSPL, V7, P49; HOWELL WM, 1991, EUR J IMMUNOGENET, V18, P81, DOI 10.1111/j.1744-313X.1991.tb00008.x; IRLE C, 1985, TRANSPLANTATION, V40, P329, DOI 10.1097/00007890-198509000-00021; KAMINSKI E, 1989, TRANSPLANTATION, V48, P608; PANINABORDIGNON P, 1991, SCIENCE, V252, P1548, DOI 10.1126/science.1710827; PERREAULT C, 1990, BLOOD, V76, P1269; STORB R, 1986, NEW ENGL J MED, V314, P729, DOI 10.1056/NEJM198603203141201; STORB R, 1990, EUR J CLIN INVEST, V20, P119, DOI 10.1111/j.1365-2362.1990.tb02258.x	21	136	137	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 23	1993	341	8839					203	205		10.1016/0140-6736(93)90067-Q	http://dx.doi.org/10.1016/0140-6736(93)90067-Q			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ219	8093498				2022-12-28	WOS:A1993KJ21900005
J	PAPADOPOULOS, EB; LADANYI, M; EMANUEL, D; MACKINNON, S; BOULAD, F; CARABASI, MH; CASTROMALASPINA, H; CHILDS, BH; GILLIO, AP; SMALL, TN; YOUNG, JW; KERNAN, NA; OREILLY, RJ				PAPADOPOULOS, EB; LADANYI, M; EMANUEL, D; MACKINNON, S; BOULAD, F; CARABASI, MH; CASTROMALASPINA, H; CHILDS, BH; GILLIO, AP; SMALL, TN; YOUNG, JW; KERNAN, NA; OREILLY, RJ			INFUSIONS OF DONOR LEUKOCYTES TO TREAT EPSTEIN-BARR VIRUS-ASSOCIATED LYMPHOPROLIFERATIVE DISORDERS AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POLYMERASE CHAIN-REACTION; VERSUS-HOST DISEASE; LYMPHOCYTES-T; MONOCLONAL-ANTIBODIES; ORGAN-TRANSPLANTATION; RECIPIENTS; LEUKEMIA; CELLS; GRAFT; DNA	Background. Lymphoma associated with Epstein-Barr virus (EBV) is a complication of bone marrow transplantation that responds poorly to standard forms of therapy. The lymphoma is usually of donor origin. We hypothesized that treatment with infusions of donor leukocytes, which contain cytotoxic T cells presensitized to EBV, might be an effective treatment. Methods. We studied five patients in whom EBV-associated lymphoproliferative disorders developed after they received a T-cell-depleted allogeneic bone marrow transplant. Biopsy specimens were immunophenotyped, subjected to the polymerase chain reaction to determine the origin of the lymphoma (donor or host) and to detect the presence of EBV, and analyzed by Southern blotting for the presence of the clonal EBV genome and immunoglobulin-gene rearrangement. Patients were treated with infusions of unirradiated donor leukocytes at doses calculated to provide approximately 1.0x10(6) CD3+ T cells per kilogram of body weight. Results. Histopathological examination of biopsy specimens from all five patients demonstrated monomorphic, malignant lymphomas of B-cell origin. Each of the four specimens that could be evaluated was of donor-cell origin. Evidence of clonality was found in two of the three samples adequate for study. EBV DNA was detected by the polymerase chain reaction in all five samples. In all five patients there were complete pathological or clinical responses, The responses were first documented histologically within 8 to 21 days after infusion. Clinical remissions were achieved within 14 to 30 days after the infusions and were sustained without further therapy in the three surviving patients for 10, 16, and 16 months. Conclusions. In a small number of patients, infusions of unirradiated donor leukocytes were an effective treatment for EBV-associated lymphoproliferative disease that arose after allogeneic bone marrow transplantation.	MEM SLOAN KETTERING CANC CTR,DEPT PEDIAT,BONE MARROW TRANSPLANTAT SERV,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,DEPT PATHOL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	PAPADOPOULOS, EB (corresponding author), MEM SLOAN KETTERING CANC CTR,DEPT MED,BONE MARROW TRANSPLANTAT SERV,1275 YORK AVE,NEW YORK,NY 10021, USA.		Mackinnon, Stephen/C-5559-2008; Ladanyi, Marc/AAG-8585-2019	Young, James/0000-0002-0032-6559	NATIONAL CANCER INSTITUTE [U01CA058260, P01CA023766] Funding Source: NIH RePORTER; NCI NIH HHS [CA23766, U01CA58260] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKAO I, 1991, LARYNGOSCOPE, V101, P279; [Anonymous], 1982, CANCER, V49, P2112; ANTIN JH, 1991, BLOOD, V78, P2139; BOURGAULT I, 1991, CLIN EXP IMMUNOL, V84, P501; CATHOMAS G, 1993, BLOOD, V81, P1909; CHEUNG A, 1982, J VIROL, V44, P286, DOI 10.1128/JVI.44.1.286-294.1982; CRAWFORD DH, 1986, TRANSPLANTATION, V42, P50, DOI 10.1097/00007890-198607000-00010; CULLIS JO, 1992, BLOOD, V79, P1379; DUNCOMBE AS, 1992, BLOOD, V79, P3059; FISCHER A, 1991, NEW ENGL J MED, V324, P1451, DOI 10.1056/NEJM199105233242102; FRIZZERA G, 1981, CANCER RES, V41, P4262; GLUCKSBERG H, 1974, TRANSPLANTATION, V18, P295, DOI 10.1097/00007890-197410000-00001; HALE G, 1988, TRANSPLANTATION, V45, P753, DOI 10.1097/00007890-198804000-00018; HANTO DW, 1985, TRANSPLANT P, V17, P89; HANTO DW, 1985, J SURG ONCOL, V30, P215, DOI 10.1002/jso.2930300406; JOHNSON BD, 1993, BONE MARROW TRANSPL, V11, P329; KATZ BZ, 1989, J INFECT DIS, V160, P589, DOI 10.1093/infdis/160.4.589; KEEVER CA, 1987, BLOOD, V70, P1893; KEEVER CA, 1989, BLOOD, V73, P1340; KERNAN NA, 1986, BLOOD, V68, P770; KOLB HJ, 1990, BLOOD, V76, P2462, DOI 10.1182/blood.V76.12.2462.2462; LOCKER J, 1989, AM J PATHOL, V135, P977; MACKINNON S, 1992, BLOOD, V80, P3235; MARTIN PJ, 1984, ANN INTERN MED, V101, P310, DOI 10.7326/0003-4819-101-3-310; MURRAY RJ, 1992, J EXP MED, V176, P157, DOI 10.1084/jem.176.1.157; NALESNIK MA, 1988, AM J PATHOL, V133, P173; OREILLY RJ, 1988, BONE MARROW TRANSPL, V3, P3; RAABTRAUB N, 1986, CELL, V47, P883, DOI 10.1016/0092-8674(86)90803-2; REISNER Y, 1981, LANCET, V2, P327; RIDDELL SR, 1992, SCIENCE, V257, P238; SEIDEN MV, 1993, HEMATOL ONCOL CLIN N, V7, P447, DOI 10.1016/S0889-8588(18)30251-X; SHAPIRO RS, 1988, NEW ENGL J MED, V318, P1334; SWERDLOW SH, 1992, HISTOPATHOLOGY, V20, P373, DOI 10.1111/j.1365-2559.1992.tb01007.x; SZER J, 1993, BONE MARROW TRANSPL, V11, P109; WEISS L, 1992, CANCER INVEST, V10, P19, DOI 10.3109/07357909209032785; ZUTTER MM, 1988, BLOOD, V72, P520	38	826	844	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 28	1994	330	17					1185	1191		10.1056/NEJM199404283301703	http://dx.doi.org/10.1056/NEJM199404283301703			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NG586	8093146				2022-12-28	WOS:A1994NG58600003
J	BOTS, ML; VANSWIETEN, JC; BRETELER, MMB; DEJONG, PTVM; VANGIJN, J; HOFMAN, A; GROBBEE, DE				BOTS, ML; VANSWIETEN, JC; BRETELER, MMB; DEJONG, PTVM; VANGIJN, J; HOFMAN, A; GROBBEE, DE			CEREBRAL WHITE MATTER LESIONS AND ATHEROSCLEROSIS IN THE ROTTERDAM STUDY	LANCET			English	Article							CAROTID-ARTERY; RISK-FACTORS; SIGNAL ABNORMALITIES; NORMAL INDIVIDUALS; WALL THICKNESS; ULTRASOUND; POPULATION; DISEASE; ULTRASONOGRAPHY; DETERMINANTS	Cerebral white matter lesions (WML) seen on magnetic resonance imaging scans are associated with cardiovascular disease and vascular risk factors. To assess the association between WML and atherosclerosis, we studied 111 people, aged 65 to 85 years, randomly sampled, and stratified by age and sex, from participants in the Rotterdam Study. Cerebral T2-weighted magnetic resonance images in the axial plane were obtained for all subjects. Carotid atherosclerosis was ultrasonographically assessed by the presence of stenosis, measurement of intima to media wall thickness (IMT), and the presence of atherosclerotic plaques. A possible or definite myocardial infarction on an electrocardiogram was used as an indicator of coronary atherosclerosis. The ankle to arm systolic blood pressure ratio (ABI) was determined, and peripheral arterial disease was defined as an ABI lower than 0.90 in at least one side. Carotid atherosclerosis was significantly more pronounced in people with WML. The difference in common carotid IMT was 0.13 mm (95% confidence interval [CI] 0.04-0.21), whereas the odds ratio of WML associated with plaques in the carotid bifurcation was 3.9. The degree of internal carotid artery stenosis was not, however, associated with WML. The mean ABI was significantly lower in people with WML than in those without lesions with a difference of -0.11 (95% CI -0.21 to -0.01). The odds ratio of WML associated with peripheral arterial disease and a possible or definite myocardial infarction was 2.4 and 3.1, respectively. We conclude that atherosclerosis, indicated by increased common carotid IMT, carotid plaques, and a lower ABI, is related to WML.	ERASMUS UNIV ROTTERDAM, SCH MED, DEPT EPIDEMIOL & BIOSTAT, POB 1738, 3000 DR ROTTERDAM, NETHERLANDS; UNIV UTRECHT HOSP, DEPT NEUROL, 3511 GV UTRECHT, NETHERLANDS; UNIV HOSP DIJKZIGT, DEPT NEUROL, ROTTERDAM, NETHERLANDS; UNIV HOSP DIJKZIGT, DEPT OPHTHALMOL, ROTTERDAM, NETHERLANDS	Erasmus University Rotterdam; Utrecht University; Utrecht University Medical Center; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC			Grobbee, Diederick/C-7651-2014; van Gijn, Jan/A-9444-2008; Breteler, Monique M.B./J-5058-2014	Grobbee, Diederick/0000-0003-4472-4468; Breteler, Monique M.B./0000-0002-0626-9305; van Swieten, John/0000-0001-6278-6844				AWAD IA, 1986, STROKE, V17, P1090, DOI 10.1161/01.STR.17.6.1090; BOONE KB, 1992, ARCH NEUROL-CHICAGO, V49, P549, DOI 10.1001/archneur.1992.00530290141024; BOTS ML, 1993, ARTERIOSCLER THROMB, V13, P64, DOI 10.1161/01.ATV.13.1.64; BOTS ML, 1992, HYPERTENSION, V19, P717, DOI 10.1161/01.HYP.19.6.717; BOWEN BC, 1990, AM J NEURORADIOL, V11, P283; BRAFFMAN BH, 1988, AM J ROENTGENOL, V151, P559, DOI 10.2214/ajr.151.3.559; BRETELER MMB, UNPUB CEREBRAL WHITE; FAZEKAS F, 1988, STROKE, V19, P1285, DOI 10.1161/01.STR.19.10.1285; FEUSSNER JR, 1988, ANN INTERN MED, V109, P805, DOI 10.7326/0003-4819-109-10-805; FOWKES FGR, 1991, INT J EPIDEMIOL, V20, P384, DOI 10.1093/ije/20.2.384; GORELICK PB, 1992, STROKE, V23, P804, DOI 10.1161/01.STR.23.6.804; HAAPANEN A, 1989, CIRCULATION, V80, P10, DOI 10.1161/01.CIR.80.1.10; HEISS G, 1991, AM J EPIDEMIOL, V134, P250, DOI 10.1093/oxfordjournals.aje.a116078; HENDRIE HC, 1989, AM J NEURORADIOL, V10, P703; HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007; HUNT AL, 1989, NEUROLOGY, V39, P1470, DOI 10.1212/WNL.39.11.1470; JUNGQUIST G, 1991, J CLIN EPIDEMIOL, V44, P347, DOI 10.1016/0895-4356(91)90073-I; JUNQUE C, 1990, ARCH NEUROL-CHICAGO, V47, P151, DOI 10.1001/archneur.1990.00530020047013; KAPPELLE LJ, 1988, STROKE, V19, P1093, DOI 10.1161/01.STR.19.9.1093; KERTESZ A, 1988, ARCH NEUROL-CHICAGO, V45, P404, DOI 10.1001/archneur.1988.00520280050015; LECHNER H, 1988, STROKE, V19, P263, DOI 10.1161/01.STR.19.2.263; MIRSEN TR, 1991, ARCH NEUROL-CHICAGO, V48, P1015, DOI 10.1001/archneur.1991.00530220031015; NORRVING B, 1989, STROKE, V20, P59, DOI 10.1161/01.STR.20.1.59; PIGNOLI P, 1986, CIRCULATION, V74, P1399, DOI 10.1161/01.CIR.74.6.1399; POLI A, 1988, ATHEROSCLEROSIS, V70, P253, DOI 10.1016/0021-9150(88)90176-1; PSATY BM, 1992, JAMA-J AM MED ASSOC, V268, P1287, DOI 10.1001/jama.268.10.1287; ROSEN GA, 1982, CARDIOVASCULAR SURVE; SALONEN R, 1990, ATHEROSCLEROSIS, V81, P33, DOI 10.1016/0021-9150(90)90056-O; SAVAGE RM, 1977, CIRCULATION, V55, P279, DOI 10.1161/01.CIR.55.2.279; SCHNEIDER R, 1987, J NEUROL, V234, P67, DOI 10.1007/BF00314104; SCHROLL M, 1981, J CHRON DIS, V34, P261, DOI 10.1016/0021-9681(81)90031-X; STARY HC, 1992, ARTERIOSCLER THROMB, V12, P120, DOI 10.1161/01.ATV.12.1.120; TAYLOR DC, 1987, J CLIN ULTRASOUND, V15, P635, DOI 10.1002/jcu.1870150906; VANGENT CM, 1977, CLIN CHIM ACTA, V75, P243, DOI 10.1016/0009-8981(77)90195-4; VANSWIETEN JC, 1991, ANN NEUROL, V30, P825, DOI 10.1002/ana.410300612; VANSWIETEN JC, 1991, BRAIN, V114, P761; VOGT MT, 1992, J CLIN EPIDEMIOL, V45, P529, DOI 10.1016/0895-4356(92)90102-S; WENDELHAG I, 1992, ARTERIOSCLER THROMB, V12, P70, DOI 10.1161/01.ATV.12.1.70; WENDELHAG I, 1991, CLIN PHYSIOL, V11, P565, DOI 10.1111/j.1475-097X.1991.tb00676.x	39	310	312	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 15	1993	341	8855					1232	1237		10.1016/0140-6736(93)91144-B	http://dx.doi.org/10.1016/0140-6736(93)91144-B			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LC497	8098390	Green Submitted			2022-12-28	WOS:A1993LC49700002
J	[Anonymous]				[Anonymous]			HIV SEROCONVERSION AFTER OCCUPATIONAL EXPOSURE DESPITE EARLY PROPHYLACTIC ZIDOVUDINE THERAPY	LANCET			English	Article							INFECTION											BRUNVEZINET F, 1992, J VIROL METHODS, V37, P177, DOI 10.1016/0166-0934(92)90045-F; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; FAHRNER R, 1992, 8 INT C AIDS 3 STD W; GILL N, 1992, OCCUPATIONAL TRANSMI; HO DD, 1989, NEW ENGL J MED, V321, P1625; JEFFRIES DJ, 1991, BRIT MED J, V302, P1349, DOI 10.1136/bmj.302.6789.1349; LANGE JMA, 1990, NEW ENGL J MED, V322, P1375, DOI 10.1056/NEJM199005103221907; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LOOKE DFM, 1990, LANCET, V335, P1280, DOI 10.1016/0140-6736(90)91343-9; PORTER JD, 1990, LANCET, V335, P113, DOI 10.1016/0140-6736(90)90582-P; ROOKE R, 1989, AIDS, V3, P411, DOI 10.1097/00002030-198907000-00001; 1984, LANCET, V2, P1376	12	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 24	1993	341	8852					1077	1078						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ018	8096971				2022-12-28	WOS:A1993KZ01800018
J	MARCHIONNI, MA; GOODEARL, ADJ; CHEN, MS; BERMINGHAMMCDONOGH, O; KIRK, C; HENDRICKS, M; DANEHY, F; MISUMI, D; SUDHALTER, J; KOBAYASHI, K; WROBLEWSKI, D; LYNCH, C; BALDASSARE, M; HILES, I; DAVIS, JB; HSUAN, JJ; TOTTY, NF; OTSU, M; MCBURNEY, RN; WATERFIELD, MD; STROOBANT, P; GWYNNE, D				MARCHIONNI, MA; GOODEARL, ADJ; CHEN, MS; BERMINGHAMMCDONOGH, O; KIRK, C; HENDRICKS, M; DANEHY, F; MISUMI, D; SUDHALTER, J; KOBAYASHI, K; WROBLEWSKI, D; LYNCH, C; BALDASSARE, M; HILES, I; DAVIS, JB; HSUAN, JJ; TOTTY, NF; OTSU, M; MCBURNEY, RN; WATERFIELD, MD; STROOBANT, P; GWYNNE, D			GLIAL GROWTH-FACTORS ARE ALTERNATIVELY SPLICED ERBB2 LIGANDS EXPRESSED IN THE NERVOUS-SYSTEM	NATURE			English	Article							SCHWANN-CELL PROLIFERATION; PERIPHERAL-NERVE; NEU ONCOGENE; GENE; ETHYLNITROSOUREA; IDENTIFICATION; REGENERATION; DEGENERATION; MITOGENS; CULTURE	Glial growth factors, proteins that are mitogenic for Schwann cells, and several ligands for the p185erbB2 receptor, are products of the same gene. Alternative splicing of the messenger RNA generates an array of putative membrane-attached, intracellular and secreted signalling proteins, at least some of which are expressed in the developing spinal cord and brain. These factors are probably important in the development and regeneration of the nervous system.	LUDWIG INST CANC RES,LONDON W1P 8BT,ENGLAND; COLUMBIA UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10032	Ludwig Institute for Cancer Research; Columbia University; Howard Hughes Medical Institute	MARCHIONNI, MA (corresponding author), CAMBRIDGE NEUROSCI INC,1 KENDALL SQ,BLDG 700,CAMBRIDGE,MA 02139, USA.		Goodearl, Andrew/AAP-5501-2020; Hsuan, Justin/C-8825-2009	Hsuan, Justin/0000-0001-6083-7564; Bermingham-McDonogh, Olivia/0000-0002-2559-4218				ACHESON A, 1991, NEURON, V7, P265, DOI 10.1016/0896-6273(91)90265-2; Aguayo A.J., 1985, SYNAPTIC PLASTICITY, P457; AGUAYO AJ, 1976, BRAIN RES, V104, P1, DOI 10.1016/0006-8993(76)90643-0; ALTMAN J, 1984, ADV ANATOMY EMBRYOLO, V85; BAEHR M, 1989, EXP NEUROL, V106, P27, DOI 10.1016/0014-4886(89)90141-6; BAICHWAL RR, 1988, P NATL ACAD SCI USA, V85, P1701, DOI 10.1073/pnas.85.5.1701; BHATTACHARYYA A, 1992, J NEUROBIOL, V23, P451, DOI 10.1002/neu.480230410; BROCKES JP, 1984, SCIENCE, V225, P1280, DOI 10.1126/science.6474177; BROCKES JP, 1986, ANN NEUROL, V20, P317, DOI 10.1002/ana.410200308; BROCKES JP, 1979, BRAIN RES, V165, P105, DOI 10.1016/0006-8993(79)90048-9; BUNGE RP, 1986, ANNU REV NEUROSCI, V9, P305; BUNGE RP, 1992, DIS NERV SYST, P87; CHAN AML, 1991, SCIENCE, V254, P1382, DOI 10.1126/science.1720571; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COHEN JA, 1992, J NEUROSCI RES, V31, P622, DOI 10.1002/jnr.490310406; DAVIS JB, 1990, J CELL BIOL, V110, P1353, DOI 10.1083/jcb.110.4.1353; DOOLITTLE RF, 1984, NATURE, V307, P558, DOI 10.1038/307558a0; ECCLESTON PA, 1992, EXP CELL RES, V199, P1, DOI 10.1016/0014-4827(92)90455-H; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FAWCETT JW, 1990, ANNU REV NEUROSCI, V13, P43, DOI 10.1146/annurev.neuro.13.1.43; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; Jessen K R, 1992, Curr Opin Neurobiol, V2, P575, DOI 10.1016/0959-4388(92)90021-C; KALLUNKI P, 1992, J CELL BIOL, V116, P559, DOI 10.1083/jcb.116.2.559; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; Le Douarin N.M., 1982, NEURAL CREST; LEMKE GE, 1984, J NEUROSCI, V4, P75; LU X, 1991, J NEUROSCI, V11, P972; LUPU R, 1992, J STEROID BIOCHEM, V43, P229, DOI 10.1016/0960-0760(92)90212-2; MATSUOKA I, 1991, J NEUROSCI, V11, P3165; MUIR D, 1989, NEUROCHEM RES, V14, P1003, DOI 10.1007/BF00965935; NIKITIN AY, 1991, P NATL ACAD SCI USA, V88, P9939, DOI 10.1073/pnas.88.22.9939; NORDLUND M, 1992, GLIA, V5, P182, DOI 10.1002/glia.440050304; PELLEGRINO RG, 1986, J NEUROCYTOL, V15, P17, DOI 10.1007/BF02057901; PERANTONI AO, 1987, P NATL ACAD SCI USA, V84, P6317, DOI 10.1073/pnas.84.17.6317; RAFF MC, 1978, CELL, V15, P813, DOI 10.1016/0092-8674(78)90266-0; SALZER JL, 1980, J CELL BIOL, V84, P753, DOI 10.1083/jcb.84.3.753; SALZER JL, 1980, J CELL BIOL, V84, P739, DOI 10.1083/jcb.84.3.739; Sambrook J, 1989, MOL CLONING LABORATO; SANDROCK AW, 1987, BRAIN RES, V425, P360, DOI 10.1016/0006-8993(87)90520-8; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHWAB ME, 1985, J NEUROSCI, V5, P2415; SENDTNER M, 1992, J CELL BIOL, V118, P139, DOI 10.1083/jcb.118.1.139; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	51	716	781	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 25	1993	362	6418					312	318		10.1038/362312a0	http://dx.doi.org/10.1038/362312a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KU176	8096067				2022-12-28	WOS:A1993KU17600050
J	FRIEDMAN, MA; CHABNER, BA; TRIMBLE, EL; ADAMS, J; ARBUCK, SG				FRIEDMAN, MA; CHABNER, BA; TRIMBLE, EL; ADAMS, J; ARBUCK, SG			UNREALISTIC EXPECTATIONS IN THE DIAGNOSIS AND TREATMENT OF OVARIAN-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter											FRIEDMAN, MA (corresponding author), NIH,BETHESDA,MD 20892, USA.		Trimble, Edward/J-9647-2019	Trimble, Edward/0000-0001-5028-0598				EINZIG A I, 1990, Proceedings of the American Association for Cancer Research Annual Meeting, V31, P187; MCGUIRE WP, 1989, ANN INTERN MED, V111, P273, DOI 10.7326/0003-4819-111-4-273; SAROSY G, 1992, P AN M AM SOC CLIN, V11, P226; THIGPEN T, 1990, P AN M AM SOC CLIN, V9, P156	4	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 4	1993	328	9					664	664						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP680	8094229				2022-12-28	WOS:A1993KP68000022
J	ONEILL, P				ONEILL, P			MENINGITIS - HOW LONG TO TREAT BACTERIAL-MENINGITIS	LANCET			English	Editorial Material							CEFTRIAXONE; CHILDREN; CHLORAMPHENICOL; MULTICENTER; CEFUROXIME; AMPICILLIN; THERAPY				ONEILL, P (corresponding author), DUDLEY RD GEN HOSP, DEPT MICROBIOL, BIRMINGHAM B18 7QH, W MIDLANDS, ENGLAND.		Henry, David/AAJ-4332-2020	Henry, David/0000-0003-2934-2242				JADAVJI T, 1986, PEDIATRICS, V78, P21; LIN TY, 1985, JAMA-J AM MED ASSOC, V253, P3559, DOI 10.1001/jama.253.24.3559; MACFARLANE JT, 1979, T ROY SOC TROP MED H, V73, P693, DOI 10.1016/0035-9203(79)90023-3; MARKS WA, 1986, J PEDIATR-US, V109, P123, DOI 10.1016/S0022-3476(86)80591-1; MARTIN E, 1990, INFECTION, V18, P70, DOI 10.1007/BF01641418; MCCRACKEN GH, 1987, PEDIATR INFECT DIS J, V6, P501, DOI 10.1097/00006454-198706000-00001; PELTOLA H, 1992, LANCET, V340, P592, DOI 10.1016/0140-6736(92)92117-X; PELTOLA H, 1989, LANCET, V1, P1281; SCHAAD UB, 1990, NEW ENGL J MED, V322, P141, DOI 10.1056/NEJM199001183220301; WALI SS, 1979, T ROY SOC TROP MED H, V73, P698, DOI 10.1016/0035-9203(79)90024-5	10	20	23	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 27	1993	341	8844					530	530		10.1016/0140-6736(93)90287-Q	http://dx.doi.org/10.1016/0140-6736(93)90287-Q			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP083	8094780				2022-12-28	WOS:A1993KP08300013
J	MIDDLETON, SJ; SHORTHOUSE, M; HUNTER, JO				MIDDLETON, SJ; SHORTHOUSE, M; HUNTER, JO			INCREASED NITRIC-OXIDE SYNTHESIS IN ULCERATIVE-COLITIS	LANCET			English	Note							L-ARGININE; NITRATES; CELLS	Nitric oxide (NO) is produced in tissues by NO synthase with the liberation of equimolar amounts of citrulline. Citrulline concentrations were significantly higher in rectal biopsy specimens from patients with active ulcerative colitis than in those from patients with quiescent disease or with normal histology. Incubation of biopsy samples from patients with ulcerative colitis with N(G)-monomethyl-L-arginine (L-NMMA) inhibited citrulline production. These findings suggest that mucosal NO biosynthesis is increased in active colitis and that NO may have a pathogenic role in ulcerative colitis.			MIDDLETON, SJ (corresponding author), ADDENBROOKES HOSP,DEPT GASTROENTEROL,CAMBRIDGE CB2 2QQ,ENGLAND.							EINARSSON S, 1983, J CHROMATOGR, V282, P609, DOI 10.1016/S0021-9673(00)91638-8; HEGESH E, 1982, CLIN CHIM ACTA, V125, P107, DOI 10.1016/0009-8981(82)90187-5; HIBBS JB, 1987, J IMMUNOL, V138, P550; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; MCCALL TB, 1989, BIOCHEM J, V261, P293, DOI 10.1042/bj2610293; MIDDLETON SJ, 1991, GUT, V32, pA1248; MONCADA S, 1991, PHARMACOL REV, V43, P109; PARK KGM, 1991, LANCET, V337, P645, DOI 10.1016/0140-6736(91)92456-C; ROEDIGER WEW, 1990, DIS COLON RECTUM, V33, P1034, DOI 10.1007/BF02139219; YEATES RA, 1985, MOL PHARMACOL, V28, P555	10	332	348	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 20	1993	341	8843					465	466		10.1016/0140-6736(93)90211-X	http://dx.doi.org/10.1016/0140-6736(93)90211-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN137	8094492				2022-12-28	WOS:A1993KN13700008
J	VANHERWEGHEM, JL; DEPIERREUX, M; TIELEMANS, C; ABRAMOWICZ, D; DRATWA, M; JADOUL, M; RICHARD, C; VANDERVELDE, D; VERBEELEN, D; VANHAELENFASTRE, R; VANHAELEN, M				VANHERWEGHEM, JL; DEPIERREUX, M; TIELEMANS, C; ABRAMOWICZ, D; DRATWA, M; JADOUL, M; RICHARD, C; VANDERVELDE, D; VERBEELEN, D; VANHAELENFASTRE, R; VANHAELEN, M			RAPIDLY PROGRESSIVE INTERSTITIAL RENAL FIBROSIS IN YOUNG-WOMEN - ASSOCIATION WITH SLIMMING REGIMEN INCLUDING CHINESE HERBS	LANCET			English	Article							NEPHRITIS; NEPHROPATHY; DISEASE	Two similar cases of rapidly progressive fibrosing interstitial nephritis in young women who followed the same slimming regimen prompted us to conduct an epidemiological survey of the nephrology centres of Brussels and to further investigate the exact nature of this slimming treatment. Seven other women under the age of 50 in terminal or preterminal renal failure were admitted for dialysis in 1991 and 1992. They had all followed a slimming regimen in the same medical clinic. Renal biopsy samples in eight of the nine cases showed extensive interstitial fibrosis without glomerular lesions. Two of the patients were seen for the first time in terminal renal failure and were started immediately on dialysis. For the seven other women, the nephropathy was characterised by a rapid deterioration in renal function, with initial serum creatinine doubling within about 3 months. The clinic had specialised in slimming treatments for the previous 15 years without any problems. In May, 1990, therapy was changed, with the introduction of two Chinese herbs (Stephania tetrandra and Magnolia officinalis). In June, 1992, three of twenty-five randomly selected women who had followed the same regimen during at least 3 months from 1990 had impaired renal function. Chemical analysis of some brands of these Chinese herbs did not show nephrotoxic contaminants of fungal or plant origin (ochratoxin or aristolochic acid) or adulteration by diuretics or antiinflammatory drugs. However, the medicinal preparation of the capsules taken by patients had different alkaloid profiles from those expected in Chinese plants. The striking relation between a specific type of fibrosing interstitial nephritis in young women and a slimming treatment involving Chinese herbs adds support to the arguments against uncontrolled therapy with herbal preparations.	UNIV LIBRE BRUXELLES,DEPT NEPHROL,B-1050 BRUSSELS,BELGIUM; UNIV LIBRE BRUXELLES,DEPT PATHOL,B-1050 BRUSSELS,BELGIUM; UNIV LIBRE BRUXELLES,PHARMACOGNOSY & BROMATOL LAB,B-1050 BRUSSELS,BELGIUM; UNIV LIBRE BRUXELLES,HOP BRUGMANN,B-1050 BRUSSELS,BELGIUM; UNIV LIBRE BRUXELLES,INST E CARELL,B-1050 BRUSSELS,BELGIUM; UNIV LIBRE BRUXELLES,HOP BRACEPS,B-1050 BRUSSELS,BELGIUM; AKAD ZICKENHUIS,BRUSSELS,BELGIUM; VRIJE UNIV BRUSSELS,B-1050 BRUSSELS,BELGIUM; UNIV CATHOLIQUE LOUVAIN,CLIN UNIV ST LUC,B-1200 BRUSSELS,BELGIUM	Universite Libre de Bruxelles; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Universite Libre de Bruxelles; Universite Libre de Bruxelles; Universite Libre de Bruxelles; Universite Libre de Bruxelles; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc			Abramowicz, Daniel/F-7578-2017; Jadoul, Michel/B-8779-2008	Abramowicz, Daniel/0000-0002-6556-9199; 				ARREY D, 1992, ANN INTERN MED, V117, P129; BARNES JM, 1977, LANCET, V1, P671; BENNETT WM, 1977, ANN INTERN MED, V87, P582, DOI 10.7326/0003-4819-87-5-582; CHANG HM, 1986, PHARM APPLICATION CH; CHE YH, 1985, HDB CHINESE HERBS FO; ELSEVIERS MM, 1988, NEPHROL DIAL TRANSPL, V2, P143; EMMERSON BT, 1970, ANN INTERN MED, V73, P854, DOI 10.7326/0003-4819-73-5-854; GUOSHI TU, 1988, PHARMACOPOEIA PEOPLE; HELD PJ, 1990, AM J KIDNEY DIS S2, V26, P22; HUXTABLE RJ, 1992, ANN INTERN MED, V117, P165, DOI 10.7326/0003-4819-117-2-165; HUXTABLE RJ, 1986, NEW ENGL J MED, V315, P1095; Ivic M, 1970, ACTA FAC MEICARE NA, V1, P9; Jackson BP, 1968, POWDERED VEGETABLE D; JORKASKY DK, 1988, SEMIN NEPHROL, V8, P62; KROCH P, 1977, ACTA PATH MICROBIO B, V85, P238; MURRAY T, 1975, ANN INTERN MED, V82, P453, DOI 10.7326/0003-4819-82-4-453; NEILSON EG, 1989, KIDNEY INT, V35, P1257, DOI 10.1038/ki.1989.118; SEGASOTHY M, 1991, NEPHRON, V59, P166, DOI 10.1159/000186543; STEFANOVIC V, 1991, AM J NEPHROL, V11, P1, DOI 10.1159/000168264; STILLMAN AE, 1977, GASTROENTEROLOGY, V73, P349; Tang W., 1992, CHINESE DRUGS PLANT, P639; Tang W.C., 1992, CHINESE DRUGS PLANT, P963; TOTO RD, 1990, AM J MED SCI, V299, P392, DOI 10.1097/00000441-199006000-00007; Tufveson G, 1989, NEPHROL DIAL TRAN S4, V4, P5; VANHERWEGHEM JL, 1982, CLIN NEPHROL, V17, P129; 1990, DRUG INFORMATION H A, V1, P813	26	821	953	6	101	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 13	1993	341	8842					387	391		10.1016/0140-6736(93)92984-2	http://dx.doi.org/10.1016/0140-6736(93)92984-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM416	8094166				2022-12-28	WOS:A1993KM41600001
J	PARKER, SE; DAVEY, PG				PARKER, SE; DAVEY, PG			ANTIMICROBIAL THERAPY - ONCE-DAILY AMINOGLYCOSIDE DOSING	LANCET			English	Editorial Material							CRITICALLY ILL				PARKER, SE (corresponding author), UNIV DUNDEE,NINEWELLS HOSP & MED SCH,PHARMACOECON RES CTR,DUNDEE DD1 9SY,SCOTLAND.							BRUSHWOOD DB, 1992, AM J HOSP PHARM, V49, P1748, DOI 10.1093/ajhp/49.7.1748; FLINT LM, 1985, ARCH SURG-CHICAGO, V120, P99; LABOVITZ E, 1974, ANTIMICROB AGENTS CH, V6, P465, DOI 10.1128/AAC.6.4.465; MARIK PE, 1991, J ANTIMICROB CHEMOTH, V27, P81, DOI 10.1093/jac/27.suppl_C.81; PARKER SE, 1992, PHARMACOECONOMICS, V2, P103; PARKER SE, IN PRESS J ANTIMICRO; SUMMER WR, 1983, CRIT CARE MED, V11, P948, DOI 10.1097/00003246-198312000-00011	7	17	17	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 6	1993	341	8841					346	347		10.1016/0140-6736(93)90143-5	http://dx.doi.org/10.1016/0140-6736(93)90143-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK939	8094120				2022-12-28	WOS:A1993KK93900011
J	TATE, JJT; LAU, WY; LEUNG, KL; LI, AKC				TATE, JJT; LAU, WY; LEUNG, KL; LI, AKC			LAPAROSCOPIC VERSUS MINI-INCISION CHOLECYSTECTOMY	LANCET			English	Letter											TATE, JJT (corresponding author), PRINCE WALES HOSP,DEPT SURG,SHA TIN,HONG KONG.							ASSALIA A, 1993, LANCET, V341, P47; BARKUN JS, 1992, LANCET, V340, P1116, DOI 10.1016/0140-6736(92)93148-G	2	24	24	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 8	1993	341	8854					1214	1215		10.1016/0140-6736(93)91042-K	http://dx.doi.org/10.1016/0140-6736(93)91042-K			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB017	8098100				2022-12-28	WOS:A1993LB01700036
J	BARNETT, DB				BARNETT, DB			HEART-FAILURE - DIAGNOSIS OF SYMPTOMLESS LEFT-VENTRICULAR DYSFUNCTION	LANCET			English	Editorial Material											BARNETT, DB (corresponding author), LEICESTER ROYAL INFIRM,DEPT PHARMACOL & THERAPEUT,LEICESTER LE2 7LX,ENGLAND.							CARLSON KJ, 1985, J CHRON DIS, V38, P733, DOI 10.1016/0021-9681(85)90115-8; FRANCIS GS, 1990, CIRCULATION, V82, P1724, DOI 10.1161/01.CIR.82.5.1724; MARANTZ PR, 1988, CIRCULATION, V77, P607, DOI 10.1161/01.CIR.77.3.607; PACKER M, 1992, LANCET, V340, P88, DOI 10.1016/0140-6736(92)90405-R; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; REMES J, 1991, EUR HEART J, V12, P315, DOI 10.1093/oxfordjournals.eurheartj.a059896; REMES J, 1991, CARDIOLOGY, V78, P267, DOI 10.1159/000174793; WHEELDON NM, 1993, Q J MED, V86, P17; 1992, NEW ENGL J MED, V327, P685	9	8	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 1	1993	341	8853					1124	1125		10.1016/0140-6736(93)93132-K	http://dx.doi.org/10.1016/0140-6736(93)93132-K			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ687	8097808				2022-12-28	WOS:A1993KZ68700008
J	KOOT, M; KEET, IPM; VOS, AHV; DEGOEDE, REY; ROOS, MTL; COUTINHO, RA; MIEDEMA, F; SCHELLEKENS, PTA; TERSMETTE, M				KOOT, M; KEET, IPM; VOS, AHV; DEGOEDE, REY; ROOS, MTL; COUTINHO, RA; MIEDEMA, F; SCHELLEKENS, PTA; TERSMETTE, M			PROGNOSTIC VALUE OF HIV-1 SYNCYTIUM-INDUCING PHENOTYPE FOR RATE OF CD4+ CELL DEPLETION AND PROGRESSION TO AIDS	ANNALS OF INTERNAL MEDICINE			English	Article						ANTIGENS, CD4; HUMAN IMMUNODEFICIENCY VIRUS TYPE-1; HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS; GIANT CELLS; ACQUIRED IMMUNODEFICIENCY SYNDROME	HUMAN-IMMUNODEFICIENCY-VIRUS; SEROPOSITIVE HOMOSEXUAL MEN; REPLICATIVE CAPACITY; NATURAL-HISTORY; IMMUNE-SYSTEM; INFECTION; VARIANTS; TROPISM; TYPE-1; PATHOGENESIS	Objective: To investigate the relation between detection of syncytium-inducing (SI), human immunodeficiency virus type 1 (HIV-1) variants, rate of CD4+ cell decline, and clinical progression. Design: Prospective study during a 2.5-year follow-up period; cohort study with pairwise matched controls. Setting: The Amsterdam cohort study on the course of HIV-1 infection in homosexual men. Participants: Asymptomatic HIV-1-infected men (n = 225) were tested for the presence of SI variants and were studied prospectively for CD4+ cell decline and clinical progression. In addition, 45 men with a defined moment of appearance of SI variants and 45 matched controls without SI variants were compared for CD4+ cell decline. Measurements: Syncytium-inducing variants were detected by cocultivation of peripheral blood mononuclear cells with the MT-2 T-cell line. Results: During a 30-month period, 70.8% of the men with SI variants progressed to AIDS, compared with 15.8% of men without SI variants at entry (P <0.0001). Multivariable Cox proportional hazard analysis, controlling for CD4+ cell count and HIV-p24 antigenemia, showed a relative hazard for SI variants of 6.7 (95% Cl, 3.5 to 12.7). In the matched control study, before the appearance of SI variants, CD4+ cell counts of 45 men with SI variants and their controls were compared. Syncytium-inducing variants emerged at a mean CD4+ cell count of 0.48 x 10(9)/L (Cl, 0.42 to 0.54), coinciding with the onset of a threefold increased rate of CD4+ cell decline. Men developing AIDS with SI variants had decreased CD4+ cell counts (0.08 x 10(9)/L; 95% Cl, 0.05 to 0.12) at the time of diagnosis compared with persons progressing to AIDS without SI variants (0.25 x 10(9)/L; 95% Cl, 0.15 to 0.41) (P = 0.0035). Conclusions: The HIV-1 biological phenotype is a practical, binary marker for progression to AIDS, which is independent of decreased CD4+ cell counts and antigenemia. Appearance of SI variants, occurring 2 years before progression to AIDS on the average, is predictive for a significantly increased rate of CD4+ cell decline.	NETHERLANDS RED CROSS, BLOOD TRANSFUS SERV,CENT LAB, DEPT CLIN VIROIMMUNOL,POB 9406, 1006 AK AMSTERDAM, NETHERLANDS; UNIV AMSTERDAM, AMSTERDAM, NETHERLANDS; MUNICIPAL HLTH SERV, DEPT PUBL HLTH & ENVIRONM, 1000 HE AMSTERDAM, NETHERLANDS	University of Amsterdam								ASJO B, 1986, LANCET, V2, P660; BOUCHER CAB, 1992, AIDS, V6, P1259, DOI 10.1097/00002030-199211000-00003; CHENGMAYER C, 1988, SCIENCE, V240, P80, DOI 10.1126/science.2832945; CLERICI M, 1989, J CLIN INVEST, V84, P1892, DOI 10.1172/JCI114376; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; COREY L, 1992, NEW ENGL J MED, V326, P484, DOI 10.1056/NEJM199202133260710; DEWOLF F, 1988, J INFECT DIS, V158, P615, DOI 10.1093/infdis/158.3.615; EVANS LA, 1987, J IMMUNOL, V138, P3415; EYSTER ME, 1987, ANN INTERN MED, V107, P1, DOI 10.7326/0003-4819-107-1-1; FENYO EM, 1989, AIDS, V3, pS5, DOI 10.1097/00002030-198901001-00002; GROENINK M, 1991, J VIROL, V65, P1968, DOI 10.1128/JVI.65.4.1968-1975.1991; HAHN BH, 1986, SCIENCE, V232, P1548, DOI 10.1126/science.3012778; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; KOOT M, 1992, AIDS, V6, P49, DOI 10.1097/00002030-199201000-00006; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; MIEDEMA F, 1990, IMMUNOL TODAY, V11, P293, DOI 10.1016/0167-5699(90)90116-Q; MIEDEMA F, 1988, J CLIN INVEST, V82, P1908, DOI 10.1172/JCI113809; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; OBRIEN WA, 1990, NATURE, V348, P69, DOI 10.1038/348069a0; PHILLIPS AN, 1991, LANCET, V337, P389; POLK BF, 1987, NEW ENGL J MED, V316, P61, DOI 10.1056/NEJM198701083160201; ROOS MTL, 1992, J INFECT DIS, V165, P427, DOI 10.1093/infdis/165.3.427; SCHELLEKENS PTA, 1992, AIDS, V6, P665, DOI 10.1097/00002030-199207000-00008; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; SCHUITEMAKER H, 1991, J VIROL, V65, P356, DOI 10.1128/JVI.65.1.356-363.1991; SHIODA T, 1991, NATURE, V349, P167, DOI 10.1038/349167a0; TERSMETTE M, 1990, AIDS (London), V4, pS57; TERSMETTE M, 1988, J VIROL, V62, P2026, DOI 10.1128/JVI.62.6.2026-2032.1988; TERSMETTE M, 1989, J VIROL, V63, P2118, DOI 10.1128/JVI.63.5.2118-2125.1989; TERSMETTE M, 1989, LANCET, V1, P983; VANGRIENSVEN GJP, 1989, BMJ-BRIT MED J, V298, P218, DOI 10.1136/bmj.298.6668.218; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; VONBRIESEN H, 1987, J MED VIROL, V23, P51, DOI 10.1002/jmv.1890230107; VONGEGERFELT A, 1991, VIROLOGY, V185, P162, DOI 10.1016/0042-6822(91)90764-3; WARD JW, 1989, NEW ENGL J MED, V321, P947, DOI 10.1056/NEJM198910053211406; 1987, MMWR S, V36, pS1	36	753	766	0	14	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1993	118	9					681	688		10.7326/0003-4819-118-9-199305010-00004	http://dx.doi.org/10.7326/0003-4819-118-9-199305010-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY502	8096374				2022-12-28	WOS:A1993KY50200004
J	BRIGGS, N				BRIGGS, N			MATERNAL HEALTH - ILLITERACY AND MATERNAL HEALTH - EDUCATE OR DIE	LANCET			English	Editorial Material											BRIGGS, N (corresponding author), UNIV PORT HARCOURT,DEPT OBSTET & GYNAECOL,PORT HARCOURT,NIGERIA.		Garattini, Silvio/AAA-6390-2020	Garattini, Silvio/0000-0003-0647-9297				ARMSTRONG S, 1990, NEW SCI         0331, P50; BRIGGS ND, 1991, LANCET, V337, P553, DOI 10.1016/0140-6736(91)91338-U; BRIGGS ND, 1992, CONT REV OBSTET GYNA, V4, P127; HARRISON KA, 1991, LANCET, V338, P382; HARRISON KA, 1992, MASS ILLITERACY IS V; HARRISON KA, 1985, BR J OBSTET GYNAE S5, V92; WHITE SM, 1987, LANCET, V2, P612; 1983, LANCET, V1, P223	8	13	13	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 24	1993	341	8852					1063	1064		10.1016/0140-6736(93)92421-O	http://dx.doi.org/10.1016/0140-6736(93)92421-O			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ018	8096968				2022-12-28	WOS:A1993KZ01800014
J	GELERNTER, J; GOLDMAN, D; RISCH, N				GELERNTER, J; GOLDMAN, D; RISCH, N			THE A1 ALLELE AT THE D2-DOPAMINE RECEPTOR GENE AND ALCOHOLISM - A REAPPRAISAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ASSOCIATION; LOCUS; DRD2	Objective.-An allelic association between the Taq I ''A'' system A1 allele at the D2 dopamine receptor locus (DRD2) and either alcoholism or severe alcoholism has been proposed. Our purpose was to evaluate whether, based on all of the accumulated evidence, this association could be considered to be proven. Data Sources.-We considered data from all published reports of DRD2 allele frequency in alcoholics, controls, or both. Study Selection.-We concentrated on the issue of replication. We therefore considered all data reported (on white samples, because DRD2 allele frequency varies by race and ethnicity) since the first report by Blum et al in 1990. Data Synthesis.-We analyzed the set of data for differences in allele frequencies between alcoholics and controls, and for heterogeneity among samples. We also investigated the influence of the data from the first group to report an association (including a subsequent report from that group) on the findings. Our analysis shows that, when all studies subsequent to the original study are considered, there is no significant difference in DRD2 A1 allele frequency between alcoholics and controls, there is significant heterogeneity among reported alcoholics and reported controls, and there is no significant difference in DRD2A1 allele frequency between severe and not severe alcoholics. Also, the two reports of Blum et al account for all of the (nonsignificant) differences seen between controls, alcoholics, and severe alcoholics. Conclusions.-In general, heterogeneity among studies (for alcoholics or controls) is considerably greater than differences between alcoholics and controls overall. The findings to date can best be explained by more conservative interpretations than a confirmed physiologically important allelic association between DRD2 alleles and alcoholism. These other possibilities include sampling error and ethnic variation in those studies that individually showed a large effect.	YALE UNIV,SCH MED,DEPT PSYCHIAT,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT EPIDEMIOL & PUBL HLTH,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510; NIAAA,NEUROGENET LAB,ROCKVILLE,MD 20852	Yale University; Yale University; Yale University; National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	GELERNTER, J (corresponding author), W HAVEN DEPT VET AFFAIRS MED CTR,950 CAMPBELL AVE,W HAVEN,CT 06516, USA.		Peng, Bo/A-6920-2009; Goldman, David/F-9772-2010; Majid, Salma/AAT-2616-2020	Peng, Bo/0000-0001-8225-2284; Goldman, David/0000-0002-1724-5405; Majid, Salma/0000-0002-1724-5405; Gelernter, Joel/0000-0002-4067-1859	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000348] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [K20MH000931] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG00348] Funding Source: Medline; NIMH NIH HHS [MH00931] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ASTON CE, 1990, AM J HUM GENET, V46, P879; BLUM K, 1990, JAMA-J AM MED ASSOC, V263, P2055, DOI 10.1001/jama.263.15.2055; BLUM K, 1991, ALCOHOL, V8, P409, DOI 10.1016/0741-8329(91)90693-Q; BOLOS AM, 1990, JAMA-J AM MED ASSOC, V264, P3156; CLONINGER CR, 1991, JAMA-J AM MED ASSOC, V266, P1833; COMINGS DE, 1991, JAMA-J AM MED ASSOC, V266, P1793, DOI 10.1001/jama.266.13.1793; COOK BL, 1992, ALCOHOL CLIN EXP RES, V16, P806, DOI 10.1111/j.1530-0277.1992.tb00683.x; GELERNTER J, 1991, JAMA-J AM MED ASSOC, V266, P1801, DOI 10.1001/jama.266.13.1801; GOLDMAN D, 1992, ACTA PSYCHIAT SCAND, V86, P351, DOI 10.1111/j.1600-0447.1992.tb03279.x; Goldman D, 1988, Recent Dev Alcohol, V6, P333; GOLDMAN D, IN PRESS ALCOHOL CLI; GORDIS E, 1990, JAMA-J AM MED ASSOC, V263, P2094, DOI 10.1001/jama.263.15.2094; GRANDY DK, 1989, AM J HUM GENET, V45, P778; HAUGE XY, 1991, GENOMICS, V10, P527, DOI 10.1016/0888-7543(91)90431-D; MONTEIRO E, 1992, AM J HUM GENET S, V51, P145; NOBLE EP, 1991, JAMA-J AM MED ASSOC, V265, P2667, DOI 10.1001/jama.1991.03460200047016; NOBLE EP, 1991, ARCH GEN PSYCHIAT, V48, P648; PARSIAN A, 1991, ARCH GEN PSYCHIAT, V48, P655; SARKAR G, 1991, GENOMICS, V11, P8, DOI 10.1016/0888-7543(91)90096-W; SCHWAB S, 1991, AM J HUM GENET, V49, P203; SMITH SS, 1991, JAMA-J AM MED ASSOC, V265, P2667, DOI 10.1001/jama.1991.03460200047017; TURNER E, 1992, BIOL PSYCHIAT, V31, P285, DOI 10.1016/0006-3223(92)90052-2	22	263	265	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 7	1993	269	13					1673	1677		10.1001/jama.269.13.1673	http://dx.doi.org/10.1001/jama.269.13.1673			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KV349	8095994				2022-12-28	WOS:A1993KV34900033
J	BLASCZYK, R; WESTHOFF, U; GROSSEWILDE, H				BLASCZYK, R; WESTHOFF, U; GROSSEWILDE, H			SOLUBLE CD4, CD8, AND HLA MOLECULES IN COMMERCIAL IMMUNOGLOBULIN PREPARATIONS	LANCET			English	Note							LINKED-IMMUNOSORBENT-ASSAY; ADHESION; BINDING; CELL	CD4 and CD8 exist in membrane-bound and soluble forms. These antigens are the physiological ligands for molecules of HLA classes I and II, which we have found in soluble form in commercial immunoglobulin preparations. We measured concentrations of soluble CD4 and CD8, as well as soluble HLA-ABC and HLA-RQP in sixteen immunoglobulin preparations by enzyme immunosorbent assays. Only two preparations contained detectable CD8, and nine had soluble CD4 in varying amounts. There was great variation in concentrations of soluble HLA molecules. It is possible that the immunomodulating effects of immunoglobulin therapy in disorders with immune aetiology are due, at least partly, to these contaminating molecules.	UNIV ESSEN GESAMTHSCH KLINIKUM,INST IMMUNOL,VIRCHOWSTR 171,W-4300 ESSEN 1,GERMANY	University of Duisburg Essen				Djukanovic, Ratko/0000-0001-6039-5612; Blasczyk, Rainer/0000-0003-3875-3190				CHIA D, 1991, TISSUE ANTIGENS, V37, P49, DOI 10.1111/j.1399-0039.1991.tb01845.x; DOXIADIS I, 1989, BLUT, V59, P449, DOI 10.1007/BF00349066; DOYLE C, 1987, NATURE, V330, P256, DOI 10.1038/330256a0; GROSSEWILDE H, 1992, TISSUE ANTIGENS, V39, P74, DOI 10.1111/j.1399-0039.1992.tb01910.x; LENERT P, 1990, SCIENCE, V248, P1639, DOI 10.1126/science.2363051; ROSENSTEIN Y, 1990, J IMMUNOL, V144, P526; ROSENSTEIN Y, 1989, J EXP MED, V169, P149, DOI 10.1084/jem.169.1.149; SULLIVAN KM, 1990, NEW ENGL J MED, V323, P705, DOI 10.1056/NEJM199009133231103; WESTHOFF U, 1991, VOX SANG, V61, P106, DOI 10.1111/j.1423-0410.1991.tb00255.x; 1991, NEW ENGL J MED, V325, P73	10	152	154	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 27	1993	341	8848					789	790		10.1016/0140-6736(93)90563-V	http://dx.doi.org/10.1016/0140-6736(93)90563-V			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU900	8096001				2022-12-28	WOS:A1993KU90000006
J	AITKENHEAD, AR				AITKENHEAD, AR			POSTOPERATIVE ISCHEMIA - CARDIAC MORBIDITY AFTER NONCARDIAC SURGERY	LANCET			English	Editorial Material							MYOCARDIAL-INFARCTION; ISCHEMIA				AITKENHEAD, AR (corresponding author), UNIV NOTTINGHAM HOSP,QUEENS MED CTR,DEPT ANAESTHESIA,NOTTINGHAM NG7 2UH,ENGLAND.							GEFT IL, 1982, CIRCULATION, V66, P1150, DOI 10.1161/01.CIR.66.6.1150; GILL NP, 1992, BRIT J ANAESTH, V68, P471, DOI 10.1093/bja/68.5.471; MANGANO DT, 1990, NEW ENGL J MED, V323, P1781, DOI 10.1056/NEJM199012273232601; MANGANO DT, 1990, ANESTHESIOLOGY, V72, P153, DOI 10.1097/00000542-199001000-00025; RABY KE, 1989, NEW ENGL J MED, V321, P1296, DOI 10.1056/NEJM198911093211904; RAO TLK, 1983, ANESTHESIOLOGY, V59, P499, DOI 10.1097/00000542-198312000-00003; VONKNORRING J, 1981, SURGERY, V90, P55	7	9	9	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 20	1993	341	8847					731	732		10.1016/0140-6736(93)90496-4	http://dx.doi.org/10.1016/0140-6736(93)90496-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KT362	8095633				2022-12-28	WOS:A1993KT36200013
J	SCHECHTER, MT; CRAIB, KJP; GELMON, KA; MONTANER, JSG; LE, TN; OSHAUGHNESSY, MV				SCHECHTER, MT; CRAIB, KJP; GELMON, KA; MONTANER, JSG; LE, TN; OSHAUGHNESSY, MV			HIV-1 AND THE ETIOLOGY OF AIDS	LANCET			English	Note							HUMAN-IMMUNODEFICIENCY-VIRUS; DISEASE	The belief that HIV-1 infection causes AIDS has been questioned, and the suggestion made that to know the correct cause of AIDS the incidence of disease in patients with and without risk behaviours and with and without antibody to HIV-1 must be known. We describe findings in such a cohort. In 715 homosexual men followed for a median of 8-6 years, all 136 AIDS cases occurred in the 365 individuals with pre-existing HIV-1 antibody. Most men negative for HIV-1 antibody reported risk behaviours but none developed any AIDS illnesses. CD4 counts fell in anti-HIV-1-positive men but remained stable in antibody-negative men, whether or not risk behaviours were present. The hypothesis that AIDS in homosexual men is caused not by HIV-1 infection but by drugs and sexual activity is rejected by these data. HIV-1 has an integral role in the pathogenesis of AIDS.	BRITISH COLUMBIA CTR EXCELLENCE HIV AIDS,VANCOUVER,BC,CANADA; BRITISH COLUMBIA CANC AGCY,VANCOUVER,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT MED,VANCOUVER V6T 1W5,BC,CANADA; ST PAULS HOSP,VANCOUVER V6Z 1Y6,BC,CANADA	B.C. Centre for Excellence in HIV/AIDS; British Columbia Cancer Agency; University of British Columbia; St. Paul's Hospital; University of Saskatchewan	SCHECHTER, MT (corresponding author), UNIV BRITISH COLUMBIA,FAC MED,DEPT HLTH CARE & EPIDEMIOL,5804 FAIRVIEW AVE,VANCOUVER V6T 1Z3,BC,CANADA.		Montaner, Julio/K-7621-2012	Schechter, Martin/0000-0001-6063-2155				DEAN M, 1992, LANCET, V339, P1286, DOI 10.1016/0140-6736(92)91604-7; DUESBERG P, 1988, SCIENCE, V242, P997, DOI 10.1126/science.242.4881.997-b; DUESBERG PH, 1987, CANCER RES, V47, P1199; DUESBERG PH, 1991, P NATL ACAD SCI USA, V88, P1575, DOI 10.1073/pnas.88.4.1575; DUESBERG PH, 1990, RES IMMUNOL, V141, P5, DOI 10.1016/0923-2494(90)90097-I; DUESBERG PH, 1989, P NATL ACAD SCI USA, V86, P755, DOI 10.1073/pnas.86.3.755; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; SCHECHTER MT, 1991, AIDS, V5, P373, DOI 10.1097/00002030-199104000-00003	8	25	25	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 13	1993	341	8846					658	659		10.1016/0140-6736(93)90421-C	http://dx.doi.org/10.1016/0140-6736(93)90421-C			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR613	8095571				2022-12-28	WOS:A1993KR61300005
J	BRILLANTI, S; FOLI, M; GAIANI, S; MASCI, C; MIGLIOLI, M; BARBARA, L				BRILLANTI, S; FOLI, M; GAIANI, S; MASCI, C; MIGLIOLI, M; BARBARA, L			PERSISTENT HEPATITIS-C VIREMIA WITHOUT LIVER-DISEASE	LANCET			English	Note							NON-B-HEPATITIS; LONG-TERM; NON-A; VIRUS; VIREMIA	In viral infections persistence of the virus is not always associated with virus-induced disease. To find out if active hepatitis C virus (HCV) infection can persist without liver disease we selected four symptom-free individuals with antibodies to HCV but normal aminotransferase levels. They were followed up for 3 years by monthly serology and a liver biopsy was done. At presentation, all four had both antibodies to HCV and circulating HCV RNA. During follow-up their sera remained persistently positive for all HCV antibodies and RNA yet aminotransferase levels did not increase and liver biopsy was normal. These findings indicate that persistent hepatitis C viraemia is not invariably associated with liver damage.	UNIV BOLOGNA,DEPT INTERNAL MED & GASTROENTEROL,I-40126 BOLOGNA,ITALY	University of Bologna			Brillanti, Stefano/E-8970-2010	Brillanti, Stefano/0000-0003-4181-795X				ALBERTI A, 1992, LANCET, V340, P697, DOI 10.1016/0140-6736(92)92234-7; BRILLANTI S, 1992, HEPATOLOGY, V15, P998, DOI 10.1002/hep.1840150604; BRILLANTI S, 1991, J MED VIROL, V34, P136, DOI 10.1002/jmv.1890340213; DIBISCEGLIE AM, 1991, HEPATOLOGY, V14, P969, DOI 10.1016/0270-9139(91)90113-A; ESTEBAN JI, 1991, ANN INTERN MED, V115, P443, DOI 10.7326/0003-4819-115-6-443; FARCI P, 1991, NEW ENGL J MED, V325, P98, DOI 10.1056/NEJM199107113250205; GARSON JA, 1990, LANCET, V336, P1022, DOI 10.1016/0140-6736(90)92487-3; WEINER AJ, 1991, VIROLOGY, V180, P842, DOI 10.1016/0042-6822(91)90104-J; ZIGNEGO AL, 1992, J HEPATOL, V15, P382, DOI 10.1016/0168-8278(92)90073-X	9	204	206	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 20	1993	341	8843					464	465		10.1016/0140-6736(93)90210-8	http://dx.doi.org/10.1016/0140-6736(93)90210-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN137	8094491				2022-12-28	WOS:A1993KN13700007
J	CORRAL, J; MARTIN, C; PEREZ, R; SANCHEZ, I; MORIES, MT; MILLAN, JLS; MIRALLES, JM; GONZALEZSARMIENTO, R				CORRAL, J; MARTIN, C; PEREZ, R; SANCHEZ, I; MORIES, MT; MILLAN, JLS; MIRALLES, JM; GONZALEZSARMIENTO, R			THYROGLOBULIN GENE POINT MUTATION ASSOCIATED WITH NONENDEMIC SIMPLE GOITER	LANCET			English	Note							SEQUENCE; ACID	Simple goitre is defined as an enlargement of the thyroid gland that is not the result of an inflammatory or neoplastic process and is not associated with thyrotoxicosis or myxoedema; the cause is unknown in most cases. Structural or regulatory defects in the proteins involved in thyroid metabolism might be involved in the functional abnormality that brings about the disorder. We have found a mutation within exon 10 of the thyroglobulin gene in 25 of 56 members of three families affected by simple goitre; 14 of the gene carriers had the disorder. DNA sequencing showed a mis-sense mutation within thyroglobulin gene exon 10, resulting in a glutamine to histidine substitution. Thus, some cases of non-endemic simple goitre are associated with a mutation at the thyroglobulin locus.	UNIV SALAMANCA,DEPT MED,UNIDAD GENET MOLEC,SALAMANCA,SPAIN; UNIV SALAMANCA,HOSP CLIN,SERV ENDOCRINOL,SALAMANCA,SPAIN; HOSP RAMON Y CAJAL,UNIDAD GENET MOLEC,MADRID,SPAIN	University of Salamanca; University of Salamanca; Hospital Universitario Ramon y Cajal			Gonzalez-Sarmiento, Rogelio/V-5526-2019; San-Millán, José L./F-9944-2015; Perez-Canaveras, Rosa M./N-4108-2014	Gonzalez-Sarmiento, Rogelio/0000-0002-2726-6795; MORIES, MARIA TERESA/0000-0002-0658-7514; Corral, Javier/0000-0003-0288-1107; Perez-Canaveras, Rosa M./0000-0002-8541-2412				ELTE JWF, 1981, NETH J MED, V24, P79; GREIG WR, 1967, Q J MED, V36, P175; LEIRI T, 1991, J CLIN INVEST, V88, P1901; LEVER EG, 1983, ENDOCR REV, V4, P213, DOI 10.1210/edrv-4-3-213; MALTHIERY Y, 1987, EUR J BIOCHEM, V165, P491, DOI 10.1111/j.1432-1033.1987.tb11466.x; MALTHIERY Y, 1989, BIOCHIMIE, V71, P195, DOI 10.1016/0300-9084(89)90057-6; MORIES T, 1991, CLIN SCI, V80, P301, DOI 10.1042/cs0800301; OHMIYA Y, 1990, J BIOL CHEM, V265, P9066; TARGOVNIK H, 1989, J CLIN ENDOCR METAB, V69, P1137, DOI 10.1210/jcem-69-6-1137; TARGOVNIK HM, 1984, EUR J BIOCHEM, V141, P271, DOI 10.1111/j.1432-1033.1984.tb08188.x	10	55	60	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 20	1993	341	8843					462	464		10.1016/0140-6736(93)90209-Y	http://dx.doi.org/10.1016/0140-6736(93)90209-Y			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN137	8094490				2022-12-28	WOS:A1993KN13700006
J	DAHLITZ, M; PARKES, JD				DAHLITZ, M; PARKES, JD			SLEEP PARALYSIS	LANCET			English	Note							NARCOLEPSY; PREVALENCE	Sleep paralysis is a common condition with a prevalence of 5-62%. Although most affected people have single or infrequent episodes, sleep paralysis may be recurrent, or occur in association with the narcoleptic syndrome. In a study of 22 subjects with frequent sleep paralysis and also excessive daytime sleepiness, episodes continued for between 5 and 35 years. In contrast to subjects with the narcoleptic syndrome, these patients did not have cataplexy, daytime sleepiness and insomnia were less severe, and there was no HLA DR2(15) or DQ1(6) association. Sleep paralysis was familial in 19 of these subjects. A non-HLA linked genetic factor, in addition to environmental factors, may thus predispose to sleep paralysis.	UNIV LONDON,INST PSYCHIAT,DEPT NEUROL,DENMARK HILL,LONDON SE5 8AF,ENGLAND; UNIV LONDON KINGS COLL,SCH MED & DENT,LONDON WC2R 2LS,ENGLAND	University of London; University of London; King's College London								Adie WJ, 1926, BRAIN, V49, P257, DOI 10.1093/brain/49.3.257; ANDREASZIETZ A, 1986, LANCET, V2, P684; BELL CC, 1984, J NATL MED ASSOC, V76, P501; DALY DD, 1974, HDB CLIN NEUROL, V15, P836; Firestone M., 1985, J PSYCHOANALYTIC ANT, V8, P47; FUKUDA K, 1987, SLEEP, V10, P279, DOI 10.1093/sleep/10.3.279; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; MACFARLANE AW, 1891, LANCET, V1, P824; Mitchell SW, 1876, VIRGINIA MED MONTHLY, V2, P769; MITLER MM, 1986, SLEEP, V9, P260, DOI 10.1093/sleep/9.1.260; NEELY S, 1987, NEUROLOGY, V37, P1858, DOI 10.1212/WNL.37.12.1858; NESS R C, 1978, Culture Medicine and Psychiatry, V2, P15, DOI 10.1007/BF00052448; SIEGEL JM, 1991, SCIENCE, V252, P1315, DOI 10.1126/science.1925546	13	59	59	0	21	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 13	1993	341	8842					406	407		10.1016/0140-6736(93)92992-3	http://dx.doi.org/10.1016/0140-6736(93)92992-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM416	8094172				2022-12-28	WOS:A1993KM41600007
J	DELCOUR, AH; TSIEN, RW				DELCOUR, AH; TSIEN, RW			ALTERED PREVALENCE OF GATING MODES IN NEUROTRANSMITTER INHIBITION OF N-TYPE CALCIUM CHANNELS	SCIENCE			English	Article							RAT SYMPATHETIC NEURONS; CHICK SENSORY NEURONS; VOLTAGE DEPENDENCE; BINDING PROTEIN; CELL-LINE; MODULATION; ACTIVATION; CURRENTS; GTP; NORADRENALINE	G protein-mediated inhibition of voltage-activated calcium channels by neurotransmitters has important consequences for the control of synaptic strength. Single-channel recordings of N-type calcium channels in frog sympathetic neurons reveal at least three distinct patterns of gating, designated low-P(o), medium-P(o), and high-P(o) modes according to their probability of being open (P(o)) at -10 millivolts. The high-P(o) mode is responsible for the bulk of divalent cation entry in the absence of neurotransmitter. Norepinephrine greatly decreased the prevalence of high-P(o) gating and increased the proportion of time a channel exhibited low-P(o) behavior or no activity at all, which thereby reduced the overall current. Directly observed patterns of transition between the various modes suggest that activated G protein alters the balance between modal behaviors that freely interconvert even in the absence of modulatory signaling.	STANFORD UNIV,MED CTR,BECKMAN CTR,DEPT MOLEC & CELLULAR PHYSIOL,STANFORD,CA 94305	Stanford University					NHLBI NIH HHS [HL13156] Funding Source: Medline; NINDS NIH HHS [NS24607] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANWYL R, 1991, BRAIN RES REV, V16, P265, DOI 10.1016/0165-0173(91)90010-6; BEAN BP, 1989, NATURE, V340, P153, DOI 10.1038/340153a0; BEECH DJ, 1992, NEURON, V8, P97, DOI 10.1016/0896-6273(92)90111-P; BEVAN JA, 1984, FED PROC, V43, P1365; BOLAND LM, 1993, J NEUROSCI, V13, P516; CARBONE E, 1989, PROG BIOPHYS MOL BIO, V54, P31, DOI 10.1016/0079-6107(89)90008-4; DELCOUR AH, IN PRESS J NEUROSCI; DOLPHIN AC, 1987, J PHYSIOL-LONDON, V386, P1; DOLPHIN AC, 1990, ANNU REV PHYSIOL, V52, P243; DUNLAP K, 1981, J PHYSIOL-LONDON, V317, P519, DOI 10.1113/jphysiol.1981.sp013841; DUNLAP K, 1978, NATURE, V276, P837, DOI 10.1038/276837a0; ELMSLIE KS, 1990, NEURON, V5, P75, DOI 10.1016/0896-6273(90)90035-E; EWALD DA, 1988, P NATL ACAD SCI USA, V85, P3633, DOI 10.1073/pnas.85.10.3633; FENWICK EM, 1982, J PHYSIOL-LONDON, V331, P599, DOI 10.1113/jphysiol.1982.sp014394; FORSCHER P, 1986, J PHYSIOL-LONDON, V379, P131, DOI 10.1113/jphysiol.1986.sp016244; GALVAN M, 1982, BRAIN RES, V244, P135, DOI 10.1016/0006-8993(82)90911-8; GRASSI F, 1989, NEUROSCI LETT, V105, P113, DOI 10.1016/0304-3940(89)90021-9; GROSS RA, 1987, P NATL ACAD SCI USA, V84, P5469, DOI 10.1073/pnas.84.15.5469; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HESS P, 1984, NATURE, V311, P538, DOI 10.1038/311538a0; HOLZ GG, 1986, NATURE, V319, P670, DOI 10.1038/319670a0; IKEDA SR, 1991, J PHYSIOL-LONDON, V439, P181, DOI 10.1113/jphysiol.1991.sp018663; JONES SW, 1991, BIOPHYS J, V60, P502, DOI 10.1016/S0006-3495(91)82077-X; KASAI H, 1992, J PHYSIOL-LONDON, V448, P189, DOI 10.1113/jphysiol.1992.sp019036; KASAI H, 1989, PFLUEGERS ARCH, V414, P415; KURACHI Y, 1990, PFLUG ARCH EUR J PHY, V416, P216, DOI 10.1007/BF00370247; LIPSCOMBE D, 1989, NATURE, V340, P639, DOI 10.1038/340639a0; LOPEZ HS, 1991, NEURON, V7, P1061, DOI 10.1016/0896-6273(91)90350-9; MARCHETTI C, 1989, BIOPHYS J, V56, P1267, DOI 10.1016/S0006-3495(89)82774-2; MARCHETTI C, 1986, PFLUG ARCH EUR J PHY, V406, P104, DOI 10.1007/BF00586670; MARKS TN, 1992, J GEN PHYSIOL, V99, P367, DOI 10.1085/jgp.99.3.367; MATHIE A, 1992, NEURON, V8, P907, DOI 10.1016/0896-6273(92)90205-R; MCMANUS OB, 1988, J PHYSIOL-LONDON, V402, P79, DOI 10.1113/jphysiol.1988.sp017195; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; PLUMMER MR, 1991, J NEUROSCI, V11, P2339; SCHULTZ G, 1990, ANNU REV PHYSIOL, V52, P275, DOI 10.1146/annurev.ph.52.030190.001423; TSIEN RW, 1988, TRENDS NEUROSCI, V11, P431, DOI 10.1016/0166-2236(88)90194-4; WANKE E, 1987, P NATL ACAD SCI USA, V84, P4313, DOI 10.1073/pnas.84.12.4313; YUE DT, 1990, P NATL ACAD SCI USA, V87, P753, DOI 10.1073/pnas.87.2.753	39	90	91	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 12	1993	259	5097					980	984		10.1126/science.8094902	http://dx.doi.org/10.1126/science.8094902			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL800	8094902				2022-12-28	WOS:A1993KL80000046
J	BOYD, O; MACKAY, CJ; LAMB, G; BLAND, JM; GROUNDS, RM; BENNETT, ED				BOYD, O; MACKAY, CJ; LAMB, G; BLAND, JM; GROUNDS, RM; BENNETT, ED			COMPARISON OF CLINICAL INFORMATION GAINED FROM ROUTINE BLOOD-GAS ANALYSIS AND FROM GASTRIC TONOMETRY FOR INTRAMURAL PH	LANCET			English	Article							CRITICALLY ILL PATIENTS; ABDOMINAL INJURY; BASE DEFICIT; OPERATIONS; INDICATOR; ACIDOSIS; TRAUMA; INDEX	The measurement of gastric intramucosal pH (pH(i)) has been advocated to assist in decision-making for critically ill patients. To assess whether the information obtained from the measurement of pH(i) can be obtained from other measurements of metabolic acidosis, we studied 20 consecutive patients admitted to the intensive care unit. A mean of eight (range two to fourteen) data sets per patient were obtained, comprising measurement of arterial pH, pO2, pCO2, and oxygen saturation, tonometer balloon fluid pCO2, arterial pressures, and cardiac output. Bicarbonate concentration, base deficit or excess in blood and extracellular fluid, and pH(i) were calculated from these measurements. Relations between the variables and pH(i) were assessed by within-subject correlation comparisons. There were significant correlations (r>0.6, p<0.001) between markers of metabolic acidosis (base deficit in blood and extracellular fluid and bicarbonate concentration) and pH(i). A blood base deficit of -4.65 or less and an extracellular-fluid base deficit of -6.13 or less could estimate pH(i) below 7.32 (lower limit of normal range) with sensitivity of at least 77% and specificity of at least 96%. There was no patient in whom either pH(i) or blood base deficit consistently reflected acidosis when the other variable did not. We conclude that the information that is obtained by gastric tonometry for pH(i) can be obtained more simply from measurements of metabolic acidosis, these variables can be calculated from routinely available blood-gas measurements.	ST GEORGE HOSP,DEPT PUBL HLTH MED,LONDON SW17 0QT,ENGLAND	St Georges University London	BOYD, O (corresponding author), ST GEORGE HOSP,GEN INTENS CARE UNIT,BLACKSHAW RD,LONDON SW17 0QT,ENGLAND.							ANTONSSON JB, 1990, AM J PHYSIOL, V259, pG519, DOI 10.1152/ajpgi.1990.259.4.G519; ARIEFF AI, 1989, UPDATE INTENSIVE CAR, P322; BERSIN RM, 1990, AM J MED, V87, P7; BRIDGES KG, 1985, CRIT CARE MED, V13, P72, DOI 10.1097/00003246-198502000-00003; COOPER DJ, 1990, ANN INTERN MED, V112, P492, DOI 10.7326/0003-4819-112-7-492; DAVIS JW, 1991, SURG GYNECOL OBSTET, V173, P473; DAVIS JW, 1991, ANN EMERG MED, V20, P842, DOI 10.1016/S0196-0644(05)81423-4; DOGLIO GR, 1991, CRIT CARE MED, V19, P1037, DOI 10.1097/00003246-199108000-00011; DUMOULIN GC, 1982, LANCET, V1, P242; FIDDIANGREEN RG, 1991, CRIT CARE MED, V19, P141, DOI 10.1097/00003246-199102000-00004; FIDDIANGREEN RG, 1987, CRIT CARE MED, V15, P153, DOI 10.1097/00003246-198702000-00015; FIDDIANGREEN RG, 1987, CRIT CARE MED, V15, P835, DOI 10.1097/00003246-198709000-00007; FIDDIANGREEN RG, 1989, SPLANCHNIC ISCHEMIA, P349; GUTIERREZ G, 1992, CRIT CARE MED, V20, P451, DOI 10.1097/00003246-199204000-00004; GUTIERREZ G, 1992, LANCET, V339, P195, DOI 10.1016/0140-6736(92)90002-K; GYS T, 1988, CRIT CARE MED, V16, P1222, DOI 10.1097/00003246-198812000-00009; HEARD SO, 1991, CRIT CARE MED, V19, P271, DOI 10.1097/00003246-199102000-00025; KNIGHTGEORGE AB, 1990, CLIN INTENSIVE CARE, V1, P249; LANDOW L, 1991, CRIT CARE MED, V19, P1226, DOI 10.1097/00003246-199110000-00003; MACKERSIE RC, 1989, ARCH SURG-CHICAGO, V124, P809; MORAES NLT, 1979, ACUTE CARE, P6; SEVERINGHAUS JW, 1976, ANESTHESIOLOGY, V45, P539; SHIEDLER MG, 1987, ARCH SURG-CHICAGO, V122, P881; SIEGEL JH, 1990, ARCH SURG-CHICAGO, V125, P498; SIGGAARDANDERSE.O, 1963, SCAND J CLIN LAB INV, V15, P211, DOI 10.3109/00365516309079734; SILVERMAN HJ, 1991, CRIT CARE MED, V19, P1223, DOI 10.1097/00003246-199110000-00001	26	100	101	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 16	1993	341	8838					142	146		10.1016/0140-6736(93)90005-2	http://dx.doi.org/10.1016/0140-6736(93)90005-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG627	8093745				2022-12-28	WOS:A1993KG62700005
J	VANTRAPPEN, G				VANTRAPPEN, G			GASTROENTEROLOGY - ACUTE COLONIC PSEUDOOBSTRUCTION	LANCET			English	Editorial Material							PSEUDOOBSTRUCTION OGILVIES SYNDROME				VANTRAPPEN, G (corresponding author), CATHOLIC UNIV LEUVEN,DEPT MED,B-3000 LOUVAIN,BELGIUM.							BONACINI M, 1991, J CLIN GASTROENTEROL, V13, P475, DOI 10.1097/00004836-199108000-00024; FAULK DL, 1978, GASTROENTEROLOGY, V74, P922; HEIMBACH DM, 1971, SURGERY, V69, P582; HUTCHINSON R, 1992, ANN ROY COLL SURG, V74, P364; MACCOLL C, 1990, GASTROENTEROLOGY, V98, P773, DOI 10.1016/0016-5085(90)90301-G; SLOYER AF, 1988, DIGEST DIS SCI, V33, P1391, DOI 10.1007/BF01536993; VANEK VW, 1986, DIS COLON RECTUM, V29, P203, DOI 10.1007/BF02555027	7	22	24	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 16	1993	341	8838					152	153		10.1016/0140-6736(93)90010-E	http://dx.doi.org/10.1016/0140-6736(93)90010-E			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG627	8093750				2022-12-28	WOS:A1993KG62700010
J	WOOSTER, R; NEUHAUSEN, SL; MANGION, J; QUIRK, Y; FORD, D; COLLINS, N; NGUYEN, K; SEAL, S; TRAN, T; AVERILL, D; FIELDS, P; MARSHALL, G; NAROD, S; LENOIR, GM; LYNCH, H; FEUNTEUN, J; DEVILEE, P; CORNELISSE, CJ; MENKO, FH; DALY, PA; ORMISTON, W; MCMANUS, R; PYE, C; LEWIS, CM; CANNONALBRIGHT, LA; PETO, J; PONDER, BAJ; SKOLNICK, MH; EASTON, DF; GOLDGAR, DE; STRATTON, MR				WOOSTER, R; NEUHAUSEN, SL; MANGION, J; QUIRK, Y; FORD, D; COLLINS, N; NGUYEN, K; SEAL, S; TRAN, T; AVERILL, D; FIELDS, P; MARSHALL, G; NAROD, S; LENOIR, GM; LYNCH, H; FEUNTEUN, J; DEVILEE, P; CORNELISSE, CJ; MENKO, FH; DALY, PA; ORMISTON, W; MCMANUS, R; PYE, C; LEWIS, CM; CANNONALBRIGHT, LA; PETO, J; PONDER, BAJ; SKOLNICK, MH; EASTON, DF; GOLDGAR, DE; STRATTON, MR			LOCALIZATION OF A BREAST-CANCER SUSCEPTIBILITY GENE, BRCA2, TO CHROMOSOME 13Q12-13	SCIENCE			English	Article							ANDROGEN RECEPTOR GENE; FAMILIAL BREAST; LINKAGE ANALYSIS; ATAXIA-TELANGIECTASIA; OVARIAN-CANCER; P53 GENE; MUTATIONS; HETEROZYGOSITY; CARCINOMA; LOCUS	A small proportion oi breast cancer, in particular those cases arising at a young age, is due to the inheritance of dominant susceptibility genes conferring a high risk of the disease. A genomic linkage search was performed with 15 high-risk breast cancer families that were unlinked to the BRCA1 locus on chromosome 17q21. This analysis localized a second breast cancer susceptibility locus, BRCA2, to a 6-centimorgan interval on chromosome 13q12-13. Preliminary evidence suggests that BRCA2 confers a high risk of breast cancer but, unlike BRCA1, does not confer a substantially elevated risk of ovarian cancer.	INST CANC RES, EPIDEMIOL SECT, SUTTON SM2 5NG, SURREY, ENGLAND; INST CANC RES, MOLEC CARCINOGENESIS SECT, SUTTON SM2 5NG, SURREY, ENGLAND; MCGILL UNIV, DIV HUMAN GENET, MONTREAL H3G 1A4, PQ, CANADA; MCGILL UNIV, DEPT MED, DIV MED GENET, MONTREAL H3G 1A4, PQ, CANADA; CREIGHTON UNIV, SCH MED, DEPT PREVENT MED & PUBL HLTH, OMAHA, NE 68178 USA; INT AGCY RES CANC, F-69372 LYON 08, FRANCE; INST GUSTAVE ROUSSY, VILLEJUIF, FRANCE; LEIDEN UNIV, DEPT PATHOL, 2333 AL LEIDEN, NETHERLANDS; LEIDEN UNIV, DEPT HUMAN GENET, 2333 AL LEIDEN, NETHERLANDS; FREE UNIV AMSTERDAM, DEPT CLIN GENET, 1007 MB AMSTERDAM, NETHERLANDS; UNIV IRELAND TRINITY COLL, ST JAMES HOSP, SCH MED, DEPT MED, DUBLIN 8, IRELAND; UNIV CAMBRIDGE, DEPT PATHOL, CRC, HUMAN CANC GENET GRP, CAMBRIDGE CB2 1QP, ENGLAND; UNIV UTAH, DEPT INTERNAL MED, SALT LAKE CITY, UT 84132 USA	University of London; Institute of Cancer Research - UK; University of London; Institute of Cancer Research - UK; McGill University; McGill University; Creighton University; World Health Organization; International Agency for Research on Cancer (IARC); UNICANCER; Gustave Roussy; Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC; Vrije Universiteit Amsterdam; Trinity College Dublin; University of Cambridge; Utah System of Higher Education; University of Utah			Lewis, Cathryn M/A-5225-2010; Narod, Steven A/AAA-6112-2022; DEVILEE, PETER/ABR-2140-2022; Feunteun, Jean/AAZ-1267-2020; Lewis, Cathryn/M-8766-2019; McManus, Ross/AAE-9236-2020	Lewis, Cathryn M/0000-0002-8249-8476; Lewis, Cathryn/0000-0002-8249-8476; Feunteun, Jean/0000-0003-1212-9189; albright, lisa/0000-0003-2602-3668; McManus, Ross/0000-0002-0529-9617	NATIONAL CANCER INSTITUTE [P01CA048711] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000571] Funding Source: NIH RePORTER; NCI NIH HHS [CA-48711, CN-05222] Funding Source: Medline; NHGRI NIH HHS [HG-00571] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		BIRCH JM, 1994, CANCER RES, V54, P1298; BISHOP DT, 1988, GENET EPIDEMIOL, V5, P151, DOI 10.1002/gepi.1370050303; CANNONALBRIGHT LA, 1992, SCIENCE, V258, P1148, DOI 10.1126/science.1439824; CLAUS EB, 1993, AM J HUM GENET, V53, P787; COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252; DENG G, 1994, CANCER RES, V54, P499; DEVILEE P, 1989, GENOMICS, V5, P554, DOI 10.1016/0888-7543(89)90023-2; EASTON D, UNPUB; EASTON DF, 1993, AM J HUM GENET, V52, P678; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; KHO CJ, 1992, P NATL ACAD SCI USA, V89, P2200, DOI 10.1073/pnas.89.6.2200; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LOBACCARO JM, 1993, NAT GENET, V5, P109, DOI 10.1038/ng1093-109; LUNDBERG C, 1987, P NATL ACAD SCI USA, V84, P2372, DOI 10.1073/pnas.84.8.2372; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; NAROD SA, 1991, LANCET, V338, P82; OTT J, 1985, ANAL HUMAN GENETIC L, P200; PROSSER J, 1991, BRIT J CANCER, V63, P181, DOI 10.1038/bjc.1991.44; ROSNET O, 1993, ONCOGENE, V8, P173; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STRATTON MR, 1994, NAT GENET, V7, P103, DOI 10.1038/ng0594-103; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TOGUCHIDA J, 1993, GENOMICS, V17, P535, DOI 10.1006/geno.1993.1368; WARREN W, 1992, ONCOGENE, V7, P1043; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WOOSTER R, 1992, NAT GENET, V2, P132, DOI 10.1038/ng1092-132; WOOSTER R, 1993, HUM GENET, V92, P91, DOI 10.1007/BF00216153; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152	31	1458	1524	2	71	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 30	1994	265	5181					2088	2090		10.1126/science.8091231	http://dx.doi.org/10.1126/science.8091231			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PJ912	8091231				2022-12-28	WOS:A1994PJ91200028
J	BRANDEIS, M; FRANK, D; KESHET, I; SIEGFRIED, Z; MENDELSOHN, M; NEMES, A; TEMPER, V; RAZIN, A; CEDAR, H				BRANDEIS, M; FRANK, D; KESHET, I; SIEGFRIED, Z; MENDELSOHN, M; NEMES, A; TEMPER, V; RAZIN, A; CEDAR, H			SP1 ELEMENTS PROTECT A CPG ISLAND FROM DE-NOVO METHYLATION	NATURE			English	Article							DNA METHYLATION; TRANSCRIPTION FACTOR; DENOVO METHYLATION; MOUSE EMBRYO; GENE; PROMOTER; CELLS; DEMETHYLATION; PATTERNS; TISSUES	ANIMAL somatic cell DNA is characterized by a bimodal pattern of methylation: tissue-specific genes are methylated in most cell types whereas housekeeping genes have 5' CpG islands which are constitutively unmethylated(1,2). Because methyl moieties derived from the gametes are erased in the morula and early blastula(3), this profile must be re-established in every generation; this is apparently accomplished by a wave of non-CpG island de novo methylation that occurs at implantation(4). Using transfection into embryonic stem cells and transgenic mice as a model system, we now show that Sp1 elements play a key role in protecting a CpG island in the adenine phosphoribosyltransferase (APRT) gene from de novo methylation. This recognition mechanism represents a critical step in embryogenesis; as it is responsible for setting up the correct genome methylation pattern which, in turn, is involved in regulating basal gene expression in the organism(5).	TECHNION ISRAEL INST TECHNOL, BRUCE RAPPAPORT FAC MED, DEPT BIOCHEM, IL-31096 HAIFA, ISRAEL; COLUMBIA UNIV, SCH MED, CTR NEUROBIOL & BEHAV, NEW YORK, NY 10032 USA	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Columbia University	BRANDEIS, M (corresponding author), HEBREW UNIV JERUSALEM, SCH MED, DEPT CELLULAR BIOCHEM, IL-91120 JERUSALEM, ISRAEL.							BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CEDAR H, 1982, COLD SPRING HARB SYM, V47, P605, DOI 10.1101/SQB.1983.047.01.071; CHOI YC, 1993, MOL CELL BIOL, V13, P5538, DOI 10.1128/MCB.13.9.5538; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; EDEN S, 1994, CURR OPIN GENET DEV, V4, P255, DOI 10.1016/S0959-437X(05)80052-8; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FRANK D, 1991, NATURE, V351, P239, DOI 10.1038/351239a0; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; HOGAN B, 1986, MANIPULATING MOUSE E; HOLLER M, 1988, GENE DEV, V2, P1127, DOI 10.1101/gad.2.9.1127; JAHNER D, 1982, NATURE, V298, P623, DOI 10.1038/298623a0; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705; KOLSTO AB, 1986, NUCLEIC ACIDS RES, V14, P9667; LICHTENSTEIN M, 1994, CELL, V76, P913, DOI 10.1016/0092-8674(94)90365-4; LOCK LF, 1987, CELL, V48, P39, DOI 10.1016/0092-8674(87)90353-9; LOWY I, 1980, CELL, V22, P817, DOI 10.1016/0092-8674(80)90558-9; MACLEOD D, IN PRESS GENES DEV; MONK M, 1987, DEVELOPMENT, V99, P371; MUMMANENI P, 1993, J BIOL CHEM, V268, P552; PFEIFER GP, 1990, GENE DEV, V4, P1277, DOI 10.1101/gad.4.8.1277; RAZIN A, 1994, CELL, V77, P473, DOI 10.1016/0092-8674(94)90208-9; SHEMER R, 1991, J BIOL CHEM, V266, P23676; STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R; SZYF M, 1990, MOL CELL BIOL, V10, P4396, DOI 10.1128/MCB.10.8.4396; VANDERPLOEG LHT, 1980, CELL, V19, P947, DOI 10.1016/0092-8674(80)90086-0; YISRAELI J, 1984, DNA METHYLATION BIOC, P353	28	630	645	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 29	1994	371	6496					435	438		10.1038/371435a0	http://dx.doi.org/10.1038/371435a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PJ285	8090226				2022-12-28	WOS:A1994PJ28500048
J	NEER, EJ; SCHMIDT, CJ; NAMBUDRIPAD, R; SMITH, TF				NEER, EJ; SCHMIDT, CJ; NAMBUDRIPAD, R; SMITH, TF			THE ANCIENT REGULATORY-PROTEIN FAMILY OF WD-REPEAT PROTEINS	NATURE			English	Article							BETA-TRANSDUCIN REPEATS; SACCHAROMYCES-CEREVISIAE; BINDING PROTEIN; GENE-PRODUCT; DROSOPHILA ENHANCER; NEGATIVE REGULATOR; EARLY EVOLUTION; GAMMA-SUBUNITS; CDC4 GENE; YEAST	WD proteins are made up of highly conserved repeating units usually ending with Trp-Asp (WD). They are found in all eukaryotes but not in prokaryotes. They regulate cellular functions, such as cell division, cell-fate determination, gene transcription, transmembrane signalling, mRNA modification and vesicle fusion. Here we define the common features of the repeating units, and criteria for grouping such proteins into functional subfamilies.	HARVARD UNIV,SCH MED,BOSTON,MA; BOSTON UNIV,DEPT PHARMACOL,BOSTON,MA 02215; BOSTON UNIV,BIOMOLEC ENGN RES CTR,BOSTON,MA 02215	Harvard University; Harvard Medical School; Boston University; Boston University	NEER, EJ (corresponding author), BRIGHAM & WOMENS HOSP,DEPT MED,75 FRANCIS ST,BOSTON,MA 02115, USA.			Schmidt, Carl/0000-0002-8386-4781				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARTAVANISTSAKONAS S, 1991, ANNU REV CELL BIOL, V7, P427; BANROQUES J, 1989, MOL CELL BIOL, V9, P3710, DOI 10.1128/MCB.9.9.3710; BERGSAGEL PL, 1992, ONCOGENE, V17, P2059; BORDONNE R, 1990, GENE DEV, V4, P1185, DOI 10.1101/gad.4.7.1185; BUBIS J, 1990, J BIOL CHEM, V265, P12995; CHOI WJ, 1990, BIOCHEM BIOPH RES CO, V172, P1324, DOI 10.1016/0006-291X(90)91594-I; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; CLARK MA, 1991, P NATL ACAD SCI USA, V88, P5418, DOI 10.1073/pnas.88.12.5418; DEHOSTOS EL, 1993, J CELL BIOL, V120, P163, DOI 10.1083/jcb.120.1.163; DENG XW, 1992, CELL, V71, P791, DOI 10.1016/0092-8674(92)90555-Q; DISATNIK MH, 1994, P NATL ACAD SCI USA, V91, P559, DOI 10.1073/pnas.91.2.559; DURONIO RJ, 1992, PROTEINS, V13, P41, DOI 10.1002/prot.340130105; DYNLACHT BD, 1993, NATURE, V363, P176, DOI 10.1038/363176a0; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; GAO B, 1987, P NATL ACAD SCI USA, V84, P6122, DOI 10.1073/pnas.84.17.6122; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; GUILLEMOT F, 1989, P NATL ACAD SCI USA, V86, P4594, DOI 10.1073/pnas.86.12.4594; HARRISONLAVOIE KJ, 1993, EMBO J, V12, P2847, DOI 10.1002/j.1460-2075.1993.tb05946.x; HATTORI M, 1994, NATURE, V370, P216, DOI 10.1038/370216a0; HEALY AM, 1991, MOL CELL BIOL, V11, P5767, DOI 10.1128/MCB.11.11.5767; HERMAN PK, 1991, CELL, V64, P425, DOI 10.1016/0092-8674(91)90650-N; ICHO T, 1988, J BIOL CHEM, V263, P1467; ISHIDA S, 1993, P NATL ACAD SCI USA, V90, P11152, DOI 10.1073/pnas.90.23.11152; JANSEN R, 1993, EMBO J, V12, P2549, DOI 10.1002/j.1460-2075.1993.tb05910.x; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KNOLL AH, 1992, SCIENCE, V256, P622, DOI 10.1126/science.1585174; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KUMAR S, 1994, J BIOL CHEM, V269, P11318; LEVINE MA, 1990, P NATL ACAD SCI USA, V87, P2329, DOI 10.1073/pnas.87.6.2329; LILLY P, 1993, GENE DEV, V7, P986, DOI 10.1101/gad.7.6.986; MARTINEZOYANEDEL J, 1991, J MOL BIOL, V222, P335, DOI 10.1016/0022-2836(91)90215-R; MAYER RE, 1991, BIOCHEMISTRY-US, V30, P3589, DOI 10.1021/bi00229a001; MAYERJAEKEL RE, 1993, CELL, V72, P621, DOI 10.1016/0092-8674(93)90080-A; MORRIS SC, 1993, NATURE, V361, P219, DOI 10.1038/361219a0; NEER EJ, 1993, NAT GENET, V4, P3; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; PETERSENBJORN S, 1989, MOL CELL BIOL, V9, P3698; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PRYER NK, 1993, J CELL BIOL, V120, P865, DOI 10.1083/jcb.120.4.865; QIAN YW, 1993, NATURE, V364, P648, DOI 10.1038/364648a0; REINER O, 1993, NATURE, V364, P717, DOI 10.1038/364717a0; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; RUGGIERI R, 1989, P NATL ACAD SCI USA, V86, P8778, DOI 10.1073/pnas.86.22.8778; RYBA NJP, 1991, BIOCHEM J, V273, P225, DOI 10.1042/bj2730225; SCHLOSS JA, 1990, MOL GEN GENET, V221, P443, DOI 10.1007/BF00259410; SCHMIDT CJ, 1993, J BIOL CHEM, V268, P25681; SCHMIDT CJ, 1991, J BIOL CHEM, V266, P4538; SETHI N, 1991, MOL CELL BIOL, V11, P5592, DOI 10.1128/MCB.11.11.5592; SHAW DR, 1989, MOL GEN GENET, V218, P453, DOI 10.1007/BF00332409; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V25, P1; SHERWOOD PW, 1993, MOL CELL BIOL, V13, P28, DOI 10.1128/MCB.13.1.28; SMITH RF, 1990, P NATL ACAD SCI USA, V87, P118, DOI 10.1073/pnas.87.1.118; Sneath P.H.A., 1973, NUMERICAL TAXONOMY; SPEVAK W, 1993, MOL CELL BIOL, V13, P4953, DOI 10.1128/MCB.13.8.4953; STENBECK G, 1993, EMBO J, V12, P2841, DOI 10.1002/j.1460-2075.1993.tb05945.x; STIFANI S, 1992, NAT GENET, V2, P119, DOI 10.1038/ng1092-119; SWOFFORD DL, 1985, PAUP USERS GUIDE; TAKAGAKI Y, 1992, J BIOL CHEM, V267, P23471; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; VANDERVOORN L, 1992, FEBS LETT, V307, P131, DOI 10.1016/0014-5793(92)80751-2; VANDERVOORN L, 1990, J MOL BIOL, V213, P17, DOI 10.1016/S0022-2836(05)80118-4; VONWEIZSACKER E, 1992, BIOCHEM BIOPH RES CO, V183, P350, DOI 10.1016/0006-291X(92)91650-F; WEINSTEIN J, 1994, MOL CELL BIOL, V14, P3350, DOI 10.1128/MCB.14.5.3350; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3; WILLIAMS FE, 1991, MOL CELL BIOL, V11, P3307, DOI 10.1128/MCB.11.6.3307; YARFITZ S, 1991, NEURON, V7, P429, DOI 10.1016/0896-6273(91)90295-B; YI F, 1991, J BIOL CHEM, V266, P3900	68	1283	1360	2	67	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 22	1994	371	6495					297	300		10.1038/371297a0	http://dx.doi.org/10.1038/371297a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH254	8090199				2022-12-28	WOS:A1994PH25400042
J	COULTER, A				COULTER, A			GYNECOLOGY - MANAGING MENORRHAGIA WITH ENDOMETRIAL RESECTION	LANCET			English	Editorial Material							ABLATION				COULTER, A (corresponding author), UNIV OXFORD,HLTH SERV RES UNIT,OXFORD,ENGLAND.		Coulter, Angela/N-6998-2019	Coulter, Angela/0000-0002-6308-8375				COULTER A, 1991, BRIT J OBSTET GYNAEC, V98, P789, DOI 10.1111/j.1471-0528.1991.tb13484.x; DWYER N, 1993, BRIT J OBSTET GYNAEC, V100, P237, DOI 10.1111/j.1471-0528.1993.tb15237.x; FRASER IS, 1984, AM J OBSTET GYNECOL, V149, P788, DOI 10.1016/0002-9378(84)90123-6; GANNON MJ, 1991, BRIT MED J, V303, P1362, DOI 10.1136/bmj.303.6814.1362; GARRY R, 1991, BRIT J OBSTET GYNAEC, V98, P357, DOI 10.1111/j.1471-0528.1991.tb13425.x; MACDONALD R, 1990, BRIT J OBSTET GYNAEC, V97, P3, DOI 10.1111/j.1471-0528.1990.tb01709.x; MAGOS AL, 1991, LANCET, V337, P1473; MILSOM I, 1991, AM J OBSTET GYNECOL, V164, P879, DOI 10.1016/S0002-9378(11)90533-X; PHIPPS JH, 1990, LANCET, V335, P374, DOI 10.1016/0140-6736(90)90207-L; SCULPHER MJ, 1993, BRIT J OBSTET GYNAEC, V100, P244, DOI 10.1111/j.1471-0528.1993.tb15238.x; SLADE RJ, 1991, LANCET, V337, P1473, DOI 10.1016/0140-6736(91)93159-7; VESSEY MP, 1992, BRIT J OBSTET GYNAEC, V99, P402, DOI 10.1111/j.1471-0528.1992.tb13758.x	12	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 8	1993	341	8854					1185	1186		10.1016/0140-6736(93)91008-A	http://dx.doi.org/10.1016/0140-6736(93)91008-A			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB017	8098081				2022-12-28	WOS:A1993LB01700010
J	SPIETH, J; BROOKE, G; KUERSTEN, S; LEA, K; BLUMENTHAL, T				SPIETH, J; BROOKE, G; KUERSTEN, S; LEA, K; BLUMENTHAL, T			OPERONS IN C-ELEGANS - POLYCISTRONIC MESSENGER-RNA PRECURSORS ARE PROCESSED BY TRANSSPLICING OF SL2 TO DOWNSTREAM CODING REGIONS	CELL			English	Article							CAENORHABDITIS-ELEGANS; LEADER SEQUENCE; ADENOSINE-TRIPHOSPHATASE; POLYADENYLATION SIGNAL; TRIMETHYLGUANOSINE CAP; POLYMERASE-II; GENE FAMILY; INVITRO; TRANSCRIPTION; PROTEIN	The MRNAs of six C. elegans genes are known to be trans-spliced to SL2. We report here that a similarly oriented gene is located 100-300 bp upstream of each. We present evidence that the genes in these clusters are cotranscribed and downstream mRNAs are formed by cleavage at the polyadenylation site and trans-splicing. From one three-gene cluster we isolated cDNA clones representing both polycistronic RNAs and mRNAs polyadenylated at the free 3' end created by trans-splicing, suggesting that polycistronic RNAs can be processed by trans-splicing. Several experiments indicate that SL2 trans-splicing is a consequence of a gene's downstream location in an operon. In particular, when an SL1-accepting gene was moved to a downstream location, its mRNA was trans-spliced largely to SL2. The possible regulatory significance of cotranscription of C. elegans genes is discussed.			SPIETH, J (corresponding author), INDIANA UNIV,DEPT BIOL,BLOOMINGTON,IN 47405, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM013595, R56GM042432, R01GM042432, R01GM030870] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30870, GM13595, GM42432] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEKTESH S, 1988, GENE DEV, V2, P1277, DOI 10.1101/gad.2.10.1277; BEKTESH SL, 1988, NUCLEIC ACIDS RES, V16, P5692, DOI 10.1093/nar/16.12.5692; BONNEVILLE JM, 1989, CELL, V59, P1135, DOI 10.1016/0092-8674(89)90769-1; BRENNER S, 1974, GENETICS, V77, P71; CONNELLY S, 1988, GENE DEV, V2, P440, DOI 10.1101/gad.2.4.440; CONRAD R, 1993, EMBO J, V12, P1249, DOI 10.1002/j.1460-2075.1993.tb05766.x; CONRAD R, 1991, MOL CELL BIOL, V11, P1921, DOI 10.1128/MCB.11.4.1921; FIRE A, 1989, EMBO J, V8, P3419, DOI 10.1002/j.1460-2075.1989.tb08506.x; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; FRANGIONE B, 1981, P NATL ACAD SCI-BIOL, V78, P7403, DOI 10.1073/pnas.78.12.7403; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; HANNON GJ, 1992, SCIENCE, V258, P1775, DOI 10.1126/science.1465612; HANNON GJ, 1991, J BIOL CHEM, V266, P22792; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; HU E, 1991, J BIOL CHEM, V266, P19796; Huang X Y, 1992, Genet Eng (N Y), V14, P211; HUANG XY, 1989, J MOL BIOL, V206, P411, DOI 10.1016/0022-2836(89)90490-7; HUANG XY, 1989, P NATL ACAD SCI USA, V86, P8640, DOI 10.1073/pnas.86.22.8640; JOHNSON PJ, 1987, CELL, V51, P273, DOI 10.1016/0092-8674(87)90154-1; KRAMER JM, 1990, MOL CELL BIOL, V10, P2081, DOI 10.1128/MCB.10.5.2081; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; KUWABARA PE, 1992, MOL BIOL CELL, V3, P461, DOI 10.1091/mbc.3.4.461; LEE SJ, 1991, P NATL ACAD SCI USA, V88, P4250, DOI 10.1073/pnas.88.10.4250; LEE YH, 1992, GENE, V121, P227, DOI 10.1016/0378-1119(92)90126-A; LEWIN B, 1990, GENES, V4; LIOU RF, 1990, MOL CELL BIOL, V10, P1764, DOI 10.1128/MCB.10.4.1764; LOGAN J, 1987, P NATL ACAD SCI USA, V84, P8306, DOI 10.1073/pnas.84.23.8306; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MUHICH ML, 1988, MOL CELL BIOL, V8, P3837, DOI 10.1128/MCB.8.9.3837; MURPHY WJ, 1986, CELL, V47, P517, DOI 10.1016/0092-8674(86)90616-1; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; NILSEN TW, 1989, MOL CELL BIOL, V9, P3543, DOI 10.1128/MCB.9.8.3543; NIWA M, 1992, NATURE, V360, P277, DOI 10.1038/360277a0; NIWA M, 1990, GENE DEV, V4, P1552, DOI 10.1101/gad.4.9.1552; NIWA M, 1991, GENE DEV, V5, P2086, DOI 10.1101/gad.5.11.2086; NIWA M, 1991, GENE EXPRESSION, V1, P5; OKKEMA PG, 1991, EMBO J, V10, P171, DOI 10.1002/j.1460-2075.1991.tb07933.x; SANDRIGOLDIN RM, 1992, GENE DEV, V6, P848, DOI 10.1101/gad.6.5.848; SHEETS MD, 1987, MOL CELL BIOL, V7, P1518, DOI 10.1128/MCB.7.4.1518; SPIETH J, 1985, MOL CELL BIOL, V5, P2495, DOI 10.1128/MCB.5.10.2495; SPIETH J, 1991, MOL CELL BIOL, V11, P4651, DOI 10.1128/MCB.11.9.4651; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; SUTTON RE, 1986, CELL, V47, P527, DOI 10.1016/0092-8674(86)90617-3; TAKACS AM, 1988, P NATL ACAD SCI USA, V85, P7932, DOI 10.1073/pnas.85.21.7932; THOMAS J, 1990, NUCLEIC ACIDS RES, V18, P2633, DOI 10.1093/nar/18.9.2633; THOMAS JD, 1988, CELL, V54, P533, DOI 10.1016/0092-8674(88)90075-X; TSCHUDI C, 1988, EMBO J, V7, P455, DOI 10.1002/j.1460-2075.1988.tb02833.x; ULLU E, 1993, MOL CELL BIOL, V13, P720, DOI 10.1128/MCB.13.1.720; VANDOREN K, 1990, MOL CELL BIOL, V10, P1769, DOI 10.1128/MCB.10.4.1769; VANDOREN K, 1988, NATURE, V335, P556; WALKER JE, 1987, BIOCHEMISTRY-US, V26, P8613, DOI 10.1021/bi00400a018	52	256	282	3	21	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 7	1993	73	3					521	532		10.1016/0092-8674(93)90139-H	http://dx.doi.org/10.1016/0092-8674(93)90139-H			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LA743	8098272				2022-12-28	WOS:A1993LA74300013
J	TERKUILE, FO; DOLAN, G; NOSTEN, F; EDSTEIN, MD; LUXEMBURGER, C; PHAIPUN, L; CHONGSUPHAJAISIDDHI, T; WEBSTER, HK; WHITE, NJ				TERKUILE, FO; DOLAN, G; NOSTEN, F; EDSTEIN, MD; LUXEMBURGER, C; PHAIPUN, L; CHONGSUPHAJAISIDDHI, T; WEBSTER, HK; WHITE, NJ			HALOFANTRINE VERSUS MEFLOQUINE IN TREATMENT OF MULTIDRUG-RESISTANT FALCIPARUM-MALARIA	LANCET			English	Article							THAI-BURMESE BORDER; SULFADOXINE-PYRIMETHAMINE; PLASMODIUM-FALCIPARUM; EFFICACY; TRIALS	The continuing spread of multidrug resistance in Plasmodium falciparum malaria makes the search for alternative treatments ever more urgent. We have investigated the relative efficacy of halofantrine and mefloquine in two paired randomised trials on the Thai-Burmese border, a multidrug-resistant area. In the first trial, 198 patients with acute uncomplicated falciparum malaria were randomly assigned either the standard halofantrine regimen (24 mg/kg) or mefloquine (25 mg/kg). The cumulative failure rates by day 28 were 35% with halofantrine and 10% with mefloquine (p = 0.0002). In the second study of 437 patients, a higher dose of halofantrine (8 mg/kg every 8 h for 3 days = 72 mg/kg) was both more effective and better tolerated than mefloquine 25 mg/kg; the failure rates were 3% and 8% (p = 0.03), respectively, or 1% vs 6% after adjustment for possible reinfections (p = 0.009). The rate of failure was higher after retreatment than after primary treatment in all study groups. Halofantrine 72 mg/kg was especially effective in the retreatment of these recrudescent infections, the failure rate was 44% with mefloquine and 15% with high-dose halofantrine (relative risk 3.0 [95% Cl 1.2-7.3], p = 0.008). Thus, high-dose halofantrine is better tolerated and more effective than mefloquine for the treatment of uncomplicated falciparum malaria in this area. However, evidence of possible cardiotoxicity will need to be investigated fully before a role can be established for halofantrine in the treatment of multidrug-resistant malaria.	MAHIDOL UNIV,FAC TROP MED,420-6 RAJVITHI RD,BANGKOK 10400,THAILAND; MALARIA RES UNIT,MAE SOT,THAILAND; US ARMED FORCES RES INST MED SCI,BANGKOK,THAILAND; UNIV AMSTERDAM,ACAD MED CTR,INFECT DIS & TROP MED UNIT,1105 AZ AMSTERDAM,NETHERLANDS; JOHN RADCLIFFE HOSP,NUFFIELD DEPT CLIN MED,OXFORD OX3 9DU,ENGLAND	Mahidol University; Walter Reed Army Institute of Research (WRAIR); Armed Forces Research Institute of Medical Science (AFRIMS); University of Amsterdam; Academic Medical Center Amsterdam; University of Oxford			White, Nick/AAC-6527-2019; Kuile, Feiko ter/ABD-6681-2020; Nosten, Francois/AAC-5509-2019; White, Nicholas J/I-4629-2012	White, Nick/0000-0002-1897-1978; Kuile, Feiko ter/0000-0003-3663-5617; Nosten, Francois/0000-0002-7951-0745; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Armitage P., 1975, SEQUENTIAL MED TRIAL; BOUDREAU EF, 1988, B WORLD HEALTH ORGAN, V66, P227; BOUDREAU EF, 1990, CLIN PHARMACOL THER, V48, P399, DOI 10.1038/clpt.1990.168; DESOUZA JM, 1985, B WORLD HEALTH ORGAN, V63, P603; EDSTEIN MD, 1991, THER DRUG MONIT, V13, P146, DOI 10.1097/00007691-199103000-00010; KARBWANG J, 1991, BRIT J CLIN PHARMACO, V31, P484, DOI 10.1111/j.1365-2125.1991.tb05567.x; KEERATITHAKUL D, 1991, THER DRUG MONIT, V13, P64, DOI 10.1097/00007691-199101000-00009; KETRANGSEE S, 1992, Southeast Asian Journal of Tropical Medicine and Public Health, V23, P55; LOOAREESUWAN S, 1992, LANCET, V339, P821, DOI 10.1016/0140-6736(92)90276-9; LOOAREESUWAN S, 1992, LANCET, V339, P369, DOI 10.1016/0140-6736(92)91690-A; MILTON KA, 1989, BRIT J CLIN PHARMACO, V28, P71, DOI 10.1111/j.1365-2125.1989.tb03507.x; NOSTEN F, 1993, LANCET, V341, P1054, DOI 10.1016/0140-6736(93)92412-M; NOSTEN F, 1987, B WORLD HEALTH ORGAN, V65, P891; NOSTEN F, 1991, LANCET, V337, P1140, DOI 10.1016/0140-6736(91)92798-7; SHANKS DG, 1992, T R SOC TROP MED HYG, V86, P233; SHANKS GD, 1991, AM J TROP MED HYG, V45, P488, DOI 10.4269/ajtmh.1991.45.488; TERKUILE FO, 1992, J INFECT DIS, V166, P1393, DOI 10.1093/infdis/166.6.1393; WATKINS WM, 1988, LANCET, V2, P247; WEBSTER HK, 1985, AM J TROP MED HYG, V34, P1022, DOI 10.4269/ajtmh.1985.34.1022; WHITE NJ, 1992, J ANTIMICROB CHEMOTH, V30, P571, DOI 10.1093/jac/30.5.571; WIRIMA J, 1988, LANCET, V2, P250; WONGSRICHANALAI C, 1992, AM J TROP MED HYG, V47, P112, DOI 10.4269/ajtmh.1992.47.112; 1986, T R SOC TROP MED H S, V80, P1; 1989, LANCET, V2, P537	24	153	153	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 24	1993	341	8852					1044	1049		10.1016/0140-6736(93)92409-M	http://dx.doi.org/10.1016/0140-6736(93)92409-M			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ018	8096956				2022-12-28	WOS:A1993KZ01800002
J	VANDISSEL, JT; VANFURTH, R; COMPIER, BA; FEUTH, HDM; FROLICH, M				VANDISSEL, JT; VANFURTH, R; COMPIER, BA; FEUTH, HDM; FROLICH, M			SURVIVAL IN SELECTED PATIENTS WITH GRAM-NEGATIVE SEPSIS AFTER ADJUNCTIVE THERAPY WITH HA-1A	LANCET			English	Letter									UNIV HOSP LEIDEN,DEPT MED INTENS CARE,2300 RC LEIDEN,NETHERLANDS; UNIV HOSP LEIDEN,DEPT SURG INTENS CARE,2300 RC LEIDEN,NETHERLANDS; UNIV HOSP LEIDEN,DEPT CLIN CHEM,2300 RC LEIDEN,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC)	VANDISSEL, JT (corresponding author), UNIV HOSP LEIDEN,DEPT INFECT DIS,2300 RC LEIDEN,NETHERLANDS.							CUNNION RE, 1992, CRIT CARE MED, V20, P721, DOI 10.1097/00003246-199206000-00001; HACK CE, 1989, BLOOD, V74, P1704; PARKER MM, 1990, ANN INTERN MED, V113, P227; WARREN HS, 1992, NEW ENGL J MED, V326, P1153, DOI 10.1056/NEJM199204233261711; WORTEL CH, 1992, J INFECT DIS, V166, P1367, DOI 10.1093/infdis/166.6.1367	5	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 10	1993	341	8850					959	960		10.1016/0140-6736(93)91250-P	http://dx.doi.org/10.1016/0140-6736(93)91250-P			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW981	8096292				2022-12-28	WOS:A1993KW98100037
J	SKINNER, J; SIDDIQUI, R; GRIBBIN, H; SINCLAIR, D				SKINNER, J; SIDDIQUI, R; GRIBBIN, H; SINCLAIR, D			STEROID TAPERING IN ACUTE ASTHMA	LANCET			English	Letter									S CLEVELAND HOSP,DEPT RESP MED,MIDDLESBROUGH,ENGLAND		SKINNER, J (corresponding author), NEWCASTLE GEN HOSP,NEWCASTLE TYNE NE4 6BE,TYNE & WEAR,ENGLAND.							[Anonymous], 1990, BMJ, V301, P651; ODRISCOLL, 1993, LANCET, V341, P324; 1990, BMJ, V301, P797	3	2	2	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 20	1993	341	8847					772	772		10.1016/0140-6736(93)90556-V	http://dx.doi.org/10.1016/0140-6736(93)90556-V			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KT362	8095687				2022-12-28	WOS:A1993KT36200073
J	TANABE, KK; ELLIS, LM; SAYA, H				TANABE, KK; ELLIS, LM; SAYA, H			EXPRESSION OF CD44R1 ADHESION MOLECULE IN COLON CARCINOMAS AND METASTASES	LANCET			English	Note							CELLS	CD44 is a cell surface adhesion molecule postulated to control lymphocyte recirculation by facilitating entry into lymphoid tissue. Tumour cells transfected to overexpress the epithelial variant CD44R1 readily gain access to lymph nodes and distant metastatic sites in animal models, possibly by mimicking circulating lymphocytes.. To investigate if human tumours display altered CD44 expression we performed reverse transcriptase a polymerase chain reaction (PCR) analysis of CD44 in 49 specimens from normal colonic mucosa, primary colon and rectal tumours, normal liver, and metastases of 20 patients. The haematopoietic variant CD44H was the principal isoform amplified in all of the specimens, However, 12/14 primary tumours and 16/16 metastatic tumours expressed CD44R1, compared with only 2 of 13 normal mucosa specimens. This increase in CD44R1 relative to CD44H expressed by human colon carcinoma cells may increase their metastatic potential. Moreover, the relative increase in PCR amplification of CD44R1 compared with that of CD44H may provide a sensitive method for detecting primary and metastatic colon carcinoma cells in small biopsy specimens.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT NEUROONCOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center	TANABE, KK (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT GEN SURG,BOX 106,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.		Saya, Hideyuki/J-4325-2013		NATIONAL CANCER INSTITUTE [P30CA016672, T32CA009599] Funding Source: NIH RePORTER; NCI NIH HHS [5T32-CA09599-04, CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; BIRCH M, 1991, CANCER RES, V51, P6660; DOUGHERTY GJ, 1992, P AM ASSOC CANC RES, V33, P34; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; JACKSON BG, 1992, J BIOL CHEM, V267, P4732; JALKANEN S, 1986, SCIENCE, V233, P556, DOI 10.1126/science.3726548; JALKANEN S, 1991, J CLIN INVEST, V87, P1835, DOI 10.1172/JCI115205; MATSUMURA Y, 1992, LANCET, V340, P1053, DOI 10.1016/0140-6736(92)93077-Z; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x	10	301	308	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 20	1993	341	8847					725	726		10.1016/0140-6736(93)90490-8	http://dx.doi.org/10.1016/0140-6736(93)90490-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KT362	8095628				2022-12-28	WOS:A1993KT36200007
J	TAYLOR, TE; WILLS, BA; KAZEMBE, P; CHISALE, M; WIRIMA, JJ; RATSMA, EYEC; MOLYNEUX, ME				TAYLOR, TE; WILLS, BA; KAZEMBE, P; CHISALE, M; WIRIMA, JJ; RATSMA, EYEC; MOLYNEUX, ME			RAPID COMA RESOLUTION WITH ARTEMETHER IN MALAWIAN CHILDREN WITH CEREBRAL MALARIA	LANCET			English	Note							QINGHAOSU	Artemisinin compounds clear parasitaemia more rapidly than other drugs do in both mild and severe malaria, but no advantage in clinical efficacy has been shown. We have compared artemether treatment with standard quinine treatment in Malawian children with cerebral malaria. 65 unconscious children were randomly allocated to intravenous quinine (n=37) or intramuscular artemether (n=28) treatment. The two groups were well matched for various prognostic features. Median parasite clearance times were shorter in the artemether group (28 [interquartile range 18-34] vs 40 [36-44] h in the quinine group, p=0.0002). Coma resolution times were also shorter with artemether than with quinine (8 [4-15] vs 14 [10-36] h, p=0.01).	QUEEN ELIZABETH CENT HOSP, BLANTYRE, MALAWI; UNIV MALAWI, COLL MED, LILONGWE, MALAWI; KAMUZU CENT HOSP, LILONGWE, MALAWI; MICHIGAN STATE UNIV, COLL OSTEOPATH MED, E LANSING, MI 48824 USA; UNIV LIVERPOOL, SCH TROP MED, LIVERPOOL L69 3BX, ENGLAND	University of Malawi; University of Malawi; Michigan State University; Michigan State University College of Osteopathic Medicine; Liverpool School of Tropical Medicine; University of Liverpool				Wills, Bridget/0000-0001-9086-8804				[Anonymous], 1991, MALARIA OBSTACLES OP; JIANG JB, 1982, LANCET, V2, P285; JIAXIANG S, 1991, ANTIMALARIA DRUG DEV; MOLYNEUX ME, 1989, Q J MED, V71, P441; MYINT PT, 1987, T ROY SOC TROP MED H, V81, P559, DOI 10.1016/0035-9203(87)90406-8; WHITE NJ, 1992, LANCET, V339, P317, DOI 10.1016/0140-6736(92)91644-N; [No title captured]	7	56	58	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 13	1993	341	8846					661	662		10.1016/0140-6736(93)90423-E	http://dx.doi.org/10.1016/0140-6736(93)90423-E			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR613	8095573				2022-12-28	WOS:A1993KR61300007
J	GOLDHABER, SZ; HAIRE, WD; FELDSTEIN, ML; MILLER, M; TOLTZIS, R; SMITH, JL; DASILVA, AMT; COME, PC; LEE, RT; PARKER, JA; MOGTADER, A; MCDONOUGH, TJ; BRAUNWALD, E				GOLDHABER, SZ; HAIRE, WD; FELDSTEIN, ML; MILLER, M; TOLTZIS, R; SMITH, JL; DASILVA, AMT; COME, PC; LEE, RT; PARKER, JA; MOGTADER, A; MCDONOUGH, TJ; BRAUNWALD, E			ALTEPLASE VERSUS HEPARIN IN ACUTE PULMONARY-EMBOLISM - RANDOMIZED TRIAL ASSESSING RIGHT-VENTRICULAR FUNCTION AND PULMONARY PERFUSION	LANCET			English	Article							TISSUE PLASMINOGEN-ACTIVATOR	Data from a non-randomised study have hinted that in patients with acute pulmonary embolism (PE), thrombolysis followed by heparin more rapidly reverses right-ventricular dysfunction and restores pulmonary tissue perfusion than does heparin alone. We have pursued this idea in a randomised protocol. 46 haemodynamically stable patients were randomised to recombinant tissue plasminogen activator (alteplase, rt-PA) 100 mg over 2 h followed by intravenous heparin and 55 to heparin alone. Right-ventricular wall motion was assessed qualitatively, and right-ventricular end diastolic area was estimated by planimetry from echocardiograms at baseline and at 3 and 24 hours. Pulmonary perfusion scans were obtained at baseline and 24 hours. In 39% of rt-PA patients but in only 17% of heparin alone patients right-ventricular wall motion at 24 hours had improved from baseline and in 2% and 17%, respectively, it worsened (p=0.005). rt-PA patients also had a significant decrease in right-ventricular end-diastolic area during the 24 hours after randomisation and a significant absolute. improvement in pulmonary perfusion (14.6% vs 1.5%). No clinical episodes of recurrent PE were noted among rt-PA patients, but there were 2 fatal and 3 non-fatal clinically suspected recurrent PEs within 14 days in patients randomised to heparin alone. rt-PA rapidly improves right-ventricular function and pulmonary perfusion among patients with PE and may lead to a lower rate of adverse clinical outcomes.	HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,BOSTON,MA 02215; UNIV NEBRASKA,MED CTR,OMAHA,NE 68105; FRONTIER SCI & TECHNOL RES FDN INC,BROOKLINE,MA; DANBURY HOSP,DANBURY,CT 06810; CHRIST HOSP,CINCINNATI,OH 45219; GEISINGER MED CTR,DANVILLE,PA 17822; GEORGETOWN UNIV HOSP,WASHINGTON,DC 20007; ST LUKES ROOSEVELT HOSP,NEW YORK,NY; EVANSTON HOSP CORP,EVANSTON,IL 60201	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of Nebraska System; University of Nebraska Medical Center; Frontier Science Foundation; Christ Hospital - Ohio; Geisinger Medical Center; Georgetown University; Mount Sinai St. Luke's; Mount Sinai West; NorthShore University Health System	GOLDHABER, SZ (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV CARDIOVASC,75 FRANCIS ST,BOSTON,MA 02115, USA.							[Anonymous], 1973, CIRCULATION, V47, P1; COME PC, 1987, J AM COLL CARDIOL, V10, P971, DOI 10.1016/S0735-1097(87)80333-9; Conover WJ, 1980, PRACTICAL NONPARAMET, P215; DALLAVOLTA S, 1992, J AM COLL CARDIOL, V20, P520, DOI 10.1016/0735-1097(92)90002-5; Fleiss J, 1981, STAT METHODS RATES P, P38; GOLDHABER SZ, 1992, J AM COLL CARDIOL, V20, P24, DOI 10.1016/0735-1097(92)90132-7; GOLDHABER SZ, 1986, LANCET, V2, P886; GOLDHABER SZ, 1992, J AM COLL CARDIOL, V19, P246, DOI 10.1016/0735-1097(92)90473-Z; GOLDHABER SZ, 1988, LANCET, V2, P293; MEHTA CR, 1983, J AM STAT ASSOC, V78, P427, DOI 10.2307/2288652; MEYER G, 1992, J AM COLL CARDIOL, V19, P239, DOI 10.1016/0735-1097(92)90472-Y; PARKER JA, 1988, RADIOLOGY, V166, P441, DOI 10.1148/radiology.166.2.3122266; SNEDECOR GW, 1980, STATISTICAL METHODS, P124; VERSTRAETE M, 1988, CIRCULATION, V77, P353, DOI 10.1161/01.CIR.77.2.353; 1992, LANCET, V340, P21; 1990, JAMA-J AM MED ASSOC, V263, P2753	16	629	657	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 27	1993	341	8844					507	511		10.1016/0140-6736(93)90274-K	http://dx.doi.org/10.1016/0140-6736(93)90274-K			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP083	8094768				2022-12-28	WOS:A1993KP08300001
J	NIEHRS, C; KELLER, R; CHO, KWY; DEROBERTIS, EM				NIEHRS, C; KELLER, R; CHO, KWY; DEROBERTIS, EM			THE HOMEOBOX GENE GOOSECOID CONTROLS CELL-MIGRATION IN XENOPUS EMBRYOS	CELL			English	Article							ECTOPIC EXPRESSION; LAEVIS; AXIS; GASTRULA; MESODERM; LINEAGE; ORGANIZER; INDUCTION; LAYER; FATE	goosecoid (gsc), a homeobox gene expressed specifically in the dorsal blastopore lip of the Xenopus gastrula, is considered to play an important role in Spemann's organizer phenomenon. Lineage tracing and time-lapse microscopy were used to follow the fate of embryonic cells microinjected with gsc mRNA. Microinjected gsc has non-cell autonomous effects, recruiting neighboring uninjected cells into a twinned dorsal axis. Ectopic expression of gsc mRNA in ventral blastomeres as well as overexpression of gsc in dorsal blastomeres leads to cell movement toward the anterior of the embryo. The results suggest a function for gsc in the control of gastrulation movements in groups of cells, but not in dissociated cells, and demonstrate that a vertebrate homeobox gene can regulate region-specific cell migration.	UNIV CALIF LOS ANGELES, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA; UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, DIV CELL & DEV BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Los Angeles; University of California System; University of California Berkeley	NIEHRS, C (corresponding author), UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA.			De Robertis, Edward/0000-0002-7843-1869	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD025594, R01HD025594, R01HD021502, R37HD021502] Funding Source: NIH RePORTER; NICHD NIH HHS [HD21502-08, HD25594] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BELOUSSOV LV, 1988, CELL DIFFER DEV, V25, P165, DOI 10.1016/0922-3371(88)90113-X; BLUMBERG B, 1991, SCIENCE, V253, P194, DOI 10.1126/science.1677215; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CHRISTIAN JL, 1993, GENE DEV, V7, P13, DOI 10.1101/gad.7.1.13; DALE L, 1987, DEVELOPMENT, V99, P527; DIRKSEN ML, 1992, GENE DEV, V6, P599, DOI 10.1101/gad.6.4.599; GERHART J, 1991, BOD MAR LAB, P57; GIMLICH RL, 1985, DEV BIOL, V109, P509, DOI 10.1016/0012-1606(85)90476-2; GIMLICH RL, 1983, NATURE, V306, P471, DOI 10.1038/306471a0; GOULD AP, 1992, DEVELOPMENT, V116, P1163; GRABA Y, 1992, EMBO J, V11, P3375, DOI 10.1002/j.1460-2075.1992.tb05416.x; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; GURDON JB, 1988, NATURE, V336, P772, DOI 10.1038/336772a0; HEMMATIBRIVANLOU A, 1990, SCIENCE, V250, P800, DOI 10.1126/science.1978411; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; JONES FS, 1992, P NATL ACAD SCI USA, V89, P2086, DOI 10.1073/pnas.89.6.2086; KELLER R, 1988, DEVELOPMENT, V103, P193; Keller R, 1992, DEVELOPMENT S, V116, P81; KELLER R, 1991, CELL CELL INTERACTIO, P31; KELLER RE, 1976, DEV BIOL, V51, P118, DOI 10.1016/0012-1606(76)90127-5; KLEIN SL, 1987, DEV BIOL, V120, P299, DOI 10.1016/0012-1606(87)90127-8; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; MONTELL DJ, 1992, CELL, V71, P51, DOI 10.1016/0092-8674(92)90265-E; MOODY SA, 1987, DEV BIOL, V122, P300, DOI 10.1016/0012-1606(87)90296-X; MOON RT, 1992, CELL, V71, P709, DOI 10.1016/0092-8674(92)90545-N; NAKATSUJI N, 1986, J CELL SCI, V86, P109; NAKATSUJI N, 1983, J CELL SCI, V59, P43; NIEHRS C, 1991, EMBO J, V10, P3621, DOI 10.1002/j.1460-2075.1991.tb04928.x; REPRESA J, 1989, International Journal of Developmental Biology, V33, P397; SALSER SJ, 1992, NATURE, V355, P255, DOI 10.1038/355255a0; SHIH J, 1992, DEVELOPMENT, V116, P901; Slack J. M. W, 1991, EGG EMBRYON REGIONAL; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; STEWART RM, 1990, DEVELOPMENT, V109, P363; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WINKLBAUER R, 1990, DEV BIOL, V142, P155, DOI 10.1016/0012-1606(90)90159-G; WINKLBAUER R, 1991, DEV BIOL, V148, P573, DOI 10.1016/0012-1606(91)90275-8; WINKLBAUER R, 1991, BOD MAR LAB, P147	44	168	170	0	5	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	FEB 26	1993	72	4					491	503		10.1016/0092-8674(93)90069-3	http://dx.doi.org/10.1016/0092-8674(93)90069-3			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KP165	8095000				2022-12-28	WOS:A1993KP16500005
J	EDWARDS, CRW; BENEDIKTSSON, R; LINDSAY, RS; SECKL, JR				EDWARDS, CRW; BENEDIKTSSON, R; LINDSAY, RS; SECKL, JR			DYSFUNCTION OF PLACENTAL GLUCOCORTICOID BARRIER - LINK BETWEEN FETAL ENVIRONMENT AND ADULT HYPERTENSION	LANCET			English	Article							BLOOD-PRESSURE; 11-BETA-HYDROXYSTEROID DEHYDROGENASE; PROTEIN-TURNOVER; BODY-WEIGHT; GROWTH; RATS; CORTISONE; EXPOSURE; DISEASE; INFANCY	Low birthweight is associated with the subsequent development of common disorders of adult life, especially hypertension; maternal malnutrition has been suggested as the cause. We suggest an alternative aetiology-increased fetal exposure to maternal glucocorticoids. This hypothesis is supported by our findings that in rats decreased activity of the enzyme that acts as a placental barrier to maternal glucocorticoids (11beta-hydroxysteroid dehydrogenase) is associated with low birthweight. Furthermore, increased exposure of the fetus to exogenous glucocorticoids leads to low birthweight and subsequent hypertension in the offspring. Glucocorticoids acting during critical periods of prenatal development may, like other steroid hormones, exert organisational effects or imprint patterns of response that persist throughout life. Thus, the lifetime risk of common disorders may be partly determined by the intrauterine environment.			EDWARDS, CRW (corresponding author), UNIV EDINBURGH,WESTERN GEN HOSP,DEPT MED,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.		Seckl, Jonathan R/C-3555-2013; Benediktsson, Rafn/R-2457-2018	Benediktsson, Rafn/0000-0002-2954-9801; Lindsay, Robert/0000-0002-9868-5217	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAGGIA S, 1990, ENDOCRINOLOGY, V126, P2742, DOI 10.1210/endo-126-5-2742; BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1989, BRIT MED J, V298, P564, DOI 10.1136/bmj.298.6673.564; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BEITINS IZ, 1973, PEDIATR RES, V7, P509, DOI 10.1203/00006450-197305000-00004; BENEDIKTSSON R, 1993, LANCET, V341, P339, DOI 10.1016/0140-6736(93)90138-7; BERNAL AL, 1980, J STEROID BIOCHEM, V13, P1081, DOI 10.1016/0022-4731(80)90140-5; BUTLER NR, 1969, 2ND 1958 BRIT PER MO; CAMPBELL AG, 1967, CIRC RES, V21, P229, DOI 10.1161/01.RES.21.2.229; CANAVAN JP, 1988, DIABETES, V37, P1671, DOI 10.2337/diabetes.37.12.1671; CSABA G, 1980, HORM METAB RES, V12, P28, DOI 10.1055/s-2007-996189; CSABA G, 1979, ACTA PHYSIOL HUNG, V53, P487; ECKLES CH, 1919, RES B MIN AGR EXP ST, P35; EDWARDS CRW, 1988, LANCET, V2, P986, DOI 10.1016/S0140-6736(88)90742-8; GODFREY KM, 1991, BRIT J OBSTET GYNAEC, V98, P886, DOI 10.1111/j.1471-0528.1991.tb13510.x; GUNBERG DL, 1957, ANAT RECORD, V129, P133, DOI 10.1002/ar.1091290202; GUSTAFSSON JA, 1974, J BIOL CHEM, V249, P711; GUSTAFSSON JA, 1974, J BIOL CHEM, V249, P719; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; Hammond J., 1944, PROC NUTRITION SOC [CAMBRIDGE], V2, P8; HAZON N, 1990, J ENDOCRINOL, V127, P243, DOI 10.1677/joe.0.1270243; HELLER CL, 1988, J STEROID BIOCHEM, V31, P119, DOI 10.1016/0022-4731(88)90214-2; HUGGETT AS, 1944, P NUTR SOC, V2, P20; KROGER H, 1970, AM J OBSTET GYNECOL, V106, P586; LAW CM, 1991, ARCH DIS CHILD, V66, P1291, DOI 10.1136/adc.66.11.1291; LEVER AF, 1992, J HYPERTENS, V10, P101, DOI 10.1097/00004872-199202000-00001; MAYER JS, 1985, PHYSL DEV, V65, P1020; MEANEY MJ, 1988, SCIENCE, V239, P766, DOI 10.1126/science.3340858; MILLER HC, 1974, PEDIATR RES, V8, P960, DOI 10.1203/00006450-197412000-00009; MOISAN MP, 1992, ENDOCRINOLOGY, V130, P400, DOI 10.1210/en.130.1.400; MONDER C, 1984, STEROIDS, V44, P383, DOI 10.1016/S0039-128X(84)80001-X; MURPHY BEP, 1974, AM J OBSTET GYNECOL, V118, P538, DOI 10.1016/S0002-9378(16)33697-3; RAVELLI GP, 1976, NEW ENGL J MED, V295, P349, DOI 10.1056/NEJM197608122950701; REINISCH JM, 1978, SCIENCE, V202, P436, DOI 10.1126/science.705336; ROBINSON J, 1988, DIABETES, V37, P1665, DOI 10.2337/diabetes.37.12.1665; RUDOLPH AM, 1984, J DEV PHYSIOL, V6, P11; SANCHIS R, 1986, ALCOHOL ALCOHOLISM, V21, P295; SEIDMAN DS, 1991, BMJ-BRIT MED J, V302, P1235, DOI 10.1136/bmj.302.6787.1235; SHAPER AG, 1981, BRIT MED J, V283, P179, DOI 10.1136/bmj.283.6285.179; Spira A, 1975, J Perinat Med, V3, P237, DOI 10.1515/jpme.1975.3.4.237; STEIN Z, 1975, DUTCH HUNGER WINTER, P119; TANNER JM, 1956, ARCH DIS CHILD, V31, P372, DOI 10.1136/adc.31.159.372; TONOLO G, 1988, J HYPERTENS, V6, P25; WALKER BR, 1992, CLIN SCI, V82, P597, DOI 10.1042/cs0820597; WALKER BR, IN PRESS CLIN ENDOCR; WHINCUP PH, 1989, BMJ-BRIT MED J, V299, P587, DOI 10.1136/bmj.299.6699.587; 1942, LANCET, V243, P10	47	488	493	0	16	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 6	1993	341	8841					355	357		10.1016/0140-6736(93)90148-A	http://dx.doi.org/10.1016/0140-6736(93)90148-A			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK939	8094124				2022-12-28	WOS:A1993KK93900016
J	COURATIER, P; HUGON, J; SINDOU, P; VALLAT, JM; DUMAS, M				COURATIER, P; HUGON, J; SINDOU, P; VALLAT, JM; DUMAS, M			CELL-CULTURE EVIDENCE FOR NEURONAL DEGENERATION IN AMYOTROPHIC-LATERAL-SCLEROSIS BEING LINKED TO GLUTAMATE AMPA KAINATE RECEPTORS	LANCET			English	Article							SPINAL-CORD; AMINO-ACIDS; KAINIC ACID; NEUROTOXICITY; METABOLISM; ASPARTATE; DISEASE; BOAA	Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder affecting motor neurons. Glutamate, a potent cental-nervous-system toxin, has been proposed as one possible factor in this motoneuron disease. Serum from patients with ALS is known to be toxic when added to neurons in culture. We report on the toxicity to rat neurons in culture of cerebrospinal fluid (CSF) from patients with ALS. CSF were obtained from 10 ALS patients, 10 neurological controls, and 10 other controls. ALS CSF was added at dilutions of 50%, 20%, or 10% and neuron survival was assessed after 24 h. The neuroprotective effects of antagonists to two glutamate receptors were also assessed. ALS CSF was significantly neurotoxic, with a neuronal survival rate of only 47% compared with 80% or so for control CSF. This neurotoxicity was blocked by CNQX, an antagonist to the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA)/kainate receptor but not by two N-methyl-D-aspartate (NMDA) antagonists. ALS CSF contains a specific neurotoxic factor which is AMPA/kainate-like which could have a role in the neuronal degeneration of this disease.	FAC MED LIMOGES, HISTOL LAB, F-87025 LIMOGES, FRANCE; CHU DUPUYTREN, DEPT NEUROL, F-87031 LIMOGES, FRANCE	CHU Limoges	COURATIER, P (corresponding author), FAC MED LIMOGES, UNITE NEUROBIOL CELLULAIRE, 2 RUE DR MARCLAND, F-87025 LIMOGES, FRANCE.			sindou, p/0000-0003-1938-8319				ALLEN CN, 1990, AMYOTROPHIC LATERAL, P41; BARNES JM, 1992, PROG NEUROBIOL, V39, P113, DOI 10.1016/0301-0082(92)90007-2; BRIDGES RJ, 1989, J NEUROSCI, V9, P2073; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1987, J NEUROSCI, V7, P369; CURTIS DR, 1985, J PHYSIOL-LONDON, V368, P99, DOI 10.1113/jphysiol.1985.sp015848; GAJDUSEK DC, 1989, AMYOTROPH LATERAL SC, P317; GREENAMYRE JT, 1986, ARCH NEUROL-CHICAGO, V43, P1058, DOI 10.1001/archneur.1986.00520100062016; HUGON J, 1989, NEUROLOGY, V39, P956, DOI 10.1212/WNL.39.7.956; HUGON J, 1989, NEUROSCI LETT, V104, P258, DOI 10.1016/0304-3940(89)90585-5; MAYER ML, 1991, TRENDS PHARMACOL SCI, P36; MELDRUM B, 1991, TRENDS PHARM SCI PHA, P54; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; PLAITAKIS A, 1988, ANN NEUROL, V24, P446, DOI 10.1002/ana.410240314; PLAITAKIS A, 1987, ANN NEUROL, V22, P575, DOI 10.1002/ana.410220503; PLAITAKIS A, 1990, ANN NEUROL, V28, P3, DOI 10.1002/ana.410280103; ROISEN FJ, 1982, MUSCLE NERVE, V5, P48, DOI 10.1002/mus.880050109; ROTHSTEIN JD, 1992, NEW ENGL J MED, V326, P1464, DOI 10.1056/NEJM199205283262204; ROTHSTEIN JD, 1990, ANN NEUROL, V28, P18, DOI 10.1002/ana.410280106; SCHWARCZ R, 1985, LANCET, V2, P140; SINDOU P, 1992, BRAIN RES, V572, P242, DOI 10.1016/0006-8993(92)90476-P; SPENCER PS, 1986, LANCET, V2, P1066, DOI 10.1016/S0140-6736(86)90468-X; SPENCER PS, 1987, SCIENCE, V237, P517, DOI 10.1126/science.3603037; WEISS JH, 1991, ADV NEUROL, V56, P311; WEISS JH, 1989, BRAIN RES, V497, P64, DOI 10.1016/0006-8993(89)90970-0; WOLFGRAM F, 1973, SCIENCE, V179, P579, DOI 10.1126/science.179.4073.579; YOUNG AB, 1990, ANN NEUROL, V28, P9, DOI 10.1002/ana.410280104; YOUNG AB, 1991, TRENDS PHARM SCI SPE, P18; 1989, INT CLASSIFICATION D	29	178	182	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 30	1993	341	8840					265	268		10.1016/0140-6736(93)92615-Z	http://dx.doi.org/10.1016/0140-6736(93)92615-Z			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK245	8093916				2022-12-28	WOS:A1993KK24500003
J	BOWSHER, D				BOWSHER, D			CEREBROVASCULAR-DISEASE - SENSORY CONSEQUENCES OF STROKE	LANCET			English	Editorial Material							PAIN				BOWSHER, D (corresponding author), WALTON HOSP,PAIN RES INST,LIVERPOOL L9 1AE,MERSEYSIDE,ENGLAND.							ARNER S, 1988, PAIN, V33, P11, DOI 10.1016/0304-3959(88)90198-4; AWERBUCH GI, 1990, INT J NEUROSCI, V55, P129, DOI 10.3109/00207459008985960; LEIJON G, 1989, PAIN, V38, P187, DOI 10.1016/0304-3959(89)90237-6; LEIJON G, 1990, PAIN S, V5, pS468; VERDUGO R, 1992, BRAIN, V115, P893, DOI 10.1093/brain/115.3.893	5	29	30	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 16	1993	341	8838					156	156		10.1016/0140-6736(93)90015-9	http://dx.doi.org/10.1016/0140-6736(93)90015-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG627	8093755				2022-12-28	WOS:A1993KG62700015
J	CLAYTON, RH; MURRAY, A; HIGHAM, PD; CAMPBELL, RWF				CLAYTON, RH; MURRAY, A; HIGHAM, PD; CAMPBELL, RWF			SELF-TERMINATING VENTRICULAR TACHYARRHYTHMIAS - A DIAGNOSTIC DILEMMA	LANCET			English	Article							TACHYCARDIA; POINTES	Ventricular fibrillation is generally regarded as being lethal unless promptly halted. There have been reports of self-terminating ventricular fibrillation, but similar events are described by some cardiologists as polymorphic ventricular tachycardia or even torsade de pointes. To examine how experienced cardiologists would diagnose such tachyarrhythmias, electrocardiograms of self-terminating ventricular tachyarrhythmias compatible with accepted definitions of ventricular fibrillation (rate >300/min) were sent to 22 cardiologists. During the study period of 19 months, 2462 patients treated in a 10-bed coronary-care unit were monitored by use of a single bipolar chest lead. 45 (2%) had episodes of ventricular fibrillation that were terminated by direct current (DC) shock. 12 self-terminating tachyarrhythmias (duration 5.2-49.5 s) were recorded from 8 patients, 3 of whom also had sustained ventricular fibrillation terminated by DC shock. The cardiologists offered 264 diagnoses for the self-terminating events; 42 (15.9%) ventricular fibrillation, 99 (37.5%) polymorphic ventricular tachycardia, 98 (37.1%) torsade de pointes, and 25 (9.5%) ''other''. The cardiologists differed (p<0.01 in their response patterns. The findings show that rapid self-terminating ventricular tachyarrhythmias are not uncommon in coronary-care unit patients, and that the diagnostic categorisation of these important events is highly subjective and inconsistent.	FREEMAN RD HOSP,DEPT ACAD CARDIOL,NEWCASTLE TYNE NE7 7DN,TYNE & WEAR,ENGLAND	Newcastle Freeman Hospital	CLAYTON, RH (corresponding author), FREEMAN RD HOSP,DEPT REG MED PHYS,NEWCASTLE TYNE NE7 7DN,TYNE & WEAR,ENGLAND.		Clayton, Richard/CAF-3400-2022	Clayton, Richard/0000-0002-8438-7518; Murray, Alan/0000-0003-2621-4632				BARDY GH, 1990, CARDIAC ELECTROPHYSI; BECHGAARD P, 1948, ACTA MED SCAND, V132, P9; CLAYTON RH, 1992, COMPUTER CARDIOLOGY, P685; DELUNA AB, 1989, J AMB MON, V2, P3; JOSEPHSON ME, 1979, AM J CARDIOL, V44, P623, DOI 10.1016/0002-9149(79)90279-0; JULIAN DG, 1980, J ROY COLL PHYS LOND, V14, P17; KRIKLER DM, 1976, BRIT HEART J, V38, P117; Murray A., 1985, Computers in Cardiology (Cat. No.85CH2217-8), P275; SCHWARTZ SP, 1932, ARCH INTERN MED, V49, P450; TZIVONI D, 1983, AM J CARDIOL, V52, P639, DOI 10.1016/0002-9149(83)90043-7; Zilcher H, 1980, Eur Heart J, V1, P63; ZIPES DP, 1975, CIRCULATION S, V3, P120	12	36	36	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 9	1993	341	8837					93	95		10.1016/0140-6736(93)92567-D	http://dx.doi.org/10.1016/0140-6736(93)92567-D			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF870	8093413				2022-12-28	WOS:A1993KF87000014
J	WOLDEGABRIEL, G; WHITE, TD; SUWA, G; RENNE, P; DEHEINZELIN, J; HART, WK; HEIKEN, G				WOLDEGABRIEL, G; WHITE, TD; SUWA, G; RENNE, P; DEHEINZELIN, J; HART, WK; HEIKEN, G			ECOLOGICAL AND TEMPORAL PLACEMENT OF EARLY PLIOCENE HOMINIDS AT ARAMIS, ETHIOPIA	NATURE			English	Article							MIDDLE-AWASH-VALLEY; STRATIGRAPHY; DISCOVERIES; HADAR; AFAR	SEDIMENTARY deposits in the Middle Awash research area of Ethiopia's Afar depression have yielded vertebrate fossils including the most ancient hominids known. Radioisotopic dating, geochemical analysis of interbedded volcanic ashes and biochronological considerations place the hominid-bearing deposits at around 4.4 million years of age. Sedimentological, botanical and faunal evidence suggests a wooded habitat for the Aramis hominids.	UNIV CALIF BERKELEY,HUMAN EVOLUTIONARY STUDIES LAB,BERKELEY,CA 94720; LOS ALAMOS NATL LAB,LOS ALAMOS,NM 87545; UNIV TOKYO,DEPT ANTHROPOL,BUNKYO KU,TOKYO 113,JAPAN; BERKELEY GEOCHRONOL CTR,BERKELEY,CA 94709; INST ROYAL SCI NAT BELGIQUE,B-1040 BRUSSELS,BELGIUM; MIAMI UNIV,DEPT GEOL,OXFORD,OH 45056	University of California System; University of California Berkeley; United States Department of Energy (DOE); Los Alamos National Laboratory; University of Tokyo; Berkeley Geochronolgy Center; University System of Ohio; Miami University			Klein, Richard G/B-5910-2009	Renne, Paul/0000-0003-1769-5235				ADAMSON DA, 1987, J HUM EVOL, V16, P597, DOI 10.1016/0047-2484(87)90015-7; ANDREWS PJ, 1989, J HUM EVOL, V18, P173, DOI 10.1016/0047-2484(89)90071-7; ASFAW B, 1987, J HUM EVOL, V16, P611, DOI 10.1016/0047-2484(87)90016-9; BONNEFILLE R, 1987, PALAEOGEOGR PALAEOCL, V60, P249, DOI 10.1016/0031-0182(87)90035-6; CLARK JD, 1984, NATURE, V307, P423, DOI 10.1038/307423a0; DEINO A, 1990, J GEOPHYS RES-SOLID, V95, P8453, DOI 10.1029/JB095iB06p08453; GORTANI M, 1973, MISSIONE GEOLOGICA A; HAILEAB B, 1992, J HUM EVOL, V22, P453, DOI 10.1016/0047-2484(92)90080-S; HILGEN FJ, 1991, EARTH PLANET SC LETT, V107, P349, DOI 10.1016/0012-821X(91)90082-S; Kalb J.E., 1982, Newsletters on Stratigraphy, V11, P95; KALB JE, 1982, NATURE, V298, P25, DOI 10.1038/298025a0; KALB JE, 1993, T AM PHILOS SOC, V83, P1; KALB JE, 1982, NATURE, V298, P17, DOI 10.1038/298017a0; LEAKEY M.D., 1987, LAETOLI PLIOCENE SIT; TAJEB M, 1974, THESIS U PARIS 6; WHITE TD, 1994, NATURE, V371, P306, DOI 10.1038/371306a0; WHITE TD, 1993, NATURE, V366, P261, DOI 10.1038/366261a0	17	201	207	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 22	1994	371	6495					330	333		10.1038/371330a0	http://dx.doi.org/10.1038/371330a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PH254	8090201				2022-12-28	WOS:A1994PH25400051
J	HORTON, R				HORTON, R			THROMBOLYSIS - TPA FAST BY GUSTO	LANCET			English	Editorial Material																			0	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 8	1993	341	8854					1188	1188		10.1016/0140-6736(93)91011-A	http://dx.doi.org/10.1016/0140-6736(93)91011-A			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB017	8098084				2022-12-28	WOS:A1993LB01700013
J	TOOLE, MJ; GALSON, S; BRADY, W				TOOLE, MJ; GALSON, S; BRADY, W			ARE WAR AND PUBLIC-HEALTH COMPATIBLE	LANCET			English	Article								A public health assessment during March, 1993, in Bosnia-Herzegovina and in the areas of Serbia and Montenegro hosting Bosnian refugees, revealed extensive disruption to basic health services, displacement of more than 1 million Bosnians, severe food shortages in Muslim enclaves in eastern Bosnia, and widespread destruction of public water and sanitation systems. War-related violence remains the most important public health risk; civilians on all sides of the conflict have been intentional targets of physical and sexual violence. The impact of the war on the health status of the population has been difficult to document; however, in the central Bosnian province of Zenica, perinatal and child mortality rates have increased twofold since 1991. The crude death rate in one Muslim enclave between April, 1992, and March, 1993, was four times the pre-war rate. Prevalence rates of severe malnutrition among both adults and children in central Bosnia have been increasing since November, 1992. Major epidemics of communicable diseases have not been reported; however, the risk may increase during the summer of 1993 when the effects of disrupted water and sanitation systems are more likely to promote enteric disease transmission. Economic sanctions against Serbia and Montenegro may lead to declining health care standards in those republics if basic medical supplies cannot effectively be exempted.			TOOLE, MJ (corresponding author), CTR DIS CONTROL & PREVENT,INT HLTH PROGRAM OFF,ATLANTA,GA 30333, USA.							ACHESON D, 1993, 12TH REPORT OFFICE W; JANGANJAC N, 1992, SARAJEVO MED REPORT; ROBERTSON A, 1992, NUTRITION MONITORING; 1993, INFORMATION NOTES FO; 1992, HLTH MONITOR WAR AFF; 1988, SEP INT C GEN; 1993, USAID8 OFF US FOR DI; 1993, EUR630193 AMN INT RE; 1992, STATE WORLDS CHILDRE	9	65	65	1	11	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 8	1993	341	8854					1193	1196		10.1016/0140-6736(93)91013-C	http://dx.doi.org/10.1016/0140-6736(93)91013-C			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LB017	8098086	Green Submitted			2022-12-28	WOS:A1993LB01700015
J	SMITH, MBH; FELDMAN, W				SMITH, MBH; FELDMAN, W			OVER-THE-COUNTER COLD MEDICATIONS - A CRITICAL-REVIEW OF CLINICAL-TRIALS BETWEEN 1950 AND 1991	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EXPERIMENTAL RHINOVIRUS COLDS; DATA-COLLECTION-SYSTEM; COMMON COLD; SYMPTOMATIC MANAGEMENT; ACUTE COUGH; CHILDREN; ANTIHISTAMINES; COMBINATION; PSEUDOEPHEDRINE; BEHAVIOR	Objective.-To determine whether over-the-counter cold medications have been shown to be effective in relieving symptoms in children, adolescents, and adults. Data Sources.-The MEDLINE database using the key words combined with medications and research and review articles. Articles were retrieved if they were written in English and published between January 1950 and January 1991. Study Selection.-Articles were selected if they described a controlled clinical trial on the treatment of the common cold. Forty-eight percent of 106 articles met the selection criteria, and these were grouped by age into child studies (<5 years old and <12 years old) and adolescent (aged 12 years and older)/adult studies. Data Extraction.-Each article was scored on 11 criteria to determine scientific validity. Those articles scoring above 70% were included in the final analysis. Two authors independently scored a sample of articles to determine interrater reliability. Data Synthesis.-Very few studies have been performed on children. Of those, two done on preschool children demonstrated no symptom relief, whereas two done on older children showed some benefit. In the adolescent/adult studies, chlorpheniramine maleate, pseudoephedrine hydrochloride, oxymetazoline hydrochloride, phenylpropanolamine hydrochloride, ipratropium bromide, and atropine methonitrate all improved nasal symptoms. Combination therapy (using an antihistamine-decongestant mix) was shown to relieve a variety of symptoms. Conclusions.-No good evidence has demonstrated the effectiveness of over-the-counter cold medications in preschool children. Further studies are required to clarify the role of these medications in children. Certain single over-the-counter medications and combinations have been shown to reduce cold symptoms in adolescents and adults.	HOSP SICK CHILDREN, DIV GEN PEDIAT, TORONTO M5G 1X8, ONTARIO, CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	SMITH, MBH (corresponding author), IZAAK WALTON KILLAM HOSP CHILDREN, DIV PEDIAT MED, HALIFAX B3J 3G9, NS, CANADA.							AKERLUND A, 1989, J LARYNGOL OTOL, V103, P743, DOI 10.1017/S0022215100109958; ASCHAN G., 1964, EYE EAR NOSE THROAT MON, V43, P66; BERKOWITZ RB, 1989, ANN ALLERGY, V63, P336; BEWS D. C., 1951, CANADIAN JOUR PUBL HEALTH, V42, P117; BORUM P, 1981, AM REV RESPIR DIS, V123, P418; BROWNING RH, 1950, NEW ENGL J MED, V243, P994, DOI 10.1056/NEJM195012212432504; BYE CE, 1980, BRIT MED J, V281, P189, DOI 10.1136/bmj.281.6234.189; COWAN DW, 1950, JAMA-J AM MED ASSOC, V143, P421, DOI 10.1001/jama.1950.02910400013004; CRUTCHER JE, 1981, J CLIN PHARMACOL, V21, P9, DOI 10.1002/j.1552-4604.1981.tb01725.x; CURLEY FJ, 1988, AM REV RESPIR DIS, V138, P305, DOI 10.1164/ajrccm/138.2.305; DIERCKX P, 1981, INT J CLIN PHARM TH, V19, P396; DIWAN J, 1982, INT J CLIN PHARM TH, V20, P373; DOYLE WJ, 1988, PEDIATR INFECT DIS J, V7, P229, DOI 10.1097/00006454-198803000-00033; FABRICANT ND, 1950, AMA ARCH OTOLARYNGOL, V52, P888; FELLER AE, 1950, NEW ENGL J MED, V242, P737, DOI 10.1056/NEJM195005112421901; FISHER P, 1951, AMA AM J DIS CHILD, V81, P530, DOI 10.1001/archpedi.1951.02040030541006; GADOMSKI A, 1992, PEDIATRICS, V89, P774; GAFFEY MJ, 1987, AM REV RESPIR DIS, V135, P241; GAFFEY MJ, 1987, AM REV RESPIR DIS, V136, P556, DOI 10.1164/ajrccm/136.3.556; GAFFEY MJ, 1988, PEDIATR INFECT DIS J, V7, P223, DOI 10.1097/00006454-198803000-00032; GRONBORG H, 1983, Rhinology (Utrecht), V21, P3; HAGGERTY RJ, 1972, PEDIATR CLIN N AM, V19, P101; HAMILTON LH, 1982, ANN OTO RHINOL LARYN, V91, P106, DOI 10.1177/000348948209100124; HENAUER SA, 1988, EUR J CLIN PHARMACOL, V34, P35, DOI 10.1007/BF01061414; HILL AB, 1962, STATISTICAL METHODS; HOAGLAND RJ, 1950, JAMA-J AM MED ASSOC, V143, P157, DOI 10.1001/jama.1950.02910370007003; HOWARD JC, 1979, JAMA-J AM MED ASSOC, V242, P2414, DOI 10.1001/jama.242.22.2414; HUTTON N, 1991, J PEDIATR-US, V118, P125, DOI 10.1016/S0022-3476(05)81865-7; JAFFE G, 1983, CURR MED RES OPIN, V8, P594, DOI 10.1185/03007998309109803; JAFFE GV, 1985, BRIT J CLIN PRACT, V39, P238; KAMINSZCZIK I, 1983, J INT MED RES, V11, P101, DOI 10.1177/030006058301100207; KANE FJ, 1966, AM J PSYCHIAT, V123, P484, DOI 10.1176/ajp.123.4.484; KUHN JJ, 1982, CHEST, V82, P713, DOI 10.1378/chest.82.6.713; LEA P, 1984, J INT MED RES, V12, P124, DOI 10.1177/030006058401200211; LEWISON E, 1970, EYE EAR NOSE THROAT, V49, P16; LITOVITZ TL, 1991, AM J EMERG MED, V9, P461, DOI 10.1016/0735-6757(91)90216-7; LITOVITZ TL, 1990, AM J EMERG MED, V8, P394, DOI 10.1016/0735-6757(90)90234-Q; LITOVITZ TL, 1989, AM J EMERG MED, V7, P495, DOI 10.1016/0735-6757(89)90252-0; LOWELL FC, 1951, NEW ENGL J MED, V244, P132, DOI 10.1056/NEJM195101252440403; Lowenstein S R, 1987, Adv Intern Med, V32, P207; MAIMAN LA, 1986, SOC SCI MED, V22, P41, DOI 10.1016/0277-9536(86)90307-2; MAIMAN LA, 1982, PUBLIC HEALTH REP, V97, P140; MATTS SGF, 1977, J INT MED RES, V5, P470; MCGUINNESS BW, 1976, BRIT J CLIN PRACT, V30, P15; MCLAURIN JW, 1966, LARYNGOSCOPE, V76, P1612, DOI 10.1002/lary.5540760914; MCLAURIN JW, 1961, LARYNGOSCOPE, V741, P54; MIDDLETON RSW, 1981, BRIT J CLIN PRACT, V35, P297; ORSON J, 1987, CLIN PEDIATR, V26, P287; PARKIN JB, 1962, PRACTITIONER, V189, P348; ROTH RP, 1977, ANN OTO RHINOL LARYN, V86, P235, DOI 10.1177/000348947708600216; SAKCHAINANONT B, 1990, Journal of the Medical Association of Thailand, V73, P96; Sengelmann H P, 1966, Ohio State Med J, V62, P141; SHAW CR, 1951, NEW YORK STATE J MED, V51, P387; SHAW CR, 1950, NEW YORK STATE J MED, V50, P1109; SILLS JA, 1984, BRIT MED J, V288, P1912, DOI 10.1136/bmj.288.6434.1912-c; SLODKI SJ, 1965, CURR THER RES CLIN E, V7, P19; SPERBER SJ, 1989, B NEW YORK ACAD MED, V65, P145; SPERBER SJ, 1988, ANTIMICROB AGENTS CH, V32, P409, DOI 10.1128/AAC.32.4.409; STRAPKOVA A, 1987, ACTA PHYSIOL HUNG, V70, P207; TAYLOR JG, 1992, SELF MED REFERENCE H, P191; THACKRAY P, 1978, J INT MED RES, V6, P161, DOI 10.1177/030006057800600218; THOMSON ME, 1984, PEDIATRICS, V73, P294; TUKIAINEN H, 1986, EUR J RESPIR DIS, V69, P95; VIRTANEN H, 1983, J LARYNGOL OTOL, V97, P159, DOI 10.1017/S0022215100093932; WEIPPL G, 1984, CLIN THER, V6, P475; WEST S, 1975, PEDIATRICS, V56, P100; WINTHER B, 1983, EUR J RESPIR DIS, V64, P447; 1950, BMJ, V2, P425; 1950, J LAB CLIN MED, V36, P555	69	168	174	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 5	1993	269	17					2258	2263		10.1001/jama.269.17.2258	http://dx.doi.org/10.1001/jama.269.17.2258			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ406	8097268				2022-12-28	WOS:A1993KZ40600035
J	MCCORMICK, J				MCCORMICK, J			OLFACTION - IN PRAISE OF STINKS	LANCET			English	Editorial Material											MCCORMICK, J (corresponding author), UNIV DUBLIN TRINITY COLL,DEPT COMMUNITY HLTH & GEN PRACTICE,DUBLIN 2,IRELAND.							FANGER PO, 1988, P INDOOR AMBIENT AIR, P365; SHUSTERMAN D, 1992, AM J PUBLIC HEALTH, V82, P1566, DOI 10.2105/AJPH.82.11.1566	2	1	1	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 1	1993	341	8853					1126	1127		10.1016/0140-6736(93)93134-M	http://dx.doi.org/10.1016/0140-6736(93)93134-M			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KZ687	8097810				2022-12-28	WOS:A1993KZ68700010
J	LI, FP; GARBER, JE				LI, FP; GARBER, JE			CANCER GENETICS - GENE FOR FAMILIAL BREAST AND OVARIAN-CANCER	LANCET			English	Editorial Material											LI, FP (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CANC EPIDEMIOL & CONTROL,BOSTON,MA 02115, USA.							EASTON DF, 1993, AM J HUM GENET, V52, P678; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; LI FP, 1992, J NATL CANCER I, V84, P1156, DOI 10.1093/jnci/84.15.1156; NAROD SA, 1991, LANCET, V338, P82; SATO T, 1991, CANCER RES, V51, P5794; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741	6	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 24	1993	341	8852					1060	1061		10.1016/0140-6736(93)92416-Q	http://dx.doi.org/10.1016/0140-6736(93)92416-Q			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ018	8096963				2022-12-28	WOS:A1993KZ01800009
J	MCDONALD, JJ; CHANDUVI, B; VELARDE, G; CAMA, R; DIAZ, F; CARRILLO, L; TORRE, V; WATANABE, J; VILLARREAL, J; RAMIREZRAMOS, A; MANTLE, R; GILMAN, RH				MCDONALD, JJ; CHANDUVI, B; VELARDE, G; CAMA, R; DIAZ, F; CARRILLO, L; TORRE, V; WATANABE, J; VILLARREAL, J; RAMIREZRAMOS, A; MANTLE, R; GILMAN, RH			BIOIMPEDANCE MONITORING OF REHYDRATION IN CHOLERA	LANCET			English	Article							BIOELECTRICAL IMPEDANCE; BODY	Measurement of bioimpedance (BI) is a simple non-invasive technique that relies on the different conductivity of tissues to define body composition and can be easily adapted to automated monitoring. We assessed the accuracy of BI in monitoring rehydration and acute fluid fluxes in 35 Peruvian cholera patients. Patients were monitored throughout the acute phase of diarrhoea and followed up at 3 and 10 days. BI was compared with other objective measures of dehydration including packed cell volume, serum protein, and calculated fluid balance. BI rapidly detected inadequate treatment and acute fluid flux, correlating highly with intravascular hydration as measured by serum protein and packed cell volume. BI values during dehydration were significantly raised compared with 10-day convalescent values and age-matched controls (p<0.05). We also encountered an unexpected difference in the bioelectrical response to dehydration and rehydration between sexes. We conclude that BI has uses in monitoring dehydrated patients, in oral rehydration trials, and in physiological studies.	JOHNS HOPKINS UNIV,615 N WOLFE ST,BALTIMORE,MD 21205; LOAYZA HOSP,LIMA,PERU; AB PRISMA,LIMA,PERU; UNIV CALIF DAVIS,DAVIS,CA 95616; UNIV VIRGINIA,CHARLOTTESVILLE,VA 22908; NYU,NEW YORK,NY 10003	Johns Hopkins University; University of California System; University of California Davis; University of Virginia; New York University			McDonald, James/E-2601-2018					DEURENBERG P, 1990, AM J CLIN NUTR, V51, P3, DOI 10.1093/ajcn/51.1.3; LUKASKI HC, 1985, AM J CLIN NUTR, V41, P810, DOI 10.1093/ajcn/41.4.810; MAEHARA T, 1991, EUR J CARDIO-THORAC, V5, P258, DOI 10.1016/1010-7940(91)90174-I; MASAKI DI, 1989, AM J OBSTET GYNECOL, V161, P680, DOI 10.1016/0002-9378(89)90379-7; SCHELTINGA MR, 1991, J SURG RES, V50, P461, DOI 10.1016/0022-4804(91)90025-H; STEEN B, 1988, NUTR REV, V46, P40	6	30	30	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 24	1993	341	8852					1049	1051		10.1016/0140-6736(93)92410-U	http://dx.doi.org/10.1016/0140-6736(93)92410-U			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ018	8096957	hybrid			2022-12-28	WOS:A1993KZ01800003
J	ZENZ, M; WILLWEBERSTRUMPF, A				ZENZ, M; WILLWEBERSTRUMPF, A			OPIOPHOBIA AND CANCER PAIN IN EUROPE	LANCET			English	Article											ZENZ, M (corresponding author), UNIV HOSP BERGMANNSHEIL,DEPT ANAESTHESIOL INTENS CARE & PAIN THERAPY,W-4630 BOCHUM 1,GERMANY.							AGENAS I, 1982, LAKARTIDNINGEN, V5, P287; ANGAROLA RT, 1990, J PAIN SYMPT MANAGEM, V2, P6; Loeser J., 1990, MANAGEMENT PAIN, P2040; PORTER J, 1980, NEW ENGL J MED, V302, P123; Sorge J, 1990, Schmerz, V4, P151, DOI 10.1007/BF02527878; Twycross RG, 1983, SYMPTOM CONTROL FAR; Willweber-Strumpf A, 1992, Schmerz, V6, P255, DOI 10.1007/BF02527815; 1986, CANCER PAIN RELIEF	8	146	148	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 24	1993	341	8852					1075	1076		10.1016/0140-6736(93)92425-S	http://dx.doi.org/10.1016/0140-6736(93)92425-S			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ018	8096970				2022-12-28	WOS:A1993KZ01800017
J	LITTLE, JM				LITTLE, JM			EUPOMPUS GAVE SPLENDOR TO ART BY NUMBERS	LANCET			English	Editorial Material							OBSTRUCTIVE-JAUNDICE; RISK; BYPASS				LITTLE, JM (corresponding author), WESTMEAD HOSP,DEPT SURG,WESTMEAD,NSW 2145,AUSTRALIA.							CLARKE JR, 1991, THEOR SURG, V6, P166; DUDLEY HAF, 1987, BRIT MED J, V295, P389, DOI 10.1136/bmj.295.6594.389-a; EDDY DM, 1992, AM COLL SURG B, V77, P36; FREIREICH EJ, 1983, CONTROVERSIES SURGER, V2, P5; LITTLE JM, 1987, SURGERY, V102, P473; LITTLE JM, 1985, AUST NZ J SURG, V55, P575, DOI 10.1111/j.1445-2197.1985.tb00948.x; LITTLE JM, 1991, AUST NZ J SURG, V62, P327; SUNDT TM, 1987, NEW ENGL J MED, V316, P814, DOI 10.1056/NEJM198703263161318; Toombs S.K, 1992, MEANING ILLNESS; 1985, NEW ENGL J MED, V313, P1191	10	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 3	1993	341	8849					878	880		10.1016/0140-6736(93)93075-C	http://dx.doi.org/10.1016/0140-6736(93)93075-C			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KV811	8096576				2022-12-28	WOS:A1993KV81100018
J	LEFF, JA; PARSONS, PE; DAY, CE; TANIGUCHI, N; JOCHUM, M; FRITZ, H; MOORE, FA; MOORE, EE; MCCORD, JM; REPINE, JE				LEFF, JA; PARSONS, PE; DAY, CE; TANIGUCHI, N; JOCHUM, M; FRITZ, H; MOORE, FA; MOORE, EE; MCCORD, JM; REPINE, JE			SERUM ANTIOXIDANTS AS PREDICTORS OF ADULT RESPIRATORY-DISTRESS SYNDROME IN PATIENTS WITH SEPSIS	LANCET			English	Article							TUMOR NECROSIS FACTOR; SUPEROXIDE-DISMUTASE; FACTOR-VIII; GLUTATHIONE; DEFICIENCY; ELASTASE; ANTIGEN; PROTEIN; INJURY	Adult respiratory distress syndrome (ARDS) can develop as a complication of various disorders, including sepsis, but it has not been possible to identify which of the patients at risk will develop this serious disorder. We have investigated the ability of six markers, measured sequentially in blood, to predict development of ARDS in 26 patients with sepsis. At the initial diagnosis of sepsis (6-24 h before the development of ARDS), serum manganese superoxide dismutase concentration and catalase activity were higher in the 6 patients who subsequently developed ARDS than in 20 patients who did not develop ARDS. These changes in antioxidant enzymes predicted the development of ARDS in septic patients with the same sensitivity, specificity, and efficiency as simultaneous assessments of serum lactate dehydrogenase activity and factor VIII concentration. By contrast, serum glutathione peroxidase activity and alpha1Pi-elastase complex concentration did not differ at the initial diagnosis of sepsis between patients who did and did not subsequently develop ARDS, and were not as effective in predicting the development of ARDS. Measurement of manganese superoxide dismutase and catalase, in addition to the other markers, should facilitate identification of patients at highest risk of ARDS and allow prospective treatment.	OSAKA UNIV,SCH MED,DEPT BIOCHEM,OSAKA,JAPAN; UNIV MUNICH,DEPT CLIN BIOCHEM,W-8000 MUNICH 2,GERMANY; UNIV COLORADO,DENVER GEN HOSP,DEPT MED,DENVER,CO 80202; UNIV COLORADO,DENVER GEN HOSP,DEPT SURG,DENVER,CO 80202	Osaka University; University of Munich; Denver Health Medical Center; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Denver Health Medical Center; University of Colorado System; University of Colorado Denver	LEFF, JA (corresponding author), WEBB WARING INST BIOMED RES,4200 E 9TH AVE,BOX C322,DENVER,CO 80262, USA.		Taniguchi, Naoyuki/I-4182-2014; Taniguchi, Naoyuki/A-7086-2016	Taniguchi, Naoyuki/0000-0001-5889-5968; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL040784, R01HL045582] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 40784, HL-01849, HL 45582] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beutler E., 1984, RED CELL METABOLISM, P1; BROWN JM, 1990, P NATL ACAD SCI USA, V87, P5026, DOI 10.1073/pnas.87.13.5026; BUHL R, 1989, LANCET, V2, P1294; CARVALHO ACA, 1982, NEW ENGL J MED, V307, P1113, DOI 10.1056/NEJM198210283071803; CEJKA J, 1982, CLIN CHEM, V28, P1356; DUSWALD KH, 1985, SURGERY, V98, P892; DWENGER A, 1991, ADULT RESPIRATORY DI, P91; HILGENFELDT U, 1990, EUR J CLIN PHARMACOL, V38, P125; KAWAGUCHI T, 1990, BIOCHEM BIOPH RES CO, V171, P1378, DOI 10.1016/0006-291X(90)90838-E; LEFF JA, 1992, FREE RADICAL BIO MED, V13, P143, DOI 10.1016/0891-5849(92)90076-S; LEFF JA, 1993, INFLAMMATION, V17, P199, DOI 10.1007/BF00916105; LEFF JA, 1992, AM REV RESPIR DIS, V146, P985, DOI 10.1164/ajrccm/146.4.985; PACHT ER, 1991, CHEST, V100, P1397, DOI 10.1378/chest.100.5.1397; PARSONS PE, 1989, AM REV RESPIR DIS, V140, P294, DOI 10.1164/ajrccm/140.2.294; REPINE JE, 1992, LANCET, V339, P466, DOI 10.1016/0140-6736(92)91067-I; ROCKER GM, 1989, LANCET, V1, P120; RUBIN DB, 1990, J CLIN INVEST, V86, P474, DOI 10.1172/JCI114733; SUTER PM, 1992, AM REV RESPIR DIS, V145, P1016, DOI 10.1164/ajrccm/145.5.1016; TANIGUCHI N, 1992, ADV CLIN CHEM, V29, P1, DOI 10.1016/S0065-2423(08)60221-8; WHITE CW, 1989, J APPL PHYSIOL, V66, P1003, DOI 10.1152/jappl.1989.66.2.1003; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703	21	103	111	1	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 27	1993	341	8848					777	780		10.1016/0140-6736(93)90558-X	http://dx.doi.org/10.1016/0140-6736(93)90558-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU900	8095998	Green Submitted			2022-12-28	WOS:A1993KU90000002
J	SPIRA, TJ; JONES, BM; NICHOLSON, JKA; LAL, RB; ROWE, T; MAWLE, AC; LAUTER, CB; SHULMAN, JA; MONSON, RA				SPIRA, TJ; JONES, BM; NICHOLSON, JKA; LAL, RB; ROWE, T; MAWLE, AC; LAUTER, CB; SHULMAN, JA; MONSON, RA			IDIOPATHIC CD4+ T-LYMPHOCYTOPENIA - AN ANALYSIS OF 5 PATIENTS WITH UNEXPLAINED OPPORTUNISTIC INFECTIONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; PNEUMOCYSTIS-CARINII PNEUMONIA; HIV INFECTION; VIRUS; ABSENCE; CELLS; CANDIDIASIS; DEFICIENCY; ANTIGEN; AIDS	Background. Although patients with idiopathic CD4+ T-lymphocytopenia and serious opportunistic infections have been described previously, the clinical and immunologic features of this condition have not been well defined. Methods. We studied in detail five patients with idiopathic CD4+ T-lymphocytopenia. The studies included serologic testing, culture, and polymerase chain reaction for the human immunodeficiency virus (HIV) types 1 and 2, serologic testing for the human T-cell lymphotropic virus (HTLV) types I and II, lymphocyte phenotyping, immunoglobulin quantitation, and lymphocyte-transformation assays, as well as attempts to isolate a retroviral agent. The results were compared with those in HIV-infected persons matched for CD4+ T-cell counts and with those in normal controls. We also studied the spouses of patients and the blood donors for one patient. Results. In these five patients, there was no evidence of either HIV or HTLV infection. All the patients had both low percentages and low counts of CD4+ T cells, with relative increases in percentages, but not counts, of CD8+ cells. Numbers of B cells and natural killer cells were generally normal. As compared with HIV-infected persons, our patients had lower percentages and counts of CD8+ cells and more lymphopenia. CD4+ counts were relatively stable over time. Instead of the high immunoglobulin levels seen in HIV infection, these patients had normal or slightly low levels of immunoglobulins. The lymphocyte-transformation response to mitogens and antigens was depressed. Results in spouses and blood donors were normal. Conclusions. Idiopathic CD4+ T-lymphocytopenia differs from HIV infection in its immunologic characteristics and in its apparent lack of progression over time. Nothing about the immunologic or viral-culture studies performed in these patients or about their family members or blood donors suggests that a transmissible agent causes this condition.	CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV VIRAL & RICKETTSIAL DIS,RETROVIRUS BRANCH,ATLANTA,GA 30333; CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV VIRAL & RICKETTSIAL DIS,HERPESVIRUS BRANCH,ATLANTA,GA 30333; WILLIAM BEAUMONT HOSP,DIV ALLERGY,ROYAL OAK,MI 48072; WILLIAM BEAUMONT HOSP,DIV IMMUNOL,ROYAL OAK,MI 48072; WILLIAM BEAUMONT HOSP,DIV INFECT DIS,ROYAL OAK,MI 48072; EMORY UNIV,SCH MED,DEPT MED,DIV INFECT DIS,ATLANTA,GA 30322; UNIV ARKANSAS MED SCI HOSP,LITTLE ROCK,AR 72205	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Beaumont Health; Beaumont Health; Beaumont Health; Emory University; University of Arkansas System; University of Arkansas Medical Sciences	SPIRA, TJ (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV HIV AIDS,IMMUNOL BRANCH,MAILSTOP D08,ATLANTA,GA 30333, USA.		Rowe, Thomas/AAW-4899-2020					ALEDORT LM, 1993, NEW ENGL J MED, V328, P441, DOI 10.1056/NEJM199302113280614; [Anonymous], 1992, MMWR MORB MORTAL WKL, V41, P541; BOFILL M, 1992, CLIN EXP IMMUNOL, V88, P243, DOI 10.1111/j.1365-2249.1992.tb03068.x; CALLARD RE, 1991, T CELL DEPENDENT IND, P139; CASTRO A, 1992, LANCET, V339, P868, DOI 10.1016/0140-6736(92)90308-P; CHESS Q, 1984, DIAGN CLIN IMMUNOL, V2, P148; COOPER DA, 1988, J INFECT DIS, V157, P889, DOI 10.1093/infdis/157.5.889; COZON G, 1990, NEW ENGL J MED, V322, P132; DAAR ES, 1990, CLIN RES, V38, pA114; DAUS H, 1989, LANCET, V2, P559; GATENBY PA, 1989, LANCET, V1, P1027, DOI 10.1016/S0140-6736(89)92677-9; GAUTIER V, 1991, CLIN EXP ALLERGY, V21, P63, DOI 10.1111/j.1365-2222.1991.tb00805.x; GOLDSMITH MF, 1992, JAMA-J AM MED ASSOC, V268, P1235, DOI 10.1001/jama.268.10.1235; GUPTA S, 1992, P NATL ACAD SCI USA, V89, P7831, DOI 10.1073/pnas.89.16.7831; HANSEN ER, 1990, ARCH DERMATOL, V126, P1604, DOI 10.1001/archderm.126.12.1604; Hollander M., 1973, NONPARAMETRIC STAT, P68; JACKSON JB, 1990, ARCH PATHOL LAB MED, V114, P249; JOWITT SN, 1991, LANCET, V337, P500, DOI 10.1016/0140-6736(91)93445-F; KACZMARSKI RS, 1992, LANCET, V340, P608; KESSLER H, 1992, Morbidity and Mortality Weekly Report, V41, P578; LANE HC, 1985, NEW ENGL J MED, V313, P79, DOI 10.1056/NEJM198507113130204; LAURENCE J, 1992, LANCET, V340, P273, DOI 10.1016/0140-6736(92)92359-N; LEHMANN PF, 1983, AM J MED, V75, P790, DOI 10.1016/0002-9343(83)90409-6; MOLLENHAUER HH, 1964, STAIN TECHNOL, V39, P111; OU CY, 1988, SCIENCE, V239, P295, DOI 10.1126/science.3336784; OU CY, 1990, AIDS RES HUM RETROV, V6, P1323, DOI 10.1089/aid.1990.6.1323; PANKHURST C, 1989, LANCET, V1, P672; REICHERT T, 1991, CLIN IMMUNOL IMMUNOP, V60, P190, DOI 10.1016/0090-1229(91)90063-G; ROGERS MF, 1983, ANN INTERN MED, V99, P151, DOI 10.7326/0003-4819-99-2-151; Scalzini A, 1990, Acta Neurol (Napoli), V12, P301; SCHNITTMAN SM, 1986, SCIENCE, V233, P1084, DOI 10.1126/science.3016902; Seligmann M, 1983, Birth Defects Orig Artic Ser, V19, P153; SELIGMANN M, 1991, LANCET, V337, P57, DOI 10.1016/0140-6736(91)93382-J; SHAFER RW, 1991, AIDS, V5, P399, DOI 10.1097/00002030-199104000-00007; SMITH DK, 1993, NEW ENGL J MED, V328, P373, DOI 10.1056/NEJM199302113280601; SPICKETT G P, 1990, Immunodeficiency Reviews, V2, P199; SPIRA TJ, 1987, J CLIN MICROBIOL, V25, P97, DOI 10.1128/JCM.25.1.97-99.1987; VELLECA WM, 1991, ISOLATION CULTURE ID; WEISS SH, 1992, LANCET, V340, P608; WILLIAMS RC, 1983, AM J MED, V75, P807, DOI 10.1016/0002-9343(83)90412-6; 1989, MMWR MORB MORTAL SS7, V38, P1	41	134	136	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 11	1993	328	6					386	392		10.1056/NEJM199302113280603	http://dx.doi.org/10.1056/NEJM199302113280603			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KL584	8093635				2022-12-28	WOS:A1993KL58400003
J	KALACHE, A; MAGUIRE, A; THOMPSON, SG				KALACHE, A; MAGUIRE, A; THOMPSON, SG			AGE AT LAST FULL-TERM PREGNANCY AND RISK OF BREAST-CANCER	LANCET			English	Article							REPRODUCTIVE FACTORS; 1ST BIRTH; PARITY; EPIDEMIOLOGY; POPULATION; WOMEN	Age at first full-term pregnancy (FTP) has long been thought to be the major reproductive risk factor in breast cancer but a Norwegian study suggested that age at last FTP might be more important. In Norway ''high parity'' means 4 or more deliveries. Does this finding hold in an area with a much broader distribution of parity? Data from a case-control study done in 1980-82 in Fortaleza and Recife, two cities in Brazil's impoverished north-east, have been used to explore further the influence of age at last FTP. The cases were 509 women with histologically diagnosed breast cancer who were matched with hospital controls for age and area of residence. The analysis was based on case-control pairs interviewed by the same person. High breast cancer risk was associated with low parity; after adjustment for parity, breast cancer risk was related both to late age at first FTP (odds ratio [OR] 1.21 for each 5 year increase, p = 0.008) and to late age at last FTP (OR 1.24, p = 0.0007). However, multivariate analysis revealed that the effect of age at last FTP dominated that of age at first FTP: once age at last FTP was taken into account the effect of age at first FTP was no longer significant (OR 1.08, p = 0.38) while the association with parity became more striking. These results challenge the view that age at first FTP is the principal reproductive variable related to breast cancer risk. Moreover, they suggest that high parity is protective independent of ages at first and last FTP. Given recent worldwide reductions in fertility rates, breast cancer incidence may be expected to increase. Balancing that may be the willingness of some women to complete their families by, say, age 35 if they were to be told that this might reduce their risk of breast cancer.	UNIV LONDON LONDON SCH HYG & TROP MED, MED STAT UNIT, LONDON WC1E 7HT, ENGLAND	University of London; London School of Hygiene & Tropical Medicine	KALACHE, A (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED, HLTH PROMOT SCI UNIT, KEPPEL ST, LONDON WC1E 7HT, ENGLAND.							ADAMI HO, 1980, BRIT J CANCER, V42, P651, DOI 10.1038/bjc.1980.298; ARRUDA JM, 1987, PESQUISA NACIONAL SA; Breslow N, 1980, STATISTICAL METHODS, V32; BRINTON LA, 1983, BRIT J CANCER, V47, P757, DOI 10.1038/bjc.1983.128; CHOI NW, 1978, AM J EPIDEMIOL, V107, P510, DOI 10.1093/oxfordjournals.aje.a112570; EWERTZ M, 1988, BRIT J CANCER, V58, P99, DOI 10.1038/bjc.1988.172; HLAING T, 1978, INT J CANCER, V21, P432, DOI 10.1002/ijc.2910210406; Kalache A., 1990, Health Policy and Planning, V5, P1, DOI 10.1093/heapol/5.1.1; KALCHE A, 1992, THESIS U LONDON; Kelsey J L, 1979, Epidemiol Rev, V1, P74; KVALE G, 1987, AM J EPIDEMIOL, V126, P842, DOI 10.1093/oxfordjournals.aje.a114721; KVALE G, 1987, AM J EPIDEMIOL, V126, P831, DOI 10.1093/oxfordjournals.aje.a114720; LAVECCHIA C, 1987, INT J EPIDEMIOL, V16, P347, DOI 10.1093/ije/16.3.347; LAYDE PM, 1986, AM J EPIDEMIOL, V124, P516; LIPNICK R, 1984, CANCER-AM CANCER SOC, V53, P1020, DOI 10.1002/1097-0142(19840215)53:4<1020::AID-CNCR2820530433>3.0.CO;2-G; MACMAHON B, 1970, B WORLD HEALTH ORGAN, V43, P209; MACMAHON B, 1982, JNCI-J NATL CANCER I, V69, P1035; MILLER A, 1984, TRENDS CANCER INCIDE, P231; MILLER AB, 1986, INT J CANCER, V37, P173, DOI 10.1002/ijc.2910370202; MIRRA AP, 1971, CANCER RES, V31, P77; PATHAK DR, 1986, INT J CANCER, V37, P21, DOI 10.1002/ijc.2910370105; PIKE MC, 1981, BANBURY REPORT, V8, P3; SOINI I, 1977, INT J EPIDEMIOL, V6, P365, DOI 10.1093/ije/6.4.365; TRAPIDO EJ, 1983, CANCER, V51, P946, DOI 10.1002/1097-0142(19830301)51:5<946::AID-CNCR2820510530>3.0.CO;2-2; TRICHOPOULOS D, 1983, INT J CANCER, V31, P701, DOI 10.1002/ijc.2910310604; TULINIUS H, 1982, INT J CANCER, V29, P365; VESSEY M, 1983, BRIT J CANCER, V47, P455, DOI 10.1038/bjc.1983.74; WYNDER EL, 1978, CANCER-AM CANCER SOC, V41, P2341, DOI 10.1002/1097-0142(197806)41:6<2341::AID-CNCR2820410637>3.0.CO;2-N; 1992, 1992 WORLD BANK WORL	29	69	71	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 2	1993	341	8836					33	36		10.1016/0140-6736(93)92497-H	http://dx.doi.org/10.1016/0140-6736(93)92497-H			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF027	8093279				2022-12-28	WOS:A1993KF02700018
J	BEKENSTEIN, JW; LOTHMAN, EW				BEKENSTEIN, JW; LOTHMAN, EW			DORMANCY OF INHIBITORY INTERNEURONS IN A MODEL OF TEMPORAL-LOBE EPILEPSY	SCIENCE			English	Article							HIPPOCAMPAL PYRAMIDAL CELLS; INDUCED EPILEPTIFORM ACTIVITY; LIMBIC STATUS EPILEPTICUS; SYNAPTIC REORGANIZATION; POSTSYNAPTIC RESPONSES; FEEDFORWARD INHIBITION; RAT HIPPOCAMPUS; NEURON LOSS; INVITRO; SEIZURES	In humans temporal lobe epilepsy (TLE) is characterized by recurrent seizures, neuronal hyperexcitability, and selective loss of certain neuronal populations in the hippocampus. Animal models of the condition indicate that a diminution of inhibition mediated by gamma-aminobutyric acid (GABA) accounts for the altered function, and it has been hypothesized that the diminution arises because GABAergic basket interneurons are ''dormant'' as a result of their being disconnected from excitatory inputs. In hippocampal slices, inhibitory postsynaptic potentials (IPSPs) were elicited in CA1 pyramidal cells by activation of basket cells; responses from an animal model of TLE were compared to those from control tissue. IPSPs evoked indirectly by activation of terminals that then excited basket cells were reduced in the epileptic tissue, whereas IPSPs evoked by direct activation of basket cells, when excitatory neurotransmission was blocked, were not different from controls. These results provide support for the ''dormant basket cell'' hypothesis and have implications for the pathophysiology and treatment of human TLE.	UNIV VIRGINIA,HLTH SCI CTR,DEPT NEUROL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,HLTH SCI CTR,NEUROSCI PROGRAM,CHARLOTTESVILLE,VA 22908	University of Virginia; University of Virginia								ALGER BE, 1982, J PHYSIOL-LONDON, V328, P105, DOI 10.1113/jphysiol.1982.sp014255; ANDERSEN P, 1969, INTERNEURON, P415; ASHWOOD TJ, 1986, BRAIN RES, V367, P390, DOI 10.1016/0006-8993(86)91625-2; ASHWOOD TJ, 1984, BRAIN RES, V293, P279, DOI 10.1016/0006-8993(84)91235-6; AVOLI M, 1992, EUR J NEUROSCI, V4, P16, DOI 10.1111/j.1460-9568.1992.tb00105.x; BABB TL, 1984, EPILEPSIA, V25, P721, DOI 10.1111/j.1528-1157.1984.tb03483.x; BABB TL, 1991, NEUROSCIENCE, V42, P351, DOI 10.1016/0306-4522(91)90380-7; BERTRAM EH, 1990, ANN NEUROL, V27, P43, DOI 10.1002/ana.410270108; BUZSAKI G, 1984, PROG NEUROBIOL, V22, P131, DOI 10.1016/0301-0082(84)90023-6; CRONIN J, 1992, BRAIN RES, V573, P305, DOI 10.1016/0006-8993(92)90777-7; CURTIS DR, 1970, BRIT J PHARMACOL, V40, P881, DOI 10.1111/j.1476-5381.1970.tb10663.x; DAM AM, 1982, ACTA NEUROL SCAND, V66, P601, DOI 10.1111/j.1600-0404.1982.tb04528.x; DAVIES CH, 1990, J PHYSIOL-LONDON, V424, P513, DOI 10.1113/jphysiol.1990.sp018080; DICHTER M, 1969, J NEUROPHYSIOL, V32, P649, DOI 10.1152/jn.1969.32.5.649; DINGLEDINE R, 1980, J PHYSIOL-LONDON, V305, P297, DOI 10.1113/jphysiol.1980.sp013364; FALCONER MA, 1974, LANCET, V2, P767; FRANCK JE, 1985, BRAIN RES, V329, P309, DOI 10.1016/0006-8993(85)90540-2; FRANCK JE, 1988, J NEUROSCI, V8, P1991; HABLITZ JJ, 1984, J NEUROPHYSIOL, V51, P1011, DOI 10.1152/jn.1984.51.5.1011; JENSEN MS, 1988, ANN NEUROL, V24, P591, DOI 10.1002/ana.410240502; KAPUR J, 1989, J NEUROPHYSIOL, V61, P427, DOI 10.1152/jn.1989.61.2.427; LACAILLE JC, 1988, J NEUROSCI, V8, P1411; LOTHMAN EW, 1990, EPILEPSY RES, V6, P110, DOI 10.1016/0920-1211(90)90085-A; LOTHMAN EW, 1991, PROG NEUROBIOL, V37, P1, DOI 10.1016/0301-0082(91)90011-O; LOTHMAN EW, 1989, EPILEPSY RES, V3, P107, DOI 10.1016/0920-1211(89)90038-7; MAGIERSON JH, 1966, BRAIN, V89, P499; MILES R, 1987, J PHYSIOL-LONDON, V388, P611, DOI 10.1113/jphysiol.1987.sp016634; MILES R, 1987, NATURE, V329, P724, DOI 10.1038/329724a0; Nakajima S, 1991, Hippocampus, V1, P67, DOI 10.1002/hipo.450010107; NEWBERRY NR, 1984, J PHYSIOL-LONDON, V348, P239, DOI 10.1113/jphysiol.1984.sp015107; RIBAK CE, 1987, SCIENCE, V238, P1292, DOI 10.1126/science.3685980; SAGAR HJ, 1987, ANN NEUROL, V22, P334, DOI 10.1002/ana.410220309; SCHWARTZKROIN PA, 1975, BRAIN RES, V85, P423, DOI 10.1016/0006-8993(75)90817-3; SCHWARTZKROIN PA, 1978, BRAIN RES, V147, P117, DOI 10.1016/0006-8993(78)90776-X; Sloviter R S, 1991, Hippocampus, V1, P41, DOI 10.1002/hipo.450010106; SLOVITER RS, 1992, NEUROSCI LETT, V137, P91, DOI 10.1016/0304-3940(92)90306-R; SLOVITER RS, 1987, SCIENCE, V238, P1292, DOI 10.1126/science.238.4831.1292-a; SLOVITER RS, 1987, SCIENCE, V235, P73, DOI 10.1126/science.2879352; SUTULA T, 1988, SCIENCE, V239, P1147, DOI 10.1126/science.2449733; SUTULA T, 1989, ANN NEUROL, V26, P321, DOI 10.1002/ana.410260303; TRAYNELIS SF, 1988, J NEUROPHYSIOL, V59, P259, DOI 10.1152/jn.1988.59.1.259; VANLANDINGHAM KE, 1991, NEUROLOGY, V41, P1942, DOI 10.1212/WNL.41.12.1942; VANLANDINGHAM KE, 1991, NEUROLOGY, V41, P1950, DOI 10.1212/WNL.41.12.1950; WIESER HG, IN PRESS SURGICAL TR; WONG RKS, 1982, J NEUROPHYSIOL, V48, P938, DOI 10.1152/jn.1982.48.4.938; WONG RKS, 1979, SCIENCE, V204, P1228, DOI 10.1126/science.451569; WOODBURY DM, 1980, ANTIEPILEPTIC DRUGS, P249	47	185	187	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 1	1993	259	5091					97	100		10.1126/science.8093417	http://dx.doi.org/10.1126/science.8093417			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KE601	8093417				2022-12-28	WOS:A1993KE60100038
J	RINGWALD, M; BALDOCK, R; BARD, J; KAUFMAN, M; EPPIG, JT; RICHARDSON, JE; NADEAU, JH; DAVIDSON, D				RINGWALD, M; BALDOCK, R; BARD, J; KAUFMAN, M; EPPIG, JT; RICHARDSON, JE; NADEAU, JH; DAVIDSON, D			A DATABASE FOR MOUSE DEVELOPMENT	SCIENCE			English	Editorial Material							COMPUTER		WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,EDINBURGH,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,DEPT ANAT,EDINBURGH,SCOTLAND	University of Edinburgh; University of Edinburgh	RINGWALD, M (corresponding author), JACKSON LAB,600 MAIN ST,BAR HARBOR,ME 04609, USA.			Baldock, Richard/0000-0003-0332-6877	Medical Research Council [MC_U127527203] Funding Source: Medline; MRC [MC_U127527203] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ASHBURNER M, 1994, DEVELOPMENT, V120, P2077; BAIROCH A, 1993, NUCLEIC ACIDS RES, V21, P3093, DOI 10.1093/nar/21.13.3093; BALDOCK R, 1992, BIOESSAYS, V14, P501, DOI 10.1002/bies.950140713; BARAITSER M, 1993, DYSMORPHOLOGY DATABA; BARKER W, 1993, NUCLEIC ACIDS RES, V21, P3089, DOI 10.1093/nar/21.13.3089; BENSON D, 1993, NUCLEIC ACIDS RES, V21, P2936; BUCHER P, 1993, EUKARYOTIC PROMOTER; BUYSE ML, 1987, AM J PERINAT, V4, P8, DOI 10.1055/s-2007-999728; CUTICCHIA AJ, 1993, NUCLEIC ACIDS RES, V21, P3003, DOI 10.1093/nar/21.13.3003; Davisson MT, 1989, GENETIC VARIANTS STR, P432; DURBIN R, 1993, 1ST P INT C INT SYST, P411; GOSH D, 1993, NUCLEIC ACIDS RES, V21, P3117; HARTENSTEIN V, 1993, DEV DROSOPHILA; JACOBS RE, 1994, SCIENCE, V263, P681, DOI 10.1126/science.7508143; Kaufman M.H., 1992, ATLAS MOUSE DEV; RICE CM, 1993, NUCLEIC ACIDS RES, V21, P2967, DOI 10.1093/nar/21.13.2967; SCHATZ BR, 1994, SCIENCE, V265, P895, DOI 10.1126/science.265.5174.895; SIKELA JM, 1993, NAT GENET, V3, P189, DOI 10.1038/ng0393-189; SMITH BR, 1994, P NATL ACAD SCI USA, V91, P3530, DOI 10.1073/pnas.91.9.3530; TAKAHASHI JS, 1994, SCIENCE, V264, P1724, DOI 10.1126/science.8209253	20	87	88	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 30	1994	265	5181					2033	2034		10.1126/science.8091224	http://dx.doi.org/10.1126/science.8091224			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PJ912	8091224				2022-12-28	WOS:A1994PJ91200019
J	BURTON, JL				BURTON, JL			DERMATOLOGY - EPIDEMIC BLACK SPOTS ON THE SCALP	LANCET			English	Editorial Material											BURTON, JL (corresponding author), BRISTOL ROYAL INFIRM & GEN HOSP,DEPT DERMATOL,BRISTOL BS2 8HW,AVON,ENGLAND.							COBB N, 1993, WESTERN J MED, V158, P139; Spitzer W O, 1987, Trans Assoc Am Physicians, V100, P40	2	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 1	1993	341	8853					1127	1127		10.1016/0140-6736(93)93135-N	http://dx.doi.org/10.1016/0140-6736(93)93135-N			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ687	8097811				2022-12-28	WOS:A1993KZ68700011
J	OGAWA, O; ECCLES, MR; SZETO, J; MCNOE, LA; YUN, K; MAW, MA; SMITH, PJ; REEVE, AE				OGAWA, O; ECCLES, MR; SZETO, J; MCNOE, LA; YUN, K; MAW, MA; SMITH, PJ; REEVE, AE			RELAXATION OF INSULIN-LIKE GROWTH FACTOR-II GENE IMPRINTING IMPLICATED IN WILMS-TUMOR	NATURE			English	Article							WIEDEMANN-BECKWITH SYNDROME; CARCINOGENESIS; DISOMY	GENOMIC imprinting has been implicated in the onset of several embryonal tumours but the mechanism is not well understood1-3. Maternal chromosome 11p15 loss of heterozygosity4 and paternal chromosome 11 isodisomy 5,6 suggest that imprinted genes are involved in the onset of Wilms' tumour and the Beckwith-Wiedemann syndrome. The insulin-like growth factor II (IGF2) gene located at 11p15.5 has been put forward as a candidate gene as it is maternally imprinted (paternally expressed) in the mouse7, and is expressed at high levels in Wilms' tumours8,9. We report here that the IGF2 gene is expressed from the paternal allele in human fetal tissue, but that in Wilms' tumour expression can occur biallelically. These results provide, to our knowledge, the first evidence that relaxation of imprinting may play a role in the onset of disease and suggest a new genetic mechanism involved in the development of cancer.	UNIV OTAGO,DEPT BIOCHEM,CANC GENET LAB,DUNEDIN,NEW ZEALAND; UNIV OTAGO,DEPT PATHOL,DUNEDIN,NEW ZEALAND; UNIV QUEENSLAND,DEPT PATHOL,HERSTON,QLD 4006,AUSTRALIA	University of Otago; University of Otago; University of Queensland								ALECK KA, 1989, AM J MED GENET, V33, P155, DOI 10.1002/ajmg.1320330202; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; FERGUSONSMITH AC, 1991, NATURE, V351, P667, DOI 10.1038/351667a0; GRUNDY P, 1991, LANCET, V338, P1079, DOI 10.1016/0140-6736(91)91937-P; HENRY I, 1991, NATURE, V351, P665, DOI 10.1038/351665a0; JUNIEN C, 1992, GENOMICS, V12, P620, DOI 10.1016/0888-7543(92)90461-Z; KOUFOS A, 1989, AM J HUM GENET, V44, P711; LITTLE M, 1991, NATURE, V351, P609, DOI 10.1038/351609a0; MOORE T, 1991, TRENDS GENET, V7, P45, DOI 10.1016/0168-9525(91)90230-N; MOUTOU C, 1992, J MED GENET, V29, P217, DOI 10.1136/jmg.29.4.217; OLSHAN AF, 1986, CANCER GENET CYTOGEN, V21, P303, DOI 10.1016/0165-4608(86)90209-8; PONDER B, 1989, NATURE, V340, P264, DOI 10.1038/340264a0; REEVE AE, 1985, NATURE, V317, P258, DOI 10.1038/317258a0; REIK W, 1989, NATURE, V338, P112, DOI 10.1038/338112a0; REIK W, 1989, TRENDS GENET, V5, P331, DOI 10.1016/0168-9525(89)90138-8; Sambrook J, 1989, MOL CLONING LABORATO; SCOTT J, 1985, NATURE, V317, P261; TADOKORO K, 1991, NUCLEIC ACIDS RES, V19, P6967, DOI 10.1093/nar/19.24.6967; VIJOEN D, 1992, J MED GENET, V29, P221; WILKINS RJ, 1988, LANCET, V1, P329	21	682	698	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 22	1993	362	6422					749	751		10.1038/362749a0	http://dx.doi.org/10.1038/362749a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KY450	8097018				2022-12-28	WOS:A1993KY45000056
J	SELBY, JV				SELBY, JV			DISEASE PREVENTION - SCREENING SIGMOIDOSCOPY FOR COLORECTAL-CANCER	LANCET			English	Editorial Material							COST-EFFECTIVENESS				SELBY, JV (corresponding author), KAISER PERMANENTE,DIV RES,OAKLAND,CA 94608, USA.							ATKIN WS, 1992, NEW ENGL J MED, V326, P658, DOI 10.1056/NEJM199203053261002; EDDY DM, 1990, ANN INTERN MED, V113, P373, DOI 10.7326/0003-4819-113-5-373; LEVIN B, 1992, CA-CANCER J CLIN, V42, P296, DOI 10.3322/canjclin.42.5.296; MORSON BC, 1976, CLIN GASTROENTEROL, V5, P505; RANSOHOFF DF, 1991, ANN INTERN MED, V114, P177, DOI 10.7326/0003-4819-114-3-177; SELBY JV, 1992, NEW ENGL J MED, V326, P653, DOI 10.1056/NEJM199203053261001; STRYKER SJ, 1987, GASTROENTEROLOGY, V93, P1009, DOI 10.1016/0016-5085(87)90563-4; WAGNER JL, 1991, ANN INTERN MED, V115, P807, DOI 10.7326/0003-4819-115-10-807; 1989, CANCER LETT, V15, P1; 1988, WORKING GUIDELINES E	10	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 20	1993	341	8847					728	729		10.1016/0140-6736(93)90493-Z	http://dx.doi.org/10.1016/0140-6736(93)90493-Z			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KT362	8095630				2022-12-28	WOS:A1993KT36200010
J	JACOBY, GC; WAGNER, WS				JACOBY, GC; WAGNER, WS			DENDOCHRONOLOGY - TREE-RING ANALYSIS - BRIDGING NOW AND THEN	LANCET			English	Editorial Material											JACOBY, GC (corresponding author), LAMONT DOHERTY EARTH OBSERV,TREE RING LAB,PALISADES,NY, USA.							Baillie M.G.L., 1982, TREE RING DATING ARC; CHRISTENSEN DJ, 1977, FORESTS PEOPLE, V27, P3; Cook E., 1992, Holocene, V2, P205, DOI 10.1177/095968369200200302; JACOBY GC, 1989, CLIMATIC CHANGE, V14, P39, DOI 10.1007/BF00140174; JACOBY GC, 1988, SCIENCE, V241, P196, DOI 10.1126/science.241.4862.196; JACOBY GC, 1992, SCIENCE, V258, P1621, DOI 10.1126/science.258.5088.1621; YAMAGUCHI DK, 1983, QUATERNARY RES, V20, P246, DOI 10.1016/0033-5894(83)90080-7	7	1	1	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 13	1993	341	8846					666	667		10.1016/0140-6736(93)90428-J	http://dx.doi.org/10.1016/0140-6736(93)90428-J			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR613	8095577				2022-12-28	WOS:A1993KR61300012
J	HENRY, DA				HENRY, DA			GASTROINTESTINAL HEMORRHAGE - FIBRINOLYSIS AND UPPER GASTROINTESTINAL-BLEEDING	LANCET			English	Editorial Material							HEMORRHAGE				HENRY, DA (corresponding author), NEWCASTLE MATER MISERICORDIAE HOSP, DEPT CLIN PHARMACOL, NEWCASTLE, NSW, AUSTRALIA.		Henry, David/AAU-4650-2020; Henry, David/L-3895-2017	Henry, David/0000-0001-7169-7704; Henry, David/0000-0003-2934-2242				BERSTAD A, 1988, SCAND J GASTROENTERO, V23, P402, DOI 10.3109/00365528809093886; BERSTAD A, 1982, SCAND J GASTROENTERO, V17, P103; BROWN C, 1992, BRIT MED J, V304, P135, DOI 10.1136/bmj.304.6820.135; COLLINS R, 1985, NEW ENGL J MED, V313, P660, DOI 10.1056/NEJM198509123131104; HENRY DA, 1989, BMJ-BRIT MED J, V298, P1142, DOI 10.1136/bmj.298.6681.1142; INFANTERIVARD C, 1989, GASTROENTEROLOGY, V96, P1087, DOI 10.1016/0016-5085(89)91627-2; ISACSON S, 1987, SCAND J GASTROENTERO, V22, P19, DOI 10.3109/00365528709089755; SACKS HS, 1990, JAMA-J AM MED ASSOC, V264, P494, DOI 10.1001/jama.264.4.494; VIOLI F, 1992, HEPATOLOGY, V15, P672, DOI 10.1002/hep.1840150420	9	2	3	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 27	1993	341	8844					527	528		10.1016/0140-6736(93)90284-N	http://dx.doi.org/10.1016/0140-6736(93)90284-N			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP083	8094777				2022-12-28	WOS:A1993KP08300010
J	GWILT, DJ				GWILT, DJ			MYOCARDIAL-INFARCTION - CARDIAC ENZYMES AT THE BEDSIDE	LANCET			English	Editorial Material											GWILT, DJ (corresponding author), MILTON KEYNES DIST GEN HOSP,MILTON KEYNES,ENGLAND.							FINEBERG HV, 1984, NEW ENGL J MED, V310, P1301, DOI 10.1056/NEJM198405173102006; LEE TH, 1985, ARCH INTERN MED, V145, P65, DOI 10.1001/archinte.145.1.65; LEE TH, 1986, ANN INTERN MED, V105, P221, DOI 10.7326/0003-4819-105-2-221; RUDE RE, 1983, AM J CARDIOL, V52, P936, DOI 10.1016/0002-9149(83)90508-8; TIMMIS AD, 1990, BMJ-BRIT MED J, V301, P941, DOI 10.1136/bmj.301.6758.941	5	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 20	1993	341	8843					469	470		10.1016/0140-6736(93)90214-2	http://dx.doi.org/10.1016/0140-6736(93)90214-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN137	8094494				2022-12-28	WOS:A1993KN13700011
J	LEE, A				LEE, A			PEPTIC-ULCERATION - H-PYLORI-INITIATED ULCEROGENESIS - LOOK TO THE HOST	LANCET			English	Editorial Material											LEE, A (corresponding author), UNIV NEW S WALES,SCH MICROBIOL & IMMUNOL,SYDNEY,NSW,AUSTRALIA.							AKOPYANZ N, 1992, NUCLEIC ACIDS RES, V20, P5137, DOI 10.1093/nar/20.19.5137; MITCHELL HM, 1992, J INFECT DIS, V166, P149, DOI 10.1093/infdis/166.1.149; NWOKOLO CU, 1992, GUT, V33, P1323, DOI 10.1136/gut.33.10.1323; SOLNICK J, IN PRESS INFECT AGEN; TAYLOR DE, 1992, ANNU REV MICROBIOL, V46, P35, DOI 10.1146/annurev.micro.46.1.35	5	39	39	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 30	1993	341	8840					280	281		10.1016/0140-6736(93)92624-3	http://dx.doi.org/10.1016/0140-6736(93)92624-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK245	8093924				2022-12-28	WOS:A1993KK24500012
J	HENNEY, AM; ADISESHIAH, M; POULTER, N; MACSWEENEY, STR; GREENHALGH, RM; POWELL, JT				HENNEY, AM; ADISESHIAH, M; POULTER, N; MACSWEENEY, STR; GREENHALGH, RM; POWELL, JT			ABDOMINAL AORTIC-ANEURYSM - REPORT OF A MEETING OF PHYSICIANS AND SCIENTISTS, UNIVERSITY-COLLEGE-LONDON MEDICAL-SCHOOL	LANCET			English	Discussion							MARFAN-SYNDROME; PROGNOSIS; MUTATION; FAMILY; GENES; MEN		UNIV COLL HOSP LONDON,WC1 LONDON,ENGLAND; UCL,SCH MED,DEPT EPIDEMIOL & PUBL HLTH,LONDON,ENGLAND; CHARING CROSS & WESTMINSTER MED SCH,DEPT SURG,LONDON,ENGLAND	University College London Hospitals NHS Foundation Trust; University of London; University College London; UCL Medical School; Imperial College London	HENNEY, AM (corresponding author), UNIV LONDON UNIV COLL,SCH MED,RAYNE INST,CTR GENET CARDIOVASC DISORDERS,UNIV ST,LONDON WC1E 6JJ,ENGLAND.		Powell, Janet/AAW-8669-2021	Powell, Janet/0000-0002-3905-1468				ADAMSON J, 1992, BRIT J SURG, V79, P897, DOI 10.1002/bjs.1800790914; AKKERSDIJK GJM, 1991, BRIT J SURG, V78, P1261, DOI 10.1002/bjs.1800781037; BEARD K, 1992, BMJ-BRIT MED J, V304, P412, DOI 10.1136/bmj.304.6824.412; BENGTSSON H, 1989, BRIT J SURG, V76, P589, DOI 10.1002/bjs.1800760620; BURTON AC, 1954, PHYSIOL REV, V34, P619, DOI 10.1152/physrev.1954.34.4.619; CAMPA JS, 1987, ATHEROSCLEROSIS, V65, P13, DOI 10.1016/0021-9150(87)90003-7; CASTLEDEN WM, 1985, BRIT J SURG, V72, P109, DOI 10.1002/bjs.1800720213; Collin J, 1989, Eur J Vasc Surg, V3, P15, DOI 10.1016/S0950-821X(89)80102-1; COLLIN J, 1988, LANCET, V2, P613; DIETZ HC, 1991, NATURE, V352, P337, DOI 10.1038/352337a0; DUBOST C, 1952, ARCH SURG-CHICAGO, V643, P405; FOWKES FGR, 1989, BRIT MED J, V298, P33, DOI 10.1136/bmj.298.6665.33; GREENHALGH RM, 1990, BRIT MED J, V301, P136, DOI 10.1136/bmj.301.6744.136; HAMMOND EC, 1969, ARCH ENVIRON HEALTH, V19, P167, DOI 10.1080/00039896.1969.10666825; JOHANSEN K, 1986, JAMA-J AM MED ASSOC, V256, P1934, DOI 10.1001/jama.256.14.1934; KONTUSAARI S, 1990, J CLIN INVEST, V86, P1465, DOI 10.1172/JCI114863; KUIVANIEMI H, 1991, FASEB J, V5, P2052, DOI 10.1096/fasebj.5.7.2010058; LABORDE JC, 1992, RADIOLOGY, V184, P185, DOI 10.1148/radiology.184.1.1535160; LEE B, 1991, NATURE, V352, P330, DOI 10.1038/352330a0; LIDDINGTON MI, 1992, EUR J VASCULAR SURG, V6, P89, DOI 10.1016/S0950-821X(05)80101-X; MACSWEENEY STR, IN PRESS BR J SURG; MELTON LJ, 1984, AM J EPIDEMIOL, V120, P379, DOI 10.1093/oxfordjournals.aje.a113902; NEVITT MP, 1989, NEW ENGL J MED, V321, P1009, DOI 10.1056/NEJM198910123211504; NORRGARD O, 1985, BRIT J SURG, V72, P113, DOI 10.1002/bjs.1800720215; OKELLY TJ, 1989, BRIT J SURG, V76, P479, DOI 10.1002/bjs.1800760517; Parodi J C, 1991, Ann Vasc Surg, V5, P491, DOI 10.1007/BF02015271; PARUMS DV, 1990, ARCH PATHOL LAB MED, V114, P383; Powell J T, 1987, Eur J Vasc Surg, V1, P29, DOI 10.1016/S0950-821X(87)80020-8; POWELL JT, 1990, CLIN SCI, V78, P13, DOI 10.1042/cs0780013; PROCKOP DJ, 1992, NEW ENGL J MED, V326, P540; SCOTT RAP, 1988, BRIT MED J, V296, P1709, DOI 10.1136/bmj.296.6638.1709-a; SMITH T, 1991, BRIT MED J, V303, P1395, DOI 10.1136/bmj.303.6814.1395; STRACHAN DP, 1991, BRIT J SURG, V78, P401, DOI 10.1002/bjs.1800780407; TILSON MD, 1984, SURG GYNECOL OBSTET, V158, P129; Volodos N L, 1991, Vasa Suppl, V33, P93; WEBSTER MW, 1991, J VASC SURG, V13, P366, DOI 10.1067/mva.1991.26359; 1992, HLTH NATION	37	33	34	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 23	1993	341	8839					215	220		10.1016/0140-6736(93)90077-T	http://dx.doi.org/10.1016/0140-6736(93)90077-T			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ219	8093508				2022-12-28	WOS:A1993KJ21900015
J	BLEI, AT; OLAFSSON, S; WEBSTER, S; LEVY, R				BLEI, AT; OLAFSSON, S; WEBSTER, S; LEVY, R			COMPLICATIONS OF INTRACRANIAL-PRESSURE MONITORING IN FULMINANT HEPATIC-FAILURE	LANCET			English	Article								In patients with fulminant hepatic failure, brain oedema and the resulting intracranial hypertension often lead to death; intracranial pressure (ICP) monitoring may therefore be valuable. However, there is uncertainty about the hazards of implanting ICP monitoring devices. We carried out a survey of complications associated with ICP monitoring among centres performing liver transplantation in the USA (n=262 patients). Epidural transducers were the most commonly used devices and had the lowest complication rate (3.8%); subdural bolts and parenchymal monitors (fibreoptic pressure transducers in direct contact with brain parenchyma and intraventricular catheters) were associated with complication rates of 20% and 22%, respectively. Fatal haemorrhage occurred in 1% of patients undergoing epidural ICP monitoring, whereas subdural and intraparenchymal devices had fatal haemorrhage rates of 5% and 4%. Thus, in the setting of fulminant hepatic failure, epidural transducers may be the safest choice for ICP monitoring, even though they are known to be less precise than the other devices.	NORTHWESTERN UNIV,SCH MED,DEPT MED,CHICAGO,IL 60611; NORTHWESTERN UNIV,SCH MED,DEPT NEUROSURG,CHICAGO,IL 60611	Northwestern University; Northwestern University								BLEI AT, 1991, HEPATOLOGY, V13, P376, DOI 10.1016/0270-9139(91)92455-H; INAGAKI M, 1992, Gastroenterology, V102, pA826; Kanter M J, 1991, Neurosurg Clin N Am, V2, P257; LIDOFSKY SD, 1992, HEPATOLOGY, V16, P1, DOI 10.1002/hep.1840160102; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; OGRADY JG, 1989, GASTROENTEROLOGY, V97, P439, DOI 10.1016/0016-5085(89)90081-4; SCHAFER DF, 1989, SEMIN LIVER DIS, V9, P189, DOI 10.1055/s-2008-1040512; STONE JL, 1989, SEMIN NEUROL, V9, P218, DOI 10.1055/s-2008-1041328; 1991, LANCET, V338, P156	9	173	177	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 16	1993	341	8838					157	158		10.1016/0140-6736(93)90016-A	http://dx.doi.org/10.1016/0140-6736(93)90016-A			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG627	8093756				2022-12-28	WOS:A1993KG62700016
J	HEATON, KW; EMMETT, PM; SYMES, CL; BRADDON, FEM				HEATON, KW; EMMETT, PM; SYMES, CL; BRADDON, FEM			AN EXPLANATION FOR GALLSTONES IN NORMAL-WEIGHT WOMEN - SLOW INTESTINAL TRANSIT	LANCET			English	Article							DANISH POPULATION; GALL-STONES; DEOXYCHOLIC-ACID; CHOLESTEROL; DISEASE; BILE; PATHOGENESIS; METABOLISM; LIPIDS; DIET	Many cases of gallstones can be explained in terms of the established risk factors, especially obesity. However, gallstones develop in some women who are not obese, and the causes are unknown. Biochemical studies have shown that slow intestinal transit is associated with lithogenic bile. We have tested the hypothesis that intestinal transit is abnormally slow in normal-weight women with gallstones. In a population survey, 1058 women aged 25-69 years, registered with general practitioners in Bristol, UK, underwent cholecystosonography. Gallstones were identified in 48 women, of whom 15 were of normal weight (body mass index less-than-or-equal-to 25 kg/m2). These women and age-matched controls with healthy gallbladders then underwent measurement of whole-gut transit time (WGTT); the measurement was done directly when possible, or calculated from records of three defaecations. The mean WGTT was significantly longer in the women with gallstones than in the controls (82 vs 63 h; mean difference 19, 95% CI 2-37 h). Stool output was also lower in the women with gallstones (74 [SD 54] vs 141 [56] g per 24 h, p = 0.015). There was no significant difference between cases and controls in body mass index, waist-hip circumference ratio, parity, plasma triglyceride concentration, or alcohol intake. Normal-weight women with gallstones tend to have slow intestinal transit and this feature could explain why they have gallstones.			HEATON, KW (corresponding author), UNIV BRISTOL,BRISTOL ROYAL INFIRM,DEPT MED,BRISTOL BS2 8HW,AVON,ENGLAND.		Emmett, Pauline/AAL-6815-2021	Emmett, Pauline/0000-0003-1076-4779				BARBARA L, 1987, HEPATOLOGY, V7, P913, DOI 10.1002/hep.1840070520; EMMETT P, 1992, J HUM NUTR DIET, V5, P245, DOI 10.1111/j.1365-277X.1992.tb00159.x; EVERSON GT, 1991, J CLIN INVEST, V87, P237, DOI 10.1172/JCI114977; Garrow J. S., 1983, Nutrition Abstracts and Reviews, A, V53, P697; HAFFNER SM, 1989, AM J EPIDEMIOL, V129, P587, DOI 10.1093/oxfordjournals.aje.a115171; HAY DW, 1990, SEMIN LIVER DIS, V10, P159, DOI 10.1055/s-2008-1040470; HEAETON KW, 1992, GUT, V33, P818; HEATON KW, 1991, GUT, V32, P316, DOI 10.1136/gut.32.3.316; HEATON KW, 1991, EUR J GASTROEN HEPAT, V3, P745; HERTZ AF, 1909, CONSTIPATION ALLIED; HUSSAINI SH, 1992, GUT, V33, pS57; JORGENSEN T, 1989, GUT, V30, P528, DOI 10.1136/gut.30.4.528; JORGENSEN T, 1989, SCAND J GASTROENTERO, V24, P916, DOI 10.3109/00365528909089235; JORGENSEN T, 1988, J BIOSOC SCI, V20, P111; JORGENSEN T, 1988, GUT, V29, P433, DOI 10.1136/gut.29.4.433; LEIJD B, 1980, CLIN SCI, V59, P203, DOI 10.1042/cs0590203; LEWIS B, 1976, HYPERLIPIDAEMIAS CLI, P131; LOWBEER TS, 1978, LANCET, V2, P1063; MACLURE KM, 1989, NEW ENGL J MED, V321, P563, DOI 10.1056/NEJM198908313210902; MARCUS SN, 1988, GUT, V29, P522, DOI 10.1136/gut.29.4.522; MARCUS SN, 1986, GUT, V27, P550, DOI 10.1136/gut.27.5.550; ODONNELL LJD, 1990, BMJ-BRIT MED J, V300, P439, DOI 10.1136/bmj.300.6722.439; OSLER W, 1982, PRINCIPLES PRACTICE, P432; PETTITI DB, 1981, NEW ENGL J MED, V304, P1396; PROBERT CJS, IN PRESS J EPIDEMIOL; RADBERG G, 1989, SCAND J GASTROENTERO, V25, P97; REUBEN A, 1985, CLIN SCI, V69, P71, DOI 10.1042/cs0690071; SCRAGG RKR, 1984, BRIT MED J, V288, P1113, DOI 10.1136/bmj.288.6424.1113; STONE BG, 1992, HEPATOLOGY, V15, P785; THIJS C, 1990, GASTROENTEROLOGY, V99, P843, DOI 10.1016/0016-5085(90)90978-A	30	96	98	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 2	1993	341	8836					8	10		10.1016/0140-6736(93)92479-D	http://dx.doi.org/10.1016/0140-6736(93)92479-D			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF027	8093323				2022-12-28	WOS:A1993KF02700003
J	BOURNE, HR; NICOLL, R				BOURNE, HR; NICOLL, R			MOLECULAR MACHINES INTEGRATE COINCIDENT SYNAPTIC SIGNALS	CELL			English	Review							LONG-TERM POTENTIATION; CEREBELLAR PURKINJE-CELLS; HIPPOCAMPAL PYRAMIDAL CELLS; MOUSE CENTRAL NEURONS; ADENYLYL CYCLASE; CLIMBING FIBER; GLUTAMATE SENSITIVITY; PARALLEL FIBER; RAT-BRAIN; DEPRESSION		UNIV CALIF SAN FRANCISCO, NEUROSCI PROGRAM, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CELL BIOL PROGRAM, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	BOURNE, HR (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA.							ABRAMS TW, 1991, J NEUROSCI, V11, P2655; AJIMA A, 1991, NEUROSCI RES, V12, P281, DOI 10.1016/0168-0102(91)90117-H; ANDRADE R, 1986, SCIENCE, V234, P1261, DOI 10.1126/science.2430334; ANDRADE R, 1993, IN PRESS NEURON; ANIKSZTEJN L, 1992, EUR J NEUROSCI, V4, P500, DOI 10.1111/j.1460-9568.1992.tb00900.x; ASCHER P, 1988, J PHYSIOL-LONDON, V399, P247; BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; BORTOLOTTO ZA, 1992, EUR J PHARMACOL, V214, P297, DOI 10.1016/0014-2999(92)90135-Q; BURNASHEV N, 1992, SCIENCE, V257, P1415, DOI 10.1126/science.1382314; CREPEL F, 1988, BRAIN RES, V458, P397, DOI 10.1016/0006-8993(88)90486-6; Crepel F, 1990, Neuroreport, V1, P133, DOI 10.1097/00001756-199010000-00013; DALY JW, 1980, J PHARMACOL EXP THER, V212, P382; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; GASIC GP, 1992, ANNU REV PHYSIOL, V54, P527; GUSTAFSSON B, 1987, J NEUROSCI, V7, P774; HAAS HL, 1983, NATURE, V302, P432, DOI 10.1038/302432a0; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HEBB DO, 1949, ORG BEHAVIOR; HIRANO T, 1991, SYNAPSE, V7, P321, DOI 10.1002/syn.890070408; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; ITO M, 1992, NEUROSCI RES, V14, P27, DOI 10.1016/S0168-0102(05)80004-5; ITO M, 1982, J PHYSIOL-LONDON, V324, P113, DOI 10.1113/jphysiol.1982.sp014103; Ito M, 1990, Neuroreport, V1, P129; Ito M, 1991, Curr Opin Neurobiol, V1, P616, DOI 10.1016/S0959-4388(05)80038-8; JAHR CE, 1987, NATURE, V325, P522, DOI 10.1038/325522a0; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; KANO M, 1987, NATURE, V325, P276, DOI 10.1038/325276a0; KARBON EW, 1985, MOL PHARMACOL, V27, P53; KATSUSHIKA S, 1992, P NATL ACAD SCI USA, V89, P8774, DOI 10.1073/pnas.89.18.8774; KAUER JA, 1988, NEURON, V1, P911, DOI 10.1016/0896-6273(88)90148-1; KELSO SR, 1986, P NATL ACAD SCI USA, V83, P5326, DOI 10.1073/pnas.83.14.5326; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; KULLMANN DM, 1992, NEURON, V9, P1175, DOI 10.1016/0896-6273(92)90075-O; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LANCASTER B, 1986, J NEUROPHYSIOL, V55, P1268, DOI 10.1152/jn.1986.55.6.1268; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; LINDEN DJ, 1991, SCIENCE, V254, P1656, DOI 10.1126/science.1721243; LINDEN DJ, 1991, NEURON, V7, P81, DOI 10.1016/0896-6273(91)90076-C; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; MADISON DV, 1982, NATURE, V299, P636, DOI 10.1038/299636a0; MADISON DV, 1986, NATURE, V321, P695, DOI 10.1038/321695a0; MADISON DV, 1986, J PHYSIOL-LONDON, V372, P245, DOI 10.1113/jphysiol.1986.sp016007; MALENKA RC, 1988, SCIENCE, V242, P81, DOI 10.1126/science.2845577; MALINOW R, 1986, NATURE, V320, P529, DOI 10.1038/320529a0; MARR D, 1969, J PHYSIOL-LONDON, V202, P437, DOI 10.1113/jphysiol.1969.sp008820; MAYER ML, 1987, J NEUROSCI, V7, P3230; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCGUINNESS N, 1991, NEUROREPORT, V2, P688, DOI 10.1097/00001756-199111000-00014; MORI H, 1992, NATURE, V358, P673, DOI 10.1038/358673a0; MULLER D, 1988, SCIENCE, V242, P1694, DOI 10.1126/science.2904701; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; PREMONT RT, 1992, P NATL ACAD SCI USA, V89, P9809, DOI 10.1073/pnas.89.20.9809; SAKURAI M, 1987, J PHYSIOL-LONDON, V394, P463, DOI 10.1113/jphysiol.1987.sp016881; SAKURAI M, 1990, P NATL ACAD SCI USA, V87, P3383, DOI 10.1073/pnas.87.9.3383; SATTIN A, 1975, J PHARMACOL EXP THER, V192, P22; SHIBUKI K, 1991, NATURE, V349, P326, DOI 10.1038/349326a0; STEVENS CF, 1993, CELL, V72, P55, DOI 10.1016/S0092-8674(05)80028-5; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TANG WJ, 1991, J BIOL CHEM, V266, P8595; UNWIN N, 1993, CELL, V72, P31, DOI 10.1016/S0092-8674(05)80026-1; YATANI A, 1988, NATURE, V336, P680, DOI 10.1038/336680a0; YOVELL Y, 1992, P NATL ACAD SCI USA, V89, P6526, DOI 10.1073/pnas.89.14.6526	67	207	208	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN	1993	72			S			65	75		10.1016/S0092-8674(05)80029-7	http://dx.doi.org/10.1016/S0092-8674(05)80029-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KL707	8094038				2022-12-28	WOS:A1993KL70700005
J	STEVENS, CF				STEVENS, CF			QUANTAL RELEASE OF NEUROTRANSMITTER AND LONG-TERM POTENTIATION	CELL			English	Review							FROG NEUROMUSCULAR-JUNCTION; DEPENDENT PROTEIN-KINASE; CENTRAL NERVOUS-SYSTEM; HIPPOCAMPAL SLICES; RAT HIPPOCAMPUS; NITRIC-OXIDE; SYNAPTIC TRANSMISSION; TRANSMITTER RELEASE; DENTATE GYRUS; PATCH-CLAMP				STEVENS, CF (corresponding author), SALK INST BIOL STUDIES,LA JOLLA,CA 92037, USA.							ABRAHAM WC, 1991, BRAIN RES, V546, P336, DOI 10.1016/0006-8993(91)91498-P; ANWYL R, 1989, BRAIN RES, V503, P148, DOI 10.1016/0006-8993(89)91716-2; ARTOLA A, 1990, NATURE, V347, P69, DOI 10.1038/347069a0; BARRETT EF, 1972, J PHYSIOL-LONDON, V227, P665, DOI 10.1113/jphysiol.1972.sp010053; BARRETT EF, 1972, J PHYSIOL-LONDON, V227, P691, DOI 10.1113/jphysiol.1972.sp010054; BASKYS A, 1991, NEUROSCI LETT, V127, P169, DOI 10.1016/0304-3940(91)90786-S; BEKKERS JM, 1990, P NATL ACAD SCI USA, V87, P5359, DOI 10.1073/pnas.87.14.5359; BEKKERS JM, 1989, NATURE, V341, P230, DOI 10.1038/341230a0; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; BLISS TVP, 1986, J PHYSIOL-LONDON, V377, P391, DOI 10.1113/jphysiol.1986.sp016193; BOHME GA, 1991, EUR J PHARMACOL, V199, P379, DOI 10.1016/0014-2999(91)90505-K; BREDT DS, 1991, NEURON, V7, P615, DOI 10.1016/0896-6273(91)90374-9; DELCASTILLO J, 1954, J PHYSIOL-LONDON, V124, P560, DOI 10.1113/jphysiol.1954.sp005129; DIONNE VE, 1975, J PHYSIOL-LONDON, V251, P245, DOI 10.1113/jphysiol.1975.sp011090; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; DUNWIDDIE T, 1978, J PHYSIOL-LONDON, V276, P353, DOI 10.1113/jphysiol.1978.sp012239; EDWARDS F, 1991, NATURE, V350, P271, DOI 10.1038/350271a0; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; EDWARDS FA, 1990, J PHYSIOL-LONDON, V430, P213, DOI 10.1113/jphysiol.1990.sp018289; FATT P, 1952, J PHYSIOL-LONDON, V117, P109; GREENGARD P, 1991, SCIENCE, V253, P1135, DOI 10.1126/science.1716001; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; KATZ B, 1965, PROC R SOC SER B-BIO, V161, P483, DOI 10.1098/rspb.1965.0016; Katz B., 1969, RELEASE NEURAL TRANS; KAUER JA, 1988, NATURE, V334, P250, DOI 10.1038/334250a0; KORN H, 1991, TRENDS NEUROSCI, V14, P439, DOI 10.1016/0166-2236(91)90042-S; KRIEBEL ME, 1974, J GEN PHYSIOL, V64, P85, DOI 10.1085/jgp.64.1.85; KRIEBEL ME, 1988, HDB EXPT PHARM, V86, P537; KULLMANN DM, 1992, NEURON, V9, P1175, DOI 10.1016/0896-6273(92)90075-O; KULLMANN DM, 1992, NATURE, V357, P240, DOI 10.1038/357240a0; LARKMAN A, 1991, NATURE, V350, P344, DOI 10.1038/350344a0; MADISON DV, 1991, ANNU REV NEUROSCI, V14, P379, DOI 10.1146/annurev.ne.14.030191.002115; MAGLEBY KL, 1981, J PHYSIOL-LONDON, V311, P267, DOI 10.1113/jphysiol.1981.sp013584; MAGLEBY KL, 1987, SYNAPTIC FUNCTION, P21; MALENKA RC, 1991, NEURON, V6, P53, DOI 10.1016/0896-6273(91)90121-F; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MALINOW R, 1991, SCIENCE, V252, P722, DOI 10.1126/science.1850871; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; MULKEY RM, 1992, NEURON, V9, P967, DOI 10.1016/0896-6273(92)90248-C; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; POCKETT S, 1990, EXP BRAIN RES, V80, P196; RAASTAD M, 1992, EUR J NEUROSCI, V4, P113, DOI 10.1111/j.1460-9568.1992.tb00114.x; REDMAN S, 1990, PHYSIOL REV, V70, P165, DOI 10.1152/physrev.1990.70.1.165; ROBITAILLE R, 1987, BRAIN RES REV, V12, P95, DOI 10.1016/0165-0173(87)90019-1; ROBITAILLE R, 1991, NEUROSCIENCE, V40, P571, DOI 10.1016/0306-4522(91)90142-B; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; Siegelbaum S A, 1991, Curr Opin Neurobiol, V1, P113, DOI 10.1016/0959-4388(91)90018-3; SILVER RA, 1992, NATURE, V355, P163, DOI 10.1038/355163a0; STANTON PK, 1989, NATURE, V339, P215, DOI 10.1038/339215a0; STAUBLI U, 1990, BRAIN RES, V513, P113, DOI 10.1016/0006-8993(90)91096-Y; TSUMOTO T, 1992, PROG NEUROBIOL, V39, P209, DOI 10.1016/0301-0082(92)90011-3; VERMA A, 1992, IN PRESS SCIENCE; WANG LY, 1991, SCIENCE, V253, P1132, DOI 10.1126/science.1653455; XIE XP, 1992, J NEUROPHYSIOL, V67, P1009, DOI 10.1152/jn.1992.67.4.1009; ZUKER RS, 1989, ANN REV NEUROSCI, V12, P13	60	159	159	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN	1993	72			S			55	63		10.1016/S0092-8674(05)80028-5	http://dx.doi.org/10.1016/S0092-8674(05)80028-5			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KL707	8094037				2022-12-28	WOS:A1993KL70700004
J	SILBERMAN, G; CROSSE, MG; PETERSON, EA; WESTON, RC; HOROWITZ, MM; APPELBAUM, FR; CHESON, BD				SILBERMAN, G; CROSSE, MG; PETERSON, EA; WESTON, RC; HOROWITZ, MM; APPELBAUM, FR; CHESON, BD			AVAILABILITY AND APPROPRIATENESS OF ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOID-LEUKEMIA IN 10 COUNTRIES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; T-CELL DEPLETION; INCREASING UTILIZATION; CHRONIC PHASE; DONORS	Background. Allogeneic bone marrow transplantation, a sophisticated and expensive procedure, is the only curative therapy for chronic myeloid leukemia (CML). We examined the availability and appropriateness of allogeneic bone marrow transplantation for CML in 10 economically advanced countries with diverse health care systems. For each country we obtained data on the likelihood of transplantation to treat CML in patients under the age of 55 years, the length of time from diagnosis to transplantation, and the stage of disease at the time of transplantation. Methods. Data were collected on 9873 allogeneic bone marrow transplantations performed at 208 centers in 10 countries from 1989 th rough 1991. Data were acquired from transplantation registries and by means of a mailed survey of all centers and teams that did not contribute data to registries. Data on the incidence of disease were drawn from national and regional cancer registries. Results. Among the 10 countries there was a twofold difference between the lowest and highest rates of transplantation to treat CML (0.26 to 0.54 per 100,000 population per year); Swedish patients were the most likely to receive a transplant, and German patients the least likely. The median length of time from diagnosis to transplantation ranged from 6.8 to 15.4 months. In all countries, most transplantations were performed in the chronic phase of the disease, but as many as a third of patients received transplants in the less favorable accelerated or blast phase. The values for the United States fell near the middle of those for the 10 countries on all measures. Conclusions. Our findings challenge the assumption that the United States is unique in providing broad access to high-technology treatments. On no measure of the availability or appropriateness of transplantation for CML did it surpass the other nine countries studied.	MED COLL WISCONSIN,INST HLTH POLICY,INT BONE MARROW TRANSPLANT REGISTRY,MILWAUKEE,WI; FRED HUTCHINSON CANC RES CTR,SEATTLE,WA; NCI,CANC THERAPY EVALUAT PROGRAM,BETHESDA,MD	Medical College of Wisconsin; Fred Hutchinson Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	SILBERMAN, G (corresponding author), US GEN ACCOUNTING OFF,DIV PROGRAM EVALUAT & METHODOL,WASHINGTON,DC 20548, USA.		horowitz, Mary/ABH-2173-2021		NATIONAL CANCER INSTITUTE [P01CA040053] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA-40053] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASH RC, 1991, BONE MARROW TRANSPL, V7, P443; BORTIN MM, 1989, TRANSPLANTATION, V48, P453, DOI 10.1097/00007890-198909000-00021; BORTIN MM, 1992, ANN INTERN MED, V116, P505, DOI 10.7326/0003-4819-116-6-505; BORTIN MM, 1986, TRANSPLANTATION, V42, P229, DOI 10.1097/00007890-198609000-00001; GOLDMAN JM, 1993, BLOOD, V82, P2235; GOLDMAN JM, 1988, ANN INTERN MED, V108, P806, DOI 10.7326/0003-4819-108-6-806; GRATWOHL A, 1991, BONE MARROW TRANSPL, V8, P197; GRATWOHL A, 1993, J INTERN MED, V233, P333, DOI 10.1111/j.1365-2796.1993.tb00681.x; HEATH CW, 1982, CANCER EPIDEMIOL, P728; HOROWITZ MM, 1992, BONE MARROW TRANSPL, P367; KERNAN NA, 1993, NEW ENGL J MED, V328, P593, DOI 10.1056/NEJM199303043280901; MCGLAVE PB, 1990, BLOOD, V75, P1728; MCGLAVE PB, 1990, BLOOD, V76, P654; SEGEL GB, 1986, BLOOD, V68, P1055; SOKAL JE, 1985, BLOOD, V66, P1352; SPECK B, 1984, LANCET, V1, P665; THOMAS ED, 1986, ANN INTERN MED, V104, P155, DOI 10.7326/0003-4819-104-2-155; THOMAS ED, 1989, BLOOD, V73, P861; 1988, BRIT J HAEMATOL, V69, P463; 1994, NEW ENGL J MED, V330, P820	20	48	48	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 20	1994	331	16					1063	1067		10.1056/NEJM199410203311606	http://dx.doi.org/10.1056/NEJM199410203311606			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL560	8090167				2022-12-28	WOS:A1994PL56000006
J	LANDER, ES; SCHORK, NJ				LANDER, ES; SCHORK, NJ			GENETIC DISSECTION OF COMPLEX TRAITS	SCIENCE			English	Review							DEPENDENT DIABETES-MELLITUS; FRAGMENT LENGTH POLYMORPHISMS; POLYCYSTIC KIDNEY-DISEASE; HAPLOTYPE-RELATIVE-RISK; DOPAMINE RECEPTOR GENOTYPE; PEDIGREE-MEMBER METHOD; HUMAN LINKAGE ANALYSIS; MATRIX MIXED MODELS; QUANTITATIVE TRAIT; LOD SCORE	Medical genetics was revolutionized during the 1980s by the application of genetic mapping to locate the genes responsible for simple Mendelian diseases. Most diseases and traits, however, do not follow simple inheritance patterns. Geneticists have thus begun taking up the even greater challenge of the genetic dissection of complex traits. Four major approaches have been developed: linkage analysis, allele-sharing methods, association studies, and polygenic analysis of experimental crosses. This article synthesizes the current state of the genetic dissection of complex traits-describing the methods, limitations, and recent applications to biological problems.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; CASE WESTERN RESERVE UNIV, SCH MED, CTR HUMAN GENET, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, SCH MED, DEPT GENET, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV HOSP, CLEVELAND, OH 44106 USA	Massachusetts Institute of Technology (MIT); Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University Hospital	LANDER, ES (corresponding author), WHITEHEAD INST BIOMED RES, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA.		Peng, Bo/A-6920-2009	Peng, Bo/0000-0001-8225-2284; Schork, Nicholas/0000-0003-0920-5013	NHGRI NIH HHS [HG00098] Funding Source: Medline	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; AMOS CI, 1994, AM J HUM GENET, V54, P535; AMOS CI, 1989, GENET EPIDEMIOL, V6, P349, DOI 10.1002/gepi.1370060205; AMOS CI, 1990, AM J HUM GENET, V47, P842; AMOS CI, 1993, AM J HUM GENET, V52, P213; AMOS CI, 1986, GENET EPIDEMIOL, V3, P255, DOI 10.1002/gepi.1370030406; ARINAMI T, 1993, BIOL PSYCHIAT, V33, P108, DOI 10.1016/0006-3223(93)90309-2; BARBOSA J, 1976, Diabete and Metabolisme, V2, P160; BARNARD GA, 1949, J ROY STAT SOC B, V11, P115; BARON M, 1993, NAT GENET, V3, P49, DOI 10.1038/ng0193-49; BECKMAN JS, 1991, GENE MAPPING TECHNIQ, P201; BELKNAP JK, 1992, BEHAV GENET, V22, P677, DOI 10.1007/BF01066638; BELL GI, 1991, P NATL ACAD SCI USA, V88, P1484, DOI 10.1073/pnas.88.4.1484; BENDER W, 1983, J MOL BIOL, V168, P17, DOI 10.1016/S0022-2836(83)80320-9; BERRETTINI WH, 1994, P NATL ACAD SCI USA, V91, P5918, DOI 10.1073/pnas.91.13.5918; BISHOP DT, 1990, AM J HUM GENET, V46, P254; BISHOP DT, 1988, GENET EPIDEMIOL, V5, P151, DOI 10.1002/gepi.1370050303; BLACKWELDER W C, 1985, Genetic Epidemiology, V2, P85, DOI 10.1002/gepi.1370020109; BLACKWELDER WC, 1982, COMMUN STAT A-THEOR, V11, P449, DOI 10.1080/03610928208828250; BLEEKERWAGEMAKERS LM, 1992, GENOMICS, V14, P811, DOI 10.1016/S0888-7543(05)80195-8; BLUM K, 1990, JAMA-J AM MED ASSOC, V263, P2055, DOI 10.1001/jama.263.15.2055; BLUM K, 1993, ALCOHOL, V10, P59, DOI 10.1016/0741-8329(93)90054-R; BOEHNKE M, 1988, AM J HUM GENET, V43, P336; BOEHNKE M, 1986, AM J HUM GENET, V39, P513; BOEHNKE M, 1994, AM J HUM GENET, V55, P379; BOEHNKE M, 1990, AM J HUM GENET, V46, P581; BOERWINKLE E, 1986, ANN HUM GENET, V50, P181, DOI 10.1111/j.1469-1809.1986.tb01037.x; BONNEY GE, 1988, AM J HUM GENET, V43, P29; BONNEY GE, 1984, AM J MED GENET, V18, P731, DOI 10.1002/ajmg.1320180420; BOTSTEIN D, 1980, AM J HUM GENET, V32, P314; BOWDEN DW, 1992, AM J HUM GENET, V50, P607; BRAUN WE, 1979, HLA DISEASE; BROWN DL, 1994, AM J HUM GENET, V54, P544; BRUL S, 1988, J CLIN INVEST, V81, P1710, DOI 10.1172/JCI113510; CAMBIEN F, 1992, NATURE, V359, P641, DOI 10.1038/359641a0; CANNINGS C, 1978, ADV APPL PROBAB, V10, P26, DOI 10.2307/1426718; CANNINGS C, 1977, CLIN GENET, V12, P208; CARBONELL EA, 1992, BIOMETRICS, V48, P305, DOI 10.2307/2532757; CARDON LR, IN PRESS AM J HUM GE; CAREY G, 1991, AM J HUM GENET, V49, P786; Castle W E, 1921, Science, V54, P223, DOI 10.1126/science.54.1393.223; CHAKRABORTY R, 1988, P NATL ACAD SCI USA, V85, P9119, DOI 10.1073/pnas.85.23.9119; CHERNOFF H, IN PRESS J STAT PLAN; CHIANO MN, 1994, ANN HUM GENET, V58, P129, DOI 10.1111/j.1469-1809.1994.tb01882.x; CHOTAI J, 1984, ANN HUM GENET, V48, P359, DOI 10.1111/j.1469-1809.1984.tb00849.x; CLARK RF, 1993, ARCH NEUROL-CHICAGO, V50, P1164, DOI 10.1001/archneur.1993.00540110044004; CLAUS EB, 1990, AM J EPIDEMIOL, V131, P961, DOI 10.1093/oxfordjournals.aje.a115616; CLERGETDARPOUX F, 1986, BIOMETRICS, V42, P393, DOI 10.2307/2531059; CLERGETDARPOUX F, 1987, J PSYCHIAT RES, V21, P625, DOI 10.1016/0022-3956(87)90113-0; CLERGETDARPOUX F, 1988, ANN HUM GENET, V52, P247, DOI 10.1111/j.1469-1809.1988.tb01102.x; CLERGETDARPOUX F, 1982, ANN HUM GENET, V46, P363, DOI 10.1111/j.1469-1809.1982.tb01587.x; Collins FS., COMMUNICATION; COOPER DN, 1992, ANN MED, V24, P29, DOI 10.3109/07853899209164142; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252; CRABBE JC, 1994, SCIENCE, V264, P1715, DOI 10.1126/science.8209252; DARVASI A, 1993, GENETICS, V134, P943; DAVIES J, IN PRESS NATURE; DETERAWADLEIGH SD, 1989, NATURE, V340, P391, DOI 10.1038/340391a0; DEWEERDK.EA, 1972, NATURE-NEW BIOL, V238, P80, DOI 10.1038/newbio238080a0; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; DOVER GJ, 1992, BLOOD, V80, P816; DURNER M, 1992, AM J HUM GENET, V51, P859; EASTON D, 1993, CANCER SURV, V18, P95; EAVES LJ, 1994, HEREDITY, V72, P175, DOI 10.1038/hdy.1994.25; Edgington E. S., 1987, RANDOMIZATION TESTS; Edwards AWF, 1992, LIKELIHOOD; EDWARDS J. H., 1960, ACTA GENET ET STATIST MED, V10, P63; EDWARDS JH, 1969, BRIT MED BULL, V25, P58, DOI 10.1093/oxfordjournals.bmb.a070672; EDWARDS JH, 1982, CYTOGENET CELL GENET, V32, P43, DOI 10.1159/000131685; EFRON B, 1994, INTRO BOOTSTRAP, P220; EGELAND JA, 1987, NATURE, V325, P783, DOI 10.1038/325783a0; ELSTON RC, 1971, HUM HERED, V21, P523, DOI 10.1159/000152448; ELSTON RC, 1992, HUM HERED, V42, P16, DOI 10.1159/000154043; ELSTON RC, 1992, 16TH P INT BIOM C HA, P39; EWENS WJ, 1986, ANN HUM GENET, V50, P399, DOI 10.1111/j.1469-1809.1986.tb01760.x; EWENS WJ, 1982, AM J HUM GENET, V34, P853; Falconer D. S., 1981, INTRO QUANTITATIVE G; FALK CT, 1987, ANN HUM GENET, V51, P227, DOI 10.1111/j.1469-1809.1987.tb00875.x; FARAWAY JJ, 1993, GENET EPIDEMIOL, V10, P75, DOI 10.1002/gepi.1370100108; FEINGOLD E, 1993, AM J HUM GENET, V53, P234; FELDMAN MW, 1979, GENETIC ANAL COMMON, P203; Festing MFW, 1979, INBRED STRAINS BIOME; FISHEL, 1994, CELL, V77, pU17; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Fisher R. A., 1919, Transactions of the Royal Society of Edinburgh, V52; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; FRANKEL WN, IN PRESS GENETICS; FROGUEL P, 1992, NATURE, V356, P162, DOI 10.1038/356162a0; FULKER DW, 1994, AM J HUM GENET, V54, P1092; GARTNER J, 1992, NAT GENET, V1, P16, DOI 10.1038/ng0492-16; GELERNTER J, 1991, JAMA-J AM MED ASSOC, V266, P1801, DOI 10.1001/jama.266.13.1801; GELERNTER J, 1993, JAMA-J AM MED ASSOC, V269, P1673, DOI 10.1001/jama.269.13.1673; GEORGE VT, 1987, GENET EPIDEMIOL, V4, P193, DOI 10.1002/gepi.1370040304; GHOSH JK, 1985, P BERKELEY C HONOR J, P807; GHOSH S, 1993, NAT GENET, V4, P404, DOI 10.1038/ng0893-404; GOLDGAR DE, 1990, AM J HUM GENET, V47, P957; GOLDMAN D, 1992, ACTA PSYCHIAT SCAND, V86, P351, DOI 10.1111/j.1600-0447.1992.tb03279.x; GOLDMAN D, 1993, ALCOHOL CLIN EXP RES, V17, P199, DOI 10.1111/j.1530-0277.1993.tb00749.x; GOLDMAN D, IN PRESS ALCOHOL CLI; GORADIA TM, 1992, HUM HERED, V42, P42, DOI 10.1159/000154045; GROOP L, COMMUNICATION; GROOT PC, 1992, FASEB J, V6, P2826, DOI 10.1096/fasebj.6.10.1634045; GUO SW, 1991, IMA J MATH APPL MED, V8, P171; GUO SW, 1992, AM J HUM GENET, V51, P1111; HALDANE JBS, 1947, ANN EUGENIC, V14, P10, DOI 10.1111/j.1469-1809.1947.tb02374.x; HALEY CS, 1992, HEREDITY, V69, P315, DOI 10.1038/hdy.1992.131; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HAMER DH, 1993, SCIENCE, V261, P321, DOI 10.1126/science.8332896; HASEMAN JK, 1972, BEHAV GENET, V2, P3, DOI 10.1007/BF01066731; HASSTEDT SJ, 1982, COMPUT BIOMED RES, V15, P295, DOI 10.1016/0010-4809(82)90064-7; HASTBACKA J, 1994, CELL, V78, P1073, DOI 10.1016/0092-8674(94)90281-X; HASTBACKA J, 1992, NAT GENET, V2, P204, DOI 10.1038/ng1192-204; HILBERT P, 1991, NATURE, V353, P521, DOI 10.1038/353521a0; HODGE SE, 1993, AM J HUM GENET, V53, P367; HODGE SE, 1992, GENET EPIDEMIOL, V9, P191, DOI 10.1002/gepi.1370090306; HODGE SE, IN PRESS GENET EPIDE; HOLMANS P, 1993, AM J HUM GENET, V52, P362; HUISMAN THJ, 1979, AM J HEMATOL, V6, P173, DOI 10.1002/ajh.2830060210; HYER RN, 1991, AM J HUM GENET, V48, P243; JACOB HJ, 1991, CELL, V67, P213, DOI 10.1016/0092-8674(91)90584-L; JACOB HJ, 1992, NAT GENET, V2, P56, DOI 10.1038/ng0992-56; JANSEN RC, 1994, GENETICS, V136, P1447; JANSEN RC, 1993, GENETICS, V135, P205; JANSEN RC, 1992, THEOR APPL GENET, V85, P252, DOI 10.1007/BF00222867; JASPERS NGJ, 1982, P NATL ACAD SCI-BIOL, V79, P2641, DOI 10.1073/pnas.79.8.2641; JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; JULIER C, 1991, NATURE, V354, P155, DOI 10.1038/354155a0; KAJIWARA K, 1994, SCIENCE, V264, P1604, DOI 10.1126/science.8202715; KELSOE JR, 1989, NATURE, V342, P238, DOI 10.1038/342238a0; KENNEDY JL, 1988, NATURE, V336, P167, DOI 10.1038/336167a0; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; Khoury M, 1993, FUNDAMENTALS GENETIC; KIDD KK, 1984, CYTOGENET CELL GENET, V37, P510; KING MC, 1984, ANNU REV PUBL HEALTH, V5, P1; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KNAPP M, 1994, HUM HERED, V44, P37, DOI 10.1159/000154187; KNAPP M, 1993, AM J HUM GENET, V52, P1085; KNOTT SA, 1992, GENETICS, V132, P1211; KONG A, 1992, AM J HUM GENET, V51, P1413; KONG A, 1993, GENET EPIDEMIOL, V10, P483, DOI 10.1002/gepi.1370100626; KRUGLYAK L, UNPUB; KUMARSINGH R, 1993, GENOMICS, V15, P212, DOI 10.1006/geno.1993.1038; LANDER ES, 1987, P NATL ACAD SCI USA, V84, P2363, DOI 10.1073/pnas.84.8.2363; LANDER ES, 1989, GENETICS, V121, P185; LANDER ES, 1986, COLD SPRING HARB SYM, V51, P49, DOI 10.1101/SQB.1986.051.01.007; LANDER ES, 1986, P NATL ACAD SCI USA, V83, P7353, DOI 10.1073/pnas.83.19.7353; LANGE K, 1986, AM J HUM GENET, V39, P148; LANGE K, 1985, AM J HUM GENET, V37, P853; LANGE K, 1975, HUM HERED, V25, P95, DOI 10.1159/000152714; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LI CC, 1987, AM J HUM GENET, V41, P517; LIU B, 1994, CANCER RES, V54, P4590; LUO ZW, 1992, HEREDITY, V69, P236, DOI 10.1038/hdy.1992.121; MACLEAN CJ, 1984, COMPUT BIOMED RES, V17, P471, DOI 10.1016/0010-4809(84)90013-2; MAJUMDER PP, 1988, AM J HUM GENET, V43, P119; MAJUMDER PP, 1985, STAT MED, V4, P163, DOI 10.1002/sim.4780040207; MARENBERG ME, 1994, NEW ENGL J MED, V330, P1041, DOI 10.1056/NEJM199404143301503; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; McKusick V.A., 1992, MENDELIAN INHERITANC; MERIKANGAS KR, 1989, ARCH GEN PSYCHIAT, V46, P1137; MOEN CJA, 1992, ONCOGENE, V7, P563; MORRISON NA, 1994, NATURE, V367, P284, DOI 10.1038/367284a0; MORTON NE, 1956, AM J HUM GENET, V8, P80; MORTON NE, 1959, AM J HUM GENET, V11, P1; MORTON NE, 1974, AM J HUM GENET, V26, P489; MORTON NE, 1983, AM J HUM GENET, V35, P201; MOSER A, COMMUNICATION; NATH SK, 1988, J HUM GENET, V43, P119; Neale MC, 1992, METHODOLOGY GENETIC; NEWMAN B, 1988, P NATL ACAD SCI USA, V85, P3044, DOI 10.1073/pnas.85.9.3044; Noreen E. W., 1989, COMPUTER INTENSIVE M; OLSON JM, 1993, GENET EPIDEMIOL, V10, P87, DOI 10.1002/gepi.1370100202; OTT J, 1979, AM J HUM GENET, V31, P161; OTT J, 1977, CLIN GENET, V12, P119; OTT J, 1990, AM J HUM GENET, V46, P219; OTT J, 1974, AM J HUM GENET, V26, P588; OTT J, 1976, AM J HUM GENET, V28, P528; OTT J, 1989, GENET EPIDEMIOL, V6, P127, DOI 10.1002/gepi.1370060124; OTT J, 1989, P NATL ACAD SCI USA, V86, P4175, DOI 10.1073/pnas.86.11.4175; OTT J, 1991, ANAL HUMAN GENETIC L, P65; OWERBACH D, 1994, AM J HUM GENET, V54, P909; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSIAN A, 1991, ARCH GEN PSYCHIAT, V48, P655; PATERSON AH, 1988, NATURE, V335, P721, DOI 10.1038/335721a0; PATO CN, 1993, AM J MED GENET, V48, P78, DOI 10.1002/ajmg.1320480204; PENROSE L S, 1953, Acta Genet Stat Med, V4, P257; PERICAKVANCE MA, 1991, AM J HUM GENET, V48, P1034; PETES TD, 1977, P NATL ACAD SCI USA, V74, P5091, DOI 10.1073/pnas.74.11.5091; PLOMIN R, 1994, BEHAV GENET, V24, P107, DOI 10.1007/BF01067815; Provine, 1971, ORIGINS THEORETICAL; PUFFENBERGER EG, 1994, HUM MOL GENET, V3, P1217; PULVER AE, 1994, AM J MED GENET, V54, P36, DOI 10.1002/ajmg.1320540108; REBAI A, 1994, GENETICS, V138, P235; REDMAN JB, 1993, JAMA-J AM MED ASSOC, V269, P1960, DOI 10.1001/jama.269.15.1960; REEDERS ST, 1987, HUM GENET, V76, P348, DOI 10.1007/BF00272443; RICH SS, 1991, DIABETOLOGIA, V34, P350, DOI 10.1007/BF00405008; RISCH N, 1990, AM J HUM GENET, V46, P229; RISCH N, 1990, AM J HUM GENET, V46, P242; RISCH N, 1990, AM J HUM GENET, V46, P222; RISCH N, 1993, AM J HUM GENET, V53, P702; RISCH N, 1993, AM J HUM GENET S, V53; RISE ML, 1991, SCIENCE, V253, P669, DOI 10.1126/science.1871601; ROMEO G, 1988, LANCET, V2, P8; RYDER LP, 1979, HLA DISEASE REGISTRY; SCHACHTER F, 1994, NAT GENET, V6, P29, DOI 10.1038/ng0194-29; SCHELLENBERG GD, 1992, SCIENCE, V258, P668, DOI 10.1126/science.1411576; SCHORK N, 1989, AM J HUM GENET, V45, P803; SCHORK N, 1991, GENET EPIDEMIOL, V8, P29, DOI 10.1002/gepi.1370080104; SCHORK NJ, 1993, AM J HUM GENET, V53, P1127; SCHORK NJ, 1992, GENET EPIDEMIOL, V9, P73, DOI 10.1002/gepi.1370090202; SCHORK NJ, 1993, AM J HUM GENET, V53, P1320; SCHORK NJ, 1992, GENET EPIDEMIOL, V9, P207, DOI 10.1002/gepi.1370090307; SCHORK NJ, UNPUB; SCHORK NJ, 1994, COMPUTING SCI STATIS; SCHORK NJ, 1991, EXPLORING LIMITS BOO; SCHUNKERT H, 1994, NEW ENGL J MED, V330, P1634, DOI 10.1056/NEJM199406093302302; SCHWAB S, 1991, AM J HUM GENET, V49, P203; SELBY JV, 1991, JAMA-J AM MED ASSOC, V265, P2079, DOI 10.1001/jama.265.16.2079; SERIKAWA T, 1992, GENETICS, V131, P701; SHERRINGTON R, 1988, NATURE, V336, P164, DOI 10.1038/336164a0; SHIMOZAWA N, 1992, SCIENCE, V255, P1132, DOI 10.1126/science.1546315; SINGER C, 1992, ARCH NEUROL-CHICAGO, V49, P13, DOI 10.1001/archneur.1992.00530250017002; SOBEL E, 1992, AM J HUM GENET, V50, P1343; SPENCE MA, 1993, HUM HERED, V43, P166; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506; SPIERER P, 1983, J MOL BIOL, V168, P35, DOI 10.1016/S0022-2836(83)80321-0; STEINBERG MH, 1983, AM J HEMATOL, V14, P405, DOI 10.1002/ajh.2830140412; STGEORGEHYSLOP PH, 1990, NATURE, V347, P194, DOI 10.1038/347194a0; Sturtevant AH, 1913, J EXP ZOOL, V14, P43, DOI 10.1002/jez.1400140104; SUAREZ BK, 1994, GENOMICS, V19, P12, DOI 10.1006/geno.1994.1005; SUAREZ BK, 1978, ANN HUM GENET, V42, P87, DOI 10.1111/j.1469-1809.1978.tb00933.x; TAGER JM, 1990, PROG CLIN BIOL RES, V321, P545; TANKSLEY SD, 1993, ANNU REV GENET, V27, P205, DOI 10.1146/annurev.ge.27.120193.001225; TERWILLIGER JD, 1992, HUM HERED, V42, P337, DOI 10.1159/000154096; TERWILLIGER JD, 1992, CYTOGENET CELL GENET, V59, P142, DOI 10.1159/000133228; THEIN SL, 1994, AM J HUM GENET, V54, P214; THOMAS DC, 1992, CYTOGENET CELL GENET, V59, P228, DOI 10.1159/000133255; THOMPSON EA, 1986, STAT MED, V5, P291, DOI 10.1002/sim.4780050402; THOMPSON EA, 1981, BIOMETRICS, V37, P313, DOI 10.2307/2530420; THOMPSON EA, 1983, THEOR POPUL BIOL, V24, P39, DOI 10.1016/0040-5809(83)90045-X; THOMPSON EA, 1981, AM J HUM GENET, V33, P968; THOMPSON G, 1989, GENET EPIDEMIOL, V6, P43; TIENARI PJ, 1994, GENOMICS, V19, P320, DOI 10.1006/geno.1994.1064; TITTERINGTON DM, 1985, STATISTICAL ANAL FIN; TOMFOHRDE J, 1994, SCIENCE, V264, P1141, DOI 10.1126/science.8178173; TURCO A, 1991, CLIN GENET, V40, P287; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; WARD R, 1990, HYPERTENSION PATHOPH, P81; WEEKS DE, 1990, GENET EPIDEMIOL, V7, P237, DOI 10.1002/gepi.1370070402; WEEKS DE, 1988, AM J HUM GENET, V42, P315; WEEKS DE, 1992, AM J HUM GENET, V50, P859; WEEKS DE, 1990, AM J HUM GENET S, V47, pA204; Weinberg W., 1912, Archiv Rassenbiol Leipzig, V9; WEISE KM, 1993, GENETIC VARIATION HU; Weiss K. M., 1993, GENETIC VARIATION HU; WEITKAMP LR, 1981, NEW ENGL J MED, V305, P1301, DOI 10.1056/NEJM198111263052201; WHITTEMORE AS, 1994, BIOMETRICS, V50, P118, DOI 10.2307/2533202; WILLIAMS RR, 1990, ARCH INTERN MED, V150, P582, DOI 10.1001/archinte.150.3.582; WILLIAMS RR, 1992, ANN MED, V24, P469, DOI 10.3109/07853899209166998; WILLIAMS W R, 1984, Genetic Epidemiology, V1, P7, DOI 10.1002/gepi.1370010104; WILLIAMSON JA, 1990, GENET EPIDEMIOL, V7, P309, DOI 10.1002/gepi.1370070502; Wright S., 1968, EVOLUTION GENETICS P, V1; YOUNG MR, 1988, AM J HUM GENET, V43, P705; YU CE, 1994, AM J HUM GENET, V54, P631; ZENG ZB, 1994, GENETICS, V136, P1457; ZENG ZB, 1993, P NATL ACAD SCI USA, V90, P10972, DOI 10.1073/pnas.90.23.10972	270	2665	2749	3	379	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 30	1994	265	5181					2037	2048		10.1126/science.8091226	http://dx.doi.org/10.1126/science.8091226			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PJ912	8091226				2022-12-28	WOS:A1994PJ91200021
J	STARK, MR; JOHNSON, AD				STARK, MR; JOHNSON, AD			INTERACTION BETWEEN 2 HOMEODOMAIN PROTEINS IS SPECIFIED BY A SHORT C-TERMINAL TAIL	NATURE			English	Article							HOMEO DOMAIN; ALPHA-2 REPRESSOR; CRYSTAL-STRUCTURE; DNA INTERACTIONS; MCM1 PROTEIN; YEAST A1; BINDING; OPERATOR; POLYMERASE; COMPLEX	TWO yeast homeodomain proteins, a1 and alpha 2, interact and cooperatively bind the haploid-specific gene (Hsg) operator, resulting in the repression of a set of genes involved in the determination of cell type(1-5). The cooperative binding of a1 and alpha 2 to DNA can be reconstituted in vitro using purified fragments of a1 and alpha 2. Only the homeodomain is needed for a1, but for alpha 2 a C-terminal 22-amino-acid tail is required as well(4,6-9). As most of the specificity of DNA binding appears to derive from a1, we proposed(4) that alpha 2 functions in the a1/alpha 2 heterodimer to contact a1 with its tail. By construction and analysis of several chimaeric proteins, we investigate how two DNA-binding proteins, one with low intrinsic specificity (alpha 2) and one with no apparent intrinsic DNA-binding ability (a1), can together create a highly specific DNA-binding activity(4). We show that the 22-amino-acid region of alpha 2 immediately C-terminal to the homeodomain, when grafted onto the a1 homeodomain, converts a1 to a strong DNA-binding protein. This alpha 2 tail can also be attached to the Drosophila engrailed homeodomain, and the chimaeric protein now binds cooperatively to DNA with a1, showing how a simple change can create a new homeodomain combination that specifically recognizes a new DNA operator.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT IMMUNOL & MICROBIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	STARK, MR (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.							CHAN SK, 1993, GENE DEV, V7, P796, DOI 10.1101/gad.7.5.796; DRANGINIS AM, 1990, NATURE, V347, P682, DOI 10.1038/347682a0; GOUTTE C, 1994, EMBO J, V13, P1434, DOI 10.1002/j.1460-2075.1994.tb06397.x; GOUTTE C, 1988, CELL, V52, P875, DOI 10.1016/0092-8674(88)90429-1; GOUTTE C, 1993, J MOL BIOL, V233, P359, DOI 10.1006/jmbi.1993.1517; GOUTTE C, 1992, COMBINATORIAL CONTRO; HALL MN, 1987, SCIENCE, V237, P1007, DOI 10.1126/science.2887035; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; Johnson A. A, 1992, TRANSCRIPTIONAL REGU, P975; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; LIN L, 1992, GENE DEV, V6, P1071, DOI 10.1101/gad.6.6.1071; MAK A, 1993, GENE DEV, V7, P1862, DOI 10.1101/gad.7.10.1862; MULLIS K, 1986, COLD SPRING HARB SYM, V51, P263, DOI 10.1101/SQB.1986.051.01.032; PHILLIPS CL, 1994, BIOCHEMISTRY-US, V33, P9294, DOI 10.1021/bi00197a033; PHILLIPS CL, 1991, GENE DEV, V5, P764, DOI 10.1101/gad.5.5.764; SAUER RT, 1988, GENE DEV, V2, P807, DOI 10.1101/gad.2.7.807; SMITH DL, 1992, CELL, V68, P133, DOI 10.1016/0092-8674(92)90212-U; STRATHERN J, 1988, GENETICS, V120, P75; STRATHERN J, 1981, J MOL BIOL, V147, P357, DOI 10.1016/0022-2836(81)90488-5; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; VERSHON AK, 1993, CELL, V72, P105, DOI 10.1016/0092-8674(93)90054-T; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; XUE D, 1993, SCIENCE, V261, P1324, DOI 10.1126/science.8103239	23	60	62	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 29	1994	371	6496					429	432		10.1038/371429a0	http://dx.doi.org/10.1038/371429a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PJ285	8090224				2022-12-28	WOS:A1994PJ28500046
J	TSAI, LH; DELALLE, I; CAVINESS, VS; CHAE, T; HARLOW, E				TSAI, LH; DELALLE, I; CAVINESS, VS; CHAE, T; HARLOW, E			P35 IS A NEURAL-SPECIFIC REGULATORY SUBUNIT OF CYCLIN-DEPENDENT KINASE-5	NATURE			English	Article							PROTEIN-KINASE; CELL-CYCLE; BRAIN	CYCLIN-dependent kinase 5 (Cdk5) was originally isolated through its structural homology to human Cdc2(1), a key regulator of cell-cycle progression(2-6). In tissue samples from adult mice, Cdk5 protein is found at the highest level in brain, at an intermediate level in testis, and at low or undetectable levels in all other tissues, but brain is the only tissue that shows Cdk5 histone H1 kinase activity(7). No equivalent kinase activity has been found in tissue culture cell lines despite high levels of Cdk5 This raised the possibility that a Cdk5 regulatory subunit was responsible for the activation of Cdk5 in brain. Here we describe the cloning and characterization of a regulatory subunit for Cdk5 known as p35. p35 displays a neuronal cell-specific pattern of expression, it associates physically with Cdk5 in vivo and activates the Cdk5 kinase. p35 differs from the mammalian cyclins and thus represents a new type of regulatory subunit for cyclin-dependent kinase activity.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT NEUROL,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,CTR CANC,BOSTON,MA 02129	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital				Delalle, Ivana/0000-0002-1873-3064				CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HELLMICH MR, 1992, P NATL ACAD SCI USA, V89, P10867, DOI 10.1073/pnas.89.22.10867; HERRMANN CH, 1991, J VIROL, V65, P5848, DOI 10.1128/JVI.65.11.5848-5859.1991; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; ISHIGURO K, 1994, FEBS LETT, V342, P203, DOI 10.1016/0014-5793(94)80501-6; LEW J, 1992, J BIOL CHEM, V267, P13383; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PINES J, 1990, New Biologist, V2, P389; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; TSAI LH, 1993, DEVELOPMENT, V119, P1029; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; YAMAMOTO M, 1981, J CELL BIOL, V91, P142, DOI 10.1083/jcb.91.1.142	18	809	837	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 29	1994	371	6496					419	423		10.1038/371419a0	http://dx.doi.org/10.1038/371419a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PJ285	8090221				2022-12-28	WOS:A1994PJ28500043
J	VERBANCK, JJ; DEMOL, JW; GHILLEBERT, GL; RUTGEERTS, LJ; SURMONT, IP				VERBANCK, JJ; DEMOL, JW; GHILLEBERT, GL; RUTGEERTS, LJ; SURMONT, IP			ULTRASOUND-GUIDED PUNCTURE OF THE GALLBLADDER FOR ACUTE CHOLECYSTITIS	LANCET			English	Article							TRANS-HEPATIC CHOLECYSTOSTOMY; PERCUTANEOUS CHOLECYSTOSTOMY	In 18 high-risk patients with acute cholecystitis and severe concurrent disease, we aspirated the gallbladder by using a percutaneous technique under ultrasound guidance. 17 of the 18 improved after aspiration, the only complication being local pain in 2.13 of the 17 who improved remained free from biliary infections during a mean follow-up period of 14 months. 4 had an uncomplicated cholecystectomy 6-10 weeks later for recurrent cholecystitis. Percutaneous transhepatic gallbladder aspiration is a safe and effective procedure in critically ill patients with acute cholecystitis.			VERBANCK, JJ (corresponding author), HEILIG HARTZIEKENHUIS,DEPT GASTROENTEROL & BACTERIOL,B-8800 ROESELARE,BELGIUM.							DUNHAM F, 1985, ENDOSCOPY, V17, P153, DOI 10.1055/s-2007-1018487; EGGERMONT AM, 1985, ARCH SURG-CHICAGO, V120, P1354; KISS J, 1988, INT SURG, V73, P35; MCGAHAN JP, 1989, RADIOLOGY, V173, P481, DOI 10.1148/radiology.173.2.2678261; VANSONNENBERG E, 1984, RADIOLOGY, V151, P377, DOI 10.1148/radiology.151.2.6709906; VERBANCK J, 1991, EUR J GASTROEN HEPAT, V3, P753	6	27	29	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 1	1993	341	8853					1132	1133		10.1016/0140-6736(93)93138-Q	http://dx.doi.org/10.1016/0140-6736(93)93138-Q			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ687	8097814				2022-12-28	WOS:A1993KZ68700014
J	DESENCLOS, JC; BIJKERK, H; HUISMAN, J				DESENCLOS, JC; BIJKERK, H; HUISMAN, J			VARIATIONS IN NATIONAL INFECTIOUS-DISEASES SURVEILLANCE IN EUROPE	LANCET			English	Article							AIDS	Because the Maastricht treaty includes a chapter on public health in the European Community (EC) public health surveillance needs to be developed at EC level. To assess the feasibility of EC surveillance we did a survey of national systems in Europe in 1991-92. In seventeen countries (twelve EC plus Austria, Finland, Norway, Sweden, and Switzerland) the public health institution(s) responsible for surveillance were visited to collect standardised data on surveillance systems for sexually transmitted diseases (STD), hepatitis, and tuberculosis (TB). Surveillance systems varied widely by type, design, and quality. Although mandatory notification has a place in nearly all countries there is a trend towards voluntary systems based on samples of physicians, clinics, or laboratories. The time unit for reporting ranged from daily to once a year. For mandatory notification systems of STD completeness of reporting varied from over 90% to less than 10% and most countries did not use case definitions. Surveillance data were disseminated through national epidemiological bulletins in twelve countries, and the bulletin was a weekly one in six. The heterogeneity of national public health surveillance systems that this survey has revealed points to the need for a coordinated approach if surveillance at an EC level is to be developed.			DESENCLOS, JC (corresponding author), HOP NATL ST MAURICE,EUROPEAN CTR EPIDEMIOL MONITORING AIDS,14 RUE DU VAL DOSNE,F-94410 ST MAURICE,FRANCE.							BIJKERK H, 1992, EXPLORATORY RES SURV; CATCHPOLE MA, 1992, CDR, V2, pR2; DOWNS AM, 1990, AIDS, V4, P1117, DOI 10.1097/00002030-199011000-00010; DOWNS AM, 1991, J ACQ IMMUN DEF SYND, V4, P805; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; LANGMUIR AD, 1980, PUBL HLTH REP, V95, P370; MAGGINI M, 1991, J CLIN EPIDEMIOL, V44, P1299, DOI 10.1016/0895-4356(91)90091-M; MAYNARD A, 1990, EUR13001 COMM EUR CO; PAPAEVANGELOU G, 1989, IATRIKI, V39, P43; PONGE A, 1992, SANTE PUBL, V3, P59; RENTON A, 1991, USING STD OCCURRENCE; SALMASO S, 1988, EUR J EPIDEMIOL, V4, P357; THACKER SB, 1988, EPIDEMIOL REV, V10, P164, DOI 10.1093/oxfordjournals.epirev.a036021; VANDENHOEK JAR, 1990, LANCET, V336, P179, DOI 10.1016/0140-6736(90)91700-K; 1992, WHO WKLY EPIEMIOL RE, V12, P83; 1989, WHO EURICPVDT011 REG; 1991, RENAGO RESEAU NATION; 1991, B EPIDEMIOL HEBD, V45, P195; 1988, MMWR, V37, pS5	19	22	23	1	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 17	1993	341	8851					1003	1006		10.1016/0140-6736(93)91084-Y	http://dx.doi.org/10.1016/0140-6736(93)91084-Y			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY368	8096889				2022-12-28	WOS:A1993KY36800015
J	BASTA, SS				BASTA, SS			ARCHITECTURAL MEDICINE - MALNUTRITION BY DESIGN	LANCET			English	Editorial Material											BASTA, SS (corresponding author), UNICEF,GENEVA,SWITZERLAND.							BASTA SS, 1979, AM J CLIN NUTR, V32, P916, DOI 10.1093/ajcn/32.4.916; BASTA SS, 1982, URBAN PLANNING PRACT; BASTA SS, 1977, ECOL FOOD NUTR, V6, P13; WHARTON BA, 1992, INT CHILD HLTH, V3, P2	4	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 10	1993	341	8850					934	934		10.1016/0140-6736(93)91222-8	http://dx.doi.org/10.1016/0140-6736(93)91222-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW981	8096275				2022-12-28	WOS:A1993KW98100014
J	HUGHES, A				HUGHES, A			ROOTS - A DILATION ON DILATATION	LANCET			English	Editorial Material											HUGHES, A (corresponding author), OXFORD UNIV PRESS,OXFORD ENGLISH DICTIONARY,OXFORD,ENGLAND.								0	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 3	1993	341	8849					867	867		10.1016/0140-6736(93)93070-H	http://dx.doi.org/10.1016/0140-6736(93)93070-H			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KV811	8096571				2022-12-28	WOS:A1993KV81100013
J	JOHNSON, BR; HORGA, M; ANDRONACHE, L				JOHNSON, BR; HORGA, M; ANDRONACHE, L			CONTRACEPTION AND ABORTION IN ROMANIA	LANCET			English	Article								After the downfall of the Ceausescu regime in December, 1989, the new Government of Romania abolished the law that prohibited abortions on request. Subsequently, the rate of legally induced abortions increased significantly while the rate of maternal mortality declined dramatically. Despite the large number of women who request induced abortions, most women and gynaecologists say that they would prefer to prevent unwanted pregnancies through the use of modern contraception. In this paper we examine factors that contribute to the disparity between women's desire to use modern contraception to prevent unwanted pregnancies and their practice of having induced abortions to prevent unwanted births. The results show that women (and suggest that men) need a wide choice of dependably available high-quality contraceptives, they need to be able to obtain information, counselling, and methods from a wide range of sources/health-care providers, both women's and men's perceptions about, and use of, modern contraception could be positively affected through sexual education started in secondary school; and, to reduce repeat abortions, women's post-abortion family-planning needs must not be neglected.	INST PUBL HLTH & MED RES, TIRGUMURES, ROMANIA; ROMANIAN MINIST HLTH, BUCHAREST, ROMANIA		JOHNSON, BR (corresponding author), INT PROJECTS ASSISTANCE SERV, POB 100, CARRBORO, NC 27510 USA.							EREN N, 1983, STUD FAMILY PLANN, V14, P43, DOI 10.2307/1965401; HORD C, 1991, STUD FAMILY PLANN, V22, P231, DOI 10.2307/1966479; STEPHENSON P, 1992, AM J PUBLIC HEALTH, V82, P1328, DOI 10.2105/AJPH.82.10.1328; 1991, WOMENS HLTH FAMILY P; 1990, REPORT MISSION ROMAN; 1991, REPORT ROMANIA NATIO	6	19	19	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 3	1993	341	8849					875	878		10.1016/0140-6736(93)93074-B	http://dx.doi.org/10.1016/0140-6736(93)93074-B			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KV811	8096575				2022-12-28	WOS:A1993KV81100017
J	WHITE, NJ				WHITE, NJ			MALARIA PARASITES GO APE	LANCET			English	Editorial Material											WHITE, NJ (corresponding author), MAHIDOL UNIV,FAC TROP MED,BANGKOK 10700,THAILAND.		White, Nick/AAC-6527-2019; White, Nicholas J/I-4629-2012	White, Nick/0000-0002-1897-1978; 				ARNOT DE, 1985, SCIENCE, V230, P815, DOI 10.1126/science.2414847; Bruce-Chwatt L. J., 1988, Malaria: principles and practice of malariology. Volume 1., P1; Garnham PCC., 1966, MALARIA PARASITES OT; HALL T, 1989, SCIENCE, V245, P973; Kitchen SF, 1949, MALARIOLOGY; SHUTE PG, 1946, T ROY SOC TROP MED H, V40, P189, DOI 10.1016/0035-9203(46)90056-9; VONWAGNERJAUREG.J, 1922, J NERV MENT DIS, V55, P369; WATERS AP, 1991, P NATL ACAD SCI USA, V88, P3140, DOI 10.1073/pnas.88.8.3140	8	8	8	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 27	1993	341	8848					793	793		10.1016/0140-6736(93)90565-X	http://dx.doi.org/10.1016/0140-6736(93)90565-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU900	8096003				2022-12-28	WOS:A1993KU90000008
J	MINTY, A; CHALON, P; DEROCQ, JM; DUMONT, X; GUILLEMOT, JC; KAGHAD, M; LABIT, C; LEPLATOIS, P; LIAUZUN, P; MILOUX, B; MINTY, C; CASELLAS, P; LOISON, G; LUPKER, J; SHIRE, D; FERRARA, P; CAPUT, D				MINTY, A; CHALON, P; DEROCQ, JM; DUMONT, X; GUILLEMOT, JC; KAGHAD, M; LABIT, C; LEPLATOIS, P; LIAUZUN, P; MILOUX, B; MINTY, C; CASELLAS, P; LOISON, G; LUPKER, J; SHIRE, D; FERRARA, P; CAPUT, D			INTERLEUKIN-13 IS A NEW HUMAN LYMPHOKINE REGULATING INFLAMMATORY AND IMMUNE-RESPONSES	NATURE			English	Article							T-CELL CLONE; HUMAN-MONOCYTES; SEQUENCE; TH1; IDENTIFICATION; LYMPHOCYTES; CYTOKINES; RECEPTOR; ANTIGEN; SIGNAL	THE discovery of new cytokines normally relies on a prior knowledge of at least one of their biological effects, which is used as a criterion either for the purification of the protein or for the isolation of the complementary DNA by expression cloning. However, the redundancy of cytokine activities complicates the discovery of novel cytokines in this way, and the pleiotropic nature of many cytokines means that the principal activities of a new cytokine may bear little relation to that used for its isolation. We have adopted an alternative approach which relies on differential screening of an organized subtracted cDNA library from activated peripheral blood mononuclear cells, using the inducibility of lymphokine messenger RNAs by anti-CD28 as a primary screening criterion. The ligation of the CD28 antigen on the T lymphocyte by a surface antigen, B7/BB-1, expressed on activated B lymphocytes and monocytes1,2 is a key step in the activation of T lymphocytes and the accumulation of lymphokine mRNAs3. Here we report the discovery by molecular cloning of a new interleukin (interleukin-13 or IL-13) expressed in activated human T lymphocytes. Recombinant IL-13 protein inhibits inflammatory cytokine production induced by lipopolysaccharide in human peripheral blood monocytes. Moreover, it synergizes with IL-2 in regulating interferon-gamma synthesis in large granular lymphocytes. Recent mapping of the IL-13 gene shows that it is closely linked to the IL-4 gene on chromosome 5q 23-31 (ref. 4). Interleukin-13 may be critical in regulating inflammatory and immune responses.	SANOFI ELF BIO RECH,F-31676 LABEGE,FRANCE; SANOFI RECH,F-34184 MONTPELLIER,FRANCE	Sanofi-Aventis; Sanofi-Aventis; Sanofi France								AARDEN LA, 1987, EUR J IMMUNOL, V17, P1411, DOI 10.1002/eji.1830171004; BOOM WH, 1988, J EXP MED, V167, P1350, DOI 10.1084/jem.167.4.1350; BRAKE AJ, 1990, METHOD ENZYMOL, V185, P408; BROWN KD, 1989, J IMMUNOL, V142, P679; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHER DJ, 1987, J IMMUNOL, V138, P3688; CHERWINSKI HM, 1987, J EXP MED, V166, P1229, DOI 10.1084/jem.166.5.1229; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DORNER AJ, 1987, J CELL BIOL, V105, P2665, DOI 10.1083/jcb.105.6.2665; GIMMI CD, 1991, P NATL ACAD SCI USA, V88, P6575, DOI 10.1073/pnas.88.15.6575; KOBAYASHI M, 1989, J EXP MED, V170, P827, DOI 10.1084/jem.170.3.827; KOYANAGI Y, 1988, SCIENCE, V241, P1673, DOI 10.1126/science.3047875; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LINSLEY PS, 1990, P NATL ACAD SCI USA, V87, P5031, DOI 10.1073/pnas.87.13.5031; MALEFYT RD, 1991, J EXP MED, V174, P1209; MONTANER LJ, 1993, J CELL BIOCH B S, V17, P94; MORGAN JG, 1992, NUCLEIC ACIDS RES, V20, P5173, DOI 10.1093/nar/20.19.5173; MORRISON BW, 1992, J BIOL CHEM, V267, P11957; OHLSSON K, 1990, NATURE, V348, P550, DOI 10.1038/348550a0; POWERS R, 1992, SCIENCE, V256, P1673, DOI 10.1126/science.256.5064.1673; SCOTT P, 1991, J IMMUNOL, V147, P3149; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; THOMPSON CB, 1989, P NATL ACAD SCI USA, V86, P1333, DOI 10.1073/pnas.86.4.1333; TIMONEN T, 1982, J IMMUNOL METHODS, V51, P269, DOI 10.1016/0022-1759(82)90393-3; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WILLIAMS RO, 1992, P NATL ACAD SCI USA, V89, P9784, DOI 10.1073/pnas.89.20.9784; ZLOTNIK A, 1991, CYTOKINE, V3, P366, DOI 10.1016/1043-4666(91)90039-G	28	870	949	0	27	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 18	1993	362	6417					248	250		10.1038/362248a0	http://dx.doi.org/10.1038/362248a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KT026	8096327				2022-12-28	WOS:A1993KT02600057
J	HAMPTON, JR; HENDERSON, RA; JULIAN, DG; PARKER, J; POCOCK, SJ; SOWTON, E; WALLWORK, J; CHAMBERLAIN, DA; DARK, JF; JOY, MD; SEED, P; YOUARD, B; YATES, AK; CURRY, PVL; DEVERALL, PB; JACKSON, G; PUMPHREY, CW; PARKER, DJ; TREASURE, T; PEPPER, J; SMITH, J; WARD, DE; BROOKS, N; MOUSSALLI, H; BENNETT, D; BRAY, C; CAMPBELL, C; DEIRANIYA, AK; JONES, M; LAWSON, R; RAHMAN, A; WARD, C; BALCON, R; MAGEE, P; LAYTON, C; TIMMIS, AD; WRIGHT, JEC; SWANTON, RH; PUGSLEY, W; HUBNER, PJB; FIRMIN, RK; GERSHLICK, AH; SPYT, T; OKEFFE, DB; OKANE, H; CLELAND, J; GLADSTONE, DJ; MORTON, P; MURTAGH, JG; SCOTT, ME; COBBE, SM; WHEATLEY, DJ; DUNN, FG; HUTTON, I; LORIMER, AR; RAE, AP; HILLIS, WS; DYMOND, DS; EDMONDSON, SJ; BANIM, SO; DAVIES, DW; NATHAN, AW; REECE, G; SPURRELL, RAJ; CUMBERLAND, DC; SMITH, GH; OAKLEY, GDG; JEWITT, DE; KEATES, JRW; BUCKNALL, CA; FORSYTH, AT; WAINWRIGHT, RJ; SHABBO, FP; ORIORDEN, JB; BLOOMFIELD, P; CAMERON, EWJ; DEBONO, D; ROTHMAN, MT; WOOD, AJ; MACDONALD, AH; MILLS, PG; LEWIS, T; FOALE, RA; STANBRIDGE, R; FOX, KAA; BRECKENRIDGE, IM				HAMPTON, JR; HENDERSON, RA; JULIAN, DG; PARKER, J; POCOCK, SJ; SOWTON, E; WALLWORK, J; CHAMBERLAIN, DA; DARK, JF; JOY, MD; SEED, P; YOUARD, B; YATES, AK; CURRY, PVL; DEVERALL, PB; JACKSON, G; PUMPHREY, CW; PARKER, DJ; TREASURE, T; PEPPER, J; SMITH, J; WARD, DE; BROOKS, N; MOUSSALLI, H; BENNETT, D; BRAY, C; CAMPBELL, C; DEIRANIYA, AK; JONES, M; LAWSON, R; RAHMAN, A; WARD, C; BALCON, R; MAGEE, P; LAYTON, C; TIMMIS, AD; WRIGHT, JEC; SWANTON, RH; PUGSLEY, W; HUBNER, PJB; FIRMIN, RK; GERSHLICK, AH; SPYT, T; OKEFFE, DB; OKANE, H; CLELAND, J; GLADSTONE, DJ; MORTON, P; MURTAGH, JG; SCOTT, ME; COBBE, SM; WHEATLEY, DJ; DUNN, FG; HUTTON, I; LORIMER, AR; RAE, AP; HILLIS, WS; DYMOND, DS; EDMONDSON, SJ; BANIM, SO; DAVIES, DW; NATHAN, AW; REECE, G; SPURRELL, RAJ; CUMBERLAND, DC; SMITH, GH; OAKLEY, GDG; JEWITT, DE; KEATES, JRW; BUCKNALL, CA; FORSYTH, AT; WAINWRIGHT, RJ; SHABBO, FP; ORIORDEN, JB; BLOOMFIELD, P; CAMERON, EWJ; DEBONO, D; ROTHMAN, MT; WOOD, AJ; MACDONALD, AH; MILLS, PG; LEWIS, T; FOALE, RA; STANBRIDGE, R; FOX, KAA; BRECKENRIDGE, IM			CORONARY ANGIOPLASTY VERSUS CORONARY-ARTERY BYPASS-SURGERY - THE RANDOMIZED INTERVENTION TREATMENT OF ANGINA (RITA) TRIAL	LANCET			English	Article							FOLLOW-UP; LONG-TERM; RESTENOSIS; SURVIVAL; REGISTRY; SERIAL	The Randomised Intervention Treatment of Angina (RITA) trial is comparing the long-term effects of percutaneous transluminal coronary angioplasty (PTCA) and coronary artery bypass surgery (CABG) in patients with one, two, or three diseased coronary arteries in whom equivalent revascularisation was deemed achievable by either procedure. This first report is for a mean 2.5 years' follow-up on the 1011 patients randomised. 59% had grade 3 or 4 angina, 59% had experienced angina at rest, and 55% had two or more diseased coronary arteries. The intended procedure was done in 98% of patients. In 97% of CABG patients all intended vessels were grafted. Dilatation of all treatment vessels was attempted in 87% of PTCA patients with an angiographic success rate per vessel of 87% (90% excluding occluded vessels). There have been 34 deaths (18 CABG, 16 PTCA) and the pre-defined combined primary event of death or definite myocardial infarction shows no evidence of a treatment difference (43 CABG, 50 PTCA; relative risk 0.88 [95% confidence interval 0.59-1.29]). 4% of PTCA patients required emergency CABG before discharge and a further 15% had CABG during follow-up. Within 2 years of randomisation 38% and 11% of the PTCA and CABG groups, respectively, required revascularisation procedure(s) or had a primary event (p < 0.001) and repeat coronary arteriography during follow-up was four times more common in PTCA than in CABG patients (31% vs 7%, p < 0.001). The prevalence of angina during follow-up was higher in the PTCA group (eg, 32% vs 11% at 6 months) but this difference became less marked after 2 years (31% vs 22%). Anti-anginal drugs were prescribed more frequently for PTCA patients. At 1 month CABG patients were less physically active, with greater coronary related unemployment and lower mean exercise times than the PTCA patients. Thereafter employment status, breathlessness, and physical activity improved, with no significant differences between the two treatment groups. At 1 year mean exercise times had increased by 3 min for both groups. These interim findings indicate that recovery after CABG, the more invasive procedure, takes longer than after PTCA. However, CABG leads to less risk of angina and fewer additional diagnostic and therapeutic interventions in the first 2 years than PTCA. So far, there is no significant difference in risk of death or myocardial infarction, and follow-up continues to at least five years.	UNIV LONDON LONDON SCH HYG & TROP MED, LONDON WC1E 7HT, ENGLAND; GUYS HOSP, LONDON SE1 9RT, ENGLAND; ST GEORGE HOSP, LONDON, ENGLAND; WYTHENSHAWE HOSP, MANCHESTER M23 9LT, LANCS, ENGLAND; LONDON CHEST HOSP, LONDON, ENGLAND; MIDDLESEX HOSP, LONDON W1, ENGLAND; GROBY RD HOSP, LEICESTER LE3 9QE, ENGLAND; GLASGOW ROYAL INFIRM, GLASGOW G4 0SF, SCOTLAND; ST BARTHOLOMEWS HOSP, LONDON EC1A 7BE, ENGLAND; NO GEN HOSP, SHEFFIELD S5 7AU, S YORKSHIRE, ENGLAND; UNIV LONDON KINGS COLL HOSP, LONDON SE5 8RX, ENGLAND; BROOK GEN HOSP, LONDON SE18 4LW, ENGLAND; ROYAL EDINBURGH & ASSOCIATED HOSP, EDINBURGH EH3 9HB, MIDLOTHIAN, SCOTLAND; ROYAL LONDON HOSP, LONDON, ENGLAND; ST MARYS HOSP, LONDON, ENGLAND; UNIV HOSP WALES, CARDIFF, WALES	University of London; London School of Hygiene & Tropical Medicine; Guy's & St Thomas' NHS Foundation Trust; St Georges University London; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; University of London; Queen Mary University London; University of London; University College London; University of Glasgow; University of London; Queen Mary University London; Northern General Hospital; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; Royal Infirmary of Edinburgh; Barts Health NHS Trust; Royal London Hospital; Imperial College London; Cardiff University	HAMPTON, JR (corresponding author), UNIV NOTTINGHAM HOSP, DEPT MED, D FLOOR S BLOCK, NOTTINGHAM NG7 2UH, ENGLAND.		Seed, Paul T/C-4435-2008; Fox, keith A A/I-3742-2013	Seed, Paul T/0000-0001-7904-7933; 				ALDERMAN EL, 1990, CIRCULATION, V82, P1629, DOI 10.1161/01.CIR.82.5.1629; CAMBEAU L, 1976, CIRCULATION, V54, P522; DETRE K, 1989, CIRCULATION, V80, P421, DOI 10.1161/01.CIR.80.3.421; DETRE K, 1988, NEW ENGL J MED, V318, P265, DOI 10.1056/NEJM198802043180501; FITZGIBBON GM, 1991, J AM COLL CARDIOL, V17, P1075, DOI 10.1016/0735-1097(91)90834-V; GRUENTZIG AR, 1987, NEW ENGL J MED, V316, P1127, DOI 10.1056/NEJM198704303161805; HAMM CW, 1992, CIRCULATION S1, V82, P373; HENDERSON RA, 1989, BRIT HEART J, V62, P411; HUBNER PJB, 1991, BRIT HEART J, V66, P469; KING SB, 1992, CIRCULATION S1, V82, P508; LYTLE BW, 1985, J THORAC CARDIOV SUR, V89, P248; NOBUYOSHI M, 1988, J AM COLL CARDIOL, V12, P616, DOI 10.1016/S0735-1097(88)80046-9; PARISI AF, 1992, NEW ENGL J MED, V326, P10, DOI 10.1056/NEJM199201023260102; RODRIGUEZ A, 1992, Journal of the American College of Cardiology, V19, p24A; SERRUYS PW, 1988, CIRCULATION, V77, P361, DOI 10.1161/01.CIR.77.2.361; SHEFFIELD LT, 1972, EXERCISE TESTING TRA, P35; VARNAUSKAS E, 1988, NEW ENGL J MED, V319, P332, DOI 10.1056/NEJM198808113190603; 1991, CIRCULATION S5, V84, P1; 1992, CIRCULATION, V86, P121; 1990, LANCET, V335, P1315	20	443	453	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 6	1993	341	8845					573	580						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KQ234	8094826				2022-12-28	WOS:A1993KQ23400001
J	CZEIZEL, AE; ELEK, C; GUNDY, S; METNEKI, J; NEMES, E; REIS, A; SPERLING, K; TIMAR, L; TUSNADY, G; VIRAGH, Z				CZEIZEL, AE; ELEK, C; GUNDY, S; METNEKI, J; NEMES, E; REIS, A; SPERLING, K; TIMAR, L; TUSNADY, G; VIRAGH, Z			ENVIRONMENTAL TRICHLORFON AND CLUSTER OF CONGENITAL-ABNORMALITIES	LANCET			English	Article							INSECTICIDES; ABERRATIONS	Of 15 live births in one Hungarian village in 1989-90, 11 (73%) were affected by congenital abnormalities and 6 were twins. Of the 11, 4 had Down syndrome. Likely causes of such clusters (known teratogenic factors, familial inheritance, consanguinity) were excluded. A case-control study and environmental investigations pointed the finger of suspicion at the excessive use of trichlorfon at local fish farms. The content of this chemical was very high in fish (100 mg/kg) and several pregnant women, including all mothers of babies with Down syndrome, had consumed contaminated fish in the critical period for the congenital abnormalities observed.	NATL INST HYG,WHO COLLABORATING CTR COMMUNITY CONTROL HEREDITARY DIS,BUDAPEST,HUNGARY; DEPT PUBL HLTH,KAPOSVAR,HUNGARY; HUNGARIAN ACAD SCI,INST MATH,H-1361 BUDAPEST 5,HUNGARY; INST HUMAN GENET,BERLIN,GERMANY	Hungarian Academy of Sciences; Hungarian Alfred Renyi Institute of Mathematics			Reis, André/D-2309-2009	Reis, André/0000-0002-6301-6363				BERGE GN, 1986, ARCH TOXICOL, V59, P26, DOI 10.1007/BF00263953; COURTNEY KD, 1986, J ENVIRON SCI HEAL B, V21, P207, DOI 10.1080/03601238609372519; CZEIZEL A, 1988, ACTA MORPHOL HUNG, V36, P63; CZEIZEL AE, 1993, BRIT MED J, V306, P499, DOI 10.1136/bmj.306.6876.499; CZEIZEL AE, 1988, MULTIPLE CONGENITAL; DEGRAEVE N, 1984, ARCH TOXICOL, V56, P66, DOI 10.1007/BF00316356; DEGRAEVE N, 1984, TOXICOL LETT, V21, P315, DOI 10.1016/0378-4274(84)90090-0; DEGRAEVE N, 1984, FOOD CHEM TOXICOL, V22, P683, DOI 10.1016/0278-6915(84)90280-1; DZWONKOWSKA A, 1986, ARCH TOXICOL, V58, P152, DOI 10.1007/BF00340974; JENEY Z, 1986, AQUACULTURA HUNGARIC, V5, P79; JENEY Z, 1985, ARCH TOXICOL S, V8, P299; KALLEN B, 1986, ACTA GENET MED GEMEL, V35, P167; MARTSON LV, 1979, GIG SANIT, V7, P70; MOUTSCHENDAHMEN J, 1981, ACTA PHARMACOL TOX, V49, P29; NEHEZ M, 1987, ECOTOX ENVIRON SAFE, V13, P216, DOI 10.1016/0147-6513(87)90010-8; SHEEHAN PME, 1983, BRIT MED J, V287, P1428, DOI 10.1136/bmj.287.6403.1428; STAPLES RE, 1979, ENVIRON HEALTH PERSP, V30, P105, DOI 10.2307/3429110; VANBAO T, 1974, HUMANGENETIK, V24, P33; 1986, WHO ENV HLTH CRITERI, V63, P181; 1991, HLTH SAFETY GUIDE	20	78	79	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 27	1993	341	8844					539	542		10.1016/0140-6736(93)90293-P	http://dx.doi.org/10.1016/0140-6736(93)90293-P			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP083	8094783				2022-12-28	WOS:A1993KP08300016
J	HILTONJONES, D; SQUIER, MV				HILTONJONES, D; SQUIER, MV			MUSCULAR-DYSTROPHY - DYSTROPHIN-ASSOCIATED PROTEIN COMPLEX - CLINICAL IMPLICATIONS	LANCET			English	Editorial Material							DUCHENNE				HILTONJONES, D (corresponding author), RADCLIFFE INFIRM,CTR MUSCLE & NERVE,MUSCULAR DYSTROPHY GRP,OXFORD OX2 6HE,ENGLAND.							BAUMBACH LL, 1989, NEUROLOGY, V39, P465, DOI 10.1212/WNL.39.4.465; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; Khurana T S, 1991, Neuromuscul Disord, V1, P185, DOI 10.1016/0960-8966(91)90023-L; MATSUMURA K, 1992, NATURE, V359, P320, DOI 10.1038/359320a0; MONACO AP, 1986, NATURE, V323, P646, DOI 10.1038/323646a0; OHLENDIECK K, IN PRESS NEUROLOGY; 1988, LANCET, V2, P429	8	4	4	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 27	1993	341	8844					528	529		10.1016/0140-6736(93)90285-O	http://dx.doi.org/10.1016/0140-6736(93)90285-O			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP083	8094778				2022-12-28	WOS:A1993KP08300011
J	RAYMOND, LA; BLACKSTONE, CD; HUGANIR, RL				RAYMOND, LA; BLACKSTONE, CD; HUGANIR, RL			PHOSPHORYLATION AND MODULATION OF RECOMBINANT GLUR6 GLUTAMATE RECEPTORS BY CAMP-DEPENDENT PROTEIN-KINASE	NATURE			English	Article							RETINAL HORIZONTAL CELLS; AMINO-ACID RECEPTORS; HIPPOCAMPAL-NEURONS; NERVOUS-SYSTEM; KAINATE; ENHANCEMENT; QUISQUALATE; ACTIVATION	GLUTAMATE-GATED ion channels mediate most excitatory synaptic transmission in the central nervous system and play crucial roles in synaptic plasticity, neuronAL development and some neuropathological conditions1-3. These ionotropic glutamate receptors have been classified according to their preferred agonists as NMDA (N-methyL-D-aspartate), AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate) and KA (kainate) receptors4. On the basis of sequence similarity and pharmacological properties, the recently cloned glutamate receptor subunits have been assigned as components of NMDA (NMDAR1, 2A-D), AMPA (GluR1-4) and KA (GluR5-7, KA1, KA2) receptors5-7. Protein phosphorylation of glutamate receptors by protein kinase C and cyclic AMP-dependent protein kinase (PKA) has been suggested to regulate their function8-18, possibly playing a prominent role in certain forms of synaptic plasticity such as long-term potentiation19 and long-term depression9. Here we report that the GluR6 glutamate receptor, transiently expressed in mammalian cells, is directly phosphorylated by PKA, and that intracellularly applied PKA increases the amplitude of the glutamate response. Site-specific mutagenesis of the serine residue (Ser 684) representing a PKA consensus site completely eliminates PKA-mediated phosphorylation of this site as well as the potentiation of the glutamate response. These results provide evidence that direct phosphorylation of glutamate receptors modulates their function.	JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT NEUROL,BALTIMORE,MD 21205	Howard Hughes Medical Institute; Johns Hopkins University			Raymond, Lynn A./R-6707-2016; Raymond, Lynn A/A-6664-2010	Raymond, Lynn A./0000-0002-8610-1042; Raymond, Lynn A/0000-0002-8610-1042				BETTLER B, 1992, NEURON, V8, P257, DOI 10.1016/0896-6273(92)90292-L; BLACKSTONE CD, 1992, J NEUROCHEM, V58, P1118, DOI 10.1111/j.1471-4159.1992.tb09370.x; CHAVEZNORIEGA LE, 1992, BRAIN RES, V574, P85, DOI 10.1016/0006-8993(92)90803-H; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; CHEN L, 1991, NEURON, V7, P319, DOI 10.1016/0896-6273(91)90270-A; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; COLLINGRIDGE GL, 1990, TRENDS PHARMACOL SCI, V11, P290, DOI 10.1016/0165-6147(90)90011-V; EGEBJERG J, 1991, NATURE, V351, P745, DOI 10.1038/351745a0; GASIC GP, 1992, ANNU REV PHYSIOL, V54, P507, DOI 10.1146/annurev.physiol.54.1.507; GERBER G, 1989, J NEUROSCI, V9, P3606; GREENGARD P, 1991, SCIENCE, V253, P1135, DOI 10.1126/science.1716001; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HUETTNER JE, 1990, NEURON, V5, P255, DOI 10.1016/0896-6273(90)90163-A; HUGANIR RL, 1984, P NATL ACAD SCI-BIOL, V81, P6968, DOI 10.1073/pnas.81.22.6968; KELLER BU, 1992, EMBO J, V11, P891, DOI 10.1002/j.1460-2075.1992.tb05127.x; KNAPP AG, 1987, NATURE, V325, P437, DOI 10.1038/325437a0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LIMAN ER, 1989, BRAIN RES, V481, P399, DOI 10.1016/0006-8993(89)90822-6; LINDEN DJ, 1991, SCIENCE, V254, P1656, DOI 10.1126/science.1721243; MADISON DV, 1991, ANNU REV NEUROSCI, V14, P379, DOI 10.1146/annurev.ne.14.030191.002115; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; OLNEY JW, 1990, ANNU REV PHARMACOL, V30, P47; SOMMER B, 1992, TRENDS PHARMACOL SCI, V13, P291, DOI 10.1016/0165-6147(92)90088-N; SWOPE SL, 1992, FASEB J, V6, P2514, DOI 10.1096/fasebj.6.8.1375568; TANG CM, 1989, SCIENCE, V243, P1474, DOI 10.1126/science.2467378; WANG LY, 1991, SCIENCE, V253, P1132, DOI 10.1126/science.1653455; WANG LY, IN PRESS SCIENCE	29	253	254	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 18	1993	361	6413					637	641		10.1038/361637a0	http://dx.doi.org/10.1038/361637a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KM776	8094892				2022-12-28	WOS:A1993KM77600064
J	DIEPPE, PA; FRANKEL, SJ; TOTH, B				DIEPPE, PA; FRANKEL, SJ; TOTH, B			IS RESEARCH INTO THE TREATMENT OF OSTEOARTHRITIS WITH NONSTEROIDAL ANTIINFLAMMATORY DRUGS MISDIRECTED	LANCET			English	Editorial Material							OSTEO-ARTHRITIS; KNEE; ACETAMINOPHEN; EPIDEMIOLOGY; MANAGEMENT		UNIV BRISTOL,DEPT EPIDEMIOL & PUBL HLTH,BRISTOL BS8 1TH,AVON,ENGLAND	University of Bristol	DIEPPE, PA (corresponding author), UNIV BRISTOL,BRISTOL ROYAL INFIRM,DEPT MED,RHEUMATOL UNIT,BRISTOL BS2 8HW,AVON,ENGLAND.			Toth, Ben/0000-0002-8465-4145				ALLISON MC, 1992, NEW ENGL J MED, V327, P749, DOI 10.1056/NEJM199209103271101; AMADIO P, 1983, CURR THER RES CLIN E, V34, P59; BRADLEY JD, 1991, NEW ENGL J MED, V325, P87, DOI 10.1056/NEJM199107113250203; BRADLOW J, 1992, PATTERNS REFERRAL ST; CUSHNAGHAN J, 1990, ANN RHEUM DIS, V49, P768, DOI 10.1136/ard.49.10.768; DONOVAN J, 1992, EPIDEMIOLOGICALLY BA; FELSON DT, 1988, EPIDEMIOL REV, V10, P1; FRANKEL S, 1991, J EPIDEMIOL COMMUN H, V45, P257, DOI 10.1136/jech.45.4.257; FRANKEL SJ, 1989, HLTH TRENDS, V21, P54; KEYS J, 1992, J ROY SOC MED, V85, P442; MCALINDON T, 1990, BRIT J RHEUMATOL, V29, P471; PARR G, 1989, BRIT J CLIN PHARMACO, V27, P235, DOI 10.1111/j.1365-2125.1989.tb05356.x; ROBBINS M, 1992, EPIDEMIOLOGICALLY BA; SOMERVILLE K, 1986, LANCET, V1, P462; SWIFT GL, 1992, BRIT J CLIN PRACT, V46, P92; WILLIAMS M, 1992, EPIDEMIOLOGICALLY BA; WRIGHT V, 1989, BRIT MED J, V299, P1476, DOI 10.1136/bmj.299.6714.1476; WYLES M, 1992, ARTHRITIS; 1988, OPCS PREVALENCE DISA	19	52	53	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 6	1993	341	8841					353	354		10.1016/0140-6736(93)90147-9	http://dx.doi.org/10.1016/0140-6736(93)90147-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK939	8094123				2022-12-28	WOS:A1993KK93900015
J	BROWN, P; KAUR, P; SULIMA, MP; GOLDFARB, LG; GIBBS, CJ; GAJDUSEK, DC				BROWN, P; KAUR, P; SULIMA, MP; GOLDFARB, LG; GIBBS, CJ; GAJDUSEK, DC			REAL AND IMAGINED CLINICOPATHOLOGICAL LIMITS OF PRION DEMENTIA	LANCET			English	Article							CREUTZFELDT-JAKOB DISEASE; PROTEINS	The term ''prion dementia'' has been proposed to replace ''spongiform encephalopathy'', to accommodate the existence of atypical forms of these ''prion protein'' (PrP) cerebral amyloidoses that may not show spongiform changes in the brain. We tested brain tissue extracts for the presence of PrP from 46 cases (including 13 familial cases) of non-spongiform dementias with a variety of associated neurological signs, referred to our laboratory for primate transmission studies. None of the cases transmitted disease to primates, and none had PrP detectable by western immunoblots of extracted brain tissue. We conclude that prion dementias are not lurking undetected within the larger landscape of neurodegenerative disorders, and that their clinicopathological limits are, except for a small number of previously reported familial cases, essentially those of spongiform encephalopathy.			BROWN, P (corresponding author), NINCDS,CNS STUDIES LAB,BLDG 36,ROOM 5B21,BETHESDA,MD 20892, USA.							BOCKMAN JM, 1985, NEW ENGL J MED, V312, P73, DOI 10.1056/NEJM198501103120202; BROWN P, 1986, NEW ENGL J MED, V314, P547, DOI 10.1056/NEJM198602273140904; BROWN P, 1992, NEUROLOGY, V42, P422, DOI 10.1212/WNL.42.2.422; BROWN P, 1985, P WORKSHOP SLOW TRAN, P27; COLLINGE J, 1992, BRAIN, V115, P687, DOI 10.1093/brain/115.3.687; COLLINGE J, 1990, LANCET, V336, P7, DOI 10.1016/0140-6736(90)91518-F; GOLDFARB LG, 1991, P NATL ACAD SCI USA, V88, P10926, DOI 10.1073/pnas.88.23.10926; HILMERT H, 1984, BIOSCIENCE REP, V4, P165, DOI 10.1007/BF01120313; JENDROSKA K, 1991, NEUROLOGY, V41, P1482, DOI 10.1212/WNL.41.9.1482; KITAMOTO T, 1989, J GEN VIROL, V70, P3371, DOI 10.1099/0022-1317-70-12-3371; KITAMOTO T, 1992, AM J PATHOL, V140, P1285; MANETTO V, 1992, NEUROLOGY, V42, P312, DOI 10.1212/WNL.42.2.312; PETERSEN RB, 1992, NEUROLOGY, V42, P1859, DOI 10.1212/WNL.42.10.1859; POWERS JM, 1991, ACTA NEUROPATHOL, V83, P95, DOI 10.1007/BF00294437; SERBAN D, 1990, NEUROLOGY, V40, P110, DOI 10.1212/WNL.40.1.110	15	37	37	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 16	1993	341	8838					127	129		10.1016/0140-6736(93)90001-W	http://dx.doi.org/10.1016/0140-6736(93)90001-W			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG627	8093741				2022-12-28	WOS:A1993KG62700001
J	PABLOSMENDEZ, A; NETTO, EM; DEFENDINI, R				PABLOSMENDEZ, A; NETTO, EM; DEFENDINI, R			INFECTIOUS PRIONS OR CYTOTOXIC METABOLITES	LANCET			English	Editorial Material							CREUTZFELDT-JAKOB DISEASE; SCRAPIE; PROTEIN; STRAUSSLER; GERSTMANN; MUTATION; HAMSTER		COLUMBIA UNIV COLL PHYS & SURG,DIV NEUROPATHOL,630 W 168TH ST,NEW YORK,NY 10032; CORNELL UNIV,MED CTR,COLL MED,DIV INT MED,NEW YORK,NY 10021; COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032	Columbia University; Cornell University; Columbia University			Netto, Eduardo/D-1432-2013	Netto, Eduardo/0000-0003-1691-6761				BOCKMAN JM, 1988, J VIROL, V62, P3120, DOI 10.1128/JVI.62.9.3120-3127.1988; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; CHENG MY, 1990, NATURE, V348, P455, DOI 10.1038/348455a0; CHESEBRO B, 1985, NATURE, V315, P331, DOI 10.1038/315331a0; COLLINGE J, 1991, LANCET, V337, P1441, DOI 10.1016/0140-6736(91)93128-V; FRASER H, CITED INDIRECTLY; GABIZON R, 1990, BIOCHEM J, V266, P1; GODEC MS, 1991, NEUROLOGY, V41, P1320, DOI 10.1212/WNL.41.8.1320; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HARRISON PJ, 1991, BRIT J PSYCHIAT, V158, P457, DOI 10.1192/bjp.158.4.457; HSIAO K, 1991, NEW ENGL J MED, V324, P1091, DOI 10.1056/NEJM199104183241604; KIMBERLIN RH, 1977, J GEN VIROL, V34, P295, DOI 10.1099/0022-1317-34-2-295; KRETZSCHMAR HA, 1991, LANCET, V337, P1160, DOI 10.1016/0140-6736(91)92826-N; MASTERS CL, 1981, BRAIN, V104, P559, DOI 10.1093/brain/104.3.559; MAYER RJ, 1992, J NEUROPATH EXP NEUR, V51, P352; MCKEE AC, 1992, J NEUROPATH EXP NEUR, V51, P359; MEDORI R, 1992, NEW ENGL J MED, V326, P444, DOI 10.1056/NEJM199202133260704; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; Outram G W, 1976, Front Biol, V44, P325; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1981, P NATL ACAD SCI-BIOL, V78, P6675, DOI 10.1073/pnas.78.11.6675; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; Prusiner SB, 1991, BRAIN PATHOL, V1, P297, DOI 10.1111/j.1750-3639.1991.tb00673.x; SCOTT M, 1989, CELL, V59, P847, DOI 10.1016/0092-8674(89)90608-9; WEISSMANN C, 1991, NATURE, V352, P679, DOI 10.1038/352679a0	26	7	7	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 16	1993	341	8838					159	161		10.1016/0140-6736(93)90018-C	http://dx.doi.org/10.1016/0140-6736(93)90018-C			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG627	8093757	hybrid			2022-12-28	WOS:A1993KG62700017
J	EDWARDS, G; LOGAN, R; COPELAND, M; REINISCH, L; DAVIDSON, J; JOHNSON, B; MACIUNAS, R; MENDENHALL, M; OSSOFF, R; TRIBBLE, J; WERKHAVEN, J; ODAY, D				EDWARDS, G; LOGAN, R; COPELAND, M; REINISCH, L; DAVIDSON, J; JOHNSON, B; MACIUNAS, R; MENDENHALL, M; OSSOFF, R; TRIBBLE, J; WERKHAVEN, J; ODAY, D			TISSUE ABLATION BY A FREE-ELECTRON LASER TUNED TO THE AMIDE-II BAND	NATURE			English	Article							ABSORPTION; DAMAGE	EFFORTS to ablate soft tissue with conventional lasers have been limited by collateral damage and by concern over potential photochemical effects(1-5). Motivated by the thermal-confinement model(6), past infrared investigations targeted the OH-stretch mode of water with fast pulses from lasers emitting near 3,000 nm (refs 1, 7-9). What does a free-electron laser offer for the investigation of tissue ablation? Operating at non-photochemical single-photon energies, these infrared sources can produce trains of picosecond pulses tunable to the vibrational modes of proteins, lipids and/or water. We report here that targeting free-electron laser radiation to the amide II band of proteins leads to tissue ablation characterized by minimal collateral damage while maintaining a substantial ablation rate. To account for these observations we propose a novel ablation mechanism based on compromising tissue through resonant denaturation of structural proteins.	VANDERBILT UNIV,SCH MED,DEPT OPHTHALMOL & VISUAL SCI,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DEPT NEUROSURG,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DEPT OTOLARYNGOL,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DEPT PATHOL,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	EDWARDS, G (corresponding author), VANDERBILT UNIV,DEPT PHYS & ASTRON,NASHVILLE,TN 37235, USA.		Mendenhall, Marcus/M-4996-2017; Reinisch, Lou/L-2638-2019	Mendenhall, Marcus/0000-0001-6236-8212; 				ALFANO RR, 1984, IEEE J QUANTUM ELECT, V20, P1342, DOI 10.1109/JQE.1984.1072330; ANDERSON RR, 1983, SCIENCE, V220, P524, DOI 10.1126/science.6836297; AUSTIN RH, 1989, PHYS REV LETT, V62, P1912, DOI 10.1103/PhysRevLett.62.1912; BERMAN ER, 1991, BIOCH EYE; BRAU CA, 1988, SCIENCE, V239, P1115, DOI 10.1126/science.239.4844.1115; BRAU CA, 1992, NUCL INSTRUM METH A, V319, P47, DOI 10.1016/0168-9002(92)90529-D; Brewer R. G., 1964, PHYS REV LETT, V13, P334; DLOTT DD, 1989, J OPT SOC AM B, V6, P977, DOI 10.1364/JOSAB.6.000977; EDWARDS GS, 1993, OPT ENG, V32, P314, DOI 10.1117/12.60753; FANN W, 1990, PHYS REV LETT, V64, P607, DOI 10.1103/PhysRevLett.64.607; Flory P., 1969, STATISTICAL MECHANIC; GRAENER H, 1991, PHYS REV LETT, V66, P2092, DOI 10.1103/PhysRevLett.66.2092; Joly M., 1965, PHYSICOCHEMICAL APPR, P153; LIEBMAN SA, 1984, PYROLYSIS GC POLYM A; MADEY JMJ, 1971, J APPL PHYS, V42, P1906, DOI 10.1063/1.1660466; MCCLAIN PE, 1972, J BIOL CHEM, V247, P692; PRIVALOV PL, 1989, J MOL BIOL, V205, P737, DOI 10.1016/0022-2836(89)90318-5; PULIAFITO CA, 1985, OPHTHALMOLOGY, V92, P741; ROBERTSON JH, 1988, LASERS NEUROSURGERY; SRINIVASAN R, 1986, SCIENCE, V234, P559, DOI 10.1126/science.3764428; STEM D, 1988, OPHTHALMOLOGY, V95, P1434; TUNCEL E, 1993, PHYS REV LETT, V70, P4146, DOI 10.1103/PhysRevLett.70.4146; WALSH JT, 1989, LASER SURG MED, V9, P314, DOI 10.1002/lsm.1900090403; WEISSBLUTH M, 1989, PHOTON ATOM INTERACT, P376; WOLBARSHT ML, 1984, IEEE J QUANTUM ELECT, V20, P1427, DOI 10.1109/JQE.1984.1072328; ZIMDARS D, 1993, PHYS REV LETT, V70, P2718, DOI 10.1103/PhysRevLett.70.2718; ZYSSET B, 1989, LASER SURG MED, V9, P193, DOI 10.1002/lsm.1900090302	27	210	231	0	29	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 29	1994	371	6496					416	419		10.1038/371416a0	http://dx.doi.org/10.1038/371416a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PJ285	8090220				2022-12-28	WOS:A1994PJ28500042
J	FIEL, SB				FIEL, SB			CLINICAL MANAGEMENT OF PULMONARY-DISEASE IN CYSTIC-FIBROSIS	LANCET			English	Article							TERM NUTRITIONAL REHABILITATION; HEART-LUNG TRANSPLANTATION; MALNOURISHED CHILDREN; BODY-COMPOSITION; EXACERBATIONS; ADOLESCENTS; INFECTIONS; EXERCISE; CF				FIEL, SB (corresponding author), MED COLL PENN,ADULT CYST FIBROSIS PROGRAM,3300 HENRY AVE,PHILADELPHIA,PA 19129, USA.							AITKEN ML, 1992, JAMA-J AM MED ASSOC, V267, P1947, DOI 10.1001/jama.267.14.1947; ALTON EWFW, 1991, EUR RESPIR J, V4, P5; BOSSO JA, 1992, J CLIN PHARM THER, V17, P263, DOI 10.1111/j.1365-2710.1992.tb01304.x; BOUCHER RC, 1992, DRUGS, V43, P431, DOI 10.2165/00003495-199243040-00001; CAINE N, 1991, TRANSPLANT P, V23, P1203; COATES AL, 1992, CHEST, V101, P2, DOI 10.1378/chest.101.1.2; DRURY DM, 1990, PEDIATR RES, V27, pA104; EGGLESTON PA, 1991, CHEST, V99, P1088, DOI 10.1378/chest.99.5.1088; FALLIERS CJ, 1966, J ALLERGY, V38, P183, DOI 10.1016/0021-8707(66)90041-4; GREENE K, 1991, CHEST, V100, pS50; HJELTE L, 1990, THORAX, V45, P397, DOI 10.1136/thx.45.5.397; HODSON ME, 1991, EUR RESPIR J, V4, P524; KEREM E, 1992, NEW ENGL J MED, V326, P1187, DOI 10.1056/NEJM199204303261804; KERREBIJN K, 1988, CHEST, V92, pS97; KNOWLES MR, 1990, NEW ENGL J MED, V322, P1189, DOI 10.1056/NEJM199004263221704; KNOWLES MR, 1991, NEW ENGL J MED, V325, P533, DOI 10.1056/NEJM199108223250802; KONSTAN MW, 1991, J PEDIATR-US, V118, P956, DOI 10.1016/S0022-3476(05)82218-8; LEONINGBAUCKE V, 1979, J PEDIATR, V95, P630; LEVY LD, 1985, J PEDIATR-US, V107, P225, DOI 10.1016/S0022-3476(85)80130-X; MCELVANEY NG, 1991, LANCET, V337, P392, DOI 10.1016/0140-6736(91)91167-S; NOYES BE, 1992, CHEST, V101, P1187, DOI 10.1378/chest.101.5.1187; ORENSTEIN DM, 1981, CHEST, V80, P392, DOI 10.1378/chest.80.4.392; PEDERSEN SS, 1987, ACTA PAEDIATR SCAND, V76, P955, DOI 10.1111/j.1651-2227.1987.tb17271.x; PETTY TL, 1990, CHEST, V97, P75, DOI 10.1378/chest.97.1.75; PROBER CG, 1991, CLIN REV ALLERG, V9, P87; RAMSEY B, 1991, PEDIATR PULM S, V6, pA7; ROSENFELD MA, 1992, CELL, V68, P143, DOI 10.1016/0092-8674(92)90213-V; SCHILDLOW D, 1991, CYSTIC FIBROSIS F, V2, P1; SEARS M, 1990, LANCET, V335, P1391; SEDDON DJ, 1988, THORAX, V43, P739, DOI 10.1136/thx.43.9.739; SMITH A, 1990, PEDIATR PULMONOL S5, V5, P93; SPECTOR ML, 1989, ANN THORAC SURG, V47, P204, DOI 10.1016/0003-4975(89)90269-5; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; STANFANGER G, 1988, EUR RESPIR J, V1, P161; STERN H, 1991, ACTA PAEDIATR SCAND, V80, P51; STERN RC, 1978, AM REV RESPIR DIS, V117, P825; SWEEZEY NB, 1990, CHEST, V97, P1322, DOI 10.1378/chest.97.6.1322; VALERIUS NH, 1991, LANCET, V338, P725, DOI 10.1016/0140-6736(91)91446-2; VANDERSCHANS CP, 1991, THORAX, V46, P252, DOI 10.1136/thx.46.4.252; VANWYE JE, 1990, PEDIATR PULM, V9, P7, DOI 10.1002/ppul.1950090104; WEINTRAUB SJ, 1989, CHEST, V95, P861, DOI 10.1378/chest.95.4.861; WINNIE GB, 1989, J PEDIATR-US, V114, P309, DOI 10.1016/S0022-3476(89)80804-2; ZACH M, 1982, ARCH DIS CHILD, V57, P587, DOI 10.1136/adc.57.8.587; ZEASKE R, 1988, J ALLERGY CLIN IMMUN, V82, P73, DOI 10.1016/0091-6749(88)90054-1; ZINMAN R, 1989, J PEDIATR-US, V114, P368, DOI 10.1016/S0022-3476(89)80553-0	45	43	43	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 24	1993	341	8852					1070	1074		10.1016/0140-6736(93)92423-Q	http://dx.doi.org/10.1016/0140-6736(93)92423-Q			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ018	8096969				2022-12-28	WOS:A1993KZ01800016
J	BARTLETT, C; GILL, N				BARTLETT, C; GILL, N			INTERNATIONAL SURVEILLANCE OF DISEASE - COMMUNICABLE DISEASE-CONTROL AFTER MAASTRICHT - GERMS AND SUBSIDIARITY	LANCET			English	Editorial Material											BARTLETT, C (corresponding author), PUBL HLTH LAB SERV,LONDON,ENGLAND.							PATTERSON B, 1991, COMMENTARY; PIUS XI, CITED INDIRECTLY; ROBERTS JA, 1989, BRIT MED J, V298, P1227, DOI 10.1136/bmj.298.6682.1227; 1992, ECEM AIDS35 EUR CTR; 1993, OFFICIAL J EUR COMMU, V62; 1992, WHOEPICEIIS92 IEU; 1992, WHO WKLY EPIDEMIOL R, V67, P301	7	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 17	1993	341	8851					997	998		10.1016/0140-6736(93)91081-V	http://dx.doi.org/10.1016/0140-6736(93)91081-V			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY368	8096953				2022-12-28	WOS:A1993KY36800013
J	ESPINER, E				ESPINER, E			MYOCARDIAL-INFARCTION - KINDRED HEARTS AND CORONARIES	LANCET			English	Editorial Material							I-CONVERTING ENZYME; ANGIOTENSIN				ESPINER, E (corresponding author), CHRISTCHURCH HOSP,DEPT ENDOCRINOL,CHRISTCHURCH,NEW ZEALAND.							CAMBIEN F, 1992, NATURE, V359, P641, DOI 10.1038/359641a0; CAMBIEN F, 1988, AM J HUM GENET, V43, P774; DOSTAL DE, 1992, AM J PHYSIOL, V263, pC851, DOI 10.1152/ajpcell.1992.263.4.C851; ERDOS EG, 1990, HYPERTENSION, V16, P363, DOI 10.1161/01.HYP.16.4.363; MIWA K, 1984, BRIT J PHARMACOL, V82, P295, DOI 10.1111/j.1476-5381.1984.tb16471.x; RIGAT B, 1990, J CLIN INVEST, V86, P1343, DOI 10.1172/JCI114844; VISWANATHAN M, 1992, J CLIN INVEST, V90, P1707, DOI 10.1172/JCI116043	7	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 17	1993	341	8851					995	996		10.1016/0140-6736(93)91078-Z	http://dx.doi.org/10.1016/0140-6736(93)91078-Z			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY368	8096950				2022-12-28	WOS:A1993KY36800010
J	VERHEUL, HA; DEKKER, E; BOSSUYT, P; MOULIJN, AC; DUNNING, AJ				VERHEUL, HA; DEKKER, E; BOSSUYT, P; MOULIJN, AC; DUNNING, AJ			BACKGROUND MORTALITY IN CLINICAL SURVIVAL STUDIES	LANCET			English	Article							HEART-VALVE REPLACEMENT; RELATIVE SURVIVAL; RATES	In long-term follow-up studies of survival after an initial event (eg, an operation) mortality f rom causes other than the one under study obscures the results, especially in elderly patients. In the traditional approach to the calculation of expected mortality a fictitious cohort is drawn from the general population, being matched for age, sex, and calendar time at the time of the initial event. The membership of this cohort is then kept constant from the intitial event until the closing date of the study. The survival and mortality of this static cohort is then compared with that of the dynamic patient cohort to throw light on mortality from extraneous causes. This method can lead to severe bias if there is a strong correlation between the duration of observation of the patients and their age. The analysis can be improved by applying rate adjustment when calculating the background component of mortality. In this approach mortality rates from the general population are adjusted (weighted) so that the age, sex, and calendar year are at all times identical with those of each of the patients still alive and under observation. This is illustrated by means of a simplified example and a real-life one from a study at survival after aortic valve replacement. Estimation of rate-adjusted background mortality provides a framework that may put long-term survival, especially of elderly patients, in proper perspective.	UNIV AMSTERDAM, ACAD MED CTR, DEPT CARDIOPULM SURG, 1105 AZ AMSTERDAM, NETHERLANDS; UNIV AMSTERDAM, ACAD MED CTR, DEPT CLIN EPIDEMIOL & BIOSTAT, 1105 AZ AMSTERDAM, NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	VERHEUL, HA (corresponding author), UNIV AMSTERDAM, ACAD MED CTR, DEPT CARDIOL, 1105 AZ AMSTERDAM, NETHERLANDS.		Bossuyt, Patrick M./B-4557-2016; Bossuyt, Patrick M/AAR-1183-2021	Bossuyt, Patrick M./0000-0003-4427-0128; Bossuyt, Patrick M/0000-0003-4427-0128				ABDELNOOR M, 1990, EUR HEART J, V11, P23, DOI 10.1093/oxfordjournals.eurheartj.a059586; [Anonymous], 1985, THEORETICAL EPIDEMIO; BROWN CC, 1983, BIOMETRICS, V39, P941, DOI 10.2307/2531329; EDERER FRED, 1961, NATL CANCER INST MONOGR, V6, P101; HAKULINEN T, 1977, J CHRON DIS, V30, P431, DOI 10.1016/0021-9681(77)90036-4; HAKULINEN T, 1985, COMPUT PROG BIOMED, V19, P197, DOI 10.1016/0010-468X(85)90011-X; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Lee E.T., 1992, STATISTICAL METHODS; LINDBLOM D, 1990, J AM COLL CARDIOL, V15, P566, DOI 10.1016/0735-1097(90)90627-2; LUND O, 1990, CIRCULATION, V82, P124, DOI 10.1161/01.CIR.82.1.124	10	48	48	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 3	1993	341	8849					872	875		10.1016/0140-6736(93)93073-A	http://dx.doi.org/10.1016/0140-6736(93)93073-A			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KV811	8096574				2022-12-28	WOS:A1993KV81100016
J	ATKIN, WS; CUZICK, J; NORTHOVER, JMA; WHYNES, DK				ATKIN, WS; CUZICK, J; NORTHOVER, JMA; WHYNES, DK			PREVENTION OF COLORECTAL-CANCER BY ONCE-ONLY SIGMOIDOSCOPY	LANCET			English	Article							OCCULT BLOOD-TESTS; FLEXIBLE SIGMOIDOSCOPY; ASYMPTOMATIC PATIENTS; FIBEROPTIC SIGMOIDOSCOPY; SCREENING-PROCEDURE; COLONIC POLYPS; FOLLOW-UP; NEOPLASMS; RISK; COLONOSCOPY	There is no national screening programme for colorectal cancer in the UK despite the fact that the annual death toll from this disease exceeds that of breast and cervical cancer. Faecal occult blood testing (FOBT) is under evaluation for screening, but screening by sigmoidoscopy is not considered viable. This situation contrasts with the USA where both annual FOBT and screening by flexible sigmoidoscopy every 3 to 5 years are recommended from 50 years old. We seek to demonstrate that most of the benefit from the US screening policy would accrue from a single flexible sigmoidoscopy examination at age 55 to 60 years with appropriate colonoscopic surveillance for the 3% to 5% found to have high-risk adenomas (greater-than-or-equal-to 1 cm or villous histology). If applied nationally, this screening regimen could prevent about 5500 colorectal cancer cases and 3500 deaths in the UK each year, thus saving 40 000 years of life. We estimate that there would be little net cost to the National Health Service because savings obtained from treating fewer patients would largely off set the cost of screening. We recommend that a randomised trial to evaluate screening by single flexible sigmoidoscopy should start without delay. Such a trial would involve about 120000 participants, and 15 years of follow-up would be required to obtain a clear answer on mortality, although information on incidence reduction would be available sooner.	IMPERIAL CANC RES FUND,DEPT MATH STAT & EPIDEMIOL,POB 123,LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND; ST MARKS HOSP,IMPERIAL CANC RES FUND,COLORECTAL UNIT,LONDON EC1V 2PS,ENGLAND; UNIV NOTTINGHAM,DEPT ECON,NOTTINGHAM NG7 2RD,ENGLAND	Cancer Research UK; Cancer Research UK; Imperial College London; University of Nottingham				Atkin, Wendy/0000-0001-9073-9658				ALLISON JE, 1990, ANN INTERN MED, V112, P328, DOI 10.7326/0003-4819-112-5-328; ATKIN WS, 1992, NEW ENGL J MED, V326, P658, DOI 10.1056/NEJM199203053261002; DAY NE, 1985, LANCET, V1, P280; EDDY DM, 1990, ANN INTERN MED, V113, P373, DOI 10.7326/0003-4819-113-5-373; FOLEY DP, 1987, GUT, V28, pA1367; FOUTCH PG, 1991, DIGEST DIS SCI, V36, P924, DOI 10.1007/BF01297142; FRIEDMAN GD, 1986, J CHRON DIS, V39, P453, DOI 10.1016/0021-9681(86)90112-8; GATTESCHI B, 1991, INT J CANCER, V49, P509, DOI 10.1002/ijc.2910490406; GILBERTSEN VA, 1978, CANCER, V41, P1137, DOI 10.1002/1097-0142(197803)41:3<1137::AID-CNCR2820410350>3.0.CO;2-G; GROSSMAN S, 1989, GASTROENTEROLOGY, V96, P299, DOI 10.1016/0016-5085(89)91551-5; HOFF G, 1985, SCAND J GASTROENTERO, V20, P351, DOI 10.3109/00365528509091663; JOHNSON DA, 1990, AM J GASTROENTEROL, V85, P969; KEWENTER J, 1991, CANCER SCREENING, P116; KRONBORG O, 1987, SCAND J GASTROENTERO, V22, P677, DOI 10.3109/00365528709011142; LIEBERMAN DA, 1988, ARCH INTERN MED, V148, P473, DOI 10.1001/archinte.148.2.473; MARKS G, 1979, DIS COLON RECTUM, V22, P162, DOI 10.1007/BF02586809; MAULE WF, 1990, GUT, V31, pA1203; MCCALLUM RW, 1984, AM J GASTROENTEROL, V79, P433; MILLER AB, 1991, CANCER SCREENING UIC, P135; MORSON BC, 1976, CLIN GASTROENTEROL, V5, P505; NEUGUT AI, 1988, GASTROENTEROLOGY, V95, P492, DOI 10.1016/0016-5085(88)90511-2; NEWCOMB PA, 1992, JNCI-J NATL CANCER I, V84, P1572, DOI 10.1093/jnci/84.20.1572; REX DK, 1991, GASTROENTEROLOGY, V100, P64, DOI 10.1016/0016-5085(91)90583-7; ROSEVELT J, 1984, DIGEST DIS SCI, V29, P161, DOI 10.1007/BF01317059; ROZEN P, 1987, CANCER-AM CANCER SOC, V60, P2553, DOI 10.1002/1097-0142(19871115)60:10<2553::AID-CNCR2820601034>3.0.CO;2-S; SELBY JV, 1992, NEW ENGL J MED, V326, P653, DOI 10.1056/NEJM199203053261001; SELBY JV, 1988, J CLIN EPIDEMIOL, V41, P427, DOI 10.1016/0895-4356(88)90043-1; SHIDA H, 1989, DIS COLON RECTUM, V32, P404, DOI 10.1007/BF02563693; STEPHENSON BM, 1991, BRIT J SURG, V78, P1162, DOI 10.1002/bjs.1800781005; STRYKER SJ, 1987, GASTROENTEROLOGY, V93, P1009, DOI 10.1016/0016-5085(87)90563-4; THOMAS W, 1991, CANCER SCREENING, P106; TRIPP MR, 1987, CANCER, V60, P1599, DOI 10.1002/1097-0142(19871001)60:7<1599::AID-CNCR2820600730>3.0.CO;2-I; WALKER AR, 1991, J CLIN EPIDEMIOL, V44, P907, DOI 10.1016/0895-4356(91)90053-C; WHERRY DC, 1981, DIS COLON RECTUM, V24, P521, DOI 10.1007/BF02604312; 1990, HLTH PERSONAL SOCIAL; 1988, GASTROINTEST ENDOSC, V34, pS6; 1993, CANCER STATISTIC MB1, V20	37	319	322	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 20	1993	341	8847					736	740		10.1016/0140-6736(93)90499-7	http://dx.doi.org/10.1016/0140-6736(93)90499-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KT362	8095636				2022-12-28	WOS:A1993KT36200016
J	CARMAN, W; THOMAS, H; DOMINGO, E				CARMAN, W; THOMAS, H; DOMINGO, E			VIRAL GENETIC-VARIATION - HEPATITIS-B VIRUS AS A CLINICAL EXAMPLE	LANCET			English	Review							RAPID EVOLUTION; E-ANTIGEN; PRE-C; ESCAPE; REGION; HETEROGENEITY; SEQUENCE; VARIANTS; MUTANT		UNIV LONDON IMPERIAL COLL SCI & TECHNOL,ST MARYS HOSP,SCH MED,DEPT MED,LONDON W3,ENGLAND; UNIV AUTONOMA MADRID,FAC CIENCIAS,CTR MOLEC BIOL,MADRID 34,SPAIN	Imperial College London; Autonomous University of Madrid	CARMAN, W (corresponding author), UNIV GLASGOW,INST VIROL,GLASGOW G11 5JR,SCOTLAND.		Thomas, Howard C/A-3152-2009; Domingo, Esteban/K-3937-2014	Domingo, Esteban/0000-0002-0573-1676	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BERTOLETTI A, 1991, P NATL ACAD SCI USA, V88, P10445, DOI 10.1073/pnas.88.23.10445; BRUNETTO MR, 1989, ITAL J GASTROENTEROL, V21, P151; CARMAN WF, 1992, J INFECT DIS, V165, P127, DOI 10.1093/infdis/165.1.127; CARMAN WF, 1990, LANCET, V336, P325, DOI 10.1016/0140-6736(90)91874-A; CARMAN WF, 1989, LANCET, V2, P588; CARMAN WF, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P216; CARMAN WF, 1992, J HEPATOL, V16, P525; DOMINGO E, 1978, CELL, V13, P735, DOI 10.1016/0092-8674(78)90223-4; DOMINGO E, 1985, GENE, V40, P1, DOI 10.1016/0378-1119(85)90017-4; Domingo E, 1992, Genet Eng (N Y), V14, P13; Domingo E., 1988, RNA GENETICS; EHATA T, 1992, J CLIN INVEST, V89, P332, DOI 10.1172/JCI115581; FIORDALISI G, 1990, J MED VIROL, V31, P297, DOI 10.1002/jmv.1890310410; FUJII H, 1992, BIOCHEM BIOPH RES CO, V184, P1152, DOI 10.1016/S0006-291X(05)80003-8; HARRISON TJ, 1991, J HEPATOL, V13, pS105, DOI 10.1016/0168-8278(91)90037-C; HOLLAND J, 1982, SCIENCE, V215, P1577, DOI 10.1126/science.7041255; KANEKO S, 1989, J INFECT DIS, V160, P903, DOI 10.1093/infdis/160.5.903; KOSAKA Y, 1991, GASTROENTEROLOGY, V100, P1087, DOI 10.1016/0016-5085(91)90286-T; LIANG TJ, 1991, NEW ENGL J MED, V324, P1705, DOI 10.1056/NEJM199106133242405; MCMAHON G, 1992, HEPATOLOGY, V15, P757, DOI 10.1002/hep.1840150503; OKAMOTO H, 1990, J VIROL, V64, P1298, DOI 10.1128/JVI.64.3.1298-1303.1990; OKAMOTO H, 1992, PEDIATR RES, V32, P264, DOI 10.1203/00006450-199209000-00002; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; PIRCHER H, 1990, NATURE, V346, P629, DOI 10.1038/346629a0; STEINHAUER DA, 1987, ANNU REV MICROBIOL, V41, P409, DOI 10.1146/annurev.mi.41.100187.002205; TEMIN HM, 1989, J ACQ IMMUN DEF SYND, V2, P1; WAKITA T, 1991, J CLIN INVEST, V88, P1793, DOI 10.1172/JCI115500; WATERS JA, 1992, J CLIN INVEST, V90, P2543, DOI 10.1172/JCI116148	28	133	149	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 6	1993	341	8841					349	353		10.1016/0140-6736(93)90146-8	http://dx.doi.org/10.1016/0140-6736(93)90146-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK939	8094122				2022-12-28	WOS:A1993KK93900014
J	COTTON, DWK; ROGERS, S				COTTON, DWK; ROGERS, S			MOLECULAR MEDICINE - AGING, CANCER, AND MITOCHONDRIAL DETERIORATION	LANCET			English	Editorial Material											COTTON, DWK (corresponding author), UNIV SHEFFIELD,SCH MED,DEPT PATHOL,SHEFFIELD S10 2TN,S YORKSHIRE,ENGLAND.							COTTON DWK, 1990, HISTOPATHOLOGY, V16, P507; de Duve, 1991, BLUEPRINT CELL; KADENBACH B, 1990, NATURWISSENSCHAFTEN, V77, P221, DOI 10.1007/BF01138485; Margulis L., 1991, SYMBIOSISOURCE EVO; Pedersen P L, 1978, Prog Exp Tumor Res, V22, P190; SHARP MGF, 1992, J PATHOL, V168, P163, DOI 10.1002/path.1711680203; TROLL W, 1991, FREE RADICAL RES COM, V12-3, P751	7	12	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 30	1993	341	8840					281	282		10.1016/0140-6736(93)92625-4	http://dx.doi.org/10.1016/0140-6736(93)92625-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK245	8093925				2022-12-28	WOS:A1993KK24500013
J	COLLIER, JD; GUO, KD; BURT, AD; BASSENDINE, MF; MAJOR, GN				COLLIER, JD; GUO, KD; BURT, AD; BASSENDINE, MF; MAJOR, GN			DEFICIENT REPAIR OF DNA LESION O6-METHYLGUANINE IN CIRRHOSIS	LANCET			English	Article							O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE	Cirrhosis is a risk factor for hepatocellular carcinoma. O6-methylguanine is a promutagenic and potentially carcinogenic DNA lesion produced by environmental alkylating agents. If it is not repaired, DNA replication can lead to a G-to-A transition mutation, which is a known mechanism of oncogene activation. We have found that the activity of the repairing methyltransferase enzyme is significantly lower in cirrhotic tissue than in non-cirrhotic diseased liver or in normal liver. This finding suggests a mechanism for cirrhosis being a risk factor for cancer of the liver: increased cellular proliferation together with persistence of O6-methylguanine might lead to malignant transformation of liver cells through mutation and oncogene activation.	UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT MED,MED MOLEC BIOL GRP,FRAMLINGTON PL,NEWCASTLE TYNE NE2 4HH,ENGLAND; UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT PATHOL,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND	Newcastle University - UK; Newcastle University - UK			Burt, Alastair D/D-3634-2013	Burt, Alastair D/0000-0002-3011-7774				BASSENDINE MF, 1987, BAILLIERE CLIN GASTR, V1, P1, DOI 10.1016/0950-3528(87)90031-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CESARONE C, 1979, ANAL BIOCHEM, V102, P188; CHALLEN C, IN PRESS HEPATOLOGY; CHENG KK, 1992, LANCET, V339, P1314, DOI 10.1016/0140-6736(92)91960-G; CRADDOCK VM, 1986, RELATIVE IMPORTANCE, P242; KYRTOPOULOS SA, 1990, CARCINOGENESIS, V11, P431, DOI 10.1093/carcin/11.3.431; MAJOR GN, 1991, BIOCHEM J, V277, P89, DOI 10.1042/bj2770089; OHGAKI H, 1992, CANCER RES, V52, P2995; PEGG AE, 1990, CANCER RES, V50, P6119	10	15	15	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 23	1993	341	8839					207	208		10.1016/0140-6736(93)90069-S	http://dx.doi.org/10.1016/0140-6736(93)90069-S			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ219	8093500				2022-12-28	WOS:A1993KJ21900007
J	HARPER, PS				HARPER, PS			INSURANCE AND GENETIC TESTING	LANCET			English	Editorial Material											HARPER, PS (corresponding author), UNIV WALES COLL MED,INST MED GENET,HEATH PK,CARDIFF CF4 4XN,S GLAM,WALES.							ABBING HDCR, 1991, HEALTH POLICY, V18, P197; BILLINGS PR, 1992, AM J HUM GENET, V50, P476; BRANDON RM, 1992, INT J HLTH SERV, V21, P265; HARPER PS, 1992, J ROY COLL PHYS LOND, V26, P184; MADDOX J, 1991, NATURE, V352, P11, DOI 10.1038/352011a0; NATOWICZ MR, 1992, AM J HUM GENET, V50, P465; POKORSKI R, 1989, POTENTIAL ROLE GENET, P8; TYLER A, 1992, BRIT J PSYCHIAT, V161, P481, DOI 10.1192/bjp.161.4.481; 1989, GENETICS SCI SOC; 1992, CYSTIC FIBROSIS DNA, P189; 1992, GENETIC TESTS HLTH I	11	40	41	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 23	1993	341	8839					224	227		10.1016/0140-6736(93)90080-Z	http://dx.doi.org/10.1016/0140-6736(93)90080-Z			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ219	8093510				2022-12-28	WOS:A1993KJ21900017
J	ALLAART, CF; POORT, SR; ROSENDAAL, FR; REITSMA, PH; BERTINA, RM; BRIET, E				ALLAART, CF; POORT, SR; ROSENDAAL, FR; REITSMA, PH; BERTINA, RM; BRIET, E			INCREASED RISK OF VENOUS THROMBOSIS IN CARRIERS OF HEREDITARY PROTEIN-C DEFICIENCY DEFECT	LANCET			English	Article							PURPURA FULMINANS; DUTCH FAMILIES; NEWBORN-INFANT; FACTOR-V; DISEASE; INACTIVATION; FREQUENCY; ABSENCE	The relevance of heterozygosity for hereditary protein C deficiency as a risk factor for venous thrombosis has been disputed because heterozygotes without symptoms have been identified among blood donors and relatives of homozygotes. As a result, clinicians do not know whether to offer prophylaxis or not. We have compared thrombosis-free survival in 161 heterozygous and normal members of the families of 24 heterozygotes for protein C deficiency referred from several centres in the Netherlands and with a history of symptoms. We studied the influence of heterozygosity and of putative additional risk factors on the occurrence of thrombotic events noted when a medical history was taken. Protein C activities were measured but a diagnosis of heterozygosity was based on the presence of the specific mutation in one of the protein C genes identified in the proband of the family. We found a significant difference in the thrombosis-free survival of the 77 heterozygotes and 84 normals: by age 45, 50% of heterozygotes and 10% of normal relatives can be expected to have had a manifestation of venous thromboembolism. The presence of such a mutation was clearly associated with an increased risk of venous thrombotic events. Thrombotic events occurred more often in years in which the patient had been immobile for more than a week or had had surgery. Other putative risk factors showed no significant effect in the incidence of thrombotic events. About 50% of all first episodes and 65% of recurrences of venous thromboembolism in the heterozygotes were spontaneous-ie, there was no predisposing event such as surgery or pregnancy. There was no increased risk for arterial occlusions in heterozygotes. We conclude that members of the family of a symptomatic heterozygote proband who are heterozygous for the mutation in the protein C gene have an increased risk of venous thrombotic events compared with their normal family members. For such individuals prophylactic anticoagulation should be considered; the decision will need to be taken on an individual basis.	LEIDEN UNIV HOSP, DEPT CLIN EPIDEMIOL, 2333 AA LEIDEN, NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC)	ALLAART, CF (corresponding author), UNIV HOSP LEIDEN, DEPT HEMATOL, THROMBOSIS & HAEMOSTASIS RES UNIT, POB 9600, 2300 RC LEIDEN, NETHERLANDS.		Bertina, Rogier/AGQ-5246-2022; Rosendaal, Frits/Q-3842-2017	Rosendaal, Frits/0000-0003-2558-7496				BENTAL O, 1989, THROMB HAEMOSTASIS, V61, P50; BERTINA RM, 1982, THROMB HAEMOSTASIS, V48, P1; BRANSON HE, 1983, LANCET, V2, P1165; BROEKMANS AW, 1983, NEW ENGL J MED, V309, P340, DOI 10.1056/NEJM198308113090604; BROEKMANS AW, 1983, THROMB HAEMOSTASIS, V50, P350; Broekmans AW, 1988, PROTEIN C RELATED PR, V3, P160; COX DR, 1972, J R STAT SOC B, V34, P187; ESMON CT, 1983, BLOOD, V62, P1155; ESTELLES A, 1984, THROMB HAEMOSTASIS, V52, P53; FULCHER CA, 1984, BLOOD, V63, P486; GLADSON CL, 1988, THROMB HAEMOSTASIS, V59, P18; GRIFFIN JH, 1981, J CLIN INVEST, V68, P1370, DOI 10.1172/JCI110385; HEIJBOER H, 1990, NEW ENGL J MED, V323, P1512, DOI 10.1056/NEJM199011293232202; HORELLOU MH, 1984, BRIT MED J, V289, P1285, DOI 10.1136/bmj.289.6454.1285; MALLAR RA, 1989, J PEDIATR, V114, P528; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MARCINIAK E, 1985, BLOOD, V65, P15; MILETICH J, 1987, NEW ENGL J MED, V317, P991, DOI 10.1056/NEJM198710153171604; PABINGERFASCHING I, 1983, THROMB HAEMOSTASIS, V50, P810; REITSMA PH, 1991, BLOOD, V78, P890, DOI 10.1182/blood.V78.4.890.bloodjournal784890; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SELIGSOHN U, 1984, NEW ENGL J MED, V310, P559, DOI 10.1056/NEJM198403013100904; SUZUKI K, 1983, J BIOL CHEM, V258, P1914; VANDENBROUCKE JP, 1982, AM J EPIDEMIOL, V115, P303, DOI 10.1093/oxfordjournals.aje.a113306; WALKER FJ, 1981, J BIOL CHEM, V256, P1128	25	332	338	1	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 16	1993	341	8838					134	138		10.1016/0140-6736(93)90003-Y	http://dx.doi.org/10.1016/0140-6736(93)90003-Y			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG627	8093743	Green Submitted			2022-12-28	WOS:A1993KG62700003
J	MOISON, RMW; PALINCKX, JJS; ROEST, M; HOUDKAMP, E; BERGER, HM				MOISON, RMW; PALINCKX, JJS; ROEST, M; HOUDKAMP, E; BERGER, HM			INDUCTION OF LIPID-PEROXIDATION OF PULMONARY SURFACTANT BY PLASMA OF PRETERM BABIES	LANCET			English	Article							EPITHELIAL LINING FLUID; LUNG SURFACTANT; TRANSFERRIN; IRON; CERULOPLASMIN; INVITRO; DISEASE; SYSTEM	Respiratory distress syndrome of the preterm baby is believed to be caused by a deficiency of pulmonary surfactant and leakage of plasma into the alveolar spaces. Since the two pathogenetic factors seem to be inter-related, we postulated that peroxidation of surfactant by plasma iron could be the linking mechanism. We obtained cord blood samples from 22 preterm babies (mean gestational age 32.2 [SD 2.7] weeks) and 24 term babies (40.1 [1.6] weeks), and venous blood samples from 18 healthy adults. No adult had detectable non-protein-bound iron in the plasma, but 10/21 (48%) preterm babies and 6/24 (25%) term babies had detectable concentrations (rate difference 23% [95% CI -5 to 51%], p=0.20). Transferrin and haptoglobin concentrations were higher and free haemoglobin concentrations lower in adults than in babies (p<0.005). Only transferrin differed significantly between term and preterm babies. Plasma from all 18 adults and from 23 (96%) term babies inhibited iron-catalysed lipid peroxidation of pulmonary surfactant liposomes. By contrast, plasma from 11 (50%) preterm babies stimulated such peroxidation (difference in stimulation rate 46% [20-71%], p<0.005 for preterm vs term babies); the ability to stimulate peroxidation was related to the presence of non-protein-bound iron (p<0.001). Peroxidation decreased in the babies when apotransferrin was added to plasma and in all subjects when alpha-tocopherol was incorporated into the surfactant liposomes. Lipid peroxidation of surfactant may contribute to the pathogenesis of respiratory distress syndrome. Possible therapeutic approaches are increasing babies' iron-binding capacity by plasma transfusions and increasing the antioxidant capacity of commercial surfactant.	UNIV HOSP LEIDEN,DEPT PAEDIAT,NEONATAL UNIT,POSTBOX 9600,2300 RC LEIDEN,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC)								AVERY ME, 1991, NEW ENGL J MED, V324, P910, DOI 10.1056/NEJM199103283241308; BAKER RR, 1990, AM J PHYSIOL, V259, pL328, DOI 10.1152/ajplung.1990.259.4.L328; BERGER HM, 1990, LANCET, V335, P933, DOI 10.1016/0140-6736(90)90997-J; CANTIN AM, 1990, J CLIN INVEST, V86, P962, DOI 10.1172/JCI114798; CATLIN EA, 1986, J PEDIATR-US, V109, P865, DOI 10.1016/S0022-3476(86)80715-6; CHATTERJEE SN, 1988, FREE RADICAL BIO MED, V4, P51, DOI 10.1016/0891-5849(88)90011-1; DACIE J, 1985, HAEMOLYTIC ANAEMIA, V1, P39; FRANK L, 1987, J PEDIATR-US, V110, P9, DOI 10.1016/S0022-3476(87)80279-2; GUTTERIDGE JMC, 1986, BIOCHIM BIOPHYS ACTA, V869, P119, DOI 10.1016/0167-4838(86)90286-4; GUTTERIDGE JMC, 1985, CRC HDB METHODS OXYG, P391; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HALLMAN M, 1991, PEDIATR RES, V29, pA370; HERNANDEZ LA, 1987, AM J PHYSIOL, V253, pG49, DOI 10.1152/ajpgi.1987.253.1.G49; HOLM BA, 1988, CHEM PHYS LIPIDS, V49, P49, DOI 10.1016/0009-3084(88)90063-1; JOBE A, 1987, AM REV RESPIR DIS, V136, P1256, DOI 10.1164/ajrccm/136.5.1256; KOBAYASHI T, 1991, PEDIATR RES, V29, P353, DOI 10.1203/00006450-199104000-00005; KOBAYASHI T, 1991, J APPL PHYSIOL, V71, P530, DOI 10.1152/jappl.1991.71.2.530; LIJANA RC, 1979, J LAB CLIN MED, V94, P266; LINDEMAN JHN, 1992, FREE RADICAL RES COM, V16, P285, DOI 10.3109/10715769209049181; LINDEMAN JHN, 1992, PEDIATRICS, V90, P200; MATALON S, 1990, BIOCHIM BIOPHYS ACTA, V1035, P121, DOI 10.1016/0304-4165(90)90105-6; MILLS AN, 1991, J THORAC CARDIOV SUR, V101, P909; MORLEY CJ, 1991, ARCH DIS CHILD-FETAL, V66, P445, DOI 10.1136/adc.66.4_Spec_No.445; PACHT ER, 1988, J APPL PHYSIOL, V64, P2092, DOI 10.1152/jappl.1988.64.5.2092; REPINE JE, 1992, LANCET, V339, P466, DOI 10.1016/0140-6736(92)91067-I; RYAN SF, 1991, AM J RESP CELL MOL, V4, P33, DOI 10.1165/ajrcmb/4.1.33; SEEGER W, 1985, BIOCHIM BIOPHYS ACTA, V835, P58, DOI 10.1016/0005-2760(85)90030-X; SMITH BT, 1979, NEW ENGL J MED, V300, P136, DOI 10.1056/NEJM197901183000308; SULLIVAN JL, 1988, AM J DIS CHILD, V142, P1341, DOI 10.1001/archpedi.1988.02150120095048; VANGOLDE LMG, 1988, PHYSIOL REV, V68, P374, DOI 10.1152/physrev.1988.68.2.374	30	83	83	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 9	1993	341	8837					79	82		10.1016/0140-6736(93)92557-A	http://dx.doi.org/10.1016/0140-6736(93)92557-A			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF870	8093405				2022-12-28	WOS:A1993KF87000004
J	MORGAN, RE; PALINKAS, LA; BARRETTCONNOR, EL; WINGARD, DL				MORGAN, RE; PALINKAS, LA; BARRETTCONNOR, EL; WINGARD, DL			PLASMA-CHOLESTEROL AND DEPRESSIVE SYMPTOMS IN OLDER MEN	LANCET			English	Article							WEIGHT CHANGE; MORTALITY; POPULATION; RISK	In several clinical trials of interventions designed to lower plasma cholesterol, reductions in coronary heart disease mortality have been offset by an unexplained rise in suicides and other violent deaths. We have tried to find out whether depressive illness is related to low plasma cholesterol concentrations in men of 50 years and older. In 1985-87, Beck depression inventories were obtained from 1020 white men, aged 50-89 years, in the Rancho Bernardo, California, cohort. Disease history and behaviours were assessed by standard questionnaires. Plasma cholesterol and weight were measured at this time, as they had been in 1972-74. Among men aged 70 years and older, categorically defined depression was three times more common in the group with low plasma cholesterol (<4.14 mmol/L) than in those with higher concentrations (5/31 [16%] vs 22/363 [6%]; p=0.033). Depressive symptom scores correlated significantly and inversely with plasma cholesterol concentrations, even after adjustment for age, health status, number of chronic illnesses, number of medications, and exercise, as well as measured weight loss and change in plasma cholesterol in the previous 13 years. Our finding that low plasma cholesterol is associated with depressive symptoms in elderly men is compatible with observations that a very low total cholesterol may be related to suicide and violent death. Since cholesterol lowering in the general population is widely recommended, this observation warrants further investigation.	UNIV CALIF SAN DIEGO,SCH MED,DEPT COMMUNITY & FAMILY MED,DIV EPIDEMIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SCH MED,DEPT COMMUNITY & FAMILY MED,DIV FAMILY MED,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031801] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG007181] Funding Source: NIH RePORTER; NIA NIH HHS [R37 AG07181-05] Funding Source: Medline; NIDDK NIH HHS [R01-DK31801] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHLEY FW, 1974, J CHRON DIS, V27, P103, DOI 10.1016/0021-9681(74)90079-4; BAKER LL, 1985, PREV MED, V14, P155, DOI 10.1016/0091-7435(85)90030-1; Beck A. T., 1960, ARCH GEN PSYCHIAT, V4, P53, DOI DOI 10.1001/ARCHPSYC.1961.01710120031004; BECK AT, 1972, POSTGRAD MED, V52, P81, DOI 10.1080/00325481.1972.11713319; BLAZER D, 1980, AM J PSYCHIAT, V137, P439; CHEN ZM, 1991, BRIT MED J, V303, P276, DOI 10.1136/bmj.303.6797.276; CRIQUI MH, 1978, AM J EPIDEMIOL, V108, P267; DAPRADA M, 1988, EXPERIENTIA, V44, P115; EISON MS, 1989, PSYCHOPATHOLOGY, V22, P13, DOI 10.1159/000284622; ENGELBERG H, 1992, LANCET, V339, P727, DOI 10.1016/0140-6736(92)90609-7; FORETTE B, 1989, LANCET, V1, P868; GALLAGHER D, 1982, J CONSULT CLIN PSYCH, V50, P152, DOI 10.1037/0022-006X.50.1.152; GUICHENEY P, 1988, J HYPERTENS, V6, P873, DOI 10.1097/00004872-198811000-00005; HOLINGER PC, 1982, SOC SCI MED, V16, P1929, DOI 10.1016/0277-9536(82)90392-6; KAPLAN JR, 1991, PSYCHOSOM MED, V53, P634, DOI 10.1097/00006842-199111000-00005; MCGEER EG, 1976, AGING-US, V3, P389; MELTZER H, 1989, BRIT J PSYCHIAT, V155, P25, DOI 10.1192/S0007125000291733; MENOTTI A, 1989, ANN MED, V21, P175, DOI 10.3109/07853898909149929; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; MURPHY JM, 1989, SOC PSYCH PSYCH EPID, V24, P134, DOI 10.1007/BF01788022; NIELSEN AC, 1980, ARCH GEN PSYCHIAT, V37, P999; OLIVER MF, 1992, BMJ-BRIT MED J, V304, P393, DOI 10.1136/bmj.304.6824.393; OSTER P, 1981, KLIN WOCHENSCHR, V59, P857, DOI 10.1007/BF01721056; PALINKAS LA, 1990, J CLIN EPIDEMIOL, V43, P1131, DOI 10.1016/0895-4356(90)90014-G; THOMPSON MP, 1991, J AM GERIATR SOC, V39, P497, DOI 10.1111/j.1532-5415.1991.tb02496.x; VANDOORNEN LJP, 1987, J PSYCHOSOM RES, V31, P239, DOI 10.1016/0022-3999(87)90081-X; WEISSENBURGER J, 1986, PSYCHIAT RES, V17, P275, DOI 10.1016/0165-1781(86)90075-2; YOUNG SN, 1988, CLIN NEUROPHARMACOL, V11, pS207; 1992, ARCH INTERN MED, V152, P1490	29	259	261	1	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 9	1993	341	8837					75	79		10.1016/0140-6736(93)92556-9	http://dx.doi.org/10.1016/0140-6736(93)92556-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KF870	8093404				2022-12-28	WOS:A1993KF87000003
J	BARDWELL, AJ; BARDWELL, L; TOMKINSON, AE; FRIEDBERG, EC				BARDWELL, AJ; BARDWELL, L; TOMKINSON, AE; FRIEDBERG, EC			SPECIFIC CLEAVAGE OF MODEL RECOMBINATION AND REPAIR INTERMEDIATES BY THE YEAST RAD1-RAD10 DNA ENDONUCLEASE	SCIENCE			English	Article							PIGMENTOSUM GROUP-F; SACCHAROMYCES-CEREVISIAE; MITOTIC RECOMBINATION; RAD10 CONSTITUTE; GENETIC-CONTROL; PROTEINS RAD1; EXCISION; PURIFICATION; PATHWAY; ERCC1	The RAD1 and RAD10 genes of Saccharomyces cerevisiae are required for both nucleotide excision repair and certain mitotic recombination events. Here, model recombination and repair intermediates were used to show that Rad1-Rad10-mediated cleavage occurs at duplex-single-strand junctions. Moreover, cleavage occurs only on the strand containing the 3' single-stranded tail. Thus, both biochemical and genetic evidence indicate a role for the Rad1-Rad10 complex in the cleavage of specific recombination intermediates. Furthermore, these data suggest that Rad1-Rad10 endonuclease incises DNA 5' to damaged bases during nucleotide excision repair.	UNIV TEXAS,SW MED CTR,MOLEC PATHOL LAB,DALLAS,TX 75235; UNIV TEXAS,HLTH SCI CTR,CTR MOLEC MED,SAN ANTONIO,TX 78245	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Health San Antonio			Bardwell, Lee/I-8284-2019	Bardwell, Lee/0000-0002-2393-8363	NATIONAL CANCER INSTITUTE [R37CA012428, R01CA012428] Funding Source: NIH RePORTER; NCI NIH HHS [CA12428] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AQUILERA A, 1989, GENETICS, V123, P683; BAILIS AM, 1992, MOL CELL BIOL, V12, P4988, DOI 10.1128/MCB.12.11.4988; BARDWELL AJ, 1994, MOL CELL BIOL, V14, P3569, DOI 10.1128/MCB.14.6.3569; BARDWELL AJ, 1993, MOL MICROBIOL, V8, P1177, DOI 10.1111/j.1365-2958.1993.tb01662.x; BARDWELL L, 1990, BIOCHEMISTRY-US, V29, P3119, DOI 10.1021/bi00464a031; BARDWELL L, 1994, P NATL ACAD SCI USA, V91, P3926, DOI 10.1073/pnas.91.9.3926; BARDWELL L, 1992, MOL CELL BIOL, V12, P3041, DOI 10.1128/MCB.12.7.3041; BIGGERSTAFF M, 1993, EMBO J, V12, P3685, DOI 10.1002/j.1460-2075.1993.tb06043.x; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; FISHMANLOBELL J, 1992, SCIENCE, V258, P480, DOI 10.1126/science.1411547; Friedberg E.C., 1991, MOL CELLULAR BIOL TE, P147; HABRAKEN Y, 1993, NATURE, V366, P365, DOI 10.1038/366365a0; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; KLEIN HL, 1988, GENETICS, V120, P367; LIN FL, 1984, MOL CELL BIOL, V4, P1020, DOI 10.1128/MCB.4.6.1020; OZENBERGER BA, 1991, MOL CELL BIOL, V11, P1222, DOI 10.1128/MCB.11.3.1222; SCHIESTL RH, 1990, MOL CELL BIOL, V10, P2485, DOI 10.1128/MCB.10.6.2485; SCHIESTL RH, 1988, MOL CELL BIOL, V8, P3619, DOI 10.1128/MCB.8.9.3619; SUNG P, 1993, J BIOL CHEM, V268, P26391; THOMAS BJ, 1989, GENETICS, V123, P725; TOMKINSON AE, 1994, BIOCHEMISTRY-US, V33, P5305, DOI 10.1021/bi00183a038; TOMKINSON AE, 1993, NATURE, V362, P860, DOI 10.1038/362860a0; VANDUIN M, 1986, CELL, V44, P913, DOI 10.1016/0092-8674(86)90014-0; VANVUUREN AJ, 1993, EMBO J, V12, P3693, DOI 10.1002/j.1460-2075.1993.tb06044.x; ZEHFUS BR, 1990, GENETICS, V126, P41	26	231	242	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 30	1994	265	5181					2082	2085		10.1126/science.8091230	http://dx.doi.org/10.1126/science.8091230			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PJ912	8091230				2022-12-28	WOS:A1994PJ91200026
J	JOHNSTON, M; ANDREWS, S; BRINKMAN, R; COOPER, J; DING, H; DOVER, J; DU, Z; FAVELLO, A; FULTON, L; GATTUNG, S; GEISEL, C; KIRSTEN, J; KUCABA, T; HILLIER, L; JIER, M; JOHNSTON, L; LANGSTON, Y; LATREILLE, P; LOUIS, EJ; MACRI, C; MARDIS, E; MENEZES, S; MOUSER, L; NHAN, M; RIFKIN, L; RILES, L; STPETER, H; TREVASKIS, E; VAUGHAN, K; VIGNATI, D; WILCOX, L; WOHLDMAN, P; WATERSTON, R; WILSON, R; VAUDIN, M				JOHNSTON, M; ANDREWS, S; BRINKMAN, R; COOPER, J; DING, H; DOVER, J; DU, Z; FAVELLO, A; FULTON, L; GATTUNG, S; GEISEL, C; KIRSTEN, J; KUCABA, T; HILLIER, L; JIER, M; JOHNSTON, L; LANGSTON, Y; LATREILLE, P; LOUIS, EJ; MACRI, C; MARDIS, E; MENEZES, S; MOUSER, L; NHAN, M; RIFKIN, L; RILES, L; STPETER, H; TREVASKIS, E; VAUGHAN, K; VIGNATI, D; WILCOX, L; WOHLDMAN, P; WATERSTON, R; WILSON, R; VAUDIN, M			COMPLETE NUCLEOTIDE-SEQUENCE OF SACCHAROMYCES-CEREVISIAE CHROMOSOME-VIII	SCIENCE			English	Article							PHYSICAL MAPS; YEAST; GENES	The complete nucleotide sequence of Saccharomyces cerevisiae chromosome VIII reveals that it contains 269 predicted or known genes (300 base pairs or larger). Fifty-nine of these genes (22 percent) were previously identified. Of the 210 novel genes, 65 are predicted to encode proteins that are similar to other proteins of known or predicted function. Sixteen genes appear to be relatively recently duplicated. On average, there is one gene approximately every 2 kilobases. Although the coding density and base composition across the chromosome are not uniform, no regular pattern of variation is apparent.	WASHINGTON UNIV,SCH MED,DEPT GENET,ST LOUIS,MO 63110	Washington University (WUSTL)	JOHNSTON, M (corresponding author), WASHINGTON UNIV,SCH MED,CTR GENOME SEQUENCING,ST LOUIS,MO 63110, USA.		Johnston, Mark/K-3543-2019; Louis, Edward/B-7920-2008; Johnston, Mark/R-6156-2019; Brinkman, Ryan/B-1108-2008; Mardis, Elaine/W-2202-2019; Wilson, Richard K./AAF-4139-2019; Cooper, John/D-4448-2014	Johnston, Mark/0000-0002-4932-7229; Louis, Edward/0000-0003-1157-3608; Brinkman, Ryan/0000-0002-9765-2990; Wilson, Richard K./0000-0002-1992-1358; Cooper, John/0000-0002-0933-4571				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; [Anonymous], UNPUB; BUSSEY H, COMMUNICATION; BUTT TR, 1987, MICROBIOL REV, V51, P351, DOI 10.1128/MMBR.51.3.351-364.1987; DUJON B, 1994, NATURE, V369, P371, DOI 10.1038/369371a0; DUJON B, COMMUNICATION; DURBIN R, UNPUB; ERICKSON JR, 1993, GENETICS, V134, P151; FICHANT GA, 1991, J MOL BIOL, V220, P659, DOI 10.1016/0022-2836(91)90108-I; HENIKOFF S, 1994, GENOMICS, V19, P97, DOI 10.1006/geno.1994.1018; HILLIER L, UNPUB; LALO D, 1993, CR ACAD SCI III-VIE, V316, P367; LOUIS EJ, 1994, YEAST, V10, P271, DOI 10.1002/yea.320100214; MORTIMER RK, 1992, YEAST, V8, P817, DOI 10.1002/yea.320081002; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; OLSON MV, 1991, MOL CELLULAR BIOL YE, V1, P1; RILES L, 1993, GENETICS, V134, P81; RILES L, UNPUB; RYMOND BC, 1992, MOL CELLULAR BIOL YE, V2, P142; SHARP PM, 1993, NUCLEIC ACIDS RES, V21, P179, DOI 10.1093/nar/21.2.179; STEENSMA HY, 1989, CURR GENET, V16, P131; VOYTAS DF, 1992, NATURE, V358, P717, DOI 10.1038/358717a0; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	23	268	619	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 30	1994	265	5181					2077	2082		10.1126/science.8091229	http://dx.doi.org/10.1126/science.8091229			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PJ912	8091229				2022-12-28	WOS:A1994PJ91200025
J	TANJI, J; SHIMA, K				TANJI, J; SHIMA, K			ROLE FOR SUPPLEMENTARY MOTOR AREA CELLS IN PLANNING SEVERAL MOVEMENTS AHEAD	NATURE			English	Article							NEURONAL-ACTIVITY; VOLUNTARY MOVEMENTS; CORTICAL AREAS; ARM MOVEMENTS; CORTEX; MONKEY; ACTIVATION; POTENTIALS; PRIMATES; PREMOTOR	To achieve a volitional goal, we need to execute multiple movements in a specific temporal order. After repetitive performance of a particular sequence of movements, we are able to memorize and execute the whole sequence without external guidance. Where and how in the brain do we store information necessary for the orderly performance of multiple movements? We have found a group of cells in the cerebral cortex of monkeys whose activity is exclusively related to a sequence of multiple movements performed in a particular order. Such cellular activity exists in the supplementary motor area(1,2), but not in the primary motor cortex(3,4). We propose that these cells contribute a signal about the order of forthcoming multiple movements, and are useful for planning and coding of several movements ahead.			TANJI, J (corresponding author), TOHOKU UNIV,SCH MED,DEPT PHYSIOL,AOBA KU,2-1 SEIRYO CHO,SENDAI,MIYAGI 980,JAPAN.							BRINKMAN C, 1979, J NEUROPHYSIOL, V42, P681, DOI 10.1152/jn.1979.42.3.681; BRINKMAN C, 1984, J NEUROSCI, V4, P918; CHEN DF, 1991, SOMATOSENS MOT RES, V8, P27; COLEBATCH JG, 1991, J NEUROPHYSIOL, V65, P1392, DOI 10.1152/jn.1991.65.6.1392; CRUTCHER MD, 1990, J NEUROPHYSIOL, V64, P151, DOI 10.1152/jn.1990.64.1.151; DEECKE L, 1976, BIOL CYBERN, V23, P99, DOI 10.1007/BF00336013; DEIBER MP, 1991, EXP BRAIN RES, V84, P393; Dick J P, 1986, Mov Disord, V1, P255, DOI 10.1002/mds.870010405; HALSBAND U, 1993, BRAIN, V116, P243, DOI 10.1093/brain/116.1.243; IKEDA A, 1992, BRAIN, V115, P1017, DOI 10.1093/brain/115.4.1017; LANG W, 1990, EXP BRAIN RES, V79, P504; LAPLANE D, 1977, J NEUROL SCI, V34, P301, DOI 10.1016/0022-510X(77)90148-4; LUPPINO G, 1991, J COMP NEUROL, V311, P463, DOI 10.1002/cne.903110403; MATELLI M, 1993, NEUROREPORT, V4, P1295, DOI 10.1097/00001756-199309150-00002; MATSUZAKA Y, 1992, J NEUROPHYSIOL, V68, P653, DOI 10.1152/jn.1992.68.3.653; MUSHIAKE H, 1991, J NEUROPHYSIOL, V66, P705, DOI 10.1152/jn.1991.66.3.705; ORGOGOZO JM, 1979, SCIENCE, V206, P847, DOI 10.1126/science.493986; Passingham RE., 1993, FRONTAL LOBES VOLUNT; Porter R, 1993, CORTICOSPINAL FUNCTI; RIZZOLATTI G, 1990, EXP BRAIN RES, V82, P337; ROLAND PE, 1980, J NEUROPHYSIOL, V43, P118, DOI 10.1152/jn.1980.43.1.118; TANJI J, 1994, NEUROSCI RES, V19, P251, DOI 10.1016/0168-0102(94)90038-8; TANJI J, 1988, J NEUROPHYSIOL, V60, P325, DOI 10.1152/jn.1988.60.1.325; TANJI J, 1987, NATURE, V327, P618, DOI 10.1038/327618a0; TANJI J, 1985, J NEUROPHYSIOL, V53, P129, DOI 10.1152/jn.1985.53.1.129; TANJI J, 1982, J NEUROPHYSIOL, V48, P633, DOI 10.1152/jn.1982.48.3.633; WIESENDANGER M, 1986, REV PHYSIOL BIOCH P, V103, P1	27	478	484	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 29	1994	371	6496					413	416		10.1038/371413a0	http://dx.doi.org/10.1038/371413a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PJ285	8090219				2022-12-28	WOS:A1994PJ28500041
J	ANDREOTTI, F; DAVIES, GJ; UJANG, SB; SRITARA, P; KLUFT, C; MASERI, A				ANDREOTTI, F; DAVIES, GJ; UJANG, SB; SRITARA, P; KLUFT, C; MASERI, A			HIGH-DOSE ASPIRIN, THROMBIN, AND CORONARY ANGIOPLASTY	LANCET			English	Letter							SMOOTH-MUSCLE		TNO, IVVO, GAUBIUS LAB, 2313 AD LEIDEN, NETHERLANDS; UNIV CATTOLICA SACRO CUORE, I-00168 ROME, ITALY	Netherlands Organization Applied Science Research; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	ANDREOTTI, F (corresponding author), ROYAL POSTGRAD MED SCH, LONDON W12 0NN, ENGLAND.		Andreotti, Felicita/A-9962-2019	Andreotti, Felicita/0000-0002-1456-6430				AGRAWAL S K, 1992, Journal of the American College of Cardiology, V19, p108A; BERK BC, 1990, J BIOL CHEM, V265, P17334; CHESEBRO JH, 1991, J AM COLL CARDIOL, V17, pB96; MCBRIDE W, 1988, NEW ENGL J MED, V318, P1734, DOI 10.1056/NEJM198806303182606; RATNATUNGA CP, 1992, CIRCULATION, V85, P1077, DOI 10.1161/01.CIR.85.3.1077; WALZ DA, 1985, P SOC EXP BIOL MED, V180, P518	6	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 1	1993	341	8853					1161	1161		10.1016/0140-6736(93)93188-7	http://dx.doi.org/10.1016/0140-6736(93)93188-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ687	8097853				2022-12-28	WOS:A1993KZ68700063
J	VONBOEHMER, H; KISIELOW, P				VONBOEHMER, H; KISIELOW, P			LYMPHOCYTE LINEAGE COMMITMENT - INSTRUCTION VERSUS SELECTION	CELL			English	Review							T-CELL-RECEPTOR; TRANSGENIC MICE; CD8 LINEAGE; ANTIGEN				VONBOEHMER, H (corresponding author), BASEL INST IMMUNOL,CH-4005 BASEL,SWITZERLAND.							BORGULYA P, 1992, CELL, V69, P529, DOI 10.1016/0092-8674(92)90453-J; BORGULYA P, 1991, EMBO J, V10, P913, DOI 10.1002/j.1460-2075.1991.tb08024.x; CHAN SH, 1993, CELL, V73, P225, DOI 10.1016/0092-8674(93)90225-F; DOYLE C, 1987, NATURE, V330, P256, DOI 10.1038/330256a0; EMMRICH F, 1986, P NATL ACAD SCI USA, V83, P8298, DOI 10.1073/pnas.83.21.8298; GABERT J, 1987, CELL, V50, P545, DOI 10.1016/0092-8674(87)90027-4; HAUGHN L, 1992, NATURE, V358, P328, DOI 10.1038/358328a0; OHASHI PS, 1990, NATURE, V346, P861, DOI 10.1038/346861a0; Robey E A, 1990, Semin Immunol, V2, P25; ROBEY EA, 1991, CELL, V64, P99, DOI 10.1016/0092-8674(91)90212-H; SEONG RH, 1992, NATURE, V356, P718, DOI 10.1038/356718a0; VONBOEHMER H, 1986, IMMUNOL TODAY, V7, P333; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531	13	61	61	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 23	1993	73	2					207	208		10.1016/0092-8674(93)90220-K	http://dx.doi.org/10.1016/0092-8674(93)90220-K			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KY505	8097429				2022-12-28	WOS:A1993KY50500001
J	MOORE, PS; MARFIN, AA; QUENEMOEN, LE; GESSNER, BD; AYUB, YS; MILLER, DS; SULLIVAN, KM; TOOLE, MJ				MOORE, PS; MARFIN, AA; QUENEMOEN, LE; GESSNER, BD; AYUB, YS; MILLER, DS; SULLIVAN, KM; TOOLE, MJ			MORTALITY-RATES IN DISPLACED AND RESIDENT POPULATIONS OF CENTRAL SOMALIA DURING 1992 FAMINE	LANCET			English	Article							REFUGEE; THAILAND	Famine and civil war have resulted in high mortality rates and large population displacements in Somalia. To assess mortality rates and risk factors for mortality, we carried out surveys in the central Somali towns of Afgoi and Baidoa in November and December, 1992. In Baidoa we surveyed displaced persons living in camps; the average daily crude mortality rate was 16.8 (95% CI 14.6-19.1) per 10 000 population during the 232 days before the survey. An estimated 74% of children under 5 years living in displaced persons camps died during this period. In Afgoi, where both displaced and resident populations were surveyed, the crude mortality rate was 4.7 (3.9-5.5) deaths per 10 000 per day. Although mortality rates for all displaced persons were high, people living in temporary camps were at highest risk of death. As in other famine-related disasters, preventable infectious diseases such as measles and diarrhoea were the primary causes of death in both towns. These mortality rates are among the highest documented for a civilian population ver a long period. Community-based public health interventions to prevent and control common infectious diseses are needed to reduce these exceptionally high mortality rates in Somalia.	CTR DIS CONTROL, NATL CTR ENVIRONM HLTH, DIV ENVIRONM HAZARDS & HLTH EFFECTS, ATLANTA, GA 30333 USA; CTR DIS CONTROL, EPIDEMIOL PROGRAM OFF, DIV FIELD SERV, ATLANTA, GA 30333 USA; CTR DIS CONTROL, NATL CTR CHRON DIS PREVENT & HLTH PROMOT, ATLANTA, GA 30333 USA; CTR DIS CONTROL, INT HLTH PROGRAMME OFF, ATLANTA, GA 30333 USA; UNICEF, SOMALI CTY OFF, NAIROBI, KENYA; EMORY UNIV, SCH PUBL HLTH, DIV EPIDEMIOL, ATLANTA, GA 30322 USA; EMORY UNIV, SCH PUBL HLTH, CTR INT HLTH, ATLANTA, GA 30322 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Emory University; Emory University	MOORE, PS (corresponding author), CTR DIS CONTROL & PREVENT, NATL CTR INFECT DIS, DIV VECTOR BORNE INFECT DIS, POB 2087, FT COLLINS, CO 80522 USA.		Moore, Patrick S./F-3960-2011; Moore, Patrick/GVR-8294-2022	Moore, Patrick S./0000-0002-8132-858X; 				DEAN AG, 1991, AM J PREV MED, V7, P178, DOI 10.1016/S0749-3797(18)30936-X; ELIAS CJ, 1990, AM J PUBLIC HEALTH, V80, P824, DOI 10.2105/AJPH.80.7.824; GLASS RI, 1980, LANCET, V1, P868; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; HAKEWILL PA, 1991, TROP DOCT, V21, P24, DOI 10.1177/00494755910210S106; Lemeshow S, 1985, World Health Stat Q, V38, P65; MANONCOURT S, 1992, LANCET, V340, P176, DOI 10.1016/0140-6736(92)93252-I; NEIBERG P, 1988, B WORLD HEALTH ORGAN, V66, P689; NICHOLS BL, 1977, AM J CLIN NUTR, V30, P1457, DOI 10.1093/ajcn/30.9.1457; TOOLE M J, 1989, Bulletin of the World Health Organization, V67, P381; TOOLE MJ, 1988, B WORLD HEALTH ORGAN, V66, P237; TOOLE MJ, 1990, JAMA-J AM MED ASSOC, V263, P3296, DOI 10.1001/jama.263.24.3296; TOOLE MJ, 1992, MMWR-MORBID MORTAL W, V41, P1; 1992, MMWR, V41, P913; 1993, MMWR, V42, P9; 1992, STATE WORLDS CHILDRE	16	61	62	0	20	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 10	1993	341	8850					935	938		10.1016/0140-6736(93)91223-9	http://dx.doi.org/10.1016/0140-6736(93)91223-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW981	8096276	Green Submitted			2022-12-28	WOS:A1993KW98100015
J	TOMASEK, L; DARBY, SC; SWERDLOW, AJ; PLACEK, V; KUNZ, E				TOMASEK, L; DARBY, SC; SWERDLOW, AJ; PLACEK, V; KUNZ, E			RADON EXPOSURE AND CANCERS OTHER THAN LUNG-CANCER AMONG URANIUM MINERS IN WEST-BOHEMIA	LANCET			English	Article							MORTALITY; RATES	Recent observations have suggested that radon in the ambient air may cause cancers at sites other than the lung, but the evidence is indirect. We have studied site-specific cancer mortality in 4320 uranium miners in West Bohemia who have been followed-up for an average of 25 years, and in whom a four-fold radon-related excess of lung cancer has already been established. For all cancers other than lung cancer the number of deaths observed was slightly greater than that expected from national rates, but the increase was not significant statistically (ratio of observed to expected deaths [O/E]=1.11, 95% confidence interval [CI]=0.98-1.24) and mortality did not increase with duration of employment underground or with cumulative exposure to radon. Non-lung cancer mortality was significantly raised among men who started mining work aged under 25 but the increase was not related to cumulative radon exposure. When twenty-eight individual sites and types of cancer were examined, significantly increased risks were found for cancers of the liver (O/E=1.67) and gallbladder and extrahepatic bileducts (O/E=2.26). For liver cancer, mortality did not increase with duration of employment underground or with cumulative radon exposure. For cancer of the gallbladder and extrahepatic bileducts, mortality did not increase with duration of employment, but increased with cumulative exposure to radon. Mortality from multiple myeloma, although not significantly increased overall (O/E=1.08), increased with cumulative exposure to radon. Mortality from leukaemia was not increased overall (O/E=0.91) and was not related to cumulative radon exposure, but did increase with increasing duration of employment in the mines. There is no evidence in these miners that a radon-rich atmosphere increases the risk of any cancer other than lung cancer. Possible exceptions are cancer of the gallbladder and extrahepatic bileducts and multiple myeloma but further study is needed before it can be concluded that the associations found are causal.	UNIV OXFORD, RADCLIFFE INFIRM,IMPERIAL CANC RES FUND, CANC EPIDEMIOL UNIT,GIBSON BLDG, OXFORD OX2 6HE, ENGLAND; NATL INST PUBL HLTH, PRAGUE, CZECHOSLOVAKIA; UNIV LONDON LONDON SCH HYG & TROP MED, LONDON WC1E 7HT, ENGLAND; HLTH INST URANIUM IND, PRIBRAM, CZECHOSLOVAKIA	Radcliffe Infirmary; University of Oxford; National Institute of Public Health (SZU) - Czech Republic; University of London; London School of Hygiene & Tropical Medicine				Swerdlow, Anthony/0000-0001-5550-4159				ANDERSSON M, 1992, J NATL CANCER I, V84, P1318, DOI 10.1093/jnci/84.17.1318; [Anonymous], 1988, SOURCES EFFECTS RISK; [Anonymous], 1990, HLTH EFFECTS EXPOSUR; BRIDGES BA, 1991, LANCET, V337, P1187, DOI 10.1016/0140-6736(91)92859-Z; CHARLES M, 1990, INT J RADIAT BIOL, V58, P859, DOI 10.1080/09553009014552231; DARBY S, 1990, RAD PROTECTION AUSTR, V8, P83; DARBY SC, 1987, BRIT J CANCER, V55, P179, DOI 10.1038/bjc.1987.35; EATOUGH JP, 1990, LANCET, V335, P1292, DOI 10.1016/0140-6736(90)91371-G; EATOUGH JP, 1992, PHYS MED BIOL, V37, P955, DOI 10.1088/0031-9155/37/4/010; EATOUGH JP, 1991, RADIAT PROT DOSIM, V39, P33; FOX AJ, 1976, LANCET, V2, P416; FOX AJ, 1976, BRIT J PREV SOC MED, V30, P225; HENSHAW DL, 1990, LANCET, V335, P1008, DOI 10.1016/0140-6736(90)91071-H; JAMES AC, IN PRESS 29TH P HANF; MORRISON HI, 1988, AM J EPIDEMIOL, V128, P1266, DOI 10.1093/oxfordjournals.aje.a115080; PLACEK V, 1966, EXPOSURE EXTERNAL GA; RADFORD EP, 1984, NEW ENGL J MED, V310, P1485, DOI 10.1056/NEJM198406073102302; RICHARDSON RB, 1991, BRIT J RADIOL, V64, P608, DOI 10.1259/0007-1285-64-763-608; ROCKETTE HE, 1977, J OCCUP ENVIRON MED, V19, P795, DOI 10.1097/00043764-197712000-00004; SECOVA M, 1978, HEALTH PHYS, V35, P803; SEVC J, 1976, HEALTH PHYS, V30, P433, DOI 10.1097/00004032-197606000-00001; SEVC J, IN PRESS HLTH PHYS; SHIMIZU Y, 1990, RADIAT RES, V121, P120, DOI 10.2307/3577495; TIRMARCHE M, IN PRESS BR J CANCER; VANKAICK G, 1989, RISKS RADIUM THOROTR; XIANGZHEN X, 1933, HEALTH PHYS, P120; 1988, MONOGRAPHS EVALUATIO, V44; 1988, HLTH RISKS RADON OTH; 1991, COMP DOSIMETRY RADON; 1990, DOCUMENTS NRPB, V1	30	82	83	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 10	1993	341	8850					919	923		10.1016/0140-6736(93)91212-5	http://dx.doi.org/10.1016/0140-6736(93)91212-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW981	8096265				2022-12-28	WOS:A1993KW98100004
J	VALERO, MV; AMADOR, LR; GALINDO, C; FIGUEROA, J; BELLO, MS; MURILLO, LA; MORA, AL; PATARROYO, G; ROCHA, CL; ROJAS, M; APONTE, JJ; SARMIENTO, LE; LOZADA, DM; CORONELL, CG; ORTEGA, NM; ROSAS, JE; ALONSO, PL; PATARROYO, ME				VALERO, MV; AMADOR, LR; GALINDO, C; FIGUEROA, J; BELLO, MS; MURILLO, LA; MORA, AL; PATARROYO, G; ROCHA, CL; ROJAS, M; APONTE, JJ; SARMIENTO, LE; LOZADA, DM; CORONELL, CG; ORTEGA, NM; ROSAS, JE; ALONSO, PL; PATARROYO, ME			VACCINATION WITH SPF66, A CHEMICALLY SYNTHESIZED VACCINE, AGAINST PLASMODIUM-FALCIPARUM MALARIA IN COLOMBIA	LANCET			English	Article							ASEXUAL BLOOD STAGES; SYNTHETIC VACCINE; PROTECTIVE IMMUNITY; OWL MONKEYS; ANTIGENS; PROTEIN; ANTIBODIES; INDUCTION; PEPTIDES	Preclinical and clinical studies have established the safety and immunogenicity of the chemically synthesised SPf66 malaria vaccine. The present study is a phase III randomised, double-blind, placebo-controlled, efficacy trial completed in La Tola, Colombia. 1548 volunteers over one year of age received three doses of either the vaccine (n = 738) or placebo (n = 810). Active and passive case detection methods were used to document clinical episodes of malaria among the study population. The follow-up period began one month after the third dose and lasted for one year. 168 and 297 episodes of Plasmodium falciparum malaria were documented in the SPf66 group and the placebo group, respectively; this corresponds to a crude protective efficacy of 38.8%. Incidence rates for first or only P falciparum malarial episodes were 22.3% per annum among the vaccinee group and 33.5% among the placebo group (RR = 1.5; 95% Cl 1.23, 1.84). Therefore, the protective efficacy of SPf66 against first or only episodes was 33.6% (95% Cl 18.8, 45.7), being highest in children aged 1-4 years (77%) and adults older than 45 years (67%). The estimated protective efficacy against second episodes was 50.5% (95% Cl 12.9-71.9). Our study shows that the chemically synthesised SPf66 malaria vaccine is safe, immunogenic, and protective against P falciparum malaria in semi-immune populations subject to natural challenge.	UNIV NACL COLOMBIA, HOSP SAN JUAN DE DIOS, INST IMMUNOL, BOGOTA, COLOMBIA; HOSP CLIN BARCELONA, FUNDACIO RECERCA BIOMED, BARCELONA, SPAIN; CSIC, INST PARASITOL LOPEZ NEYRA, GRANADA, SPAIN	Universidad Nacional de Colombia; University of Barcelona; Hospital Clinic de Barcelona; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN)			Alonso, Pedro L/AAZ-3645-2020; Patarroyo, Manuel-Elkin/S-1422-2017	Alonso, Pedro L/0000-0003-3292-3443; Patarroyo, Manuel-Elkin/0000-0002-1119-6040; Valero-Bernal, Maria Victoria/0000-0002-7926-8944				AMADOR R, 1992, VACCINE, V10, P179, DOI 10.1016/0264-410X(92)90009-9; AMADOR R, 1992, J INFECT DIS, V166, P139, DOI 10.1093/infdis/166.1.139; BALLOU WR, 1987, LANCET, V1, P1277; BONILLA E, 1989, THESIS U LOS ANDES B; BOUHAROUNTAYOUN H, 1992, INFECT IMMUN, V60, P1473, DOI 10.1128/IAI.60.4.1473-1481.1992; COX FEG, 1991, TRENDS BIOTECHNOL, V9, P389, DOI 10.1016/0167-7799(91)90131-Z; DYSON HJ, 1988, ANNU REV BIOPHYS BIO, V17, P305; FRIES LF, 1992, INFECT IMMUN, V60, P1834, DOI 10.1128/IAI.60.5.1834-1839.1992; GOOD MF, 1989, VACCINE, V7, P3, DOI 10.1016/0264-410X(89)90002-9; HERRINGTON DA, 1987, NATURE, V328, P257, DOI 10.1038/328257a0; HOLDER AA, 1988, PROG ALLERGY, V41, P72; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; INSELBURG J, 1991, INFECT IMMUN, V59, P1247, DOI 10.1128/IAI.59.4.1247-1250.1991; KASLOW DC, 1988, NATURE, V333, P74, DOI 10.1038/333074a0; KHUSMITH S, 1991, SCIENCE, V252, P715, DOI 10.1126/science.1827210; MOLANO A, 1992, PARASITE IMMUNOL, V14, P111, DOI 10.1111/j.1365-3024.1992.tb00010.x; MORENO A, 1989, BLOOD, V74, P537; MURILLO LA, 1992, PARASITE IMMUNOL, V14, P87, DOI 10.1111/j.1365-3024.1992.tb00008.x; MURILLO LA, 1991, PARASITE IMMUNOL, V13, P201, DOI 10.1111/j.1365-3024.1991.tb00275.x; NOLTE D, 1991, MOL BIOCHEM PARASIT, V49, P253, DOI 10.1016/0166-6851(91)90069-I; NUSSENZWEIG RS, 1989, REV INFECT DIS, V11, pS579; NUSSENZWEIG V, 1986, AM J TROP MED HYG, V35, P678, DOI 10.4269/ajtmh.1986.35.678; PATARROYO G, 1992, VACCINE, V10, P175, DOI 10.1016/0264-410X(92)90008-8; PATARROYO ME, 1991, PARASITE IMMUNOL, V13, P509, DOI 10.1111/j.1365-3024.1991.tb00547.x; PATARROYO ME, 1987, NATURE, V328, P629, DOI 10.1038/328629a0; PATARROYO ME, 1988, NATURE, V332, P158, DOI 10.1038/332158a0; QUINONES ML, 1987, COLOMB MEDICA, V18, P19; RILEY EM, 1991, PARASITOL TODAY, V7, P5, DOI 10.1016/0169-4758(91)90076-Z; ROCHA CL, 1992, PARASITE IMMUNOL, V14, P95, DOI 10.1111/j.1365-3024.1992.tb00009.x; RODRIGUEZ R, 1990, AM J TROP MED HYG, V43, P339, DOI 10.4269/ajtmh.1990.43.339; RUEBUSH TK, 1990, AM J TROP MED HYG, V43, P355, DOI 10.4269/ajtmh.1990.43.355; SALCEDO M, 1991, CLIN EXP IMMUNOL, V84, P122, DOI 10.1111/j.1365-2249.1991.tb08134.x; SIM BKL, 1990, J CELL BIOL, V111, P1877, DOI 10.1083/jcb.111.5.1877; STURCHLER D, 1989, PARASITOL TODAY, V5, P39, DOI 10.1016/0169-4758(89)90188-9; SZARFMAN A, 1988, PARASITE IMMUNOL, V10, P339, DOI 10.1111/j.1365-3024.1988.tb00225.x; TARGETT G, 1990, SCAND J INFECT DIS, P79; TAVERNE J, 1990, PARASITE IMMUNOL, V12, P33, DOI 10.1111/j.1365-3024.1990.tb00934.x; THOMAS AW, 1990, MOL BIOCHEM PARASIT, V43, P211, DOI 10.1016/0166-6851(90)90146-D; TROYEBLOMBERG M, 1987, IMMUNE REGULATION CH, P699; ZHU JD, 1991, MOL BIOCHEM PARASIT, V48, P223, DOI 10.1016/0166-6851(91)90117-O	40	182	187	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 20	1993	341	8847					705	710		10.1016/0140-6736(93)90483-W	http://dx.doi.org/10.1016/0140-6736(93)90483-W			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KT362	8095622				2022-12-28	WOS:A1993KT36200001
J	WATIER, H; AURIAULT, C; CAPRON, A				WATIER, H; AURIAULT, C; CAPRON, A			DOES EPSTEIN-BARR-VIRUS INFECTION CONFER SELECTIVE ADVANTAGE TO MALARIA-INFECTED CHILDREN	LANCET			English	Note							PLASMODIUM-FALCIPARUM MALARIA; TUMOR-NECROSIS FACTOR; PROTECTION		INST PASTEUR,CTR IMMUNOL & BIOL PARASITAIRE,F-59000 LILLE,FRANCE; FAC MED TOURS,IMMUNOL LAB,F-37032 TOURS,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille								BIGGAR RJ, 1978, INT J CANCER, V22, P239, DOI 10.1002/ijc.2910220304; BURDIN N, 1992, 8TH INT C IMM BUD, P201; CARTER R, 1992, PARASITOL TODAY, V8, P41, DOI 10.1016/0169-4758(92)90077-F; CHIZZOLINI C, 1990, CLIN EXP IMMUNOL, V79, P95, DOI 10.1111/j.1365-2249.1990.tb05133.x; CLARK IA, 1987, PARASITOL TODAY, V3, P300, DOI 10.1016/0169-4758(87)90187-6; GAZZINELLI RT, 1992, J IMMUNOL, V148, P1792; GRAU GE, 1989, IMMUNOL REV, V112, P49, DOI 10.1111/j.1600-065X.1989.tb00552.x; HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0; HOWARD M, 1992, IMMUNOL TODAY, V13, P198, DOI 10.1016/0167-5699(92)90153-X; HSU DH, 1990, SCIENCE, V250, P830, DOI 10.1126/science.2173142; KARUNAWEERA ND, 1992, CLIN EXP IMMUNOL, V88, P499, DOI 10.1111/j.1365-2249.1992.tb06478.x; KERN P, 1989, AM J MED, V87, P139, DOI 10.1016/S0002-9343(89)80688-6; KWIATKOWSKI D, 1990, LANCET, V336, P1201, DOI 10.1016/0140-6736(90)92827-5; LAM KMC, 1991, LANCET, V337, P876, DOI 10.1016/0140-6736(91)90203-2; WATIER H, 1992, INFECT IMMUN, V60, P136, DOI 10.1128/IAI.60.1.136-142.1992	15	11	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 6	1993	341	8845					612	613		10.1016/0140-6736(93)90364-M	http://dx.doi.org/10.1016/0140-6736(93)90364-M			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KQ234	8094840				2022-12-28	WOS:A1993KQ23400016
J	HARRISON, BC; MARCHESERAGONA, SP; GILBERT, SP; CHENG, NQ; STEVEN, AC; JOHNSON, KA				HARRISON, BC; MARCHESERAGONA, SP; GILBERT, SP; CHENG, NQ; STEVEN, AC; JOHNSON, KA			DECORATION OF THE MICROTUBULE SURFACE BY ONE KINESIN HEAD PER TUBULIN HETERODIMER	NATURE			English	Article							MOTILITY; ATPASE; IDENTIFICATION	KINESIN, a microtubule-dependent ATPase, is believed to be involved in anterograde axonal transport. The kinesin head, which contains both microtubule and ATP binding sites, has the necessary components for the generation of force and motility1. We have used saturation binding and electron microscopy to examine the interaction of the kinesin motor domain with the microtubule surface and found that binding saturated at one kinesin head per tubulin heterodimer. Both negative staining and cryo-electron microscopy revealed a regular pattern of kinesin bound to the microtubule surface, with an axial repeat of 8 nm. Optical diffraction analysis of decorated microtubules showed a strong layer-line at this spacing, confirming that one kinesin head binds per tubulin heterodimer. The addition of Mg-ATP to the microtubule-kinesin complex resulted in the complete dissociation of kinesin from the microtubule surface.	PENN STATE UNIV,DEPT MOLEC & CELL BIOL,UNIV PK,PA 16802; NIAMSD,STRUCT BIOL LAB,BETHESDA,MD 20892	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)								AMOS LA, 1974, J CELL SCI, V14, P523; BOOY FP, 1991, CELL, V64, P1007, DOI 10.1016/0092-8674(91)90324-R; BRADY ST, 1985, NATURE, V317, P73, DOI 10.1038/317073a0; GILBERT SP, IN PRESS BIOCHEMISTR; GRIMSTONE AV, 1966, J CELL SCI, V1, P351; INGOLD AL, 1988, J CELL BIOL, V107, P2657, DOI 10.1083/jcb.107.6.2657; KUZNETSOV SA, 1989, J BIOL CHEM, V264, P589; KUZNETSOV SA, 1986, P NATL ACAD SCI USA, V83, P8530, DOI 10.1073/pnas.83.22.8530; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; SCHOLEY JM, 1985, NATURE, V318, P483, DOI 10.1038/318483a0; STEVEN AC, 1980, P NATL ACAD SCI-BIOL, V77, P4721, DOI 10.1073/pnas.77.8.4721; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332	13	75	75	1	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 4	1993	362	6415					73	75		10.1038/362073a0	http://dx.doi.org/10.1038/362073a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KP976	8095324				2022-12-28	WOS:A1993KP97600064
J	ASSICOT, M; GENDREL, D; CARSIN, H; RAYMOND, J; GUILBAUD, J; BOHUON, C				ASSICOT, M; GENDREL, D; CARSIN, H; RAYMOND, J; GUILBAUD, J; BOHUON, C			HIGH SERUM PROCALCITONIN CONCENTRATIONS IN PATIENTS WITH SEPSIS AND INFECTION	LANCET			English	Article							GENE-RELATED PEPTIDE; CALCITONIN; PLASMA	High concentrations of calcitonin-like immunoreactivity have been found in the blood of patients with various extrathyroid diseases. By means of a monoclonal immunoradiometric assay for calcitonin precursors, we have measured serum concentrations of procalcitonin in patients with various bacterial and viral infections. 79 children (newborn to age 12 years) in hospital with suspected infections were investigated prospectively. 19 patients with severe bacterial infections had very high serum concentrations of procalcitonin at diagnosis (range 6-53 ng/mL) in comparison with 21 children found to have no signs of infection (baseline concentrations < 0.1 ng/m L). Serum procalcitonin values decreased rapidly during antibiotic therapy. 11 patients with peripheral bacterial colonisation or local infections without invasive sepsis and 18 (86%) of 21 patients with viral infections had concentrations within or slightly above the normal range (0.1-1.5 ng/mL). Among 9 severely burned patients studied in an intensive care unit, the post-traumatic course of procalcitonin concentrations (range 0.1-120 ng/mL) was closely related to infectious complications and acute septic episodes. Concentrations of mature calcitonin were normal in all subjects, whatever procalcitonin concentrations were found. Concentrations of a substance immunologically identical to procalcitonin are raised during septic conditions. Serum concentrations seem to be correlated with the severity of microbial invasion.	INST GUSTAVE ROUSSY,DEPT BIOL CLIN,F-94805 VILLEJUIF,FRANCE; HOP ST VINCENT DE PAUL,DEPT PEDIAT,PARIS,FRANCE; HOP ST VINCENT DE PAUL,MICROBIOL LAB,PARIS,FRANCE; HOP INSTRUCT ARMEES PERCY,CTR TRAITEMENT BRULES,F-92141 CLAMART,FRANCE	UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite								BECKER KL, 1981, CHEST, V79, P211, DOI 10.1378/chest.79.2.211; BECKER KL, 1980, ARCH PATHOL LAB MED, V104, P196; BORN W, 1991, REGUL PEPTIDES, V32, P311, DOI 10.1016/0167-0115(91)90024-B; CANALE DD, 1975, J CLIN ENDOCR METAB, V40, P738, DOI 10.1210/jcem-40-4-738; Colon JM, 1988, BIOCHEMISTRY-US, V256, P245; COOMBES RC, 1974, LANCET, V1, P1080; DEFTOS LJ, 1975, J CLIN ENDOCR METAB, V40, P409, DOI 10.1210/jcem-40-3-409; FAUCHALD P, 1985, SCAND J CLIN LAB INV, V45, P229, DOI 10.3109/00365518509161000; GHILLANI PP, 1989, CANCER RES, V49, P6845; GILLQUIST J, 1977, SCAND J GASTROENTERO, V12, P21, DOI 10.1080/00365521.1977.12031105; HEATH H, 1979, J LAB CLIN MED, V93, P390; JOYCE CD, 1990, SURGERY, V108, P1097; MALLET E, 1983, LANCET, V1, P294; MILHAUD G, 1974, LANCET, V1, P462; MINVIELLE S, 1991, J BIOL CHEM, V266, P24627; ROOS BA, 1983, J CLIN ENDOCR METAB, V56, P802, DOI 10.1210/jcem-56-4-802; SILVA OL, 1977, NEPHRON, V19, P12, DOI 10.1159/000180860	17	1442	1628	2	125	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 27	1993	341	8844					515	518		10.1016/0140-6736(93)90277-N	http://dx.doi.org/10.1016/0140-6736(93)90277-N			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP083	8094770	Green Published			2022-12-28	WOS:A1993KP08300003
J	IERODIAKONOU, K; VANDENBROUCKE, JP				IERODIAKONOU, K; VANDENBROUCKE, JP			MEDICINE AS A STOCHASTIC ART	LANCET			English	Editorial Material							NEED		UNIV HOSP LEIDEN,DEPT CLIN EPIDEMIOL,BLDG 1-CO-P,POB 9600,2300 RC LEIDEN,NETHERLANDS; UNIV LONDON,KINGS COLL LONDON,DEPT PHILOSOPHY,LONDON WC2R 2LS,ENGLAND	Leiden University; Leiden University Medical Center (LUMC); University of London; King's College London			Vandenbroucke, Jan/AAM-3928-2020	Vandenbroucke, Jan/0000-0001-5668-6716				Cullen W., 1987, P ROYAL COLLEGE PHYS, V17, P268; DONABEDIAN A, 1980, DEFINITION QUALITY A; FIRTH WJ, 1991, BRIT MED J, V303, P1565, DOI 10.1136/bmj.303.6817.1565; GREENE R, 1976, ASSURING QUALITY MED; GREENWOOD M, 1936, MED DICTATOR; IERODIAKONOU K, 1992, IN PRESS APR P C ANC; PALMER T, 1989, NEW SCI         1111, P56; SMITH R, 1990, BRIT MED J, V301, P679, DOI 10.1136/bmj.301.6754.679; TARLOV AR, 1989, JAMA-J AM MED ASSOC, V262, P925, DOI 10.1001/jama.262.7.925; TARNOWMORDI W, 1990, BRIT MED J, V300, P1611, DOI 10.1136/bmj.300.6740.1611; Wulff H R, 1988, Proc R Coll Physicians Edinb, V18, P204; YUSUF S, 1984, STAT MED, V3, P409, DOI 10.1002/sim.4780030421; 1987, MEASURING MED PRACTI, P41	13	27	27	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 27	1993	341	8844					542	543		10.1016/0140-6736(93)90294-Q	http://dx.doi.org/10.1016/0140-6736(93)90294-Q			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP083	8094784				2022-12-28	WOS:A1993KP08300017
J	CLARK, AJL; MCLOUGHLIN, L; GROSSMAN, A				CLARK, AJL; MCLOUGHLIN, L; GROSSMAN, A			FAMILIAL GLUCOCORTICOID DEFICIENCY ASSOCIATED WITH POINT MUTATION IN THE ADRENOCORTICOTROPIN RECEPTOR	LANCET			English	Note								Familial glucocorticoid deficiency is an uncommon disorder that appears to be due to congenital insensitivity or resistance to adrenocorticotropin (ACTH), and is usually inherited in an autosomal recessive pattern. We investigated the DNA base sequence in a family with this condition by polymerase chain reaction amplification of DNA with pairs of primers that span the ACTH-receptor domain. The affected male proband showed a single base mutation, ser74-->ile, in the sequence coding for the second transmembrane domain of the ACTH receptor. A similar defect was found in an affected sister, a normal sequence in an unaffected brother, and both alleles in each parent. This is only the second clinical disorder associated with a GTP-binding-protein-linked hormone-receptor mutation.	ST BARTHOLOMEWS HOSP,DEPT ENDOCRINOL,LONDON EC1A 7BE,ENGLAND; ST BARTHOLOMEWS HOSP,DEPT CHEM ENDOCRINOL,LONDON EC1A 7BE,ENGLAND	University of London; Queen Mary University London; University of London; Queen Mary University London								ALLGROVE J, 1978, LANCET, V1, P1284; DRYJA TP, 1990, NEW ENGL J MED, V323, P1302, DOI 10.1056/NEJM199011083231903; MIGEON CJ, 1968, PEDIATR RES, V2, P501, DOI 10.1203/00006450-196811000-00008; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; ROSENTHAL W, 1992, NATURE, V359, P233, DOI 10.1038/359233a0; Sambrook J., 1989, MOL CLONING; SHEPARD TH, 1959, AMA J DIS CHILD, V97, P154, DOI 10.1001/archpedi.1959.02070010156002; THISTLETHWAITE D, 1975, ARCH DIS CHILD, V50, P291, DOI 10.1136/adc.50.4.291; YAMOAKA T, 1992, J CLIN ENDOCR METAB, V75, P270	9	204	211	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 20	1993	341	8843					461	462		10.1016/0140-6736(93)90208-X	http://dx.doi.org/10.1016/0140-6736(93)90208-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN137	8094489				2022-12-28	WOS:A1993KN13700005
J	BULL, RH; COBURN, PR; MORTIMER, PS				BULL, RH; COBURN, PR; MORTIMER, PS			PRETIBIAL MYXEDEMA - A MANIFESTATION OF LYMPHEDEMA	LANCET			English	Note							ISOTOPE LYMPHOGRAPHY; LYMPHATICS; MYXEDEMA; LIMB	Pretibial myxoedema (PTM) in its most extreme form clinically resembles lymphoedema. Studies with quantitative lymphoscintigraphy and fluorescence microlymphography in two patients with extensive PTM confirmed the presence of both functional and structural changes in the lymphatic system. We suggest that mucin deposition in the dermis causes compression of the dermal lymphatics, which results in dermal oedema and the clinical features of lymphoedema.	ROYAL W SUSSEX HOSP,CHICHESTER,W SUSSEX,ENGLAND		BULL, RH (corresponding author), ST GEORGE HOSP,DEPT DERMATOL,BLACKSHAW RD,LONDON SW17 0QT,ENGLAND.							ALEVIZAKIHARHALAKI M, 1983, J NUCL MED, V24, P174; CHEUNG HS, 1978, J INVEST DERMATOL, V71, P12, DOI 10.1111/1523-1747.ep12543646; ELTE JWF, 1983, NETH J MED, V26, P220; JAGER K, 1983, INT ANGIOL, V2, P129; MORTIMER PS, 1983, BRIT J DERMATOL, V108, P561, DOI 10.1111/j.1365-2133.1983.tb01057.x; PROBY CM, 1990, BRIT J DERMATOL, V123, P29, DOI 10.1111/j.1365-2133.1990.tb01821.x; ROBERTS SOB, 1986, TXB DERMATOLOGY, P2343; STEWART G, 1985, BRIT J SURG, V72, P906, DOI 10.1002/bjs.1800721120; STEWART G, 1984, ANN ROY COLL SURG, V66, P391; WORSTMAN J, 1981, ARCH DERMATOL, V117, P635	10	38	39	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 13	1993	341	8842					403	404		10.1016/0140-6736(93)92990-B	http://dx.doi.org/10.1016/0140-6736(93)92990-B			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM416	8094170				2022-12-28	WOS:A1993KM41600005
J	CUTTS, FT				CUTTS, FT			MEASLES CONTROL IN YOUNG INFANTS - WHERE DO WE GO FROM HERE	LANCET			English	Editorial Material							IMMUNIZATION				CUTTS, FT (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,COMMUNICABLE DIS EPIDEMIOL UNIT,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.							BECKER RA, 1984, B PAN AM HLTH ORGAN, V18, P397; Boerma J. T., 1990, IMMUNIZATION LEVELS; CUTTS FT, 1991, B WORLD HEALTH ORGAN, V69, P1; DABIS F, 1988, AM J EPIDEMIOL, V127, P171, DOI 10.1093/oxfordjournals.aje.a114778; GARENNE M, 1990, J INFECT DIS, V161, P1088, DOI 10.1093/infdis/161.6.1088; KAMBARAMI RA, 1991, B WORLD HEALTH ORGAN, V69, P213; PANNUTI CS, 1991, B WORLD HEALTH ORGAN, V69, P557; TAYLOR WR, 1988, AM J EPIDEMIOL, V127, P788, DOI 10.1093/oxfordjournals.aje.a114860; WEISS R, 1992, SCIENCE, V258, P5546; 1989, WEEKLY EPIDEMIOL REC, V64, P5; 1992, LANCET, V340, P232; 1991, JAMA-J AM MED ASSOC, V266, P1547	12	10	10	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 30	1993	341	8840					290	291		10.1016/0140-6736(93)92629-8	http://dx.doi.org/10.1016/0140-6736(93)92629-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK245	8093929				2022-12-28	WOS:A1993KK24500017
J	LONDON, NJM; BOLIA, A; BELL, PRF				LONDON, NJM; BOLIA, A; BELL, PRF			SUBINTIMAL ANGIOPLASTY FOR FEMOROPOPLITEAL ARTERY-OCCLUSION	LANCET			English	Letter											LONDON, NJM (corresponding author), UNIV LEICESTER,LEICESTER ROYAL INFIRM,SCH MED,CLIN SCI BLDG,POB 65,LEICESTER LE2 7LX,W YORKSHIRE,ENGLAND.							BOLIA A, 1990, CARDIOVASC INTER RAD, V13, P357, DOI 10.1007/BF02578675; LAMMER, 1992, LANCET, V340, P1183	2	14	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 23	1993	341	8839					238	238		10.1016/0140-6736(93)90098-2	http://dx.doi.org/10.1016/0140-6736(93)90098-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ219	8093515				2022-12-28	WOS:A1993KJ21900025
J	CUMMINGS, SR; BLACK, DM; NEVITT, MC; BROWNER, W; CAULEY, J; ENSRUD, K; GENANT, HK; PALERMO, L; SCOTT, J; VOGT, TM				CUMMINGS, SR; BLACK, DM; NEVITT, MC; BROWNER, W; CAULEY, J; ENSRUD, K; GENANT, HK; PALERMO, L; SCOTT, J; VOGT, TM			BONE-DENSITY AT VARIOUS SITES FOR PREDICTION OF HIP-FRACTURES	LANCET			English	Article							PROXIMAL FEMUR; WHITE WOMEN; OSTEOPOROSIS; DENSITOMETRY; MASS; RISK; CURVES; SPINE	Women with low bone density in the radius or calcaneus are at increased risk of hip fracture. To see whether bone density of the hip measured by dual X-ray absorptiometry is a better predictor of hip fracture than measurements of other bones, we assessed bone density at several sites in 8134 women aged 65 years or more. 65 women had hip fractures during a mean follow-up of 1.8 years. Each SD decrease in femoral neck bone density increased the age-adjusted risk of hip fracture 2.6 times (95% CL 1.9, 3.6). Women with bone density in the lowest quartile had an 8.5-fold greater risk of hip fracture than those in the highest quartile. Bone density of the femoral neck was a better predictor than measurements of the spine (p<0.0001), radius (p<0.002), and moderately better than the calcaneus (p=0.10). Low hip bone density is a stronger predictor of hip fracture than bone density at other sites. Efforts to prevent hip fractures should focus on women with low hip bone density.	KAISER PERMANENTE CTR HLTH RES,PORTLAND,OR; UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT RADIOL,SAN FRANCISCO,CA 94143; UNIV PITTSBURGH,DEPT EPIDEMIOL,PITTSBURGH,PA 15260; UNIV MINNESOTA,SCH PUBL HLTH,DIV EPIDEMIOL,MINNEAPOLIS,MN 55455; UNIV MARYLAND,DEPT EPIDEMIOL & PREVENT MED,COLL PK,MD 20742	Kaiser Permanente; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Minnesota System; University of Minnesota Twin Cities; University System of Maryland; University of Maryland College Park	CUMMINGS, SR (corresponding author), UNIV CALIF SAN FRANCISCO,DIV GEN INTERNAL MED,BOX 0886,SAN FRANCISCO,CA 94143, USA.		Cauley, Jane A/N-4836-2015	Cauley, Jane A/0000-0003-0752-4408; Ensrud, Kristine/0000-0002-9069-3036	NIAMS NIH HHS [1-RO1-AR35582] Funding Source: Medline; NIA NIH HHS [5-RO1-AG05394, 1-RO1-AG05407] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG005407, R01AG005394] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALOIA JF, 1992, OSTEOPOROSIS INT, V2, P88, DOI 10.1007/BF01623842; BLACK DM, 1992, J BONE MINER RES, V7, P633; BLACK DM, 1992, J BONE MINER RES, V7, P639; COX DR, 1972, J R STAT SOC B, V34, P187; CUMMINGS SR, 1989, J GERONTOL, V44, pM107; CUMMINGS SR, 1990, JAMA-J AM MED ASSOC, V263, P665, DOI 10.1001/jama.263.5.665; CUMMINGS SR, 1985, AM J MED, V78, P487, DOI 10.1016/0002-9343(85)90343-2; FARMER ME, 1984, AM J PUBLIC HEALTH, V74, P1374, DOI 10.2105/AJPH.74.12.1374; GARDSELL P, 1989, CALCIFIED TISSUE INT, V44, P235, DOI 10.1007/BF02553757; GRISSO JA, 1991, NEW ENGL J MED, V324, P1326, DOI 10.1056/NEJM199105093241905; HANLEY JA, 1983, RADIOLOGY, V148, P839, DOI 10.1148/radiology.148.3.6878708; HUI SL, 1989, ANN INTERN MED, V111, P355, DOI 10.7326/0003-4819-111-5-355; Mazess R. B., 1988, OSTEOPOROSIS ETIOLOG, P251; MAZESS RB, 1988, J BONE MINER RES, V3, P13; MCNEIL BJ, 1984, MED DECIS MAKING, V4, P137, DOI 10.1177/0272989X8400400203; NEVITT MC, 1992, AM J EPIDEMIOL, V135, P490, DOI 10.1093/oxfordjournals.aje.a116315; RIGGS BL, 1982, J CLIN INVEST, V70, P716, DOI 10.1172/JCI110667; ROSNER B, 1989, STAT MED, V8, P1051, DOI 10.1002/sim.4780080905; ROSS PD, 1990, CALCIFIED TISSUE INT, V46, P149, DOI 10.1007/BF02555036; SARTORIS DJ, 1989, AM J ROENTGENOL, V152, P241, DOI 10.2214/ajr.152.2.241; SEELEY DG, 1991, ANN INTERN MED, V115, P837, DOI 10.7326/0003-4819-115-11-837; STEIGER P, 1992, J BONE MINER RES, V7, P625; TOSTESON ANA, 1990, ANN INTERN MED, V113, P594, DOI 10.7326/0003-4819-113-8-594; Vega E, 1991, Osteoporos Int, V1, P81, DOI 10.1007/BF01880448	24	2012	2056	2	58	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 9	1993	341	8837					72	75		10.1016/0140-6736(93)92555-8	http://dx.doi.org/10.1016/0140-6736(93)92555-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF870	8093403				2022-12-28	WOS:A1993KF87000002
J	CLARKE, IMC				CLARKE, IMC			MANAGEMENT OF POSTOPERATIVE PAIN	LANCET			English	Editorial Material																		[Anonymous], 1992, ACUTE PAIN MANAGEMEN; AVERYJONES F, 1961, PYES SURGICAL HANDIC, V1, P197; GOULD TH, 1992, BRIT MED J, V305, P1187, DOI 10.1136/bmj.305.6863.1187; PAPPER EM, 1952, SURGERY, V32, P107; READY LB, 1988, ANESTHESIOLOGY, V68, P100, DOI 10.1097/00000542-198801000-00016; Ready LB, 1992, MANAGEMENT ACUTE PAI; 1990, REPORT WORKING PARTY	7	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 2	1993	341	8836					27	27		10.1016/0140-6736(93)92492-C	http://dx.doi.org/10.1016/0140-6736(93)92492-C			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF027	8093275				2022-12-28	WOS:A1993KF02700014
J	DARNELL, RB; DEANGELIS, LM				DARNELL, RB; DEANGELIS, LM			REGRESSION OF SMALL-CELL LUNG-CARCINOMA IN PATIENTS WITH PARANEOPLASTIC NEURONAL ANTIBODIES	LANCET			English	Note								We describe three patients with known or suspected small-cell lung cancer (SCLC), paraneoplastic neurological syndromes, and antineuronal antibodies who had unusually benign clinical courses. One patient survived 8 years free of disease and was positive for the anti-Hu antibody. A second patient survived 6 years after spontaneous tumour regression and had an atypical antineuronal antibody. A third patient with both the anti-Hu and atypical antineuronal antibody had spontaneous regression of a lung mass. All three patients had a subacute sensory neuropathy, Since paraneoplastic antineuronal antibodies also bind to tumour cells, these cases suggest that some (paraneoplastic) neurological syndromes without identifiable tumour may result from immune-mediated eradication of tumour cells.	MEM SLOAN KETTERING CANC CTR,DEPT NEUROL,NEW YORK,NY 10021; CORNELL UNIV,MED CTR,COLL MED,DEPT NEUROL & NEUROSCI,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Cornell University			Darnell, Robert B/B-9022-2008	Darnell, Robert B/0000-0002-5134-8088	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001461] Funding Source: NIH RePORTER; NINDS NIH HHS [1KO8 NS01461-01] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		DALMAU J, 1992, MEDICINE, V71, P59, DOI 10.1097/00005792-199203000-00001; DALMAU J, 1990, ANN NEUROL, V27, P544, DOI 10.1002/ana.410270515; DARNELL R B, 1991, Neurology, V41, P363; DARNELL RB, 1991, J NEUROSCI, V11, P1224, DOI 10.1523/jneurosci.11-05-01224.1991; DEVITA VT, 1989, CANCER PRINCIPLES PR; Everson TC, 1966, SPONTANEOUS REGRESSI; LOWY AD, 1986, CANCER, V58, P978, DOI 10.1002/1097-0142(19860815)58:4<978::AID-CNCR2820580430>3.0.CO;2-G; POSNER JB, 1990, IMMUNOLOGIC MECHANIS; SEIFTER EJ, 1988, LUNG CANCER COMPREHE; SMITH RA, 1971, BMJ-BRIT MED J, V2, P563, DOI 10.1136/bmj.2.5761.563	10	200	207	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 2	1993	341	8836					21	22		10.1016/0140-6736(93)92485-C	http://dx.doi.org/10.1016/0140-6736(93)92485-C			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF027	8093269	hybrid			2022-12-28	WOS:A1993KF02700008
J	KELLY, RB				KELLY, RB			STORAGE AND RELEASE OF NEUROTRANSMITTERS	CELL			English	Review							PROTEIN-KINASE-C; TEMPERATURE-SENSITIVE MUTANT; FROG NEUROMUSCULAR-JUNCTION; SYNAPTIC VESICLE MEMBRANE; TRANSMITTER RELEASE; SECRETORY GRANULE; CHROMAFFIN CELLS; PHORBOL ESTERS; DROSOPHILA-MELANOGASTER; ENDOPLASMIC-RETICULUM				KELLY, RB (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.							ALDER J, 1992, SCIENCE, V257, P657, DOI 10.1126/science.1353905; BAJJALIEH SM, 1992, SCIENCE, V257, P1271, DOI 10.1126/science.1519064; BARNEKOW A, 1990, ONCOGENE, V5, P1019; Barr F A, 1992, Trends Cell Biol, V2, P91, DOI 10.1016/0962-8924(92)90001-4; BAUMERT M, 1990, J CELL BIOL, V110, P1285, DOI 10.1083/jcb.110.4.1285; BENNETT MK, 1992, J CELL BIOL, V116, P761, DOI 10.1083/jcb.116.3.761; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BITTNER MA, 1990, J NEUROCHEM, V54, P205, DOI 10.1111/j.1471-4159.1990.tb13302.x; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; BOMSEL M, 1992, IN PRESS MOL BIOL CE; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOWSER R, 1992, J CELL BIOL, V118, P1041, DOI 10.1083/jcb.118.5.1041; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; BURGOYNE RD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P174, DOI 10.1016/0304-4157(91)90024-Q; CAIN CC, 1992, J BIOL CHEM, V267, P11681; CALLE R, 1992, J BIOL CHEM, V267, P18723; CAMERON PL, 1991, J CELL BIOL, V115, P151, DOI 10.1083/jcb.115.1.151; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; CHOW RH, 1992, NATURE, V356, P60, DOI 10.1038/356060a0; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; COHEN MW, 1991, J NEUROSCI, V11, P1032; CUTLER DF, 1990, J CELL BIOL, V110, P721, DOI 10.1083/jcb.110.3.721; DEKKER LV, 1991, J NEUROCHEM, V56, P1146, DOI 10.1111/j.1471-4159.1991.tb11404.x; FEANY MB, 1992, CELL, V70, P861, DOI 10.1016/0092-8674(92)90319-8; FLOOR E, 1990, J NEUROCHEM, V55, P1663, DOI 10.1111/j.1471-4159.1990.tb04954.x; GERDES HH, 1989, J BIOL CHEM, V264, P12009; GERST JE, 1992, P NATL ACAD SCI USA, V89, P4338, DOI 10.1073/pnas.89.10.4338; GOTOW T, 1991, NEUROSCIENCE, V40, P587, DOI 10.1016/0306-4522(91)90143-C; GRANT NJ, 1990, EUR J CELL BIOL, V52, P36; GREEN SA, 1992, J CELL BIOL, V117, P47, DOI 10.1083/jcb.117.1.47; GRIMES M, 1992, J CELL BIOL, V117, P539, DOI 10.1083/jcb.117.3.539; HACKETT JT, 1990, J NEUROPHYSIOL, V63, P701, DOI 10.1152/jn.1990.63.4.701; HAN HQ, 1991, NATURE, V349, P697, DOI 10.1038/349697a0; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HAY JC, 1992, J CELL BIOL, V119, P139, DOI 10.1083/jcb.119.1.139; HEUSER JE, 1981, J CELL BIOL, V88, P564, DOI 10.1083/jcb.88.3.564; HURLBUT WP, 1990, J PHYSIOL-LONDON, V425, P501, DOI 10.1113/jphysiol.1990.sp018115; JUNG LJ, 1991, SCIENCE, V251, P1330, DOI 10.1126/science.2003219; Katz B., 1969, RELEASE NEURAL TRANS; KELLY R B, 1991, Current Opinion in Cell Biology, V3, P654, DOI 10.1016/0955-0674(91)90037-Y; KILEY SC, 1992, MOL ENDOCRINOL, V6, P120, DOI 10.1210/me.6.1.120; KOENIG JH, 1989, J NEUROSCI, V9, P1937; KOENIG JH, 1989, J NEUROSCI, V9, P3844; KOSAKA T, 1983, J CELL BIOL, V97, P499, DOI 10.1083/jcb.97.2.499; LEVEQUE C, 1992, P NATL ACAD SCI USA, V89, P3625, DOI 10.1073/pnas.89.8.3625; LIN HC, 1992, CELL, V70, P283, DOI 10.1016/0092-8674(92)90102-I; LINSTEDT AD, 1991, J PHYSIOL-PARIS, V85, P90; LINSTEDT AD, 1992, J CELL BIOL, V117, P1077, DOI 10.1083/jcb.117.5.1077; LINSTEDT AD, 1991, NEURON, V7, P309, DOI 10.1016/0896-6273(91)90269-6; LIU Y, 1992, P NATL ACAD SCI USA, V89, P9074, DOI 10.1073/pnas.89.19.9074; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; LLINAS R, 1991, J PHYSIOL-LONDON, V436, P257, DOI 10.1113/jphysiol.1991.sp018549; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; LU B, 1992, NEURON, V8, P521, DOI 10.1016/0896-6273(92)90280-Q; MARTIN TFJ, 1989, J BIOL CHEM, V264, P10299; MATTEOLI M, 1992, J CELL BIOL, V117, P849, DOI 10.1083/jcb.117.4.849; MATTEOLI M, 1991, J CELL BIOL, V115, P625, DOI 10.1083/jcb.115.3.625; MCMAHON HT, 1991, BIOCHIM BIOPHYS ACTA, V1059, P243, DOI 10.1016/S0005-2728(05)80210-5; MOCHLYROSEN D, 1992, BIOCHEMISTRY-US, V31, P8120, DOI 10.1021/bi00150a003; MONCK JR, 1990, P NATL ACAD SCI USA, V87, P7804, DOI 10.1073/pnas.87.20.7804; MORGAN A, 1992, NATURE, V355, P833, DOI 10.1038/355833a0; Mostov K, 1991, Semin Cell Biol, V2, P411; NELSON N, 1989, J BIOENERG BIOMEMBR, V21, P553, DOI 10.1007/BF00808113; OBERHAUSER AF, 1992, BIOPHYS J, V61, P800, DOI 10.1016/S0006-3495(92)81884-2; PETRENKO AG, 1991, NATURE, V353, P65, DOI 10.1038/353065a0; REGNIERVIGOUROUX A, 1991, EMBO J, V10, P3589, DOI 10.1002/j.1460-2075.1991.tb04925.x; SARAFIAN T, 1991, J CELL BIOL, V114, P1135, DOI 10.1083/jcb.114.6.1135; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SHAPIRA R, 1987, NATURE, V325, P58, DOI 10.1038/325058a0; SHIRATAKI H, 1992, J BIOL CHEM, V267, P10946; SHOJIKASAI Y, 1992, SCIENCE, V256, P1820, DOI 10.1126/science.256.5065.1820; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SMITH SJ, 1988, TRENDS NEUROSCI, V11, P458, DOI 10.1016/0166-2236(88)90199-3; SONTAG JM, 1988, EUR J CELL BIOL, V46, P316; SPRUCE AE, 1991, P NATL ACAD SCI USA, V88, P3623, DOI 10.1073/pnas.88.9.3623; SPRUCE AE, 1990, NEURON, V4, P643, DOI 10.1016/0896-6273(90)90192-I; STEVENS CF, 1993, CELL, V72, P55, DOI 10.1016/S0092-8674(05)80028-5; STONE DK, 1989, J BIOENERG BIOMEMBR, V21, P605, DOI 10.1007/BF00808116; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; SWOPE SL, 1992, FASEB J, V6, P2514, DOI 10.1096/fasebj.6.8.1375568; TABB JS, 1992, J BIOL CHEM, V267, P15412; TAKAHASHI M, 1991, BRAIN RES, V551, P279, DOI 10.1016/0006-8993(91)90942-O; THOMAS L, 1988, SCIENCE, V242, P1050, DOI 10.1126/science.2461586; TOOZE J, 1989, J CELL BIOL, V109, P35, DOI 10.1083/jcb.109.1.35; TOOZE SA, 1991, J CELL BIOL, V115, P1491, DOI 10.1083/jcb.115.6.1491; TRIFARO JM, 1992, EUR J PHARM-MOLEC PH, V225, P83, DOI 10.1016/0922-4106(92)90088-D; TRIMBLE WS, 1991, ANNU REV NEUROSCI, V14, P93, DOI 10.1146/annurev.ne.14.030191.000521; TSURUHARA T, 1990, CELL TISSUE RES, V259, P199, DOI 10.1007/BF00318441; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; VALETTI C, 1991, J CELL BIOL, V115, P983, DOI 10.1083/jcb.115.4.983; VALTORTA F, 1992, J BIOL CHEM, V267, P7195; VALTORTA F, 1992, J BIOL CHEM, V267, P11281; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VITALE ML, 1991, J CELL BIOL, V113, P1057, DOI 10.1083/jcb.113.5.1057; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0; VONZASTROW M, 1987, J CELL BIOL, V105, P2675, DOI 10.1083/jcb.105.6.2675; WALENT JH, 1992, CELL, V70, P765, DOI 10.1016/0092-8674(92)90310-9; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531; WU YN, 1992, J BIOL CHEM, V267, P8396; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	106	251	252	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN	1993	72			S			43	53		10.1016/S0092-8674(05)80027-3	http://dx.doi.org/10.1016/S0092-8674(05)80027-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KL707	8094036				2022-12-28	WOS:A1993KL70700003
J	CONRAD, B; WEIDMANN, E; TRUCCO, G; RUDERT, WA; BEHBOO, R; RICORDI, C; RODRIQUEZRILO, H; FINEGOLD, D; TRUCCO, M				CONRAD, B; WEIDMANN, E; TRUCCO, G; RUDERT, WA; BEHBOO, R; RICORDI, C; RODRIQUEZRILO, H; FINEGOLD, D; TRUCCO, M			EVIDENCE FOR SUPERANTIGEN INVOLVEMENT IN INSULIN-DEPENDENT DIABETES-MELLITUS ETIOLOGY	NATURE			English	Article							GLUTAMIC-ACID DECARBOXYLASE; POLYMERASE CHAIN-REACTION; RENAL GRAFT-SURVIVAL; MAMMARY-TUMOR VIRUS; MOLECULAR COMPATIBILITY; T-CELLS; ISLETS; USAGE; MICE; MLS	INSULIN-DEPENDENT diabetes mellitus (IDDM) is a T-cell-mediated autoimmune disease whose onset is believed to be triggered by unknown environmental factors acting on a predisposing genetic background. Islet-infiltrating T (IIT) cells from two IDDM patients, who had died at the onset of the disease from brain swelling as a complication of ketoacidosis, were analysed. The results provided evidence for the involvement of a pancreatic islet cell membrane-bound superantigen(1,2) as a diabetes aetiopathogenetic factor. There was a selective expansion of a T-cell receptor (TCR) variable segment of the beta-chain (V beta 7) in these IIT cells in association with unselected V alpha-chain segments; extensive junctional diversity of the TCR V beta 7 chains; and evidence of positive selection, after exposure to diabetic islet cell membrane preparations, of V beta 7(+) T-cell clones among peripheral blood lymphocytes from non-diabetic individuals.	CHILDRENS HOSP PITTSBURGH,RANGOS RES CTR,DEPT PEDIAT,DIV IMMUNOGENET,PITTSBURGH,PA 15213; UNIV PITTSBURGH,SCH MED,DEPT PATHOL,PITTSBURGH,PA 15213; UNIV PITTSBURGH,SCH MED,DEPT SURG,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh			RICORDI, CAMILLO/AAA-4740-2019	Ricordi, Camillo/0000-0001-8092-7153; Finegold, David/0000-0001-9901-2578				ACHAORBEA H, 1991, IMMUNOL TODAY, V12, P356, DOI 10.1016/0167-5699(91)90066-3; ACHAORBEA H, 1991, NATURE, V350, P207, DOI 10.1038/350207a0; BULUWELA L, 1989, NUCLEIC ACIDS RES, V17, P452, DOI 10.1093/nar/17.1.452; CALLAN MFC, 1993, P NATL ACAD SCI USA, V90, P10454, DOI 10.1073/pnas.90.22.10454; CHOI YW, 1989, P NATL ACAD SCI USA, V86, P8941, DOI 10.1073/pnas.86.22.8941; CHOI YW, 1991, NATURE, V350, P203, DOI 10.1038/350203a0; GENEVEE C, 1992, EUR J IMMUNOL, V22, P1261, DOI 10.1002/eji.1830220522; GIORDA R, 1991, LANCET, V338, P1469, DOI 10.1016/0140-6736(91)92781-V; GORGA JC, 1987, J BIOL CHEM, V262, P16087; HAND SL, 1993, TUMOUR IMMUNOBIOLOGY, P143; HSIA S, 1993, TRANSPLANTATION, V55, P395, DOI 10.1097/00007890-199302000-00030; JANEWAY CA, 1989, IMMUNOL REV, V107, P61, DOI 10.1111/j.1600-065X.1989.tb00003.x; KARALAINEN J, 1992, NEW ENGL J MED, V327, P302; KAUFMAN DL, 1993, NATURE, V366, P69, DOI 10.1038/366069a0; KOHSAKA H, 1993, EUR J IMMUNOL, V23, P1895, DOI 10.1002/eji.1830230825; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; MALISSEN M, 1992, IMMUNOL TODAY, V13, P315, DOI 10.1016/0167-5699(92)90044-8; Maniatis T., 1982, MOL CLONING; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; NOTKINS AL, 1984, CONCEPTS VIRAL PATHO, P241; RICORDI C, 1992, TRANSPLANTATION, V53, P407, DOI 10.1097/00007890-199202010-00027; RICORDI C, 1988, DIABETES, V37, P413, DOI 10.2337/diabetes.37.4.413; TISCH R, 1993, NATURE, V366, P72, DOI 10.1038/366072a0; TONG JY, 1993, TRANSPLANTATION, V55, P390, DOI 10.1097/00007890-199302000-00029; TRUCCO M, 1992, DIABETES CARE, V15, P705, DOI 10.2337/diacare.15.5.705; WEIDMANN E, 1992, CANCER RES, V52, P5913	26	298	303	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 22	1994	371	6495					351	355		10.1038/371351a0	http://dx.doi.org/10.1038/371351a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH254	8090207				2022-12-28	WOS:A1994PH25400058
J	OSMAN, LM; ABDALLA, MI; BEATTIE, JAG; ROSS, SJ; RUSSELL, IT; FRIEND, JA; LEGGE, JS; DOUGLAS, JG				OSMAN, LM; ABDALLA, MI; BEATTIE, JAG; ROSS, SJ; RUSSELL, IT; FRIEND, JA; LEGGE, JS; DOUGLAS, JG			REDUCING HOSPITAL ADMISSION THROUGH COMPUTER-SUPPORTED EDUCATION FOR ASTHMA PATIENTS	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; ADULT ASTHMA; PROGRAM; MORBIDITY; KNOWLEDGE	Objective-To evaluate a personalised computer supported education programme for asthma patients. Design-Pragmatic randomised trial comparing outcomes over 12 months between patients taking part in an enhanced education programme (our personalised booklets, sent by post) and patients receiving conventional oral education at outpatient or surgery visits. Setting-Hospital outpatient clinics and general practices in north east Scotland. Subjects-801 adults attending hospital outpatient clinics, with a diagnosis of asthma confirmed by a chest physician and pulmonary function reversibility of at least 20%. Main outcome measures-Numbers of hospital admissions, consultations with general practitioner for asthma, steroid courses used, bronchodilators and inhaled steroids prescribed, days of restricted activity, and disturbed nights. Results-Patients with asthma judged too severe for randomisation between clinic care and integrated care and thus retained in clinic care had 54% fewer hospital admissions after receiving enhanced education than did the control group (95% confidence interval 30% to 97%; P < 0.05) over the study year. Patients had not all spent a full year as ''educated'' patients within the study year: when ''educated days'' were controlled for, annual admission rates for the entire enhanced education group were 49% (31% to 78%) of those in the control group. Among patients with sleep variation, sleep disturbance in the education group in the week before a regular review was 80% (65% to 97%) of that in the control group. There was no significant difference in days of restricted activity, prescription of bronchodilators or inhaled steroids, use of oral steroids, or number of general practitioner consultations for asthma, and no significant interaction between ownership of a peak flow meter and education. Conclusions-An asthma education programme based on computerised booklets can reduce hospital admissions and improve morbidity among hospital outpatients.	UNIV ABERDEEN,HLTH SERV RES UNIT,ABERDEEN AB9 2ZD,ABERDEEN,SCOTLAND; CITY HOSP,ABERDEEN ROYAL HOSP TRUST,THORAC MED UNIT,ABERDEEN AB9 8AU,ABERDEEN,SCOTLAND	University of Aberdeen			Russell, Ian T/H-1181-2012					AITKEN M, 1989, STATISTICAL MODELLIN; BAILEY W C, 1989, American Review of Respiratory Disease, V139, pA144; BEASLEY R, 1989, THORAX, V44, P200, DOI 10.1136/thx.44.3.200; CHARLTON I, 1991, BRIT J GEN PRACT, V41, P227; ELLIS DA, 1979, BRIT MED J, V1, P456, DOI 10.1136/bmj.1.6161.456; ELLIS ME, 1985, BRIT J DIS CHEST, V79, P43, DOI 10.1016/0007-0971(85)90006-3; HERINGA P, 1987, HEALTH EDUC QUART, V14, P309, DOI 10.1177/109019818701400305; HILTON S, 1986, LANCET, V1, P26; JANSONBJERKLIE S, 1988, HEART LUNG, V17, P543; JENKINSON D, 1988, BRIT MED J, V297, P267, DOI 10.1136/bmj.297.6643.267; MAES S, 1988, SOC SCI MED, V26, P359, DOI 10.1016/0277-9536(88)90401-7; MAIMAN LA, 1979, JAMA-J AM MED ASSOC, V241, P1919; MAYO PH, 1990, ANN INTERN MED, V112, P864, DOI 10.7326/0003-4819-112-11-864; PETRIE JC, 1985, BRIT MED J, V290, P1960, DOI 10.1136/bmj.290.6486.1960; RINGSBERG KC, 1990, EUR RESPIR J, V3, P33; YOON R, 1991, THORAX, V46, P886, DOI 10.1136/thx.46.12.886; 1994, BRIT MED J, V308, P559; 1994, BRIT MED J, V308, P564; [No title captured]	19	130	131	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 26	1994	308	6928					568	571		10.1136/bmj.308.6928.568	http://dx.doi.org/10.1136/bmj.308.6928.568			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY714	8093148	Green Published			2022-12-28	WOS:A1994MY71400020
J	SMALL, PM; SHAFER, RW; HOPEWELL, PC; SINGH, SP; MURPHY, MJ; DESMOND, E; SIERRA, MF; SCHOOLNIK, GK				SMALL, PM; SHAFER, RW; HOPEWELL, PC; SINGH, SP; MURPHY, MJ; DESMOND, E; SIERRA, MF; SCHOOLNIK, GK			EXOGENOUS REINFECTION WITH MULTIDRUG-RESISTANT MYCOBACTERIUM-TUBERCULOSIS IN PATIENTS WITH ADVANCED HIV-INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EPIDEMIOLOGY; SEQUENCES; TOOL	Background. In the United States there have been recent outbreaks of multidrug-resistant tuberculosis. These outbreaks have primarily involved persons infected with the human immunodeficiency virus (HIV). Methods. We collected clinical information on 17 patients seen at a New York City hospital who had repeatedly positive cultures for Mycobacterium tuberculosis. Analysis of restriction-fragment-length polymorphisms (RFLPs) was performed on serial isolates of M. tuberculosis obtained from these patients. Results. Six patients had isolates that remained drug-susceptible, and the RFLP patterns of these isolates did not change over time. Eleven patients had isolates that became resistant to antimicrobial agents. The RFLP patterns of the isolates from six of these patients remained essentially unchanged (two strains showed one additional band) despite the development of drug resistance. In five other patients, however, the RFLP patterns of the isolates changed dramatically at the time that drug resistance was detected. The change in the RFLP pattern of the isolate from one patient appeared to be the result of contamination during processing in the laboratory. In the remaining four patients, all of whom had advanced HIV disease, the clinical and microbiologic evidence was consistent with the presence of active tuberculosis caused by a new strain of M. tuberculosis. Conclusions. Resistance to antituberculous drugs can develop not only in the strain that caused the initial disease, but also as a result of reinfection with a new strain of M. tuberculosis that is drug-resistant. Exogenous reinfection with multidrug-resistant M. tuberculosis can occur either during therapy for the original infection or after therapy has been completed.	STANFORD UNIV,DEPT MED,DIV INFECT DIS & GEOG MED,STANFORD,CA 94306; STANFORD UNIV,CTR AIDS RES,DEPT MED,STANFORD,CA 94306; SAN FRANCISCO GEN HOSP,MED SERV,SAN FRANCISCO,CA 94110; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143; SUNY HLTH SCI CTR,DEPT MED,DIV INFECT DIS,BROOKLYN,NY; SUNY HLTH SCI CTR,DEPT PATHOL,BROOKLYN,NY; CALIF DEPT HLTH SERV,MICROBIAL DIS LAB,BERKELEY,CA 94704	Stanford University; Stanford University; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; California Department of Health Care Services	SMALL, PM (corresponding author), STANFORD UNIV,HOWARD HUGHES MED INST,RM 251,BECKMAN CTR,STANFORD,CA 94306, USA.		Sierra, Maria/GYU-1134-2022		NIAID NIH HHS [AI27762-03, AI07089-11] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027762, T32AI007089] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DOOLEY SW, 1992, JAMA-J AM MED ASSOC, V267, P2632, DOI 10.1001/jama.267.19.2632; DOOLEY SW, 1992, ANN INTERN MED, V117, P257, DOI 10.7326/0003-4819-117-3-257; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; EISENACH KD, 1988, J CLIN MICROBIOL, V26, P2240, DOI 10.1128/JCM.26.11.2240-2245.1988; FISCHL MA, 1992, ANN INTERN MED, V117, P177, DOI 10.7326/0003-4819-117-3-177; GODFREYFAUSSETT P, 1992, BRIT MED J, V305, P221, DOI 10.1136/bmj.305.6847.221; HERMANS PWM, 1990, J CLIN MICROBIOL, V28, P2051, DOI 10.1128/JCM.28.9.2051-2058.1990; JONES WD, 1988, TUBERCLE, V69, P43, DOI 10.1016/0041-3879(88)90039-6; MAZUREK GH, 1991, J CLIN MICROBIOL, V29, P2030, DOI 10.1128/JCM.29.9.2030-2033.1991; NARDELL E, 1986, NEW ENGL J MED, V315, P1570, DOI 10.1056/NEJM198612183152502; OTAL E, 1992, J CLIN MICROBIOL, V29, P1252; PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191; REVES R, 1981, AM J EPIDEMIOL, V113, P423, DOI 10.1093/oxfordjournals.aje.a113110; RICH AR, 1944, PATHOGENESIS TUBERCU, P779; ROMEYN JA, 1970, AM REV RESPIR DIS, V101, P923; SHAFER RW, 1991, MEDICINE, V70, P384, DOI 10.1097/00005792-199111000-00004; SHAFER RW, 1991, AIDS, V5, P399, DOI 10.1097/00002030-199104000-00007; SNIDER DE, 1992, NEW ENGL J MED, V326, P703, DOI 10.1056/NEJM199203053261011; STEAD WW, 1967, AM REV RESPIR DIS, V95, P729; VANEMBDEN JDA, 1992, RES MICROBIOL, V143, P385, DOI 10.1016/0923-2508(92)90051-O; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406, DOI 10.1128/JCM.31.2.406-409.1993; VANSOOLINGEN D, 1991, J CLIN MICROBIOL, V29, P2578, DOI 10.1128/JCM.29.11.2578-2586.1991; 1991, MMWR MORB MORTAL WKL, V40, P585; 1991, MMWR MORB MORTAL WKL, V40, P129; 1992, MMWR MORB MORTAL WKL, V41, P61; 1992, MMWR MORB MORTAL WKL, V41, P5; 1990, NCCLS M24P NAT COMM; 1984, DEFINITIONS DRUG RES, P7; 1990, MMWR MORB MORTAL WKL, V39, P718	31	460	471	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 22	1993	328	16					1137	1144		10.1056/NEJM199304223281601	http://dx.doi.org/10.1056/NEJM199304223281601			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY447	8096066				2022-12-28	WOS:A1993KY44700001
J	LAITINEN, LA; LAITINEN, A; HAAHTELA, T; VILKKA, V; SPUR, BW; LEE, TH				LAITINEN, LA; LAITINEN, A; HAAHTELA, T; VILKKA, V; SPUR, BW; LEE, TH			LEUKOTRIENE-E(4) AND GRANULOCYTIC INFILTRATION INTO ASTHMATIC AIRWAYS	LANCET			English	Note							ANTAGONIST	Sulphidopeptide leukotrienes are potent bronchoconstrictors and increase bronchial hyperreactivity, one of the hallmarks of asthma. We have demonstrated that leukotriene LTE4, the most stable of the sulphidopeptide leukotrienes, elicited an increase in the numbers of eosinophils and neutrophils in the lamina propria of the airway mucosa 4 h after inhalation in 4 asthmatic subjects. The numbers of eosinophils were, on average, 10-fold greater than those of neutrophils. There was no significant change in numbers of lymphocytes, plasma cells, mast cells, or macrophages. Since LTE4 recruits granulocytes, the potential of antisulphidopeptide leukotriene drugs as anti-inflammatory and ''steroid-sparing'' agents should be tested.	GUYS HOSP,DEPT ALLERGY & ALLIED RESP DISORDERS,4TH FLOOR,HUNTS HOUSE,LONDON SE1 9RT,ENGLAND; UNIV HELSINKI,CENT HOSP,INST ANAT,DEPT PULM MED,SF-00100 HELSINKI 10,FINLAND; UNIV HELSINKI,CENT HOSP,INST ANAT,DEPT ALLERG DIS,SF-00100 HELSINKI 10,FINLAND; TIURU HOSP,HELSINKI,FINLAND	Guy's & St Thomas' NHS Foundation Trust; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital			Lee, Tak/AAA-9526-2020	Lee, Tak/0000-0002-7554-4059; Spur, Bernd/0000-0002-7581-4741				BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; CHAN CC, 1990, EUR J PHARMACOL, V191, P273; CLOUD ML, 1989, AM REV RESPIR DIS, V140, P1336, DOI 10.1164/ajrccm/140.5.1336; FOSTER A, IN PRESS INT ARCH AL; GADDY J, 1990, Journal of Allergy and Clinical Immunology, V85, P197; ISRAEL E, 1992, J ALLERGY CLIN IMMUN, V89, P236; LAITINEN LA, 1992, J ALLERGY CLIN IMMUN, V90, P32, DOI 10.1016/S0091-6749(06)80008-4; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; OHICKEY SP, 1991, AM REV RESPIR DIS, V144, P1053, DOI 10.1164/ajrccm/144.5.1053; 1992, NIH923091 NAT HEART	10	440	445	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 17	1993	341	8851					989	990		10.1016/0140-6736(93)91073-U	http://dx.doi.org/10.1016/0140-6736(93)91073-U			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY368	8096945				2022-12-28	WOS:A1993KY36800005
J	VAARALA, O; ALFTHAN, G; JAUHIAINEN, M; LEIRISALOREPO, M; AHO, K; PALOSUO, T				VAARALA, O; ALFTHAN, G; JAUHIAINEN, M; LEIRISALOREPO, M; AHO, K; PALOSUO, T			CROSS-REACTION BETWEEN ANTIBODIES TO OXIDIZED LOW-DENSITY-LIPOPROTEIN AND TO CARDIOLIPIN IN SYSTEMIC LUPUS-ERYTHEMATOSUS	LANCET			English	Note							OXIDATIVE MODIFICATION	Serum lipoproteins contain phospholipids and modified low-density lipoprotein (LDL) may thus act as a target for antiphospholipid antibodies. Raised concentrations of IgG antibodies against oxidised LDL were found in 47 of 61 (80%) patients with systemic lupus erythematosus (SLE). 46% of patients also had raised concentrations of IgG anticardiolipin antibodies. Binding of anticardiolipin antibodies to solid-phase cardiolipin was inhibited by oxidised LDL but not by native LDL in 16 of 21 sera from SLE patients. These observations suggest crossreactivity between antiphospholipid antibodies, which are closely associated with thrombosis in SLE, and antibodies to oxidised LDL, thus providing a possible link between thrombotic and atherosclerotic complications in SLE.	NATL PUBL HLTH INST,DEPT IMMUNOBIOL,MANNERHEIMINTIE 166,SF-00300 HELSINKI,FINLAND; NATL PUBL HLTH INST,DEPT NUTR,SF-00300 HELSINKI,FINLAND; NATL PUBL HLTH INST,DEPT BIOCHEM,SF-00300 HELSINKI,FINLAND; UNIV HELSINKI,CENT HOSP,DEPT MED 2,SF-00100 HELSINKI 10,FINLAND	Finland National Institute for Health & Welfare; Finland National Institute for Health & Welfare; Finland National Institute for Health & Welfare; University of Helsinki; Helsinki University Central Hospital								HARRIS EN, 1987, CLIN EXP IMMUNOL, V68, P215; MCNEIL HP, 1990, P NATL ACAD SCI USA, V87, P4120, DOI 10.1073/pnas.87.11.4120; MENEIL HP, 1991, ADV IMMUNOL, V49, P193; MORTON KE, 1986, LANCET, V2, P1353; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; PALINSKI W, 1990, ARTERIOSCLEROSIS, V10, P325, DOI 10.1161/01.ATV.10.3.325; PARUMS DV, 1990, ARCH PATHOL LAB MED, V114, P383; SALONEN JT, 1992, LANCET, V339, P883, DOI 10.1016/0140-6736(92)90926-T; VAARALA O, 1991, J AUTOIMMUN, V8, P419; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499	10	336	346	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 10	1993	341	8850					923	925		10.1016/0140-6736(93)91213-6	http://dx.doi.org/10.1016/0140-6736(93)91213-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW981	8096266				2022-12-28	WOS:A1993KW98100005
J	PIATAK, M; SAAG, MS; YANG, LC; CLARK, SJ; KAPPES, JC; LUK, KC; HAHN, BH; SHAW, GM; LIFSON, JD				PIATAK, M; SAAG, MS; YANG, LC; CLARK, SJ; KAPPES, JC; LUK, KC; HAHN, BH; SHAW, GM; LIFSON, JD			HIGH-LEVELS OF HIV-1 IN PLASMA DURING ALL STAGES OF INFECTION DETERMINED BY COMPETITIVE PCR	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; POLYMERASE CHAIN-REACTION; T-CELL RECEPTOR; HTLV-III; LEUKEMIA-VIRUS; SAN-FRANCISCO; MESSENGER-RNA; AIDS; DISEASE; QUANTITATION	Quantitative competitive polymerase chain reaction (QC-PCR) methods were used to quantify virion-associated human immunodeficiency virus type-1 (HIV-1) RNA in plasma from 66 patients with Centers for Disease Control stage I to IVC1 infection. HIV-1 RNA, ranging from 100 to nearly 22,000,000 copies per milliliter of plasma (corresponding to 50 to 11,000,000 virions per milliliter), was readily quantified in all subjects, was significantly associated with disease stage and CD4+ T cell counts, and decreased by as much as 235-fold with resolution of primary infection or institution of antiretroviral therapy. Plasma virus levels determined by QC-PCR correlated with, but exceeded by an average of 60,000-fold, virus titers measured by endpoint dilution culture. Quantitation of HIV-1 in plasma by QC-PCR may be useful in assessing the efficacy of antiretroviral agents, especially in early stage disease when conventional viral markers are often negative.	GENELABS TECHNOL INC,DIV HIV & EXPLORATORY RES,REDWOOD CITY,CA 94063; UNIV ALABAMA,DEPT MED,DIV HEMATOL ONCOL,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT MED,DIV INFECT DIS,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham				Hahn, Beatrice/0000-0002-9400-9887	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI027290, U01AI025922, U01AI032775] Funding Source: NIH RePORTER; NIAID NIH HHS [AI27290, AI25922, AI32775] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMADORI A, 1990, AIDS RES HUM RETROV, V6, P581, DOI 10.1089/aid.1990.6.581; AMEISEN JC, 1991, IMMUNOL TODAY, V12, P102; ANDERSON RM, 1988, J ACQ IMMUN DEF SYND, V1, P241; AOKISEI S, 1992, AIDS RES HUM RETROV, V8, P1263, DOI 10.1089/aid.1992.8.1263; ARTHUR LO, 1992, SCIENCE, V258, P1935, DOI 10.1126/science.1470916; AZIZ DC, 1989, NATURE, V338, P505, DOI 10.1038/338505a0; BACCHETTI P, 1989, NATURE, V338, P251, DOI 10.1038/338251a0; BAGNARELLI P, 1992, J VIROL, V66, P7328, DOI 10.1128/JVI.66.12.7328-7335.1992; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BECKERANDRE M, 1989, NUCLEIC ACIDS RES, V17, P9437, DOI 10.1093/nar/17.22.9437; BOURINBAIAR AS, 1991, NATURE, V349, P111, DOI 10.1038/349111b0; CHATTOPADHYAY SK, 1989, P NATL ACAD SCI USA, V86, P3862, DOI 10.1073/pnas.86.10.3862; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; CLERICI M, 1991, J INFECT DIS, V164, P178, DOI 10.1093/infdis/164.1.178; CLERICI M, 1992, J INFECT DIS, V165, P1012, DOI 10.1093/infdis/165.6.1012; COHEN J, 1992, SCIENCE, V258, P388, DOI 10.1126/science.1357750; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; DICKOVER RE, 1990, J CLIN MICROBIOL, V28, P2130, DOI 10.1128/JCM.28.9.2130-2133.1990; FAUCI AS, 1991, ANN INTERN MED, V114, P678, DOI 10.7326/0003-4819-114-8-678; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; Gilliland G., 1990, PCR PROTOCOLS GUIDE, P60; GRAZIOSI C, 1992, CLIN RES, V40, P333; GROUX H, 1992, J EXP MED, V175, P331, DOI 10.1084/jem.175.2.331; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HOLODNIY M, 1991, J CLIN INVEST, V88, P1755, DOI 10.1172/JCI115494; HOLODNIY M, 1992, BIOTECHNIQUES, V12, P36; IMBERTI L, 1991, SCIENCE, V254, P860, DOI 10.1126/science.1948066; JURRIAANS S, 1992, AIDS, V6, P635, DOI 10.1097/00002030-199207000-00004; LANE HC, 1985, NEW ENGL J MED, V313, P79, DOI 10.1056/NEJM198507113130204; LAURENTCRAWFORD AG, 1991, VIROLOGY, V185, P829, DOI 10.1016/0042-6822(91)90554-O; LAYNE SP, 1992, VIROLOGY, V189, P695, DOI 10.1016/0042-6822(92)90593-E; LEVY JA, 1984, SCIENCE, V225, P840, DOI 10.1126/science.6206563; LI YX, 1992, J VIROL, V66, P6587, DOI 10.1128/JVI.66.11.6587-6600.1992; LI YX, 1991, J VIROL, V65, P3973, DOI 10.1128/JVI.65.8.3973-3985.1991; LINETTE GP, 1988, SCIENCE, V241, P573, DOI 10.1126/science.2899908; MANN DL, 1987, J IMMUNOL, V138, P2640; MARGOLICK JB, 1987, J IMMUNOL, V138, P1719; MCKEATING JA, 1991, NATURE, V349, P660, DOI 10.1038/349660b0; MENZO S, 1992, J CLIN MICROBIOL, V30, P1752, DOI 10.1128/JCM.30.7.1752-1757.1992; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; MEYERHANS A, 1989, CELL, V58, P901, DOI 10.1016/0092-8674(89)90942-2; MICHAEL NL, 1992, J VIROL, V66, P310, DOI 10.1128/JVI.66.1.310-316.1992; MITTLER RS, 1989, SCIENCE, V245, P1380, DOI 10.1126/science.2571187; MOORE JP, 1990, SCIENCE, V250, P1139, DOI 10.1126/science.2251501; MUNOZ A, 1989, AM J EPIDEMIOL, V130, P530, DOI 10.1093/oxfordjournals.aje.a115367; MURAKAWA GJ, 1988, DNA CELL BIOL, V239, P295; MYERS G, 1991, HUMAN RETROVIRUSES A; NARA PL, 1991, FASEB J, V5, P2437, DOI 10.1096/fasebj.5.10.1712328; NEWELL MK, 1990, NATURE, V347, P286, DOI 10.1038/347286a0; NOONAN KE, 1990, P NATL ACAD SCI USA, V87, P7160, DOI 10.1073/pnas.87.18.7160; OTTMANN M, 1991, J VIROL METHODS, V31, P273, DOI 10.1016/0166-0934(91)90165-V; OVERBAUGH J, 1988, SCIENCE, V239, P906, DOI 10.1126/science.2893454; PANTALEO G, 1991, P NATL ACAD SCI USA, V88, P9838, DOI 10.1073/pnas.88.21.9838; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; PIATAK M, 1993, BIOTECHNIQUES, V14, P70; PIATAK M, UNPUB; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; ROBERTGUROFF M, 1985, NATURE, V316, P72, DOI 10.1038/316072a0; SAAG MS, 1991, J INFECT DIS, V164, P72, DOI 10.1093/infdis/164.1.72; SCADDEN DT, 1992, J INFECT DIS, V165, P1119, DOI 10.1093/infdis/165.6.1119; SCHNITTMAN SM, 1991, AIDS RES HUM RETROV, V7, P361, DOI 10.1089/aid.1991.7.361; SHALABY MR, 1987, CELL IMMUNOL, V110, P140, DOI 10.1016/0008-8749(87)90108-0; STEIN DS, 1992, J INFECT DIS, V165, P352, DOI 10.1093/infdis/165.2.352; STIEGER M, 1991, J VIROL METHODS, V34, P149, DOI 10.1016/0166-0934(91)90095-H; TERAI C, 1991, J CLIN INVEST, V87, P1710, DOI 10.1172/JCI115188; TERSMETTE M, 1989, J VIROL, V63, P2118, DOI 10.1128/JVI.63.5.2118-2125.1989; TERSMETTE M, 1989, LANCET, V1, P983; WEISS RA, 1985, NATURE, V316, P69, DOI 10.1038/316069a0; 1986, MORBID MORTAL WEEKLY, V35, P334	71	1144	1189	0	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 19	1993	259	5102					1749	1754		10.1126/science.8096089	http://dx.doi.org/10.1126/science.8096089			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KT810	8096089				2022-12-28	WOS:A1993KT81000036
J	HARDINGPINK, D				HARDINGPINK, D			OPIOID TOXICITY - METHADONE - ONE PERSONS MAINTENANCE DOSE IS ANOTHERS POISON	LANCET			English	Editorial Material											HARDINGPINK, D (corresponding author), DELEGAT INT COMM RED CROSS,PRETORIA,SOUTH AFRICA.							BADEN MM, 1970, INT J ADDICT, V5, P489, DOI 10.3109/10826087009057014; BIETER RN, 1948, ANN NY ACAD SCI, V51, P137, DOI 10.1111/j.1749-6632.1948.tb27258.x; DOLE VP, 1968, J AMER MED ASSOC, V206, P2708, DOI 10.1001/jama.206.12.2708; DRUMMER OH, 1992, AM J FOREN MED PATH, V13, P346, DOI 10.1097/00000433-199212000-00017; Greene M H, 1974, J Forensic Sci, V19, P575; HARDINGPINK D, 1991, J TOXICOL CLIN EXPER, V11, P31; MOLYNEUX E, 1991, BRIT MED J, V303, P922, DOI 10.1136/bmj.303.6807.922-a; NAEVE W, 1955, ARCH TOXICOL, V73, P96; ORDING J, 1988, METHADONE MANAGEMENT, P100; ZIMMEY EL, 1981, J FORENSIC SCI, V26, P462; 1951, LANCET, V2, P156	11	42	42	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 13	1993	341	8846					665	666		10.1016/0140-6736(93)90427-I	http://dx.doi.org/10.1016/0140-6736(93)90427-I			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KR613	8095576				2022-12-28	WOS:A1993KR61300011
J	GOLDHABER, SZ				GOLDHABER, SZ			CORONARY-DISEASE - ANGIOPLASTY OR CORONARY-BYPASS GRAFT	LANCET			English	Editorial Material											GOLDHABER, SZ (corresponding author), BRIGHAM & WOMENS HOSP,DIV CARDIOVASC,BOSTON,MA 02115, USA.							HILBORNE LH, 1993, JAMA-J AM MED ASSOC, V269, P761, DOI 10.1001/jama.269.6.761; LEAPE LL, 1993, JAMA-J AM MED ASSOC, V269, P753, DOI 10.1001/jama.269.6.753; TOWNES BD, 1989, J THORAC CARDIOV SUR, V98, P774; 1992, CIRCULATION, V86, P121	4	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 6	1993	341	8845					599	600		10.1016/0140-6736(93)90357-M	http://dx.doi.org/10.1016/0140-6736(93)90357-M			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KQ234	8094834				2022-12-28	WOS:A1993KQ23400009
J	MACFARLANE, JK; RYALL, RDH; HEALD, RJ				MACFARLANE, JK; RYALL, RDH; HEALD, RJ			MESORECTAL EXCISION FOR RECTAL-CANCER	LANCET			English	Article							ADJUVANT THERAPY; CARCINOMA; RADIOTHERAPY; RISK	Concern about world wide local recurrence rates for rectal cancer of 20-45%, together with anxiety at the recent proliferation of adjuvant therapies, led us to review the efficacy of total mesorectal excision (TME) with which no adjuvant therapy had been combined. Precise, sharp dissection is undertaken around the integral mesentery of the hind gut, which envelopes the entire mid rectum. This procedure adds to operative time and complications but has been' claimed to eliminate virtually all locally recurrent disease after ''curative'' surgery. Independent analysis (J. K. M.) of prospective follow-up data extended over a 13-year interval (1978-91; mean 7.5 years). The actuarial local recurrence rate after curative anterior resection at 5 years is 4% (95% CI 0-7.5%) and the overall recurrence rate is 18% (10-25%). 10-year figures are 4% (0-11%) and 19% (7-32%). In view of the high-risk classification used for the North Central Cancer Treatment G roup (NCCTG), which has led to a trend to chemoradiotherapy, a similar group of high-risk Basingstoke cases was constructed for comparison purposes. This group included 135 consecutive Dukes' B (B2) and Dukes' C cancer operations, both anterior resection and abdominal-perineal excision, for tumours below 12 cm from the anal verge. Results from TM E alone are substantially superior to the best reported (NCCTG) from conventional surgery plus radiotherapy or combination chemoradiotherapy: 5% local recurrence at 5 years compared with 25% and 13.5%, respectively; and 22% overall recurrence compared with 62.7% and 41.5%, respectively (Dukes' B cases [B2], 15%; Dukes' C cases, 32%). Meticulous TME, which encompasses the whole field of tumour spread, can improve cure rates and reduce the variability of outcomes between surgeons. Far more genuine ''cures'' of rectal cancer are possible by surgery alone than have generally been believed or are currently accepted. Better surgical results are an essential background for the more selective use of adjuvant therapy in the future.	BASINGSTOKE DIST GEN HOSP, COLORECTAL RES UNIT, ALDERMASTON RD, BASINGSTOKE RG24 9NA, HANTS, ENGLAND; WESSEX RADIOTHERAPY CTR, SOUTHAMPTON, ENGLAND; UNIV BRITISH COLUMBIA, VANCOUVER V6T 1W5, BC, CANADA	University of British Columbia								[Anonymous], 1985, NEW ENGL J MED, V312, P1465; FISHER B, 1988, JNCI-J NATL CANCER I, V80, P21, DOI 10.1093/jnci/80.1.21; GALANDIUK S, 1992, SURG GYNECOL OBSTET, V174, P27; GERARD A, 1988, ANN SURG, V208, P606, DOI 10.1097/00000658-198811000-00011; HALL WH, 1990, JAMA-J AM MED ASSOC, V264, P1444; HEALD RJ, 1986, LANCET, V1, P1479; HEALD RJ, 1988, J ROY SOC MED, V81, P503, DOI 10.1177/014107688808100904; HEALD RJ, 1982, BRIT J SURG, V69, P613, DOI 10.1002/bjs.1800691019; ISBISTER WH, 1990, AUST NZ J SURG, V60, P243, DOI 10.1111/j.1445-2197.1990.tb07361.x; IZAR F, 1992, WORLD J SURG, V16, P106, DOI 10.1007/BF02067122; KARANJIA ND, 1991, BRIT J SURG, V78, P196, DOI 10.1002/bjs.1800780221; KROOK JE, 1991, NEW ENGL J MED, V324, P709, DOI 10.1056/NEJM199103143241101; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; NILSSON E, 1992, ONKOLOGISK FORUM NOV; PAHLMAN L, 1985, BRIT J SURG, V72, P961, DOI 10.1002/bjs.1800721209; Silen W, 1983, YB SURGERY, P368	16	1293	1343	1	21	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 20	1993	341	8843					457	460		10.1016/0140-6736(93)90207-W	http://dx.doi.org/10.1016/0140-6736(93)90207-W			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN137	8094488				2022-12-28	WOS:A1993KN13700004
J	BAKER, SR; BURNAND, KG; SOMMERVILLE, KM; THOMAS, ML; WILSON, NM; BROWSE, NL				BAKER, SR; BURNAND, KG; SOMMERVILLE, KM; THOMAS, ML; WILSON, NM; BROWSE, NL			COMPARISON OF VENOUS REFLUX ASSESSED BY DUPLEX SCANNING AND DESCENDING PHLEBOGRAPHY IN CHRONIC VENOUS DISEASE	LANCET			English	Article							VENOGRAPHY; INCOMPETENCE	Venous reflux was assessed by duplex scanning and descending phlebography in 98 limbs of 52 patients. There was moderately good agreement for deep vein reflux elicited by a standardised Valsalva manoeuvre, classified by a modified Kistner grading (0 to IV). The same grade was found in 58 limbs, with a difference of one grade in 27 limbs, and more than one grade in 13. Descending phlebography underestimated reflux in the lower leg compared with duplex scanning. The presence of reflux found on duplex scan correlated with the half-volume refilling time on a foot-volume plethysmogram with a below-knee tourniquet. There was no correlation between descending phlebography and the half-refilling time. Ascending phlebography showed post-thrombotic changes in 23 limbs. The duplex scan confirmed severe reflux (grades III and IV) in 14 of these 23 limbs, and demonstrated isolated reflux below normal valves in 4 other limbs. Severe reflux was seen on the descending phlebogram in only 10 of the 23 limbs with post-thrombotic changes. Duplex scanning may be a better method for detecting reflux than descending phlebography and is more acceptable to the patient. Ascending phlebography remains essential to display anatomical abnormalities found in some post-thrombotic limbs that are not associated with reflux.	ST THOMAS HOSP, DEPT SURG, LONDON SE1 7EH, ENGLAND; ST THOMAS HOSP, DEPT RADIOL, LONDON SE1 7EH, ENGLAND	Guy's & St Thomas' NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust			Baker, Spencer/HHC-3931-2022					BROWSE NL, 1988, CALF PUMP FAILURE SY, P306; Edwards EA, 1937, SURG GYNECOL OBSTET, V65, P310; Edwards JE, 1940, AM HEART J, V19, P338, DOI 10.1016/S0002-8703(40)90007-2; Hall C, 1991, PRACTICAL STAT MED R, P404; HANRAHAN LM, 1991, J VASC SURG, V13, P805; HERMAN RJ, 1980, RADIOLOGY, V137, P63, DOI 10.1148/radiology.137.1.7422863; HOARE MC, 1984, AUST NZ J SURG, V54, P49, DOI 10.1111/j.1445-2197.1984.tb06684.x; Hojensgard JC, 1953, ACTA PHYSL SCAND, V27, P49; KISTNER RL, 1986, J VASC SURG, V4, P464, DOI 10.1067/mva.1986.avs0040464; KISTNER RL, 1978, VENOUS PROBLEMS, P493; LAWRENCE D, 1979, TECHNIQUES ANGIOLOGY; NICOLAIDES AN, 1990, ACTA CHIR SCAND, P175; POLLACK AA, 1949, J CLIN INVEST, V28, P559, DOI 10.1172/JCI102105; THOMAS ML, 1982, PHLEBOGRAPHY LOWER L; TYSON MD, 1945, SURGERY, V18, P669; VANBEMMELEN PS, 1989, J VASC SURG, V10, P425; VASDEKIS SN, 1989, J VASC SURG, V10, P670, DOI 10.1067/mva.1989.16372; WHITEHEAD S, 1983, THESIS U CAMBRIDGE	18	104	110	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 13	1993	341	8842					400	403		10.1016/0140-6736(93)92989-7	http://dx.doi.org/10.1016/0140-6736(93)92989-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM416	8094169				2022-12-28	WOS:A1993KM41600004
J	OHOY, KL; TSILFIDIS, C; MAHADEVAN, MS; NEVILLE, CE; BARCELO, J; HUNTER, AGW; KORNELUK, RG				OHOY, KL; TSILFIDIS, C; MAHADEVAN, MS; NEVILLE, CE; BARCELO, J; HUNTER, AGW; KORNELUK, RG			REDUCTION IN SIZE OF THE MYOTONIC-DYSTROPHY TRINUCLEOTIDE REPEAT MUTATION DURING TRANSMISSION	SCIENCE			English	Article							DNA; RECOMBINATION; CHROMOSOME-19; CONVERSION; EVOLUTION; REGION; GENES; LOCUS	Myotonic dystrophy (DM) is an autosomal-dominant disorder that affects 1 in 8000 individuals. Amplification of an unstable trinucleotide CTG repeat, located within the 3' untranslated region of a gene, correlates with a more severe DM phenotype. In three cases, the number of CTG repeats was reduced during the transmission of the DM allele; in one of these cases, the number was reduced to within the normal range and correlated at least with a delay in the onset of clinical signs of DM. Haplotype data of six polymorphic markers in the DM gene region indicate that, in this latter case, two stretches of the affected chromosome had been exchanged with that region of the wild-type chromosome.	UNIV OTTAWA,DEPT MICROBIOL & IMMUNOL,OTTAWA K1H 8M5,ONTARIO,CANADA; CHILDRENS HOSP EASTERN ONTARIO,DIV GENET,OTTAWA K1H 8L1,ONTARIO,CANADA	University of Ottawa; University of Ottawa; Children's Hospital of Eastern Ontario								BISHOP DK, 1986, MOL CELL BIOL, V6, P3401, DOI 10.1128/MCB.6.10.3401; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; FU YH, 1991, CELL, V67, P1; Harper P.S., 1989, MYOTONIC DYSTROPHY; HASTINGS PJ, 1988, GENETIC RECOMBINATIO, P397; HOWELER CJ, 1989, BRAIN, V112, P779, DOI 10.1093/brain/112.3.779; HUNTER A, 1992, J MED GENET, V29, P774, DOI 10.1136/jmg.29.11.774; HUNTER AGW, 1993, AM J MED GENET, V45, P401, DOI 10.1002/ajmg.1320450330; JOHNSON K, 1990, AM J HUM GENET, V46, P1073; KORNELUK RG, 1989, GENOMICS, V5, P596, DOI 10.1016/0888-7543(89)90028-1; MAEDA N, 1986, ANNU REV GENET, V20, P81; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; MICHELSON AM, 1983, J BIOL CHEM, V258, P5245; NEVILLE CE, UNPUB; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; ORRWEAVER TL, 1985, MICROBIOL REV, V49, P33, DOI 10.1128/MMBR.49.1.33-58.1985; SHELBOURNE P, 1992, HUM MOL GENET, V1, P467, DOI 10.1093/hmg/1.7.467; SHUTLER G, 1992, GENOMICS, V13, P518, DOI 10.1016/0888-7543(92)90119-D; STOECKERT CJ, 1984, NUCLEIC ACIDS RES, V12, P4469, DOI 10.1093/nar/12.11.4469; SYMINGTON LS, 1988, MOL CELL BIOL, V8, P595, DOI 10.1128/MCB.8.2.595; TSILFIDIS C, 1992, NAT GENET, V1, P192, DOI 10.1038/ng0692-192; TSILFIDIS C, UNPUB; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179	25	108	108	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 5	1993	259	5096					809	812		10.1126/science.8094260	http://dx.doi.org/10.1126/science.8094260			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL110	8094260				2022-12-28	WOS:A1993KL11000032
J	BROOKS, PM				BROOKS, PM			CLINICAL MANAGEMENT OF RHEUMATOID-ARTHRITIS	LANCET			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ANTI-INFLAMMATORY DRUGS; RARE ADVERSE REACTIONS; CONTROLLED TRIAL; THERAPY; PROGRESSION; DIET				BROOKS, PM (corresponding author), UNIV NEW S WALES,ST VINCENTS HOSP,DEPT MED,SYDNEY,NSW,AUSTRALIA.							AHERN MJ, 1991, ANN RHEUM DIS, V50, P477, DOI 10.1136/ard.50.7.477; BOERS M, 1991, J RHEUMATOL, V18, P316; BROOK A, 1977, ANN RHEUM DIS, V36, P71, DOI 10.1136/ard.36.1.71; BROOKS P, 1992, Current Opinion in Rheumatology, V4, P309, DOI 10.1097/00002281-199206000-00004; BROOKS PM, 1991, NEW ENGL J MED, V324, P1716; BROOKS PM, 1992, RHEUMATOL REV, V1, P137; BUCHANAN HM, 1991, BRIT J RHEUMATOL, V30, P125; BURMESTER GR, 1992, BAILLIERE CLIN RHEUM, V6, P415, DOI 10.1016/S0950-3579(05)80183-9; CAPELL HA, 1992, ANN RHEUM DIS, V51, P424, DOI 10.1136/ard.51.3.424; CHAMPION GD, 1990, BAILLIERE CLIN RHEUM, V4, P491, DOI 10.1016/S0950-3579(05)80005-6; CHAMPION GD, 1988, MED J AUSTRALIA, V149, P203, DOI 10.5694/j.1326-5377.1988.tb120573.x; CLELAND LG, 1988, J RHEUMATOL, V15, P1471; CLIVE DM, 1984, NEW ENGL J MED, V310, P563, DOI 10.1056/NEJM198403013100905; CORKILL MM, 1990, BRIT J RHEUMATOL, V29, P274; DAY RO, 1988, BAILLIERE CLIN RHEUM, V2, P363, DOI 10.1016/S0950-3579(88)80019-0; DAYER JM, 1992, BAILLIERE CLIN RHEUM, V6, P485, DOI 10.1016/S0950-3579(05)80186-4; DONOVAN S, 1990, BRIT J RHEUMATOL, V29, P201; EPSTEIN WV, 1991, ANN INTERN MED, V114, P437, DOI 10.7326/0003-4819-114-6-437; FELSON DT, 1990, ARTHRITIS RHEUM, V33, P1449, DOI 10.1002/art.1780331001; FRIES JF, 1991, J RHEUMATOL, V18, P6; FRIES JF, 1990, J RHEUMATOL, V17, P12; HOWARD JM, 1990, BAILLIERE CLIN RHEUM, V4, P269, DOI 10.1016/S0950-3579(05)80021-4; HUSKISSON EC, 1976, BRIT MED J, V1, P1048, DOI 10.1136/bmj.1.6017.1048; KINGSLEY G, 1992, BAILLIERE CLIN RHEUM, V6, P435, DOI 10.1016/S0950-3579(05)80184-0; KJELDSENKRAGH J, 1991, LANCET, V338, P899, DOI 10.1016/0140-6736(91)91770-U; LANGMAN MJS, 1989, GASTROENTEROLOGY, V96, P640, DOI 10.1016/S0016-5085(89)80060-5; LINDROTH Y, 1989, BRIT J RHEUMATOL, V28, P7; MARKENSON JA, 1991, SEMIN ARTHRITIS R S1, V212, P4; MATTESON EL, 1991, J RHEUMATOL, V18, P809; OBRIEN WM, 1985, J RHEUMATOL, V12, P562; OBRIEN WM, 1985, J RHEUMATOL, V12, P13; OBRIEN WM, 1985, J RHEUMATOL, V12, P347; OBRIEN WM, 1985, J RHEUMATOL, V12, P785; PIPER JM, 1991, ANN INTERN MED, V114, P735, DOI 10.7326/0003-4819-114-9-735; SCOTT DL, 1992, BAILLIERE CLIN RHEUM, V6, P1, DOI 10.1016/S0950-3579(05)80336-X; SPECTOR TD, 1990, RHEUM DIS CLIN N AM, V16, P513; TETT S, 1990, BAILLIERE CLIN RHEUM, V4, P467, DOI 10.1016/S0950-3579(05)80004-4; TONKIN AL, 1988, BAILLIERE CLIN RHEUM, V2, P455, DOI 10.1016/S0950-3579(88)80022-0; VANDENBROUCKE JP, 1984, J RHEUMATOL, V11, P158; VANDERHEIJDE DM, 1989, LANCET, V1, P1036, DOI 10.1016/S0140-6736(89)92442-2; VEYS EM, 1992, BAILLIERE CLIN RHEUM, V6, P455, DOI 10.1016/S0950-3579(05)80185-2; WOLFE F, 1990, J RHEUMATOL, V17, P994; WOLFE F, 1990, J RHEUMATOL, V17, P24	43	39	41	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 30	1993	341	8840					286	290		10.1016/0140-6736(93)92628-7	http://dx.doi.org/10.1016/0140-6736(93)92628-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK245	8093928				2022-12-28	WOS:A1993KK24500016
J	WEBB, AT; REAVELEY, DA; ODONNELL, M; OCONNOR, B; SEED, M; BROWN, EA				WEBB, AT; REAVELEY, DA; ODONNELL, M; OCONNOR, B; SEED, M; BROWN, EA			DOES CYCLOSPORINE INCREASE LIPOPROTEIN(A) CONCENTRATIONS IN RENAL-TRANSPLANT RECIPIENTS	LANCET			English	Article							PLASMA; CHOLESTEROL; ASSOCIATION; PHENOTYPES	Cyclosporin, the immunosuppressant of choice for renal transplant recipients, has been implicated as the cause of abnormalities in serum lipid concentrations in these patients. We have measured serum lipoprotein(a) concentrations and analysed the distribution of apoprotein(a) isoforms in 90 renal transplant recipients receiving cyclosporin and prednisolone (with or without azathioprine), 59 patients receiving azathioprine and prednisolone alone, and 146 non-hyperlipidaemic controls. Cyclosporin-treated patients had significantly higher lipoprotein(a) concentrations (median 170 [interquartile range 55-382] mg/L) than those receiving azathioprine and prednisolone (64 [10-204] mg/L, p = 0.001 ) or the healthy controls (94 [18-280] mg/L, p = 0.008). The difference between the azathioprine and prednisolone group and the controls was not significant. Although the time since transplantation was significantly shorter for the cyclosporin-treated group, there was no correlation between lipoprotein(a) concentration and time since transplantation (r = -0.13, p = 0.18). Apoprotein(a) phenotyping showed no significant differences in the distribution of apoprotein(a) isoforms between the treatment groups or between patient and control groups. Lipoprotein(a) concentrations are higher in renal transplant recipients treated with cyclosporin than in those maintained on azathioprine and prednisolone. The mechanisms underlying this abnormality remain to be elucidated.	CHARING CROSS HOSP,CHARING CROSS & WESTMINSTER MED SCH,DEPT CHEM PATHOL,LONDON W6 8RF,ENGLAND	Imperial College London	WEBB, AT (corresponding author), CHARING CROSS HOSP,CHARING CROSS & WESTMINSTER MED SCH,DEPT MED,FULHAM PALACE RD,LONDON W6 8RF,ENGLAND.							ARMSTRONG VW, 1986, ATHEROSCLEROSIS, V62, P249, DOI 10.1016/0021-9150(86)90099-7; BALLANTYNE CM, 1989, JAMA-J AM MED ASSOC, V262, P53, DOI 10.1001/jama.262.1.53; BLACK IW, 1992, CLIN CHEM, V38, P353; BOERWINKLE E, 1989, HUM GENET, V82, P73, DOI 10.1007/BF00288277; CANAFAX DM, 1986, TRANSPLANT P, V18, P192; FARMER JA, 1991, J AM COLL CARDIOL, V18, P926, DOI 10.1016/0735-1097(91)90748-X; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GURECKI J, 1985, TRANSPLANT P, V17, P1997; HEIMANN P, 1991, AM J NEPHROL, V11, P470, DOI 10.1159/000168361; KANDOUSSI A, 1992, KIDNEY INT, V42, P424, DOI 10.1038/ki.1992.304; KASISKE BL, 1991, AM J KIDNEY DIS, V17, P700, DOI 10.1016/S0272-6386(12)80355-6; KRAFT HG, 1989, J CLIN INVEST, V83, P137, DOI 10.1172/JCI113849; MILES LA, 1989, NATURE, V339, P301, DOI 10.1038/339301a0; Odlind B, 1988, Contrib Nephrol, V68, P149; PRINCEN HMG, 1987, HEPATOLOGY, V7, P1109; RAINE AEG, 1988, NEPHROL DIAL TRANSPL, V3, P458, DOI 10.1093/oxfordjournals.ndt.a091698; RATH M, 1989, ARTERIOSCLEROSIS, V9, P579, DOI 10.1161/01.ATV.9.5.579; SANDKAMP M, 1990, CLIN CHEM, V36, P20; SCHORN TF, 1991, TRANSPLANT INT, V4, P92, DOI 10.1111/j.1432-2277.1991.tb01955.x; Siegel S., 1956, NONPARAMETRIC STAT B; THOMAS ME, 1992, NEPHROL DIAL TRANSPL, V7, P597, DOI 10.1093/ndt/7.7.597; WEBB AT, 1992, NEPHROL DIAL TRANSPL, V7, P636	22	85	86	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 30	1993	341	8840					268	270		10.1016/0140-6736(93)92616-2	http://dx.doi.org/10.1016/0140-6736(93)92616-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK245	8093917				2022-12-28	WOS:A1993KK24500004
J	SAUDOU, F; AMARA, DA; DIERICH, A; LEMEUR, M; RAMBOZ, S; SEGU, L; BUHOT, MC; HEN, R				SAUDOU, F; AMARA, DA; DIERICH, A; LEMEUR, M; RAMBOZ, S; SEGU, L; BUHOT, MC; HEN, R			ENHANCED AGGRESSIVE-BEHAVIOR IN MICE LACKING 5-HT1B RECEPTOR	SCIENCE			English	Article							SEROTONIN; AGONIST; RATS; LOCALIZATION; EXPRESSION; RU-24969	The neuromodulator serotonin (5-hydroxytryptamine, 5-HT) has been associated with mood disorders such as depression, anxiety, and impulsive violence. To define the contribution of 5-HT receptor subtypes to behavior, mutant mice lacking the 5-HT1B receptor were generated by homologous recombination. These mice did not exhibit any obvious developmental or behavioral defects. However, the hyperlocomotor effect of the 5-HT1A/(1B) agonist RU24969 was absent in mutant mice, indicating that this effect is mediated by 5-HT1B receptors. Moreover, when confronted with an intruder, mutant mice attacked the intruder faster and more intensely than did wild-type mice, suggesting the participation of 5-HT1B receptors in aggressive behavior.	CNRS, RECH NEUROSCI GRP, EQUIPE MEMOIRE & RECEPTEURS, F-13402 MARSEILLE 20, FRANCE	Centre National de la Recherche Scientifique (CNRS)	SAUDOU, F (corresponding author), FAC MED STRASBOURG, CNRS,GENET MOLEC EUCARYOTES LAB,INSERM,U184, 11 RUE HUMANN, F-67085 STRASBOURG, FRANCE.		Belzung, Catherine/P-6512-2016; SAUDOU, Frédéric/L-3454-2014	Belzung, Catherine/0000-0001-6095-5974; SAUDOU, Frédéric/0000-0001-6107-1046				ALT D, UNPUB; BOSCHERT U, 1994, NEUROSCIENCE, V58, P167, DOI 10.1016/0306-4522(94)90164-3; BOURGAULT PC, 1963, LIFE SCI, P533; BRUINVELS AT, 1993, N-S ARCH PHARMACOL, V347, P569, DOI 10.1007/BF00166939; BRUINVELS AT, 1994, NEUROPHARMACOLOGY, V33, P367, DOI 10.1016/0028-3908(94)90067-1; DAVIS M, 1994, TRENDS NEUROSCI, V17, P208, DOI 10.1016/0166-2236(94)90106-6; EICHELMAN B, 1992, ARCH GEN PSYCHIAT, V49, P488; FLANNELLY KJ, 1985, PSYCHOPHARMACOLOGY, V87, P86, DOI 10.1007/BF00431784; GREEN AR, 1984, NEUROPHARMACOLOGY, V23, P655, DOI 10.1016/0028-3908(84)90147-3; HIGLEY JD, 1992, ARCH GEN PSYCHIAT, V49, P436; HOYER D, 1994, PHARMACOL REV, V46, P157; LAGERSPE.KY, 1968, SCAND J PSYCHOL, V9, P157, DOI 10.1111/j.1467-9450.1968.tb00530.x; LAGERSPETZ KM, 1971, SCAND J PSYCHOL, V12, P241, DOI 10.1111/j.1467-9450.1971.tb00627.x; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; MAAS JW, 1962, SCIENCE, V137, P621, DOI 10.1126/science.137.3530.621; MAROTEAUX L, 1992, P NATL ACAD SCI USA, V89, P3020, DOI 10.1073/pnas.89.7.3020; MOLINA V, 1987, PHARMACOL BIOCHEM BE, V27, P123, DOI 10.1016/0091-3057(87)90486-2; MOS J, 1992, DRUG DEVELOP RES, V26, P343, DOI 10.1002/ddr.430260311; OBERLANDER C, 1987, EUR J PHARMACOL, V139, P205, DOI 10.1016/0014-2999(87)90253-6; OBERLANDER C, 1986, NEUROSCI LETT, V67, P113, DOI 10.1016/0304-3940(86)90382-4; OLIVIER B, 1989, PSYCHOPHARMACOLOGY, V97, P154, DOI 10.1007/BF00442239; OLIVIER B, 1980, AGGRESSIVE BEHAV, V6, P262; OLIVIER B, 1986, Drugs of the Future, V11, P473; PARMIGIANI S, 1983, BEHAV PROCESS, V8, P45, DOI 10.1016/0376-6357(83)90042-6; Roy A, 1991, SEROTONIN MAJOR PSYC, P187; SAUDOU F, IN PRESS NEUROCHEM I; SEGU L, 1990, J NEUROSCI METH, V31, P197, DOI 10.1016/0165-0270(90)90111-R; SIJBESMA H, 1991, PHARMACOL BIOCHEM BE, V38, P447, DOI 10.1016/0091-3057(91)90305-L; SLEIGHT AJ, 1991, SEROTONIN RECEPTOR S, P211; VERGNES M, 1986, PHYSIOL BEHAV, V36, P653, DOI 10.1016/0031-9384(86)90349-5; VIRKKUNEN M, 1994, ARCH GEN PSYCHIAT, V51, P20; Wilkinson LO, 1991, SEROTONIN RECEPTOR S, P147	32	672	688	3	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 23	1994	265	5180					1875	1878		10.1126/science.8091214	http://dx.doi.org/10.1126/science.8091214			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH258	8091214				2022-12-28	WOS:A1994PH25800036
J	NGHIEM, P; OLLICK, T; GARDNER, P; SCHULMAN, H				NGHIEM, P; OLLICK, T; GARDNER, P; SCHULMAN, H			INTERLEUKIN-2 TRANSCRIPTIONAL BLOCK BY MULTIFUNCTIONAL CA2+/CALMODULIN KINASE	NATURE			English	Article							DEPENDENT PROTEIN-KINASE; LYMPHOCYTE-T ACTIVATION; CALMODULIN KINASE; CLONAL ANERGY; CAM KINASE; CALCIUM; EXPRESSION; CALCINEURIN; TRANSACTIVATION; PROMOTER	IN the presence of costimulation(1), Ca2+ influx in T cells leads to activation (transcription of interleukin-2; ref 2) via calcineurin(3,4). In the absence of costimulation, Ca2+ influx results in anergy (interleukin-2 transcriptional block(5)) through an unknown mechanism. Specific attenuation of interleukin-2 transcriptional induction occurs in Jurkat T cells following pretreatment with a Ca2+ ionophore. A >90% block of inducible interleukin-2 reporter gene activity was initiated by transfection of a constitutively active mutant of multifunctional Ca2+/calmodulin-dependent protein kinase (CaM kinase or CaM kinase II)(6), but not by constitutive mutants of CaM kinase IV, calcineurin or protein kinase C. The block was complete six hours after kinase transfection and showed specificity for interleukin-2; there was no change in beta-actin transcription or in c-fos transcription induced by phorbol myristyl acetate, and a Rous sarcoma virus promoter was stimulated threefold. Multifunctional CaM kinase also attenuated interleukin-2 activation by calcineurin plus phorbol ester. T-cell receptor signalling activates multifunctional CaM kinase. These findings suggest that two Ca2+/calmodulin-responsive enzymes, multifunctional CaM kinase and calcineurin, could mediate the divergent effects of Ca2+ signals in T-lymphocyte regulation.	STANFORD UNIV,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305; STANFORD UNIV,SCH MED,DEPT MOLEC PHARMACOL & MED,STANFORD,CA 94305	Stanford University; Stanford University			Nghiem, Paul T/A-9210-2011	Nghiem, Paul T/0000-0003-2784-963X				CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; CRUZALEGUI FH, 1993, J BIOL CHEM, V268, P26171; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; GARDNER P, 1989, CELL, V59, P15, DOI 10.1016/0092-8674(89)90865-9; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HANISSIAN SH, 1993, J BIOL CHEM, V268, P20055; HANSON PI, 1992, REV BIOCH, V61, P559; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; KANG SM, 1992, SCIENCE, V257, P1134, DOI 10.1126/science.257.5073.1134; KAPILOFF MS, 1991, P NATL ACAD SCI USA, V88, P3710, DOI 10.1073/pnas.88.9.3710; LI X, 1994, CYTOGENET CELL GENET, V66, P113, DOI 10.1159/000133679; LISMAN J, 1989, P NATL ACAD SCI USA, V86, P9574, DOI 10.1073/pnas.86.23.9574; MACNICOL M, 1990, J BIOL CHEM, V265, P18055; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; MURAMATSU MA, 1989, MOL CELL BIOL, V9, P831, DOI 10.1128/MCB.9.2.831; NGHIEM P, 1993, J BIOL CHEM, V268, P5471; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; SCHULMAN H, 1992, CELL CALCIUM, V13, P401, DOI 10.1016/0143-4160(92)90053-U; Schulman H, 1993, CURR OPIN CELL BIOL, V5, P247, DOI 10.1016/0955-0674(93)90111-3; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TRAYSTMAN MD, 1991, CLIN EXP IMMUNOL, V86, P291, DOI 10.1111/j.1365-2249.1991.tb05812.x	30	94	94	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 22	1994	371	6495					347	350		10.1038/371347a0	http://dx.doi.org/10.1038/371347a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH254	8090206				2022-12-28	WOS:A1994PH25400057
J	BOOTH, IW				BOOTH, IW			PEDIATRIC GASTROENTEROLOGY - DIETARY-MANAGEMENT OF ACUTE DIARRHEA IN CHILDHOOD	LANCET			English	Editorial Material							CHILDREN; MILK				BOOTH, IW (corresponding author), UNIV BIRMINGHAM,INST CHILD HLTH,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.							ARMITSTEAD J, 1989, J PEDIATR GASTR NUTR, V8, P240, DOI 10.1097/00005176-198902000-00019; BOUDRAA G, 1990, J PEDIATR GASTR NUTR, V11, P509, DOI 10.1097/00005176-199011000-00011; BROWN KH, 1988, J PEDIATR-US, V112, P191, DOI 10.1016/S0022-3476(88)80055-6; CHUNG AW, 1948, J PEDIATR-US, V33, P1, DOI 10.1016/S0022-3476(48)80147-2; FILHO LAD, 1993, LANCET, V341, P194; GODARD C, 1989, J PEDIATR GASTR NUTR, V9, P473, DOI 10.1097/00005176-198911000-00014; REES L, 1979, LANCET, V1, P770; WHARTON BA, 1988, BMJ-BRIT MED J, V296, P450, DOI 10.1136/bmj.296.6620.450; 1987, LANCET, V1, P23	9	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 17	1993	341	8851					996	997		10.1016/0140-6736(93)91079-2	http://dx.doi.org/10.1016/0140-6736(93)91079-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY368	8096951				2022-12-28	WOS:A1993KY36800011
J	BENNETT, G				BENNETT, G			PEST-CONTROL - COCKROACHES AS CARRIERS OF BACTERIA	LANCET			English	Editorial Material											BENNETT, G (corresponding author), PURDUE UNIV,DEPT ENTOMOL,W LAFAYETTE,IN 47907, USA.							ALCAMO IE, 1980, J ENVIRON HEALTH, V42, P263; Bennett G. W., 1986, ADV URBAN PEST MANAG; CLOAREC A, 1992, EPIDEMIOL INFECT, V109, P483, DOI 10.1017/S0950268800050470; GRAFFAR M, 1950, ANN I PASTEUR PARIS, V79, P654; Roth Louis M., 1957, MED VET IMPORTANCE C	5	16	18	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 20	1993	341	8847					732	732		10.1016/0140-6736(93)90497-5	http://dx.doi.org/10.1016/0140-6736(93)90497-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KT362	8095634				2022-12-28	WOS:A1993KT36200014
J	WILLIAMS, C; GUY, C; GILLIES, D; SAUNDERS, B				WILLIAMS, C; GUY, C; GILLIES, D; SAUNDERS, B			ELECTRONIC 3-DIMENSIONAL IMAGING OF INTESTINAL ENDOSCOPY	LANCET			English	Note							COLONOSCOPY; FLUOROSCOPY	Endoscopists, especially those investigating the colon, need to know where the tip of the instrument is and whether the tube is kinking. A three-dimensional real-time imaging system consisting of sensors, within or taped to the endoscope, to detect weak electric currents in a wire grid below the mattress yields the information needed and should greatly facilitate performance and teaching of endoscopy.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,DEPT PHYS,LONDON SW7 2AZ,ENGLAND; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,DEPT COMP,LONDON SW7 2AZ,ENGLAND	Imperial College London; Imperial College London	WILLIAMS, C (corresponding author), ST MARKS HOSP DIS RECTUM & COLON,ENDOSCOPY UNIT,LONDON EC1 2PS,ENGLAND.		Saunders, Brian/AAP-4137-2020					CIROCCO WC, 1991, SURG ENDOSC-ULTRAS, V5, P200, DOI 10.1007/BF02653264; FRAGER DH, 1987, GASTROINTEST RADIOL, V12, P343, DOI 10.1007/BF01885178; RAUH SM, 1989, AM SURGEON, V55, P669; ROGERS BHG, 1990, GASTROINTEST ENDOSC, V36, P71	4	34	35	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 20	1993	341	8847					724	725		10.1016/0140-6736(93)90489-4	http://dx.doi.org/10.1016/0140-6736(93)90489-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KT362	8095627				2022-12-28	WOS:A1993KT36200006
J	LEVY, SB				LEVY, SB			TUBERCULOSIS - DETECTING MULTIDRUG RESISTANT TUBERCULOSIS EARLY	LANCET			English	Editorial Material											LEVY, SB (corresponding author), TUFTS UNIV,SCH MED,CTR ADAPT GENET & DRUG RESISTANCE,BOSTON,MA 02111, USA.							BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; Levy Stuart B., 1992, ANTIBIOTIC PARADOX M; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; PHELPS CE, 1989, MED CARE, V27, P194, DOI 10.1097/00005650-198902000-00009; Tenover Fred C., 1992, ASM NEWS, V58, P669; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0	6	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 13	1993	341	8846					664	665		10.1016/0140-6736(93)90426-H	http://dx.doi.org/10.1016/0140-6736(93)90426-H			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR613	8095575				2022-12-28	WOS:A1993KR61300010
J	RUCKLEY, CV				RUCKLEY, CV			VENOUS DISEASE - DOES VENOUS REFLUX MATTER	LANCET			English	Editorial Material							ULCERATION; LEG				RUCKLEY, CV (corresponding author), ROYAL EDINBURGH & ASSOCIATED HOSP,VASC SURG UNIT,EDINBURGH EH3 9HB,MIDLOTHIAN,SCOTLAND.							CALLAM MJ, 1987, BRIT MED J, V295, P1382, DOI 10.1136/bmj.295.6610.1382; CALLAM MJ, 1985, BRIT MED J, V290, P1855, DOI 10.1136/bmj.290.6485.1855; Dale J J, 1983, Health Bull (Edinb), V41, P310; LAING W, 1992, CHRONIC VENOUS DISEA, P25; SETHIA KK, 1984, BRIT J SURG, V71, P754, DOI 10.1002/bjs.1800711006	5	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 13	1993	341	8842					411	412		10.1016/0140-6736(93)92997-8	http://dx.doi.org/10.1016/0140-6736(93)92997-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM416	8094177				2022-12-28	WOS:A1993KM41600012
J	EPSTEIN, PR; CLAPP, RW				EPSTEIN, PR; CLAPP, RW			RADIOECOLOGY - SOVIET NUCLEAR MISHAPS PRE-CHERNOBYL	LANCET			English	Editorial Material							WEST CUMBRIA; FOLLOW		BOSTON UNIV,SCH PUBL HLTH,DEPT ENVIRONM HLTH,BOSTON,MA 02215	Boston University	EPSTEIN, PR (corresponding author), HARVARD UNIV,CAMBRIDGE HOSP,SCH MED,CAMBRIDGE,MA 02138, USA.							CLAPP RW, 1987, LANCET, V1, P1324; DRAPER GJ, 1993, BRIT MED J, V306, P89, DOI 10.1136/bmj.306.6870.89; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; GARDNER MJ, 1987, BRIT MED J, V295, P822, DOI 10.1136/bmj.295.6602.822; JOHNSON KC, 1991, TRITIUM RELEASES PIC; KENDALL GM, 1992, RAD PROTECT B, V128, P5; KOSSENKO MM, 1992, PSR Q, V4, P187; MORRIS MS, 1992, THESIS ANN ARBOR; OZONOFF DM, 1992, PSR Q, V4, P233; WING S, 1991, JAMA-J AM MED ASSOC, V265, P1397, DOI 10.1001/jama.265.11.1397	10	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 6	1993	341	8841					346	346						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK939	8094119				2022-12-28	WOS:A1993KK93900010
J	STEWART, GSAB				STEWART, GSAB			BIOSENSORS - BACTERIAL LUMINESCENCE - DEVELOPMENT AND APPLICATION	LANCET			English	Editorial Material							ESCHERICHIA-COLI; BIOLUMINESCENCE; GENE				STEWART, GSAB (corresponding author), UNIV NOTTINGHAM,DEPT APPL BIOCHEM & FOOD SCI,NOTTINGHAM NG7 2RD,ENGLAND.							GUZZO A, 1991, APPL ENVIRON MICROB, V57, P2255, DOI 10.1128/AEM.57.8.2255-2259.1991; HEITZER A, 1992, APPL ENVIRON MICROB, V58, P1839, DOI 10.1128/AEM.58.6.1839-1846.1992; JASSIM SAA, 1990, J BIOLUM CHEMILUM, V5, P115, DOI 10.1002/bio.1170050207; KORPELA M, 1989, J BIOLUM CHEMILUM, V4, P551, DOI 10.1002/bio.1170040172; LILIUS EM, 1986, BIOLUMINESCENCE CHEM, P431; MEIGHEN EA, 1988, ANNU REV MICROBIOL, V42, P151, DOI 10.1146/annurev.mi.42.100188.001055; MOELDERS H, 1990, Patent No. 239981; RYCHERT R, 1991, ENVIRON TOXIC WATER, V6, P415, DOI 10.1002/tox.2530060406; SHAW JJ, 1986, BIO-TECHNOL, V4, P560, DOI 10.1038/nbt0686-560; STEWART GSAB, 1992, J GEN MICROBIOL, V138, P1289, DOI 10.1099/00221287-138-7-1289	10	5	5	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 30	1993	341	8840					279	280		10.1016/0140-6736(93)92622-Z	http://dx.doi.org/10.1016/0140-6736(93)92622-Z			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK245	8093923				2022-12-28	WOS:A1993KK24500010
J	TREASURE, T				TREASURE, T			CORONARY INVESTIGATION - UNITED-STATES DOUBTS ABOUT ANGIOGRAPHY	LANCET			English	Editorial Material											TREASURE, T (corresponding author), ST GEORGE HOSP,LONDON,ENGLAND.							GRABOYS TB, 1992, JAMA-J AM MED ASSOC, V268, P2537, DOI 10.1001/jama.268.18.2537; GRAY D, 1990, LANCET, V335, P1317, DOI 10.1016/0140-6736(90)91196-H; HENDERSON RA, IN PRESS BR HEART J; HUBNER PJB, 1992, BRIT HEART J, V68, P434; PARISI AF, 1992, NEW ENGL J MED, V326, P10, DOI 10.1056/NEJM199201023260102; 1992, BRIT HEART J, V67, P106	6	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 16	1993	341	8838					154	155		10.1016/0140-6736(93)90012-6	http://dx.doi.org/10.1016/0140-6736(93)90012-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG627	8093752				2022-12-28	WOS:A1993KG62700012
J	BATES, C				BATES, C			VITAMIN-A AND INFANT IMMUNITY	LANCET			English	Editorial Material							DEFICIENCY											BENDICH A, 1990, ANN NY ACAD SCI, V587, P168, DOI 10.1111/j.1749-6632.1990.tb00144.x; MEYDANI SN, 1991, AM J CLIN NUTR, V53, P1275, DOI 10.1093/ajcn/53.5.1275; SEMBA RD, 1992, J NUTR, V122, P101, DOI 10.1093/jn/122.1.101; THURNHAM DI, 1989, T ROY SOC TROP MED H, V83, P721, DOI 10.1016/0035-9203(89)90308-8	5	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 2	1993	341	8836					28	28		10.1016/0140-6736(93)92494-E	http://dx.doi.org/10.1016/0140-6736(93)92494-E			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF027	8093277				2022-12-28	WOS:A1993KF02700016
J	MING, XF; BURGERING, BMT; WENNSTROM, S; CLAESSONWELSH, L; HELDIN, CH; BOS, JL; KOZMA, SC; THOMAS, G				MING, XF; BURGERING, BMT; WENNSTROM, S; CLAESSONWELSH, L; HELDIN, CH; BOS, JL; KOZMA, SC; THOMAS, G			ACTIVATION OF P70/P85 S6 KINASE BY A PATHWAY INDEPENDENT OF P21(RAS)	NATURE			English	Article							GROWTH-FACTOR RECEPTOR; PROTEIN-KINASE; SIGNALING PATHWAYS; TYROSINE KINASE; RAS; PHOSPHORYLATION; MOLECULES; P70(S6K); MUTANT; RAF-1	THE enzymes p70(s6k) and p85(s6k) two isoforms of the same kinase(1,2) and are important in mitogenesis(2-4). Both isoforms are activated by a complex phosphorylation event(5) and lie on a common signalling pathway(4), distinct from that of the p42(mapk)/p44(mapk) kinases(6). Activation of p42(mapk)/p44(mapk) is triggered by sequential activation of the GDP-GTP exchange factor Sos, the GTP-binding protein p21(ras), and protein kinases p74(raf) and p47(mek) (refs 7-10). As p21(ras) transformed cells have increased S6 phosphorylation(11), we tested whether the p70(s6k)/p85(s6k) signalling pathway bifurcates between p21(ras) and p42(mapk)/p44(mapk). We found that mutants of p74(raf) and p21(ras) blocked activation of epitope-tagged p44(mapk) but not epitope-tagged p70(s6k). Moreover, in cells expressing human platelet-derived growth factor receptors lacking the kinase-insert domain, the growth factor activates p21(ras) but not p70(s6k)/p85(s6k). The critical autophosphorylation site for p70(s6k)/p85(s6k) activation within this domain is a tyrosine at residue 751. Our results show that the p70(s6k)/p85(s6k) signalling pathway is independent of p21(ras), that it bifurcates from the p21(ras) pathway at the receptor, and that it is initiated by autophosphorylation at a specific site.	FRIEDRICH MIESCHER INST, CH-4002 BASEL, SWITZERLAND; UNIV UTRECHT, PHYSIOL CHEM LAB, 3584 CG UTRECHT, NETHERLANDS; BIOMED CTR, LUDWIG INST CANC RES, S-75124 UPPSALA, SWEDEN	Friedrich Miescher Institute for Biomedical Research; Utrecht University; Ludwig Institute for Cancer Research								ARVIDSSON AK, IN PRESS MOL CELL BI; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BLENIS J, 1984, J VIROL, V50, P966, DOI 10.1128/JVI.50.3.966-969.1984; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BURGERING BM, 1994, CELL GROWTH DIFFER, V5, P1; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FERRARI S, 1993, J BIOL CHEM, V268, P16091; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KOZMA SC, IN PRESS PROTEIN KIN; LANE HA, 1992, EMBO J, V11, P1743, DOI 10.1002/j.1460-2075.1992.tb05226.x; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; PELECH SL, 1993, CURR BIOL, V3, P513, DOI 10.1016/0960-9822(93)90043-N; REINHARD C, 1994, EMBO J, V13, P1557, DOI 10.1002/j.1460-2075.1994.tb06418.x; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; WENNSTROM S, 1994, ONCOGENE, V9, P651; WESTERMARK B, 1990, P NATL ACAD SCI USA, V87, P128, DOI 10.1073/pnas.87.1.128; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	30	207	210	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 29	1994	371	6496					426	429		10.1038/371426a0	http://dx.doi.org/10.1038/371426a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PJ285	8090223				2022-12-28	WOS:A1994PJ28500045
J	WILLEMSEN, W; KRUITWAGEN, R; BASTIAANS, B; HANSELAAR, T; ROLLAND, R				WILLEMSEN, W; KRUITWAGEN, R; BASTIAANS, B; HANSELAAR, T; ROLLAND, R			OVARIAN STIMULATION AND GRANULOSA-CELL TUMOR	LANCET			English	Article							BINDING-SITES; GONADOTROPIN; CANCER	Ovarian stimulation in the treatment of infertility is far from physiological because patients and their ovaries are exposed to high concentrations of gonadotropins. Many studies have focused on the two most common side-effects of ovarian stimulation-ie, hyperstimulation and multiple pregnancy. We describe 12 patients in whom granulosa-cell tumour was discovered after ovarian stimulation treatment with clomiphene citrate and/or gonadotropins. Although we cannot prove a causal link between the tumour and the medication, investigations in animals have shown a relation between gonadotropin exposition and the development of granulosa-cell tumours. The possible relation of ovarian stimulation and granulosa-cell tumours in human beings has not been published before. We postulate three explanations for this finding; first, the granulosa-cell tumour is present in the ovary, waiting for a hormonal trigger; second, increased follicle stimulating hormone concentrations are oncogenic to granulosa cell; and third, the onset of the granulosa-cell tumour during ovarian stimulation is coincidental. We recommend that ovarian stimulation is done only if there is a valid indication after proper assessment of the ovaries, and that women who have had ovarian stimulation are followed for longer than at present.	CATHOLIC UNIV NIJMEGEN,RADBOUD HOSP,DEPT PATHOL,6500 HB NIJMEGEN,NETHERLANDS	Radboud University Nijmegen	WILLEMSEN, W (corresponding author), CATHOLIC UNIV NIJMEGEN,RADBOUD HOSP,DEPT OBSTET & GYNAECOL,POB 9101,6500 HB NIJMEGEN,NETHERLANDS.			Kruitwagen, Roy F.P.M./0000-0002-1305-9541				BENGTSSON M, 1988, XENOBIOTICA, V18, P1255, DOI 10.3109/00498258809042249; BISKIND GR, 1953, CANCER RES, V13, P216; BISKIND GR, 1948, SCIENCE, V108, P137, DOI 10.1126/science.108.2797.137; CRAMER DW, 1983, JNCI-J NATL CANCER I, V71, P717; DAVY M, 1977, ACTA ENDOCRINOL-COP, V85, P615, DOI 10.1530/acta.0.0850615; DINNERSTEIN AJ, 1986, OBSTET GYNECOL, V31, P654; HENDERSON BE, 1988, CANCER RES, V48, P246; KOLSTAD P, 1975, DIAGNOSIS TREATMENT, P56; LAPPOHN RE, 1989, NEW ENGL J MED, V321, P790, DOI 10.1056/NEJM198909213211204; MCGOWAN L, 1970, P SOC EXP BIOL MED, V134, P507; NAKANO R, 1989, AM J OBSTET GYNECOL, V161, P905, DOI 10.1016/0002-9378(89)90749-7; OHEL G, 1983, GYNECOL ONCOL, V15, P278, DOI 10.1016/0090-8258(83)90083-5; RAO AR, 1981, INT J CANCER, V28, P105, DOI 10.1002/ijc.2910280118; Richards J.S., 1978, P331; SHIRAMA K, 1992, J ENDOCRINOL INVEST, V15, P417, DOI 10.1007/BF03348764; Stadel B V, 1975, Am J Obstet Gynecol, V123, P772; STOUFFER RL, 1984, J CLIN ENDOCR METAB, V59, P441, DOI 10.1210/jcem-59-3-441	17	125	128	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 17	1993	341	8851					986	988		10.1016/0140-6736(93)91071-S	http://dx.doi.org/10.1016/0140-6736(93)91071-S			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY368	8096944				2022-12-28	WOS:A1993KY36800004
J	BOOTH, IW; MAGNAY, AR				BOOTH, IW; MAGNAY, AR			PEDIATRICS - PEPTIC DISEASE AND CHILDHOOD DIABETES	LANCET			English	Editorial Material							CHILDREN; GASTRITIS; ULCER				BOOTH, IW (corresponding author), UNIV BIRMINGHAM,INST CHILD HLTH,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.							BARNETT JL, 1988, GASTROENTEROLOGY, V94, P739, DOI 10.1016/0016-5085(88)90248-X; BURGHEN GA, 1992, AM J DIS CHILD, V146, P718, DOI 10.1001/archpedi.1992.02160180078021; DIXON MF, 1986, J CLIN PATHOL, V39, P524, DOI 10.1136/jcp.39.5.524; DOTEVALL G, 1959, ACTA MED SCAND, V164, P463; EASTHAM EJ, 1991, PEDIATRIC GASTROINTE, P438; FIEDOREK SC, 1991, PEDIATRICS, V88, P578; KILBRIDGE PM, 1988, AM J DIS CHILD, V142, P1149, DOI 10.1001/archpedi.1988.02150110027012; TAM PKH, 1986, J PEDIATR SURG, V21, P15, DOI 10.1016/S0022-3468(86)80642-X	8	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 3	1993	341	8849					868	868		10.1016/0140-6736(93)93071-8	http://dx.doi.org/10.1016/0140-6736(93)93071-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KV811	8096572				2022-12-28	WOS:A1993KV81100014
J	MOYA, FR; HOFFMAN, DR; ZHAO, B; JOHNSTON, JM				MOYA, FR; HOFFMAN, DR; ZHAO, B; JOHNSTON, JM			PLATELET-ACTIVATING-FACTOR IN SURFACTANT PREPARATIONS	LANCET			English	Note							LUNG	Surfactant administration is used for treatment of neonatal respiratory distress syndrome. We studied whether currently used surfactant preparations contain platelet-activating factor (PAF), a potent lipid mediator produced by fetal lungs. Three surfactant preparations from animal sources contained between 36 and 218 pmol of PAF per mL, whereas PAF was undetectable in an artificial surfactant. Based on current recommendations, about 144-654 pmol PAF would be administered per dose of natural surfactant, sufficient to exert possible physiological effects on the lung. The action of PAF may be exacerbated by low activity of PAF-acetylhydrolase, which inactivates PAF, in tracheal fluid from infants with respiratory distress syndrome.	UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,5323 HARRY HINES BLVD,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT PEDIAT,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT OBSTET & GYNECOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NICHD NIH HHS [HD13912] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD013912] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANGLE MJ, 1987, LAB INVEST, V57, P321; BOURBON JR, 1991, EXP LUNG RES, V17, P789, DOI 10.3109/01902149109062878; CAPLAN MS, 1990, J PEDIATR-US, V116, P960, DOI 10.1016/S0022-3476(05)80661-4; CAPLAN MS, 1990, AM REV RESPIR DIS, V142, P1258, DOI 10.1164/ajrccm/142.6_Pt_1.1258; HOFFMAN DR, 1988, J BIOL CHEM, V263, P9316; HOFFMAN DR, 1987, BIOCHIM BIOPHYS ACTA, V879, P88; JOHNSTON JM, 1989, PAF HLTH DISEASE, P297; MIWA M, 1988, J CLIN INVEST, V82, P1983, DOI 10.1172/JCI113818; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; YEE WFH, 1991, PEDIATR PULM, V11, P65, DOI 10.1002/ppul.1950110111	10	38	39	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 3	1993	341	8849					858	860						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KV811	8096563				2022-12-28	WOS:A1993KV81100005
J	DEMPSTER, DW; LINDSAY, R				DEMPSTER, DW; LINDSAY, R			PATHOGENESIS OF OSTEOPOROSIS	LANCET			English	Article							GLUCOCORTICOID-INDUCED OSTEOPOROSIS; BLOOD MONONUCLEAR-CELLS; GROWTH FACTOR-I; BONE; RELEASE; CALVARIAE; AGE		COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032; HELEN HAYES HOSP,DEPT MED,W HAVERSTRAW,NY 10993	Columbia University; Columbia University	DEMPSTER, DW (corresponding author), HELEN HAYES HOSP,REG BONE CTR,ROUTE 9W,W HAVERSTRAW,NY 10993, USA.				NIAMS NIH HHS [AR39191] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P50AR039191] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BOYCE RW, 1991, J BONE MINER RES  S1, V6, pS218; COOPER C, 1992, OSTEOPOROSIS INT, V2, P285, DOI 10.1007/BF01623184; DEMPSTER DW, 1989, J BONE MINER RES, V4, P137; EPSTEIN S, 1986, BONE, V7, P421, DOI 10.1016/8756-3282(86)90001-3; ERIKSEN EF, 1988, SCIENCE, V241, P84, DOI 10.1126/science.3388021; ERNST M, 1989, ENDOCRINOLOGY, V125, P825, DOI 10.1210/endo-125-2-825; FEYEN JHM, 1987, ENDOCRINOLOGY, V121, P819, DOI 10.1210/endo-121-2-819; HEANEY RP, 1993, NEW ENGL J MED, V328, P503, DOI 10.1056/NEJM199302183280710; JILJA R, 1992, SCIENCE, V257, P88; JOHNSTON CC, 1992, NEW ENGL J MED, V327, P82, DOI 10.1056/NEJM199207093270204; KIMBLE RB, 1992, J BONE MINER RES, V7, pS116; LUKERT BP, 1990, ANN INTERN MED, V112, P352, DOI 10.7326/0003-4819-112-5-352; MCCARTHY TL, 1989, ENDOCRINOLOGY, V124, P1247, DOI 10.1210/endo-124-3-1247; MELLISH RWE, 1989, BONE MINER, V6, P331, DOI 10.1016/0169-6009(89)90038-X; MELTON LJ, 1987, CALCIFIED TISSUE INT, V41, P57; MOHAN S, 1991, CLIN ORTHOP RELAT R, V263, P30; OURSLER MJ, 1991, P NATL ACAD SCI USA, V88, P6613, DOI 10.1073/pnas.88.15.6613; PACIFICI R, 1992, CALCIFIED TISSUE INT, V50, P295, DOI 10.1007/BF00301625; PACIFICI R, 1987, P NATL ACAD SCI USA, V84, P4616, DOI 10.1073/pnas.84.13.4616; PACIFICI R, 1991, P NATL ACAD SCI USA, V88, P5134, DOI 10.1073/pnas.88.12.5134; PARFITT AM, 1992, BONE, V13, pS41, DOI 10.1016/8756-3282(92)90196-4; PARFITT AM, 1988, OSTEOPOROSIS ETIOLOG, P355; PARISIEN M, 1992, J BONE MINER RES, V7, P913; RALSTON SH, 1990, J BONE MINER RES, V5, P983; RIGGS BL, 1988, CECIL TXB MED, P1510; STEVENSON JC, 1983, VITAMIN D, P43; [No title captured]; [No title captured]; 1991, OSTEOPOROSIS INT, V1, P114; [No title captured]	30	224	227	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 27	1993	341	8848					797	801		10.1016/0140-6736(93)90570-7	http://dx.doi.org/10.1016/0140-6736(93)90570-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU900	8096008				2022-12-28	WOS:A1993KU90000013
J	STRAUSS, WM; DAUSMAN, J; BEARD, C; JOHNSON, C; LAWRENCE, JB; JAENISCH, R				STRAUSS, WM; DAUSMAN, J; BEARD, C; JOHNSON, C; LAWRENCE, JB; JAENISCH, R			GERM LINE TRANSMISSION OF A YEAST ARTIFICIAL CHROMOSOME SPANNING THE MURINE ALPHA(1)(I) COLLAGEN LOCUS	SCIENCE			English	Article							GENETIC-LINKAGE MAP; ALPHA-1(I) COLLAGEN; INSITU HYBRIDIZATION; MAMMALIAN-CELLS; MOUSE; INTERPHASE; CLONING; GENOME; DNA; RNA	Molecular complementation of mutant phenotypes by transgenic technology is a potentially important tool for gene identification. A technology was developed that allows the transfer of a physically intact yeast artificial chromosome (YAC) into the germ line of the mouse. A purified 150-kilobase YAC encompassing the murine gene Col1a1 was efficiently introduced into embryonic stem (ES) cells via lipofection. Chimeric founder mice were derived from two transfected ES cell clones. These chimeras transmitted the full length transgene through the germ line, generating two transgenic mouse strains. Transgene expression was visualized as nascent transcripts in interphase nuclei and quantitated by ribonuclease protection analysis. Both assays indicated that the transgene was expressed at levels comparable to the endogenous collagen gene.	MIT, DEPT BIOL, CAMBRIDGE, MA 02142 USA; UNIV MASSACHUSETTS, SCH MED, WORCESTER, MA 01655 USA	Massachusetts Institute of Technology (MIT); University of Massachusetts System; University of Massachusetts Worcester	STRAUSS, WM (corresponding author), MIT, WHITEHEAD INST BIOMED RES, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA.			Lawrence, Jeanne/0000-0001-6572-3128	NCI NIH HHS [5 R35 CA44339-05] Funding Source: Medline; NHGRI NIH HHS [HG00198-01] Funding Source: Medline; NIGMS NIH HHS [5 F32 GM13756-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044339] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000198, R37HG000198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM013756] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; CHOI T, IN PRESS NATURE; CHUMAKOV I, 1992, NATURE, V359, P380, DOI 10.1038/359380a0; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; DIETRICH W, 1992, GENETICS, V131, P423; DONISKELLER H, 1987, CELL, V51, P319, DOI 10.1016/0092-8674(87)90158-9; DURSO M, 1990, GENOMICS, V7, P531, DOI 10.1016/0888-7543(90)90196-2; FOOTE S, 1992, SCIENCE, V258, P60, DOI 10.1126/science.1359640; GITSCHIER J, 1984, NATURE, V312, P326, DOI 10.1038/312326a0; GNIRKE A, 1991, EMBO J, V10, P1629, DOI 10.1002/j.1460-2075.1991.tb07685.x; GNIRKE A, 1991, SOMAT CELL MOLEC GEN, V17, P573, DOI 10.1007/BF01233622; HUANG S, 1991, Genes and Development, V5, P2288, DOI 10.1101/gad.5.12a.2288; KOENIG M, 1987, CELL, V50, P509, DOI 10.1016/0092-8674(87)90504-6; LAWRENCE JB, 1990, SCIENCE, V249, P928, DOI 10.1126/science.2203143; LAWRENCE JB, 1989, CELL, V57, P493, DOI 10.1016/0092-8674(89)90924-0; LEVENTIS R, 1990, BIOCHIM BIOPHYS ACTA, V1023, P124, DOI 10.1016/0005-2736(90)90017-I; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MOOSLEHNER K, 1988, NUCLEIC ACIDS RES, V16, P773, DOI 10.1093/nar/16.2.773; MUNKE M, 1986, CYTOGENET CELL GENET, V43, P140, DOI 10.1159/000132312; PACHNIS V, 1990, P NATL ACAD SCI USA, V87, P5109, DOI 10.1073/pnas.87.13.5109; PAVAN WJ, 1990, MOL CELL BIOL, V10, P4163, DOI 10.1128/MCB.10.8.4163; RAAP AK, 1991, EXP CELL RES, V197, P319, DOI 10.1016/0014-4827(91)90439-2; RIELE HT, 1992, P NATL ACAD SCI USA, V89, P5128, DOI 10.1073/pnas.89.11.5128; SCHEDL A, 1992, NUCLEIC ACIDS RES, V20, P3073, DOI 10.1093/nar/20.12.3073; SCHNIEKE A, 1983, NATURE, V304, P315, DOI 10.1038/304315a0; STRAUSS WM, 1992, MAMM GENOME, V2, P150, DOI 10.1007/BF00302873; STRAUSS WM, UNPUB; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; VOLLRATH D, 1992, SCIENCE, V258, P52, DOI 10.1126/science.1439769; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WU H, 1990, MOL CELL BIOL, V10, P1452, DOI 10.1128/MCB.10.4.1452; XING Y, 1991, METHOD CELL BIOL, V35, P75; ZIJLSTRA M, 1989, NATURE, V342, P435, DOI 10.1038/342435a0	35	108	147	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 26	1993	259	5103					1904	1907		10.1126/science.8096090	http://dx.doi.org/10.1126/science.8096090			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KU172	8096090				2022-12-28	WOS:A1993KU17200034
J	BARNETT, DB				BARNETT, DB			FLOSEQUINAN	LANCET			English	Article							CONGESTIVE HEART-FAILURE; PHARMACOKINETICS; HEMODYNAMICS; HYPERTENSION				BARNETT, DB (corresponding author), LEICESTER ROYAL INFIRM,DEPT PHARMACOL & THERAPEUT,CLIN SCI BLDG,LEICESTER LE2 7LX,ENGLAND.							ALLCCK AA, 1987, BRIT J PHARMACOL, V94, pP430; COWLEY AJ, 1987, EUR J CLIN PHARMACOL, V33, P203, DOI 10.1007/BF00544568; COWLEY AJ, 1988, BRIT MED J, V297, P169, DOI 10.1136/bmj.297.6642.169; COWLEY AJ, 1991, BRIT HEART J, V66, P68; DUPONT AG, 1989, CURR THER RES CLIN E, V46, P423; DURANTEAU J, 1992, BRIT J CLIN PHARMACO, V34, P207, DOI 10.1111/j.1365-2125.1992.tb04126.x; ELBORN JS, 1989, BRIT HEART J, V61, P33; FRODSHAM G, 1992, EUR J PHARMACOL, V211, P383, DOI 10.1016/0014-2999(92)90396-L; GOTLIEB SS, 1991, CIRCULATION S2, V84, P241; HAAS GJ, 1989, AM J CARDIOL, V63, P1354, DOI 10.1016/0002-9149(89)91048-5; HAAS GJ, 1990, CLIN CARDIOL, V13, P414; KAMALI F, 1991, BRIT J CLIN PHARMACO, V32, P124, DOI 10.1111/j.1365-2125.1991.tb05624.x; KANEL WB, 1989, CARDIOL CLIN, V7, P1; KESSLER P, 1986, CIRCULATION, V74, P509; KESSLER PD, 1987, AM HEART J, V113, P137, DOI 10.1016/0002-8703(87)90021-4; KROMER EP, 1990, J CARDIOL S1, V79, P150; LANG D, 1992, EUR J PHARM-MOLEC PH, V226, P259, DOI 10.1016/0922-4106(92)90070-C; PACKER M, 1980, CIRCULATION, V82, P1280; PITT B, 1991, CIRCULATION, V84, P1238; REIGGER GAJ, 1990, CARDIOVASC DRUG THER, V4, P1395; SCOTT RA, 1991, BRIT J CLIN PHARMACO, V31, P41, DOI 10.1111/j.1365-2125.1991.tb03855.x; SILKE B, 1992, EUR HEART J, V13, P1092, DOI 10.1093/oxfordjournals.eurheartj.a060320; WYNNE RD, 1985, EUR J CLIN PHARMACOL, V28, P659, DOI 10.1007/BF00607911; YATES DB, 1991, AM HEART J, V121, P974, DOI 10.1016/0002-8703(91)90229-B; 1992, LANCET, V340, P1197	25	14	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 20	1993	341	8847					733	736		10.1016/0140-6736(93)90498-6	http://dx.doi.org/10.1016/0140-6736(93)90498-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KT362	8095635				2022-12-28	WOS:A1993KT36200015
J	COLLINS, RH; ANASTASI, J; TERSTAPPEN, LWMM; NIKAEIN, A; FENG, JJ; FAY, JW; KLINTMALM, G; STONE, MJ				COLLINS, RH; ANASTASI, J; TERSTAPPEN, LWMM; NIKAEIN, A; FENG, JJ; FAY, JW; KLINTMALM, G; STONE, MJ			DONOR-DERIVED LONG-TERM MULTILINEAGE HEMATOPOIESIS IN A LIVER-TRANSPLANT RECIPIENT	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							VERSUS-HOST DISEASE; BONE-MARROW TRANSPLANTATION; INSITU HYBRIDIZATION; STEM-CELLS; GRAFT	GRAFT-VERSUS-HOST disease (GVHD) has been well documented in several recipients of liver transplants.1-8 In this syndrome alloreactive cells from the donor attack the recipient's skin, gastrointestinal tissue, and hematopoietic tissue. Severe myelosuppression commonly results, but there has been a degree of recovery of hematopoiesis in some patients after immunosuppressive therapy. The recovery of hematopoiesis resulted from the recovery of the recipient's bone marrow in some cases,1,3 but it also could be due to the proliferation of hematopoietic precursor cells in the donor's liver, since the liver is a site of hematopoiesis in fetuses and, under certain circumstances, in adults. We investigated this possibility in a liver-transplant recipient in whom hematopoiesis recovered after treatment of GVHD. We found that the hematopoiesis in our patient derived from stem cells present in the donor's liver.	BECTON DICKINSON IMMUNOCYTOMETRY SYST, SAN JOSE, CA USA; BAYLOR UNIV, MED CTR, TRANSPLANTAT SERV, DALLAS, TX USA; UNIV CHICAGO, DEPT HEMATOPATHOL, CHICAGO, IL 60637 USA	Becton Dickinson; Baylor University; Baylor University Medical Center; University of Chicago	COLLINS, RH (corresponding author), BAYLOR UNIV, MED CTR,CHARLES A SAMMONS CANC CTR,SAMMONS TOWER, SUITE 410, 3409 WORTH ST, DALLAS, TX 75246 USA.		terstappen, leon/O-4923-2018	terstappen, leon/0000-0001-5944-3787				ANASTASI J, 1991, BLOOD, V77, P2456; BARR RD, 1975, SCIENCE, V190, P284, DOI 10.1126/science.1179209; BHADURI BR, 1990, TRANSPLANT P, V22, P2378; BURDICK JF, 1988, NEW ENGL J MED, V318, P689, DOI 10.1056/NEJM198803173181107; COLLINS RH, 1992, ANN INTERN MED, V116, P391, DOI 10.7326/0003-4819-116-5-391; COMENZO RL, 1992, NEW ENGL J MED, V326, P867, DOI 10.1056/NEJM199203263261305; DEPAOLI AM, 1992, ANN INTERN MED, V117, P170, DOI 10.7326/0003-4819-117-2-170_1; HAYS EF, 1978, EXP HEMATOL, V6, P18; HUANG S, 1992, NATURE, V360, P745, DOI 10.1038/360745a0; JAMIESON NV, 1991, TRANSPLANT INT, V4, P67, DOI 10.1111/j.1432-2277.1991.tb01950.x; KNOWLTON RG, 1986, BLOOD, V68, P378; LICHTMAN MA, 1990, HEMATOLOGY, P223; MARUBAYASHI S, 1990, TRANSPLANTATION, V50, P709; ROBERTS JP, 1991, HEPATOLOGY, V14, P274, DOI 10.1016/0270-9139(91)91415-W; TAVASSOLI M, 1991, BLOOD CELLS, V17, P269; TERSTAPPEN LWMM, 1991, BLOOD, V77, P1218; VANDEKKEN H, 1989, LEUKEMIA, V3, P724	17	88	88	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 18	1993	328	11					762	765		10.1056/NEJM199303183281104	http://dx.doi.org/10.1056/NEJM199303183281104			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR848	8094887				2022-12-28	WOS:A1993KR84800004
J	HIEN, TT; WHITE, NJ				HIEN, TT; WHITE, NJ			QINGHAOSU	LANCET			English	Article							ACUTE FALCIPARUM-MALARIA; ANTIMALARIAL ACTIVITY; ORAL QUININE; ARTEMISININ; MEFLOQUINE; DIHYDROARTEMISININ; SUPPOSITORIES; DRUGS		CHO QUAN HOSP, CTR TROP DIS, WELLCOME TRUST CLIN RES UNIT, 190 BEN HAM TU Q5, HO CHI MINH CITY 10700, VIETNAM; MAHIDOL UNIV, FAC TROP MED, BANGKOK, THAILAND; UNIV OXFORD, NUFFIELD DEPT CLIN MED, TROP MED UNIT, OXFORD, ENGLAND	Mahidol University; University of Oxford			White, Nick/AAC-6527-2019; White, Nicholas J/I-4629-2012; Torero, Rebeca/C-1703-2012	White, Nick/0000-0002-1897-1978; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALIN MH, 1990, T ROY SOC TROP MED H, V84, P635, DOI 10.1016/0035-9203(90)90129-3; [Anonymous], 1979, CHINESE MED J-PEKING, V92, P811; ARNOLD K, 1990, T ROY SOC TROP MED H, V84, P499, DOI 10.1016/0035-9203(90)90012-4; BREWER TG, 1992, AM J TROP MED HYG, V47; CHAWIRA AN, 1987, T ROY SOC TROP MED H, V81, P554, DOI 10.1016/0035-9203(87)90404-4; China Copperative Research Group, 1982, J TRADIT CHIN MED, V2, P31; EDWARDS G, IN PRESS J PHARM PHA; HIEN TT, 1992, T ROY SOC TROP MED H, V86, P584, DOI 10.1016/0035-9203(92)90138-3; HIEN TT, 1992, T ROY SOC TROP MED H, V86, P582, DOI 10.1016/0035-9203(92)90137-2; HIEN TT, 1991, T ROY SOC TROP MED H, V85, P210, DOI 10.1016/0035-9203(91)90024-S; JIANG JB, 1982, LANCET, V2, P285; Karbwang Juntra, 1992, Southeast Asian Journal of Tropical Medicine and Public Health, V23, P768; KLAYMAN DL, 1985, SCIENCE, V228, P1049, DOI 10.1126/science.3887571; KRUNGKRAI SR, 1987, T ROY SOC TROP MED H, V81, P710, DOI 10.1016/0035-9203(87)90003-4; LEE IS, 1990, PHARMACOL THERAPEUT, V48, P345, DOI 10.1016/0163-7258(90)90053-5; LI G, 1982, Journal of Traditional Chinese Medicine, V2, P125; LI GQ, 1984, LANCET, V2, P1360; LI GQ, 1990, CLIN TRIALS QINGHAOS, V1, P1; LIN AJ, 1987, J MED CHEM, V30, P2147, DOI 10.1021/jm00394a037; LOOAREESUWAN S, 1992, LANCET, V339, P821, DOI 10.1016/0140-6736(92)90276-9; LOOAREESUWAN S, 1992, AM J TROP MED HYG, V47, P794, DOI 10.4269/ajtmh.1992.47.794; MELENDEZ V, 1991, J PHARM SCI, V80, P132, DOI 10.1002/jps.2600800209; MESHNICK SR, 1992, 13 INT C TROP MED MA, P86; Shen JX., 1989, ANTIMALARIAL DRUG DE, P31; SHWE T, 1989, T ROY SOC TROP MED H, V83, P489, DOI 10.1016/0035-9203(89)90261-7; SHWE T, 1988, T ROY SOC TROP MED H, V82, P665, DOI 10.1016/0035-9203(88)90187-3; TERKUILE F, IN PRESS EXP PARASIT; TITULAER HAC, 1990, J PHARM PHARMACOL, V42, P810, DOI 10.1111/j.2042-7158.1990.tb07030.x; UDOMSANGPETCH R, 1992, AM J TROP MED HYG, V47; WALKER O, 1992, 5TH INT C INF DIS NA; WANG T, 1989, Journal of Traditional Chinese Medicine, V9, P28; Wang T Y, 1985, J Tradit Chin Med, V5, P240; WANG TY, 1991, MED PHARM YUNNAN, V12, P114; WANWIMOLRUK S, 1992, 13 INT C TROP MED MA; WHITE NJ, 1992, ADV PARASIT, V31, P83, DOI 10.1016/S0065-308X(08)60021-4; WHITE NJ, 1989, T ROY SOC TROP MED H, V83, P767, DOI 10.1016/0035-9203(89)90322-2; WHITE NJ, 1992, LANCET, V339, P317, DOI 10.1016/0140-6736(92)91644-N; WOERDENBAG HJ, 1990, PHARM WEEKBLAD, V12, P169, DOI 10.1007/BF01980041; YANG SD, 1986, CHIN J CLIN PHARM, V1, P106	39	479	495	1	50	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 6	1993	341	8845					603	608						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KQ234	8094838				2022-12-28	WOS:A1993KQ23400014
J	WILLETT, WC; STAMPFER, MJ; MANSON, JE; COLDITZ, GA; SPEIZER, FE; ROSNER, BA; SAMPSON, LA; HENNEKENS, CH				WILLETT, WC; STAMPFER, MJ; MANSON, JE; COLDITZ, GA; SPEIZER, FE; ROSNER, BA; SAMPSON, LA; HENNEKENS, CH			INTAKE OF TRANS-FATTY-ACIDS AND RISK OF CORONARY HEART-DISEASE AMONG WOMEN	LANCET			English	Article							UNITED-STATES; HIGH-DENSITY; DIET; EMPHASIS; ISOMERS; TISSUE; FOOD; CIS	Trans isomers of fatty acids, formed by the partial hydrogenation of vegetable oils to produce margarine and vegetable shortening, increase the ratio of plasma low-density-lipoprotein to high-density-lipoprotein cholesterol, so it is possible that they adversely influence risk of coronary heart disease (CHD). To investigate this possibility, we studied dietary data from participants in the Nurses' Health Study. We calculated intake of trans fatty acids from dietary questionnaires completed by 85 095 women without diagnosed CHD, stroke, diabetes, or hypercholesterolaemia in 1980. During 8 years of follow-up, there were 431 cases of new CHD (non-fatal myocardial infarction or death from CHD). After adjustment for age and total energy intake, intake of trans isomers was directly related to risk of CHD (relative risk for highest vs lowest quintile 1.50 [95% CI 1.12-2.00], p for trend=0.001). Additional control for established CHD risk factors, multivitamin use, and intakes of saturated fat, monounsaturated fat, and linoleic acid, dietary cholesterol, vitamins E or C, carotene, or fibre did not change the relative risk substantially. The association was stronger for the 69 181 women whose margarine consumption over the previous 10 years had been stable (1.67 [1.05-2.66], p for trend=0.002). Intakes of foods that are major sources of trans isomers (margarine, cookies [biscuits], cake, and white bread) were each significantly associated with higher risks of CHD. These findings support the hypothesis that consumption of partially hydrogenated vegetable oils may contribute to occurrence of CHD.	HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,CHANNING LAB,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PREVENT MED,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	WILLETT, WC (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,665 HUNTINGTON AVE,BOSTON,MA 02115, USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [R37CA040356, R01CA040356] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034594] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40356] Funding Source: Medline; NHLBI NIH HHS [HL 34594] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOOYENS J, 1986, MED HYPOTHESES, V21, P387, DOI 10.1016/0306-9877(86)90034-4; EMKEN EA, 1984, ANNU REV NUTR, V4, P339, DOI 10.1146/annurev.nu.04.070184.002011; ENIG MG, 1983, J AM OIL CHEM SOC, V60, P1788, DOI 10.1007/BF02680357; HUNTER JE, 1991, AM J CLIN NUTR, V54, P363, DOI 10.1093/ajcn/54.2.363; KINSELLA JE, 1981, AM J CLIN NUTR, V34, P2307, DOI 10.1093/ajcn/34.10.2307; KUMMEROW FA, 1979, AM J CLIN NUTR, V32, P58, DOI 10.1093/ajcn/32.1.58; LAGROST L, 1992, BIOCHIM BIOPHYS ACTA, V1124, P159, DOI 10.1016/0005-2760(92)90092-A; LONDON SJ, 1991, AM J CLIN NUTR, V54, P340, DOI 10.1093/ajcn/54.2.340; MENSINK RP, 1987, LANCET, V1, P122, DOI 10.1016/S0140-6736(87)91965-9; MENSINK RP, 1990, NEW ENGL J MED, V323, P439, DOI 10.1056/NEJM199008163230703; MENSINK RP, 1992, J LIPID RES, V33, P1493; NESTEL P, 1992, J LIPID RES, V33, P1029; PARODI PW, 1976, J DAIRY SCI, V50, P1870; PARTHASARATHY S, 1990, P NATL ACAD SCI USA, V87, P3894, DOI 10.1073/pnas.87.10.3894; PEACOCK LIL, 1988, BIOCHEM SOC T, V16, P291, DOI 10.1042/bst0160291; ROSENTHAL MD, 1983, BIOCHIM BIOPHYS ACTA, V753, P450, DOI 10.1016/0005-2760(83)90070-X; SENTI FRE, 1988, HLTH ASPECTS DIETARY; SLOVER HT, 1985, J AM OIL CHEM SOC, V62, P775, DOI 10.1007/BF03028753; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; STEPHEN AM, 1990, AM J CLIN NUTR, V52, P457, DOI 10.1093/ajcn/52.3.457; THOMAS LH, 1983, J EPIDEMIOL COMMUN H, V37, P16, DOI 10.1136/jech.37.1.16; WILLETT WC, 1990, NEW ENGL J MED, V323, P1664, DOI 10.1056/NEJM199012133232404; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; WILLETT WC, 1989, NUTRITONAL EPIDEMIOL; ZOCK PL, 1992, J LIPID RES, V33, P399; 1971, WHO IHD 5TH REP; 1963, AGR HDB SERIES, V8	28	770	790	2	81	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 6	1993	341	8845					581	585		10.1016/0140-6736(93)90350-P	http://dx.doi.org/10.1016/0140-6736(93)90350-P			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KQ234	8094827				2022-12-28	WOS:A1993KQ23400002
J	HEATH, CW				HEATH, CW			PASSIVE SMOKING - ENVIRONMENTAL TOBACCO-SMOKE AND LUNG-CANCER	LANCET			English	Editorial Material											HEATH, CW (corresponding author), AMER CANC SOC,DEPT EPIDEMIOL & STAT,ATLANTA,GA, USA.							[Anonymous], 1986, ENV TOBACCO SMOKE ME; FONTHAM ETH, 1991, CANCER EPIDEM BIOMAR, V1, P35; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; 1986, EVALUATION CARCINOGE, V38, P303; 1986, HLTH CONSEQUENCES IN; 1992, RESPIRATORY HLTH EFF	6	7	7	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 27	1993	341	8844					526	526		10.1016/0140-6736(93)90282-L	http://dx.doi.org/10.1016/0140-6736(93)90282-L			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP083	8094775				2022-12-28	WOS:A1993KP08300008
J	ORTQVIST, A				ORTQVIST, A			RESPIRATORY-INFECTION - COMMUNITY-ACQUIRED LOWER RESPIRATORY-INFECTION	LANCET			English	Editorial Material							PNEUMONIA; ETIOLOGY				ORTQVIST, A (corresponding author), KAROLINSKA INST,DEPT INFECT DIS,DANDERYD,SWEDEN.							DIXON RE, 1985, AM J MED, V78, P45, DOI 10.1016/0002-9343(85)90363-8; GWALTNEY JM, 1990, PRINCIPLES PRACTICE, P529; JOKINEN C, 1991, THESIS U KUOPIO; MACFARLANE JT, 1982, LANCET, V2, P255; ORTQVIST A, 1990, EUR RESPIR J, V3, P1105; VENKATESAN P, 1992, THORAX, V47, P329, DOI 10.1136/thx.47.5.329; VERHEIJ TJM, 1989, FAM PRACT, V6, P66, DOI 10.1093/fampra/6.1.66; WOODHEAD MA, 1987, LANCET, V1, P671	8	2	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 27	1993	341	8844					529	530						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP083	8094779				2022-12-28	WOS:A1993KP08300012
J	SMYTH, ET; PAVORD, ID; WONG, CS; WISNIEWSKI, AFZ; WILLIAMS, J; TATTERSFIELD, AE				SMYTH, ET; PAVORD, ID; WONG, CS; WISNIEWSKI, AFZ; WILLIAMS, J; TATTERSFIELD, AE			INTERACTION AND DOSE EQUIVALENCE OF SALBUTAMOL AND SALMETEROL IN PATIENTS WITH ASTHMA	BRITISH MEDICAL JOURNAL			English	Article							PRESCRIBED FENOTEROL; NEW-ZEALAND; AGONIST; DEATH	Objective-To examine the pharmacological interaction of salmeterol and salbutamol and to derive an estimate of dose equivalence of salmeterol for airway and systemic effects in patients with asthma. Design-Randomised double blind crossover study. Subjects-12 patients with mild asthma. Intervention-Placebo or salmeterol 50, 100, 200 mug given on separate days followed two hours later by inhaled salbutamol in cumulative doses up to 3600 mug. Main outcome measures-Change in forced expiratory volume in one second (FEV1), heart rate, plasma potassium concentration, QTc interval, tremor amplitude, and creatine kinase myocardial isoenzyme concentration. Results-Compared with placebo, the mean (95% confidence interval) changes in FEV1 and heart rate after salmeterol 200 mug were 0.61 (0.32 to 0.90) l and 7.0 (3.8 to 10.2) beats/min. Adding salbutamol caused a large increase in FEV1 after placebo (0.69 l) with progressively smaller changes after increasing doses of salmeterol (0.19 l after salmeterol 200 mug). Heart rate and QTc interval increased and plasma potassium concentration decreased roughly in parallel on the four study days with a suggestion of convergence at higher doses of salbutamol. Geometric mean dose equivalences for salmeterol 50 mug and 100 mug compared with salbutamol were 4.9 and 7.8 (mean 6.4) for FEV1 and ranged from 7.1 (2.9 to 17.0) to 12.6 (4.4 to 36.4) for heart rate, plasma potassium, and tremor (mean 9.5). Conclusions-The effect of adding salbutamol to salmeterol is largely additive. Weight for weight salmeterol may be up to 10 times more potent than salbutamol. Considering its longer duration of action salmeterol 50 mug twice daily could be equivalent to salbutamol in doses up to 500 mug four to six hourly.	CITY HOSP NOTTINGHAM,RESP MED UNIT,NOTTINGHAM NG5 1PB,ENGLAND	Nottingham University Hospital NHS Trust; Nottingham City Hospital				Pavord, Ian/0000-0002-4288-5973				BALL DI, 1991, BRIT J PHARMACOL, V104, P665, DOI 10.1111/j.1476-5381.1991.tb12486.x; BRITTON J, 1984, THORAX, V39, P597, DOI 10.1136/thx.39.8.597; BUTCHERS P R, 1987, British Journal of Pharmacology, V92, p745P; CAMPOSGONGORA H, 1991, AM REV RESPIR DIS, V144, P626; COLLIER JG, 1980, BRIT J CLIN PHARMACO, V9, P273, DOI 10.1111/j.1365-2125.1980.tb04837.x; CRANE J, 1989, LANCET, V1, P917; DEROM EY, 1992, J ALLERGY CLIN IMMUN, V89, P811, DOI 10.1016/0091-6749(92)90435-5; FLATT A, 1990, POSTGRAD MED J, V66, P98, DOI 10.1136/pgmj.66.772.98; GRAINGER J, 1991, THORAX, V46, P105, DOI 10.1136/thx.46.2.105; INMAN WHW, 1969, LANCET, V2, P279; PEARCE N, 1990, THORAX, V45, P170, DOI 10.1136/thx.45.3.170; PEARLMAN DS, 1992, NEW ENGL J MED, V327, P1420, DOI 10.1056/NEJM199211123272004; Pratt W.B., 1990, PRINCIPLES DRUG ACTI, V3rd; SANDSTROM T, 1989, American Review of Respiratory Disease, V139, pA64; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; STOLLEY PD, 1972, AM REV RESPIR DIS, V105, P883; TATTERSFIELD AE, 1969, NEW ENGL J MED, V281, P1323, DOI 10.1056/NEJM196912112812402; ULLMAN A, 1988, THORAX, V43, P674, DOI 10.1136/thx.43.9.674; ULLMAN A, 1990, AM REV RESPIR DIS, V142, P571, DOI 10.1164/ajrccm/142.3.571; WONG CS, 1990, LANCET, V336, P1396, DOI 10.1016/0140-6736(90)93099-B; 1992, 24 JOINT FORM COMM B, P113	21	55	55	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 27	1993	306	6877					543	545		10.1136/bmj.306.6877.543	http://dx.doi.org/10.1136/bmj.306.6877.543			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP886	8096416	Green Published, Bronze			2022-12-28	WOS:A1993KP88600017
J	WADDINGTON, JL				WADDINGTON, JL			SCHIZOPHRENIA - DEVELOPMENTAL NEUROSCIENCE AND PATHOBIOLOGY	LANCET			English	Article							DOPAMINE; PREVALENCE				WADDINGTON, JL (corresponding author), ROYAL COLL SURG IRELAND,DEPT CLIN PHARMACOL,ST STEPHENS GREEN,DUBLIN 2,IRELAND.							ANDREASEN NC, 1991, SCHIZOPHRENIA BULL, V17, P27, DOI 10.1093/schbul/17.1.27; BENNATHAN D, 1991, LIFE SCI, V48, P1493, DOI 10.1016/0024-3205(91)90187-G; BRACHA HS, 1992, AM J PSYCHIAT, V149, P1355; COOPER SJ, 1992, BRIT J PSYCHIAT, V161, P394, DOI 10.1192/bjp.161.3.394; CROW TJ, 1991, BRIT J PSYCHIAT, V159, P76, DOI 10.1192/S0007125000296530; DAVIS KL, 1991, AM J PSYCHIAT, V148, P1474; DONE DJ, 1991, BRIT MED J, V302, P1576, DOI 10.1136/bmj.302.6792.1576; EAGLES JM, 1991, BRIT J PSYCHIAT, V158, P834, DOI 10.1192/bjp.158.6.834; FALKAI P, 1992, SCHIZOPHR RES, V7, P23, DOI 10.1016/0920-9964(92)90070-L; FLINT J, 1992, PSYCHOL MED, V22, P5, DOI 10.1017/S0033291700032669; GIRARD NJ, 1992, J COMPUT ASSIST TOMO, V16, P265, DOI 10.1097/00004728-199203000-00016; JASKIW GE, IN PRESS SEM NEUROSC; KENDELL RE, 1991, BRIT J PSYCHIAT, V158, P758, DOI 10.1192/bjp.158.6.758; KERWIN RW, 1992, SCHIZOPHR RES, V7, P1, DOI 10.1016/0920-9964(92)90067-F; KHOURY MJ, 1992, AM J MED GENET, V43, P1016, DOI 10.1002/ajmg.1320430620; KILIDIREAS K, 1992, LANCET, V340, P569, DOI 10.1016/0140-6736(92)92105-O; KNIGHT J, 1992, BRIT J PSYCHIAT, V160, P533, DOI 10.1192/bjp.160.4.533; LEWIS G, 1992, LANCET, V340, P137, DOI 10.1016/0140-6736(92)93213-7; LEWIS S, 1992, BRIT J PSYCHIAT, V161, P445, DOI 10.1192/bjp.161.4.445; LIDDLE PF, 1992, BRIT J PSYCHIAT, V160, P179, DOI 10.1192/bjp.160.2.179; MARKOW TA, 1992, PSYCHOL MED, V22, P295, DOI 10.1017/S0033291700030233; MELLOR CS, 1992, BRIT J PSYCHIAT, V160, P467, DOI 10.1192/bjp.160.4.467; MIDGARD R, 1991, NEUROLOGY, V41, P887, DOI 10.1212/WNL.41.6.887; MURRAY RM, 1987, BRIT MED J, V295, P681, DOI 10.1136/bmj.295.6600.681; OCALLAGHAN E, 1991, AM J PSYCHIAT, V148, P479; OCALLAGHAN E, 1992, BRIT MED J, V305, P1256, DOI 10.1136/bmj.305.6864.1256; OWEN M, 1992, BRIT MED J, V305, P664, DOI 10.1136/bmj.305.6855.664; REYNOLDS GP, 1989, BRIT J PSYCHIAT, V155, P305, DOI 10.1192/bjp.155.3.305; SHENTON ME, 1992, NEW ENGL J MED, V327, P604, DOI 10.1056/NEJM199208273270905; SOBRIAN SK, 1992, PHARMACOL BIOCHEM BE, V43, P537, DOI 10.1016/0091-3057(92)90189-M; SUSSER ES, 1992, ARCH GEN PSYCHIAT, V49, P983; TAMMINGA CA, 1992, ARCH GEN PSYCHIAT, V49, P522; TIENARI PJ, 1992, LANCET, V340, P987, DOI 10.1016/0140-6736(92)93007-A; TORREY EF, 1991, SCHIZOPHRENIA BULL, V17, P15, DOI 10.1093/schbul/17.1.15; TORREY EF, 1992, SCHIZOPHRENIA BULL, V18, P159, DOI 10.1093/schbul/18.2.159; TORREY EF, 1989, PSYCHOL MED, V19, P285, DOI 10.1017/S0033291700012320; TSUANG MT, 1990, BRIT J PSYCHIAT, V156, P17, DOI 10.1192/bjp.156.1.17; WADDINGTON JL, 1989, BRIT J PSYCHIAT, V154, P433, DOI 10.1192/bjp.154.4.433; WADDINGTON JL, 1993, SCHIZOPHRENIA BULL, V19, P55, DOI 10.1093/schbul/19.1.55; WADDINGTON JL, 1991, ARCH GEN PSYCHIAT, V48, P271; WADDINGTON JL, 1992, ARCH GEN PSYCHIAT, V49, P990; WADDINGTON JL, IN PRESS ANTIIPSYCHO; WADDINGTON JL, 1992, AN PSIQUUIAT S1, V8, P6; WEINBERGER DR, 1992, AM J PSYCHIAT, V149, P890; WEINBERGER DR, 1987, ARCH GEN PSYCHIAT, V44, P660, DOI 10.1001/archpsyc.1987.01800190080012; WITELSON SF, 1992, J COMP NEUROL, V323, P326, DOI 10.1002/cne.903230303; YOUSSEF HA, 1991, ARCH GEN PSYCHIAT, V48, P254	47	171	174	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 27	1993	341	8844					531	536		10.1016/0140-6736(93)90288-R	http://dx.doi.org/10.1016/0140-6736(93)90288-R			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KP083	8094781				2022-12-28	WOS:A1993KP08300014
J	KAJIKAWA, M; NONAMI, T; KUROKAWA, T; HARADA, A; NAKAO, A; TAKAGI, H				KAJIKAWA, M; NONAMI, T; KUROKAWA, T; HARADA, A; NAKAO, A; TAKAGI, H			RECOMBINANT-HUMAN-ERYTHROPOIETIN AND HYPOPHOSPHATEMIA IN PATIENTS WITH CIRRHOSIS	LANCET			English	Letter							AUTOLOGOUS BLOOD; DISEASE				KAJIKAWA, M (corresponding author), NAGOYA UNIV,SCH MED,DEPT SURG 2,NAGOYA,AICHI 466,JAPAN.		Kurokawa, Tomohiro/AFS-8825-2022	Kurokawa, Tomohiro/0000-0002-7932-8724				AMATUZIO DS, 1952, J LAB CLIN MED, V39, P26; CANIGGIA A, 1977, VITAMIN D BIOCH CHEM, P755; CUMMING AD, 1987, BRIT MED J, V295, P490, DOI 10.1136/bmj.295.6596.490; GEORGE R, 1992, SURGERY, V111, P281; GOODNOUGH LT, 1989, NEW ENGL J MED, V321, P1163, DOI 10.1056/NEJM198910263211705; LONG RG, 1976, LANCET, V2, P650; NANJI AA, 1985, J CLIN GASTROENTEROL, V7, P338, DOI 10.1097/00004836-198508000-00014; THOMPSON FL, 1991, AM J MED, V90, P398, DOI 10.1016/0002-9343(91)90584-K	8	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 20	1993	341	8843					503	504		10.1016/0140-6736(93)90268-L	http://dx.doi.org/10.1016/0140-6736(93)90268-L			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN137	8094533				2022-12-28	WOS:A1993KN13700062
J	ALLEMANN, Y; HORBER, FF; COLOMBO, M; FERRARI, P; SHAW, S; JAEGER, P; WEIDMANN, P				ALLEMANN, Y; HORBER, FF; COLOMBO, M; FERRARI, P; SHAW, S; JAEGER, P; WEIDMANN, P			INSULIN SENSITIVITY AND BODY-FAT DISTRIBUTION IN NORMOTENSIVE OFFSPRING OF HYPERTENSIVE PARENTS	LANCET			English	Article							MINIMAL MODEL METHOD; DIABETES-MELLITUS; ADIPOSE-TISSUE; OBESITY; GLUCOSE; RESISTANCE; METABOLISM; HYPERINSULINEMIA; WOMEN; PROFILES	Lean, healthy normotensive sons of essential hypertensive parents (OHyp) have lower insulin sensitivity (S(l)) than sons of normotensive parents (ONorm). We have tried to find out whether this disturbance in insulin metabolism is related to altered body fat distribution, fuel metabolism, or both. 21 OHyp and 21 ONorm of similar age and body-mass index were investigated after fasting overnight. Body composition was assessed by dual-energy X-ray absorptiometry and fuel metabolism by indirect calorimetry and urinary nitrogen excretion. Plasma insulin and glucose concentrations were measured during the frequent sampling intravenous glucose tolerance test, and S(l) was calculated by the minimum model method. Systolic blood pressure and heart rate were slightly but not significantly higher in OHyp than ONorm but the groups did not differ in fasting plasma insulin or glucose concentrations, carbohydrate or lipid oxidation, lean and fat mass, bone mineral content, or distribution of body fat. By contrast, S(l) was significantly lower in OHyp than ONorm (8.2 (0.7] vs 13.4 [1.5] 10(-4) L mU-1 min-1, p<0.01). Within the whole study population upper-body fat mass was positively correlated with fasting plasma insulin (r=0.33, p<0.03) and lipid oxidation was positively correlated with S(l)(r=0.35, p<0.04) and negatively correlated with subscapular/triceps skinfold thickness (r= -0.43, p<0.01 ). Thus, impairment of S(l) precedes both the development of overt hypertension and gain or redistribution of body fat. Therefore, the concept that S(l) is low as a result of altered fat distribution has to be reconsidered, at least in young male offspring of hypertensive parents.	UNIV BERN,MED POLIKLIN,FREIBURGSTR 3,CH-3010 BERN,SWITZERLAND	University of Bern			horber, Fritz/AAL-5419-2020	Ferrari, Paolo/0000-0002-9619-3104				AEBI H, 1984, ZWEITER SCHWEIZERISC, P76; ASHWELL M, 1985, BRIT MED J, V290, P1692, DOI 10.1136/bmj.290.6483.1692; BAUMGARTNER RN, 1987, AM J EPIDEMIOL, V126, P614, DOI 10.1093/oxfordjournals.aje.a114701; BEARD JC, 1986, DIABETES, V35, P362, DOI 10.2337/diabetes.35.3.362; BERGMAN RN, 1987, J CLIN INVEST, V79, P790, DOI 10.1172/JCI112886; BJORNTORP P, 1988, DIABETES METAB REV, V4, P615, DOI 10.1002/dmr.5610040607; Bjorntorp P, 1988, Horm Metab Res Suppl, V19, P23; BLAIR D, 1984, AM J EPIDEMIOL, V119, P526, DOI 10.1093/oxfordjournals.aje.a113770; CARO JF, 1991, J CLIN ENDOCR METAB, V73, P691, DOI 10.1210/jcem-73-4-691; ENDRE T, 1992, J HYPERTENS       S4, V10, P36; EVANS DJ, 1984, METABOLISM, V33, P68, DOI 10.1016/0026-0495(84)90164-1; FACCHINI FS, 1992, LANCET, V339, P1128, DOI 10.1016/0140-6736(92)90730-Q; FELDMAN R, 1969, DIABETES, V18, P478, DOI 10.2337/diab.18.7.478; FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605; FERRANNINI E, 1983, J CLIN INVEST, V72, P1737, DOI 10.1172/JCI111133; FERRARI P, 1991, AM J MED, V91, P589, DOI 10.1016/0002-9343(91)90211-F; FERRARI P, 1991, DIABETOLOGIA, V34, P527, DOI 10.1007/BF00403291; HORBER FF, 1992, BRIT J RADIOL, V65, P895, DOI 10.1259/0007-1285-65-778-895; HORBER FF, 1991, DIABETES, V40, P141, DOI 10.2337/diabetes.40.1.141; HORBER FF, 1987, J CLIN INVEST, V79, P1181, DOI 10.1172/JCI112935; JENSEN MD, 1989, J CLIN INVEST, V83, P1168, DOI 10.1172/JCI113997; JENSEN MD, 1991, AM J CLIN NUTR, V53, P172, DOI 10.1093/ajcn/53.1.172; KISSEBAH AH, 1976, DIABETOLOGIA, V12, P563, DOI 10.1007/BF01220632; KROTKIEWSKI M, 1990, J INTERN MED, V228, P385, DOI 10.1111/j.1365-2796.1990.tb00250.x; LANDIN K, 1990, EUR J CLIN INVEST, V20, P530, DOI 10.1111/j.1365-2362.1990.tb01897.x; MODAN M, 1985, J CLIN INVEST, V75, P809, DOI 10.1172/JCI111776; NUTTALL FQ, 1985, J AM COLL NUTR, V4, P437, DOI 10.1080/07315724.1985.10720086; OHLSON LO, 1985, DIABETES, V34, P1055, DOI 10.2337/diabetes.34.10.1055; PEIRIS AN, 1988, J CLIN ENDOCR METAB, V67, P760, DOI 10.1210/jcem-67-4-760; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; SIMONSON DC, 1990, AM J PHYSIOL, V258, pE399, DOI 10.1152/ajpendo.1990.258.3.E399; STROMBLAD G, 1986, METABOLISM, V35, P323, DOI 10.1016/0026-0495(86)90148-4; YANG YJ, 1987, AM J PHYSIOL, V253, pE595, DOI 10.1152/ajpendo.1987.253.6.E595	33	116	121	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 6	1993	341	8841					327	331		10.1016/0140-6736(93)90135-4	http://dx.doi.org/10.1016/0140-6736(93)90135-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK939	8094112				2022-12-28	WOS:A1993KK93900003
J	WILSON, APR				WILSON, APR			DATA PRESENTATION - BOX-PLOTS FOR MICROBIOLOGISTS	LANCET			English	Editorial Material											WILSON, APR (corresponding author), UNIV COLL HOSP LONDON,DEPT CLIN MICROBIOL,WC1 LONDON,ENGLAND.							DONNELLY JP, 1992, J ANTIMICROB CHEMOTH, V30, P713, DOI 10.1093/jac/30.5.713; FEINSTEIN AR, 1987, J CHRON DIS, V40, P283, DOI 10.1016/0021-9681(87)90043-9; HUNTER PR, 1990, ANTIMICROB AGENTS CH, V34, P1769, DOI 10.1128/AAC.34.9.1769; MCGILL R, 1978, AM STAT, V32, P12, DOI 10.2307/2683468; SIMPSON RJ, 1988, AM HEART J, V116, P1663, DOI 10.1016/0002-8703(88)90791-0; WILLIAMSON DF, 1989, ANN INTERN MED, V110, P916, DOI 10.7326/0003-4819-110-11-916	6	7	7	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 30	1993	341	8840					282	282						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK245	8093926				2022-12-28	WOS:A1993KK24500014
J	CHEW, F; PENNA, FJ; PERET, LA; QUAN, C; LOPES, MC; MOTA, JAC; FONTAINE, O				CHEW, F; PENNA, FJ; PERET, LA; QUAN, C; LOPES, MC; MOTA, JAC; FONTAINE, O			IS DILUTION OF COWS MILK FORMULA NECESSARY FOR DIETARY-MANAGEMENT OF ACUTE DIARRHEA IN INFANTS AGED LESS THAN 6 MONTHS	LANCET			English	Article							ACUTE GASTROENTERITIS; LACTOSE-MALABSORPTION; ORAL REHYDRATION; CHILDREN; INTOLERANCE; CHILDHOOD	There is concern that feeding full-strength animal milk to infants aged less than 6 months with diarrhoea may have adverse consequences. We assessed the effects on clinical course of two feeding regimens in 159 Guatemalan and Brazilian infants aged 2 weeks to 6 months who had had acute diarrhoea for 120 h or less, showed signs of mild to moderate dehydration, and had no complications. After correction of dehydration, infants were assigned randomly to receive continued full-strength milk feeding or initial feeding with diluted milk with regrading to full-strength milk over 48 h. There were no significant differences between feeding groups in rate of treatment failures (- 1%, 95% CI - 14 to 12%) or mean (SD) total stool output (full-strength milk 335 [268] g/kg, diluted milk 338 [354] g/kg) and duration of diarrhoea (92 [50] vs 92 [44] h). A significant association was found between presence of reducing substances in stools and treatment failure (OR 4.3, 95% CI 1.1 to 16.8), but reducing substances in stools were common both in treatment successes (61%) and in failures (87%). Our study supports the conclusion that, for infants under 6 months of age with diarrhoea whose only food is animal milk or formula, the milk or formula normally given should be provided in full strength as soon as dehydration has been corrected.	WHO,DIARRHOEAL DIS CONTROL PROGRAMME,CH-1211 GENEVA 27,SWITZERLAND; UNIV FED MINAS GERAIS,HOSP CLIN,BR-30000 BELO HORIZON,MG,BRAZIL; CNPQ,CONSELHO NACL DESENVOLVIMENTO CIENT & TECNOL,RIO JANEIRO,BRAZIL; INST NUTR CENT AMER & PANAMA,GUATEMALA CITY,GUATEMALA	World Health Organization; Universidade Federal de Minas Gerais; Institute of Nutrition of Central America & Panama (INCAP)								ARMITSTEAD J, 1989, J PEDIATR GASTR NUTR, V8, P240, DOI 10.1097/00005176-198902000-00019; BOOTH IW, 1991, TXB PEDIATRIC NUTRIT, P157; BROWN KH, 1980, AM J CLIN NUTR, V33, P2226, DOI 10.1093/ajcn/33.10.2226; BROWN KH, 1991, J PEDIATR-US, V118, pS92, DOI 10.1016/S0022-3476(05)81434-9; DUGDALE A, 1982, ARCH DIS CHILD, V57, P76; ELLIS ME, 1984, BRIT MED J, V288, P521, DOI 10.1136/bmj.288.6416.521; FOX R, 1990, ARCH DIS CHILD, V65, P936, DOI 10.1136/adc.65.9.936; GARDNER MJ, 1989, STATISTICS CONFIDENC; GAZALA E, 1988, ISRAEL J MED SCI, V24, P175; HAQUE KN, 1983, TROP GEOGR MED, V35, P369; HJELT K, 1989, J PEDIATR GASTR NUTR, V8, P75, DOI 10.1097/00005176-198901000-00014; HYAMS JS, 1981, J PEDIATR-US, V99, P916, DOI 10.1016/S0022-3476(81)80020-0; ISOLAURI E, 1985, J PEDIATR GASTR NUTR, V4, P366, DOI 10.1097/00005176-198506000-00008; JELLIFFE DB, 1991, DIETARY MANAGEMENT Y; KERRY KR, 1964, LANCET, V1, P981; LIFSHITZ F, 1971, J PEDIATR-US, V79, P760, DOI 10.1016/S0022-3476(71)80388-8; MAUNG UK, 1985, BRIT MED J, V290, P587; PIZARRO D, 1986, J PEDIATR GASTR NUTR, V5, P6, DOI 10.1097/00005176-198601000-00003; PLACZEK M, 1984, J PEDIATR GASTR NUTR, V3, P245, DOI 10.1097/00005176-198403000-00014; POCOCK SJ, 1987, CLIN TRIALS PRACTICA, P123; REES L, 1979, LANCET, V1, P770; TORUN B, 1979, ARCH LATINOAM NUTR, V24, P446; TOUHAMI M, 1989, ARCH FR PEDIATR, V46, P25; TROUNCE JQ, 1985, ARCH DIS CHILD, V60, P986, DOI 10.1136/adc.60.10.986; 1977, NATIONAL CTR HLTH 11, V165	25	30	30	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 23	1993	341	8839					194	197		10.1016/0140-6736(93)90063-M	http://dx.doi.org/10.1016/0140-6736(93)90063-M			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ219	8093495				2022-12-28	WOS:A1993KJ21900002
J	KIRKHAM, N; NEWTON, J; THOMAS, M				KIRKHAM, N; NEWTON, J; THOMAS, M			MALIGNANT-MELANOMA EXCISION MARGINS	LANCET			English	Letter											KIRKHAM, N (corresponding author), ROYAL LONDON HOSP,DEPT DERMATOL,LONDON E1 1BB,ENGLAND.								0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 16	1993	341	8838					184	184						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG627	8093790				2022-12-28	WOS:A1993KG62700057
J	HARDING, T; UMMEL, M				HARDING, T; UMMEL, M			CONSENSUS ON NONDISCRIMINATION IN HIV POLICY	LANCET			English	Editorial Material																		[Anonymous], 1992, AIDS WORLD; HARDING TW, 1989, LANCET, V1, P1191; 1991, LANCET, V338, P1559; 1992, CPTINF926 COUNC EUR; 1992, CPTINF924 COUNC REP; 1989, R8914 COMM MIN COUNC	6	2	2	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 2	1993	341	8836					24	25		10.1016/0140-6736(93)92488-F	http://dx.doi.org/10.1016/0140-6736(93)92488-F			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF027	8093271				2022-12-28	WOS:A1993KF02700010
J	KRONENBERG, F; KONIG, P; LHOTTA, K; KONIGSRAINER, A; SANDHOLZER, C; UTERMANN, G; DIEPLINGER, H				KRONENBERG, F; KONIG, P; LHOTTA, K; KONIGSRAINER, A; SANDHOLZER, C; UTERMANN, G; DIEPLINGER, H			CYCLOSPORINE AND SERUM-LIPIDS IN RENAL-TRANSPLANT RECIPIENTS	LANCET			English	Letter									UNIV INNSBRUCK, INST HUMAN GENET, A-6020 INNSBRUCK, AUSTRIA; UNIV INNSBRUCK, DEPT CLIN NEPHROL, A-6020 INNSBRUCK, AUSTRIA; UNIV INNSBRUCK, DEPT TRANSPLANT SURG, A-6020 INNSBRUCK, AUSTRIA	University of Innsbruck; University of Innsbruck; University of Innsbruck	KRONENBERG, F (corresponding author), UNIV INNSBRUCK, INST MED BIOL, A-6020 INNSBRUCK, AUSTRIA.		Hoitsma, A.J./L-4382-2015; Kronenberg, Florian/B-1736-2008; Irish, Ashley/H-5468-2019; Hilbrands, Luuk/B-4921-2011	Kronenberg, Florian/0000-0003-2229-1120; Irish, Ashley/0000-0002-9577-3764; Hilbrands, Luuk/0000-0002-4935-9765				BLACK IW, 1992, CLIN CHEM, V38, P353	1	32	32	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 20	1993	341	8847					765	765		10.1016/0140-6736(93)90546-S	http://dx.doi.org/10.1016/0140-6736(93)90546-S			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KT362	8095674				2022-12-28	WOS:A1993KT36200056
J	HILBRANDS, LB; DEMACKER, PNM; HOITSMA, AJ				HILBRANDS, LB; DEMACKER, PNM; HOITSMA, AJ			CYCLOSPORINE AND SERUM-LIPIDS IN RENAL-TRANSPLANT RECIPIENTS	LANCET			English	Letter									UNIV HOSP NIJMEGEN,DEPT MED,DIV GEN INTERNAL MED,6500 HB NIJMEGEN,NETHERLANDS	Radboud University Nijmegen	HILBRANDS, LB (corresponding author), UNIV HOSP NIJMEGEN,DEPT MED,DIV NEPHROL,6500 HB NIJMEGEN,NETHERLANDS.		Hoitsma, A.J./L-4382-2015; Kronenberg, Florian/B-1736-2008; Irish, Ashley/H-5468-2019; Hilbrands, Luuk/B-4921-2011	Kronenberg, Florian/0000-0003-2229-1120; Irish, Ashley/0000-0002-9577-3764; Hilbrands, Luuk/0000-0002-4935-9765				DEMACKER PNM, 1980, CLIN CHEM, V26, P1775; LOPESVIRELLA MFL, 1980, CLIN CHEM, V26, P1205; UTERMANN G, 1987, J CLIN INVEST, V80, P458, DOI 10.1172/JCI113093; WEBB, 1993, LANCET, V341, P268	4	32	32	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 20	1993	341	8847					765	766		10.1016/0140-6736(93)90546-S	http://dx.doi.org/10.1016/0140-6736(93)90546-S			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KT362	8095674				2022-12-28	WOS:A1993KT36200057
